PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MARSHALL, H; NONCHEV, S; SHAM, MH; MUCHAMORE, I; LUMSDEN, A; KRUMLAUF, R				MARSHALL, H; NONCHEV, S; SHAM, MH; MUCHAMORE, I; LUMSDEN, A; KRUMLAUF, R			RETINOIC ACID ALTERS HINDBRAIN HOX CODE AND INDUCES TRANSFORMATION OF RHOMBOMERES 2-3 INTO A 4-5 IDENTITY	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; MOUSE HINDBRAIN; EXPRESSION; SEGMENTATION; DISRUPTION; VERTEBRAE; DEFECTS; HOX-1.1; EMBRYOS; HOX-2.9	IT has been suggested that Hox genes play an important part in the patterning of limbs1-3, vertebrae4-6 and craniofacial structures5,7-9 by providing an ordered molecular system of positional values, termed the Hox code10,11. Little is known about the nature of the signals that govern the establishment and regulation of Hox genes, but retinoic acid can affect the expression of these genes in cell lines12-14 and in embryonic tissues2,11,15-17. On the basis of experimental and clinical evidence, the hindbrain and branchial region of the head are particularly sensitive to the effects of retinoic acid 15,18-21, but the phenotypes are complex and hard to interpret, and how and if they relate to Hox expression has not been clear. Here we follow the changes induced by retinoic acid to hindbrain segmentation and the branchial arches using transgenic mice which contain lacZ reporter genes that reveal the endogenous segment-restricted expression of the Hox-B1 (Hox-2.9), Hox-B2(Hox-2.8) and Krox-20 genes. Our results show that these genes rapidly respond to exposure to retinoic acid at preheadfold stages and undergo a progressive series of changes in segmental expression that are associated with specific phenotypes in hindbrain of first branchial arch. Together the molecular and anatomical alterations indicate that retinoic acid has induced changes in the hindbrain Hox code which result in the homeotic transformation of rhombomeres (r) 2/3 to an r4/5 identity. A main feature of this rhombomeric phenotype is that the trigeminal motor nerve is transformed to a facial identity. Furthermore, in support of this change in rhombomeric identity, neural crest cells derived from r2/3 also express posterior Hox markers suggesting that the retinoic acid-induced transformation extends to multiple components of the first branchial arch.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,MRC,LONDON SE1 9RT,ENGLAND	MRC National Institute for Medical Research; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	KRUMLAUF, R (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Krumlauf, Robb/AAH-5012-2019; Lumsden, Andrew/C-5146-2009; Sham, Mai Har/AAX-3781-2020	Krumlauf, Robb/0000-0001-9102-7927; Sham, Mai Har/0000-0003-1179-7839; Muchamore, Ian/0000-0003-2121-1539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CANLON R, 1992, DEVELOPMENT, V116, P357; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DOLE P, 1989, NATURE, V342, P767; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HOGAN B, 1986, MANIPULATING MOUSE E; HOLDER N, 1991, DEVELOPMENT, V113, P1159; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Morris G. M., 1978, DEV MAMMALS, V3, P363; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHAM MH, IN PRESS CELL; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	32	427	433	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					737	741		10.1038/360737a0	http://dx.doi.org/10.1038/360737a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1361214				2022-12-28	WOS:A1992KE47200033
J	SELWYN, PA; ALCABES, P; HARTEL, D; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; DAVENNY, K; FRIEDLAND, GH				SELWYN, PA; ALCABES, P; HARTEL, D; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; DAVENNY, K; FRIEDLAND, GH			CLINICAL MANIFESTATIONS AND PREDICTORS OF DISEASE PROGRESSION IN DRUG-USERS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; NEW-YORK-CITY; HIV-INFECTION; MAINTENANCE TREATMENT; BACTERIAL PNEUMONIA; CONTROLLED TRIAL; NATURAL-HISTORY; HOMOSEXUAL MEN; ZIDOVUDINE AZT; UNITED-STATES	Background and Methods. To examine the clinical course of human immunodeficiency virus (HIV) infection in injection-drug users, we conducted a prospective study of a cohort of patients in a methadone-treatment program in New York City from July 1985 through December 1990. The patients underwent standardized evaluations at base line and semiannually thereafter and received on-site primary medical care. Rates of progression to the acquired immunodeficiency syndrome (AIDS) and major outcomes before the development of AIDS were examined by univariate analyses; the risk of AIDS was also assessed by product-limit survival analysis and proportional-hazards regression. Results. Of 318 HIV-seropositive patients who did not yet have AIDS (171 men and 147 women), 90 were black, 179 were Hispanic, and 49 were white; the median age was 33 years. Over a median of 3.0 years of follow-up, 55 (17 percent) received a diagnosis of AIDS (incidence per 100 person-years, 5.8). Major outcomes before the development of AIDS included oral candidiasis (incidence per 100 person-years, 11.2), pyogenic bacterial infections including pneumonia and sepsis (8.0), pulmonary tuberculosis (1.2), multiple constitutional symptoms (13.6), and herpes zoster (1.3). There were 41 deaths from AIDS, and 13 seropositive patients without AIDS (4.1 percent) died of bacterial infections, as compared with only 1 of 411 seronegative patients studied (P<0.001). The incidence of AIDS was 62 percent lower among those who took zidovudine than among those who did not (P = 0.02). In the multivariate analysis, progression to AIDS was best predicted by low numbers and percentages of CD4+ lymphocytes, nonuse of zidovudine, and the presence of oral candidiasis, bacterial infections, or tuberculosis. There was no consistent relation between progression to disease and the continued use of injection drugs. Conclusions. HIV-infected injection-drug users have progression to AIDS at rates comparable to those of other HIV-infected groups, but they have substantial pre-AIDS morbidity and mortality, particularly from bacterial infections, which also appear to predict disease progression.	MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT INTERNAL MED, DIV INFECT DIS, BRONX, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine				Schoenbaum, Ellie/0000-0002-0878-284X	NIDA NIH HHS [DAO4347-05] Funding Source: Medline; PHS HHS [U64CCU200714] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1992, AIDS, V6, P421; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRETTLE RP, 1991, AIDS, V5, P125, DOI 10.1097/00002030-199102000-00001; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CASABONA J, 1990, J ACQ IMMUN DEF SYND, V3, P272; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; COATES RA, 1990, AM J EPIDEMIOL, V132, P717, DOI 10.1093/oxfordjournals.aje.a115713; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GATES JR, 1991, 7TH INT C AIDS FLOR, V2, P377; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; JARLAIS DCD, 1987, AIDS, V1, P105; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MARGOLICK JB, 1992, JAMA-J AM MED ASSOC, V267, P1631, DOI 10.1001/jama.267.12.1631; MIENTJES GH, 1992, AIDS, V6, P207, DOI 10.1097/00002030-199202000-00012; MIENTJES GH, 1991, AIDS, V5, P35, DOI 10.1097/00002030-199101000-00005; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PAYNE SF, 1990, AIDS, V4, P335, DOI 10.1097/00002030-199004000-00008; PERUCCI CA, 1991, AM J PUBLIC HEALTH, V81, P1307, DOI 10.2105/AJPH.81.10.1307; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PHILLIPS AN, 1991, LANCET, V337, P389; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SELWYN PA, 1991, 119TH ANN M AM PUBL, P153; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; WILLOCKS L, 1992, J INFECTION, V24, P37, DOI 10.1016/0163-4453(92)90898-G; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; 1989, MMWR MORB MORTAL WKL, V38, P165; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, WKLY EPIDEMIOL REC, V66, P33; 1991, REPORT TWIN EPIDEMIC; 1991, MMWR MORB MORTAL WKL, V40, P891	64	299	300	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1697	1703		10.1056/NEJM199212103272401	http://dx.doi.org/10.1056/NEJM199212103272401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1359411				2022-12-28	WOS:A1992KA89700001
J	COLE, SPC; BHARDWAJ, G; GERLACH, JH; MACKIE, JE; GRANT, CE; ALMQUIST, KC; STEWART, AJ; KURZ, EU; DUNCAN, AMV; DEELEY, RG				COLE, SPC; BHARDWAJ, G; GERLACH, JH; MACKIE, JE; GRANT, CE; ALMQUIST, KC; STEWART, AJ; KURZ, EU; DUNCAN, AMV; DEELEY, RG			OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE	SCIENCE			English	Article							P-GLYCOPROTEIN GENE; INSITU HYBRIDIZATION; CYSTIC-FIBROSIS; BACTERIAL TRANSPORT; CONFOCAL MICROSCOPY; COMPLEMENTARY-DNA; HL-60 CELLS; EXPRESSION; LOCALIZATION; MDR1	The doxorubicin-selected lung cancer cell line H69AR is resistant to many chemotherapeutic agents. However, like most tumor samples from individuals with this disease, it does not overexpress P-glycoprotein, a transmembrane transport protein that is dependent on adenosine triphosphate (ATP) and is associated with multidrug resistance. Complementary DNA (cDNA) clones corresponding to messenger RNAs (mRNAs) overexpressed in H69AR cells were isolated. One cDNA hybridized to an mRNA of 7.8 to 8.2 kilobases that was 100- to 200-fold more expressed in H69AR cells relative to drug-sensitive parental H69 cells. Overexpression was associated with amplification of the cognate gene located on chromosome 16 at band p13.1. Reversion to drug sensitivity was associated with loss of gene amplification and a marked decrease in mRNA expression. The mRNA encodes a member of the ATP-binding cassette transmembrane transporter superfamily.	KINGSTON GEN HOSP,DEPT PATHOL,KINGSTON K7L 2V7,ONTARIO,CANADA	Queens University - Canada	COLE, SPC (corresponding author), QUEENS UNIV,CANC RES LABS,KINGSTON K7L 3N6,ONTARIO,CANADA.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884; Stewart, Alistair J./0000-0001-8984-5146				ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BAIROCH A, 1989, PROSITE DICT PROTEIN; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CALLEN DF, 1987, HUM GENET, V77, P142, DOI 10.1007/BF00272381; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Cole S., UNPUB; COLE SPC, 1992, CAN J PHYSIOL PHARM, V70, P313, DOI 10.1139/y92-040; COLE SPC, 1989, BRIT J CANCER, V59, P42, DOI 10.1038/bjc.1989.9; COLE SPC, 1991, CANCER RES, V51, P3345; COLE SPC, 1990, CANCER CHEMOTH PHARM, V26, P250, DOI 10.1007/BF02897225; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUDLER R, 1992, J BIOL CHEM, V267, P5882; DUNCAN AMV, 1988, CYTOGENET CELL GENET, V49, P309, DOI 10.1159/000132684; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GAZDAR AF, 1980, CANCER RES, V40, P3502; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GERLACH JH, 1986, CANCER SURV, V5, P25; GERVASONI JE, 1991, CANCER RES, V51, P4955; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HINDENBURG AA, 1989, CANCER RES, V49, P4607; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEIZER HG, 1989, CANCER RES, V49, P2988; KING CR, 1979, J BIOL CHEM, V254, P6781; LAI SL, 1989, J NATL CANCER I, V81, P1144, DOI 10.1093/jnci/81.15.1144; LIN CC, 1985, CYTOGENET CELL GENET, V39, P269, DOI 10.1159/000132156; MARQUARDT D, 1991, JNCI-J NATL CANCER I, V83, P1098, DOI 10.1093/jnci/83.15.1098; MILROY R, 1992, ANTICANCER RES, V12, P193; MIRSKI SEL, 1987, CANCER RES, V47, P2594; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLAIFER D, 1990, BRIT J CANCER, V62, P177, DOI 10.1038/bjc.1990.256; SCHUURHUIS GJ, 1991, BRIT J CANCER, V64, P857, DOI 10.1038/bjc.1991.413; SCHUURHUIS GJ, 1989, J NATL CANCER I, V81, P1887, DOI 10.1093/jnci/81.24.1887; SUGAWARA I, 1992, JPN J CANCER RES, V83, P131, DOI 10.1111/j.1349-7006.1992.tb00076.x; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEYAMA H, 1984, MOL CELL BIOL, V4, P1073, DOI 10.1128/MCB.4.6.1073; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEAVER JL, 1991, EXP CELL RES, V196, P323, DOI 10.1016/0014-4827(91)90267-X; WEINSTEIN RS, 1990, HUM PATHOL, V21, P34, DOI 10.1016/0046-8177(90)90073-E; WILLINGHAM MC, 1986, CANCER RES, V46, P5941	52	2926	3069	3	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1650	1654		10.1126/science.1360704	http://dx.doi.org/10.1126/science.1360704			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360704				2022-12-28	WOS:A1992KA89600038
J	FAHNESTOCK, ML; TAMIR, I; NARHI, L; BJORKMAN, PJ				FAHNESTOCK, ML; TAMIR, I; NARHI, L; BJORKMAN, PJ			THERMAL-STABILITY COMPARISON OF PURIFIED EMPTY AND PEPTIDE-FILLED FORMS OF A CLASS-I MHC MOLECULE	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; HLA-B-ANTIGENS; HEAVY-CHAIN; VIRAL PEPTIDES; LYMPHOCYTES-T; BETA-2-MICROGLOBULIN; CELLS; BINDING; SURFACE; EXPRESSION	A secreted form of a class I major histocompatibility complex (MHC) molecule was denatured and renatured in vitro in the absence of peptide. The resulting empty class I heterodimer was immunologically reactive and structurally similar to a heterodimer renatured in the presence of an appropriate restricted peptide. Thermal stability profiles indicated that the two forms of heterodimer differed in their resistance to denaturation by heat but that a significant portion of the empty class I heterodimers had a native conformation at physiological temperatures. Free energies calculated from these data gave a direct measure of the stabilization of the class I MHC molecule that resulted from peptide binding.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; AMGEN INC, BIOPHYS, THOUSAND OAKS, CA 91320 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Amgen					NIAID NIH HHS [AI28931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FAHNESTOCK ML, UNPUB; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GASTINEL LN, UNPUB; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GROVES ML, 1982, J BIOL CHEM, V257, P2619; HARLOW E, 1982, ANTIBODIES LABORATOR, P522; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MCINTOSH K, 1982, J CLIN MICROBIOL, V16, P329, DOI 10.1128/JCM.16.2.329-333.1982; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARHAM P, 1983, J BIOL CHEM, V258, P6179; PARHAM P, 1979, J BIOL CHEM, V254, P8709; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RAGHAVAN M, UNPUB; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YOKOYAMA K, 1985, BIOCHEMISTRY-US, V24, P3002, DOI 10.1021/bi00333a029	39	128	134	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1658	1662		10.1126/science.1360705	http://dx.doi.org/10.1126/science.1360705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360705				2022-12-28	WOS:A1992KA89600040
J	CZEISLER, CA; DUMONT, M; DUFFY, JF; STEINBERG, JD; RICHARDSON, GS; BROWN, EN; SANCHEZ, R; RIOS, CD; RONDA, JM				CZEISLER, CA; DUMONT, M; DUFFY, JF; STEINBERG, JD; RICHARDSON, GS; BROWN, EN; SANCHEZ, R; RIOS, CD; RONDA, JM			ASSOCIATION OF SLEEP-WAKE HABITS IN OLDER-PEOPLE WITH CHANGES IN OUTPUT OF CIRCADIAN PACEMAKER	LANCET			English	Article							BRIGHT LIGHT; SUPRACHIASMATIC NUCLEI; TEMPERATURE RHYTHMS; HUMAN-BRAIN; AGE; EXPOSURE; DEMENTIA; MEN; SEX	Many elderly people complain of disturbed sleep patterns but there is no evidence that the need to sleep decreases with age; it seems rather that the timing and consolidation of sleep change. We tried to find out whether there is a concurrent change in the output of the circadian pacemaker with age. The phase and amplitude of the pacemaker's output were assessed by continuous measurement of the core body temperature during 40 h ot sustained wakefulness under constant behavioural and environmental conditions. 27 young men (18-31 years) were compared with 21 older people (65-85 years; 11 men, 10 women); all were healthy and without sleep complaints. The mean amplitude of the endogenous circadian temperature oscillation (ECA) was 40% greater in young men than in the older group. Older men had a lower mean temperature ECA than older women. The minimum of the endogenous phase of the circadian temperature oscillation (ECP) occurred 1 h 52 min earlier in the older than in the young group. Customary bedtimes and waketimes were also earlier in the older group, as was their daily alertness peak. There was a close correlation between habitual waketime and temperature ECP in young men, which may lose precision with age, especially among women. These findings provide evidence for systematic age-related changes in the output of the human circadian pacemaker. We suggest that these changes may underlie the common complaints of sleep disturbance among elderly people. These changes could reflect the observed age-related deterioration of the hypothalmic nuclei that drive mammalian circadian rhythms.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CZEISLER, CA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02115, USA.		Duffy, Jeanne F./AAJ-4845-2020	Duffy, Jeanne F./0000-0003-4177-4179	NIA NIH HHS [1-RO1-AG06072, 1-P01-AG09975] Funding Source: Medline; NIMH NIH HHS [H5-ROI-MH45130] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006072, P01AG009975] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BROWN EN, IN PRESS J BIOL RHYT; Campbell S. S, 1991, SLEEP RES, V20, P448; CAMPBELL SS, 1988, PHYSIOL BEHAV, V42, P141, DOI 10.1016/0031-9384(88)90289-2; COBLENTZ JM, 1973, ARCH NEUROL-CHICAGO, V29, P299, DOI 10.1001/archneur.1973.00490290039003; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; CZEISLER CA, 1978, THESIS STANFORD U ST; DAVIS FC, 1984, J COMP PHYSIOL, V154, P221, DOI 10.1007/BF00604987; Dement W, 1985, HDB BIOL AGING, P692; DUMONT M, 1990, SLEEP RES, V19, P217; DUMONT M, 1990, 2ND M SOC RES BIOL R, P66; HOFMAN MA, 1988, J ANAT, V160, P127; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; JEWETT ME, 1991, NATURE, V350, P59, DOI 10.1038/350059a0; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MANT A, 1988, COMMUNITY HEALTH ST, V12, P192; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; MINORS D S, 1984, Chronobiology International, V1, P205, DOI 10.3109/07420528409063897; MOE KE, 1991, J AM GERIATR SOC, V39, P383, DOI 10.1111/j.1532-5415.1991.tb02904.x; Monk TH, 1992, J GERONTOL PSYCH SCI, V47, P221; MORIN LP, 1988, J BIOL RHYTHM, V3, P237, DOI 10.1177/074873048800300302; PICKARD GE, 1985, J COMP PHYSIOL A, V156, P803, DOI 10.1007/BF00610832; PITTENDRIGH CS, 1974, SCIENCE, V186, P548, DOI 10.1126/science.186.4163.548; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; VITIELLO MV, 1986, NEUROBIOL AGING, V7, P97, DOI 10.1016/0197-4580(86)90146-6; WEITZMAN ED, 1982, NEUROBIOL AGING, V3, P299, DOI 10.1016/0197-4580(82)90018-5; WELSH DK, 1986, J GERONTOL, V41, P579, DOI 10.1093/geronj/41.5.579; Wever R.A., 1979, CIRCADIAN SYSTEM MAN	30	313	315	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					933	936		10.1016/0140-6736(92)92817-Y	http://dx.doi.org/10.1016/0140-6736(92)92817-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357348				2022-12-28	WOS:A1992JT82300003
J	ANTINORI, A; MURRI, R; TAMBURRINI, E; DELUCA, A; ORTONA, L				ANTINORI, A; MURRI, R; TAMBURRINI, E; DELUCA, A; ORTONA, L			FAILURE OF LOW-DOSE DAPSONE-PYRIMETHAMINE IN PRIMARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA	LANCET			English	Letter							PREVENTION				ANTINORI, A (corresponding author), UNIV CATTOLICA SACRO CUORE, INFECT DIS CLIN, I-00168 ROME, ITALY.		Antinori, Andrea/K-7125-2016; De Luca, Andrea/G-8810-2011	Antinori, Andrea/0000-0003-2121-4684; TAMBURRINI, Enrica/0000-0003-4930-426X; De Luca, Andrea/0000-0002-9561-9193; Murri, Rita/0000-0001-9468-5458				CLOTET B, 1991, AIDS, V5, P601, DOI 10.1097/00002030-199105000-00024; GIRARD PM, 1992, 8 INT C AIDS AMST; HUGHES WT, 1990, LANCET, V336, P1066, DOI 10.1016/0140-6736(90)92533-N; MALLOLAS J, 1991, LANCET, V337, P1162, DOI 10.1016/0140-6736(91)92829-Q	4	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					788	788		10.1016/0140-6736(92)92326-B	http://dx.doi.org/10.1016/0140-6736(92)92326-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356193				2022-12-28	WOS:A1992JP86900026
J	PILOWSKY, LS; COSTA, DC; ELL, PJ; MURRAY, RM; VERHOEFF, NPLG; KERWIN, RW				PILOWSKY, LS; COSTA, DC; ELL, PJ; MURRAY, RM; VERHOEFF, NPLG; KERWIN, RW			CLOZAPINE, SINGLE PHOTON-EMISSION TOMOGRAPHY, AND THE D2 DOPAMINE RECEPTOR BLOCKADE HYPOTHESIS OF SCHIZOPHRENIA	LANCET			English	Article							ATYPICAL NEUROLEPTICS; BRAIN; BINDING; INVIVO	According to the dopamine hypothesis of schizophrenia, D2 receptor blockade is essential for a drug to have antipsychotic potency, and antipsychotic potency and D2 blockade are linearly related in vitro. To test this assumption in vivo, we have compared clinical response with central D2 dopamine receptor availability measured by I-123-iodobenzamide single photon emission tomography in two groups of schizophrenic patients. 6 patients were on typical antipsychotic drugs and 10 were on the atypical antipsychotic clozapine, including 2 patients from the first group. The patients on typical antipsychotics showed poor therapeutic response despite D2 receptor blockade. Significant clinical improvement occurred in all patients on clozapine, but at a lower level of D2 blockade by the drug. These findings suggest a more complex relation between D2 blockade and clinical efficacy than was previously thought.	UNIV COLL & MIDDLESEX SCH MED,INST NUCL MED,LONDON,ENGLAND; AMSTERDAM MED CTR,EINDHOVEN,NETHERLANDS	University of London; University College London	PILOWSKY, LS (corresponding author), INST PSYCHIAT,DEPT NEUROSCI & PSYCHIAT GENET,LONDON SE5 8AF,ENGLAND.		Costa, Durval C C./F-1744-2018; Murray, Robin M/F-8658-2012	Costa, Durval C C./0000-0001-8039-4924; Murray, Robin M/0000-0003-0829-0519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAVI A, 1989, Journal of Nuclear Medicine, V30, P731; ANDERSEN PH, 1986, EUR J PHARMACOL, V120, P143, DOI 10.1016/0014-2999(86)90656-4; BRUCKE T, 1992, LANCET, V339, P497, DOI 10.1016/0140-6736(92)91108-K; BRUCKE T, 1991, CEREBROVASC J BLOOD, V11, P220; BURGEN ASV, 1966, J PHARM PHARMACOL, V18, P137, DOI 10.1111/j.2042-7158.1966.tb07840.x; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; COSTA DC, 1990, EUR J NUCL MED, V16, P813, DOI 10.1007/BF00833017; COWARD DM, 1989, PSYCHOPHARMACOLOGY, V99, pS6, DOI 10.1007/BF00442552; CROW TJ, 1980, BRIT MED J, V280, P66, DOI 10.1136/bmj.280.6207.66; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; FARDE L, 1989, PSYCHOPHARMACOLOGY, V99, pS28, DOI 10.1007/BF00442555; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; HIPPIUS H, 1989, PSYCHOPHARMACOLOGY, V99, pS3, DOI 10.1007/BF00442551; HIRSCH SR, 1986, PSYCHOPHARMACOLOGY T, P286; HITZEMANN R, 1988, TRENDS PHARMACOL SCI, V9, P408, DOI 10.1016/0165-6147(88)90068-5; HORNYKIEWICZ O, 1982, NATURE, V299, P484, DOI 10.1038/299484a0; JOHNSTONE EC, 1978, LANCET, V1, P848; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KERWIN R, 1992, J PSYCHOPHARMACOL, V6, P230, DOI 10.1177/026988119200600217; KOLAKOWSKA T, 1985, BRIT J PSYCHIAT, V146, P229, DOI 10.1192/bjp.146.3.229; KUNG HF, 1988, J MED CHEM, V31, P1039, DOI 10.1021/jm00400a027; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P44; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PEROUTKA SJ, 1980, AM J PSYCHIAT, V137, P1518; REYNOLDS GP, 1988, PSYCHOL MED, V18, P793, DOI 10.1017/S0033291700009715; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; VERHOEFF NPL, 1990, EUR J NUCL MED, P1; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495; 1987, DIAGNOSTIC STATISTIC	29	184	185	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					199	202		10.1016/0140-6736(92)90467-H	http://dx.doi.org/10.1016/0140-6736(92)90467-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JE758	1353135				2022-12-28	WOS:A1992JE75800003
J	BROWN, P; PREECE, MA; WILL, RG				BROWN, P; PREECE, MA; WILL, RG			FRIENDLY FIRE IN MEDICINE - HORMONES, HOMOGRAFTS, AND CREUTZFELDT-JAKOB DISEASE	LANCET			English	Review							HUMAN GROWTH-HORMONE; PERSON TRANSMISSION; RECIPIENT; THERAPY; GRAFT		INST CHILD HLTH,DEPT GROWTH & DEV,LONDON WC1N 1EH,ENGLAND; WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of London; University College London; University of Edinburgh	BROWN, P (corresponding author), NINCDS,CENT NERVOUS SYST STUDIES LAB,BLDG 36,ROOM 5B21,BETHESDA,MD 20892, USA.							ANDERSON J R, 1990, Neuropathology and Applied Neurobiology, V16, P543; BERNOULLI C, 1977, LANCET, V1, P478; BUCHANAN CR, 1991, BRIT MED J, V302, P824, DOI 10.1136/bmj.302.6780.824; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; CROXSON M, 1988, NEUROLOGY, V38, P1128, DOI 10.1212/WNL.38.7.1128; DEVILEMEUR B, 1992, REV NEUROL, V148, P328; DEVILLEMEUR TB, 1991, LANCET, V337, P864, DOI 10.1016/0140-6736(91)92583-N; DUFFY P, 1974, NEW ENGL J MED, V290, P692; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; GIBBS CJ, 1985, NEW ENGL J MED, V313, P734, DOI 10.1056/NEJM198509193131207; GOLDFARB LG, IN PRESS PRION DISEA; GORMAN DG, 1992, NEUROLOGY, V42, P463, DOI 10.1212/WNL.42.2.463; KOCH TK, 1985, NEW ENGL J MED, V313, P731, DOI 10.1056/NEJM198509193131206; MACARIO ME, 1991, BRIT MED J, V302, P1149, DOI 10.1136/bmj.302.6785.1149; MARKUS HS, 1992, Q J MED, V82, P43; MARZEWSKI DJ, 1988, NEUROLOGY, V38, P1131, DOI 10.1212/WNL.38.7.1131; MASULLO C, 1989, J NEUROSURG, V71, P954; MILLER DC, 1988, NEW ENGL J MED, V318, P853, DOI 10.1056/NEJM198803313181312; MIYASHITA K, 1991, NEUROLOGY, V41, P940, DOI 10.1212/WNL.41.6.940; NEW MI, 1988, NEUROLOGY, V38, P1133, DOI 10.1212/WNL.38.7.1133; NISBET TJ, 1989, JAMA-J AM MED ASSOC, V261, P1118; POCCHIARI M, 1991, HORM RES, V35, P161, DOI 10.1159/000181894; POWELLJACKSON J, 1985, LANCET, V2, P244; SCHOENE WC, 1981, ARCH NEUROL-CHICAGO, V38, P473, DOI 10.1001/archneur.1981.00510080035002; SITWELL L, 1988, NEW ENGL J MED, V318, P854; TANGE RA, 1990, EUR ARCH OTO-RHINO-L, V247, P199; THADANI V, 1988, J NEUROSURG, V69, P766, DOI 10.3171/jns.1988.69.5.0766; TINTNER R, 1986, NEUROLOGY, V36, P932, DOI 10.1212/WNL.36.7.932; WILL RG, 1982, J NEUROL NEUROSUR PS, V45, P235, DOI 10.1136/jnnp.45.3.235	30	331	357	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					24	27		10.1016/0140-6736(92)92431-E	http://dx.doi.org/10.1016/0140-6736(92)92431-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351607				2022-12-28	WOS:A1992JC35400011
J	CLARK, SG; STERN, MJ; HORVITZ, HR				CLARK, SG; STERN, MJ; HORVITZ, HR			C-ELEGANS CELL-SIGNALING GENE SEM-5 ENCODES A PROTEIN WITH SH2 AND SH3 DOMAINS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; PHOSPHOLIPASE-C; CYTOPLASMIC PROTEIN; SEQUENCE; SRC; SIMILARITY; LINEAGES; ONCOGENE; HOMOLOGY	THE induction of the hermaphrodite vulva 1 and the migration of the sex myoblast 2,3 in the nematode Caenorhabditis elegans are both controlled by intercellular signalling. The gonadal anchor cell induces formation of the vulva from nearby hypodermal cells 4, and a set of somatic gonadal cells attract the migrating sex myoblasts to their final positions 2. Many genes required for vulval induction have been identified 1, including the let-23 receptor tyrosine kinase gene 5-7 and the let-60 ras gene 8-10. We report here the identification and characterization of a new gene, sem-5 (sem, sex muscle abnormal), that acts both in vulval induction and in sex myoblast migration. On the basis of its DNA sequence, sem-5 encodes a novel 228-amino-acid protein which consists almost entirely of one SH2 (SH, src homology region) and two SH3 domains. SH2 and SH3 domains are present in many signalling proteins regulated by receptor and non-receptor tyrosine kinases 11. Mutations that impair sem-5 activity alter residues that are highly conserved among different SH2 and SH3 domains. Our results indicate that the sem-5 gene encodes a novel protein that functions in at least two distinct cell-signalling processes.			CLARK, SG (corresponding author), MIT,DEPT BIOL,HOWARD HUGHES MED INST,ROOM 56-629,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STERN MJ, 1991, DEVELOPMENT, V113, P797; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; [No title captured]	42	577	598	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					340	344		10.1038/356340a0	http://dx.doi.org/10.1038/356340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1372395				2022-12-28	WOS:A1992HK79400065
J	SONG, KN; WANG, YQ; SASSOON, D				SONG, KN; WANG, YQ; SASSOON, D			EXPRESSION OF HOX-7.1 IN MYOBLASTS INHIBITS TERMINAL DIFFERENTIATION AND INDUCES CELL-TRANSFORMATION	NATURE			English	Article							HOMEOBOX GENE; GROWTH-FACTOR; EMBRYOGENESIS; MYOGENIN; FAMILY	THE terminal differentiation of myogenic cells initiates in the proximal portion of the limb bud whereas the distal region remains undifferentiated and proliferative1-3 . The apical ectodermal ridge maintains the progress zone in an undifferentiated state4 and induces proliferation of limb mesenchymal cells5. Hox-7.1, a homeobox-containing gene, is expressed throughout the limb bud when limb outgrowth begins, whereas transcripts are later restricted to distal limb mesenchyme6,7 which is the proposed site of positional specification2. Transplantation of proximal limb bud tissue into the distal portion of the limb results in a re-expression of Hox-7.1 in the transplanted mesenchyme8. Similar grafts result in a positional reassignment to distal structures9 as well as dedifferentiation of the grafted proximal tissue10. Because of the association of Hox-7.1 expression with proliferative and undifferentiated cells, we tested whether Hox-7.1 regulates differentiation by transfection of Hox-7.1 complementary DNA into determined myogenic cells which represent one mesenchymal lineage in the limb. Here we report that forced expression of Hox-7.1 blocks terminal differentiation and results in a corresponding decrease in steady-state levels of MyoD1. Consistent with the association of Hox-7.1 with proliferation, Hox-7.1-expressing cells also acquire a transformed phenotype. Forced expression of Hox-8.1, a related Hox-gene, does not affect terminal differentiation indicating that the effects of Hox-7.1 are specific.			SONG, KN (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, 80 E CONCORD ST, BOSTON, MA 02118 USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM ME, 1984, MOL BIOL DEV, V19, P275; CHEVALLIER A, 1978, ROUX ARCH DEV BIOL, V184, P57, DOI 10.1007/BF00848669; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; HAMPE A, 1960, J EMBRYOL EXP MORPH, V8, P241; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; KIENY M, 1986, BIBL ANAT, V29, P65; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MOORE JW, 1991, DEVELOPMENT, V111, P741; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; Sambrook J, 1989, MOL CLONING LABORATO; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SAUNDERS JW, 1959, DEV BIOL, V1, P281, DOI 10.1016/0012-1606(59)90030-2; SOLURSH M, 1981, DEV BIOL, V86, P471, DOI 10.1016/0012-1606(81)90205-0; SUMMERBELL D, 1972, NATURE-NEW BIOL, V239, P24, DOI 10.1038/newbio239024a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	21	202	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					477	481		10.1038/360477a0	http://dx.doi.org/10.1038/360477a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1360150				2022-12-28	WOS:A1992KA79700064
J	SEMPRINI, AE; LEVISETTI, P; BOZZO, M; RAVIZZA, M; TAGLIORETTI, A; SULPIZIO, P; ALBANI, E; ONETA, M; PARDI, G				SEMPRINI, AE; LEVISETTI, P; BOZZO, M; RAVIZZA, M; TAGLIORETTI, A; SULPIZIO, P; ALBANI, E; ONETA, M; PARDI, G			INSEMINATION OF HIV-NEGATIVE WOMEN WITH PROCESSED SEMEN OF HIV-POSITIVE PARTNERS	LANCET			English	Note								Many HIV-discordant couples want to have children so much that they are willing to abandon condom-protected sexual intercourse irrespective of the risks. Previous testing in our laboratory showed that gradient centrifugation followed by a swim-up procedure effectively removed HIV-1-infected cells from the semen of HIV-seropositive men. 85 HIV-discordant couples were screened for fertility; 29 women were found suitable for a timed in semination course with the processed semen of their HIV-seropositive partner. None of the inseminated women seroconverted, and 17 pregnancies were achieved in 15 women. All 10 babies born to these mothers remain HIV seronegative. The findings may help in the counselling of such couples and also give them hope of having healthy babies.			SEMPRINI, AE (corresponding author), UNIV MILAN,SCH MED,SAN PAOLO BIOMED INST,DEPT OBSTET & GYNAECOL,VIA RUDINI 8,I-21042 MILAN,ITALY.		Setti, Paolo Emanuele Levi/AAB-9718-2019; SEMPRINI, AUGUSTO ENRICO/S-6415-2017	Levi-Setti, Paolo Emanuele/0000-0003-1024-4386; SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012				ANDERSON DJ, 1992, 48TH ANN M AM FERT S; ASHIDA ER, 1987, P NATL ACAD SCI USA, V84, P3395, DOI 10.1073/pnas.84.10.3395; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; SARACCO A, IN PRESS J ACQUIR IM; SEMPRINI AE, 1991, SUCCESSFUL REMOVAL H, P534; SEMPRINI AE, 1990, 6 INT C AIDS SAN FRA, P267; Semprini AE, 1987, C INSERM, V154, P462; WOLFF H, 1988, 4 INT C AIDS STOCKH; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1992, REPORT AIDS CASES	10	260	267	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1317	1319		10.1016/0140-6736(92)92495-2	http://dx.doi.org/10.1016/0140-6736(92)92495-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360037				2022-12-28	WOS:A1992KA26200006
J	LLOYD, DK; PILGRIM, AJ				LLOYD, DK; PILGRIM, AJ			SUMATRIPTAN AND RECURRENCE OF MIGRAINE	LANCET			English	Letter									GLAXO GRP RES LTD,DEPT CARDIOVASC,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline	LLOYD, DK (corresponding author), GLAXO GRP RES LTD,INT MED AFFAIRS,DEPT CARDIOVASC & METAB MED,UXBRIDGE UB11 1BT,MIDDX,ENGLAND.							DAHLOF, 1992, LANCET, V340, P909	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1110	1110		10.1016/0140-6736(92)93144-C	http://dx.doi.org/10.1016/0140-6736(92)93144-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357515				2022-12-28	WOS:A1992JV77500064
J	MANSKE, CL; WANG, Y; RECTOR, T; WILSON, RF; WHITE, CW				MANSKE, CL; WANG, Y; RECTOR, T; WILSON, RF; WHITE, CW			CORONARY REVASCULARIZATION IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH CHRONIC-RENAL-FAILURE	LANCET			English	Article							ARTERY DISEASE; ADRENERGIC MODULATION; POTASSIUM METABOLISM; TRANSPLANTATION	Insulin-dependent diabetic patients found to have substantial coronary artery disease at the time of assessment for renal transplantation have 2-year survival of less than 50%. Because most of these patients have no angina symptoms their management is controversial. We tried to find out whether coronary artery revascularisation in such patients might decrease the combined incidence of unstable angina, myocardial infarction, and cardiac death. 151 consecutive insulin-dependent diabetic candidates for renal transplantation underwent coronary angiography. 31 had stenoses greater than 75% in one or more coronary arteries, atypical chest pain or no chest pain, and a left ventricular ejection fraction greater than 0.35. Of these, 26 agreed to be randomly assigned medical treatment (a calcium-channel-blocking drug plus aspirin) or revascularisation (angioplasty or coronary bypass surgery). 10 of 13 medically managed and 2 of 13 revascularised patients had a cardiovascular endpoint within a median of 8.4 months of coronary angiography (p<0.01). 4 medically managed patients died of myocardial infarction during follow-up. Thus, revascularisation decreased the frequency of cardiac events in insulin-dependent diabetic patients with chronic renal failure and symptomless coronary artery stenoses. These findings suggest that diabetic renal transplant candidates should be screened for silent coronary artery disease, because revascularisation may decrease cardiac morbidity and mortality in this population.			MANSKE, CL (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,BOX 736 UMHC,516 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NCRR NIH HHS [MOI RR004400] Funding Source: Medline; NHLBI NIH HHS [HL 39185] Funding Source: Medline; NIDDK NIH HHS [DK13038] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039185, R55HL039185] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT WM, 1978, AM J MED, V65, P779, DOI 10.1016/0002-9343(78)90796-9; BOUDREAU RJ, 1990, RADIOLOGY, V175, P103, DOI 10.1148/radiology.175.1.2315467; BRAUN WE, 1983, TRANSPLANT P, V15, P1114; BRAUN WE, 1984, TRANSPLANT P, V16, P603; CASTELLINO P, 1990, KIDNEY INT, V37, P793, DOI 10.1038/ki.1990.47; CASTELLINO P, 1987, AM J PHYSIOL, V252, pE68, DOI 10.1152/ajpendo.1987.252.1.E68; KAPLAN EL, 1958, J AM STAT ASSOC, V88, P346; LORBER MI, 1987, TRANSPLANT P, V19, P1539; MACHIN D, 1988, BRIT MED J, V296, P1369, DOI 10.1136/bmj.296.6633.1369; MARWICK TH, 1990, TRANSPLANTATION, V49, P100, DOI 10.1097/00007890-199001000-00022; MOLLEY JL, 1991, AM J MED, V90, P563; MORROW CE, 1983, AM J SURG, V146, P331, DOI 10.1016/0002-9610(83)90409-9; NESTO RW, 1986, AM J MED, V80, P40, DOI 10.1016/0002-9343(86)90451-1; PETO R, 1972, J R STAT SOC A STAT, V135, P135; PHILIPSON JD, 1986, AM J MED, V81, P630, DOI 10.1016/0002-9343(86)90549-8; ROSA RM, 1980, NEW ENGL J MED, V302, P431, DOI 10.1056/NEJM198002213020803; SUBRAMANIAN UB, 1981, AM J CARDIOL, V48, P797; WEINRAUCH L, 1978, CIRCULATION, V58, P1184, DOI 10.1161/01.CIR.58.6.1184; WEINRAUCH LA, 1978, ANN INTERN MED, V88, P346, DOI 10.7326/0003-4819-88-3-346; 1987, ARCH INTERN MED, V147, P830; 1990, ANN DATA REPORT	21	285	289	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					998	1002		10.1016/0140-6736(92)93010-K	http://dx.doi.org/10.1016/0140-6736(92)93010-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357450				2022-12-28	WOS:A1992JV01400004
J	KAHN, JO; LAGAKOS, SW; RICHMAN, DD; CROSS, A; PETTINELLI, C; LIOU, SH; BROWN, M; VOLBERDING, PA; CRUMPACKER, CS; BEALL, G; SACKS, HS; MERIGAN, TC; BELTANGADY, M; SMALDONE, L; DOLIN, R				KAHN, JO; LAGAKOS, SW; RICHMAN, DD; CROSS, A; PETTINELLI, C; LIOU, SH; BROWN, M; VOLBERDING, PA; CRUMPACKER, CS; BEALL, G; SACKS, HS; MERIGAN, TC; BELTANGADY, M; SMALDONE, L; DOLIN, R			A CONTROLLED TRIAL COMPARING CONTINUED ZIDOVUDINE WITH DIDANOSINE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; TOXICITY; INVITRO; THERAPY; HIV; 2',3'-DIDEOXYINOSINE; INHIBITION	Background, Although zidovudine is effective in patients with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment from zidovudine to didanosine. Methods. This multicenter, double-blind study involved 913 patients who had tolerated zidovudine for at least 16 weeks. The patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex with less-than-or-equal-to 300 CD4 cells per cubic millimeter, or asymptomatic HIV infection with less-than-or-equal-to 200 CD4 cells per cubic millimeter. They were randomly assigned to receive 600 mg per day of zidovudine, 750 mg per day of didanosine, or 500 mg per day of didanosine. Results. There were significantly fewer new AIDS-defining events and deaths among the 298 subjects assigned to 500 mg per day of didanosine than among the subjects who continued to receive zidovudine (relative risk, 1.39; 95 percent confidence interval, 1.06 to 1.82; P = 0.015). With 750 mg of didanosine, there was no clear benefit over zidovudine (relative risk, 1.10; 95 percent confidence interval, 0.86 to 1.42). The efficacy of didanosine was unrelated to the duration of previous zidovudine treatment. In the two didanosine groups, there were improvements in the number of CD4 cells (P<0.001 for both groups) and in p24 antigen levels (P = 0.03 in the 500-mg group; P = 0.005 in the 750-mg group), as compared with the zidovudine group. Conclusions. Changing treatment from zidovudine to 500 mg per day of didanosine appears to slow the progression of HIV disease.	UNIV ROCHESTER,ROCHESTER,NY 14627; VET AFFAIRS MED CTR,SAN DIEGO,CA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,WALLINGFORD,CT; STANFORD UNIV,STANFORD,CA 94305; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509; HARVARD UNIV,BOSTON,MA 02115; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103; NIAID,DIV AIDS,BETHESDA,MD 20892	University of Rochester; US Department of Veterans Affairs; Veterans Health Administration (VHA); Bristol-Myers Squibb; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KAHN, JO (corresponding author), SAN FRANCISCO GEN HOSP,AIDS PROGRAM,WARD 84,995 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.		Merigan, Thomas/AGQ-7464-2022					AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; [Anonymous], 1991, NEUROLOGY, V41, P778; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COX DR, 1972, J R STAT SOC B, V34, P187; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAGAKOS SW, 1990, STAT MED, V9, P1417, DOI 10.1002/sim.4780091204; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MOLINA JM, 1989, NEW ENGL J MED, V321, P1478; PETO R, 1977, BRIT J CANCER, V5, P1; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1990, AM J MED, V88, pS8, DOI 10.1016/0002-9343(90)90414-9; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI LJ, 1985, BIOMETRIKA, V72, P359; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; 1987, MMWR MORB MORTAL W S, V36, pS1	37	365	368	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					581	587		10.1056/NEJM199208273270901	http://dx.doi.org/10.1056/NEJM199208273270901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1353607				2022-12-28	WOS:A1992JK20400001
J	HENRY, JA; JEFFREYS, KJ; DAWLING, S				HENRY, JA; JEFFREYS, KJ; DAWLING, S			TOXICITY AND DEATHS FROM 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)	LANCET			English	Article							MDMA ECSTASY; METHYLENEDIOXYMETHAMPHETAMINE MDMA; HYPERTHERMIA; PSYCHOSIS; NEUROTOXICITY; TERMINALS	The risk of adverse reactions to 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as ''ecstasy'', is now widely known in both the USA and UK, but the patterns of illness remain varied. We report our experience during 1990 and 1991. There has been a recent increase in cases of severe toxicity following recreational misuse of small amounts of MDMA. Among 7 fatalities, the pattern of toxicity included fulminant hyperthermia, convulsions, disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. Until now, there have been few reports of this type of toxicity from MDMA, which may be related both to the potential of the drug to alter thermoregulation and to the circumstances of misuse. In addition, we have monitored 7 cases of hepatotoxicity and suspect that the frequency of this complication is increasing; a history of MDMA misuse should be sought in young people presenting with unexplained jaundice or hepatomegaly. We also describe 5 subjects involved in road traffic accidents in whom MDMA was identified. Misuse of MDMA can have severe acute toxic effects; few data are available concerning long-term morbidity, and this deserves close monitoring in future.			HENRY, JA (corresponding author), GUYS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND.							BENAZZI F, 1991, LANCET, V338, P1520, DOI 10.1016/0140-6736(91)92332-V; BROWN C, 1987, JAMA-J AM MED ASSOC, V258, P780, DOI 10.1001/jama.258.6.780; CAMPKIN NTA, 1992, J ROY SOC MED, V85, P61; CHADWICK IS, 1991, J ROY SOC MED, V84, P371, DOI 10.1177/014107689108400622; CREIGHTON FJ, 1991, BRIT J PSYCHIAT, V159, P713, DOI 10.1192/bjp.159.5.713; DOWLING GP, 1987, JAMA-J AM MED ASSOC, V257, P1615, DOI 10.1001/jama.257.12.1615; FAHAL IH, 1992, BRIT MED J, V305, P29, DOI 10.1136/bmj.305.6844.29; GINSBERG MD, 1970, ANN INTERN MED, V73, P81, DOI 10.7326/0003-4819-73-1-81; GORDON CJ, 1991, PHARMACOL BIOCHEM BE, V38, P339, DOI 10.1016/0091-3057(91)90288-D; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; MCGUIRE P, 1991, BRIT MED J, V302, P697, DOI 10.1136/bmj.302.6778.697; OHEARN E, 1988, J NEUROSCI, V8, P2788; PEROUTKA SJ, 1987, NEW ENGL J MED, V317, P1542; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; SCHMIDT CJ, 1990, BRAIN RES, V529, P85, DOI 10.1016/0006-8993(90)90813-Q; SUAREZ RV, 1988, AM J FOREN MED PATH, V9, P339, DOI 10.1097/00000433-198812000-00015; WHITAKERAZMITIA PM, 1989, AM J PSYCHIAT, V146, P119	18	546	556	0	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					384	387		10.1016/0140-6736(92)91469-O	http://dx.doi.org/10.1016/0140-6736(92)91469-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353554				2022-12-28	WOS:A1992JJ44900002
J	MOLLER, JC; NACHTRODT, G; RICHTER, A; TEGTMEYER, FK				MOLLER, JC; NACHTRODT, G; RICHTER, A; TEGTMEYER, FK			PROPHYLACTIC VANCOMYCIN TO PREVENT STAPHYLOCOCCAL SEPTICEMIA IN VERY-LOW-BIRTH-WEIGHT INFANTS	LANCET			English	Letter							COAGULASE-NEGATIVE STAPHYLOCOCCI; INTENSIVE-CARE UNIT; BACTEREMIA; RESISTANCE				MOLLER, JC (corresponding author), UNIV LUBECK,SCH MED,PAEDIATR CLIN,W-2400 LUBECK,GERMANY.							BARD H, 1973, ARCH DIS CHILD, V48, P630, DOI 10.1136/adc.48.8.630; FLEER A, 1983, PEDIATR INFECT DIS J, V2, P426, DOI 10.1097/00006454-198311000-00003; FREEMAN J, 1990, AM J DIS CHILD, V144, P324, DOI 10.1001/archpedi.1990.02150270074029; ODIO C, 1984, AM J DIS CHILD, V138, P17, DOI 10.1001/archpedi.1984.02140390009004; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; WATANAKUNAKORN C, 1990, J ANTIMICROB CHEMOTH, V25, P69, DOI 10.1093/jac/25.1.69	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					424	424		10.1016/0140-6736(92)91502-Y	http://dx.doi.org/10.1016/0140-6736(92)91502-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353571				2022-12-28	WOS:A1992JJ44900028
J	SURPRENANT, A; HORSTMAN, DA; AKBARALI, H; LIMBIRD, LE				SURPRENANT, A; HORSTMAN, DA; AKBARALI, H; LIMBIRD, LE			A POINT MUTATION OF THE ALPHA-2-ADRENOCEPTOR THAT BLOCKS COUPLING TO POTASSIUM BUT NOT CALCIUM CURRENTS	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; BINDING PROTEIN; ADENYLYL CYCLASE; LIGAND-BINDING; ALPHA-SUBUNITS; INHIBITION; IDENTIFICATION; GI2; SOMATOSTATIN	The alpha-2A-adrenergic receptor (adrenoceptor) was stably expressed in AtT20 mouse pituitary tumor cells; adrenoceptor agonists inhibited adenylyl cyclase, inhibited voltage-dependent calcium currents, and increased inwardly rectifying potassium currents. An aspartic acid residue (Asp79) highly conserved among guanine nucleotide-binding protein (G protein)-coupled receptors was mutated to asparagine; in cells transfected with the mutant alpha-2-receptor, agonists inhibited adenylyl cyclase and calcium currents but did not increase potassium currents. Because distinct G proteins appear to couple adrenoceptors to potassium and calcium currents, the present findings suggest that the mutant alpha-2-adrenoceptor cannot achieve the conformation necessary to activate G proteins that mediate potassium channel activation.	UNIV CALGARY, DEPT MED PHYSIOL, CALGARY T2N 4N1, ALBERTA, CANADA; VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA	University of Calgary; Vanderbilt University	SURPRENANT, A (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		Akbarali, Hamid/Q-9344-2019; Akbarali, Hamid I/B-3236-2012	Akbarali, Hamid/0000-0003-1423-0774				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN DA, 1989, ANN NY ACAD SCI, V560, P358; BROWN DA, 1990, ANNU REV PHYSIOL, V52, P215; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HARRIS GC, 1992, J PHARMACOL EXP THER, V261, P476; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEFKOWITZ RJ, 1987, RECENT PROG HORM RES, V43, P469; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUINI A, 1986, J NEUROSCI, V6, P3128; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; PENNEFATHER PS, 1988, BRAIN RES, V444, P346, DOI 10.1016/0006-8993(88)90944-4; REISINE T, 1985, ENDOCRINOLOGY, V116, P2259, DOI 10.1210/endo-116-6-2259; SHEN KZ, 1990, BRIT J PHARMACOL, V101, P925, DOI 10.1111/j.1476-5381.1990.tb14182.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STACK J, 1990, THESIS OREGON HLTH S; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURPRENANT A, 1988, PROC R SOC SER B-BIO, V234, P85, DOI 10.1098/rspb.1988.0039; SURPRENANT A, 1989, SEMIN NEUROSCI, V1, P126; TALLENT M, 1992, MOL PHARMACOL, V41, P452; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	37	132	134	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					977	980		10.1126/science.1354394	http://dx.doi.org/10.1126/science.1354394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1354394				2022-12-28	WOS:A1992JH82700039
J	SNOW, RW; ARMSTRONG, JRM; FORSTER, D; WINSTANLEY, MT; MARSH, VM; NEWTON, CRJC; WARUIRU, C; MWANGI, I; WINSTANLEY, PA; MARSH, K				SNOW, RW; ARMSTRONG, JRM; FORSTER, D; WINSTANLEY, MT; MARSH, VM; NEWTON, CRJC; WARUIRU, C; MWANGI, I; WINSTANLEY, PA; MARSH, K			CHILDHOOD DEATHS IN AFRICA - USES AND LIMITATIONS OF VERBAL AUTOPSIES	LANCET			English	Article							PRIMARY HEALTH-CARE; RURAL AREA; MORTALITY; CHILDREN; COMMUNITY; EPIDEMIOLOGY; BANGLADESH; TRIAL	The verbal autopsy (VA) is an epidemiological tool that is widely used to ascribe causes of death by interviewing bereaved relatives of children who were not under medical supervision at the time of death. This technique was assessed by comparison with a prospective survey of 303 childhood deaths at a district hospital in Kenya where medically confirmed diagnoses were available. Common causes of death were detected by VA with specificities greater than 80%. Sensitivity of the VA technique was greater than 75% for measles, neonatal tetanus, malnutrition, and trauma-related deaths; however, malaria, anaemia, acute respiratory-tract infection, gastroenteritis, and meningitis were detected with sensitivities of less than 50%. There may have been unwarranted optimism in the ability of VAs to detect some of the major causes of death, such as malaria, in African children. VA used in malaria-specific intervention trials should be interpreted with caution and only in the light of known sensitivities and specificities.	UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, TROP HLTH EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND	University of Oxford; University of London; London School of Hygiene & Tropical Medicine	SNOW, RW (corresponding author), KENYA GOVT MED RES CTR, COASTAL UNIT, POB 230, KILIFI, KENYA.		Newton, Charles/C-6222-2009; Snow, Robert William/AFR-1436-2022; Newton, Charles RJC/B-7578-2014	Snow, Robert William/0000-0003-3725-6088; Newton, Charles RJC/0000-0002-6999-5507; Marsh, Vicki/0000-0002-5178-4250	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; CHEN LC, 1980, INT J EPIDEMIOL, V9, P25, DOI 10.1093/ije/9.1.25; FAUVEAU V, 1989, INT J EPIDEMIOL, V18, P139, DOI 10.1093/ije/18.1.139; FIVAWO M, 1986, PRACTICAL CONSIDERAT, P76; GAURENNE M, 1986, ASSESSING PROBABLE C; GRAY RH, 1990, USE VERBAL AUTOPSIES; GREENWOOD BM, 1988, LANCET, V1, P1121; GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91, DOI 10.1080/02724936.1987.11748482; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; MIRZA NM, 1990, E AFR MED J, V67, P693; MOIR JS, 1989, ANN TROP MED PARASIT, V83, P305, DOI 10.1080/00034983.1989.11812349; MTANGO FDE, 1986, T ROY SOC TROP MED H, V80, P851, DOI 10.1016/0035-9203(86)90241-5; OMONDIODHIAMBO AM, 1984, MATERNAL CHILD HLTH; PACQUEMARGOLIS S, 1990, SOC SCI MED, V31, P585, DOI 10.1016/0277-9536(90)90094-9; SNOW RW, 1992, HLTH POL PLAN, V7, P67; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; VICTORA CG, 1987, LANCET, V2, P319; 1989, TDRMAPAVEPF1895 WHO; [No title captured]; 1991, GUIDELINES DEV PROTO; [No title captured]	23	246	247	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1992	340	8815					351	355		10.1016/0140-6736(92)91414-4	http://dx.doi.org/10.1016/0140-6736(92)91414-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353814				2022-12-28	WOS:A1992JH12500013
J	SWERDLOW, DL; MINTZ, ED; RODRIGUEZ, M; TEJADA, E; OCAMPO, C; ESPEJO, L; GREENE, KD; SALDANA, W; SEMINARIO, L; TAUXE, RV; WELLS, JG; BEAN, NH; RIES, AA; POLLACK, M; VERTIZ, B; BLAKE, PA				SWERDLOW, DL; MINTZ, ED; RODRIGUEZ, M; TEJADA, E; OCAMPO, C; ESPEJO, L; GREENE, KD; SALDANA, W; SEMINARIO, L; TAUXE, RV; WELLS, JG; BEAN, NH; RIES, AA; POLLACK, M; VERTIZ, B; BLAKE, PA			WATERBORNE TRANSMISSION OF EPIDEMIC CHOLERA IN TRUJILLO, PERU - LESSONS FOR A CONTINENT AT RISK	LANCET			English	Article							BIOTYPE EL-TOR; VIBRIO-CHOLERAE; UNITED-STATES; SLUMS	The epidemic of cholera that began in Peru in January, 1991, marked the first such epidemic in South America this century. Subsequently, over 533 000 cases and 4700 deaths have been reported from nineteen countries in that hemisphere. We investigated the epidemic in Trujillo, the second largest city in Peru. Trujillo's water supply was unchlorinated and water contamination was common. Suspect cholera cases were defined as persons presenting to a health facility with acute diarrhoea between Feb 1, and March 31, 1991. We studied a cohort of 150 patients who had been admitted to hospital and conducted a matched case-control study with 46 cases and 65 symptom-free and serologically uninfected controls; we also carried out a water quality study. By March 31, 1991, 16 400 cases of suspected cholera (attack rate 2.6%), 6673 hospital admissions, and 71 deaths (case-fatality rate 0.4%) had been reported in the province of Trujillo. 79% of stool cultures of patients with diarrhoea presenting to a single hospital yielded Vibrio cholerae O1. In the case-control study, drinking unboiled water (odds ratio [OR] 3.1, 95% confidence interval [CI] 1.3-7.3), drinking water from a household water storage container in which hands had been introduced into the water (4.2, 1.2-14.9), and going to a fiesta (social event) (3.6, 1.1-11.1) were associated with illness. The water quality study showed progressive contamination during distribution and storage in the home: faecal coliform counts were highest in water from household storage containers and lowest in city well water. V cholerae 01, biotype El Tor, serotype Inaba, was isolated from three city water samples. Cholera control measures in Trujillo should focus on treatment of water and prevention of contamination during distribution and in the home. Trujillo's water and sanitation problems are common in South America; similar control measures are needed throughout the continent to prevent spread of epidemic cholera.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; UNIDADE DEPT SALUD,TRUJILLO,PERU; NATL UNIV TRUJILLO,TRUJILLO,PERU; MINIST HLTH,GEN OFF EPIDEMIOL,LIMA,PERU; HOSP BELEN,TRUJILLO,PERU	Centers for Disease Control & Prevention - USA; Universidad Nacional de Trujillo	SWERDLOW, DL (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ENTER DIS BRANCH,ATLANTA,GA 30333, USA.							[Anonymous], 1989, STANDARD METHODS EXA, V17th; BARRETT TJ, 1981, J CLIN MICROBIOL, V13, P126, DOI 10.1128/JCM.13.1.126-129.1981; BARRY AL, 1985, MANUAL CLIN MICROBIO, P878; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; CLEMENTS ML, 1982, J INFECT DIS, V145, P465, DOI 10.1093/infdis/145.4.465; COHEN J, 1971, LANCET, V2, P86; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; DEB BC, 1982, INDIAN J MED RES, V76, P814; Feachem R, 1981, Trop Dis Bull, V78, P865; GERICHTER CB, 1975, ISRAEL J MED SCI, V11, P889; HARRIS JR, 1986, AM J EPIDEMIOL, V123, P424, DOI 10.1093/oxfordjournals.aje.a114257; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; PAVIA AT, 1987, JAMA-J AM MED ASSOC, V258, P2374, DOI 10.1001/jama.1987.03400170060012; RICE EW, 1991, LANCET, V338, P455, DOI 10.1016/0140-6736(91)91086-A; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SACK DA, 1980, J CLIN MICROBIOL, V11, P35, DOI 10.1128/JCM.11.1.35-40.1980; SNYDER JD, 1981, J INFECT DIS, V143, P182, DOI 10.1093/infdis/143.2.182; SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P730, DOI 10.1128/AEM.42.4.730-733.1981; STLOUIS ME, 1990, AM J EPIDEMIOL, V13, P719; WACHSMUTH IK, 1991, LANCET, V337, P1097; YOUNG CR, 1986, MANUAL CLIN LABORATO, P363; 1991, MMWR, V40, P108; 1991, MMWR, V40, P287; 1991, MMWR, V40, P516; 1991, MMWR, V40, P860	25	156	159	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					28	32		10.1016/0140-6736(92)92432-F	http://dx.doi.org/10.1016/0140-6736(92)92432-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351608				2022-12-28	WOS:A1992JC35400012
J	NAKAMURA, S; SAKURADA, S; SALAHUDDIN, SZ; OSADA, Y; TANAKA, NG; SAKAMOTO, N; SEKIGUCHI, M; GALLO, RC				NAKAMURA, S; SAKURADA, S; SALAHUDDIN, SZ; OSADA, Y; TANAKA, NG; SAKAMOTO, N; SEKIGUCHI, M; GALLO, RC			INHIBITION OF DEVELOPMENT OF KAPOSIS-SARCOMA RELATED LESIONS BY A BACTERIAL-CELL WALL COMPLEX	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LONG-TERM CULTURE; HOMOSEXUAL MEN; ANGIOGENESIS; THERAPY; GROWTH	In vitro and in vivo model systems for the study of human immunodeficiency virus (HIV-associated Kaposi's sarcoma (KS) were used to evaluate compounds for their potential as therapeutic agents. A sulfated polysaccharide-peptidoglycan compound (SP-PG) produced by bacteria controlled the in vitro growth of acquired immunodeficiency syndrome (AIDS)-associated, KS-derived spindle-shaped cells (AIDS-KS cells) at noncytotoxic concentrations. Angiogenesis induced by AIDS-KS cells in the chicken chorioallantoic membrane assay was blocked by SP-PG, which also inhibited the vascular hyperpermeability response and the angiogenesis associated with the induction of KS-like lesions that develop after subcutaneous inoculation of AIDS-KS cells into nude mice. Suramin, pentosan polysulfate, and interferon-alpha, which are currently in use for therapy of KS, were either less effective than SP-PG or much more cytotoxic, or both.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; UNIV SO CALIF,DEPT INTERNAL MED,LOS ANGELES,CA 90089; DAIICHI PHARMACEUT CO LTD,TOKYO 103,JAPAN; HUNTINGTON MEM HOSP,INST MOLEC MED & TECHNOL,PASADENA,CA 91105	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; Daiichi Sankyo Company Limited; University of Southern California; Huntington Memorial Hospital								BIESERT L, 1988, AIDS, V2, P449, DOI 10.1097/00002030-198812000-00007; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; GALLO RC, 1989, 4 C CENT GARD, P113; GILL P, 1990, AM J CLIN ONCOL-CANC, V13, P315, DOI 10.1097/00000421-199008000-00010; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INOUE K, 1982, J BIOCHEM-TOKYO, V92, P1775, DOI 10.1093/oxfordjournals.jbchem.a134107; KROWN SE, 1983, NEW ENGL J MED, V308, P1071, DOI 10.1056/NEJM198305053081806; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCNUTT NS, 1983, AM J PATHOL, V111, P62; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; NAKAMURA S, UNPUB; SAKURADA S, UNPUB; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SATO K, 1989, J PHARM SCI, V78, P11, DOI 10.1002/jps.2600780105; TANAKA N, 1989, CANCER RES, V49, P6726; TANAKA NG, 1991, INT J RADIAT BIOL, V60, P79, DOI 10.1080/09553009114551601; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335; YARCHOAN R, COMMUNICATION	23	84	90	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1437	1440		10.1126/science.1371891	http://dx.doi.org/10.1126/science.1371891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1371891				2022-12-28	WOS:A1992HH74400058
J	PORTER, SB; SANDE, MA				PORTER, SB; SANDE, MA			TOXOPLASMOSIS OF THE CENTRAL-NERVOUS-SYSTEM IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; MAINTENANCE THERAPY; CEREBRAL TOXOPLASMOSIS; AIDS PATIENTS; ENCEPHALITIS; PYRIMETHAMINE; CLINDAMYCIN; EFFICACY; COMBINATION	Background and Methods. Toxoplasmosis is the most common opportunistic infection of the central nervous system in patients with the acquired immunodeficiency syndrome (AIDS). To investigate its clinical course, we reviewed the records of 115 patients with AIDS and central nervous system toxoplasmosis treated at San Francisco General Hospital between 1981 and 1990. Results. The most common presenting symptoms were headache (in 55 percent), confusion (52 percent), and fever (47 percent). Focal neurologic deficits were present in 79 patients (69 percent). The median CD4 cell count at presentation was 50 per cubic millimeter (50x10(6) per liter). Thirteen of 80 patients with clinical toxoplasmosis (16 percent) and 4 of 18 patients with pathologically proved disease (22 percent) had undetectable antitoxoplasma IgG antibodies by indirect immunofluorescence assay. Of 103 patients, 94 (91 percent) had enhancing lesions on CT. Single lesions were seen in 28 of 103 patients (27 percent) on CT, and such lesions were seen in 3 of 21 patients (14 percent) on magnetic resonance imaging. Over 90 percent of patients who eventually had clinical and radiographic improvement had evidence of improvement by day 14 of therapy. Adverse drug reactions occurred in 71 patients (62 percent) and led to a change in therapy in 50 patients (43 percent). Among the patients who survived a first episode of toxoplasmosis, the median survival was 265 days. Conclusions. Toxoplasmosis occurs in advanced stages of human immunodeficiency virus infection, and the absence of antitoxoplasma antibodies on immunofluorescence assay does not exclude the diagnosis. The clinical and radiographic response to therapy is usually rapid, but treatment is frequently limited by adverse drug effects.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SANDE, MA (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,RM 5H22,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							CARRAZANA EJ, 1989, CLIN NEUROL NEUROSUR, V91, P291, DOI 10.1016/0303-8467(89)90004-8; CIRICILLO SF, 1971, J NEUROSURG, V74, P1029; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DINA TS, 1991, RADIOLOGY, V179, P823, DOI 10.1148/radiology.179.3.2027999; FOPPA CU, 1991, EUR J CLIN MICROBIOL, V10, P187, DOI 10.1007/BF01964458; GONZALEZCLEMENTE JM, 1990, MED CLIN-BARCELONA, V95, P441; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; KATLAMA C, 1991, EUR J CLIN MICROBIOL, V10, P189, DOI 10.1007/BF01964459; LEPORT C, 1989, J INFECT DIS, V160, P557, DOI 10.1093/infdis/160.3.557; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVY RM, 1988, J ACQ IMMUN DEF SYND, V1, P41; LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MILLER CN, 1990, 30TH INT C ANT AG CH; NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; WANKE C, 1987, AM J TROP MED HYG, V36, P509, DOI 10.4269/ajtmh.1987.36.509; WONG B, 1984, ANN INTERN MED, V100, P36, DOI 10.7326/0003-4819-100-1-36	20	455	467	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1643	1648		10.1056/NEJM199212033272306	http://dx.doi.org/10.1056/NEJM199212033272306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1359410				2022-12-28	WOS:A1992KA26000006
J	LEHNER, T; BERGMEIER, LA; PANAGIOTIDI, C; TAO, L; BROOKES, R; KLAVINSKIS, LS; WALKER, P; WALKER, J; WARD, RG; HUSSAIN, L; GEARING, AJH; ADAMS, SE				LEHNER, T; BERGMEIER, LA; PANAGIOTIDI, C; TAO, L; BROOKES, R; KLAVINSKIS, LS; WALKER, P; WALKER, J; WARD, RG; HUSSAIN, L; GEARING, AJH; ADAMS, SE			INDUCTION OF MUCOSAL AND SYSTEMIC IMMUNITY TO A RECOMBINANT SIMIAN IMMUNODEFICIENCY VIRAL PROTEIN	SCIENCE			English	Article							VIRUS-LIKE PARTICLES; CHOLERA-TOXIN; MACAQUE MONKEYS; IGG ANTIBODIES; RETROVIRUS; VACCINE; ANTIGEN; AIDS; IMMUNIZATION; EXPRESSION	Heterosexual transmission through the cervico-vaginal mucosa is the principal route of human immunodeficiency virus (HIV) infection in Africa and is increasing in the United States and Europe. Vaginal immunization with simian immunodeficiency virus (SIV) had not yet been studied in nonhuman primates. Immune responses in macaques were investigated by stimulation of the genital and gut-associated lymphoid tissue with a recombinant, particulate SIV antigen. Vaginal, followed by oral, administration of the vaccine elicited three types of immunity: (i) gag protein p27-specific, secretory immunoglobulin A (IgA) and immunoglobulin G (IgG) in the vaginal fluid, (ii) specific CD4+ T cell proliferation and helper function in B cell p27-specific IgA synthesis in the genital lymph nodes, and (iii) specific serum IgA and IgG, with CD4+ T cell proliferative and helper functions in the circulating blood.	BRITISH BIOTECHNOL LTD, COWLEY OX4 5LY, OXON, ENGLAND		LEHNER, T (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DIV IMMUNOL, LONDON BRIDGE, LONDON SE1 9RT, ENGLAND.			Brookes, Roger/0000-0002-5361-0617; Klavinskis, Linda S./0000-0001-5828-6978				ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; ALMOND N, 1990, J VIROL METHODS, V28, P305, DOI 10.1016/0166-0934(90)90124-X; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BELL EB, 1967, NATURE, V214, P423, DOI 10.1038/214423a0; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; BURNS NR, 1990, J MOL BIOL, V216, P207, DOI 10.1016/S0022-2836(05)80308-0; BURNS NR, 1991, METHOD MOL BIOL, V8, P277; CULLITON BJ, 1991, NATURE, V352, P15, DOI 10.1038/352015a0; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; ELSON CO, 1984, J IMMUNOL, V133, P2892; FELLOWES R, 1990, J IMMUNOL METHODS, V132, P165, DOI 10.1016/0022-1759(90)90026-R; GRIFFITHS JC, 1991, J VIROL, V65, P450, DOI 10.1128/JVI.65.1.450-456.1991; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; LANDE IJM, 1986, J REPROD IMMUNOL, V9, P57, DOI 10.1016/0165-0378(86)90025-2; Lehner T, 1992, VACCINE RES, V3, P319; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LYCKE N, 1986, IMMUNOLOGY, V59, P301; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER MD, 1990, J IMMUNOL, V144, P122; MILLS KHG, 1991, J IMMUNOL, V147, P3560; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; OGRA PL, 1973, J IMMUNOL, V110, P1307; PARR EL, 1988, J REPROD IMMUNOL, V14, P165, DOI 10.1016/0165-0378(88)90067-8; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STURN B, 1978, MED MICROBIOL IMMUN, V165, P119, DOI 10.1007/BF02122747; WIRA CR, 1989, IMMUNOLOGY, V68, P24; WIRA CR, 1987, J IMMUNOL, V138, P4159; YANG SL, 1979, FERTIL STERIL, V32, P588	32	144	152	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1365	1369		10.1126/science.1360702	http://dx.doi.org/10.1126/science.1360702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1360702				2022-12-28	WOS:A1992JY95800041
J	WOLLE, D; DEAN, DR; HOWARD, JB				WOLLE, D; DEAN, DR; HOWARD, JB			NUCLEOTIDE IRON-SULFUR CLUSTER SIGNAL TRANSDUCTION IN THE NITROGENASE IRON-PROTEIN - THE ROLE OF ASP(125)	SCIENCE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; AZOTOBACTER-VINELANDII; FE-PROTEIN; ADENOSINE 5'-TRIPHOSPHATE; KLEBSIELLA-PNEUMONIAE; BINDING; MGATP; MECHANISM; LIGANDS	Electron transfer in nitrogenase involves a gating process initiated by MgATP (magnesium adenosine triphosphate) binding to Fe-protein. The redox site, an 4Fe:4S cluster, is structurally separated from the MgATP binding site. For MgATP hydrolysis to be coupled to electron transfer, a signal transduction mechanism is proposed that is similar to that in guanosine triphosphatase proteins. Based on the three-dimensional structure of Fe-protein, Asp125 is likely to be part of a putative transduction path. Altered Fe-protein with Glu replacing Asp has been prepared and retains the ability for the initial nucleotide-dependent conformational change. However, either MgADP or MgATP can induce the shift and Mg binding to the nucleotide is no longer essential.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061	Virginia Polytechnic Institute & State University								BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; DEITS TL, 1989, J BIOL CHEM, V264, P6619; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HIROSE M, 1971, BIOCHIM BIOPHYS ACTA, V251, P376, DOI 10.1016/0005-2795(71)90125-5; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; IMPERIAL J, 1988, NITROGEN FIXATION 10, P128; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWE D, 1984, MOLYBDENUM ENZYMES, P222; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Press WH, 1986, NUMERICAL RECIPES AR, P521; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; THORNELEY RNF, 1989, BIOCHEM J, V264, P657, DOI 10.1042/bj2640657; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; TSO MYW, 1973, BIOCHIM BIOPHYS ACTA, V309, P263, DOI 10.1016/0005-2744(73)90024-7; WALKER G, 1974, BIOCHEMISTRY-US, V13, P1872; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WOLLE D, 1992, J BIOL CHEM, V267, P3667; YATES G, 1992, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	33	75	75	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					992	995		10.1126/science.1359643	http://dx.doi.org/10.1126/science.1359643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359643				2022-12-28	WOS:A1992JW79600034
J	VACHON, G; COHEN, B; PFEIFLE, C; MCGUFFIN, ME; BOTAS, J; COHEN, SM				VACHON, G; COHEN, B; PFEIFLE, C; MCGUFFIN, ME; BOTAS, J; COHEN, SM			HOMEOTIC GENES OF THE BITHORAX COMPLEX REPRESS LIMB DEVELOPMENT IN THE ABDOMEN OF THE DROSOPHILA EMBRYO THROUGH THE TARGET GENE DISTAL-LESS	CELL			English	Article							SEGMENT-POLARITY GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ULTRABITHORAX PROTEINS; HOMEODOMAIN PROTEINS; IMAGINAL DISKS; FUSHI-TARAZU; MELANOGASTER; EXPRESSION; WINGLESS	Homeotic genes encode transcription factors that are thought to specify segmental identity by regulating expression of subordinate genes. Limb development is repressed in the abdominal segments of the Drosophila embryo by the hometic genes of the Bithorax complex (BX-C). Localized expression of the homeobox gene Distal-less (DII) is required for leg development in thoracic segments. We have identified a minimal cis-regulatory enhancer element that directs DII expression in the larval leg primordia. We present evidence that the BX-C proteins repress DII expression in abdominal segments by binding to a small number of specific sites in this element. Mutating these sites eliminates BX-C protein binding and renders the element insensitive to BX-C-mediated repression in vivo. Repression of limb development in the abdomen appears to be controlled at the DII enhancer. Thus DII may serve as a downstream target gene through which the homeotic genes control abdominal segment identity in the Drosophila embryo.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	VACHON, G (corresponding author), BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; CASANOVA J, 1987, EMBO J, V6, P3103, DOI 10.1002/j.1460-2075.1987.tb02619.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON ML, 1989, CELL, V57, P1045, DOI 10.1016/0092-8674(89)90342-5; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SIMCOX AA, 1991, MECH DEVELOP, V34, P11, DOI 10.1016/0925-4773(91)90087-M; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THALI M, 1988, NATURE, V336, P598, DOI 10.1038/336598a0; THUMMEL C, 1992, IN PRESS DROS INF SE; TREISMAN J, 1989, CELL, V59, P553; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wieschaus E., 1986, P199; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	57	318	327	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					437	450		10.1016/0092-8674(92)90513-C	http://dx.doi.org/10.1016/0092-8674(92)90513-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1358457				2022-12-28	WOS:A1992JW43500010
J	EKBOM, A; TRICHOPOULOS, D; ADAMI, HO; HSIEH, CC; LAN, SJ				EKBOM, A; TRICHOPOULOS, D; ADAMI, HO; HSIEH, CC; LAN, SJ			EVIDENCE OF PRENATAL INFLUENCES ON BREAST-CANCER RISK	LANCET			English	Article							PREGNANCY; BIRTH; ASSOCIATIONS; HYPOTHESIS; EXCRETION; ESTROGENS; AGE	Intrauterine exposure to high concentrations of endogenous pregnancy oestrogens may be important in the aetiology of breast cancer. In a nested case-control study we have assessed the relation between breast cancer risk and indicators of pregnancy oestrogen concentrations; preeclampsia/eclampsia is negatively related and measures of fetal size are positively related to oestrogen concentrations. Standard records for women born at Uppsala University Hospital between 1874 and 1954 were linked with records of invasive breast cancer cases, identified through their unique national registration numbers in the Swedish Cancer Registry during 1958-90. For each breast cancer case, we selected as potential controls female offspring of the first three mothers admitted to the hospital after the case's mother; only controls still living in Sweden and free from breast cancer when it was diagnosed in the case were finally included. Conditional logistic regression analysis was done for 458 breast cancer cases and 1197 matched controls. Pre-eclampsia/eclampsia was associated with a breast cancer rate ratio of 0.24 (95% confidence interval 0.09-0.70, p = 0.01). Linear trends for breast cancer incidence with increasing birth weight, birth length, and placental weight were positive but not significant. Thus, prenatal factors are important in breast carcinogenesis. Concentrations of pregnancy oestrogens may be one such factor, but other prenatal or perinatal factors cannot be excluded.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	EKBOM, A (corresponding author), UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, S-75185 UPPSALA, SWEDEN.							ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BERSTEIN LM, 1988, ADV CANCER RES, V50, P231, DOI 10.1016/S0065-230X(08)60439-X; COLE P, 1969, LANCET, V1, P604; Davies AM., 1983, OBSTETRICAL EPIDEMIO, P167; Davis W, 1980, IARC SCI PUBL, V32, P192; DEWAARD F, 1988, INT J CANCER, V41, P666, DOI 10.1002/ijc.2910410505; EKBOM A, 1991, AM J EPIDEMIOL, V134, P876, DOI 10.1093/oxfordjournals.aje.a116162; GANT NF, 1971, AM J OBSTET GYNECOL, V111, P555, DOI 10.1016/0002-9378(71)90472-8; GAROFF L, 1976, AM J OBSTET GYNECOL, V126, P1027, DOI 10.1016/0002-9378(76)90696-7; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; Gluckman P.D., 1986, OXF REV REPROD BIOL, V8, P1; HSIEH CC, 1991, CANCER CAUSE CONTROL, V2, P95, DOI 10.1007/BF00053127; HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P5; KLOPPER A, 1975, J STEROID BIOCHEM, V6, P651, DOI 10.1016/0022-4731(75)90047-3; LONG PA, 1979, AM J OBSTET GYNECOL, V135, P344, DOI 10.1016/0002-9378(79)90702-6; LUNDE AS, 1980, PHS801358 DEP HLTH H, P5; MARSHALL JR, 1989, STAT MED, V8, P1041, DOI 10.1002/sim.4780080904; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; ROSING U, 1984, GYNECOL OBSTET INVES, V18, P199, DOI 10.1159/000299081; SANDSON TA, 1992, LANCET, V339, P523, DOI 10.1016/0140-6736(92)90341-Y; TAMBYRAJA RL, 1981, TWIN RES 3 A, V69, P189; THOMPSON JA, 1990, EPIDEMIOLOGY, V1, P101; THOMPSON WD, 1989, JNCI-J NATL CANCER I, V81, P1571, DOI 10.1093/jnci/81.20.1571; Thomson AM, 1983, OBSTETRICAL EPIDEMIO, P89; Tomatis L, 1989, IARC Sci Publ, P1; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; YEN SSC, 1989, MATERNAL FETAL MED P, P375; 1990, CANCER INCIDENCE SWE	35	299	303	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					1015	1018		10.1016/0140-6736(92)93019-J	http://dx.doi.org/10.1016/0140-6736(92)93019-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357410				2022-12-28	WOS:A1992JV01400012
J	STEINBECK, G; ANDRESEN, D; BACH, P; HABERL, R; OEFF, M; HOFFMANN, E; VONLEITNER, ER				STEINBECK, G; ANDRESEN, D; BACH, P; HABERL, R; OEFF, M; HOFFMANN, E; VONLEITNER, ER			A COMPARISON OF ELECTROPHYSIOLOGICALLY GUIDED ANTIARRHYTHMIC DRUG-THERAPY WITH BETA-BLOCKER THERAPY IN PATIENTS WITH SYMPTOMATIC, SUSTAINED VENTRICULAR TACHYARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; MYOCARDIAL-INFARCTION; TACHYCARDIA; SELECTION; EFFICACY	Background. Antiarrhythmic drug therapy guided by invasive electrophysiologic testing is now widely used in patients with symptomatic, sustained ventricular tachyarrhythmias. Methods. We conducted a prospective, randomized trial in 170 patients to investigate whether this approach would improve long-term outcome. Patients whose arrhythmia was inducible by programmed electrical stimulation were assigned to treatment with electrophysiologically guided drug therapy based on serial testing (61 patients) or with metoprolol (54 patients). Electrophysiologically guided therapy consisted of serial testing of antiarrhythmic agents to identify the first one that rendered the arrhythmia noninducible. The 55 patients whose arrhythmia was noninducible during the initial electrophysiologic test were also treated with metoprolol. Results. During a mean (+/-SD) follow-up period of 23+/-17 months, recurrent, nonfatal arrhythmia occurred in 44 patients and sudden death due to cardiac factors in 27. The incidence of symptomatic arrhythmia and sudden death combined was virtually the same in the two groups with inducible arrhythmia after two years of observation (electrophysiologically guided therapy vs. metoprolol therapy, 46 percent vs. 48 percent). The outcome was more favorable in the patients with noninducible arrhythmia at base line (75 percent had neither adverse event after two years) than in those with inducible arrhythmia who were assigned to metoprolol therapy (P = 0.009 by log-rank test). Only 6 of the 29 patients (21 percent) with inducible arrhythmia that became noninducible during drug therapy had recurrent arrhythmia or sudden death, as compared with 21 of the 32 patients (66 percent) with arrhythmia that continued to be inducible (P<0.001). A multivariate regression analysis identified continued inducibility of the arrhythmia as an independent predictor of recurrent arrhythmia or sudden death (relative risk, 7.3; 95 percent confidence interval, 2.3 to 23.2; P<0.001). Conclusions. As compared with metoprolol therapy, electrophysiologically guided antiarrhythmic drug therapy did not improve the overall outcome of patients with sustained ventricular tachyarrhythmias. However, effective suppression of inducible arrhythmia by antiarrhythmic drugs was associated with a better outcome than was lack of suppression.	FREE UNIV BERLIN, KLINIKUM STEGLITZ, DEPT CARDIOL, W-1000 BERLIN 45, GERMANY	Free University of Berlin	STEINBECK, G (corresponding author), UNIV MUNICH, KLINIKUM GROSSHADERN, MED HOSP 1, POB 701260, W-8000 MUNICH 70, GERMANY.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; BRODSKY MA, 1988, AM HEART J, V115, P799, DOI 10.1016/0002-8703(88)90882-4; Cox DR., 1970, ANAL BINARY DATA; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; HOROWITZ LN, 1978, CIRCULATION, V58, P986, DOI 10.1161/01.CIR.58.6.986; JAZAYERI MR, 1989, J AM COLL CARDIOL, V14, P705, DOI 10.1016/0735-1097(89)90114-9; JOSEPHSON ME, 1978, CIRCULATION, V57, P431, DOI 10.1161/01.CIR.57.3.431; MASON JW, 1978, CIRCULATION, V58, P971, DOI 10.1161/01.CIR.58.6.971; MEREDITH IT, 1991, NEW ENGL J MED, V325, P618, DOI 10.1056/NEJM199108293250905; POOLE JE, 1990, J AM COLL CARDIOL, V16, P657, DOI 10.1016/0735-1097(90)90357-U; RUSKIN JN, 1980, NEW ENGL J MED, V303, P607, DOI 10.1056/NEJM198009113031103; STEINBECK G, 1986, J AM COLL CARDIOL, V8, P949, DOI 10.1016/S0735-1097(86)80440-5; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; WALLER TJ, 1987, J AM COLL CARDIOL, V10, P83, DOI 10.1016/S0735-1097(87)80164-X; WELLENS HJ, 1972, CIRCULATION, V46, P216, DOI 10.1161/01.CIR.46.2.216; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	18	163	163	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					987	992		10.1056/NEJM199210013271404	http://dx.doi.org/10.1056/NEJM199210013271404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1355595				2022-12-28	WOS:A1992JQ22500004
J	MARONGIU, F; SORANO, GG; CONTI, M; MAMELI, G; BIONDI, G; LICHERI, D; BALASTRIERI, A				MARONGIU, F; SORANO, GG; CONTI, M; MAMELI, G; BIONDI, G; LICHERI, D; BALASTRIERI, A			KNOWN VITAMIN-K INTAKE AND MANAGEMENT OF POORLY CONTROLLED ORAL ANTICOAGULANT-THERAPY	LANCET			English	Letter									UNIV CAGLIARI,INST HUMAN PHYSIOL,I-09100 CAGLIARI,ITALY	University of Cagliari	MARONGIU, F (corresponding author), UNIV CAGLIARI,INST INTERNAL MED,I-09100 CAGLIARI,ITALY.			Marongiu, Francesco/0000-0001-7277-2868				Drug Interactions with coumarin derivative anticoagulants, 1982, BMJ-BRIT MED J, V285, P274; DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; KALRA PA, 1988, LANCET, V1, P803; KARLSON B, 1986, ACTA MED SCAND, V220, P347; KUMAR S, 1989, THROMB HAEMOSTASIS, V62, P729; OLSON JA, 1987, AM J CLIN NUTR, V45, P687, DOI 10.1093/ajcn/45.4.687; PARRISH DB, 1980, CRC CRITICAL REV FOO, P337; PATERSON CE, 1986, ARCH INTERN MED, V146, P581; 1990, J CLIN PATHOL, V43, P177	9	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					545	546		10.1016/0140-6736(92)91739-U	http://dx.doi.org/10.1016/0140-6736(92)91739-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354291				2022-12-28	WOS:A1992JL23400021
J	NJOLSTAD, I; AARAAS, I; LUNDEVALL, S				NJOLSTAD, I; AARAAS, I; LUNDEVALL, S			LOOK AT THE PATIENT, NOT THE NOTES	LANCET			English	Editorial Material											NJOLSTAD, I (corresponding author), UNIV TROMSO,INST COMMUNITY MED,N-9037 TROMSO,NORWAY.		Njolstad, Inger/X-3784-2019					BARSKY AJ, 1981, ANN INTERN MED, V94, P492, DOI 10.7326/0003-4819-94-4-492; BYRNE PS, 1984, DOCTORS TALKING PATI; BYRNE PS, 1986, J R COLL GEN PRACT, V63, P405; QUILL TE, 1989, ANN INTERN MED, V111, P151; Wittgenstein L., 1958, PHILOS INVESTIGATION	5	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					413	414						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353567				2022-12-28	WOS:A1992JJ44900015
J	BARNES, DM; HANBY, AM; GILLETT, CE; MOHAMMED, S; HODGSON, S; BOBROW, LG; LEIGH, IM; PURKIS, T; MACGEOCH, C; SPURR, NK; BARTEK, J; VOJTESEK, B; PICKSLEY, SM; LANE, DP				BARNES, DM; HANBY, AM; GILLETT, CE; MOHAMMED, S; HODGSON, S; BOBROW, LG; LEIGH, IM; PURKIS, T; MACGEOCH, C; SPURR, NK; BARTEK, J; VOJTESEK, B; PICKSLEY, SM; LANE, DP			ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT	LANCET			English	Article							LI-FRAUMENI SYNDROME; SKIN FIBROBLASTS; P53; MUTATIONS; ONCOGENE; COLON; DNA	Mutations in the p53 gene are the commonest specific genetic change in human cancer. In normal tissues, p53 protein is present in such low quantities that it is not readily detectable by immunochemical techniques. However, in many tumour cells large amounts of p53 protein accumulate and can be seen by simple immunohistochemical staining; this is generally attributed to the accumulation of stabilised, mutant protein. We have found a mother and daughter, who both have a history of breast cancer, who show strong immunohistochemical staining of p53 in most of their normal epithelial and mesenchymal cells. Their family has a history of multiple cancers developing at an early age. Detailed protein analysis and gene sequencing of material obtained from cultured cells, grown from a skin biopsy taken from the daughter, suggest that her cells contained large quantities of normal (unmutated) p53. We suggest that this phenotype defines a new inherited cancer susceptibility syndrome that is distinct from the germ-line mutations in p53 found in some Li-Fraumeni families. This new syndrome affects p53 tumour suppressor function through an indirect mechanism that stabilises normal p53. It remains to be established whether this mechanism also contributes to the accumulation of p53 in sporadic cancers.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; ROYAL LONDON HOSP, IMPERIAL CANC RES FUND, SKIN LAB, LONDON, ENGLAND; INST HEMATOL & BLOOD TRANSFUS, PRAGUE 10, CZECHOSLOVAKIA; GUYS HOSP, IMPERIAL CANC RES FUND, CLIN ONCOL UNIT, LONDON SE1 9RT, ENGLAND; IMPERIAL CANC RES FUND, HISTOPATHOL UNIT, LONDON WC2A 3PX, ENGLAND; GUYS HOSP, CLIN GENET UNIT, LONDON SE1 9RT, ENGLAND; CLARE HALL LABS, POTTERS BAR, ENGLAND	University of Dundee; Barts Health NHS Trust; Royal London Hospital; Cancer Research UK; Institute of Hematology Prague; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014					BARTEK J, 1990, ONCOGENE, V5, P893; BENNETT WP, 1991, ONCOGENE, V6, P1779; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HARLOW E, 1988, ANTIBODIES LABORATOR; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KASTAN MB, 1991, CANCER RES, V51, P6304; KOPELOVICH L, 1984, CANCER INVEST, V2, P333, DOI 10.3109/07357908409040309; KOPELOVICH L, 1986, J NATL CANCER I, V77, P1241; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS JR, 1991, CANCER RES, V51, P2979; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIDGLEY CA, 1992, J CELL SCI, V101, P183; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WARREN W, 1992, ONCOGENE, V7, P1043	23	230	230	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1992	340	8814					259	263		10.1016/0140-6736(92)92354-I	http://dx.doi.org/10.1016/0140-6736(92)92354-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353190				2022-12-28	WOS:A1992JG66500002
J	LEVENO, KJ; CUNNINGHAM, FG				LEVENO, KJ; CUNNINGHAM, FG			BETA-ADRENERGIC AGONISTS FOR PRETERM LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RITODRINE HYDROCHLORIDE; MIMETIC AGENT				LEVENO, KJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DALLAS, TX 75235 USA.							BARDEN TP, 1980, OBSTET GYNECOL, V56, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; FREDHOLM BB, 1982, ACTA OBSTET GYN SCAN, P53; Hankins G.D.V., 1991, CRITICAL CARE OBSTET, P231; KING JF, 1988, BRIT J OBSTET GYNAEC, V95, P211, DOI 10.1111/j.1471-0528.1988.tb06860.x; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; LEVENO KJ, 1986, LANCET, V1, P1293; LIPSHITZ J, 1981, SEMIN PERINATOL, V5, P252; MERKATZ IR, 1980, OBSTET GYNECOL, V56, P7; MOUTQUIN JM, 1992, NEW ENGL J MED, V327, P308; RYDEN G, 1982, ACTA OBSTET GYN SCAN, P47; SPELLACY WN, 1979, OBSTET GYNECOL, V54, P220; WESSELIU.A, 1971, BMJ-BRIT MED J, V3, P144; 1990, MMWR MORB MORTAL WKL, V39, P148; 1981, NEW ENGL J MED, V304, P485; 1980, FDA DRUG B, V10, P22	16	47	48	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					349	351		10.1056/NEJM199207303270510	http://dx.doi.org/10.1056/NEJM199207303270510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1352375				2022-12-28	WOS:A1992JF65500010
J	PLOEG, RJ; VANBOCKEL, JH; LANGENDIJK, PTH; GROENEWEGEN, M; VANDERWOUDE, FJ; PERSIJN, GG; THOROGOOD, J; HERMANS, J				PLOEG, RJ; VANBOCKEL, JH; LANGENDIJK, PTH; GROENEWEGEN, M; VANDERWOUDE, FJ; PERSIJN, GG; THOROGOOD, J; HERMANS, J			EFFECT OF PRESERVATION SOLUTION ON RESULTS OF CADAVERIC KIDNEY-TRANSPLANTATION	LANCET			English	Article							ACUTE TUBULAR-NECROSIS; COLD-STORAGE; UW SOLUTION; RENAL-ALLOGRAFTS; ALG-AZATHIOPRINE; DELAYED FUNCTION; RECIPIENTS; LIVER; CYCLOSPORINE; PROGNOSIS	University of Wisconsin (UW) preservation solution has been reported to be beneficial for canine organ transplants and for human liver and pancreas transplants. To examine whether it affects renal graft survival, a randomised multicentre trial was conducted to compare its effect with that of EuroCollins solution on delayed graft function, renal function, and patient and graft survival in 695 recipients of cadaveric renal transplants. 352 kidneys were preserved with UW and 343 with EuroCollins solution. Delayed graft function occurred in 23% of the UW group and in 33% of the EuroCollins group (p=0.003). Three factors other than type of preservation fluid were associated with a higher incidence of delayed graft function: older donor age, intracerebral haemorrhage in the donor, and oliguria in the donor. Renal function as indicated by serum creatinine concentration was better in the UW than in the EuroCollins group. Patient survival in the UW and EuroCollins groups after 1 year was 95% and 94%, respectively. In both groups, delayed graft function reduced 1-year graft survival by 15% (p = 0.0001). 1-year graft survival of UW-preserved kidneys was 6% higher than that of controls (88.2% vs 82.5%, p=0.04). Delayed graft function is significantly associated with a reduction in 1-year graft survival. The preservation solution is the most important factor influencing development of delayed graft function, and UW solution is superior to EuroCollins solution in reducing occurrence of delayed graft function, improving graft function, extending graft survival.	UNIV HOSP LEIDEN,DEPT NEPHROL,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,DEPT MED STAT,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,EUROTRANSPLANT FDN,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	PLOEG, RJ (corresponding author), UNIV HOSP LEIDEN,DEPT SURG,POB 9600,2300 RC LEIDEN,NETHERLANDS.							ALIJANI MR, 1985, TRANSPLANTATION, V40, P659, DOI 10.1097/00007890-198512000-00017; [Anonymous], 1983, LANCET, V2, P986; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; BELZER FO, 1990, LANCET, V335, P362, DOI 10.1016/0140-6736(90)90656-P; BROPHY D, 1980, TRANSPLANTATION, V29, P245, DOI 10.1097/00007890-198003000-00016; CANAFAX DM, 1986, TRANSPLANTATION, V41, P177, DOI 10.1097/00007890-198602000-00009; DREIKORN K, 1989, EUROTRANSPLANT MANUA, V39, P45; Fleiss JL, 1981, STAT METHODS RATES P; HEIL J, 1984, TRANSPLANT P, V16, P270; Henny F C, 1986, Nephrol Dial Transplant, V1, P44; HOITSMA AJ, 1987, LANCET, V1, P584; IGURO T, 1985, CLIN KIDNEY TRANSPLA, P167; JAMIESON NV, 1988, TRANSPLANTATION, V46, P517, DOI 10.1097/00007890-198810000-00010; KALAYOGLU M, 1988, LANCET, V1, P617; KJELLSTRAND CM, 1976, AM J MED, V61, P190, DOI 10.1016/0002-9343(76)90169-8; MATTHEWS DE, 1988, USING UNDERSTANDING; PLOEG RJ, 1988, TRANSPLANTATION, V46, P191, DOI 10.1097/00007890-198808000-00002; PRIEN T, 1986, LANCET, V1, P1319; RIJKSEN J, 1986, EUROTRANSPLANT MANUA, V53, P64; ROCHER LL, 1987, CLIN TRANSPLANT, V1, P29; SANFILIPPO F, 1985, TRANSPLANT P, V17, P13; SOLLINGER HW, 1989, SURGERY, V106, P685; SPEES EK, 1984, TRANSPLANT P, V16, P177; TODO S, 1989, JAMA-J AM MED ASSOC, V261, P711, DOI 10.1001/jama.261.5.711; UEDA Y, 1989, TRANSPLANTATION, V48, P9143; VANRENTERGHEM Y, 1989, LANCET, V2, P745; VAUGHN WK, 1988, TRANSPLANT P, V20, P835; VAUGHN WK, 1981, TRANSPLANTATION, V32, P490, DOI 10.1097/00007890-198112000-00008; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002; 1984, KNOWLEDGEMAN; 1983, NEW ENGL J MED, V309, P809; 1986, NEW ENGL J MED, V314, P1219	32	168	174	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					129	137		10.1016/0140-6736(92)93212-6	http://dx.doi.org/10.1016/0140-6736(92)93212-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352564				2022-12-28	WOS:A1992JE38200001
J	ROBERTS, E				ROBERTS, E			MEDICINE AND THE LAW - CONSENT, REFUSAL, AND MINORS	LANCET			English	Editorial Material																		1992, LANCET, V339, P108	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					169	170		10.1016/0140-6736(92)93236-G	http://dx.doi.org/10.1016/0140-6736(92)93236-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352579				2022-12-28	WOS:A1992JE38200017
J	GRANAI, CO				GRANAI, CO			OVARIAN-CANCER - UNREALISTIC EXPECTATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CA-125 LEVELS; SERUM CA-125; CARCINOMA; AGENT; NEOPLASMS; TUMORS; TAXOL				GRANAI, CO (corresponding author), BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,PROVIDENCE,RI 02905, USA.							ALBERTS DS, 1988, SEMIN ONCOL, V15, P22; ANDOLF E, 1990, OBSTET GYNECOL, V75, P106; [Anonymous], 1991, J CLIN ONCOL, V9, P1668; BAKER TR, 1991, FEMALE PATIENT, V16, P49; BARBER HRK, 1990, FEMALE PATIENT, V15, P11; BELINSON JL, 1990, GYNECOL ONCOL, V37, P66, DOI 10.1016/0090-8258(90)90310-H; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; Chabner B. A., 1991, TAXOL PRINCIPLES PRA, V5, P1; CHEN DX, 1990, OBSTET GYNECOL, V75, P701; CHEN DX, 1988, OBSTET GYNECOL, V72, P23; EINZIG A I, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P187; HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O; HENAHAN JF, 1990, ONCOLOGY BIOTECH AUG, P1; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KREBS HB, 1986, OBSTET GYNECOL, V67, P473; MANETTA A, 1990, GYNECOL ONCOL, V36, P93, DOI 10.1016/0090-8258(90)90115-2; MARECHAL F, 1989, ANTICANCER RES, V9, P593; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; PIVER MS, 1990, GILDA RADNER FAMILIA; PODESTA JS, 1991, PEOPLE          0603, P76; ROWINSKY EK, 1991, J NATL CANCER I, V83, P1778, DOI 10.1093/jnci/83.24.1778; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Song J I, 1991, JAMA, V266, P1281, DOI 10.1001/jama.266.9.1281; STTLE G, 1990, CANCER MANUAL, P245; SUTTON GP, 1989, J CLIN ONCOL, V7, P1672, DOI 10.1200/JCO.1989.7.11.1672; SUTTON GP, 1989, J CLIN ONCOL, V7, P23; SWANSON RA, 1990, LAB LINE         JUL, P2; THIGPEN T, 1990, P AN M AM SOC CLIN, V9, P156; van Nagell J R Jr, 1991, Gynecol Oncol, V43, P89, DOI 10.1016/0090-8258(91)90050-F; VANNAGELL JR, 1991, CANCER, V68, P679, DOI 10.1002/1097-0142(19910815)68:4<679::AID-CNCR2820680402>3.0.CO;2-J; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VARDI JR, 1989, OBSTET GYNECOL, V74, P379; ZURAWSKI VR, 1990, 10TH ANN M NEW ENGL; 1989, CLIN GYNECOLOGIC ONC, P328; 1991, ACOG NEWSLETTER  FEB, P8; 1989, CLIN GYNECOLOGIC ONC, V335, P392; 1990, CANCER FACTS FIGURES, P11; 1991, PROVIDENCE J B, pA21; 1991, BMJ, V303, P884; 1980, TIME            0331, P60	44	31	31	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					197	200		10.1056/NEJM199207163270313	http://dx.doi.org/10.1056/NEJM199207163270313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1351658				2022-12-28	WOS:A1992JD31900013
J	JOPLIN, R; LINDSAY, JG; JOHNSON, GD; STRAIN, A; NEUBERGER, J				JOPLIN, R; LINDSAY, JG; JOHNSON, GD; STRAIN, A; NEUBERGER, J			MEMBRANE DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2) ON HUMAN BILIARY EPITHELIAL-CELLS IN PRIMARY BILIARY-CIRRHOSIS	LANCET			English	Note							CULTURE; LIVER	Primary biliary cirrhosis (PBC) is associated with serum antibodies that react with the dihydrolipoamide acetyltransferase component (E2) of the mitochondrial pyruvate dehydrogenase complex. We have sought the presence of E2 on the surface of human intrahepatic biliary epithelial cells (BEC). Cultured BECs from PBC but not normal liver were found to have E2 on the membrane after three days' culture. Isolated, viable cells examined by laser-scanning confocal microscopy revealed the pattern of E2 staining on the membrane to be similar to that seen with the membrane glycoprotein marker, HEA-125. By contrast, BECs from normal liver showed membrane staining only with HEA-125. When BECs were fixed before incubation with antibody to E2, cytoplasmic staining was observed. Our results suggest that E2 is present on the surface of biliary epithelial cells in PBC, and support the idea of a pathogenetic association between antimitochondrial antibodies and bileduct damage.	QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND	University of Birmingham; University of Birmingham; University of Glasgow			Neuberger, James/ABG-3010-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; GERKEN G, 1988, HEPATOLOGY, V8, P705; GHADIMINEJAD I, 1987, HEPATOLOGY, V7, P743, DOI 10.1002/hep.1840070421; HUNTER A, 1989, EUR J BIOCHEM, V155, P103; JOPLIN R, 1989, IN VITRO CELL DEV B, V25, P1189; JOPLIN R, 1990, J PATHOL, V162, P255, DOI 10.1002/path.1711620312; JOPLIN R, 1991, HEPATOLOGY, V14, P442, DOI 10.1016/0270-9139(91)90181-T; KRAMS SM, 1989, HEPATOLOGY, V9, P414; VANDEWATER R, 1991, J IMMUNOL, V146, P89; YEAMAN SJ, 1986, TRENDS BIOCHEM SCI, V11, P293, DOI 10.1016/0968-0004(86)90033-2	10	94	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					93	94		10.1016/0140-6736(92)91001-O	http://dx.doi.org/10.1016/0140-6736(92)91001-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1370237				2022-12-28	WOS:A1992GZ15600005
J	BARBIR, M; KUSHWAHA, S; HUNT, B; MACKEN, A; THOMPSON, GR; MITCHELL, A; ROBINSON, D; YACOUB, M				BARBIR, M; KUSHWAHA, S; HUNT, B; MACKEN, A; THOMPSON, GR; MITCHELL, A; ROBINSON, D; YACOUB, M			LIPOPROTEIN(A) AND ACCELERATED CORONARY-ARTERY DISEASE IN CARDIAC TRANSPLANT RECIPIENTS	LANCET			English	Article								High concentrations of serum lipoprotein(a) (Lp(a)) are associated with an increased risk of atherosclerotic vascular disease in the non-transplanted population. However its relation with accelerated coronary artery disease (CAD) in cardiac transplant recipients has not been reported. We measured serum Lp(a) in 130 cardiac transplant recipients undergoing routine follow-up, which included annual coronary angiography. The median Lp (a) concentration in 33 patients with CAD was 71 mg/dl, which was significantly higher than the corresponding value of 22 mg/dL in the 97 patients without CAD (p = 0.0006). Multivariant analysis showed the serum Lp(a) value to be a higher significant risk factor for CAD irrespective of the other factors included in the regression analysis. Thus a high concentration of serum Lp(a) is an important, independent risk factor for the development of accelerated CAD in transplant recipients.	HAREFIELD HOSP,THORAC & CARDIAC SURG UNIT,UXBRIDGE UB9 6JH,MIDDX,ENGLAND; HAMMERSMITH HOSP,MRC LIPOPROT TEAM,LONDON W12 0HS,ENGLAND; UNIV SUSSEX,SCH MATH & PHYS SCI,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London; University of Sussex	YACOUB, M (corresponding author), HAREFIELD HOSP,THORAC & CARDIAC SURG UNIT,UXBRIDGE UB9 6JH,MIDDX,ENGLAND.							ALONSO DR, 1977, AM J PATHOL, V87, P415; Altman DG, 1991, PRACTICAL STATISTICS; BARBIR M, 1991, INT J CARDIOL, V32, P51, DOI 10.1016/0167-5273(91)90043-O; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; GAO SZ, 1989, AM J CARDIOL, V64, P1093, DOI 10.1016/0002-9149(89)90858-8; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; HESS ML, 1983, CIRCULATION, V68, P94; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; SCHROEDER JS, 1986, NEW ENGL J MED, V315, P961, DOI 10.1056/NEJM198610093151511; SCOTT J, 1991, BRIT MED J, V303, P663, DOI 10.1136/bmj.303.6804.663; STEINBERG D, 1989, NEW ENGL J MED, V320, P1915; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827; WINTER GL, 1990, J HEART TRANSPLANT, V9, P367	16	77	79	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1500	1502		10.1016/0140-6736(92)92756-6	http://dx.doi.org/10.1016/0140-6736(92)92756-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361597				2022-12-28	WOS:A1992KD06900005
J	DAGAN, R; ENGLEHARD, D; PICCARD, E				DAGAN, R; ENGLEHARD, D; PICCARD, E			EPIDEMIOLOGY OF INVASIVE CHILDHOOD PNEUMOCOCCAL INFECTIONS IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; SEROTYPE DISTRIBUTION; BACTERIAL-MENINGITIS; ANTIMICROBIAL RESISTANCE; POLYSACCHARIDE VACCINE; CEREBROSPINAL-FLUID; CHARLESTON COUNTY; RESPIRATORY-TRACT; SOUTH-CAROLINA; UNITED-STATES	Objective.-To study the epidemiology of childhood pneumococcal invasive infections in Israel as a background for immunization programs. Design.-A 2-year (October 1988 through September 1990) prospective, nationwide surveillance of all invasive pediatric pneumococcal infections. Setting.-All 25 medical centers hospitalizing children in Israel, including all laboratories performing blood cultures from pediatric patients. Patients.-Infants and children aged 0 to 12 years visiting the pediatric emergency department or hospitalized in pediatric departments were included if Streptococcus pneumoniae was isolated from blood or cerebrospinal fluid. Results.-Four hundred sixty-nine invasive infections were diagnosed. Pneumonia, bacteremia without apparent focus, meningitis, and cellulitis were found in 39%, 37%, 17%, and 3%, respectively. The annual incidence was 42 per 100 000 for children younger than 5 years of age (104 per 100 000 for those <12 months old). The two most common serotypes were 1 and 5, which are rare in Western 'Europe and North America. Eight groups comprised 82% of all invasive infections. Extrapolated to a population in which 100 000 live births occur yearly, the total annual hospitalizations for pneumococci infections was calculated to be 1928 days. The overall case-fatality rate was 2.2%, but it was 30% during the first month of life. Conclusions.-Pneumococcal invasive infections are common in children in Israel and carry considerable morbidity.	HADASSAH MED CTR,DEPT PEDIAT,JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84105 BEER SHEVA,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Ben Gurion University	DAGAN, R (corresponding author), BEN GURION UNIV NEGEV,PEDIAT INFECT DIS UNIT,SOROKA MED CTR,POB 151,IL-84105 BEER SHEVA,ISRAEL.							ANDERSEN AH, 1989, IEEE T MED IMAGING, V8, P50, DOI 10.1109/42.20361; AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; BAIRD DR, 1976, LANCET, V2, P1344; BARKER J, 1989, J INFECT DIS, V159, P348, DOI 10.1093/infdis/159.2.348; Baron EJ, 1990, BAILEY SCOTTS DIAGNO, P333; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRIMBLECOMBE FSW, 1958, BRIT MED J, V1, P119, DOI 10.1136/bmj.1.5063.119; BURKE JP, 1971, AM J DIS CHILD, V121, P353, DOI 10.1001/archpedi.1971.02100150127021; BURMAN LA, 1986, SCAND J INFECT DIS, V18, P45, DOI 10.3109/00365548609032305; BURMAN LA, 1985, REV INFECT DIS, V7, P133; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FENOLL A, 1991, REV INFECT DIS, V13, P56; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; GIEBINK GS, 1985, PEDIATR INFECT DIS J, V4, P343, DOI 10.1097/00006454-198507000-00001; GRAY BM, 1979, J INFECT DIS, V140, P979, DOI 10.1093/infdis/140.6.979; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; GREENWOOD BM, 1980, LANCET, V1, P360; GUIRGUIS N, 1983, B WORLD HEALTH ORGAN, V61, P517; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; JACOBS NM, 1979, PEDIATRICS, V64, P296; JETTE LP, 1989, J CLIN MICROBIOL, V27, P1; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KLUGMAN KP, 1988, J INFECT DIS, V158, P956, DOI 10.1093/infdis/158.5.956; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LAFONG AC, 1988, J INFECTION, V16, P235, DOI 10.1016/S0163-4453(88)97556-1; LEIONEN M, 1986, PEDIAT INFECT DIS, V5, P39; LODA FA, 1975, J PEDIATR-US, V87, P1087, DOI 10.1016/S0022-3476(75)80120-X; LUND E, 1970, ACTA PATHOLOG MICROB, V78, P333; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; ONYEMELUKWE GC, 1983, J INFECTION, V5, P157; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; ROGOT E, 1976, AM J EPIDEMIOL, V103, P198, DOI 10.1093/oxfordjournals.aje.a112218; SARNAIK S, 1990, PEDIATR INFECT DIS J, V9, P181, DOI 10.1097/00006454-199003000-00007; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SCHWARZMANN SW, 1971, ARCH INTERN MED, V127, P1037, DOI 10.1001/archinte.127.6.1037; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; STATES SJ, 1977, INT J BIOMETEOROL, V21, P7, DOI 10.1007/BF01552962; TAKALA AK, 1992, 8TH ANN M EUR SOC PE; VERHAEGEN J, 1990, EUR J CLIN MICROBIOL, V9, P390, DOI 10.1007/BF01979467; 1991, PEDIATRICS, V88, P169; 1989, STATISTICAL ABSTRACT	44	147	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3328	3332		10.1001/jama.268.23.3328	http://dx.doi.org/10.1001/jama.268.23.3328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1364814				2022-12-28	WOS:A1992KB73200024
J	DARBYSHIRE, JH; ABOULKER, JP				DARBYSHIRE, JH; ABOULKER, JP			DIDANOSINE FOR ZIDOVUDINE-INTOLERANT PATIENTS WITH HIV DISEASE	LANCET			English	Letter									INSERM,UNITE RECH STAT,F-94800 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	DARBYSHIRE, JH (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT CLIN EPIDEMIOL,MRC,HIV CLIN TRIALS CTR,LONDON SW3 6NP,ENGLAND.							KHAN JO, 1992, NEW ENGL J MED, V327, P581	1	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1346	1347		10.1016/0140-6736(92)92524-J	http://dx.doi.org/10.1016/0140-6736(92)92524-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360049				2022-12-28	WOS:A1992KA26200022
J	ROCK, JA; MARKHAM, SM				ROCK, JA; MARKHAM, SM			PATHOGENESIS OF ENDOMETRIOSIS	LANCET			English	Article							PERITONEAL-FLUID; PELVIC ENDOMETRIOSIS; SPONTANEOUS-ABORTION; WOMEN; INFERTILITY; MACROPHAGES; DYSFUNCTION; APPEARANCE; PHASE; PAIN		GEORGETOWN UNIV, SCH MED, DEPT OBSTET & GYNECOL, WASHINGTON, DC 20057 USA	Georgetown University	ROCK, JA (corresponding author), EMORY UNIV, SCH MED, DEPT GYNECOL & OBSTET, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.			Rock, John/0000-0002-9970-8417				AYERS JWT, 1987, FERTIL STERIL, V47, P925; BRAUN DP, 1992, FERTIL STERIL, V57, P1203; CAMPBELL JS, 1985, OCT ANN M ONT ASS PA; CHACHO KJ, 1986, AM J OBSTET GYNECOL, V154, P1290, DOI 10.1016/0002-9378(86)90715-5; CORNILLIE FJ, 1990, FERTIL STERIL, V53, P978; DONNEZ J, 1992, FERTIL STERIL, V57, P980; DOODY MC, 1988, FERTIL STERIL, V49, P47; FAKIH H, 1987, FERTIL STERIL, V47, P213; FITZSIMMONS J, 1987, FERTIL STERIL, V47, P696; HALME J, 1987, AM J OBSTET GYNECOL, V156, P783, DOI 10.1016/0002-9378(87)90333-4; HALME J, 1983, AM J OBSTET GYNECOL, V145, P333, DOI 10.1016/0002-9378(83)90720-2; HALME J, 1984, OBSTET GYNECOL, V64, P151; HALME J, 1991, ANN NY ACAD SCI, V622, P266; HILL JA, 1988, FERTIL STERIL, V50, P216; JANSEN RPS, 1986, AM J OBSTET GYNECOL, V155, P1154, DOI 10.1016/0002-9378(86)90136-5; JEFFCOATE TNA, 1967, PRINCIPLES GYNAECOLO, P452; JONES HW, 1976, REGULATION HUMAN FER, P181; KAUMA S, 1988, OBSTET GYNECOL, V72, P13; KONINCKX PR, 1991, FERTIL STERIL, V55, P759; MARTIN DC, 1990, LAPAROSCOPIC APPEARA, V3, P1; MATHUR S, 1982, CLIN EXP IMMUNOL, V50, P259; McArthur J W, 1965, Obstet Gynecol Surv, V20, P709, DOI 10.1097/00006254-196510000-00001; METZGER DA, 1986, FERTIL STERIL, V45, P18; MOORE JG, 1988, AM J OBSTET GYNECOL, V158, P1291, DOI 10.1016/0002-9378(88)90359-6; OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45; PITTAWAY DE, 1989, FERTIL STERIL, V51, P68; REDWINE DB, 1987, FERTIL STERIL, V48, P1062; SCHENKEN RS, 1984, FERTIL STERIL, V41, P122; STOVALL DW, 1992, FERTIL STERIL, V57, P984; STRIPLING MC, 1988, FERTIL STERIL, V49, P427; SUELDO CE, 1987, FERTIL STERIL, V48, P697; SWITCHENKO AC, 1991, FERTIL STERIL, V56, P235; TUMMON IS, 1988, FERTIL STERIL, V50, P716; Verkauf B S, 1987, J Fla Med Assoc, V74, P671; WEED J C, 1980, Clinical Obstetrics and Gynecology, V23, P885; WHEELER JM, 1989, J REPROD MED, V34, P41; WHEELER JM, 1983, FERTIL STERIL, V39, P656; WOOD DH, 1983, AVIAT SPACE ENVIR MD, V54, P718; ZELLER JM, 1987, AM J REPROD IMMUNOL, V13, P78	39	79	82	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1992	340	8830					1264	1267		10.1016/0140-6736(92)92959-J	http://dx.doi.org/10.1016/0140-6736(92)92959-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359329				2022-12-28	WOS:A1992JZ23700013
J	JOBST, KA; SMITH, AD; SZATMARI, M; MOLYNEUX, A; ESIRI, ME; KING, E; SMITH, A; JASKOWSKI, A; MCDONALD, B; WALD, N				JOBST, KA; SMITH, AD; SZATMARI, M; MOLYNEUX, A; ESIRI, ME; KING, E; SMITH, A; JASKOWSKI, A; MCDONALD, B; WALD, N			DETECTION IN LIFE OF CONFIRMED ALZHEIMERS-DISEASE USING A SIMPLE MEASUREMENT OF MEDIAL TEMPORAL-LOBE ATROPHY BY COMPUTED-TOMOGRAPHY	LANCET			English	Article							CEREBRAL STRUCTURE; HIPPOCAMPAL; CT; DIAGNOSIS; VOLUME; BRAIN; MRI; AGE	The medial temporal lobe of the brain is important for normal cognitive function, notably for memory, and is the region with the most extensive pathological change in Alzheimer's disease (AD). We wanted to find out if atrophy of the medial temporal lobe could be detected in life in patients in whom a diagnosis of AD was subsequently established histopathologically. The minimum width of the medial temporal lobe, measured by temporal-lobe-oriented computed tomography (CT) about one year before death, in 44 patients with a histopathological diagnosis of AD (cases) was nearly half (0.56 of the median) that in 75 controls of the same age with no clinical evidence of dementia (95% confidence interval 0.51-0.61). There was little overlap between the distributions of measurements in cases and controls. A cut-off (< 0.79 MoM) selected to yield a 5% false-positive rate gave an expected detection rate of 92%. A cut-off selected to yield a false-positive rate of 1% (< 0.70 MoM) yielded a 79% detection rate. 20 of the 44 patients with histopathologically diagosed AD had been scanned more than once before death, and the test (cut-off < 0.79 MoM) was positive in all 20 more than a year before and in 9/10 more than 2 years before death. In 10 subjects with dementia but with histopathology excluding AD, the mean minimum width of the medial temporal lobe was significantly greater than that in the cases with AD, but was not significantly different from that in controls. Medial temporal lobe CT is a non-invasive, rapid, simple and effective test for AD which could have immediate application firstly in improving the accuracy of prevalence and incidence studies and, secondly, for the identification of groups of high-risk patients in the evaluation of novel treatments for AD. In the future, it could be applied as a screening test.	UNIV OXFORD, DEPT PHARMACOL, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; UNIV OXFORD, DEPT PSYCHIAT, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; UNIV OXFORD, DEPT CLIN NEUROL, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1A 7BE, ENGLAND; RADCLIFFE INFIRM, DEPT RADIOL, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, DEPT NEUROPATHOL, OXFORD OX2 6HE, ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of London; Queen Mary University London; Radcliffe Infirmary; Radcliffe Infirmary			Wald, Nicholas/AAY-8924-2021; Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722				ANDERSON JM, 1983, J NEUROL SCI, V58, P235, DOI 10.1016/0022-510X(83)90220-4; BOGERTS B, 1990, SCHIZOPHR RES, V3, P295, DOI 10.1016/0920-9964(90)90013-W; CASCINO GD, 1991, ANN NEUROL, V30, P31, DOI 10.1002/ana.410300107; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DUARA R, 1992, CLIN BRAIN IMAGING P, P294; ESIRI MM, 1989, DIAGNOSTIC NEUROPATH, P109; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GEORGE AE, 1990, AM J NEURORADIOL, V11, P101; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P68, DOI 10.1016/0006-3223(91)90211-4; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P55, DOI 10.1016/0006-3223(91)90210-D; JOBST KA, 1992, J NEUROL NEUROSUR PS, V55, P190, DOI 10.1136/jnnp.55.3.190; KESSLAK JP, 1991, NEUROLOGY, V41, P51, DOI 10.1212/WNL.41.1.51; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KIDO DK, 1989, AM J NEURORADIOL, V10, P551; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; RAPOPORT SI, 1991, CEREBROVAS BRAIN MET, V3, P297; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SEAB JP, 1988, MAGN RESON MED, V8, P200, DOI 10.1002/mrm.1910080210; STRAITON JA, 1991, NEURORADIOLOGY, V33, P19, DOI 10.1007/BF00593327; 1987, DIAGNOSTIC STATISTIC	24	245	246	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1179	1183						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359259				2022-12-28	WOS:A1992JY38600002
J	STOSCHITZKY, K; LINDNER, W; KLEIN, W				STOSCHITZKY, K; LINDNER, W; KLEIN, W			STEREOSELECTIVE RELEASE OF (S)-ATENOLOL FROM ADRENERGIC-NERVE ENDINGS AT EXERCISE	LANCET			English	Note							ATENOLOL; PHARMACOKINETICS; PROPRANOLOL; ENANTIOMERS	In-vitro studies have shown that atenolol, a beta-blocking agent, is stereoselectively taken up by and released from adrenergic nerve endings by membrane depolarisation. To investigate the potential importance of these findings, blood samples were taken at rest and after exercise testing from 10 patients (mean [SE] age 60 [3] years) receiving long-term treatment with racemic atenolol. At rest, mean plasma concentration of (R)-atenolol was higher than that of (S)-atenolol (ratio 1.14, p<0.01), but after exercise there was a stereoselective increase in (S)-atenolol concentration, which changed the ratio to 0.66 (p<0.01 ). Since (S)-atenolol but not (R)-atenolol causes clinically relevant beta-blockade, our findings may have importance for the management of patients receiving beta-blocking drugs.	GRAZ UNIV,INST PHARMACEUT CHEM,A-8036 GRAZ,AUSTRIA	University of Graz	STOSCHITZKY, K (corresponding author), GRAZ UNIV,DEPT MED,DIV CARDIOL,AUANBRUGGERPL 15,A-8036 GRAZ,AUSTRIA.							BAGWELL EE, 1989, J PHARMACOL EXP THER, V249, P476; BOYD RA, 1989, CLIN PHARMACOL THER, V45, P403, DOI 10.1038/clpt.1989.47; BRIGHT PS, 1985, BRIT J PHARMACOL, V84, P499, DOI 10.1111/j.1476-5381.1985.tb12934.x; HURWITZ GA, 1983, BRIT J CLIN PHARMACO, V16, P599, DOI 10.1111/j.1365-2125.1983.tb02228.x; LINDNER W, 1991, 2ND P INT S CHIR DIS, P238; MEHVAR R, 1990, J PHARM SCI, V79, P881, DOI 10.1002/jps.2600791007; STOSCHITZKY K, 1992, CLIN PHARMACOL THER, V51, P445, DOI 10.1038/clpt.1992.45; WALLE T, 1988, BIOCHEM PHARMACOL, V37, P115, DOI 10.1016/0006-2952(88)90763-0; WEBB JG, 1988, J PHARMACOL EXP THER, V247, P958	9	22	23	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					696	697		10.1016/0140-6736(92)92233-6	http://dx.doi.org/10.1016/0140-6736(92)92233-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355800				2022-12-28	WOS:A1992JN78000005
J	ROTH, DB; MENETSKI, JP; NAKAJIMA, PB; BOSMA, MJ; GELLERT, M				ROTH, DB; MENETSKI, JP; NAKAJIMA, PB; BOSMA, MJ; GELLERT, M			V(D)J RECOMBINATION - BROKEN DNA-MOLECULES WITH COVALENTLY SEALED (HAIRPIN) CODING ENDS IN SCID MOUSE THYMOCYTES	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; COMBINED IMMUNE-DEFICIENCY; ANTIGEN RECEPTOR GENES; SUPERCOILED DNA; DELTA-GENES; MICE; REARRANGEMENT; MUTATION; PROTEIN; REPAIR	Lymphoid cells from scid mice initiate V(D)J recombination normally but have a severely reduced ability to join coding segments. Thymocytes from scid mice contain broken DNA molecules at the TCR-delta locus that have coding ends, as well as molecules with signal ends, whereas in normal mice we previously detected only signal ends. Remarkably, these coding (but not signal) ends are sealed into hairpin structures. The formation of hairpins at coding ends may be a universal, early step in V(D)J recombination; this would provide a simple explanation for the origin of P nucleotides in coding joints. These findings may shed light on the mechanism of cleavage and suggest a possible role for the scid factor.	FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center	ROTH, DB (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R01CA004946, R37CA004946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013323] Funding Source: NIH RePORTER; NCI NIH HHS [CA-04946] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NIAID NIH HHS [AI-13323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILAR LK, 1991, J IMMUNOL, V146, P1348; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARROLL AM, 1989, CURR TOP MICROBIOL, V152, P63; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; ELLIOTT JF, 1988, NATURE, V331, P627; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; KIENKER LJ, 1991, J IMMUNOL, V147, P4351; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; REDDY MK, 1989, J BIOL CHEM, V264, P443; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; Sambrook J, 1989, MOL CLONING LABORATO; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; VANDERENDE A, 1981, NUCLEIC ACIDS RES, V9, P2037, DOI 10.1093/nar/9.9.2037; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x	35	391	393	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					983	991		10.1016/0092-8674(92)90248-B	http://dx.doi.org/10.1016/0092-8674(92)90248-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356077				2022-12-28	WOS:A1992JN78100013
J	ANGELETTI, LR; AGRIMI, U; CURIA, C; FRENCH, D; MARIANICOSTANTINI, R				ANGELETTI, LR; AGRIMI, U; CURIA, C; FRENCH, D; MARIANICOSTANTINI, R			HEALING RITUALS AND SACRED SERPENTS	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR	Votive tablets found during the excavation of shrines of the Graeco-Roman god of medicine (Asklepios or Aesculapius) associate the healing of superficial lesions with contact with the oral cavity of non-poisonous serpents. We suggest that this may have been the empirical exploitation of the healing properties of salivary growth factors. By immunohistochemistry and immunoblotting we demonstrate the expression of the epidermal growth factor and its receptor in the oral, upper digestive, and salivary epithelia of Elaphe quatuorlineata, a species probably used in healing rituals.	UNIV CASSINO,DEPT PHILOL & HIST,MED HIST SECT,CASSINO,ITALY; IST SUPER SANITA,VET LAB,I-00161 ROME,ITALY; UNIV ROME LA SAPIENZA,DEPT EXPTL MED,I-00185 ROME,ITALY; GABRIELE DANNUNZIO UNIV,INST HUMAN PATHOL,CHIETI,ITALY	University of Cassino; Istituto Superiore di Sanita (ISS); Sapienza University Rome; G d'Annunzio University of Chieti-Pescara			Mariani-Costantini, Renato/B-6637-2012; Agrimi, Umberto/C-9956-2015	Mariani-Costantini, Renato/0000-0002-4440-1848; Agrimi, Umberto/0000-0001-7828-0186				ALDROVANDI U, 1640, SERPENTUM DRACONUM H, P67; ANGLETTI LR, 1989, MED SECOLI, V1, P273; ANGLETTI LR, 1991, TRENDS EXP MED, V1, P4; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BROWN GL, 1986, J EXP MED, V163, P1319; Bruno S, 1990, SERPENTI ITALIA EURO; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COHEN S, 1962, J BIOL CHEM, V237, P1555; EDELSTEIN L, 1945, ASCLEPIUS, P233; FACCIOLATI J, 1827, TYPIS SEMINARII, P195; FRATI C, 1973, CHRON DERMATOL, V4, P57; Jones W H. S., 1918, PAUSANIAS DESCRIPTIO; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; Lyons AS, 1978, MED ILLUSTRATED HIST; METAZA L, 1823, MONOGRAFIA SERPENTI; Morse D., 1976, MED HIST, V20, P461; MURARO R, 1991, INT S BIOTECHNOLOGY; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; 1981, HIPPOCRATES DECORUM, V2, P289; 1940, HIST NATURALIS, V11; 1940, HIST NATURALIS, V8	22	50	52	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					223	225		10.1016/0140-6736(92)90480-Q	http://dx.doi.org/10.1016/0140-6736(92)90480-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353146				2022-12-28	WOS:A1992JE75800014
J	MEIJERINK, WJHJ; VONMEYENFELDT, MF; ROUFLART, MMJ; SOETERS, PB				MEIJERINK, WJHJ; VONMEYENFELDT, MF; ROUFLART, MMJ; SOETERS, PB			EFFICACY OF PERIOPERATIVE NUTRITIONAL SUPPORT	LANCET			English	Letter							TOTAL PARENTERAL-NUTRITION; CLINICAL-TRIALS				MEIJERINK, WJHJ (corresponding author), UNIV LIMBURG HOSP,DEPT SURG,6202 AZ MAASTRICHT,NETHERLANDS.		Meijerink, Wilhelmus JHJ/T-3619-2017	Meijerink, Wilhelmus JHJ/0000-0002-5402-0811				BRENNAN MF, 1981, NEW ENGL J MED, V305, P375, DOI 10.1056/NEJM198108133050705; BUZBY GP, 1988, AM J CLIN NUTR, V47, P357, DOI 10.1093/ajcn/47.2.357; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; KLEIN S, 1986, CANCER, V58, P1378, DOI 10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S; MEGUID MM, 1990, AM J SURG, V159, P345, DOI 10.1016/S0002-9610(05)81234-6; MUELLER J M, 1982, Lancet, V1, P68; 1991, NEW ENGL J MED, V325, P525	7	21	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					187	188		10.1016/0140-6736(92)93278-U	http://dx.doi.org/10.1016/0140-6736(92)93278-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352609				2022-12-28	WOS:A1992JE38200053
J	DEKEYSER, J; DEKLIPPEL, N; MERKX, H; VERVAECK, M; HERROELEN, L				DEKEYSER, J; DEKLIPPEL, N; MERKX, H; VERVAECK, M; HERROELEN, L			SERUM CONCENTRATIONS OF VITAMIN-A AND VITAMIN-E AND EARLY OUTCOME AFTER ISCHEMIC STROKE	LANCET			English	Article							LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; BETA-CAROTENE	Formation of free radicals and subsequent lipid peroxidation may have an important role in tissue injury and neuronal cell death after cerebral ischaemia. We conducted a prospective, controlled study to determine whether the endogenous antioxidant vitamins A and E had a protective function in acute ischaemic stroke. The study population consisted of 80 patients seen at the Free University Hospital in Brussels. Entry criteria were occurrence of sudden focal neurological deficit lasting more than 3 h; deficit due to acute ischaemia in the territory of the middle cerebral artery; and investigation within 24 h of onset of the episode. Outcome was assessed within the first 21 days. 80 controls matched for age and sex had various neurological disorders other than acute ischaemia. Serum concentrations of vitamins A and E were similar in the study and control groups. In the study population a serum vitamin A concentration higher than the mean of 2.27-mu-mol/I was associated with a higher frequency of complete recovery within the first 24 h (p<0.05), decreased mortality (p=0.038), and a better outcome as assessed by the Mathew scale of neurological deficit (p<0.03) and the Barthel index. There was no significant difference in outcome between patients with vitamin E concentrations above or below the mean of 35.3-mu-mol/l. Our results suggest a beneficial effect of a high serum vitamin A concentration on early outcome in ischaemic stroke.			DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS, ACAD ZIEKENHUIS, DEPT NEUROL, LAARBEEKLAAN 101, B-1090 BRUSSELS, BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HARPER HA, 1979, REV PHYSL CHEM, P147; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; MAHONEY F I, 1965, Md State Med J, V14, P61; MATHEW NT, 1972, LANCET, V2, P1327; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHMIDLEY JW, 1990, STROKE, V25, P7; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SILVIA RC, 1987, NEUR ABST, V13, P1499; SUNDT TM, 1969, J NEUROSURG, V31, P311, DOI 10.3171/jns.1969.31.3.0311; VUILLEUMIER JP, 1983, INT J VITAM NUTR RES, V53, P265; YAMAMOTO M, 1983, STROKE, V14, P977, DOI 10.1161/01.STR.14.6.977; YOSHIDA S, 1989, ANN NY ACAD SCI, V570, P219; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x; 1991, LANCET, V338, P1129	18	39	40	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1992	339	8809					1562	1565		10.1016/0140-6736(92)91830-2	http://dx.doi.org/10.1016/0140-6736(92)91830-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351549				2022-12-28	WOS:A1992JB20200003
J	JUULMOLLER, S; EDVARDSSON, N; JAHNMATZ, B; ROSEN, A; SORENSEN, S; OMBLUS, R				JUULMOLLER, S; EDVARDSSON, N; JAHNMATZ, B; ROSEN, A; SORENSEN, S; OMBLUS, R			DOUBLE-BLIND TRIAL OF ASPIRIN IN PRIMARY PREVENTION OF MYOCARDIAL-INFARCTION IN PATIENTS WITH STABLE CHRONIC ANGINA-PECTORIS	LANCET			English	Article							CORONARY-ARTERY LESIONS; THROMBOSIS; DEATH	Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) is the first prospective study of aspirin in stable angina. 2035 patients were randomised double-blind to treatment with aspirin 75 mg daily or placebo. All patients were treated with sotalol for control of symptoms. The median duration of follow-up was 50 months. Compared with the placebo+sotalol group, the aspirin+sotalol group had a 34% (81 vs 124 patients) reduction in primary outcome events (myocardial infarction and sudden death; 95% confidence interval 24-49%; p=0.003) and the reduction observed in secondary outcome events (vascular events, vascular death, all cause mortality, stroke) ranged from 22% to 32%. Treatment withdrawal caused by adverse events occurred in 109 patients in the aspirin+sotalol group and 100 in patients in the placebo+sotalol group; major bleeds, including haemorrhagic stroke, occurred in 20 and 13 patients, respectively (not significant). The addition of a low dose of aspirin to sotalol treatment showed significant benefit in terms of cardiovascular events, including a significant reduction in the incidence of first myocardial infarction in patients with symptoms of stable angina pectoris.	BRISTOL MYERS SQUIBB,STOCKHOLM,SWEDEN; CTY HOSP VASTERAS,VASTERAS,SWEDEN	Bristol-Myers Squibb; Vasteras Central Hospital	JUULMOLLER, S (corresponding author), MALMO GEN HOSP,DEPT MED,CARDIOL SECT,S-21401 MALMO,SWEDEN.							[Anonymous], 1989, NEW ENGL J MED, V321, P129; COBB LA, 1975, CIRCULATION, V52, P223; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; Grande P, 1990, CIRCULATION S1, V81, pI16; HAGMAN M, 1987, THESIS GOTEBORG; HANSEN O, 1991, AM J EPIDEMIOL, V133, P721, DOI 10.1093/oxfordjournals.aje.a115947; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; WILHELMSSON C, 1982, EUR J CLIN PHARMACOL, V21, P461, DOI 10.1007/BF00542039; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; 1988, LANCET, V1, P349; 1990, LANCET, V336, P827; 1971, 5TH WORK GROUP INCL; 1992, LANCET, V339, P753; 1991, LANCET, V338, P1345	18	405	420	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1421	1425		10.1016/0140-6736(92)92619-Q	http://dx.doi.org/10.1016/0140-6736(92)92619-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360557				2022-12-28	WOS:A1992KC28400001
J	NI, HL; KNIGHT, AI; CARTWRIGHT, K; PALMER, WH; MCFADDEN, J				NI, HL; KNIGHT, AI; CARTWRIGHT, K; PALMER, WH; MCFADDEN, J			POLYMERASE CHAIN-REACTION FOR DIAGNOSIS OF MENINGOCOCCAL MENINGITIS	LANCET			English	Article							ACUTE BACTERIAL-MENINGITIS	Meningococcal disease is normally suspected on clinical grounds but confirmed by isolation of Neisseria meningitidis from blood or cerebrospinal fluid (CSF), or by detection of gram-negative diplococci in CSF. After parenteral antibiotics are started the isolation rate of meningococci from blood cultures drops from 50% to less than 5% and the chances of CSF being positive by culture or microscopy are also reduced. We used the polymerase chain reaction (PCR) in a blinded study to detect meningococcal DNA in 54 CSF samples from patients with meningococcal disease or from controls. The PCR primers were specific for the meningococcal insertion sequence IS1106. The sensitivity and specificity of this PCR for diagnosis of meningococcal meningitis were both 91%. Sensitivity was not affected by prior antibiotic treatment. The IS1106 PCR is a rapid and sensitive test for confirmation of the diagnosis of meningococcal meningitis.	UNIV SURREY, SCH BIOL SCI, MOLEC MICROBIOL GRP, GUILDFORD GU2 5XH, SURREY, ENGLAND; GLOUCESTERSHIRE ROYAL HOSP, PUBL HLTH LAB, GLOUCESTER, ENGLAND	University of Surrey; Gloucestershire Royal Hospital				McFadden, Johnjoe/0000-0003-2145-0046				BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT KAV, 1986, LANCET, V2, P558; GOLDACRE MJ, 1977, ARCH DIS CHILD, V52, P501, DOI 10.1136/adc.52.6.501; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; KNIGHT AI, 1992, MOL MICROBIOL, V6, P1565, DOI 10.1111/j.1365-2958.1992.tb00878.x; KRISTIANSEN BE, 1991, LANCET, V337, P1568, DOI 10.1016/0140-6736(91)93262-8; NI H, 1992, EPIDEMIOL INFECT, V109, P227, DOI 10.1017/S0950268800050184; SABOOR SA, 1992, LANCET, V339, P1012, DOI 10.1016/0140-6736(92)90535-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; 1988, DHSS PLCMO882 DEP HL	14	106	112	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1992	340	8833					1432	1434		10.1016/0140-6736(92)92622-M	http://dx.doi.org/10.1016/0140-6736(92)92622-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360560				2022-12-28	WOS:A1992KC28400004
J	SAINTMARC, T; TOURAINE, JL; BERRA, N				SAINTMARC, T; TOURAINE, JL; BERRA, N			BENEFICIAL-EFFECTS OF INTRAVENOUS IMMUNOGLOBULINS IN AIDS	LANCET			English	Letter											SAINTMARC, T (corresponding author), HOP EDOUARD HERRIOT,TRANSPLANTAT & CLIN IMMUNOL UNIT,PAVILL P,F-69437 LYON,FRANCE.							BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; 1991, NEW ENGL J MED, V325, P73	2	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1347	1347		10.1016/0140-6736(92)92526-L	http://dx.doi.org/10.1016/0140-6736(92)92526-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360051				2022-12-28	WOS:A1992KA26200024
J	CHATTERJEE, S; JOHNSON, PR; WONG, KK				CHATTERJEE, S; JOHNSON, PR; WONG, KK			DUAL-TARGET INHIBITION OF HIV-1 INVITRO BY MEANS OF AN ADENOASSOCIATED VIRUS ANTISENSE VECTOR	SCIENCE			English	Article							TRANS-ACTIVATION; GENE-EXPRESSION; RNA; REPLICATION; CELLS; CLONING; DNA; TRANSDUCTION; INTEGRATION; RESISTANCE	An adeno-associated virus vector encoding an antisense RNA was used to transduce stable intracellular resistance to human immunodeficiency virus-1 (HIV-1) in human hemopoietic and non-hemopoietic cell lines. The antisense targets are present in all HIV-1 transcripts and include the TAR sequence, which is critical for transcription and virus replication, and the polyadenylation signal. Cell lines expressing antisense RNA showed up to 95 percent inhibition of gene expression directed by the HIV-1 long terminal repeat and greater than 99 percent reduction in infectious HIV-1 production, with no detectable cellular toxicity. Because of their efficient transcription and inability to recombine with HIV-1, adeno-associated virus vectors represent a promising form of anti-retroviral gene therapy.	NIAID,VIRAL DIS LAB,ROCKVILLE,MD 20852; GEORGETOWN UNIV,DEPT MICROBIOL,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD; NIAID,INFECT DIS LAB,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Johnson, Philip R/A-6892-2009					BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BERNS KI, 1987, ADV VIRUS RES, V32, P243, DOI 10.1016/S0065-3527(08)60479-0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHATTERJEE S, UNPUB; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FENRICK R, 1989, J VIROL, V63, P5006, DOI 10.1128/JVI.63.12.5006-5012.1989; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GOLDSTEIN S, 1990, J ACQ IMMUN DEF SYND, V3, P98; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMONAT PL, 1984, P NATL ACAD SCI-BIOL, V81, P6466, DOI 10.1073/pnas.81.20.6466; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; Johnson V., 1990, TECHNIQUES HIV RES; JOSHI S, 1991, J VIROL, V65, P5524, DOI 10.1128/JVI.65.10.5524-5530.1991; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LAFACE D, 1988, VIROLOGY, V162, P483, DOI 10.1016/0042-6822(88)90491-6; LAUGHLIN CA, 1983, GENE, V23, P65, DOI 10.1016/0378-1119(83)90217-2; LEBKOWSKI JS, 1988, MOL CELL BIOL, V8, P3988, DOI 10.1128/MCB.8.10.3988; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MENDELSON E, 1992, VIROLOGY, V187, P453, DOI 10.1016/0042-6822(92)90447-W; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RHODES A, 1990, J GEN VIROL, V71, P1965, DOI 10.1099/0022-1317-71-9-1965; SAMULSKI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P2077, DOI 10.1073/pnas.79.6.2077; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMADA T, 1991, Antiviral Chemistry and Chemotherapy, V2, P133; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WEEKS DL, 1983, MOL CELL BIOL, V3, P1222, DOI 10.1128/MCB.3.7.1222; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WILEY JA, 1989, AIDS, V3, pS71, DOI 10.1097/00002030-198901001-00011; WONG KL, UNPUB	37	183	229	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1485	1488		10.1126/science.1359646	http://dx.doi.org/10.1126/science.1359646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1359646	Green Submitted			2022-12-28	WOS:A1992JZ62500029
J	NIWA, M; MACDONALD, CC; BERGET, SM				NIWA, M; MACDONALD, CC; BERGET, SM			ARE VERTEBRATE EXONS SCANNED DURING SPLICE-SITE SELECTION	NATURE			English	Article							MESSENGER-RNAS; POLY(A) SITE; POLYADENYLATION; SEQUENCES; INVITRO; DEFINITION; INTRON; MODEL	PAIRWISE recognition of splice sites as a result of a scanning mechanism is an attractive model to explain the coordination of vertebrate splicing1. Such a mechanism would predict a polarity-of-site recognition in the scanned unit, but no evidence for a polarity gradient across introns has been found2-4. We have suggested that the exon rather than the intron is the unit of recognition in vertebrates5 and that polyadenylation and splicing factors interact during recognition of 3'-terminal exons6-8. Interaction is reflected in maximal rates of in vitro polyadenylation. If scanning across the exon is operating during this interaction, then insertion of a 5' splice site should depress polyadenylation. Here we report recognition in vitro and in vivo of a 5' splice site situated within a 3'-terminal exon, and a concomitant depression of polyadenylation and ultraviolet crosslinking of a polyadenylation factor. Decreased crosslinking was only found when the 3' and 5' splice sites were within 300 nucleotides of each other. These results are consistent with an exon scanning mechanism for splice-site selection.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	NIWA, M (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCCLEAN DEPT BIOCHEM,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			MacDonald, Clinton/0000-0003-3209-1982				ADAMI G, 1988, EMBO J, V7, P2107, DOI 10.1002/j.1460-2075.1988.tb03050.x; AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BRADY HA, 1988, MOL CELL BIOL, V8, P3291, DOI 10.1128/MCB.8.8.3291; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CUNNINGHAM SA, 1991, J MOL BIOL, V217, P265, DOI 10.1016/0022-2836(91)90541-D; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; KUHNE T, 1983, EMBO J, V2, P727, DOI 10.1002/j.1460-2075.1983.tb01492.x; LANG KM, 1983, SCIENCE, V220, P1351, DOI 10.1126/science.6304877; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NIWA M, 1991, GENE EXPRESSION, V1, P5; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112	19	117	118	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					277	280		10.1038/360277a0	http://dx.doi.org/10.1038/360277a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359430				2022-12-28	WOS:A1992JY96000058
J	PEARLMAN, DS; CHERVINSKY, P; LAFORCE, C; SELTZER, JM; SOUTHERN, DL; KEMP, JP; DOCKHORN, RJ; GROSSMAN, J; LIDDLE, RF; YANCEY, SW; COCCHETTO, DM; ALEXANDER, WJ; VANAS, A				PEARLMAN, DS; CHERVINSKY, P; LAFORCE, C; SELTZER, JM; SOUTHERN, DL; KEMP, JP; DOCKHORN, RJ; GROSSMAN, J; LIDDLE, RF; YANCEY, SW; COCCHETTO, DM; ALEXANDER, WJ; VANAS, A			A COMPARISON OF SALMETEROL WITH ALBUTEROL IN THE TREATMENT OF MILD-TO-MODERATE ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AGONIST; SALBUTAMOL	Background. An effective, long-acting bronchodilator could benefit patients with asthma who have symptoms not controlled by antiinflammatory drugs. We compared a new long-acting, inhaled beta2-adrenoceptor agonist, salmeterol, with a short-acting beta2-agonist, albuterol, in the treatment of mild-to-moderate asthma. Methods. We randomly assigned 234 patients (150 male and 84 female patients 12 to 73 years old) to one of three treatment groups: one group received 42 mug of salmeterol twice daily, one received 180 mug of albuterol four times daily, and one received placebo. Treatment was assigned in a double-blind fashion, and all patients could use supplemental inhaled albuterol as needed during the 12-week treatment period. Results. Measurements of the forced expiratory volume in one second, performed hourly for 12 consecutive hours, showed that a single dose of salmeterol produced a greater mean area under the curve than two doses of albuterol taken 6 hours apart (6.3 vs. 4.9 liter . hr, P<0.05). The difference was significant on day 1 and at week 4 of the study, but not at week 8 or 12. Salmeterol was also more effective than albuterol or placebo (with albuterol taken as needed) in increasing the morning peak expiratory flow rate: salmeterol induced a mean increase of 24 liters per minute over the pretreatment values, as compared with a decrease of 6 liters per minute with albuterol (P<0.001) and an increase of 1 liter per minute with placebo (P = 0.002). The mean overall symptom score was improved most by salmeterol treatment (P<0.05), with the number of days with symptoms and of nights with awakenings decreasing by 22 percent and 52 percent. respectively; there were no differences in results between albuterol treatment and placebo administration. We found no evidence of tolerance to the bronchodilating effects of salmeterol, and adverse reactions to all the treatments were infrequent and mild. Conclusions. For the management ot mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed.	ALLERGY & ASTHMA CTR,N DARTMOUTH,MA; CAROLINA ALLERGY & ASTHMA CONSULTANTS,RALEIGH,NC; CLIN RES INST,SAN DIEGO,CA; PRINCETON ALLERGY & ASTHMA ASSOC,PRINCETON,NJ; ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA; IMMUNOALLERGY TECH CONSULTANTS,PRAIRIE VILLAGE,KS; UNION UNIV,DIV ALLERGY,ALBANY,NY 12208; GLAXO RES INST,RES TRIANGLE PK,NC	Union College; GlaxoSmithKline	PEARLMAN, DS (corresponding author), COLORADO ALLERGY & ASTHMA CLIN,1450 S HAVANA ST,AURORA,CO 80012, USA.							BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BRADSHAW J, 1987, British Journal of Pharmacology, V92, p590P; BRITTON M, 1990, EUR RESPIR J S10, V3, pS226; BUTCHERS P R, 1987, British Journal of Pharmacology, V92, p745P; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAHL R, 1991, EUR RESPIR J, V4, P1178; DEROM E, 1990, American Review of Respiratory Disease, V141, pA469; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; JOHNSON M, 1991, EUR RESPIR REV, V1, P253; MACONOCHIE JG, 1988, BRIT J CLIN PHARMACO, V25, pP115; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; NEWNAM D, 1991, American Review of Respiratory Disease, V143, pA29; Polgar G, 1971, PULMONARY FUNCTION T; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHEPHERD GL, 1981, BRIT J DIS CHEST, V75, P215, DOI 10.1016/0007-0971(81)90057-7; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; van Elteren PH, 1960, B INT STAT I, V37, P351; VISKUM K, 1990, EUR RESPIR J S10, V3, pS235; 1987, AM REV RESPIR DIS, V136, P225; 1991, NIH913042 NAT ASTHM	24	305	309	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1420	1425		10.1056/NEJM199211123272004	http://dx.doi.org/10.1056/NEJM199211123272004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1357554				2022-12-28	WOS:A1992JX47900004
J	STACEYCLEAR, A; MCCARTHY, KA; HALL, DA; PILESPELLMAN, E; WHITE, G; HULKA, C; WHITMAN, GJ; MAHONEY, E; KOPANS, DB				STACEYCLEAR, A; MCCARTHY, KA; HALL, DA; PILESPELLMAN, E; WHITE, G; HULKA, C; WHITMAN, GJ; MAHONEY, E; KOPANS, DB			BREAST-CANCER SURVIVAL AMONG WOMEN UNDER AGE 50 - IS MAMMOGRAPHY DETRIMENTAL	LANCET			English	Article							SCREENING TRIAL; MORTALITY; REDUCTION	Great uncertainty exists about the benefit of detecting breast cancer by mammography in women under 50 years of age. We have reviewed the survival of patients aged 49 years or less whose cancers were detected by mammography alone. 117 women under the age of 50 years were diagnosed with breast cancer between 1978 and 1991 based only on an abnormal mammogram. Ductal carcinoma in-situ (DCIS) was found in 47 (40%) of these women, whilst 70 (60%) had infiltrating ductal or infiltrating lobular carcinomas. During the same interval, 928 women in this age group presented with palpable breast cancer. DCIS was diagnosed in 82 (9%) of these women, whilst 846 (91%) had infiltrating carcinoma. Among the infiltrating cancers detected by mammography alone, 50% were stage I, whilst only 30% of the women with palpable cancers were stage I. Five-year survival for all mammographically detected cancer patients was 95%, whereas for women with palpable cancers the survival was 74% (p < 0.00005). If DCIS is not included, the corresponding survivals are 91% for mammographically detected infiltrating cancers and 72% for palpable infiltrating cancers. Only 1 woman who died among those with palpable cancer had had a mammogram before diagnosis. Our data contradict the suggestion that women under 50 are put at a survival disadvantage by undergoing mammography. We believe that investigators who have reported negative results in this age group must examine other causes for their results.	MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV SURG ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; JOENSUU H, 1992, LANCET, V339, P315, DOI 10.1016/0140-6736(92)91396-P; KOPANS DB, IN PRESS SCREENING M; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; MILLER BA, 1991, J NATL CANCER I, V83, P678; MOSKOWITZ M, 1992, RADIOL CLIN N AM, V30, P221; MOSKOWITZ M, 1982, AM J ROENTGENOL, V138, P911, DOI 10.2214/ajr.138.5.911; MUIR BB, 1984, RADIOLOGY, V151, P39, DOI 10.1148/radiology.151.1.6701330; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; SEIDMAN H, 1987, CA-CANCER J CLIN, V37, P258, DOI 10.3322/canjclin.37.5.258; Shapiro S, 1988, PERIODIC SCREENING B; STOMPER PC, 1989, HEMATOL ONCOL CLIN N, V3, P611, DOI 10.1016/S0889-8588(18)30523-9; TABAR L, 1985, DIAGN IMAG CLIN MED, V54, P158; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; WATMOUGH DJ, 1992, LANCET, V340, P122, DOI 10.1016/0140-6736(92)90451-8; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546; 1991, LANCET, V337, P1575	21	36	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357448				2022-12-28	WOS:A1992JV01400002
J	BOOY, R; MOXON, ER; MACFARLANE, JA; MAYONWHITE, RT; SLACK, MPE				BOOY, R; MOXON, ER; MACFARLANE, JA; MAYONWHITE, RT; SLACK, MPE			EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINE IN OXFORD REGION	LANCET			English	Letter									JOHN RADCLIFFE HOSP,DEPT PUBL HLTH,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT BACTERIOL,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford	BOOY, R (corresponding author), JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.								0	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					847	847		10.1016/0140-6736(92)92719-V	http://dx.doi.org/10.1016/0140-6736(92)92719-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357260				2022-12-28	WOS:A1992JR16800027
J	MONSON, JRT; DARZI, A; CAREY, PD; GUILLOU, PJ				MONSON, JRT; DARZI, A; CAREY, PD; GUILLOU, PJ			PROSPECTIVE EVALUATION OF LAPAROSCOPIC-ASSISTED COLECTOMY IN AN UNSELECTED GROUP OF PATIENTS	LANCET			English	Article								Laparoscopic technology is likely to have an increasing impact on surgical procedures that have previously required an open approach. We have prospectively evaluated laparoscopic colectomy in 40 patients requiring elective colonic excision mainly for malignant disease. 33 of 40 patients had a successfully completed laparoscopic colectomy, although there was one postoperative death. Seven operations were unsuccessful and required conversion to conventional open laparotomy. Morbidity was low with no wound infections and only two chest infections in the 32 survivors. Early mobilisation and discharge from hospital (mean 8 days) was a notable feature. Previous abdominal surgery was not an absolute contraindication to laparoscopic colectomy. However, the inability to palpate the colon directly to confirm the site of laparoscopically impalpable lesions leads us to recommend contrast radiology to confirm the location of colonoscopically diagnosed lesions before laparoscopically assisted colectomy. Preliminary pathological assessment of resected tumour specimens revealed a satisfactory tumour clearance. We conclude that laparoscopic colectomy is a feasible operation in most patients and leads to a substantial patient benefit without compromising the chance of a surgical cure of cancer.			MONSON, JRT (corresponding author), ST MARYS HOSP,SCH MED,ACAD SURG UNIT,LONDON W2 1NY,ENGLAND.							CUSCHIERI A, 1992, AM J SURG, V163, P425, DOI 10.1016/0002-9610(92)90046-T; KATKHOUDA N, 1991, AM J SURG, V161, P361, DOI 10.1016/0002-9610(91)90598-8; MYERS WC, 1991, NEW ENGL J MED, V324, P1073; NEZHAT CR, 1992, AM J OBSTET GYNECOL, V166, P864, DOI 10.1016/0002-9378(92)91351-A; NYHUS LM, 1992, ARCH SURG-CHICAGO, V127, P137; PAGET GW, 1992, MED J AUSTRALIA, V156, P508; PETERS JH, 1990, ANN SURG, V213, P3; SCHLINKERT RT, 1991, DIS COLON RECTUM, V34, P1030, DOI 10.1007/BF02049971; TOMPKINS RK, 1990, ARCH SURG-CHICAGO, V125, P1245	9	249	253	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					831	833		10.1016/0140-6736(92)92694-B	http://dx.doi.org/10.1016/0140-6736(92)92694-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357253				2022-12-28	WOS:A1992JR16800013
J	NYMAN, I; LARSSON, H; WALLENTIN, L				NYMAN, I; LARSSON, H; WALLENTIN, L			PREVENTION OF SERIOUS CARDIAC EVENTS BY LOW-DOSE ASPIRIN IN PATIENTS WITH SILENT-MYOCARDIAL-ISCHEMIA	LANCET			English	Article							CORONARY-ARTERY DISEASE; CASS REGISTRY; BYPASS-SURGERY; ISCHEMIA; INFARCTION; ANGINA; RISK; DEPRESSION; THERAPY; TRIALS	On exercise testing after an episode of unstable coronary artery disease (CAD; unstable angina or non-Q-wave myocardial infarction), a proportion of patients show ST-segment depression, indicating myocardial ischaemia, but do not report concomitant symptoms of angina. Treatment of such "silent" ischaemia aims mainly to reduce the risk of subsequent cardiac events. We have studied the effect of low-dose aspirin in patients with myocardial ischaemia defined at the predischarge test as silent (though patients might have had symptomatic ischaemia at other times) or symptomatic. 740 men with unstable CAD aged 70 years or less underwent symptom-limited exercise testing before hospital discharge; 144 showed ST depression without pain and 230 ST depression with simultaneous chest pain. Of the silent ischaemia group, 67 were randomly assigned placebo and 77 aspirin (75 mg daily); the corresponding numbers in the symptomatic group were 125 and 105. Angina symptoms were less common in the silent than in the symptomatic ischaemia group both before inclusion and during follow-up, and a greater proportion of the silent ischaemia group were included because of myocardial infarction. In both ischaemia groups aspirin treatment reduced the risk of subsequent myocardial infarction or death by 3 months' follow-up (silent 4% of aspirin-treated vs 21% of placebo-treated patients, p=0.004; symptomatic 9% vs 18%, p=0.05); at 12 months' follow-up a significant benefit of aspirin was still apparent in the silent ischaemia group (9% vs 28%, p=0.005) but not in the symptomatic group (13% vs 22%, p=0.109). Low-dose aspirin reduced the risk of subsequent myocardial infarction at least as well in silent as in symptomatic myocardial ischaemia. Since improvement of outlook is the main treatment objective in symptom-free patients, aspirin should be a mainstay of their treatment.	UNIV HOSP UPPSALA, DEPT INTERNAL MED, DIV CARDIOL, S-75185 UPPSALA, SWEDEN; DIST HOSP EKSJO, DEPT INTERNAL MED, EKSJO, SWEDEN; LINKOPING UNIV HOSP, DEPT CARDIOL, S-58185 LINKOPING, SWEDEN	Uppsala University; Uppsala University Hospital; Linkoping University								[Anonymous], 1988, LANCET, V2, P349; BERGLUND U, 1991, EUR HEART J, V12, P428, DOI 10.1093/oxfordjournals.eurheartj.a059912; BORG G, 1986, WENNERGREN CTR INT S, V46; CAMPEAU I, 1975, CIRCULATION, V54, P222; CECCHI AC, 1983, J AM COLL CARDIOL, V1, P934, DOI 10.1016/S0735-1097(83)80213-7; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; GIBSON RS, 1987, CIRCULATION, V75, P36; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GOTTLIEB SO, 1988, JAMA-J AM MED ASSOC, V259, P1030, DOI 10.1001/jama.259.7.1030; HELLER LI, 1990, AM J CARDIOL, V65, P718, DOI 10.1016/0002-9149(90)91377-I; JULIAN DG, 1985, EUR HEART J, V6, P37, DOI 10.1093/eurheartj/6.suppl_A.37; KJELSBERG MO, 1985, AM J CARDIOL, V55, P16; MAHONY C, 1989, AM J CARDIOL, V64, P387, DOI 10.1016/0002-9149(89)90541-9; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; NADEMANEE K, 1987, J AM COLL CARDIOL, V10, P1, DOI 10.1016/S0735-1097(87)80152-3; NYMAN I, 1992, AM HEART J, V123, P324, DOI 10.1016/0002-8703(92)90642-9; PEPINE CJ, 1990, CIRCULATION, V82, P135; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P123; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; STERN S, 1975, CIRCULATION, V52, P1045, DOI 10.1161/01.CIR.52.6.1045; STONE PH, 1990, SILENT MYOCARDIAL IS, P328; TAYLOR HA, 1989, CIRCULATION, V79, P1171, DOI 10.1161/01.CIR.79.6.1171; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; WALLENTIN L, 1990, LANCET, V336, P827; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; WEINER DA, 1989, AM HEART J, V118, P649, DOI 10.1016/0002-8703(89)90574-7; WEINER DA, 1988, J AM COLL CARDIOL, V12, P595, DOI 10.1016/S0735-1097(88)80043-3; WEINER DA, 1988, AM J CARDIOL, V62, P1155, DOI 10.1016/0002-9149(88)90251-2; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	30	66	67	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1992	340	8818					497	501		10.1016/0140-6736(92)91706-E	http://dx.doi.org/10.1016/0140-6736(92)91706-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354274				2022-12-28	WOS:A1992JL23400001
J	RAVUSSIN, E; SWINBURN, BA				RAVUSSIN, E; SWINBURN, BA			PATHOPHYSIOLOGY OF OBESITY	LANCET			English	Article							DOUBLY-LABELED WATER; ENERGY-EXPENDITURE; WEIGHT-GAIN; PHYSICAL-ACTIVITY; METABOLIC-RATE; PIMA-INDIANS; DIETARY-FAT; CARBOHYDRATE; OXIDATION; DETERMINANTS		UNIV AUCKLAND, SCH MED, DEPT COMMUNITY HLTH, AUCKLAND, NEW ZEALAND	University of Auckland	RAVUSSIN, E (corresponding author), NIDDKD, CLIN DIABET & NUTR SECT, 4212 N 16TH ST, ROOM 541-A, PHOENIX, AZ 85016 USA.		Steib, Lori/B-6628-2014	Steib, Lori/0000-0001-8274-318X; Ravussin, Eric/0000-0003-2129-547X				ABBOTT WGH, 1988, AM J PHYSIOL, V255, pE332, DOI 10.1152/ajpendo.1988.255.3.E332; ABBOTT WGH, 1990, J CLIN INVEST, V86, P642, DOI 10.1172/JCI114756; ACHESON KJ, 1987, AM J CLIN NUTR, V45, P78, DOI 10.1093/ajcn/45.1.78; ALPERT SS, 1990, AM J CLIN NUTR, V52, P784, DOI 10.1093/ajcn/52.5.784; BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421; BLUNDELL JE, IN PRESS AM J CLIN N; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; Bogardus C., 1989, Nutrition and the origins of disease., P145; BOUCHARD C, 1989, METABOLISM, V38, P364, DOI 10.1016/0026-0495(89)90126-1; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BOUCHARD C, 1988, INT J OBESITY, V12, P205; BRAY GA, 1991, ANN INTERN MED, V115, P152, DOI 10.7326/0003-4819-115-2-152; BRUNDIN T, 1992, METABOLISM, V41, P49, DOI 10.1016/0026-0495(92)90190-L; FERRARO R, 1991, AM J CLIN NUTR, V53, P1368, DOI 10.1093/ajcn/53.6.1368; FLATT JP, 1985, J CLIN INVEST, V76, P1019, DOI 10.1172/JCI112054; FLATT JP, 1988, DIABETES METAB REV, V4, P571, DOI 10.1002/dmr.5610040603; GRIFFITHS M, 1990, LANCET, V336, P76, DOI 10.1016/0140-6736(90)91592-X; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; PITTET P, 1976, BRIT J NUTR, V35, P281, DOI 10.1079/BJN19760033; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; RAVUSSIN E, 1991, FASEB J, V5, pA554; RAVUSSIN E, IN PRESS OBESITY THE; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; SCHOELLER DA, 1991, ANNU REV NUTR, V11, P355, DOI 10.1146/annurev.nu.11.070191.002035; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; SUTER PM, 1992, NEW ENGL J MED, V326, P983, DOI 10.1056/NEJM199204093261503; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; THORNE A, 1990, ACTA CHIR SCAND, P6; ZELEWSKI M, 1990, COMP BIOCHEM PHYS B, V95, P469, DOI 10.1016/0305-0491(90)90004-D; ZURLO F, 1990, AM J PHYSIOL, V259, pE650	37	192	195	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1992	340	8816					404	408		10.1016/0140-6736(92)91480-V	http://dx.doi.org/10.1016/0140-6736(92)91480-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353565				2022-12-28	WOS:A1992JJ44900013
J	SNYDER, SH				SNYDER, SH			NITRIC-OXIDE - 1ST IN A NEW CLASS OF NEUROTRANSMITTERS	SCIENCE			English	Editorial Material							RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; SMOOTH-MUSCLE; NONCHOLINERGIC RELAXATION; NERVE-STIMULATION; RELAXING FACTOR; TARGET-CELLS; ACTIVATION; NEURONS; INHIBITION				SNYDER, SH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R44DA027190, R43DA027190, P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-271-90-7408] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLANCHARD JC, 1991, EUR J PHARMACOL, V199, P379; BOECKXSTAENS GE, 1990, EUR J PHARMACOL, V190, P239, DOI 10.1016/0014-2999(90)94132-H; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V103, P1085, DOI 10.1111/j.1476-5381.1991.tb12304.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; BURNSTOCK G, 1972, BRIT J PHARMACOL, V46, P234, DOI 10.1111/j.1476-5381.1972.tb06868.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COSTA M, 1991, P AUST PHYSL PHARM S, V22, pP97; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DAWSON VL, IN PRESS SOC NEUR AB; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; FERRENDELLI JA, 1974, J NEUROCHEM, V22, P535, DOI 10.1111/j.1471-4159.1974.tb06890.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HAGLUND L, 1984, NATURE, V307, P259, DOI 10.1038/307259a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRSCH D, IN PRESS SOC NEUR AB; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V143, P299, DOI 10.1111/j.1748-1716.1991.tb09236.x; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V141, P441, DOI 10.1111/j.1748-1716.1991.tb09103.x; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LAMAS S, IN PRESS P NATL ACAD; LLEWELLYNSMITH IJ, IN PRESS BRAIN RES; LOWENSTEIN CJ, IN PRESS P NATL ACAD; LYONS CR, 1992, J BIOL CHEM, V267, P6370; LYONS CR, 1992, SCIENCE, V256, P225; MAINES MD, 1988, FASEB J, V2, P2257; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; NOZAKI K, IN PRESS J NEUROSCI; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PICKARD RS, 1991, BRIT J PHARMACOL, V104, P755, DOI 10.1111/j.1476-5381.1991.tb12500.x; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TODA N, 1991, J PHARMACOL EXP THER, V258, P1027; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; ZHANG J, IN PRESS P NATL ACAD	64	954	974	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					494	496		10.1126/science.1353273	http://dx.doi.org/10.1126/science.1353273			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1353273				2022-12-28	WOS:A1992JE75500017
J	HAMPSON, NB; NORKOOL, DM				HAMPSON, NB; NORKOOL, DM			CARBON-MONOXIDE POISONING IN CHILDREN RIDING IN THE BACK OF PICKUP TRUCKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective. - To describe the case characteristics of a series of children poisoned with carbon monoxide while traveling in the back of pickup trucks. Design. - Pediatric cases referred for treatment of carbon monoxide poisoning with hyperbaric oxygen between 1986 and 1991 were reviewed. Those cases that occurred during travel in the back of pickup trucks were selected. Clinical follow-up by telephone interview ranged from 2 to 55 months. Setting. - A private, urban, tertiary care center in Seattle, Wash. Patients. - Twenty children ranging from 4 to 16 years of age. Intervention. - All patients were treated with hyperbaric oxygen. Main Outcome Measures. - Characteristics of the poisoning incident and clinical patient outcome. Results. - Of 68 pediatric patients treated for accidental carbon monoxide poisoning, 20 cases occurred as children rode in the back of pickup trucks. In 17 of these, the children were riding under a rigid closed canopy on the rear of the truck, while three episodes occurred as children rode beneath a tarpaulin. Average carboxyhemoglobin level on emergency department presentation was 18.2% +/- 2.4% (mean +/- SEM; range, 1.6% to 37.0%). Loss of consciousness occurred in 15 of the 20 children. One child died of cerebral edema, one had permanent neurologic deficits, and 18 had no recognizable sequelae related to the episode. In all cases, the truck exhaust system had a previously known leak or a tail pipe that exited at the rear rather than at the side of the pickup truck. Conclusions. - Carbon monoxide poisoning is a significant hazard for children who ride in the back of pickup trucks. If possible, this practice should be avoided.	VIRGINIA MASON MED CTR,DEPT HYPERBAR,SEATTLE,WA 98101	Virginia Mason Medical Center	HAMPSON, NB (corresponding author), VIRGINIA MASON CLIN,DEPT MED,1100 9TH AVE,SEATTLE,WA 98111, USA.							ANGRAN PF, 1990, JAMA-J AM MED ASSOC, V264, P712; BARRET L, 1985, CLIN TOXICOL, V23, P309; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; GUSS DA, 1990, J RESPIR DIS, V11, P773; JOHNSON CJ, 1975, AM J PUBLIC HEALTH, V65, P1327, DOI 10.2105/AJPH.65.12.1327; MYERS RAM, 1983, AM J EMERG MED, V2, P226; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; TONG T, 1989, AM J DIS CHILD, V143, P997, DOI 10.1001/archpedi.1989.02150210013004; TURNBULL TL, 1988, ANN EMERG MED, V17, P478, DOI 10.1016/S0196-0644(88)80240-3; 1991, DIGEST MOTOR LAWS; 1982, MMWR, V31, P529	12	39	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					538	540		10.1001/jama.267.4.538	http://dx.doi.org/10.1001/jama.267.4.538			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1370334				2022-12-28	WOS:A1992GZ43900031
J	JACOBY, NM				JACOBY, NM			KROOKS DYSLEXIA	LANCET			English	Article											JACOBY, NM (corresponding author), BROOMYFIELDS,MARK BEECH,EDENBRIDGE TN8 5PA,KENT,ENGLAND.								0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1521	1522		10.1016/0140-6736(92)92769-C	http://dx.doi.org/10.1016/0140-6736(92)92769-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361609				2022-12-28	WOS:A1992KD06900017
J	SIMOES, EAF; MCGRATH, EJ				SIMOES, EAF; MCGRATH, EJ			RECOGNITION OF PNEUMONIA BY PRIMARY HEALTH-CARE WORKERS IN SWAZILAND WITH A SIMPLE CLINICAL ALGORITHM	LANCET			English	Note								In developing countries primary health care workers are being trained to manage and treat acute respiratory infections with a protocol developed by the WHO. We tested the ability of nurses and nursing assistants in Swaziland to recognise the signs and symptoms of pneumonia; with the results of a paediatrician's examination as "gold standard", sensitivities and specificities were calculated. Danger signs of stridor and abnormal sleepiness were poorly recognised (sensitivity 0-50%) by the health care workers, as was audible wheeze. Severe undernutrition, tachypnoea, and chest wall indrawing were well recognised. Overall, the recognition of pneumonia was good (sensitivity 71-83%, specificity 84-85%). These findings highlight topics for emphasis in training.	MINIST HLTH, MBABANE, SWAZILAND		SIMOES, EAF (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, 4200 E 9TH AVE, BOX C-227, DENVER, CO 80262 USA.							BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; CHERIAN T, 1990, AM J DIS CHILD, V144, P1026, DOI 10.1001/archpedi.1990.02150330086028; CHERIAN T, 1988, LANCET, V2, P125; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; Leowski J, 1986, World Health Stat Q, V39, P138; MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004; SIMOES EAF, 1991, ARCH DIS CHILD, V66, P1199, DOI 10.1136/adc.66.10.1199; SNEDECOR GW, 1980, STATISTICAL METHODS, P121; 1992, ACUTE RESPIRATORY IN; 1990, SUPERVISORY SKILLS M	10	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	1992	340	8834-5					1502	1503		10.1016/0140-6736(92)92757-7	http://dx.doi.org/10.1016/0140-6736(92)92757-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361598				2022-12-28	WOS:A1992KD06900006
J	CHANDRA, RK				CHANDRA, RK			EFFECT OF VITAMIN AND TRACE-ELEMENT SUPPLEMENTATION ON IMMUNE-RESPONSES AND INFECTION IN ELDERLY SUBJECTS	LANCET			English	Article							NUTRITION; POPULATION; FUTURE; CELLS	Ageing is associated with impaired immune responses and increased infection-related morbidity. This study assessed the effect of physiological amounts of vitamins and trace elements on immunocompetence and occurrence of infection-related illness. 96 independently living, healthy elderly individuals were randomly assigned to receive nutrient supplementation or placebo. Nutrient status and immunological variables were assessed at baseline and at 12 months, and the frequency of illness due to infection was ascertained. Subjects in the supplement group had higher numbers of certain T-cell subsets and natural killer cells, enhanced proliferation response to mitogen, increased interleukin-2 production, and higher antibody response and natural killer cell activity. These subjects were less likely than those in the placebo group to have illness due to infections (mean [SD] 23 [5] vs 48 [7] days per year, p = 0.002). Supplementation with a modest physiological amount of micronutrients improves immunity and decreases the risk of infection in old age.	WHO,CTR NUTR IMMUNOL,CH-1211 GENEVA 27,SWITZERLAND; MEM UNIV NEWFOUNDLAND,ST JOHNS A1C 5S7,NEWFOUNDLAND,CANADA	World Health Organization; Memorial University Newfoundland								BENDICH A, 1990, ANTIOXIDANT NUTRIENT; CHANDRA RK, 1983, LANCET, V1, P688; CHANDRA RK, 1984, JAMA-J AM MED ASSOC, V252, P1443, DOI 10.1001/jama.252.11.1443; CHANDRA RK, 1989, IMMUNOLOGY, V67, P141; CHANDRA RK, 1983, CLIN EXP IMMUNOL, V51, P126; CHANDRA RK, 1991, CAN MED ASSOC J, V145, P1475; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; CHANDRA RK, 1992, J NUTR, V122, P754, DOI 10.1093/jn/122.suppl_3.754; CHANDRA RK, 1977, NUTRITION IMMUNITY I; CHANDRA RK, 1985, BMJ-BRIT MED J, V291, P709; CHANDRA RK, 1992, NUTRITION IMMUNITY I; CHAVANCE M, 1989, EUR J CLIN NUTR, V43, P827; CHOWDHURY BA, 1989, IMMUNOL LETT, V22, P287, DOI 10.1016/0165-2478(89)90167-3; DEWECK AL, 1992, NUTR ELDERLY, P89; DUCHATEAU J, 1981, AM J MED, V70, P1001, DOI 10.1016/0002-9343(81)90849-4; FOX RA, 1984, IMMUNOLOGY INFECTION, P289; GOODE HF, 1991, AGE AGEING, V20, P345, DOI 10.1093/ageing/20.5.345; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MILLER LT, 1990, ANN NY ACAD SCI, V587, P49; MUNRO H, 1992, NUTRITION ELDERLY; NAGEL JE, 1988, J CLIN INVEST, V81, P1096, DOI 10.1172/JCI113422; NIEDERMAN MS, 1991, RESPIRATORY INFECTIO; PAYETTE H, 1990, AM J CLIN NUTR, V52, P927, DOI 10.1093/ajcn/52.5.927; PENN ND, 1991, AGE AGEING, V20, P169, DOI 10.1093/ageing/20.3.169; SUBOTICANEC K, 1989, INT J VITAM NUTR RES, V50, P20	25	422	436	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1124	1127		10.1016/0140-6736(92)93151-C	http://dx.doi.org/10.1016/0140-6736(92)93151-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359211				2022-12-28	WOS:A1992JX13400004
J	MADGE, P; PATON, JY; MCCOLL, JH; MACKIE, PLK				MADGE, P; PATON, JY; MCCOLL, JH; MACKIE, PLK			PROSPECTIVE CONTROLLED-STUDY OF 4 INFECTION-CONTROL PROCEDURES TO PREVENT NOSOCOMIAL INFECTION WITH RESPIRATORY SYNCYTIAL VIRUS	LANCET			English	Article							VIRAL-INFECTIONS; TRANSMISSION; MASKS; PERSONNEL; CHILDREN; GOGGLES; GOWNS	To determine the most effective infection control procedure in preventing nosocomial infection with respiratory syncytial virus (RSV), we did a prospective controlled study of four infection-control strategies in four wards in a large paediatric hospital in the west of Scotland. All children under two years old admitted to four general wards during three winter RSV epidemics (1989-92) were screened for RSV infection (by nasopharyngeal aspirate and direct immunofluorescence) within 18 hours of admission. The main outcome measure was the occurrence of nosocomial infection, defined as the number of children initially RSV negative who became RSV positive 7 days or more after hospital admission (incubation period for RSV infection is 5-8 days). Without special precautions, there was a high rate of nosocomial RSV infection (26%). Nosocomial infection was significantly reduced by the combination of cohort nursing with the wearing of gowns and gloves for all contacts of RSV-infected children (p = 0.0022). Neither the use of gowns and gloves alone nor cohort nursing alone produced a significant reduction in cross-infection. In the final year, general clinical use of a policy of cohort nursing with gowns and gloves resulted in a reduction in the cross-infection rate by two-thirds of its original value (9.5% vs 26%). Combined with rapid laboratory diagnosis, cohort nursing and the wearing of gowns and gloves for all contacts with RSV-infected children can significantly reduce the risk of nosocomial RSV infection.	ROYAL HOSP SICK CHILDREN, DEPT MICROBIOL, GLASGOW G3 8SJ, SCOTLAND; UNIV GLASGOW, DEPT CHILD HLTH, GLASGOW G12 8QQ, SCOTLAND; UNIV GLASGOW, DEPT STAT, GLASGOW G12 8QQ, SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow			Paton, James/B-9541-2008	McColl, John/0000-0002-6008-2349				AGAH R, 1987, AM J DIS CHILD, V141, P695, DOI 10.1001/archpedi.1987.04460060111049; CONLY JM, 1989, AM J INFECT CONTROL, V17, P330, DOI 10.1016/0196-6553(89)90002-3; Cox D. R., 1984, ANAL SURVIVAL DATA; DITCHBURN RK, 1971, BMJ-BRIT MED J, V3, P671, DOI 10.1136/bmj.3.5776.671; EVERITT BS, 1989, STATISTICAL METHODS; GALA C L, 1986, Journal of the American Medical Association, V256, P2706, DOI 10.1001/jama.256.19.2706; GOLDMANN D, 1992, NEW ENGL J MED, V327, P120, DOI 10.1056/NEJM199207093270211; HALL CB, 1978, PEDIATRICS, V62, P728; HALL CB, 1981, INFECT IMMUN, V33, P779, DOI 10.1128/IAI.33.3.779-783.1981; HALL CB, 1980, J INFECT DIS, V141, P98, DOI 10.1093/infdis/141.1.98; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; HALL CB, 1981, AM J DIS CHILD, V135, P512, DOI 10.1001/archpedi.1981.02130300012006; HALL CB, 1981, J PEDIATR-US, V99, P100, DOI 10.1016/S0022-3476(81)80969-9; ISAACS D, 1991, ARCH DIS CHILD, V66, P227, DOI 10.1136/adc.66.2.227; KRASINSKI K, 1990, J PEDIATR-US, V116, P894, DOI 10.1016/S0022-3476(05)80646-8; LECLAIR JM, 1987, NEW ENGL J MED, V317, P329, DOI 10.1056/NEJM198708063170601; MACDONALD NE, 1982, NEW ENGL J MED, V307, P397, DOI 10.1056/NEJM198208123070702; MURPHY D, 1981, J PEDIATR-US, V99, P746, DOI 10.1016/S0022-3476(81)80401-5	18	135	136	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1992	340	8827					1079	1083		10.1016/0140-6736(92)93088-5	http://dx.doi.org/10.1016/0140-6736(92)93088-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357462				2022-12-28	WOS:A1992JV77500012
J	MILORD, F; PEPIN, J; LOKO, L; ETHIER, L; MPIA, B				MILORD, F; PEPIN, J; LOKO, L; ETHIER, L; MPIA, B			EFFICACY AND TOXICITY OF EFLORNITHINE FOR TREATMENT OF TRYPANOSOMA-BRUCEI-GAMBIENSE SLEEPING SICKNESS	LANCET			English	Article							DL-ALPHA-DIFLUOROMETHYLORNITHINE; ORNITHINE DECARBOXYLASE; AFRICAN TRYPANOSOMIASIS; INDUCED ENCEPHALOPATHY; DFMO; CHEMOTHERAPY; MELARSOPROL; COMBINATION; INHIBITOR; SURAMIN	The usual first-line treatment for Trypanosoma brucei gambiense sleeping sickness is melarsoprol, but when that fails the outlook has hither-to been grim. The polyamine synthesis inhibitor eflornithine (difluoromethylornithine, DFMO) has emerged as an alternative therapy. 207 patients with late-stage T b gambiense sleeping sickness were treated in rural Zaire with three different regimens of DFMO in an open-trial design. During treatment, trypanosomes disappeared from the CSF of all 87 patients in whom parasites had been seen before DFMO administration, and there was a sharp fall in CSF white cell count from a mean of 186/mu-l to 21/mu-l. 152 patients have been followed for at least a year after DFMO treatment, and only 13 (9%) have relapsed. Treatment failures were more common in children less than 12 years, among patients treated with oral DFMO only, and among patients who received DFMO as the initial treatment of their recently diagnosed trypanosomiasis. Toxicity was acceptable. Only 4 patients died during or shortly after treatment. Bone marrow suppression resulting in anaemia (43%) or leucopenia (53%) was common but bore little consequence. This open trial shows that DFMO is as active as and possibly less toxic than melarsoprol. For economic and logistic reasons DFMO may not be the first-choice therapy in rural Africa but for the vast majority of patients who relapse after melarsoprol DFMO will be curative.	ZONE SANTE RURALE, NIOKI, DEM REP CONGO; UNIV SHERBROOKE, DEPT MED, SHERBROOKE J1K 2R1, QUEBEC, CANADA	University of Sherbrooke								BACCHI CJ, 1987, AM J TROP MED HYG, V36, P46, DOI 10.4269/ajtmh.1987.36.46; BACCHI CJ, 1990, ANTIMICROB AGENTS CH, V34, P1183, DOI 10.1128/AAC.34.6.1183; BITONTI AJ, 1986, BIOCHEM PHARMACOL, V35, P331, DOI 10.1016/0006-2952(86)90534-4; CLARKSON AB, 1984, AM J TROP MED HYG, V33, P1073, DOI 10.4269/ajtmh.1984.33.1073; DEGEE ALW, 1983, J PARASITOL, V69, P818, DOI 10.2307/3281038; DOUA F, 1987, AM J TROP MED HYG, V37, P525, DOI 10.4269/ajtmh.1987.37.525; Eozenou P, 1989, Med Trop (Mars), V49, P149; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; HAEGELE KD, 1981, CLIN PHARMACOL THER, V30, P210, DOI 10.1038/clpt.1981.150; HARDENBERG J, 1991, 21ST M INT SCI COUNC; JENNINGS FW, 1988, B SOC PATHOL EXOT, V81, P595; JENNINGS FW, 1988, T ROY SOC TROP MED H, V82, P572, DOI 10.1016/0035-9203(88)90512-3; KAZYUMBA GL, 1988, B SOC PATHOL EXOT, V81, P591; MILORD F, 1991, 21ST M INT SCI COUNC; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; PEPIN J, 1987, LANCET, V2, P1431, DOI 10.1016/S0140-6736(87)91131-7; PEPIN J, IN PRESS AM J TROP M; SCHECHTER PJ, 1987, MED TROPICALE NELLA, V3, P122; TAELMAN H, 1987, AM J MED, V82, P607, DOI 10.1016/0002-9343(87)90107-0; VANNIEUWENHOVE S, 1988, B SOC PATHOL EXOT, V81, P608; VANNIEUWENHOVE S, 1985, T ROY SOC TROP MED H, V79, P692, DOI 10.1016/0035-9203(85)90195-6; 1991, LNACET, V337, P42	23	88	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1992	340	8820					652	655		10.1016/0140-6736(92)92180-N	http://dx.doi.org/10.1016/0140-6736(92)92180-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355219				2022-12-28	WOS:A1992JM85100012
J	PEARSON, ML; JEREB, JA; FRIEDEN, TR; CRAWFORD, JT; DAVIS, BJ; DOOLEY, SW; JARVIS, WR				PEARSON, ML; JEREB, JA; FRIEDEN, TR; CRAWFORD, JT; DAVIS, BJ; DOOLEY, SW; JARVIS, WR			NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS - A RISK TO PATIENTS AND HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; DRUG RESISTANCE, MICROBIAL; CROSS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME		Objective: To determine the factors associated with the development of multidrug-resistant tuberculosis among patients at a New York City Hospital and to investigate possible nosocomial transmission. Design: A retrospective case-control study and tuberculin skin test survey. Patients: Twenty-three patients with tuberculosis whose isolates were resistant to at least isoniazid and rifampin (case patients) were compared with patients with tuberculosis whose isolates were susceptible to all agents tested (controls). Tuberculin skin test conversion rates were compared among health care workers assigned to wards where patients with tuberculosis were frequently or rarely admitted. Setting: A large, teaching hospital in New York City. Measurements: Mycobacterium tuberculosis isolates from case patients and controls were typed by restriction fragment length polymorphism analysis. Results: Case patients were younger (median age, 34 compared with 42 years; P = 0.006), more likely to be seropositive for HIV (21 of 23 compared with 11 of 23 patients; odds ratio, 11.5; 95% Cl, 1.9 to 117), and more likely to have had a previous hospital admission within 7 months before the onset of tuberculosis (19 of 23 compared with 5 of 23 patients; odds ratio, 17.1; Cl, 3.3 to 97), particularly on one ward (12 of 23 compared with 0 of 23 patients; odds ratio, undefined; P = 0.002). Health care workers assigned to wards housing case patients were more likely to have tuberculin skin test conversions than were health care workers assigned to other wards (11 of 32 compared with 1 of 47 health care workers; P < 0.001). Few (6 of 23) case patients were placed in acid-fast bacilli isolation, and no rooms tested had negative pressure. Of 16 available multidrug-resistant isolates obtained from case patients, 14 had identical banding patterns by restriction fragment length polymorphism analysis. In contrast, M. tuberculosis isolates from controls with drug-susceptible tuberculosis had patterns distinct from each other and from those of case patients. Conclusions: These data suggest nosocomial transmission of multidrug-resistant tuberculosis occurred from patient to patient and from patient to health care worker and underscore the need for effective acid-fast bacilli isolation facilities and adherence to published infection control guidelines in health care institutions.	CTR DIS CONTROL, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, OFF DIRECTOR, ATLANTA, GA 30333 USA; CTR DIS CONTROL, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene	PEARSON, ML (corresponding author), CTR DIS CONTROL, HOSP INFECT PROGRAM, MAILSTOP A-07, ATLANTA, GA 30333 USA.							CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DEAN AG, 1991, EPI INFO VERSION 501; GURDIP FS, 1990, CHEST, V98, P1056; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KENT PT, 1985, PUBLIC HLTH MYCOBACT, P166; NOBLE RC, 1981, AM J INFECT CONTROL, V9, P6, DOI 10.1016/S0196-6553(81)80003-X; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; 1991, MMWR, V40, P585; 1991, MMWR, V40, P129; 1990, MMWR, V39, P1; 1991, LANCET, V337, P852	11	484	494	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					191	196		10.7326/0003-4819-117-3-191	http://dx.doi.org/10.7326/0003-4819-117-3-191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1352093				2022-12-28	WOS:A1992JF30400003
J	MALICKI, J; CIANETTI, LC; PESCHLE, C; MCGINNIS, W				MALICKI, J; CIANETTI, LC; PESCHLE, C; MCGINNIS, W			A HUMAN HOX4B REGULATORY ELEMENT PROVIDES HEAD-SPECIFIC EXPRESSION IN DROSOPHILA EMBRYOS	NATURE			English	Article							HOMEOBOX GENE; SEGMENTATION; MELANOGASTER; HINDBRAIN	LIKE other homeobox genes of the Antennapedia and bithorax complexes (collectively called the HOM complex1,2), the Drosophila Deformed (Dfd) gene has structural homologues in the Hox/HOX complexes of mouse and humans, one of which is human HOX4B (refs 3, 4). Previous experiments indicated that HOX4B protein can specifically activate the expression of the endogenous Dfd transcription unit in Drosophila embryos and larvae5. We therefore asked whether HOX4B cis-regulatory elements could mimic the function of a Dfd autoregulatory element6-8 in Drosophila embryos. Here we show that a HOX4B upstream element can surprisingly provide expression in a posterior head segment of Drosophila. One possible mechanism for the axial position-specificity of the human element may involve the conservation of a Dfd-specific autoregulatory circuit in both arthropod and chordate lineages. This possibility is supported by the finding that a Drosophila Dfd autoregulatory element supplies spatially localized expression in the hindbrain of mouse embryos9.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,POB 6666,260 WHITNEY AVE,NEW HAVEN,CT 06511; IST SUPER SANITA,DEPT HEMATOL & ONCOL,I-00161 ROME,ITALY; YALE UNIV,DEPT GENET,NEW HAVEN,CT 06511	Yale University; Istituto Superiore di Sanita (ISS); Yale University			malicki, jarema/G-8611-2014	malicki, jarema/0000-0002-5947-8805				AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FIBI M, 1988, DEVELOPMENT, V102, P349; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; OLDENWALD WF, 1989, GENE DEV, V3, P158; POPPERL H, IN PRESS EMBO J; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; TURNER FR, 1979, DEV BIOL, V68, P96, DOI 10.1016/0012-1606(79)90246-X; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	29	82	88	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					345	347		10.1038/358345a0	http://dx.doi.org/10.1038/358345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353609				2022-12-28	WOS:A1992JE68400068
J	MORGAN, BA; IZPISUABELMONTE, JC; DUBOULE, D; TABIN, CJ				MORGAN, BA; IZPISUABELMONTE, JC; DUBOULE, D; TABIN, CJ			TARGETED MISEXPRESSION OF HOX-4.6 IN THE AVIAN LIMB BUD CAUSES APPARENT HOMEOTIC TRANSFORMATIONS	NATURE			English	Article							SARCOMA; EMBRYO	IN the limb bud the 5' members of the Hox-4 gene cluster are expressed in a nested set of overlapping domains which are progressively restricted in the posterior and distal directions1. These domains arise early in limb bud development and come to approximate the primordia of the major structural elements of the limb along the anterior/posterior axis2 (Fig. 1). This pattern, and the fact that surgical manipulations which lead to mirror image duplications along the anterior/posterior axis give rise to mirror image duplications of the domains of expression of these genes, have led to the proposal that these transcription factors specify positional identity along the anterior/posterior axis3,4. Here we test this hypothesis directly using replication-competent retroviral vectors to expand the domain of expression of the Hox-4.6 gene anteriorly during limb development in vivo. We report that alteration of the domain of expression of the Hox-4.6 gene in the developing limb leads to reproducible pattern alterations consistent with a posterior homeotic transformation.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	MORGAN, BA (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.			duboule, denis/0000-0001-9961-2960				BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; CEPKO C, 1989, NEUROMETHODS, V16, P177; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HURLE JM, 1987, ANAT EMBRYOL, V176, P393, DOI 10.1007/BF00310193; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; MACLEOD M, 1980, J TERATOL, V22, P299; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; ROGINA B, 1992, DEV DYNAM, V193, P92, DOI 10.1002/aja.1001930112; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	15	283	292	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					236	239		10.1038/358236a0	http://dx.doi.org/10.1038/358236a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1352858				2022-12-28	WOS:A1992JD58700054
J	CARR, A; TINDALL, B; BREW, BJ; MARRIOTT, DJ; HARKNESS, JL; PENNY, R; COOPER, DA				CARR, A; TINDALL, B; BREW, BJ; MARRIOTT, DJ; HARKNESS, JL; PENNY, R; COOPER, DA			LOW-DOSE TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; TOXOPLASMOSIS; PNEUMONIA, PNEUMOCYSTIS-CARINII; DOSE-RESPONSE RELATIONSHIP, DRUG	NERVOUS-SYSTEM TOXOPLASMOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-INFECTED PATIENTS; PYRIMETHAMINE; PREVALENCE; EFFICACY; THERAPY; GONDII	Objective: To determine the efficacy of low-dose trimethoprim-sulfamethoxazole (trimethoprim, 160 mg plus sulfamethoxazole, 800 mg; one tablet twice daily, 2 days per week) as primary prophylaxis against toxoplasmic encephalitis in patients with human immunodeficiency virus (HIV) infection and previous Pneumocystis carinii pneumonia. Design: A retrospective study. Setting: Tertiary referral teaching hospital. Patients: During a 3-year period after primary episodes of P. carinii pneumonia, 60 patients received trimethoprim-sulfamethoxazole, and 95 patients received pentamidine (aerosolized in 78 patients and intravenous in 17 patients) as secondary prophylaxis. Results: No patient in the trimethoprim-sulfamethoxazole group and no patient seronegative for Toxoplasma gondii developed toxoplasmic encephalitis, compared with 12 of 36 (33%; 95% CI, 19% to 51%) seropositive patients in the pentamidine group (trimethoprim-sulfamethoxazole compared with pentamidine, P = 0.008). A significant difference was seen in the time to development of toxoplasmic encephalitis between the trimethoprim-sulfamethoxazole group (no case at 1153 days) and the pentamidine group (median time, 460 days) (P = 0.004). Neither the CD4+ lymphocyte count at the start of prophylaxis nor zidovudine therapy during the period of prophylaxis influenced the rate of toxoplasmic encephalitis in any group. Conclusions: Low-dose trimethoprim-sulfamethoxazole (four tablets per week) appears to be effective prophylaxis against toxoplasmic encephalitis in HIV-infected patients with previous P. carinii pneumonia. A prospective, randomized, controlled study is needed to further evaluate these findings.	NATL CTR HIV EPIDEMIOL & CLIN RES, SYDNEY 2010, AUSTRALIA	University of New South Wales Sydney; Kirby Institute	CARR, A (corresponding author), ST VINCENTS HOSP, CTR IMMUNOL, SYDNEY, NSW 2010, AUSTRALIA.		McLean, Emma/F-4616-2012; Brew, Bruce/J-6513-2012					CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DEROUIN F, 1990, AIDS, V4, P1036; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; GRUNEWALD T, 1991, JUN NEUR HIV INF PAD; HERRERA G, 1991, 7TH INT C AIDS FLOR; HOLLIMAN RE, 1990, EPIDEMIOL INFECT, V105, P415, DOI 10.1017/S0950268800047993; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; ISRAELSKI DM, 1989, ANTIMICROB AGENTS CH, V33, P30, DOI 10.1128/AAC.33.1.30; ISRAELSKI DM, 1990, MED MANAGEMENT AIDS, P241; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LIDMAN C, 1989, SCAND J INFECT DIS, V21, P381, DOI 10.3109/00365548909167441; LINDSAY DS, 1991, ANTIMICROB AGENTS CH, V35, P1914, DOI 10.1128/AAC.35.9.1914; LUFT BJ, 1990, AIDS, V4, P593, DOI 10.1097/00002030-199006000-00018; MASLO M, 1991, 7TH INT C AIDS FLOR; MENICHETTI F, 1991, 7TH INT C AIDS FLOR; NIELSEN TL, 1990, 6TH INT C AIDS SAN F; OFARRELL N, 1991, 7TH INT C AIDS FLOR; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127; RAVIGLIONE MC, 1990, LANCET, V336, P180, DOI 10.1016/0140-6736(90)91701-B; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; WEISS LM, 1988, J INFECT DIS, V157, P580, DOI 10.1093/infdis/157.3.580; 1990, BRIT MED J, V301, P226; 1985, SAS STAT GUIDE PERSO; 1989, MMWR, V38, P1	27	231	235	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					106	111		10.7326/0003-4819-117-2-106	http://dx.doi.org/10.7326/0003-4819-117-2-106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1351371				2022-12-28	WOS:A1992JD12300002
J	BONUCCELLI, U; DELDOTTO, P; PICCINI, P; BEHGE, F; CORSINI, GU; MURATORIO, A				BONUCCELLI, U; DELDOTTO, P; PICCINI, P; BEHGE, F; CORSINI, GU; MURATORIO, A			DEXTROMETHORPHAN AND PARKINSONISM	LANCET			English	Letter							ANTAGONIST MK-801; AGENTS; RATS		GENTILI INST,CLIN RES DEPT,PISA,ITALY; UNIV PISA,INST PHARMACOL,I-56100 PISA,ITALY	University of Pisa	BONUCCELLI, U (corresponding author), UNIV PISA,INST CLIN NEUROL,I-56100 PISA,ITALY.		Bonuccelli, Ubaldo/K-8681-2016	Bonuccelli, Ubaldo/0000-0001-6218-6312; Piccini, Paola/0000-0003-4162-6141				CARLSSON M, 1989, J NEURAL TRANSM, V75, P221, DOI 10.1007/BF01258633; CHURCH J, 1989, CAN J PHYSIOL PHARM, V67, P561, DOI 10.1139/y89-090; GRAHAM WC, 1990, LIFE SCI, V47, pPL91, DOI 10.1016/0024-3205(90)90376-3; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; KLOCKGETHER T, 1990, ANN NEUROL, V28, P539, DOI 10.1002/ana.410280411; KORNHUBER J, 1991, EUR J PHARM-MOLEC PH, V206, P297, DOI 10.1016/0922-4106(91)90113-V; OLNEY JW, 1987, EUR J PHARMACOL, V142, P319, DOI 10.1016/0014-2999(87)90123-3; RIEDERER P, 1991, LANCET, V338, P1022, DOI 10.1016/0140-6736(91)91888-2; SCHMIDT WJ, 1989, PHARMACOL BIOCHEM BE, V32, P621, DOI 10.1016/0091-3057(89)90007-5	9	46	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					53	53		10.1016/0140-6736(92)92466-S	http://dx.doi.org/10.1016/0140-6736(92)92466-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351627				2022-12-28	WOS:A1992JC35400036
J	FRANKLYN, JA; BETTERIDGE, J; DAYKIN, J; HOLDER, R; OATES, GD; PARLE, JV; LILLEY, J; HEATH, DA; SHEPPARD, MC				FRANKLYN, JA; BETTERIDGE, J; DAYKIN, J; HOLDER, R; OATES, GD; PARLE, JV; LILLEY, J; HEATH, DA; SHEPPARD, MC			LONG-TERM THYROXINE TREATMENT AND BONE-MINERAL DENSITY	LANCET			English	Article							THYROID-HORMONE; SUBCLINICAL HYPERTHYROIDISM; REPLACEMENT TREATMENT; THERAPY; WOMEN	Studies of the effect of thyroxine replacement therapy on bone mineral density have given conflicting results; the reductions in bone mass reported by some have prompted recommendations that prescribed doses of thyroxine should be reduced. We have examined the effect of long-term thyroxine treatment in a large homogeneous group of patients; all had undergone thyroidectomy for differentiated thyroid cancer but had no history of other thyroid disorders. The 49 patients were matched with controls for age, sex, menopausal status, body mass index, smoking history, and calcium intake score; in all subjects bone mineral density at several femoral and vertebral sites was measured by dual-energy X-ray absorptiometry. Despite long-term thyroxine therapy (mean duration 7.9 [range 1-19] years) at doses (mean 191 [SD 50]mu-g/day) that resulted in higher serum thyroxine and lower serum thyrotropin concentrations than in the controls, the patients showed no evidence of lower bone mineral density than the controls at any site. Nor was bone mineral density correlated with dose, duration of therapy, or cumulative intake, or with tests of thyroid function. There was a decrease in bone density with age in both groups. We suggest that thyroxine alone does not have a significant effect on bone mineral density and hence on risk of osteoporotic fractures.	GEN HOSP,THYROID CLIN,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT STAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT NUCL MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham								BARAN DT, 1991, J CLIN ENDOCR METAB, V72, P1182, DOI 10.1210/jcem-72-6-1182; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FRANKLYN JA, 1990, BRIT MED J, V300, P693, DOI 10.1136/bmj.300.6726.693; FRANKLYN JA, 1992, TRENDS ENDOCRIN MET, V3, P113, DOI 10.1016/1043-2760(92)90098-L; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; Lilley J, 1991, Osteoporos Int, V1, P141, DOI 10.1007/BF01625443; Meunier PJ, 1972, ORTHOPEDIA CLINICS N, V3, P745; PACINI F, 1985, CLIN ENDOCRINOL, V23, P405, DOI 10.1111/j.1365-2265.1985.tb01098.x; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PEARCE CJ, 1984, BRIT MED J, V288, P693, DOI 10.1136/bmj.288.6418.693; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSS DS, 1989, J CLIN ENDOCR METAB, V69, P684, DOI 10.1210/jcem-69-3-684; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOFT AD, 1991, CLIN ENDOCRINOL, V34, P103, DOI 10.1111/j.1365-2265.1991.tb00278.x; TOH SH, 1990, J BONE MINER RES, V5, P463, DOI 10.1002/jbmr.5650050507; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; UTIGER RD, 1990, NEW ENGL J MED, V323, P126; VONRECKLINGHAUS.F, 1891, R VIRCHOW FESTSCHRIF, P20; 1990, LANCET, V336, P1352	24	180	187	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					9	13		10.1016/0140-6736(92)92423-D	http://dx.doi.org/10.1016/0140-6736(92)92423-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351654				2022-12-28	WOS:A1992JC35400003
J	BERENDT, AR; MCDOWALL, A; CRAIG, AG; BATES, PA; STERNBERG, MJE; MARSH, K; NEWBOLD, CI; HOGG, N				BERENDT, AR; MCDOWALL, A; CRAIG, AG; BATES, PA; STERNBERG, MJE; MARSH, K; NEWBOLD, CI; HOGG, N			THE BINDING-SITE ON ICAM-1 FOR PLASMODIUM-FALCIPARUM INFECTED ERYTHROCYTES OVERLAPS, BUT IS DISTINCT FROM, THE LFA-1-BINDING SITE	CELL			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; IMMUNOGLOBULIN-LIKE DOMAINS; HUMAN MALARIA PARASITES; MAJOR GROUP RECEPTOR; MEMBRANE GLYCOPROTEIN; RHINOVIRUS RECEPTOR; CEREBRAL MALARIA; CD4 ANTIGEN; IDENTIFICATION; CYTOADHERENCE	The intercellular adhesion molecule-1 (ICAM-1, CD54) is one of three putative endothelial receptors that mediate in vitro cytoadherence of P. falciparum-infected erythrocytes. Since cytoadherence to postcapillary venular endothelium is thought to be a major factor in the virulence of P. falciparum malaria, we have examined the interaction between ICAM-1 and the P. falciparum-infected cell, and have compared it with the interaction to the physiological counter receptor, the leukocyte integrin LFA-1. Our results demonstrate that the malaria-binding site resides in the first two domains of the ICAM-1 molecule and overlaps, but is distinct from, the LFA-1 site.	IMPERIAL CANC RES FUND, MACROPHAGE LAB, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, BIOMOLEC MODELLING LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK; Cancer Research UK	BERENDT, AR (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC PARASITOL GRP, OXFORD OX3 9DU, ENGLAND.		Bates, Paul A/AAF-8561-2020	Bates, Paul A/0000-0003-0621-0925; McDowall, Alison/0000-0003-2018-1462; Craig, Alister/0000-0003-0914-6164; Newbold, Chris/0000-0002-9274-3789; Sternberg, Michael/0000-0002-1884-5445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALLANTYNE CM, 1989, NUCLEIC ACIDS RES, V17, P5853, DOI 10.1093/nar/17.14.5853; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BATES PA, 1989, PROTEIN ENG, V3, P13, DOI 10.1093/protein/3.1.13; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BERENDT AR, 1990, PARASITOL TODAY, V6, P247, DOI 10.1016/0169-4758(90)90184-6; BOYD AW, 1988, P NATL ACAD SCI USA, V85, P3095, DOI 10.1073/pnas.85.9.3095; COX FEG, 1991, NATURE, V349, P193, DOI 10.1038/349193a0; CRAIG AG, 1991, CHEM IMMUNOL, V50, P116; CRANSTON HA, 1984, SCIENCE, V223, P400, DOI 10.1126/science.6362007; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GREENWOOD BM, 1990, PARASITOL TODAY, V6, P188, DOI 10.1016/0169-4758(90)90351-4; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAYNES JD, 1976, NATURE, V263, P767, DOI 10.1038/263767a0; HOGG N, 1991, CHEM IMMUNOL, V50, P98; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; HOWARD RJ, 1989, BLOOD, V74, P2603; JOHNSON JP, 1988, IMMUNOBIOLOGY, V178, P275, DOI 10.1016/S0171-2985(88)80071-8; JOHNSON JP, 1989, LEUCOCYTE TYPING, V4, P681; LINEBERGER DW, 1990, J VIROL, V64, P2582, DOI 10.1128/JVI.64.6.2582-2587.1990; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MOLGG M, 1991, IMMUNOL LETT, V28, P237, DOI 10.1016/0165-2478(91)90010-8; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NEWBOLD C, 1990, NATURE, V345, P202, DOI 10.1038/345202a0; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCHULZ TF, 1988, EUR J IMMUNOL, V18, P7, DOI 10.1002/eji.1830180103; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	47	244	257	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					71	81		10.1016/0092-8674(92)90207-S	http://dx.doi.org/10.1016/0092-8674(92)90207-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370656				2022-12-28	WOS:A1992GZ58300010
J	LEWIS, DL; ARENS, M; APPLETON, SS; NAKASHIMA, K; RYU, J; BOE, RK; PATRICK, JB; WATANABE, DT; SUZUKI, M				LEWIS, DL; ARENS, M; APPLETON, SS; NAKASHIMA, K; RYU, J; BOE, RK; PATRICK, JB; WATANABE, DT; SUZUKI, M			CROSS-CONTAMINATION POTENTIAL WITH DENTAL EQUIPMENT	LANCET			English	Article							BACTERIAL-CONTAMINATION; WATER	Some types of reused dental equipment, especially handpieces and their attachments for drilling and cleaning teeth, might be responsible for cross-contamination if patient material were to lodge temporarily in difficult-to-disinfect internal mechanisms. This possibility is worrisome with respect to transmission of hepatitis B and human immunodeficiency viruses (HBV, HIV). Previous cross-contamination studies have relied on laboratory experiments with bacteria or dye tracers. To assess possible risks more thoroughly, we tested 30 new prophylaxis angles and 12 new high-speed handpieces to see whether they would take up and expel contaminants in laboratory and clinical trials. In treatments of three patients, including two infected with HIV, human-specific DNA (beta-globin, HLA DQalpha) and HIV proviral DNA were detected inside or coming back from the devices. Similarly, when handpieces were operated in contact with blood pooled from HBV-infected patients, HBV DNA was detected in samples taken from inside the equipment and from their attached air/water hoses. When we used bacteriophage phiX174 as a model virus in laboratory tests, many infective viral particles were recovered from internal mechanisms of handpieces, their connecting air/water hoses, and from water spray expelled when the equipment was reused. We recommend that reused high-speed, air-driven handpieces and prophylaxis angles should be cleaned and heat-treated between patients. Further studies are needed to determine ways of eliminating the risks associated with exhaust hoses and air/water input lines.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; LOMA LINDA UNIV,SCH DENT,LOMA LINDA,CA 92350; LOMA LINDA UNIV,SCH MED,DEPT MICROBIOL,LOMA LINDA,CA 92354	Washington University (WUSTL); Loma Linda University; Loma Linda University	LEWIS, DL (corresponding author), UNIV GEORGIA,FAC ECOL,ATHENS,GA 30602, USA.			Lewis, David/0000-0003-0777-2460				ABEL LC, 1971, J DENT RES, V50, P1567, DOI 10.1177/00220345710500063601; ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; BAGGA BSR, 1984, J AM DENT ASSOC, V109, P712, DOI 10.14219/jada.archive.1984.0168; CHRISTENSEN GJ, 1991, J AM DENT ASSOC, V122, P99, DOI 10.14219/jada.archive.1991.0233; Erlich H. A., 1990, PCR PROTOCOLS, P261; LEWIS DL, 1992, J CLIN MICROBIOL, V30, P401, DOI 10.1128/JCM.30.2.401-406.1992; MARTIN MV, 1987, BRIT DENT J, V163, P152, DOI 10.1038/sj.bdj.4806220; PELZNER RB, 1977, J DENT RES, V56, P1629, DOI 10.1177/00220345770560123601; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEID RC, 1982, J AM DENT ASSOC, V105, P658, DOI 10.14219/jada.archive.1982.0438; 1990, MMWR, V39, P489	11	70	73	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1252	1254		10.1016/0140-6736(92)92950-K	http://dx.doi.org/10.1016/0140-6736(92)92950-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359320				2022-12-28	WOS:A1992JZ23700004
J	KERSTJENS, HAM; BRAND, PLP; HUGHES, MD; ROBINSON, NJ; POSTMA, DS; SLUITER, HJ; BLEECKER, ER; DEKHUIJZEN, PNR; DEJONG, PM; MENGELERS, HJJ; OVERBEEK, SE; SCHOONBROOD, DFME				KERSTJENS, HAM; BRAND, PLP; HUGHES, MD; ROBINSON, NJ; POSTMA, DS; SLUITER, HJ; BLEECKER, ER; DEKHUIJZEN, PNR; DEJONG, PM; MENGELERS, HJJ; OVERBEEK, SE; SCHOONBROOD, DFME			A COMPARISON OF BRONCHODILATOR THERAPY WITH OR WITHOUT INHALED CORTICOSTEROID-THERAPY FOR OBSTRUCTIVE AIRWAYS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; LONG-TERM TREATMENT; IPRATROPIUM BROMIDE; CHRONIC-BRONCHITIS; LUNG-FUNCTION; PULMONARY-DISEASE; BETA-AGONISTS; ASTHMA; BUDESONIDE; HYPERRESPONSIVENESS	Background. The morbidity from obstructive airways disease (asthma and chronic obstructive pulmonary disease) is considerable, and the mortality rate is rising in several countries. It has been hypothesized that long-term improvement in prognosis might result from vigorous bronchodilator or antiinflammatory therapy. Methods. In a multicenter trial we compared three inhalation regimens in which a beta2-agonist (terbutaline, 2000 mug daily) was combined with a corticosteroid (beclomethasone, 800 mug daily), an anticholinergic bronchodilator (ipratropium bromide, 160 mug daily), or placebo. Patients with airways hyperresponsiveness and obstruction who were 18 to 60 years old were followed for 2 1/2 years. Results. Of the 274 patients enrolled, 56 percent had allergies. The mean forced expiratory volume in one second (FEV1) was 64 percent of the predicted value. The mean PC20 (the concentration of inhaled histamine causing a 20 percent decrease in FEV1, a measure of hyperresponsiveness) was 0.26 mg per milliliter. Withdrawal from the study, due mainly to pulmonary symptoms, was less frequent in the corticosteroid group (12 of 91 patients) than in the anticholinergic-drug group (45 of 92 patients) or the placebo group (44 of 91 patients; P<0.001). The mean FEV1 (+/-SE) increased by 10.3+/-1.3 percent of the predicted value in the corticosteroid group within three months and remained stable thereafter, whereas it did not change in the other two groups (P<0.001). The PC20 increased by 2.0 doubling concentrations in the corticosteroid group but did not change in the other groups (P<0.001). In the corticosteroid group, patients who did not smoke, who had allergies, or who were less than 40 years old benefited more from their treatment than did those who smoked, did not have allergies, or were over 40, but all subgroups of the corticosteroid group had improvement as compared with the anticholinergic-drug or placebo group. Conclusions. The addition of an inhaled corticosteroid - but not an inhaled anticholinergic agent - to maintenance treatment with a beta2-agonist (terbutaline) substantially reduced morbidity, hyperresponsiveness, and airways obstruction in patients with a spectrum of obstructive airways disease.	UNIV GRONINGEN HOSP,DEPT PULM,9713 EZ GRONINGEN,NETHERLANDS; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND; UNIV MARYLAND,SCH MED,DEPT PULM & CRIT CARE MED,BALTIMORE,MD 21201; CATHOLIC UNIV NIJMEGEN,HOSP ST RADBOUD,DEPT PULM,NIJMEGEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT PULM,2333 AA LEIDEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT PULM,3511 GV UTRECHT,NETHERLANDS; UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT PULM,ROTTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PULM,1105 AZ AMSTERDAM,NETHERLANDS	University of Groningen; University of London; London School of Hygiene & Tropical Medicine; University System of Maryland; University of Maryland Baltimore; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam			Brand, Paul/ABB-3693-2021; Kerstjens, Huib/N-4754-2017; Dekhuijzen, P NR/H-8024-2014	Kerstjens, Huib/0000-0001-7705-7927; Dekhuijzen, P NR/0000-0003-1365-900X				ANTHONISEN NR, 1989, AM REV RESPIR DIS, V140, pS95, DOI 10.1164/ajrccm/140.3_Pt_2.S95; ARMITAGE P, 1987, STATISTICAL METHODS; AUFFARTH B, 1991, THORAX, V46, P372, DOI 10.1136/thx.46.5.372; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARTER CE, 1976, AM REV RESPIR DIS, V113, P305; BRAND PLP, 1992, EUR RESPIR J, V5, P21; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRANE J, 1989, LANCET, V1, P917; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; ENGEL T, 1989, EUR RESPIR J, V2, P935; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HIGGINS RM, 1988, CHEST, V94, P718, DOI 10.1378/chest.94.4.718; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MANFREDA J, 1989, AM REV RESPIR DIS, V140, pS19, DOI 10.1164/ajrccm/140.3_Pt_2.S19; MILLER MR, 1988, THORAX, V43, P265, DOI 10.1136/thx.43.4.265; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P84; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; POSTMA DS, 1988, EUR RESPIR J, V1, P22; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; PRICE NB, 1989, EUR RESPIR J, V2, P702; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RENKEMA T E J, 1990, American Review of Respiratory Disease, V141, pA504; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STORMS WW, 1986, AM J MED, V81, P61, DOI 10.1016/0002-9343(86)90464-X; TASHKIN DP, 1986, AM J MED, V81, P81, DOI 10.1016/0002-9343(86)90468-7; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TURNERWARWICK M, 1982, CHEST, V82, pS3, DOI 10.1378/chest.82.1_Supplement.3S; VANESSENZANDVLIET EEM, 1990, IMMUNOL ALLERGY CLIN, V10, P483; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; WATSON WTA, 1988, J ALLERGY CLIN IMMUN, V82, P1012, DOI 10.1016/0091-6749(88)90138-8; WEIR DC, 1990, THORAX, V45, P118, DOI 10.1136/thx.45.2.118; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112; 1987, AM REV RESPIR DIS, V136, P225	44	262	268	2	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1413	1419		10.1056/NEJM199211123272003	http://dx.doi.org/10.1056/NEJM199211123272003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1357553				2022-12-28	WOS:A1992JX47900003
J	REDD, SC; BLOLAND, PB; KAZEMBE, PN; PATRICK, E; TEMBENU, R; CAMPBELL, CC				REDD, SC; BLOLAND, PB; KAZEMBE, PN; PATRICK, E; TEMBENU, R; CAMPBELL, CC			USEFULNESS OF CLINICAL CASE-DEFINITIONS IN GUIDING THERAPY FOR AFRICAN CHILDREN WITH MALARIA OR PNEUMONIA	LANCET			English	Article							PRIMARY HEALTH-CARE; PERENNIAL TRANSMISSION; PLASMODIUM-FALCIPARUM; EARLY-CHILDHOOD; DIAGNOSIS; POPULATION; INFECTIONS; EFFICACY; DISEASE; INTENSE	The World Health Organisation has developed disease-specific clinical case-definitions to guide management of children with fever or cough, the cardinal signs of malaria and pneumonia. To assess the usefulness of the case-definitions and to investigate their interaction, we studied children with fever or cough brought to a hospital in Lilongwe, Malawi. For all children, a thick blood smear was examined for Plasmodium falciparum parasites. Chest radiography was done only for children with parasitaemia and those who satisfied the clinical case-definition for pneumonia; others were assumed to have normal chest radiographs. Of 1599 enrolled children, 566 (35%) had parasitaemia and 116 had radiographic evidence of pneumonia; 43 had both pneumonia and parasitaemia. Of the 471 children who met the clinical definition for pneumonia, 449 (95%) also met the malaria clinical definition. Among children with radiographic evidence of pneumonia, the clinical definition for malaria was not predictive of parasitaemia (sensitivity 93%, specificity 5%). Whether malaria parasitaemia was present or absent, the pneumonia clinical definition distinguished children with and without radiographic evidence of pneumonia (sensitivity and specificity >60%). Children who satisifed the pneumonia clinical definition were more likely to have radiographic evidence of pneumonia (odds ratio 10.4, 95% confidence interval 5.2-20.7), parasitaemia (1.6, 1.2-2.2), or both at the same time (4.2, 2.1-8.4) than were children who did not meet the definition. Children who satisfy the malaria and pneumonia clinical definitions need treatment for both disorders. Scarce diagnostic methods, especially microscopy, are needed for more specific treatment of children with fever and cough.	CTR DIS CONTROL,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; MALAWI MINIST HLTH,LILONGWE,MALAWI; EMORY UNIV,SCH MED,DEPT RADIOL,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Emory University	REDD, SC (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,MAILSTOP F12,ATLANTA,GA 30333, USA.							BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; CAMPBELL H, 1988, LANCET, V2, P742; CAMPBELL H, 1988, LANCET, V2, P1182; DARAMOLA OO, 1991, T R SOC TROP MED HYG, V84, P345; FREUND RJ, 1982, SAS SYSTEM LINEAR MO, P9; GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91, DOI 10.1080/02724936.1987.11748482; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; HENDRICKSE RG, 1971, ANN TROP MED PARASIT, V65, P1; HEYMANN DL, 1987, T ROY SOC TROP MED H, V81, P722, DOI 10.1016/0035-9203(87)90005-8; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KHOROMANA CO, 1986, AM J TROP MED HYG, V35, P465, DOI 10.4269/ajtmh.1986.35.465; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P; RUEBUSH TK, 1986, REV INFECT DIS, V8, P454; SARMA PS, 1989, ANN INTERN MED, V111, P336, DOI 10.7326/0003-4819-111-4-336; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; TRAPE JF, 1987, AM J EPIDEMIOL, V126, P193, DOI 10.1093/aje/126.2.193; TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P435, DOI 10.1016/0035-9203(85)90054-9; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; 1990, SUPERVISORY SKILLS M; 1990, WHOARI905 WORLD HLTH; 1986, SUGI SUPPLEMENTAL LI, P269; 1986, WHO TECH REP SER, V375	23	64	65	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1140	1143		10.1016/0140-6736(92)93160-O	http://dx.doi.org/10.1016/0140-6736(92)93160-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359219	Bronze			2022-12-28	WOS:A1992JX13400012
J	ALMSTROM, H; AXELSSON, O; CNATTINGIUS, S; EKMAN, G; MAESEL, A; ULMSTEN, U; ARSTROM, K; MARSAL, K				ALMSTROM, H; AXELSSON, O; CNATTINGIUS, S; EKMAN, G; MAESEL, A; ULMSTEN, U; ARSTROM, K; MARSAL, K			COMPARISON OF UMBILICAL-ARTERY VELOCIMETRY AND CARDIOTOCOGRAPHY FOR SURVEILLANCE OF SMALL-FOR-GESTATIONAL-AGE FETUSES	LANCET			English	Article							INTRAUTERINE GROWTH-RETARDATION; SECONDARY DIAGNOSTIC-TEST; VELOCITY WAVE FORM; ULTRASONIC MEASUREMENT; FETAL; PREGNANCIES; WAVEFORMS; FLOW; CURVES; WEIGHT	Intrauterine growth retardation is associated with an increased risk of fetal asphyxia as well as greater perinatal morbidity and mortality. Ultrasound fetometry enables detection of fetuses that are small for gestational age. Doppler velocimetry of the umbilical artery has good predictive ability for fetal distress, but it is not yet clear whether it could replace cardiotocography in antenatal surveillance of small-for-gestational-age fetuses. We have done a randomised comparison of the two methods. At four obstetric departments in Sweden, women with fetuses found to be small on ultrasound examination at 31 completed weeks of pregnancy or later were randomly assigned to antenatal surveillance with either doppler velocimetry (doppler; 214) or cardiotocography (CTG; 212). Pregnancies in the doppler group were managed according to a protocol based on blood-flow classes deriving from the semiquantitative evaluation of umbilical-artery velocity waveforms; unless the pregnancy was complicated by any other disorder, no antenatal cardiotocography was done. By comparison with the CTG group, the doppler group had fewer monitoring occasions (mean 4.1 [SD 3.1] vs 8.2 [6.2], p < 0.01), antenatal hospital admissions (68 [31.3%] vs 97 [45.8%], p < 0.01), inductions of labour (22 [10.3%] vs 46 [21.7%], p < 0.01), emergency caesarean sections for fetal distress (11 [5.1] vs 30 [14.2%], p < 0.01), and admissions to neonatal intensive care (76 [35.5%] vs 92 [43.4%], p=0.10). The groups did not differ in gestational age at birth, birthweight, Apgar scores, or total number of caesarean deliveries. Umbilical-artery doppler velocimetry of small-for-gestational-age fetuses allows antenatal monitoring and obstetric interventions to be aimed more precisely than does cardiotocography.	UNIV UPPSALA, DEPT OBSTET & GYNAECOL, S-75105 UPPSALA, SWEDEN; UNIV UPPSALA, DEPT SOCIAL MED, S-75105 UPPSALA, SWEDEN; CTY HOSP KARLSTAD, KARLSTAD, SWEDEN; UNIV LUND, MALMO GEN HOSP, DEPT OBSTET & GYNAECOL, S-21401 MALMO, SWEDEN	Uppsala University; Uppsala University; Lund University	ALMSTROM, H (corresponding author), KAROLINSKA INST, DANDERYDS HOSP, DEPT OBSTET & GYNAECOL, S-10401 STOCKHOLM 60, SWEDEN.							ARDUINI D, 1991, J ULTRAS MED, V10, P331; BEATTIE RB, 1989, BRIT MED J, V298, P631, DOI 10.1136/bmj.298.6674.631; BERKOWITZ GS, 1988, AM J OBSTET GYNECOL, V158, P1149, DOI 10.1016/0002-9378(88)90243-8; CNATTINGIUS S, 1988, BMJ-BRIT MED J, V297, P258, DOI 10.1136/bmj.297.6643.258; FLEISCHER A, 1985, AM J OBSTET GYNECOL, V151, P502, DOI 10.1016/0002-9378(85)90278-9; Gosling RG., 1975, ARTERIES VEINS, P61; GRANT A, 1982, EFFECTIVENESS SATISF, P266; GRENNERT L, 1978, ACTA OBSTET GYN SCAN, P5; GUDMUNDSSON S, 1988, ACTA OBSTET GYN SCAN, V67, P347, DOI 10.3109/00016348809004234; GUDMUNDSSON S, 1988, EUR J OBSTET GYN R B, V27, P187, DOI 10.1016/0028-2243(88)90122-0; HEINONEN K, 1985, J PERINAT MED, V13, P171, DOI 10.1515/jpme.1985.13.4.171; JONES RAK, 1984, CLIN OBSTET GYNAECOL, V11, P499; LAURIN J, 1987, OBSTET GYNECOL, V69, P895; LOW JA, 1975, AM J OBSTET GYNECOL, V121, P456, DOI 10.1016/0002-9378(75)90074-5; LOWERY CL, 1990, AM J OBSTET GYNECOL, V162, P710, DOI 10.1016/0002-9378(90)90991-F; MALCUS P, 1991, ULTRASOUND OBST GYN, V1, P1; MANDRUZZATO GP, 1991, ULTRASOUND OBST GYN, V1, P192, DOI 10.1046/j.1469-0705.1991.01030192.x; MANNING FA, 1981, AM J OBSTET GYNECOL, V139, P254, DOI 10.1016/0002-9378(81)90004-1; MANNING FA, 1980, AM J OBSTET GYNECOL, V136, P787, DOI 10.1016/0002-9378(80)90457-3; MARSAL K, 1988, J CLIN ULTRASOUND, V16, P239, DOI 10.1002/jcu.1870160405; MARSAL K, 1991, J PERINAT MED, V19, P299; PERSSON PH, 1986, ACTA OBSTET GYN SCAN, V65, P169, DOI 10.3109/00016348609158374; PERSSON PH, 1986, ACTA OBSTET GYN SCAN, V65, P759, DOI 10.3109/00016348609161496; SMITH CV, 1987, BAILLIERE CLIN OB GY, V1, P17, DOI 10.1016/S0950-3552(87)80021-4; SOLUM T, 1979, Z GEBURTSH PERINATOL, V183, P212; TRUDINGER BJ, 1986, BRIT J OBSTET GYNAEC, V93, P171, DOI 10.1111/j.1471-0528.1986.tb07882.x; TRUDINGER BJ, 1987, LANCET, V1, P188; 1976, BR J RADIOL S, V20, P26	28	87	90	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1992	340	8825					936	940		10.1016/0140-6736(92)92818-Z	http://dx.doi.org/10.1016/0140-6736(92)92818-Z			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357349				2022-12-28	WOS:A1992JT82300004
J	VANBOCKXMEER, FM; MAMOTTE, CDS				VANBOCKXMEER, FM; MAMOTTE, CDS			APOLIPOPROTEIN EPSILON-4 HOMOZYGOSITY IN YOUNG MEN WITH CORONARY HEART-DISEASE	LANCET			English	Note							E POLYMORPHISM	We have compared apolipoprotein E gene polymorphism in 91 Australian men aged 30-50 who had been referred for coronary angioplasty and in 172 healthy younger men. 5 of the 19 patients who were less than 40 years of age were homozygous for the epsilon4 allele, representing a 16-fold increase in prevalence compared with controls. In patients aged 40-50 the epsilon4 allele frequency was 60% higher than it was in controls. Inheritance of epsilon4 seems to confer risk of premature ischaemic heart disease in males, homozygotes being especially at risk at a younger age.			VANBOCKXMEER, FM (corresponding author), ROYAL PERTH HOSP,DEPT BIOCHEM,GPO BOX X2213,PERTH,WA 6001,AUSTRALIA.		Mamotte, Cyril/AAF-9603-2020	Mamotte, Cyril/0000-0003-1831-3921				DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1991, ATHEROSCLEROSIS, V90, P169, DOI 10.1016/0021-9150(91)90111-F; ETO M, 1989, CLIN GENET, V36, P183; HIXSON JE, 1990, J LIPID RES, V31, P545; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LAAKSO M, 1991, BMJ-BRIT MED J, V303, P1159, DOI 10.1136/bmj.303.6811.1159; NIEMINEN MS, 1992, ARTERIOSCLER THROMB, V12, P58, DOI 10.1161/01.ATV.12.1.58; PEACOCK R, 1992, ATHEROSCLEROSIS, V92, P151, DOI 10.1016/0021-9150(92)90274-K; REARDON MF, 1985, CIRCULATION, V71, P881, DOI 10.1161/01.CIR.71.5.881; STUYT PMJ, 1991, SCAND J CLIN LAB INV, V51, P425, DOI 10.3109/00365519109091636	10	178	182	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					879	880		10.1016/0140-6736(92)93288-X	http://dx.doi.org/10.1016/0140-6736(92)93288-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357300				2022-12-28	WOS:A1992JT32700007
J	TODD, D				TODD, D			THE HONG-KONG-ACADEMY-OF-MEDICINE	LANCET			English	Editorial Material											TODD, D (corresponding author), QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					835	836		10.1016/0140-6736(92)92696-D	http://dx.doi.org/10.1016/0140-6736(92)92696-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357255				2022-12-28	WOS:A1992JR16800015
J	ALBERTI, A; MORSICA, G; CHEMELLO, L; CAVALLETTO, D; NOVENTA, F; PONTISSO, P; RUOL, A				ALBERTI, A; MORSICA, G; CHEMELLO, L; CAVALLETTO, D; NOVENTA, F; PONTISSO, P; RUOL, A			HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV	LANCET			English	Note							NON-B-HEPATITIS; NON-A; BLOOD-DONORS; VIRUS; ANTIBODIES; GENOME	There is controversy about clinical management of patients who persistently have antibodies to hepatitis C virus (anti-HCV) but who have no symptoms and signs of liver disease. We have taken liver biopsy samples from 23 such patients (1 6 of whom had normal alanine aminotransferase [ALT] values) to assess prevalence of liver disease and to see whether anti-HCV and HCV-RNA correlated with histological findings. 16 patients had histological evidence of chronic hepatitis, which was not predicted by serum ALT or by the pattern of specificity of anti-HCV. All 16 cases with hepatitis C viraemia (HCV-RNA detected by polymerase chain reaction), including 9 with normal ALT, had chronic hepatitis on biopsy (p<0.001), whereas 7 HCV-RNA-negative cases had normal liver histology. These findings indicate that serum HCV-RNA is a sensitive and specific marker of liver disease in anti-HCV-positive subjects, independent of ALT values, and challenge the idea of the existence of "true" healthy carriers of HCV.	UNIV PADUA,DEPT INTERNAL MED 2,I-35100 PADUA,ITALY	University of Padua			Morsica, Giulia/AAC-4993-2019; Noventa, Franco/C-1202-2008; chemello, liliana/AAU-9414-2020; PONTISSO, PATRIZIA/K-3574-2018	Morsica, Giulia/0000-0003-4891-5376; Noventa, Franco/0000-0003-4622-5523; ALBERTI, ALFREDO/0000-0001-9926-2382; PONTISSO, PATRIZIA/0000-0003-2077-9202				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; [Anonymous], 1977, Lancet, V2, P914; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; OKAMOTO H, 1990, JPN J EXP MED, V60, P167	9	423	422	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					697	698		10.1016/0140-6736(92)92234-7	http://dx.doi.org/10.1016/0140-6736(92)92234-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355801				2022-12-28	WOS:A1992JN78000006
J	BERGMAN, U; ROSA, FW; BAUM, C; WIHOLM, BE; FAICH, GA				BERGMAN, U; ROSA, FW; BAUM, C; WIHOLM, BE; FAICH, GA			EFFECTS OF EXPOSURE TO BENZODIAZEPINE DURING FETAL LIFE	LANCET			English	Article							PREGNANCY; INUTERO	Dysmorphism and mental retardation have been reported in 7 Swedish children born of mothers who had taken high doses of benzodiazepines regularly during pregnancy. To explore this association further, we examined benzodiazepine use during pregnancy in 104 000 women whose deliveries were registered by the US public health insurance system, Medicaid, during 1980-83. Fetal outcomes were assessed from the health claims profiles of their offspring, up to 6-9 years after delivery. 80 pregnant women had received 10 or more benzodiazepine prescriptions during the 4 years. Their records showed heavy general use of health care and frequent alcohol and substance abuse, and other disorders that could confound any effect of the benzodiazepines. For the 80 pregnancies, 3 intrauterine deaths were identified as well as 2 infants with congenital abnormalities whose curtailed records suggested neonatal death. Records of 64 surviving children could be linked to these 80 pregnancies whilst records for 11 apparent survivors could not be located. 6 of the 64 survivors had diagnoses consistent with teratogenic abnormalities. The high rate of teratogenicity after heavy maternal benzodiazepine use occurs with multiple alcohol and substance exposure and thus may not be due to benzodiazepine exposure.	US FDA, OFF EPIDEMIOL & BIOSTAT, ROCKVILLE, MD 20857 USA; MED PROD AGCY, UPPSALA, SWEDEN	US Food & Drug Administration (FDA); Medical Products Agency	BERGMAN, U (corresponding author), KAROLINSKA INST, HUDDINGE HOSP, DEPT CLIN PHARMACOL, S-14186 HUDDINGE, SWEDEN.							BARRY WS, 1987, LANCET, V1, P1436; BERGMAN U, 1990, J PEDIATR-US, V116, P490, DOI 10.1016/S0022-3476(05)82853-7; Bergman U, 1991, Bratisl Lek Listy, V92, P560; DUKES MNG, 1986, SIDE EFFECTS DRUGS A, V10, P50; FAICH GA, 1989, CLIN PHARMACOL THER, V46, P387, DOI 10.1038/clpt.1989.155; LAEGREID L, 1987, LANCET, V2, P1405; LAEGREID L, 1987, LANCET, V1, P108; LAEGREID L, 1989, J PEDIATR-US, V114, P126, DOI 10.1016/S0022-3476(89)80619-5; LAEGREID L, 1992, NEUROPEDIATRICS, V23, P18, DOI 10.1055/s-2008-1071305; NELSON LB, 1987, AM J DIS CHILD, V141, P175, DOI 10.1001/archpedi.1987.04460020065028; OLEGARD R, 1979, ACTA PAEDIATR SCAND, P112; PIPER JM, 1987, AM J OBSTET GYNECOL, V157, P148, DOI 10.1016/S0002-9378(87)80368-X; STROM BL, 1991, STAT MED, V10, P565, DOI 10.1002/sim.4780100408; WEBER LWD, 1985, BIOL RES PREG PERIN, V6, P151; WINTER RM, 1987, LANCET, V1, P627	15	77	77	4	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					694	696		10.1016/0140-6736(92)92232-5	http://dx.doi.org/10.1016/0140-6736(92)92232-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355799				2022-12-28	WOS:A1992JN78000004
J	LIVINGSTONE, LR; WHITE, A; SPROUSE, J; LIVANOS, E; JACKS, T; TISTY, TD				LIVINGSTONE, LR; WHITE, A; SPROUSE, J; LIVANOS, E; JACKS, T; TISTY, TD			ALTERED CELL-CYCLE ARREST AND GENE AMPLIFICATION POTENTIAL ACCOMPANY LOSS OF WILD-TYPE P53	CELL			English	Article							NUCLEOTIDE-SEQUENCE; DNA AMPLIFICATION; CANCER SYNDROME; HAMSTER-CELLS; CAD GENE; TRANSFORMATION; PROTEIN; MUTATIONS; ONCOGENE; LINES	Gene amplification occurs at high frequency in transformed cells (10(-3)-10(-5)), but is undetectable in normal diploid fibroblasts (<10(-9)). This study examines whether alterations of one or both p53 alleles were sufficient to allow gene amplification to occur. Cells retaining one wild-type p53 allele mimicked the behavior of primary diploid cells: they arrested growth in the presence of drug and failed to demonstrate amplification. Cells losing the second p53 allele failed to arrest when placed in drug and displayed the ability to amplify at a high frequency. Thus, loss of wild-type p53 may lead to amplification, possibly caused by changes in cell cycle progression. Other determinants can bypass this p53 function, however, since tumor cells with wild-type p53 have the ability to amplify genes.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; UNIV N CAROLINA,SCH MED,CURRICULUM GENET,CHAPEL HILL,NC 27599	Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	LIVINGSTONE, LR (corresponding author), UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA051912] Funding Source: NIH RePORTER; NCI NIH HHS [CA51912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1984, AM J HUM GENET, V36, P1159; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN YM, 1991, ONCOGENE, V6, P1799; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOULDS L, 1959, NEOPLASTIC DEV, V2; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; KASTAN MB, 1991, CANCER RES, V51, P6304; KAVATHAS P, 1983, NATURE, V306, P385, DOI 10.1038/306385a0; KUERBITZ SJ, 1992, IN PRESS P NATL ACAD; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO E, 1989, J BIOL CHEM, V264, P3390; POSTE G, 1986, CANCER TREAT REP, V70, P183; ROBERTSON EJ, 1987, STEM CELLS; ROWLEY JD, 1983, CHROMOSOMES CANCER; SAGER R, 1985, P NATL ACAD SCI USA, V82, P7015, DOI 10.1073/pnas.82.20.7015; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; TISTY TD, 1992, SCIENCE, V255, P1425; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOUNG JL, 1981, NCI MONOGRAPH, V57; ZIEG J, 1983, MOL CELL BIOL, V3, P2089, DOI 10.1128/MCB.3.11.2089	52	1408	1423	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					923	935		10.1016/0092-8674(92)90243-6	http://dx.doi.org/10.1016/0092-8674(92)90243-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356076				2022-12-28	WOS:A1992JN78100008
J	MOSES, S; MANJI, F; BRADLEY, JE; NAGELKERKE, NJD; MALISA, MA; PLUMMER, FA				MOSES, S; MANJI, F; BRADLEY, JE; NAGELKERKE, NJD; MALISA, MA; PLUMMER, FA			IMPACT OF USER FEES ON ATTENDANCE AT A REFERRAL CENTER FOR SEXUALLY-TRANSMITTED DISEASES IN KENYA	LANCET			English	Article							HEALTH-SERVICES; PRICE; PAY	We investigated the impact of a short-lived policy of charging fees to patients attending public-sector outpatient health facilities in Kenya by collecting data on attendance at Nairobi's Special Treatment Clinic for sexually transmitted diseases (STDs) before (23 months), during (9 months), and after (15 months) the user-charge period. During the user-charge period, the seasonally adjusted total mean monthly attendance of men decreased significantly to 40% (95% CI 36-45) of that before fees were levied. Attendance rose in the post-user-charge period, but reached only 64% (59-68) of the pre-user-charge level. For women, the adjusted total mean monthly attendance during the user-charge period was reduced significantly to 65% (55-77) of the pre-user-charge level. Mean monthly attendance by women rose in the post-user-charge period to 22% (9-37) above the pre-user-charge level. There was no evidence of an increase in attendance over the course of the user-charge period among either men or women. The introduction of user fees probably increased the number of untreated STDs in the population, with potentially serious long-term health implications. The user-fee experience in Kenya should be carefully evaluated before similar measures are introduced elsewhere.	UNIV NAIROBI, DEPT MED MICROBIOL, NAIROBI, KENYA; UNIV MANITOBA, DEPT COMMUNITY HLTH SCI, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT MED, WINNIPEG R3T 2N2, MANITOBA, CANADA; INT DEV RES CTR, DIV HLTH SCI, REG OFF EASTERN & SOUTHERN AFRICA, NAIROBI, KENYA; NAIROBI CITY COMMISS, SPECIAL TREATMENT CLIN, NAIROBI, KENYA	University of Nairobi; University of Manitoba; University of Manitoba; University of Manitoba	MOSES, S (corresponding author), UNIV NAIROBI, DEPT COMMUNITY HLTH, POB 19676, NAIROBI, KENYA.							Abel-Smith B, 1991, World Health Forum, V12, P191; ABELSMITH B, 1989, DISCUSSION PAPER ISS; BECK RG, 1980, MED CARE, V18, P787, DOI 10.1097/00005650-198008000-00001; BENNET S, 1989, LESOTHO EPIDEMIOL B, V4; De Bethune X., 1989, Health Policy and Planning, V4, P76, DOI 10.1093/heapol/4.1.76; CAMERON DW, 1989, LANCET, V2, P403; Creese Andrew L., 1990, USER CHARGES HLTH CA; de Ferranti D, 1984, World Health Stat Q, V37, P428; DEFERRANTI D, 1985, 721 WORLD BAND STAFF; GRIFFIN C, 1988, 37 EC DEV I SEM PAP; KANJI N, 1991, SOC SCI MED, V33, P985, DOI 10.1016/0277-9536(91)90003-U; Kanji N., 1989, Health Policy and Planning, V4, P110, DOI 10.1093/heapol/4.2.110; MWABU GM, 1986, SOC SCI MED, V22, P763, DOI 10.1016/0277-9536(86)90228-5; ODADA JE, 1990, SOCIOECONOMIC PROFIL; PEPIN J, 1989, AIDS, V3, P3; STANTON B, 1989, SOC SCI MED, V29, P1119; TEMMERMAN M, 1991, 6TH INT C AIDS AFR D; Waddington C., 1990, International Journal of Health Planning and Management, V5, P287, DOI 10.1002/hpm.4740050405; Waddington C. J., 1989, International Journal of Health Planning and Management, V4, P17, DOI 10.1002/hpm.4740040104; YODER RA, 1989, SOC SCI MED, V29, P35, DOI 10.1016/0277-9536(89)90125-1; 1987, FINANCING HLTH SERVI; 1988, NAIROBI AREA STUDY	22	89	89	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1992	340	8817					463	466		10.1016/0140-6736(92)91778-7	http://dx.doi.org/10.1016/0140-6736(92)91778-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354792				2022-12-28	WOS:A1992JJ87700012
J	GARROW, JS				GARROW, JS			TREATMENT OF OBESITY	LANCET			English	Article							ENERGY-REQUIREMENTS; WEIGHT-LOSS				GARROW, JS (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT HUMAN NUTR, CHARTERHOUSE SQ, LONDON EC1M 6BQ, ENGLAND.							ASTWOOD EB, 1962, ENDOCRINOLOGY, V71, P337, DOI 10.1210/endo-71-2-337; BJORVELL H, 1985, BRIT MED J, V291, P379, DOI 10.1136/bmj.291.6492.379; DARGA LL, 1991, AM J CLIN NUTR, V54, P321, DOI 10.1093/ajcn/54.2.321; DORE C, 1982, HUM NUTR-CLIN NUTR, V36, P41; GARROW JS, 1986, P NUTR SOC, V45, pA119; GARROW JS, 1985, INT J OBESITY, V9, P147; GARROW JS, 1989, LANCET, V1, P1429; GARROW JS, 1974, P NUTR SOC, V33, pA29; GARROW JS, 1988, OBESITY RELATED DISE, P329; GUYGRAND B, 1989, LANCET, V2, P1142; KRAL JG, 1992, AM J CLIN NUTR, V55, P552, DOI 10.1093/ajcn/55.2.552s; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MORRIS JK, 1992, BRIT MED J, V304, P536, DOI 10.1136/bmj.304.6826.536; PACY PJ, 1985, AM J CLIN NUTR, V42, P764, DOI 10.1093/ajcn/42.5.764; PENTECOST BL, 1991, MED ASPECTS EXERCISE; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; SCHULZ LO, 1991, AM J PHYSIOL, V260, pE257, DOI 10.1152/ajpendo.1991.260.2.E257; SHAPER AG, 1988, CORONARY HEART DISEA; STUNKARD AJ, 1987, AM J CLIN NUTR, V45, P1142, DOI 10.1093/ajcn/45.5.1142; TREMBLAY A, 1991, AM J CLIN NUTR, V54, P506, DOI 10.1093/ajcn/54.3.506	20	70	71	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1992	340	8816					409	413		10.1016/0140-6736(92)91481-M	http://dx.doi.org/10.1016/0140-6736(92)91481-M			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353566				2022-12-28	WOS:A1992JJ44900014
J	SUTHERLAND, G; STAPLETON, JA; RUSSELL, MAH; JARVIS, MJ; HAJEK, P; BELCHER, M; FEYERABEND, C				SUTHERLAND, G; STAPLETON, JA; RUSSELL, MAH; JARVIS, MJ; HAJEK, P; BELCHER, M; FEYERABEND, C			RANDOMIZED CONTROLLED TRIAL OF NASAL NICOTINE SPRAY IN SMOKING CESSATION	LANCET			English	Article							CHEWING-GUM; CIGARETTE WITHDRAWAL; PREDICTORS; SMOKERS; PATCH	Studies with nicotine chewing gum and nicotine skin patches indicate that nicotine replacement can help people to give up smoking. The rapidity with which nicotine is absorbed when given as a nasal spray suggests that it might be effective for those for whom the other means of replacement are too slow. The efficacy and safety of a nasal nicotine spray as an adjunct to group treatment for stopping smoking were assessed in a randomised, double-blind, placebo-controlled trial in which 227 cigarette smokers attending the Maudsley Hospital Smokers Clinic received 4 weeks of supportive group treatment plus active nicotine (0.5 mg per shot) or placebo nasal spray. The main end-point was biochemically validated complete abstinence from smoking from the third week of group treatment until the 12-month follow-up. Side-effects were assessed by self-reports and, where necessary, by physical examination. Of subjects assigned to active treatment 26% (n = 30) were validated abstinent throughout the year, compared with 10% (n = 11) of those assigned to placebo (relative abstinence rate 2.6, 95% Cl 1.5-4.5, p < 0.001). The advantage of the active spray was greatest in the heaviest smokers. Plasma nicotine concentrations from the spray were typically between one-half and three-quarters of baseline smoking levels. Tobacco-withdrawal symptoms, craving for cigarettes, and weight gain in abstinent subjects were reduced by the active spray. Minor irritant side-effects were frequent in both active and placebo sprays, but only 2 subjects had the spray discontinued as a result. No serious adverse effects were encountered. Nasal nicotine spray combined with supportive group treatment is an effective aid to smoking cessation.	NEW CROSS HOSP,POISONS UNIT,LONDON SE14 5ER,ENGLAND	New Cross Hospital	SUTHERLAND, G (corresponding author), INST PSYCHIAT,NATL ADDICT CTR,HLTH BEHAV UNIT,4 WINDSOR WALK,LONDON SE5 8AF,ENGLAND.		Jarvis, Martin J/B-1034-2008; Stapleton, John A/I-6550-2012	Jarvis, Martin J/0000-0001-9238-8038; 				ABELIN T, 1989, LANCET, V1, P7; [Anonymous], 1990, HLTH BENEFITS SMOKIN; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BIGELOW G, 1986, HLTH PSYCHOL S, V5, P3; FAGERSTROM KO, 1988, NICOTINE REPLACEMENT, P109; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HAJEK P, 1988, JAMA-J AM MED ASSOC, V260, P1593, DOI 10.1001/jama.260.11.1593; HAJEK P, 1989, BRIT J ADDICT, V84, P591; HAJEK P, 1985, BRIT J CLIN PSYCHOL, V24, P289, DOI 10.1111/j.2044-8260.1985.tb00661.x; HUGHES JR, 1988, NICOTINE REPLACEMENT, P261; JACKSON PH, 1986, PREV MED, V15, P244, DOI 10.1016/0091-7435(86)90044-7; JARVIS MJ, 1987, BRIT J ADDICT, V82, P983; JARVIS MJ, 1982, BRIT MED J, V285, P537, DOI 10.1136/bmj.285.6341.537; KLESGES RC, 1988, INT J EAT DISORDER, V7, P413, DOI 10.1002/1098-108X(198805)7:3<413::AID-EAT2260070314>3.0.CO;2-D; LAM W, 1987, LANCET, V2, P27; RUSSELL MAH, 1980, LANCET, V1, P474; RUSSELL MAH, 1988, NICOTINE REPLACEMENT, P187; SUTHERLAND G, IN PRESS PSYCHOPHARM; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; WEST RJ, 1985, PSYCHOPHARMACOLOGY, V87, P334, DOI 10.1007/BF00432717; 1991, JAMA-J AM MED ASSOC, V266, P3133	21	238	243	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					324	329		10.1016/0140-6736(92)91403-U	http://dx.doi.org/10.1016/0140-6736(92)91403-U			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353803				2022-12-28	WOS:A1992JH12500002
J	WATSON, EK; MAYALL, ES; LAMB, J; CHAPPLE, J; WILLIAMSON, R				WATSON, EK; MAYALL, ES; LAMB, J; CHAPPLE, J; WILLIAMSON, R			PSYCHOLOGICAL AND SOCIAL-CONSEQUENCES OF COMMUNITY CARRIER SCREENING-PROGRAM FOR CYSTIC-FIBROSIS	LANCET			English	Article								We have assessed the effect of screening for cystic fibrosis (CF) carrier status on anxiety levels, attitudes, knowledge and actions of participants in a pilot programme conducted through primary health care services. Over 3000 individuals were screened and 100 carriers with no previous family history were identified. Varying degrees of anxiety were found to be associated initially with a positive result, but most of this was allayed by genetic counselling, and we find no adverse long-term psychological consequences in carriers. Most discussed carrier status with their partner (89%), parents, other relatives and also with friends; 87% of partners to whom testing was suggested have been screened. Those testing positive indicated that knowledge of carrier status would be considered in future reproductive decisions, and after 6 months carriers retained a reasonable level of knowledge about CF and its inheritance. Carriers and non-carriers uniformly approve of screening and are glad to have been tested. Knowledge of CF in the sample of non-carriers has also increased after testing, suggesting screening may improve understanding of CF among the entire target population. Fears of possible social costs of screening may be ill-founded.	IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET, REG DNA LAB, LONDON W2 1PG, ENGLAND	Imperial College London								BONDUELLE M, 1990, HUM GENET, V85, P436; EVERSKIEBOOMS G, 1979, CLIN GENET, V15, P465; HOLTZMAN NA, 1989, PROCEED CAUTION, P174; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; Spielberger C. D., 1970, SELF EVALUATION QUES; TSUI LC, 1992, CYSTIC FIBROSIS GENE; WATSON EK, 1990, HUM GENET, V85, P435, DOI 10.1007/BF02428303; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1990, NEW ENGL J MED, V323, P70	10	91	92	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					217	220		10.1016/0140-6736(92)90477-K	http://dx.doi.org/10.1016/0140-6736(92)90477-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353144				2022-12-28	WOS:A1992JE75800012
J	DELIGNIERES, B; BOUSSER, MG				DELIGNIERES, B; BOUSSER, MG			MIGRAINE	LANCET			English	Letter							MENSTRUAL MIGRAINE; PERCUTANEOUS ESTRADIOL		HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS 12, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	DELIGNIERES, B (corresponding author), HOP NECKER ENFANTS MALAD, DEPT ENDOCRINOL & REPROD MED, F-75730 PARIS 15, FRANCE.							DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; DENNERSTEIN L, 1988, GYNECOL ENDOCRINOL, V2, P113, DOI 10.3109/09513598809023619; MAGOS AL, 1983, J NEUROL NEUROSUR PS, V46, P1044, DOI 10.1136/jnnp.46.11.1044	3	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1992	340	8810					61	62						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351646				2022-12-28	WOS:A1992JC35400058
J	WINQVIST, O; KARLSSON, FA; KAMPE, O				WINQVIST, O; KARLSSON, FA; KAMPE, O			21-HYDROXYLASE, A MAJOR AUTOANTIGEN IN IDIOPATHIC ADDISONS-DISEASE	LANCET			English	Article							AUTOANTIBODIES; SEQUENCE; ANTIGEN; GENE; IDENTIFICATION; EXPRESSION; PROTEINS; CLONING; P450C21	Sera from patients with idiopathic Addison's disease commonly react with the zona glomerulosa of adrenal cortex. We used high-resolution western blot analysis of an adrenal microsomal fraction to investigate the target of these antibodies. A protein with an apparent molecular weight of 54 kDa was recognised as the common and major component. Sera identifying this autoantigen (from 12 of 16 patients) also showed strong immunofluorescence staining of a steroid-producing human adrenal adrenocortical cell line, NCI-H295. On application of antisera specific for different cytochrome P450 steroidogenic enzymes (side-chain cleavage enzyme, 21-hydroxylase, 17-alpha-hydroxylase, 11-beta-hydroxylase)the mobility of the 54 kDa protein in western blots corresponded to that of 21 -hydroxylase. This parallel behaviour was confirmed by immunoprecipitation, electrophoresis, and autoradiography with the various sera and S-35-methionine-labelled NCI-H295 cell lysates. Preabsorptions of S-35-methionine-labelled cell lysates with the antiserum to 21-hydroxylase, but not with the other enzyme antisera, abolished precipitation of the 54 kDa autoantigen with the patient sera. These results indicate that 21-hydroxylase (P450c21), prominent in the zona glomerulosa of the adrenal cortex, is a major autoantigen in idiopathic Addison's disease.	UNIV HOSP UPPSALA,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital				winqvist, Ola/0000-0003-0842-4441				ANDERSON J. R., 1968, CLIN EXP IMMUNOL, V3, P107; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BANGA JP, 1991, AUTOIMMUNITY, V9, P177, DOI 10.3109/08916939109006755; BLIZZARD RM, 1962, LANCET, V2, P901; BLIZZARD RM, 1963, J CLIN INVEST, V42, P1653, DOI 10.1172/JCI104851; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRIGHT GM, 1990, J CLIN ENDOCR METAB, V70, P95, DOI 10.1210/jcem-70-1-95; CHOINARD ML, 1990, MOL CELL ENDOCRINOL, V68, P29; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; FURMANIAK J, 1988, FEBS LETT, V231, P25, DOI 10.1016/0014-5793(88)80695-1; GAZDAR AF, 1990, CANCER RES, V50, P5488; GOUDIE R. B., 1968, CLIN EXP IMMUMOL, V3, P119; GOUDIE RB, 1966, LANCET, V1, P1173; JONSSON J, 1981, OPUSC MED, V26, P1; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KROHN K, 1992, LANCET, V339, P770, DOI 10.1016/0140-6736(92)91894-E; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; MULLER J, 1991, ENDOCR RES, V17, P165; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; SOTSIOU F, 1980, CLIN EXP IMMUNOL, V39, P97; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WELLER TH, 1954, P SOC EXP BIOL MED, V86, P789, DOI 10.3181/00379727-86-21235; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	27	305	313	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1559	1562		10.1016/0140-6736(92)91829-W	http://dx.doi.org/10.1016/0140-6736(92)91829-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351548				2022-12-28	WOS:A1992JB20200002
J	VALVERDE, MA; DIAZ, M; SEPULVEDA, FV; GILL, DR; HYDE, SC; HIGGINS, CF				VALVERDE, MA; DIAZ, M; SEPULVEDA, FV; GILL, DR; HYDE, SC; HIGGINS, CF			VOLUME-REGULATED CHLORIDE CHANNELS ASSOCIATED WITH THE HUMAN MULTIDRUG-RESISTANCE P-GLYCOPROTEIN	NATURE			English	Article							CYSTIC-FIBROSIS; CELL-LINE; EXPRESSION; GENE; IDENTIFICATION; CONDUCTANCE; EPITHELIUM; TRANSPORT; PROTEINS; TISSUES	EXPRESSION of P-glycoprotein, the product of the MDR1 gene, confers multidrug resistance on cell lines and human tumours (reviewed in refs 1, 2). P-glycoprotein (relative molecular mass 170,000) is an ATP-dependent, active transporter which pumps hydrophobic drugs out of cells 3, but its normal physiological role is unknown. It is a member of the ABC (ATP-binding cassette) superfamily of transporters 4, which includes many bacterial transport systems, the putative peptide transporter from the major histocompatibility locus, and the product of the cystic fibrosis gene (the cystic fibrosis transmembrane regulator, CFTR). CFTR is located in the apical membranes of many secretory epithelia 5 and is associated with a cyclic AMP-regulated chloride channel 6-8. At least two other chloride channels are present in epithelial cells, regulated by cell volume and by intracellular Ca2+, respectively 9,10. Because of the structural and sequence similarities between P-glycoprotein and CFTR 4,11, and because P-glycoprotein is abundant in many secretory epithelia 12-14, we examined whether P-glycoprotein might be associated with one or other of these channels. We report here that expression of P-glycoprotein generates volume-regulated, ATP-dependent, chloride-selective channels, with properties similar to channels characterized previously in epithelial cells.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES LABS,OXFORD OX3 9DU,ENGLAND	University of Oxford	VALVERDE, MA (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND.		Diaz, Mario/C-1916-2014	Diaz, Mario/0000-0001-5692-8906; Hyde, Stephen/0000-0002-8877-4005; Gill, Deborah/0000-0002-5264-054X; Valverde, Miguel A./0000-0002-6961-3361; Sepulveda Valenzuela, Francisco Leandro/0000-0003-0022-6598				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BAAS F, 1990, CANCER RES, V50, P5392; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIRALDEZ F, 1988, BIOCHIM BIOPHYS ACTA, V942, P353, DOI 10.1016/0005-2736(88)90037-5; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARGER BD, 1990, FOCUS, V12, P25; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; MORRIS DI, IN PRESS BIOCHEMISTR; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEPPARD DN, 1991, J PHYSIOL-LONDON, V433, P663, DOI 10.1113/jphysiol.1991.sp018449; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	30	606	620	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					830	833		10.1038/355830a0	http://dx.doi.org/10.1038/355830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1371598				2022-12-28	WOS:A1992HF63600057
J	AUCHTER, RM				AUCHTER, RM			G-CSF FOR FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											AUCHTER, RM (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					269	270						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1370183				2022-12-28	WOS:A1992HA43100015
J	BRAHAMS, D				BRAHAMS, D			DEATH OF REMAND PRISONER	LANCET			English	Editorial Material																		Brahams D., 1990, LANCET, V336, P431	1	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1462	1462		10.1016/0140-6736(92)92643-T	http://dx.doi.org/10.1016/0140-6736(92)92643-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360574				2022-12-28	WOS:A1992KC28400017
J	WANG, RYH; SHIH, JWK; GRANDINETTI, T; PIERCE, PF; HAYES, MM; WEAR, DJ; ALTER, HJ; LO, SC				WANG, RYH; SHIH, JWK; GRANDINETTI, T; PIERCE, PF; HAYES, MM; WEAR, DJ; ALTER, HJ; LO, SC			HIGH-FREQUENCY OF ANTIBODIES TO MYCOPLASMA-PENETRANS IN HIV-INFECTED PATIENTS	LANCET			English	Article							AIDS; PROTEINS; AGENT	Mycoplasma penetrans, a novel mycoplasma isolated from HIV-1-infected patients with AIDS, has pathogenic properties associated with in-vivo virulence. Enzyme-linked immunosorbent assay and western blotting detected a more than 100 times higher frequency of antibodies to the mycoplasma in serum from HIV-1-infected patients with AIDS (40%) than from HIV-negative controls (0.3%). Serum from 20% of HIV-1-infected, symptom-free individuals also had M penetrans specific antibodies. The antibodies major immunoreactivity was directed against P35 and P38, the two main lipid-associated membrane protein antigens of the organism. Patients attending sexually transmitted disease clinics had a low frequency of antibody (0.9%). None of 178 HIV-negative patients with different non-AIDS diseases, many associated with immune dysfunction and/or low white cell counts, tested positive for the antibodies. M penetrans, apparently not a commensal and not a simple opportunist, is uniquely associated with HIV-1 infection and AIDS.	ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,AMER REGISTRY PATHOL,WASHINGTON,DC 20306; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892; AMER RED CROSS,NATL CAPITAL CHAPTER,WASHINGTON,DC; GEORGETOWN UNIV HOSP,HIV CLIN PROGRAM,WASHINGTON,DC 20007	United States Department of Defense; National Institutes of Health (NIH) - USA; American Red Cross; Georgetown University					NIAID NIH HHS [AI-31830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; COLE BC, 1985, MYCOPLASMAS, V4, P203; DELGIUDICE RA, 1985, INT J SYST BACTERIOL, V35, P285, DOI 10.1099/00207713-35-3-285; HAWKINS RE, 1992, J INFECT DIS, V165, P581, DOI 10.1093/infdis/165.3.581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAITRE M, 1992, INFECT IMMUN, V60, P742; LO SC, 1989, AM J TROP MED HYG, V40, P399, DOI 10.4269/ajtmh.1989.40.399; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LO SC, 1989, AM J TROP MED HYG, V40, P213, DOI 10.4269/ajtmh.1989.40.213; LO SC, 1991, LANCET, V338, P1415, DOI 10.1016/0140-6736(91)92721-D; LO SC, 1992, INT J SYST BACTERIOL, V42, P357, DOI 10.1099/00207713-42-3-357; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; LO SC, 1991, MODERN PATHOL, V6, P750; MONTAGNIER L, 1990, RETROVIRUSES HUMAN A, P9; ROSENGARTEN R, 1990, SCIENCE, V247, P315, DOI 10.1126/science.1688663; RUUTH E, 1989, IMMUNOL REV, V112, P133, DOI 10.1111/j.1600-065X.1989.tb00556.x; Somerson N. L., 1979, MYCOPLASMAS, V2, P191; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WISE KS, 1987, J BACTERIOL, V169, P5546, DOI 10.1128/jb.169.12.5546-5555.1987; Wright K, 1990, Science, V248, P682, DOI 10.1126/science.2333519; 1991, LANCET, V337, P20	22	78	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1312	1316		10.1016/0140-6736(92)92493-Y	http://dx.doi.org/10.1016/0140-6736(92)92493-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360035	Green Submitted			2022-12-28	WOS:A1992KA26200004
J	NAYLOR, JA; GREEN, PM; RIZZA, CR; GIANNELLI, F				NAYLOR, JA; GREEN, PM; RIZZA, CR; GIANNELLI, F			FACTOR-VIII GENE EXPLAINS ALL CASES OF HEMOPHILIA-A	LANCET			English	Note							HEMOPHILIA-A; MUTATIONS; HALF	Using an mRNA-based method to examine haemophilia A mutations we provide an explanation for the puzzling report that half of the mutations causing severe disease are not detected by analysis of the putative promoter, exons, and most exon/intron boundaries of the factor VIII gene. An unusual cluster of mutations involving regions of intron 22 not examined earlier leads to defective joining of exons 22 and 23 in the mRNA and caused haemophilia A in 10/24 severely affected UK patients.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford								GITSCHIER J, 1991, THROMB HAEMOSTASIS, V65, P662; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NAYLOR JA, 1991, LANCET, V337, P635, DOI 10.1016/0140-6736(91)92450-G; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P1612, DOI 10.1001/jama.266.12.1612; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331	7	71	72	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1066	1067		10.1016/0140-6736(92)93080-7	http://dx.doi.org/10.1016/0140-6736(92)93080-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357455				2022-12-28	WOS:A1992JV77500005
J	DIAZORTEGA, JL; LUNAABASCAL, M; VALDESPINO, JL; SEPULVEDA, J; MARKOWITZ, LE; ZELL, ER				DIAZORTEGA, JL; LUNAABASCAL, M; VALDESPINO, JL; SEPULVEDA, J; MARKOWITZ, LE; ZELL, ER			MORTALITY AND MORBIDITY AFTER HIGH TITER MEASLES-VACCINE IN MEXICO	LANCET			English	Letter									CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	DIAZORTEGA, JL (corresponding author), MINIST HLTH,MEXICO CITY,MEXICO.				NHLBI NIH HHS [BST-5947-P-HI-4265] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AABY P, 1992, LANCET, V340, P923, DOI 10.1016/0140-6736(92)93344-M; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903; 1991, WKLY EPID REC, V66, P249	4	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					924	924		10.1016/0140-6736(92)93345-N	http://dx.doi.org/10.1016/0140-6736(92)93345-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357345				2022-12-28	WOS:A1992JT32700061
J	PIERRE, P; SCHEEL, J; RICKARD, JE; KREIS, TE				PIERRE, P; SCHEEL, J; RICKARD, JE; KREIS, TE			CLIP-170 LINKS ENDOCYTIC VESICLES TO MICROTUBULES	CELL			English	Article							SEQUENCE-ANALYSIS; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; TRANSFERRIN RECEPTOR; CYTOPLASMIC DYNEIN; MOLECULAR-CLONING; BINDING-PROTEINS; CARRIER VESICLES; FUSION INVITRO; HEAVY-CHAIN	Binding of endocytic carrier vesicles to microtubules depends on the microtubule-binding protein CLIP-170 in vitro. In vivo, CLIP-170 colocalizes with a subset of transferrin receptor-positive endocytic structures and, more extensively, with endosomal tubules induced by brefeldin A. The structure of CLIP-170 has been analyzed by cloning its cDNA. The predicted non-helical C- and N-terminal domains of the homodimeric protein are connected by a long coiled-coil domain. We have identified a novel motif present in a tandem repeat in the N-terminal domain of CLIP-170 that is involved in binding to microtubules. This motif is also found in the Drosophila Glued and yeast BIK1 proteins. These features, together with its very elongated structure, suggest that CLIP-170 belongs to a novel class of proteins, cytoplasmic linker proteins (CLIPs), mediating interactions of organelles with microtubules.	UNIV GENEVA,DEPT CELL BIOL,SCI 3,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	PIERRE, P (corresponding author), EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY.			pierre, philippe/0000-0003-0863-8255				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; BAIROCH A, 1989, EMBL4 EUR MOL BIOL L; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HINZIKER W, 1991, CELL, V67, P5617; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INGOLD AL, 1988, J CELL BIOL, V107, P2659; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; Sambrook J, 1989, MOL CLONING LABORATO; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHLIWA M, 1989, CELL, V56, P719, DOI 10.1016/0092-8674(89)90672-7; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIBBALD PR, 1990, COMPUT APPL BIOSCI, V6, P279; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1992, IN PRESS GUIDEBOOK C; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WEST RR, 1991, J BIOL CHEM, V266, P21886; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	67	328	340	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					887	900		10.1016/0092-8674(92)90240-D	http://dx.doi.org/10.1016/0092-8674(92)90240-D			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356075				2022-12-28	WOS:A1992JN78100005
J	KUPFER, Y; NAMBA, T; KALDAWI, E; TESSLER, S				KUPFER, Y; NAMBA, T; KALDAWI, E; TESSLER, S			PROLONGED WEAKNESS AFTER LONG-TERM INFUSION OF VECURONIUM BROMIDE	ANNALS OF INTERNAL MEDICINE			English	Note						VECURONIUM; RESPIRATORY INSUFFICIENCY; MUSCULAR WEAKNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ASTHMA; STATUS ASTHMATICUS	NEUROMUSCULAR BLOCKADE; PATIENT	Neuromuscular blocking agents, increasingly used in intensive care units, have been retrospectively reported to cause weakness after prolonged use. This study prospectively compared ten patients with respiratory failure requiring prolonged muscle relaxation using vecuronium and 18 asthmatic patients with respiratory failure requiring mechanical ventilation without vecuronium. Serial neurologic and electrodiagnostic studies were done. Seven of ten patients (70%; 95% CI, 35% to 93%) experienced weakness 24 hours after discontinuation of vecuronium. The weakness was due to prolonged neuromuscular blockade for up to 3 days in two patients and to polyneuropathy characterized by weakness of all extremities, loss of tendon reflexes, and muscle atrophy lasting 5 days to 6 months in five patients. The only factors that correlated with the development of polyneuropathy were the dose (P = 0.047) and duration (P = 0.047) of vecuronium use, None of the control patients with asthma developed weakness. Caution must be exercised when using large doses of vecuronium for a prolonged period.	MAIMONIDES HOSP, DIV PULM & CRIT CARE MED, 4802 10TH AVE, BROOKLYN, NY 11219 USA; MAIMONIDES HOSP, DIV NEUROMUSCULAR DIS, BROOKLYN, NY 11219 USA	Maimonides Medical Center; Maimonides Medical Center								GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; KUPFER Y, 1987, CRIT CARE MED, V15, P795, DOI 10.1097/00003246-198708000-00019; MORRIS RB, 1983, ANESTHESIOLOGY, V58, P438, DOI 10.1097/00000542-198305000-00008; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHANKS AB, 1985, BRIT J ANAESTH, V57, P807, DOI 10.1093/bja/57.8.807; SLATER RM, 1988, ANAESTHESIA, V43, P250; STARSNIC MA, 1989, CAN J ANAESTH, V36, P35, DOI 10.1007/BF03010884; VANMARLE W, 1980, BRIT MED J, V281, P271, DOI 10.1136/bmj.281.6235.271-a; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	10	91	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					484	486		10.7326/0003-4819-117-6-484	http://dx.doi.org/10.7326/0003-4819-117-6-484			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354426				2022-12-28	WOS:A1992JN25700008
J	HEDLUND, JU; ORTQVIST, AB; KALIN, M; SCALIATOMBA, G; GIESECKE, J				HEDLUND, JU; ORTQVIST, AB; KALIN, M; SCALIATOMBA, G; GIESECKE, J			RISK OF PNEUMONIA IN PATIENTS PREVIOUSLY TREATED IN HOSPITAL FOR PNEUMONIA	LANCET			English	Note							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL VACCINE; IMMUNIZATION; CARE	Although elderly patients who are admitted to hospital for any disease have a higher risk of pneumonia subsequently, whether those treated in hospital for pneumonia are at even greater risk is unknown. Therefore we retrospectively assessed morbidity and mortality due to pneumonia after discharge in 573 consecutive patients admitted to hospital for pneumonia, gastrointestinal infection, renal infection, or erysipelas. Average follow-up was 34 months. The incidence rate for pneumonia was 5.45 times higher in the group of patients discharged after pneumonia than in the other groups combined (95% confidence interval 2.89-10.26; p<0.001), and this group also had more deaths due to pneumonia (p=0.06). For patients 50 years or older Streptococcus pneumoniae is the main cause of pneumonia. Pneumococcal vaccination after hospital treatment for an episode of pneumonia might be a cost-effective means of preventing disease in this group.	KAROLINSKA INST,DEPT INFECT DIS,S-10401 STOCKHOLM 60,SWEDEN; UNIV STOCKHOLM,DEPT MATH STAT,S-10691 STOCKHOLM,SWEDEN	Karolinska Institutet; Stockholm University	HEDLUND, JU (corresponding author), KAROLINSKA INST,DANDERYD HOSP,UNIV CLIN INFECT DIS,S-18288 DANDERYD,SWEDEN.							AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; FEDSON D, 1989, INFECTION, V17, P437, DOI 10.1007/BF01645568; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1982, JAMA-J AM MED ASSOC, V248, P1989; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; ORTQVIST A, 1988, SCAND J INFECT DIS, V20, P163, DOI 10.3109/00365548809032433; VENKATESAN P, 1990, THORAX, V45, P254, DOI 10.1136/thx.45.4.254; 1989, JAMA-J AM MED ASSOC, V261, P1265	9	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					396	397		10.1016/0140-6736(92)91473-L	http://dx.doi.org/10.1016/0140-6736(92)91473-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353558				2022-12-28	WOS:A1992JJ44900006
J	HOWS, JM; BRADLEY, BA; MARSH, JCW; LUFT, T; COUTINHO, L; TESTA, NG; DEXTER, TM				HOWS, JM; BRADLEY, BA; MARSH, JCW; LUFT, T; COUTINHO, L; TESTA, NG; DEXTER, TM			GROWTH OF HUMAN UMBILICAL-CORD BLOOD IN LONG-TERM HEMATOPOIETIC CULTURES	LANCET			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW TRANSPLANTATION; STROMAL CELLS; DONORS; ANEMIA	Cryopreserved human umbilical-cord (HUC) blood is an alternative to bone marrow as a source of haemopoietic "stem" cells for HLA-identical transplantation of children with leukaemia or Fanconi's anaemia. We have studied the in-vitro growth potential of HUC blood in clonogenic assays and in longterm haemopoietic cultures. Clonogenic assays showed that HUC blood produced as many haemopoietic-cell colonies as normal adult bone marrow and a higher proportion of primitive-cell colonies. In longterm culture on preformed irradiated marrow stroma, both progenitor-cell production and lifespan of cultures were significantly greater in HUC blood than in normal bone marrow (p=0.0007). Our findings indicate that the quality and quantity of HUC-blood-derived haemopoietic "stem" cells are better than those of normal bone marrow. Therefore, single HUC-blood donations are probably sufficient for adults requiring transplantation for leukaemia and other haemopoietic disorders. Banking of HLA-typed HUC blood to facilitate transplantation of patients who lack a family donor should be considered.	CANC RES CAMPAIGN,PATERSON INST,KAY KENDALL LAB,MANCHESTER,ENGLAND; UNIV BRISTOL,DEPT TRANSPLANTAT SCI,BRISTOL BS8 1TH,AVON,ENGLAND	Paterson Institute for Cancer Research; University of Bristol								AUERBACH AD, 1990, TRANSFUSION, V30, P682, DOI 10.1046/j.1537-2995.1990.30891020324.x; BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BIDWELL J L, 1990, Technique (Philadelphia), V2, P93; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; CLAY TM, 1991, LANCET, V337, P1049, DOI 10.1016/0140-6736(91)91704-X; CLEMENT LT, 1990, J IMMUNOL, V145, P102; COUTINHO LH, 1990, BRIT J HAEMATOL, V75, P16, DOI 10.1111/j.1365-2141.1990.tb02611.x; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DONAY L, 1986, EXP HEMATOL, V14, P358; FAUSER AA, 1978, BLOOD, V52, P1243; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GORIN NC, 1986, CLIN HAEMATOL, V15, P19, DOI 10.1016/S0308-2261(86)80004-2; HOWARD MR, 1990, TRANSPLANTATION, V49, P547, DOI 10.1097/00007890-199003000-00015; LINCH DC, 1989, NATURE, V340, P676, DOI 10.1038/340676a0; MA DDF, 1987, LEUKEMIA RES, V11, P141, DOI 10.1016/0145-2126(87)90019-1; MESSNER HA, 1982, J CELL PHYSL S, V1, P45; RUUTU T, 1990, BONE MARROW TRANSPL, V5, P273; SIMMONS PJ, 1987, NATURE, V328, P429, DOI 10.1038/328429a0; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; VILMER E, 1991, BONE MARROW TRANS S2, V7, P199	22	205	212	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					73	76		10.1016/0140-6736(92)90396-K	http://dx.doi.org/10.1016/0140-6736(92)90396-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352013				2022-12-28	WOS:A1992JC58200003
J	PACKER, M				PACKER, M			TREATMENT OF CHRONIC HEART-FAILURE	LANCET			English	Article							LEFT-VENTRICULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; DILATED CARDIOMYOPATHY; VASODILATOR THERAPY; CAPTOPRIL; COMBINATION; NIFEDIPINE; EFFICACY				PACKER, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV CIRCULATORY PHYSIOL, NEW YORK, NY 10032 USA.							AGOSTONI PG, 1986, BRIT HEART J, V55, P391; [Anonymous], 1990, Lancet, V336, P1; BAYLISS J, 1985, BRIT MED J, V290, P1861, DOI 10.1136/bmj.290.6485.1861; BINKLEY PF, 1992, J AM COLL CARDIOL, V19, P1121; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DUNSELMAN PHJM, 1989, EUR HEART J, V10, P354, DOI 10.1093/oxfordjournals.eurheartj.a059493; ELBORN JS, 1989, BRIT HEART J, V61, P331; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; FERGUSON DW, 1989, CIRCULATION, V80, P65, DOI 10.1161/01.CIR.80.1.65; FRANCIOSA JA, 1984, CIRCULATION, V70, P63, DOI 10.1161/01.CIR.70.1.63; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; GOLDSTEIN RE, 1991, CIRCULATION, V83, P52, DOI 10.1161/01.CIR.83.1.52; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; NORTHRIDGE DB, 1990, AM J HYPERTENS, V3, P682, DOI 10.1093/ajh/3.9.682; PACKER M, 1987, NEW ENGL J MED, V317, P799, DOI 10.1056/NEJM198709243171304; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1989, CIRCULATION, V80, P59; PACKER M, 1991, J AM COLL CARDIOL, V17, P740, DOI 10.1016/S0735-1097(10)80193-7; PACKER M, 1988, J AM COLL CARDIOL, V12, P1299, DOI 10.1016/0735-1097(88)92615-0; PACKER M, 1992, Journal of the American College of Cardiology, V19, p260A; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; SHARPE N, 1988, LANCET, V1, P255; SINOWAY L, 1987, AM J CARDIOL, V60, P107, DOI 10.1016/0002-9149(87)90995-7; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	32	71	73	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1992	340	8811					92	95		10.1016/0140-6736(92)90406-S	http://dx.doi.org/10.1016/0140-6736(92)90406-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352023	hybrid			2022-12-28	WOS:A1992JC58200013
J	SHERWOOD, T				SHERWOOD, T			EXITUS-AUDITUS - NO FUN	LANCET			English	Editorial Material											SHERWOOD, T (corresponding author), UNIV CAMBRIDGE,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							CARLEN R, 1991, LANCET, V338, P822, DOI 10.1016/0140-6736(91)90710-7	1	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					37	38						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351611				2022-12-28	WOS:A1992JC35400015
J	SAHNI, P; REDDY, PP; KIRAN, R; REDDY, KS; PANDE, GK; NUNDY, S				SAHNI, P; REDDY, PP; KIRAN, R; REDDY, KS; PANDE, GK; NUNDY, S			INDIAN MEDICAL JOURNALS	LANCET			English	Editorial Material								Although Indian doctors produce half the articles published from the third world, little has been written about Indian medical journals. We examined 75 of the 113 serious English-language journals published in India. Of the 22 included in the Cumulated Index Medicus only 8 were judged by Indian and foreign referees to be of international standard. A survey of Indian authors indicated that foreign journals were chosen for the best papers because of their wider circulation, better refereeing practices, and punctuality. More than 98% of medical articles from India probably go unnoticed by the international medical community.	ALL INDIA INST MED SCI,DEPT GASTROINTESTINAL SURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi				Nundy, Samiran/0000-0002-1757-3919				ARUNACHALAM S, 1988, J SCI IND RES INDIA, V47, P359; GARFIELD E, 1983, CURR CONTENTS, V33, P6; KRISHNAN CN, 1987, PPST B, V11, P1; NUNDY S, 1991, BRIT MED J, P74	4	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1589	1591		10.1016/0140-6736(92)91844-X	http://dx.doi.org/10.1016/0140-6736(92)91844-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JB202	1351561				2022-12-28	WOS:A1992JB20200015
J	STARZL, TE; DEMETRIS, AJ; MURASE, N; ILDSTAD, S; RICORDI, C; TRUCCO, M				STARZL, TE; DEMETRIS, AJ; MURASE, N; ILDSTAD, S; RICORDI, C; TRUCCO, M			CELL-MIGRATION, CHIMERISM, AND GRAFT ACCEPTANCE	LANCET			English	Review							ALLOGRAFT-REJECTION; LIVER-TRANSPLANTATION; DENDRITIC CELLS; BONE-MARROW; SURVIVAL; HEART; SUPPRESSION; RECIPIENTS; INDUCTION; ANTIGENS		UNIV PITTSBURGH,HLTH SCI CTR,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PATHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,HLTH SCI CTR,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK029961-19, DK 29961] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG HE, 1987, J EXP MED, V164, P891; ARNAUDBATTANDIER F, 1985, TRANSPLANT P, V17, P1440; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CRANSTON D, 1991, TRANSPLANTATION, V52, P789, DOI 10.1097/00007890-199111000-00006; DAVIES HFS, 1989, TRANSPLANTATION, V47, P524; DEMETRIS AJ, 1992, LANCET, V339, P1610, DOI 10.1016/0140-6736(92)91875-9; DEMETRIS AJ, 1991, AM J PATHOL, V138, P609; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FUNG JJ, 1985, HUM IMMUNOL, V14, P287, DOI 10.1016/0198-8859(85)90236-8; GHJERTSON DW, 1991, NEW ENGL J MED, V324, P1032; HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; IWAKI Y, 1991, LANCET, V337, P818, DOI 10.1016/0140-6736(91)92517-6; KASHIWAGI N, 1969, Surgical Forum (Chicago), V20, P374; KASHIWAGI N, 1969, EXPERIENCE HEPATIC T, P394; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; MARKUS BH, 1988, TRANSPLANTATION, V46, P372; MEDAWAR PB, 1965, BRIT MED BULL, V21, P97, DOI 10.1093/oxfordjournals.bmb.a070392; MONACO AP, 1988, TRANSPLANT P, V20, P1207; MURASE N, 1991, SURGERY, V110, P87; MURASE N, 1991, TRANSPLANT P, V23, P3246; MURASE N, 1990, TRANSPLANTATION, V50, P739, DOI 10.1097/00007890-199011000-00002; MURASE N, 1990, TRANSPLANTATION, V50, P186, DOI 10.1097/00007890-199008000-00002; MURASE N, IN PRESS TRANSPLANTA; PORTER KA, 1969, EXPERIENCE HEPATIC T, P464; Prop J, 1985, J Heart Transplant, V4, P433; RAMSEY G, 1984, NEW ENGL J MED, V311, P1167, DOI 10.1056/NEJM198411013111807; RICORDI C, 1992, LANCET, V339, P1610, DOI 10.1016/0140-6736(92)91876-A; SELBY R, 1991, NEW ENGL J MED, V324, P39, DOI 10.1056/NEJM199101033240107; SINGH PB, 1988, J EXP MED, V168, P195, DOI 10.1084/jem.168.1.195; SLAVIN S, 1977, J EXP MED, V146, P34, DOI 10.1084/jem.146.1.34; STARZL TE, 1974, TRANSPLANT P, V6, P129; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1991, SURG GYNECOL OBSTET, V172, P335; STARZL TE, 1969, EXPERIENCE HEPATIC T, P198; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; STEINMULLER D, 1967, SCIENCE, V158, P127, DOI 10.1126/science.158.3797.127; TODO S, IN PRESS ANN SURG; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Wilson W. E. C., 1964, EXPERIENCE RENAL TRA, P239; WOODRUFF MFA, 1950, PHILOS T R SOC B, V234, P559, DOI 10.1098/rstb.1950.0011; WOODRUFF MFA, 1959, BIOLOGICAL PROBLEMS, P83	45	920	966	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1579	1582		10.1016/0140-6736(92)91840-5	http://dx.doi.org/10.1016/0140-6736(92)91840-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351558	Green Accepted			2022-12-28	WOS:A1992JB20200012
J	TILL, J; HERXHEIMER, A				TILL, J; HERXHEIMER, A			DEATH OF CHILD WITH SUPRAVENTRICULAR TACHYCARDIA	LANCET			English	Editorial Material																		[Anonymous], 1989, NEW ENGL J MED, V321, P406; FISH FA, 1991, J AM COLL CARDIOL, V18, P356, DOI 10.1016/0735-1097(91)90586-X; GARRATT C, 1989, BMJ-BRIT MED J, V299, P805, DOI 10.1136/bmj.299.6703.805; JONES R, 1992, BRIT MED J, V304, P4, DOI 10.1136/bmj.304.6818.4; PERRY JC, 1989, J AM COLL CARDIOL, V14, P185, DOI 10.1016/0735-1097(89)90070-3; PERRY JC, 1991, J AM COLL CARDIOL, V18, P366, DOI 10.1016/0735-1097(91)90587-Y; PERRY JC, IN PRESS AM J CARDIO; TILL JA, 1989, BRIT HEART J, V62, P133; 1991, EL91217 NHS MAN EX	9	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1992	339	8809					1597	1598		10.1016/0140-6736(92)91851-X	http://dx.doi.org/10.1016/0140-6736(92)91851-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351563				2022-12-28	WOS:A1992JB20200017
J	RENAUD, S; DELORGERIL, M				RENAUD, S; DELORGERIL, M			WINE, ALCOHOL, PLATELETS, AND THE FRENCH PARADOX FOR CORONARY HEART-DISEASE	LANCET			English	Article							MODERATE ALCOHOL; CONSUMPTION; RISK; MEN; MORTALITY; COUNTRIES; ETHANOL; FARMERS	In most countries, high intake of saturated fat is positively related to high mortality from coronary heart disease (CHD). However, the situation in France is paradoxical in that there is high intake of saturated fat but low mortality from CHD. This paradox may be attributable in part to high wine consumption. Epidemiological studies indicate that consumption of alcohol at the level of intake in France (20-30 g per day) can reduce risk of CHD by at least 40%. Alcohol is believed to protect from CHD by preventing atherosclerosis through the action of high-density-lipoprotein cholesterol, but serum concentrations of this factor are no higher in France than in other countries. Re-examination of previous results suggests that, in the main, moderate alcohol intake does not prevent CHD through an effect on atherosclerosis, but rather through a haemostatic mechanism. Data from Caerphilly, Wales, show that platelet aggregation, which is related to CHD, is inhibited significantly by alcohol at levels of intake associated with reduced risk of CHD. Inhibition of platelet reactivity by wine (alcohol) may be one explanation for protection from CHD in France, since pilot studies have shown that platelet reactivity is lower in France than in Scotland.			RENAUD, S (corresponding author), INSERM,U63,NUTR & VASC PHYSIOPATHOL RES UNIT,22 AVE DOYEN LEPINE,CP 18,F-69675 BRON,FRANCE.							BARAONA E, 1979, J LIPID RES, V20, P289; BLACKBURN H, 1986, AM J CARDIOL, V58, P161, DOI 10.1016/0002-9149(86)90262-6; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DOUSTEBLAZY P, 1988, REV EPIDEMIOL SANTE, V6, P342; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; JOST JP, 1990, REV EPIDEMIOL SANTE, V38, P517; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KOZAREVIC D, 1988, INT J EPIDEMIOL, V12, P145; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; LITSIE AM, 1976, B WORLD HEALTH ORGAN, V53, P623; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; NORDOY A, 1984, EUR J CLIN INVEST, V14, P339, DOI 10.1111/j.1365-2362.1984.tb01193.x; PUCHOIS P, 1990, ARCH INTERN MED, V150, P1638, DOI 10.1001/archinte.150.8.1638; RENAUD S, 1986, ATHEROSCLEROSIS, V60, P37, DOI 10.1016/0021-9150(86)90085-7; RENAUD S, 1985, CARDIOVASC RES, V19, P155, DOI 10.1093/cvr/19.3.155; RENAUD S, 1989, J INTERN MED, V225, P39, DOI 10.1111/j.1365-2796.1989.tb01434.x; RENAUD S, 1984, DIET DIABETES ATHERO, P177; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; RHOADS GG, 1978, LAB INVEST, V38, P304; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RUDEL LL, 1981, ARTERIOSCLEROSIS, V1, P144, DOI 10.1161/01.ATV.1.2.144; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1989, WORLD HLTH STATISTIC	31	2812	2928	6	358	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1523	1526		10.1016/0140-6736(92)91277-F	http://dx.doi.org/10.1016/0140-6736(92)91277-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351198				2022-12-28	WOS:A1992HZ17500016
J	KAGAN, BL; BALDWIN, RL; MUNOZ, D; WISNIESKI, BJ				KAGAN, BL; BALDWIN, RL; MUNOZ, D; WISNIESKI, BJ			FORMATION OF ION-PERMEABLE CHANNELS BY TUMOR-NECROSIS-FACTOR-ALPHA	SCIENCE			English	Article							PLANAR LIPID BILAYERS; DIPHTHERIA-TOXIN; MOLECULAR-CLONING; SKELETAL-MUSCLE; MEMBRANES; RECEPTOR; RESOLUTION; EXPRESSION; MEDIATOR; VESICLES	Tumor necrosis facto-alpha (TNF, cachectin), a protein secreted by activated macrophages, participates in inflammatory responses and in infectious and neoplastic disease states. The mechanisms by which TNF exerts cytotoxic, hormonal, and other specific effects are obscure. Structural studies of the TNF trimer have revealed a central pore-like region. Although several amino acid side chains appear to preclude an open channel, the ability of TNF to insert into lipid vesicles raised the possibility that opening might occur in a bilayer milieu. Acidification of TNF promoted conformational changes concordant with increased surface hydrophobicity and membrane insertion. Furthermore, TNF formed pH-dependent, voltage-dependent, ion-permeable channels in planar lipid bilayer membranes and increased the sodium permeability of human U937 histiocytic lymphoma cells. Thus, some of the physiological effects of TNF may bc elicited through its intrinsic ion channel-forming activity.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,INST NEUROPSYCHIAT,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles			Kagan, Bruce/ABD-7389-2020		NHLBI NIH HHS [2 T32 HL07386] Funding Source: Medline; NIGMS NIH HHS [GM22240] Funding Source: Medline; NIMH NIH HHS [MH43433] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043433] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALDWIN RL, 1988, J IMMUNOL, V141, P2352; BALDWIN RL, 1990, THESIS U CALIFORNIA; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Chang M.-W., UNPUB; CHANG MP, 1990, INFECT IMMUN, V58, P2644, DOI 10.1128/IAI.58.8.2644-2650.1990; CUNNINGHAM JN, 1971, J CLIN INVEST, V50, P49, DOI 10.1172/JCI106483; Dawson RMC, 1969, DATA BIOCH RES, P501; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; EARL CQ, 1990, J BIOL RESP MODIF, V9, P361; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FAJARDO LF, 1991, WESTERN J MED, V154, P88; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; JOHNSON JD, 1979, BIOCHEMISTRY-US, V18, P1292, DOI 10.1021/bi00574a027; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KULL FC, 1990, J CELL BIOCHEM, V42, P1, DOI 10.1002/jcb.240420102; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Montal M, 1974, Methods Enzymol, V32, P545; OKU N, 1987, J BIOCHEM-TOKYO, V102, P1303, DOI 10.1093/oxfordjournals.jbchem.a122168; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUSSELL SM, 1990, CANCER RES, V50, P6028; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH JB, 1978, P NATL ACAD SCI USA, V75, P5560, DOI 10.1073/pnas.75.11.5560; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SPRANG SR, 1990, CURRENT RES PROTEIN, pCH35; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TRACEY KJ, 1986, J EXP MED, V164, P1368, DOI 10.1084/jem.164.4.1368; VANHAESEBROECK B, 1990, FEBS LETT, V261, P329; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1; YOSHIMURA T, 1987, J BIOL CHEM, V262, P4597; YOUNG JDE, 1988, IMMUNOL LETT, V19, P287, DOI 10.1016/0165-2478(88)90157-5	38	141	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1427	1430		10.1126/science.1371890	http://dx.doi.org/10.1126/science.1371890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1371890				2022-12-28	WOS:A1992HH74400054
J	PITHIE, AD; CHICKSEN, B				PITHIE, AD; CHICKSEN, B			FINE-NEEDLE EXTRATHORACIC LYMPH-NODE ASPIRATION IN HIV-ASSOCIATED SPUTUM-NEGATIVE TUBERCULOSIS	LANCET			English	Note							UGANDA; AIDS	HIV-associated tuberculosis is increasingly seen in Zimbabwe and other developing countries. The clinical and radiological features are often atypical, and diagnostic confusion may arise when sputum smears are negative. Patients with suspected intrathoracic tuberculosis frequently have palpable extrathoracic lymph nodes. In this study, Ziehl-Neelsen staining of aspirates from extrathoracic lymph nodes revealed acid-fast bacilli in 20 (71%) of 28 patients with suspected tuberculosis, and 20 (87%) of 23 patients in whom a final diagnosis of tuberculosis was made Aspiration is simple, rapid, and cheap and may be of value in the diagnosis of tuberculosis, especially in developing countries with limited diagnostic and therapeutic resources.	UNIV ZIMBABWE,DEPT MED,HARARE,ZIMBABWE	University of Zimbabwe	PITHIE, AD (corresponding author), E BIRMINGHAM HOSP NHS TRUST,DEPT INFECT & TROP MED,BORDESLEY GREEN E,BIRMINGHAM B9 5ST,ENGLAND.							ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; MASON PR, 1992, 1ST AFR IMM C HAR; MORRISSEY AB, 1992, J ACQ IMMUN DEF SYND, V5, P477; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; OKELLO DO, 1990, J INFECT DIS, V162, P208, DOI 10.1093/infdis/162.1.208; PERRONNE C, 1992, TUBERCLE LUNG DIS, V73, P39, DOI 10.1016/0962-8479(92)90078-X; VOETBERG A, 1991, LANCET, V337, P56, DOI 10.1016/0140-6736(91)93380-R; 1987, MMWR S, V36, pS1	10	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1504	1505		10.1016/0140-6736(92)92758-8	http://dx.doi.org/10.1016/0140-6736(92)92758-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361599				2022-12-28	WOS:A1992KD06900007
J	LEHNER, PJ; DAVIES, KA; WALPORT, MJ; COPE, AP; WURZNER, R; ORREN, A; MORGAN, BP; COHEN, J				LEHNER, PJ; DAVIES, KA; WALPORT, MJ; COPE, AP; WURZNER, R; ORREN, A; MORGAN, BP; COHEN, J			MENINGOCOCCAL SEPTICEMIA IN A C6-DEFICIENT PATIENT AND EFFECTS OF PLASMA TRANSFUSION ON LIPOPOLYSACCHARIDE RELEASE	LANCET			English	Note							NEISSERIA-MENINGITIDIS INFECTIONS; 6TH COMPONENT; COMPLEMENT; DEFICIENCY; DISEASE	Patients whose blood is deficient in the terminal component of complement have an increased susceptibility to meningococcal infection. However, mortality from meningococcal infection is lower in these patients than in immunocompetent subjects, We studied a C6-deficient patient with meningococcal sepsis who received fresh frozen plasma (FFP). The patient's initial plasma endotoxin, C6, and terminal-complement-complex concentrations were low, but rose sharply after treatment with FFP. Samples of the patient's serum taken shortly after admission did not cause endotoxin release from Escherichia coli J5 in vitro, but endotoxin-releasing activity was restored in serum samples taken after infusion of FFP. It is possible that C6-deficient patients have reduced mortality from meningococcal infection because their serum cannot cause acute release of endotoxin from the invading organism and extensive tissue damage is thus avoided.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,DUCANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND; CHARING CROSS SUNLEY MED RES CTR,LONDON,ENGLAND; MRC,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES	Imperial College London; Imperial College London; University of Oxford; Cardiff University				Cope, Andrew/0000-0001-6735-5496; Lehner, Paul Joseph/0000-0001-9383-1054; Walport, Mark/0000-0001-7220-5273; Morgan, Paul/0000-0003-4075-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; COHEN J, 1984, J INFECT DIS, V150, P916, DOI 10.1093/infdis/150.6.916; CRAVEN DE, 1982, INFECT IMMUN, V37, P132, DOI 10.1128/IAI.37.1.132-137.1982; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; ORREN A, 1987, IMMUNOLOGY, V62, P249; POTTER PC, 1990, J INFECT DIS, V161, P932, DOI 10.1093/infdis/161.5.932; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; WURZNER R, 1991, CLIN EXP IMMUNOL, V83, P430	9	61	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1379	1381		10.1016/0140-6736(92)92561-S	http://dx.doi.org/10.1016/0140-6736(92)92561-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360091				2022-12-28	WOS:A1992KB20200005
J	HALLENBERGER, S; BOSCH, V; ANGLIKER, H; SHAW, E; KLENK, HD; GARTEN, W				HALLENBERGER, S; BOSCH, V; ANGLIKER, H; SHAW, E; KLENK, HD; GARTEN, W			INHIBITION OF FURIN-MEDIATED CLEAVAGE ACTIVATION OF HIV-1 GLYCOPROTEIN-GP160	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; ENDOPROTEOLYTIC CLEAVAGE; BIOSYNTHESIS; PRECURSOR; TRANSPORT; GP160; CELLS	THE envelope glycoprotein of human immunodeficiency virus (HIV) initiates infection1 by mediating fusion of the viral envelope with the cell membrane. Fusion activity requires proteolytic cleavage of the gp160 protein into gp120 and gp41 at a site containing several arginine and lysine residues2. Activation at basic cleavage sites is observed with many membrane proteins of cellular and viral origin. We have recently found that the enzyme activating the haemagglutinin of fowl plague virus (FPV), an avian influenza virus, is furin3. Furin, a subtilisin-like eukaryotic endoprotease4-6, has a substrate specificity for the consensus amino-acid sequence Arg-X-Lys/Arg-Arg at the cleavage site7. We show here that the glycoprotein of HIV-1, which has the same protease recognition motif as the FPV haemagglutinin, is also activated by furin.	DEUTSCH KREBSFORSCHUNGSZENTRUM HEIDELBERG,INST ANGEW TUMORVIROL,W-6900 HEIDELBERG 1,GERMANY; FRIEDRICH MIESCHER INST BASEL,CH-4002 BASEL,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Miescher Institute for Biomedical Research	HALLENBERGER, S (corresponding author), UNIV MARBURG,INST VIROL,ROBERT KOCHSTR 17,W-3550 MARBURG,GERMANY.							BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; MYERS G, 1991, HUMAN RETROVIRUSES A; OWENS RJ, 1989, J VIROL, V63, P978, DOI 10.1128/JVI.63.2.978-982.1989; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; VONDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664; WILK T, 1992, VIRUS GENES, V6, P229, DOI 10.1007/BF01702562; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; WILLEY RL, 1991, VIROLOGY, V184, P319, DOI 10.1016/0042-6822(91)90848-6; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9368	22	484	502	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					358	361		10.1038/360358a0	http://dx.doi.org/10.1038/360358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1360148				2022-12-28	WOS:A1992JZ63000056
J	XIONG, Y; ZHANG, H; BEACH, D				XIONG, Y; ZHANG, H; BEACH, D			D-TYPE CYCLINS ASSOCIATE WITH MULTIPLE PROTEIN-KINASES AND THE DNA-REPLICATION AND REPAIR FACTOR PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; S-PHASE; AUXILIARY PROTEIN; POLYMERASE-DELTA; CDC2; MITOSIS; ACTIVATION; GENE	Human cyclin D1 has been associated with a wide variety of proliferative diseases but its biochemical role is unknown. In diploid fibroblasts we find that cyclin D1 is complexed with many other cellular proteins. Among them are protein kinase catalytic subunits CDK2, CDK4 (previously called PSK-J3), and CDK5 (also called PSSALRE). In addition, polypeptides of 21 kd and 36 kd are identified in association with cyclin D1. We show that the 36 kd protein is the proliferating cell nuclear antigen, PCNA. Cyclin D3 also associates with multiple protein kinases, p21 and PCNA. It is proposed that there exists a quaternary complex of D cyclin, CDK, PCNA, and p21 and that many combinatorial variations (cyclin D1, D3, CDK2, 4, and 5) may assemble in vivo. These findings link a human putative G1 cyclin that is associated with oncogenesis with a well-characterized DNA replication and repair factor.			XIONG, Y (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039620] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39620-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1984, EMBO J, V3, P3177, DOI 10.1002/j.1460-2075.1984.tb02276.x; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1988, ANTIBODIES LABORATOR; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WON KA, 1992, IN PRESS P NATL ACAD; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	1015	1057	12	155	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					505	514		10.1016/0092-8674(92)90518-H	http://dx.doi.org/10.1016/0092-8674(92)90518-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1358458				2022-12-28	WOS:A1992JW43500015
J	CHEUNG, D; TIMMERS, MC; ZWINDERMAN, AH; BEL, EH; DIJKMAN, JH; STERK, PJ				CHEUNG, D; TIMMERS, MC; ZWINDERMAN, AH; BEL, EH; DIJKMAN, JH; STERK, PJ			LONG-TERM EFFECTS OF A LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSIVENESS IN PATIENTS WITH MILD ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL RESPONSIVENESS; INHALED CORTICOSTEROIDS; ANTIASTHMATIC DRUGS; FORMOTEROL; SALBUTAMOL; METHACHOLINE; BRONCHOCONSTRICTION; BRONCHODILATOR; TERBUTALINE; INHALATION	Background. Asthma is characterized by hyperresponsiveness of the airways to bronchoconstrictive stimuli. Long-acting beta2-adrenoceptor agonists have been introduced as a new therapeutic approach, but there is growing concern about whether control of asthma may deteriorate with the regular use of these agents. We investigated the long-term effects of the beta2-agonist salmeterol on bronchodilation and on airway hyperresponsiveness to the bronchoconstrictive agent methacholine in mild asthma. Methods. In a parallel, double-blind study, 24 patients with mild asthma were randomly assigned to treatment with either inhaled salmeterol (50 mug, twice daily) (n = 12) or placebo (n = 12) during an eight-week trial. Methacholine challenge was performed before, during, and after the treatment period. Methacholine responsiveness was measured as the provocative concentration (PC20) that caused a 20 percent decrease in the forced expiratory volume in one second (FEV1). Results. There was a significant increase in FEV1 one hour after the inhalation of salmeterol (P = 0.006), which did not differ significantly on days 0, 28, and 56 of the treatment period (increase, 9.8, 9.4, and 8.8 percent of predicted FEV1, respectively; P = 0.91). On the first treatment day, salmeterol afforded significant protection against methacholine-induced bronchoconstriction, as shown by a 10-fold increase in the PC20 as compared with the value at entry (P<0.001). After four and eight weeks of treatment, however, the salmeterol-induced change in the PC20 was significantly attenuated (P<0.001) to only a twofold increase. Two and four days after treatment ended, the PC20 was not significantly different from the value before treatment (P = 0.15). Conclusions. Regular treatment of patients with mild asthma with salmeterol leads to tolerance to its protective effects against a bronchoconstrictor stimulus, in this case inhaled methacholine, despite well-maintained bronchodilation. This finding raises concern about the effectiveness of prolonged therapy with long-acting beta2-adrenoceptor agonists in asthma.	UNIV HOSP LEIDEN,DEPT PULMONOL,LUNG FUNCT LAB,C2-P,POB 9600,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT MED STAT,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Sterk, P.J./AAK-8175-2020					Ariens E.J., 1987, BRONCHIAL HYPERRESPO, P7; ARMITAGE P, 1987, STATISTICAL METHODS; ARVIDSSON P, 1989, EUR RESPIR J, V2, P325; BAKER A J, 1990, American Review of Respiratory Disease, V141, pA394; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BEL EH, 1991, THORAX, V46, P9, DOI 10.1136/thx.46.1.9; BERNSTEIN IL, 1986, J ALLERGY CLIN IMMUN, V78, P489, DOI 10.1016/0091-6749(86)90093-X; BUTCHERS P R, 1987, British Journal of Pharmacology, V92, p745P; COCKCROFT DW, 1985, ANN ALLERGY, V55, P527; DAHL R, 1991, American Review of Respiratory Disease, V143, pA649; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; HALL IP, 1992, ASTHMA, P341; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; Jeppsson A B, 1989, Pulm Pharmacol, V2, P81, DOI 10.1016/0952-0600(89)90028-8; JONGEJAN R C, 1991, American Review of Respiratory Disease, V143, pA421; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LOFDAHL CG, 1989, ALLERGY, V44, P264, DOI 10.1111/j.1398-9995.1989.tb01068.x; LOFDAHL CG, 1991, EUR RESPIR J, V4, P218; MITA H, 1983, ALLERGY, V38, P547, DOI 10.1111/j.1398-9995.1983.tb04138.x; NELSON HS, 1991, AM REV RESPIR DIS, V144, P249, DOI 10.1164/ajrccm/144.2.249; NEWHOUSE MT, 1984, METERED DOSE INHALER, P6; NIJKAMP FP, 1992, PHYSIOL REV, V72, P323, DOI 10.1152/physrev.1992.72.2.323; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RAMSDALE EH, 1991, AM REV RESPIR DIS, V143, P998, DOI 10.1164/ajrccm/143.5_Pt_1.998; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; STERK PJ, 1985, AM REV RESPIR DIS, V132, P272; STERK PJ, 1991, AM REV RESPIR DIS, V143, P1433, DOI 10.1164/ajrccm/143.6.1433; SVEDMYR N, 1990, AM REV RESPIR DIS, V141, pS31; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; VANAMSTERDAM RGM, 1990, AM REV RESPIR DIS, V142, P1124, DOI 10.1164/ajrccm/142.5.1124; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; 1987, AM REV RESPIR DIS, V136, P225	39	395	398	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1198	1203		10.1056/NEJM199210223271703	http://dx.doi.org/10.1056/NEJM199210223271703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1357550				2022-12-28	WOS:A1992JU39300003
J	LEARMONT, J; TINDALL, B; EVANS, L; CUNNINGHAM, A; CUNNINGHAM, P; WELLS, J; PENNY, R; KALDOR, J; COOPER, DA				LEARMONT, J; TINDALL, B; EVANS, L; CUNNINGHAM, A; CUNNINGHAM, P; WELLS, J; PENNY, R; KALDOR, J; COOPER, DA			LONG-TERM SYMPTOMLESS HIV-1 INFECTION IN RECIPIENTS OF BLOOD PRODUCTS FROM A SINGLE DONOR	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEROPOSITIVE HOMOSEXUAL MEN; BISEXUAL MEN; TYPE-1 HIV-1; CD4+ CELLS; AIDS; RISK; TRANSPLANTATION; REPLICATION; PROGRESSION	There have been reported cases of long-term symptomless human immunodeficiency virus type 1 (HIV-1) infection, but it is not clear whether the benign course of infection was due to host, viral, or other unknown factors. During follow-up of subjects with transfusion-acquired HIV-1 infection in New South Wales, Australia, we identified a group of 6 subjects who had been infected through a single common donor. We were therefore able to study the contributions of various factors to the course of infection. Throughout follow-up (range 6.8-10.1 years after infection), 5 of the recipients and the donor (last follow-up 10.2 years after infection of the first recipient) remained clinically free of symptoms, with normal CD4 cell counts and no p24 antigenaemia. HIV-1 was isolated from only 1 recipient; the isolate did not induce syncytia in a SUPT1 co-culture assay and had a limited in-vitro host range. 1 infected recipient (who had received extensive immunosuppressive treatment for systemic lupus erythematosus) developed Pneumocystis carinii pneumonia and died 4.3 years after infection. The frequency of progression to AIDS or a CD4 cell count below 0.50 x 10(9)/I was significantly lower among the 6 subjects with a common donor (1/6) than among 101 other HIV-infected transfusion recipients for whom data from 7 years of follow-up were available (94/101; p < 0.0001 ). These findings suggest that the subjects were infected by a less virulent strain of HIV-1. The identification of this group of subjects should stimulate a search for other similar groups, which will provide important information on the immunopathogenesis of HIV-1 disease.	UNIV NEW S WALES, NATL CTR HIV EPIDEMIOL & CLIN RES, 376 VICTORIA ST, SYDNEY, NSW 2010, AUSTRALIA; UNIV NEW S WALES, NEW S WALES RED CROSS BLOOD TRANSFUS SERV, SYDNEY, NSW, AUSTRALIA; ST VINCENTS HOSP, CTR IMMUNOL, SYDNEY, NSW 2010, AUSTRALIA; ROYAL N SHORE HOSP, ST LEONARDS, NSW 2065, AUSTRALIA; WESTMEAD HOSP, DEPT VIROL, WESTMEAD, AUSTRALIA	University of New South Wales Sydney; Kirby Institute; Australian Red Cross Blood Service; University of New South Wales Sydney; St Vincents Hospital Sydney; Royal North Shore Hospital; University of Sydney			Cunningham, Philip/GZH-1820-2022	Cunningham, Anthony/0000-0002-6744-5667; Cunningham, Philip/0000-0003-2613-6910				APPERLEY JF, 1987, EUR J HAEMATOL, V39, P185; ARDNER GT, 1988, 4 INT C AIDS STOCKH, P354; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; COOPER DA, 1988, J INFECT DIS, V157, P889, DOI 10.1093/infdis/157.5.889; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; EVANS LA, 1988, SCIENCE, V240, P1522, DOI 10.1126/science.2836951; FORTENBERRY JD, 1989, J ADOLESCENT HEALTH, V10, P570, DOI 10.1016/0197-0070(89)90028-4; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOLD J, 1984, MED J AUSTRALIA, V141, P569; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; LEVY JA, 1985, J INFECT DIS, V152, P734, DOI 10.1093/infdis/152.4.734; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; PEDERSEN C, 1989, AIDS, V3, P45, DOI 10.1097/00002030-198911000-00009; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; RUUTU P, 1987, SCAND J INFECT DIS, V19, P369, DOI 10.3109/00365548709018484; TERSMETTE M, 1990, AIDS (London), V4, pS57; TERSMETTE M, 1989, LANCET, V1, P983; TINDALL B, 1990, MED J AUSTRALIA, V153, P260, DOI 10.5694/j.1326-5377.1990.tb136897.x; VANGRIENSVEN GJP, 1990, AM J EPIDEMIOL, V132, P203; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WIVIOTT LD, 1990, CELL IMMUNOL, V128, P628, DOI 10.1016/0008-8749(90)90054-U	29	196	200	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1992	340	8824					863	867		10.1016/0140-6736(92)93281-Q	http://dx.doi.org/10.1016/0140-6736(92)93281-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357294				2022-12-28	WOS:A1992JT32700001
J	FOOTE, S; VOLLRATH, D; HILTON, A; PAGE, DC				FOOTE, S; VOLLRATH, D; HILTON, A; PAGE, DC			THE HUMAN Y-CHROMOSOME - OVERLAPPING DNA CLONES SPANNING THE EUCHROMATIC REGION	SCIENCE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN X-CHROMOSOME; SEX-DETERMINING REGION; HUMAN GENOME; PSEUDOAUTOSOMAL REGION; ENZYMATIC AMPLIFICATION; DROSOPHILA GENOME; PHYSICAL MAP; SHORT ARM; LONG ARM	The human Y chromosome was physically mapped by assembling 196 recombinant DNA clones, each containing a segment of the chromosome, into a single overlapping array. This array included more than 98 percent of the euchromatic portion of the Y chromosome. First, a library of yeast artificial chromosome (YAC) clones was prepared from the genomic DNA of a human XYYYY male. The library was screened to identify clones containing 160 sequence-tagged sites and the map was then constructed from this information. In all, 207 Y-chromosomal DNA loci were assigned to 127 ordered intervals on the basis of their presence or absence in the YAC's, yielding ordered landmarks at an average spacing of 220 kilobases across the euchromatic region. The map reveals that Y-chromosomal genes are scattered among a patchwork of X-homologous, Y-specific repetitive, and single-copy DNA sequences. This map of overlapping clones and ordered, densely spaced markers should accelerate studies of the chromosome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	FOOTE, S (corresponding author), MIT,WHITEHEAD INST,HOWARD HUGHES RES LABS,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Foote, Simon J/F-2802-2013	Foote, Simon/0000-0002-9142-2107				ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; AJIOKA JW, 1991, CHROMOSOMA, V100, P495, DOI 10.1007/BF00352200; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FROMMER M, 1984, NUCLEIC ACIDS RES, V12, P2887, DOI 10.1093/nar/12.6.2887; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; GOUGH NM, 1990, NATURE, V345, P734, DOI 10.1038/345734a0; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GUIOLI S, 1992, NAT GENET, V1, P337, DOI 10.1038/ng0892-337; HENKE A, 1991, AM J HUM GENET, V49, P811; INCERTI B, IN PRESS NATURE GENE; KNOWLTON RG, 1989, NUCLEIC ACIDS RES, V17, P423, DOI 10.1093/nar/17.1.423; KUSPA A, 1989, P NATL ACAD SCI USA, V86, P8917, DOI 10.1073/pnas.86.22.8917; LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888-7543(89)90295-4; LITTLE RD, 1992, P NATL ACAD SCI USA, V89, P177, DOI 10.1073/pnas.89.1.177; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1987, CELL, V50, P495; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PEDICINI A, 1991, GENOMICS, V11, P482, DOI 10.1016/0888-7543(91)90167-D; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; RAPPOLD G, 1988, NUCLEIC ACIDS RES, V16, P5631; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBERG AA, 1985, Y CHROMOSOME A; SCHLESSINGER D, 1991, GENOMICS, V11, P783, DOI 10.1016/0888-7543(91)90001-U; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SIROTA L, 1981, CLIN GENET, V19, P87; SMITH DR, IN PRESS METHODS ENZ; SMITH KD, 1987, DEVELOPMENT, V101, P77; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7	57	403	415	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					60	66		10.1126/science.1359640	http://dx.doi.org/10.1126/science.1359640			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1359640				2022-12-28	WOS:A1992JQ61900025
J	BRAHAMS, D				BRAHAMS, D			EUTHANASIA - DOCTOR CONVICTED OF ATTEMPTED MURDER	LANCET			English	Editorial Material																			0	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					782	783		10.1016/0140-6736(92)92314-6	http://dx.doi.org/10.1016/0140-6736(92)92314-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356188				2022-12-28	WOS:A1992JP86900016
J	HART, JT				HART, JT			2 PATHS FOR MEDICAL-PRACTICE	LANCET			English	Article							STATES HEALTH-CARE; GENERAL-PRACTICE; CHRONIC DISEASE; BLOOD-PRESSURE; INNER-CITY; FOLLOW-UP; PERSPECTIVE; OUTCOMES; PATIENT; CONSULTATION											ALDIS WL, 1989, LANCET, V2, P1456; BANOS JE, 1992, LANCET, V339, P799; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BUCHAN IC, 1973, SCOTTISH HLTH STUDIE, V27; BURROWS PJ, 1987, J ROY COLL GEN PRACT, V37, P65; CONEY S, 1991, LANCET, V338, P374; COOPER C, 1992, BRIT MED J, V304, P793, DOI 10.1136/bmj.304.6830.793; DEAN M, 1990, LANCET, V336, P1369, DOI 10.1016/0140-6736(90)92909-2; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; DOWIE R, 1984, GEN PRACT, P171; Drury V W, 1976, J R Coll Gen Pract, V26, P712; EISENBERG L, 1988, AM J MED, V84, P483; Enthoven A.C., 1985, REFLECTIONS MANAGEME; ESSEX BJ, 1975, BRIT MED J, V3, P34, DOI 10.1136/bmj.3.5974.34; ETTLINGER PRA, 1981, BRIT MED J, V282, P1192, DOI 10.1136/bmj.282.6271.1192; FINNERTY FA, 1973, CIRCULATION, V47, P76, DOI 10.1161/01.CIR.47.1.76; FLEMING DM, 1983, BRIT MED J, V287, P1852, DOI 10.1136/bmj.287.6408.1852; FREEMAN GK, 1990, BMJ-BRIT MED J, V301, P1028, DOI 10.1136/bmj.301.6759.1028; FRY J, 1990, LANCET, V336, P558; Gervas J J, 1991, Aten Primaria, V8, P202; GIBBONS B, 1991, BRIT MED J, V303, P1066; GOTTLIEB B, 1969, UPDATE, V5, P917; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HART JT, 1990, BRIT J GEN PRACT, V40, P255; HART JT, 1992, BRIT J GEN PRACT, V42, P116; HARTWIG JH, 1988, CELL PHYSL BLOOD, P125; HASTINGS A, 1991, BRIT MED J, V303, P1271, DOI 10.1136/bmj.303.6812.1271-b; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HORDER J, 1990, BRIT J GEN PRACT, V40, P442; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; INUI TS, 1976, ANN INTERN MED, V84, P646, DOI 10.7326/0003-4819-84-6-646; JONES K, 1991, FAM PRACT, V8, P97, DOI 10.1093/fampra/8.1.97; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LINDGREN B, 1990, HLTH CARE SYSTEMS TR; LUSH N, 1991, LANCET, V338, P562; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MARSH GN, 1982, BRIT MED J, V284, P1176, DOI 10.1136/bmj.284.6323.1176; MARTYS CR, 1992, BRIT MED J, V304, P758, DOI 10.1136/bmj.304.6829.758; MCCARTY DJ, 1987, NEW ENGL J MED, V317, P567, DOI 10.1056/NEJM198708273170909; MCPHERSON K, 1990, OECD SOCIAL POLICY S, V7, P17; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; PORTER AMW, 1969, BMJ-BRIT MED J, V1, P218, DOI 10.1136/bmj.1.5638.218; QUAM L, 1987, BRIT MED J, V294, P1597, DOI 10.1136/bmj.294.6587.1597; QUAM L, 1987, BRIT MED J, V294, P1529, DOI 10.1136/bmj.294.6586.1529; RIDDLE MC, 1980, LANCET, V2, P734; RIDSDALE L, 1989, J ROY COLL GEN PRACT, V39, P488; SANDIER S, 1990, OECD POLICY STUDIES, V7, P41; SCHIEBER GJ, 1988, HEALTH AFFAIR, V7, P105, DOI 10.1377/hlthaff.7.4.105; SHEPHERD M, 1989, BRIT MED J, V299, P666, DOI 10.1136/bmj.299.6700.666; SHEPHERD M, 1991, BRIT J GEN PRACT, V41, P252; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WHITFIELD M, 1988, BRIT MED J, V297, P398, DOI 10.1136/bmj.297.6645.398; WILKIN D, 1990, PATTERNS HOSPITAL RE, P23; WILSON A, 1992, BMJ-BRIT MED J, V304, P227, DOI 10.1136/bmj.304.6821.227; WILSON A, 1991, BRIT J GEN PRACT, V41, P119; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WORMALD WPL, 1992, BRIT MED J, V304, P1226; 1989, COMPENDIUM HLTH STAT	63	39	39	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1992	340	8822					772	775		10.1016/0140-6736(92)92304-X	http://dx.doi.org/10.1016/0140-6736(92)92304-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356187				2022-12-28	WOS:A1992JP86900013
J	ZAAIJER, HL; VONEXELOEHLERS, P; KRAAIJEVELD, T; ALTENA, E; LELIE, PN				ZAAIJER, HL; VONEXELOEHLERS, P; KRAAIJEVELD, T; ALTENA, E; LELIE, PN			EARLY DETECTION OF ANTIBODIES TO HIV-1 BY 3RD-GENERATION ASSAYS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD-DONORS; P24 ANTIGEN; INFECTION; TYPE-1; EFFICACY	Third-generation immunoassays for detection of antibody to human immunodeficiency virus (HIV) have reduced the interval between infection and antibody detection. Might such earlier detection diminish the value of the western blot as a confirmatory assay? We compared the sensitivity of one second-generation and two third-generation anti-HIV enzyme immunoassays (EIAs) with the results from HIV-antigen testing and western blot. 1045 western-blot confirmed anti-HIV positive samples were tested with a detection rate of 100% for all three EIAs. The detection rate in 36 samples drawn from different persons in early stages of HIV infection was 89% for the second-generation EIA and 94% for both third-generation EIAs. With carefully selected seroconversion panels that included sampling intervals during seroconversion of one week or less, we found that both third-generation EIAs detected seroconversion on average 5 days earlier (range 0-13) than did the second-generation assay. Western blot is commonly used to confirm HIV infection. In 6 of 10 seroconversions, one or both third-generation EIAs were reactive before any band appeared in the western blot. Since HIV antigen was detectable in these cases, the HIV antigen test may serve as a confirmatory assay for anti-HIV EIA-positive, western-blot negative, samples.			ZAAIJER, HL (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.							ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; BUSCH MP, 1990, NEW ENGL J MED, V323, P1308, DOI 10.1056/NEJM199011083231904; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; LELIE PN, 1989, VOX SANG, V56, P59, DOI 10.1111/j.1423-0410.1989.tb03051.x; LELIE PN, 1988, VOX SANG, V54, P84, DOI 10.1111/j.1423-0410.1988.tb01622.x; MEHRABOON SI, 1991, NEW ENGL J MED, V325, P1174; REESINK HW, 1986, LANCET, V2, P483; STRAMER SL, 1989, JAMA-J AM MED ASSOC, V262, P64, DOI 10.1001/jama.262.1.64	8	97	103	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					770	772		10.1016/0140-6736(92)92303-W	http://dx.doi.org/10.1016/0140-6736(92)92303-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356186				2022-12-28	WOS:A1992JP86900012
J	ROSENTHAL, W; SEIBOLD, A; ANTARAMIAN, A; LONERGAN, M; ARTHUS, MF; HENDY, GN; BIRNBAUMER, M; BICHET, DG				ROSENTHAL, W; SEIBOLD, A; ANTARAMIAN, A; LONERGAN, M; ARTHUS, MF; HENDY, GN; BIRNBAUMER, M; BICHET, DG			MOLECULAR-IDENTIFICATION OF THE GENE RESPONSIBLE FOR CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS	NATURE			English	Article							DNA; VASOPRESSIN; POLYMERASE; RECEPTORS; LOCUS	ANTIDIURETIC hormone (arginine vasopressin) binds to and activates V2 receptors in renal collecting tubule cells. Subsequent stimulation of the G(s)/adenylyl cyclase system promotes insertion of water pores into the luminal membrane and thereby reabsorption of fluid. In congenital nephrogenic diabetes insipidus (CNDI)1, an X-linked recessive disorder, the kidney fails to respond to arginine vasopressin. Here we report that an affected male of a family with CNDI2,3 has a deletion in the open reading frame of the V2 receptor gene, causing a frame shift and premature termination of translation in the third intracellular loop of the receptor protein. A normal receptor gene was found in the patient's brother. Both the normal and the mutant allele were detected in his mother. A different mutation, causing a codon change in the third transmembrane domain of the V2 receptor, was found in the open reading frame of an affected male but not in the unaffected brother belonging to another family suffering from CNDI.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; HOP SACRE COEUR,CTR RECH,SERV NEPHROL,MONTREAL H4J 1C5,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA	Baylor College of Medicine; Universite de Montreal; Universite de Montreal				BICHET, DANIEL-G/0000-0003-2856-6850				BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BICHET DG, IN PRESS AM J HUM GE; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; DILELLA AG, 1987, METHOD ENZYMOL, V152, P199; GIBBS RA, 1991, METHOD MOL BIOL, V8, P9; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JANS DA, 1990, J BIOL CHEM, V265, P15379; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOSES AM, 1982, J CLIN ENDOCR METAB, V55, P699, DOI 10.1210/jcem-55-4-699; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; REEVES WB, 1989, METABOLIC BASIS INHE, P1985; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIBOLD A, IN PRESS AM J HUM GE; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840	22	260	263	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					233	235		10.1038/359233a0	http://dx.doi.org/10.1038/359233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1356229				2022-12-28	WOS:A1992JN94400060
J	MERTENS, WC; BRAMWELL, VHC; GWADRYSRIDHAR, F; ROMANO, W; BANERJEE, D; LALA, PK				MERTENS, WC; BRAMWELL, VHC; GWADRYSRIDHAR, F; ROMANO, W; BANERJEE, D; LALA, PK			EFFECT OF INDOMETHACIN PLUS RANITIDINE IN ADVANCED MELANOMA PATIENTS ON HIGH-DOSE INTERLEUKIN-2	LANCET			English	Note							METASTATIC MALIGNANT-MELANOMA; ACTIVATED KILLER-CELLS; CONTINUOUS INFUSION INTERLEUKIN-2; PHASE-II; THERAPY	Preclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases. A phase II trial was done in patients with advanced melanoma. Indomethacin and ranitidine were begun at least one week before IL-2. Of the objective responses in 3 patients, 2 were achieved on ranitidine and indomethacin alone, before start of IL-2. Indomethacin and ranitidine may be responsible for some responses in melanoma patients previously attributed to IL-2.	UNIV MICHIGAN,DEPT RADIOL,ANN ARBOR,MI 48109; UNIV WESTERN ONTARIO,DEPT PATHOL,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT ANAT,LONDON N6A 3K7,ONTARIO,CANADA	University of Michigan System; University of Michigan; Western University (University of Western Ontario); Western University (University of Western Ontario)	MERTENS, WC (corresponding author), LONDON REG CANC CTR,DEPT MED ONCOL,790 COMMISS RD E,LONDON N6A 4L6,ONTARIO,CANADA.							BAR MH, 1990, J CLIN ONCOL, V8, P1138, DOI 10.1200/JCO.1990.8.7.1138; DUTCHER JP, 1991, J CLIN ONCOL, V9, P641, DOI 10.1200/JCO.1991.9.4.641; DUTCHER JP, 1989, J CLIN ONCOL, V7, P477, DOI 10.1200/JCO.1989.7.4.477; LALA PK, 1988, CANCER RES, V48, P1072; MANDANAS R, 1991, AM J CLIN ONCOL-CANC, V14, P397, DOI 10.1097/00000421-199110000-00007; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1650, DOI 10.1200/JCO.1990.8.10.1650; ROSENBERG SA, 1989, CANCER TREAT REV, V16, P115, DOI 10.1016/0305-7372(89)90031-5; SMITH T, 1987, ARCH INTERN MED, V147, P1815, DOI 10.1001/archinte.147.10.1815; SMITH T, 1990, Comprehensive Therapy, V16, P8	9	24	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					397	398		10.1016/0140-6736(92)91474-M	http://dx.doi.org/10.1016/0140-6736(92)91474-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353559	Green Submitted			2022-12-28	WOS:A1992JJ44900007
J	FEWTRELL, L; GODFREE, AF; JONES, F; KAY, D; SALMON, RL; WYER, MD				FEWTRELL, L; GODFREE, AF; JONES, F; KAY, D; SALMON, RL; WYER, MD			HEALTH-EFFECTS OF WHITE-WATER CANOEING	LANCET			English	Article							RISKS	There is little quantitative information on the relation between water quality and disease attack rates after recreational activities in fresh water. We conducted a prospective cohort study to measure the health effects of white-water and slalom canoeing in two channels with different degrees of microbial contamination. Site A, fed by a lowland river, showed high enterovirus concentrations (arithmetic mean 198 pfu per 10 litre and moderate faecal coliform concentrations (geometric mean 285/dl); at site B, from an upland impoundment, all samples were free of enteroviruses and the geometric mean faecal coliform concentration was 22/dl. Between 5 and 7 days after exposure canoeists using site A had significantly higher incidences of gastrointestinal and upper respiratory symptoms than canoeists using site B or non-exposed controls (spectators). Like seawater bathers, fresh-water canoeists can be made ill by sewage contamination. The hazard of fresh water may be best measured by counting of viruses rather than bacteria.	ACER ENVIRONM,DARESBURY,CHESHIRE,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,WELSH UNIT,CARDIFF,WALES		FEWTRELL, L (corresponding author), UNIV WALES,CTR RES ENVIRONM & HLTH,LAMPETER SA48 7ED,DYFED,WALES.							ALICO RK, 1986, APPL ENVIRON MICROB, V51, P699, DOI 10.1128/AEM.51.4.699-702.1986; FERLEY JP, 1989, INT J EPIDEMIOL, V18, P198, DOI 10.1093/ije/18.1.198; FEWTRELL L, 1991, APPL GEOGR, V11, P215, DOI 10.1016/0143-6228(91)90031-4; GODFREE A, 1990, MAR POLLUT BULL, V21, P414, DOI 10.1016/0025-326X(90)90760-6; JONES F, 1991, J INST WATER ENV MAN, V5, P91; LIGHTFOOD NE, 1989, THESIS U TORONTO; MERRETTJONES M, 1991, SEP M HLTH REL MICR, P158; PHILIPP R, 1989, PUBLIC HEALTH, V103, P123, DOI 10.1016/S0033-3506(89)80026-5; PHILIPP R, 1985, INT J EPIDEMIOL, V14, P624, DOI 10.1093/ije/14.4.624; STEVENSON AH, 1953, AM J PUBLIC HEALTH, V43, P529; 1983, 71 REP; 1986, EPA440584002; 1988, PECD77260 CONS ENV S; 1976, OFFIC J EUROP COMM L, V31, P1; [No title captured]	15	33	35	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1587	1589		10.1016/0140-6736(92)91843-W	http://dx.doi.org/10.1016/0140-6736(92)91843-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JB202	1351560				2022-12-28	WOS:A1992JB20200014
J	TOUGAARD, L; KRONE, T; SORKNAES, A; ELLEGAARD, H				TOUGAARD, L; KRONE, T; SORKNAES, A; ELLEGAARD, H			ECONOMIC-BENEFITS OF TEACHING PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE ABOUT THEIR ILLNESS	LANCET			English	Article								By instructing patients in how to deal with their disease financial demands on health services may be reduced. 100 consecutive patients (aged 48 to 89) admitted to a general medical ward in Denmark with chronic obstructive pulmonary disease (COPD) were allocated randomly to receive either "personalised hospital practice" (PHP), which includes training in aspects of their disease, or standard hospital practice. Changes in "consumption" of health services per patient from 1 year before until 1 year after the intervention admission were evaluated in 82 (PHP group 42, controls 40) patients who completed the intervention phase. Each group contained about the same percentage of asthmatics and smokers. The increase in consumption of health services after intervention was on average Kr15 298 per patient per year less in the PHP group than in the control group (p=0.048, Wilcoxon test). Consumption of general practitioner services was significantly increased in the control group compared with the PHP group (mean [95% Cl] Kr1346 [549 to 2143] vs - 89 [-423 to 245] per patient per year; p=0.001, Wilcoxon test). These differences could not be explained by changes in smoking habits. PHP reduces the consumption of health services by patients with COPD, probably by increasing patients' knowledge of disease and hence their ability to manage themselves.	FYNS COUNTRY DEPT HOSP ADM,ODENSE,DENMARK		TOUGAARD, L (corresponding author), FAABORG HOSP,DEPT INTERNAL MED,DK-5600 FABORG,DENMARK.							RINGSBERG KC, 1990, EUR RESPIR J, V3, P33; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; TOUGAARD L, 1991, UGESKRIFT LAEGER, V153, P1306	3	42	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1517	1520		10.1016/0140-6736(92)91274-C	http://dx.doi.org/10.1016/0140-6736(92)91274-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HZ175	1351196				2022-12-28	WOS:A1992HZ17500014
J	FALK, RJ; HOGAN, SL; MULLER, KE; JENNETTE, JC				FALK, RJ; HOGAN, SL; MULLER, KE; JENNETTE, JC			TREATMENT OF PROGRESSIVE MEMBRANOUS GLOMERULOPATHY - A RANDOMIZED TRIAL COMPARING CYCLOPHOSPHAMIDE AND CORTICOSTEROIDS WITH CORTICOSTEROIDS ALONE	ANNALS OF INTERNAL MEDICINE			English	Article						GLOMERULONEPHRITIS, MEMBRANOUS; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; KIDNEY FAILURE; ADRENAL CORTEX HORMONES	RENAL-FUNCTION; UNTREATED PATIENTS; NATURAL-HISTORY; NEPHROPATHY; METHYLPREDNISOLONE; GLOMERULONEPHRITIS; CHLORAMBUCIL; PREDNISONE; PROGNOSIS	Objective: To determine if deterioration in renal function could be ameliorated by adding cyclophosphamide to corticosteroid therapy in patients with progressive membranous glomerulopathy. Design: Randomized, controlled treatment trial. Patients were followed for a mean of 29.2 +/- 17.1 months. Setting: Collaborative network of 120 university and private-practice nephrologists. Participants: Patients with membranous glomerulopathy whose renal function deteriorated (as evidenced by doubling of the serum creatinine level, a 50% fall in the glomerular filtration rate, or a sustained serum creatinine level of greater than 2.0 mg/dL [reciprocal creatinine value, 0.5], or whose nephrotic range proteinuria persisted in association with morbid complications. Of 156 patients with biopsy-proven membranous glomerulopathy, 36 became eligible for randomization. Twenty-six of these 36 patients were randomly assigned to receive one of the two treatments. Interventions: Pulse methylprednisolone, oral corticosteroids, and 6 months of intravenous cyclophosphamide or alternate-day corticosteroid therapy alone. Main Results: At entry, no statistical differences were found between the treatment groups in duration of renal disease, age, gender, serum creatinine level, 24-hour urine protein excretion, or biopsy stage. The groups showed no difference in mean arterial blood pressure during follow-up. Four of the 13 patients receiving corticosteroids alone and 4 of the 13 patients receiving corticosteroids plus intravenous cyclophosphamide progressed to end-stage renal disease during follow-up. Reciprocal creatinine values tested at 6-month intervals showed no statistical differences between treatment groups at any time point. The log of the 24-hour protein excretion values showed no statistical differences between treatment groups after treatment. The power to detect a substantial improvement in renal function, defined as a doubling of the reciprocal of the serum creatinine, at the 0.05 significance level was 0.92. Conclusions: Combination therapy with intravenous cyclophosphamide and corticosteroids, when compared with corticosteroid therapy alone, does not improve renal function in patients with progressive membranous glomerulopathy.	UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	FALK, RJ (corresponding author), UNIV N CAROLINA, DEPT MED, DIV NEPHROL, CB 7155, 3034 OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.			Jennette, John Charles/0000-0002-8081-6565	NCRR NIH HHS [RR00046] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BRUNS FJ, 1991, ANN INTERN MED, V114, P725, DOI 10.7326/0003-4819-114-9-725; CAMERON JS, 1990, Q J MED, V74, P133, DOI 10.1093/oxfordjournals.qjmed.a068422; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; EHRENREICH T, 1976, NEW ENGL J MED, V295, P741, DOI 10.1056/NEJM197609302951401; GLASSOCK RJ, 1991, SEMIN NEPHROL, V11, P138; MATHIESON PW, 1988, LANCET, V2, P869; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; PONTICELLI C, 1986, KIDNEY INT, V29, P927, DOI 10.1038/ki.1986.88; RAMZY MH, 1981, CLIN NEPHROL, V16, P13; Schluchter MD., 1990, J STAT COMPUT SIM, V37, P69, DOI [10.1080/00949659008811295, DOI 10.1080/00949659008811295]; SHORT CD, 1987, Q J MED, V65, P929; TU WH, 1984, NEPHRON, V36, P118, DOI 10.1159/000183130; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247; 1989, SAS STAT USERS GUIDE, V2, P1027	22	86	87	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					438	445		10.7326/0003-4819-116-6-438	http://dx.doi.org/10.7326/0003-4819-116-6-438			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1371211				2022-12-28	WOS:A1992HJ59800002
J	SCHMIDT, HHHW; WARNER, TD; ISHII, K; SHENG, H; MURAD, F				SCHMIDT, HHHW; WARNER, TD; ISHII, K; SHENG, H; MURAD, F			INSULIN-SECRETION FROM PANCREATIC B-CELLS CAUSED BY L-ARGININE DERIVED NITROGEN-OXIDES	SCIENCE			English	Article							NITRIC-OXIDE; DIABETES-MELLITUS; RELEASE; CALMODULIN; CALCIUM; ISLETS; LIVER; RATS	L-Arginine causes insulin release from pancreatic B cells. Data from three model systems support the hypothesis that L-arginine-derived nitrogen oxides (NOs) mediate insulin release stimulated by L-arginine in the presence of D-glucose and by the hypoglycemic drug tolbutamide. The formation of NO in pancreatic B cells was detected both chemically and by the NO-induced accumulation of guanosine 3',5'-monophosphate. N(G)-substituted L-arginine analogs inhibited the release of both insulin and NO. Protein immunoblot and histochemical analysis with antiserum to type I NO synthase suggest that the formation of NO in pancreatic B cells is catalyzed by an NADPH- (reduced form of nicotinamide adenine dinucleotide phosphate), Ca2+/calmodulin-dependent type I NO synthase of about 150 kilodaltons.	UNIV SHIZUOKA,SCH PHARMACEUT SCI,DEPT PHARMACOL,SHIZUOKA 422,JAPAN; ABBOTT LABS,ABBOTT PK,IL 60064	University of Shizuoka; Abbott Laboratories	SCHMIDT, HHHW (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611, USA.		Warner, Timothy D/A-1980-2009; Schmidt, Harald HHW/B-1549-2008	Warner, Timothy D/0000-0003-3988-4408; Schmidt, Harald HHW/0000-0003-0419-5549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030787] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28474] Funding Source: Medline; NIDDK NIH HHS [DK 30787] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJAALAND T, 1988, BIOCHEM SOC T, V16, P1017, DOI 10.1042/bst0161017; BJAALAND T, 1990, DIABETOLOGIA, V32, pA467; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GAGLIARDINO JJ, 1980, BIOCHEM J, V192, P919, DOI 10.1042/bj1920919; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HELLMAN B, 1971, ENDOCRINOLOGY, V89, P1432, DOI 10.1210/endo-89-6-1432; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUGHES SJ, 1990, BIOCHEM J, V267, P227, DOI 10.1042/bj2670227; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; ISHII K, 1990, EUR J PHARMACOL, V176, P219; KAMATA K, 1989, BRIT J PHARMACOL, V97, P614, DOI 10.1111/j.1476-5381.1989.tb11993.x; KIMURA H, 1975, J BIOL CHEM, V250, P8016; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LAYCHOCK SG, 1981, ENDOCRINOLOGY, V108, P1197, DOI 10.1210/endo-108-4-1197; LUHESHI GN, 1990, BRIT J PHARMACOL, V101, P411, DOI 10.1111/j.1476-5381.1990.tb12723.x; MANN GE, 1990, NITRIC OXIDE L ARGIN, P331; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MULLOY AL, 1982, HORM METAB RES, V14, P471, DOI 10.1055/s-2007-1019050; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PANTEN U, 1975, P115; PANTEN U, 1973, N-S ARCH PHARMACOL, V276, P55, DOI 10.1007/BF00500778; SCHMIDT H, UNPUB; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V154, P213, DOI 10.1016/0014-2999(88)90101-X; SENER A, 1990, ENDOCRINOLOGY, V127, P107, DOI 10.1210/endo-127-1-107; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; VERSPOHL EJ, 1989, N-S ARCH PHARMACOL, V339, P348; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; WOLLHEIM CB, 1975, J BIOL CHEM, V250, P1354	33	394	403	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					721	723		10.1126/science.1371193	http://dx.doi.org/10.1126/science.1371193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1371193				2022-12-28	WOS:A1992HC50600039
J	EDWARDS, IR				EDWARDS, IR			DRUG SAFETY MONITORING IN EUROPE	LANCET			English	Letter											EDWARDS, IR (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							1992, LANCET, V340, P1028	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1355	1356		10.1016/0140-6736(92)92541-M	http://dx.doi.org/10.1016/0140-6736(92)92541-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360070	Bronze			2022-12-28	WOS:A1992KA26200045
J	KARBWANG, J; BANGCHANG, KN; THANAVIBUL, A; BUNNAG, D; CHONGSUPHAJAISIDDHI, T; HARINASUTA, T				KARBWANG, J; BANGCHANG, KN; THANAVIBUL, A; BUNNAG, D; CHONGSUPHAJAISIDDHI, T; HARINASUTA, T			COMPARISON OF ORAL ARTEMETHER AND MEFLOQUINE IN ACUTE UNCOMPLICATED FALCIPARUM-MALARIA	LANCET			English	Article							CLINICAL-TRIAL; THAILAND	Plasmodium falciparum malaria in Thailand is highly resistant to available antimalarials, and alternative drugs are needed urgently. Artemether is effective against falciparum malaria but associated with a high recrudescence rate. The proper dosage regimen remains to be defined. We have done a clinical trial comparing mefloquine 1250 mg in divided doses with oral artemether at 700 mg total dose given over 5 days in acute uncomplicated falciparum malaria. 46 patients, admitted to the Bangkok Hospital for Tropical Diseases, were randomised to receive either mefloquine (12) or artemether (34). Hospital follow-up was 28 days for the artemether group and 42 days for the mefloquine group. Oral artemether gave a significantly faster parasite clearance time than mefloquine (30 vs 64 h), and a significantly better cure rate (97 vs 640/o) with fewer episodes of dizziness and vomiting. Oral artemether at 700 mg given over 5 days is effective and well tolerated. The cure rate with this regimen is higher than that reported by previous studies with 600 mg intramuscular artemether given over 5 days. Oral artemether can be considered as an alternative drug for multiple-drug-resistant falciparum malaria.	MAHIDOL UNIV, FAC TROP MED, HOSP TROP DIS, BANGKOK 10400, THAILAND	Mahidol University	KARBWANG, J (corresponding author), MAHIDOL UNIV, FAC TROP MED, DEPT CLIN TROP MED, CLIN PHARMACOL UNIT, BANGKOK 10400, THAILAND.							BOUDREAU EF, 1982, LANCET, V2, P1335; BUNNAG D, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P534; BUNNAG D, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P539; BUNNAG D, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P380; BUNNAG D, 1990, 7 INT C PAR PAR; BUNNAG D, 1986, PARASITOLOGY QUO VAD, P180; BUNNAG D, IN PRESS SE ASIAN J; HARINASUTA T, 1983, B WORLD HEALTH ORGAN, V61, P299; HARINASUTA T, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P552; HARINASUTA T, 1985, LANCET, V1, P885; KARBWANG J, 1992, CHEMOTHERAPY MALARIA, P48; LI G, 1982, Journal of Traditional Chinese Medicine, V2, P125; LOOAREESUWAN S, 1992, LANCET, V339, P821, DOI 10.1016/0140-6736(92)90276-9; MURRAY CJL, 1990, T ROY SOC TROP MED H, V84, P1, DOI 10.1016/0035-9203(90)90364-K; MYINT PT, 1987, T ROY SOC TROP MED H, V81, P559, DOI 10.1016/0035-9203(87)90406-8; Pe Than Myint, 1986, Southeast Asian J Trop Med Public Health, V17, P19; TRIGG PI, 1987, EC MED PLANT RES, V3, P20; Wang T Y, 1985, J Tradit Chin Med, V5, P240; 1973, WHO TECH REPORT SER, V529	19	48	48	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1992	340	8830					1245	1248		10.1016/0140-6736(92)92947-E	http://dx.doi.org/10.1016/0140-6736(92)92947-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359318				2022-12-28	WOS:A1992JZ23700002
J	SMIDTJENSEN, S; PERMIN, M; PHILIP, J; LUNDSTEEN, C; ZACHARY, JM; FOWLER, SE; GRUNING, K				SMIDTJENSEN, S; PERMIN, M; PHILIP, J; LUNDSTEEN, C; ZACHARY, JM; FOWLER, SE; GRUNING, K			RANDOMIZED COMPARISON OF AMNIOCENTESIS AND TRANSABDOMINAL AND TRANSCERVICAL CHORIONIC VILLUS SAMPLING	LANCET			English	Article							PRENATAL-DIAGNOSIS; 1ST TRIMESTER; SEPTIC SHOCK; REDUCTION; DEFECTS; BIOPSY; WOMEN	We have compared three methods of prenatal diagnosis in two large obstetric centres in Denmark. Women were randomly assigned transabdominal (TA) chorionic villus sampling (CVS), transcervical (TC) CVS, or second-trimester amniocentesis (AC); women at high genetic risk were randomised between the two CVS groups only. Analysis of 45 epidemiological variables showed the three procedure groups to be similar at enrolment. All women were followed up until completion of pregnancy. Among 3079 women at low genetic risk total fetal loss rates were 10.9% for TC CVS, 6.3% for TA CVS, and 6.4% for AC (p < 0.001). More women had bleeding after the procedure in the CVS groups (p < 0.001), whereas more amniotic fluid leakage (p < 0.001) was reported after AC. No uterine infections occurred in any group. No case of oromandibular-limb abnormality was seen in the CVS groups, but 1 child in the AC group had aplasia of the right hand. The two CVS approaches were compared among 2882 women at low and high genetic risk who were found to have cytogenetically normal fetuses. Rates of unintentional loss after the procedure were 7.7% for TC CVS and 3.7% for TA CVS (p < 0.001; 95% CI of difference 2.3-5.8%). At baseline ultrasound scanning after establishment of optimum sampling conditions, more TC than TA procedures (p < 0.001) were judged not to be feasible. We found that TA CVS allows better access to the placental site than TC sampling, is an easier skill to acquire, and has the potential that more villi can be aspirated when needed. The risk of fetal loss is similar after TA CVS and AC. However, losses after AC are at a later stage and are therefore more distressing. TA procedures remain the first choice for prenatal diagnosis. Since, in our hands, TC sampling carries a greater risk to the fetus, we have abandoned TC CVS in our two study centres.	SONDERBORG HOSP,DEPT OBSTET & GYNAECOL,DK-6400 SONDERBORG,DENMARK; GEORGE WASHINGTON UNIV,CTR BIOSTAT,WASHINGTON,DC 20052	George Washington University	SMIDTJENSEN, S (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT OBSTET & GYNAECOL,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.							[Anonymous], 1991, LANCET, V337, P1491; BARELA AI, 1986, AM J OBSTET GYNECOL, V154, P1100, DOI 10.1016/0002-9378(86)90761-1; BLAKEMORE KJ, 1986, AM J OBSTET GYNECOL, V155, P988, DOI 10.1016/0002-9378(86)90332-7; BOVICELLI L, 1988, PRENATAL DIAG, V8, P495, DOI 10.1002/pd.1970080704; BRAMBATI B, 1985, LANCET, V2, P609; BRAMBATI B, 1991, PRENATAL DIAG, V11, P285, DOI 10.1002/pd.1970110503; BRANDENBURG H, 1990, AM J MED GENET, V35, P178, DOI 10.1002/ajmg.1320350207; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; Everitt B.S., 1977, ANAL CONTINGENCY TAB; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; Fleiss JL, 1981, STAT METHODS RATES P; FOY HM, 1970, AM J OBSTET GYNECOL, V106, P635, DOI 10.1016/0002-9378(70)90381-9; HARREL FE, 1988, SUGI SUPPLEMENTAL LI; HOLLANDER M, 1973, NONPARAMETRIC STATIS; JACKSON LG, 1992, NEW ENGL J MED, V327, P594, DOI 10.1056/NEJM199208273270903; JAHODA MGJ, 1990, PRENATAL DIAG, V10, P307, DOI 10.1002/pd.1970100506; LILFORD RJ, 1987, LANCET, V1, P1415; MUGGAH HF, 1987, LANCET, V1, P867; RHOADES GG, 1989, NEW ENGL J MED, V320, P610; SAURA R, 1990, PRENATAL DIAG, V10, P461, DOI 10.1002/pd.1970100708; SCHULMAN JD, 1987, LANCET, V1, P1085; SCHULMAN LP, 1990, AM J OBSTET GYNECOL, V162, P1185; SIMONI G, 1983, HUM GENET, V63, P349, DOI 10.1007/BF00274761; SMIDTJENSEN S, 1989, PRENATAL DIAG, V9, P309, DOI 10.1002/pd.1970090503; SMIDTJENSEN S, 1984, PRENATAL DIAG, V4, P163, DOI 10.1002/pd.1970040302; TABOR A, 1986, LANCET, V1, P1282; VANDENANKER JN, 1991, LANCET, V338, P1332, DOI 10.1016/0140-6736(91)92628-F; WARD RHT, 1988, BRIT J OBSTET GYNAEC, V95, P1030, DOI 10.1111/j.1471-0528.1988.tb06509.x; 1985, BASICS STATISTICS	30	113	117	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1237	1244		10.1016/0140-6736(92)92946-D	http://dx.doi.org/10.1016/0140-6736(92)92946-D			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359317				2022-12-28	WOS:A1992JZ23700001
J	POWLES, TJ				POWLES, TJ			THE CASE FOR CLINICAL-TRIALS OF TAMOXIFEN FOR PREVENTION OF BREAST-CANCER	LANCET			English	Editorial Material									ROYAL MARSDEN HOSP,BREAST UNIT,SUTTON SM2 5PT,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust	POWLES, TJ (corresponding author), ROYAL MARSDEN HOSP,BREAST UNIT,DOWNS RD,LONDON,ENGLAND.							BLACKBURN AM, 1984, BRIT MED J, V289, P288, DOI 10.1136/bmj.289.6440.288; CHING CK, 1992, LANCET, V339, P940, DOI 10.1016/0140-6736(92)90991-B; CRESPI CL, 1991, CARCINOGENESIS, V12, P355, DOI 10.1093/carcin/12.2.355; CUZICK J, 1986, LANCET, V1, P83; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FERRAZZI E, 1977, BRIT MED J, V1, P1351, DOI 10.1136/bmj.1.6072.1351-e; FORNANDER T, 1989, LANCET, V1, P117; HAN XL, 1992, CANCER RES, V52, P1360; JORDAN VC, 1976, EUR J CANCER, V12, P419, DOI 10.1016/0014-2964(76)90030-X; KAISERKUPFER MI, 1978, CANCER TREAT REP, V62, P315; LIPTON A, 1984, CANCER TREAT REP, V68, P887; LONGSTAFF S, 1989, EUR J CANCER CLIN ON, V25, P1805, DOI 10.1016/0277-5379(89)90351-9; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NEVEN P, 1989, LANCET, V1, P375; PAVLIDIS NA, 1992, CANCER, V69, P2961, DOI 10.1002/1097-0142(19920615)69:12&lt;2961::AID-CNCR2820691215&gt;3.0.CO;2-W; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; STEWART HJ, 1989, LANCET, V1, P375; TANINGHER M, 1990, ENVIRON HEALTH PERSP, V84, P183, DOI 10.2307/3430720; 1989, INT J CANCER, V43, P254	21	92	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1145	1147		10.1016/0140-6736(92)93162-G	http://dx.doi.org/10.1016/0140-6736(92)93162-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359221				2022-12-28	WOS:A1992JX13400014
J	FOTHERBY, MD; HARPER, GD; POTTER, JF				FOTHERBY, MD; HARPER, GD; POTTER, JF			GENERAL-PRACTITIONERS MANAGEMENT OF HYPERTENSION IN ELDERLY PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; STROKE; TRIAL; MORTALITY; MORBIDITY; THERAPY	Objective-To assess general practitioners' attitudes to the diagnosis and management of hypertension in elderly patients. Design - Postal questionnaire to all general practitioners in Leicestershire. Results-360 of 451 general practitioners (80%) responded. 81% (292) reported rechecking an initially high blood pressure on two or three occasions before starting treatment, 56% (202) measured sitting blood pressure only, and just 28% (100) took sitting and standing levels. 36% (128) had no upper age limit for starting anti-hypertensive treatment; of the 58% (206) who did, the median was 80 (range 70-99) years. Blood pressure levels reported for starting treatment in patients aged 70-79 years were 180 (150-240)/106 (90-120) mm Hg. 34% of general practitioners (121) would not treat isolated systolic hypertension. The most popular first line treatment for an elderly hypertensive patient was a thiazide diuretic; only 17% of general practitioners (61) initially tried non-pharmacological methods. 34% (122) would continue anti-hypertensive treatment unchanged in the period immediately after stroke. Conclusions-The variation among general practitioners in the criteria for the measurement, diagnosis, and treatment of hypertension in elderly patients emphasises the need for clear management guidelines in this age group.			FOTHERBY, MD (corresponding author), UNIV LEICESTER, LEICESTER GEN HOSP, DEPT MED ELDERLY, LEICESTER LE5 4PW, ENGLAND.							AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BRITTON M, 1980, ACTA MED SCAND, V207, P253; BULPITT CJ, 1989, HDB HYPERTENSION, V12, P153; CAIRD FI, 1973, BRIT HEART J, V35, P527; CARTER AB, 1970, LANCET, V1, P485; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P368; MADER SL, 1987, JAMA-J AM MED ASSOC, V258, P1511, DOI 10.1001/jama.258.11.1511; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Meyer JS, 1973, STROKE, V4, P169, DOI 10.1161/01.STR.4.2.169; PATTERSON HR, 1984, J ROY COLL GEN PRACT, V34, P97; SMITH TDW, 1990, BMJ-BRIT MED J, V300, P74, DOI 10.1136/bmj.300.6717.74; SMITH WCS, 1985, BRIT MED J, V291, P1483, DOI 10.1136/bmj.291.6507.1483; WALLACE JD, 1981, JAMA-J AM MED ASSOC, V246, P2177, DOI 10.1001/jama.246.19.2177; WALLER PC, 1990, J HUM HYPERTENS, V4, P509; 1989, BMJ, V298, P294; 1987, DAN MED B S1, V34, P5; 1974, JAMA-J AM MED ASSOC, V229, P409; 1989, J HYPERTENS, V7, P689	23	49	49	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1992	305	6856					750	752		10.1136/bmj.305.6856.750	http://dx.doi.org/10.1136/bmj.305.6856.750			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1358373	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JQ52000024
J	TIBBALLS, J; SHANN, FA; LANDAU, LI				TIBBALLS, J; SHANN, FA; LANDAU, LI			PLACEBO-CONTROLLED TRIAL OF PREDNISOLONE IN CHILDREN INTUBATED FOR CROUP	LANCET			English	Article							RANDOMIZED DOUBLE-BLIND; CORTICOSTEROID TREATMENT; ACUTE LARYNGOTRACHEITIS; DEXAMETHASONE; STEROIDS	Many studies have attempted to find out whether steroid treatment is beneficial in children with croup, but the results have been inconclusive. We have done a prospective placebo-controlled study of the effect of prednisolone on two clinical endpoints-the duration of intubation and the need for reintubation. Reasons for exclusion were age under 6 months, congenital airway anomalies, and previous intubation. 70 eligible children were randomly assigned treatment with prednisolone 1 mg/kg (n = 38) or placebo (n = 32) every 12 h given by nasogastric tube until 24 h after extubation. 11 (34%) placebo-treated and only 2 (5%) prednisolone-treated patients required reintubation after accidental or elective extubation (p = 0.004, Fisher's exact test; odds ratio 8.9, 95% confidence interval 1.7-59.3). Survival analysis with log-normal regression showed that the duration of intubation was shorter with steroid therapy (p < 0.003) and increasing age (p < 0.02), but was not influenced by endotracheal tube size or abnormality on chest radiograph. The median duration of intubation was 138 (95% CI 118-160) h in children who received placebo and 98 (85-113) h in the prednisolone group. Steroid therapy reduces the duration of intubation and the need for reintubation in children intubated for croup.	PRINCESS MARGARET HOSP,DEPT PAEDIAT & RESP MED,PERTH,AUSTRALIA		TIBBALLS, J (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,FLEMINGTON RD,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					Altman DG, 1991, PRACTICAL STAT MED R, P365; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; EDEN AN, 1967, J AMER MED ASSOC, V200, P403, DOI 10.1001/jama.200.5.403; EDEN AN, 1964, PEDIATRICS, V33, P768; FREEZER N, 1990, ANAESTH INTENS CARE, V18, P224, DOI 10.1177/0310057X9001800212; JAMES JA, 1969, AM J DIS CHILD, V117, P511, DOI 10.1001/archpedi.1969.02100030513003; KAIRYS SW, 1989, PEDIATRICS, V83, P683; KOREN G, 1983, AM J DIS CHILD, V137, P941, DOI 10.1001/archpedi.1983.02140360005002; KUUSELA AL, 1988, ACTA PAEDIATR SCAND, V77, P99, DOI 10.1111/j.1651-2227.1988.tb10606.x; LEIPZIG B, 1979, J PEDIATR-US, V94, P194, DOI 10.1016/S0022-3476(79)80821-5; MARTENSSON B, 1960, Acta Otolaryngol Suppl, V158, P62; MUHLENDAHL KE, 1982, HELV PAEDIATR ACTA, V37, P431; NARCY P, 1991, ARCH FR PEDIATR, V48, P389; NOVIK A, 1960, Acta Otolaryngol Suppl, V158, P20; PHELAN PD, 1990, RESPIRATORY ILLNESS, P47; RIVERA R, 1992, CRIT CARE MED, V20, P193, DOI 10.1097/00003246-199202000-00008; ROSS JAT, 1969, LARYNGOSCOPE, V79, P1218, DOI 10.1288/00005537-196907000-00002; SKOWRON PN, 1966, CAN MED ASSOC J, V94, P528; SMITH DS, 1989, J PEDIATR-US, V115, P256, DOI 10.1016/S0022-3476(89)80074-5; SUPER DM, 1989, J PEDIATR-US, V115, P323, DOI 10.1016/S0022-3476(89)80095-2; SUSSMAN S, 1964, PEDIATRICS, V34, P851; TIBBALLS J, 1990, INTENSIVE CARE MANUA, P666; TUNNESSEN WW, 1980, J PEDIATR-US, V96, P751	24	87	88	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					745	748		10.1016/0140-6736(92)92293-O	http://dx.doi.org/10.1016/0140-6736(92)92293-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356176				2022-12-28	WOS:A1992JP86900002
J	SMITH, GD; PHILLIPS, AN; NEATON, JD				SMITH, GD; PHILLIPS, AN; NEATON, JD			SMOKING AS INDEPENDENT RISK FACTOR FOR SUICIDE - ILLUSTRATION OF AN ARTIFACT FROM OBSERVATIONAL EPIDEMIOLOGY	LANCET			English	Article							CIGARETTE-SMOKING; CERVICAL-CANCER; MEN; ASSOCIATION; MORTALITY; DISEASE; LIFE	Two widely used criteria for determining whether an association between a risk factor and a disease is causal are dose response and independence from other factors. Data from a large US risk factor study (MRFIT) throw up a relation between cigarette smoking and suicide that meets these criteria, yet appears to be biologically implausible. It is likely that many more such associations, for other exposures and other diseases, are equally spurious, but are protected by their lack of obvious implausibility.	UNIV COLL & MIDDLESEX SCH MED, ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA	University of London; University College London; University of Minnesota System; University of Minnesota Twin Cities	SMITH, GD (corresponding author), UNIV GLASGOW, DEPT PUBL HLTH, 2 LILYBANK GARDENS, GLASGOW G12 8RZ, SCOTLAND.		Davey Smith, George/A-7407-2013; Phillips, Andrew N/B-4427-2008	Davey Smith, George/0000-0002-1407-8314; Phillips, Andrew N/0000-0003-2384-4807				ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; COLIN L, 1882, REV SCI, V1, P397; COX DR, 1972, J R STAT SOC B, V34, P187; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HILL AB, 1953, NEW ENGL J MED, V248, P995, DOI 10.1056/NEJM195306112482401; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hopkins P N, 1986, Cardiol Clin, V4, P3; KADUNCE DP, 1991, ANN INTERN MED, V114, P840, DOI 10.7326/0003-4819-114-10-840; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; Kramer Larry, 1978, FAGGOTS; KREITMAN N, 1991, J EPIDEMIOL COMMUN H, V45, P195, DOI 10.1136/jech.45.3.195; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MARMOR M, 1982, LANCET, V1, P1083; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; NEATON JD, 1987, CONTROL CLIN TRIALS, V8, pS41; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSS RK, 1990, PREV MED, V19, P323, DOI 10.1016/0091-7435(90)90032-F; SKRABANEK P, 1992, PERSPECT BIOL MED, V35, P182; SLATTERY ML, 1989, JAMA-J AM MED ASSOC, V261, P1593, DOI 10.1001/jama.261.11.1593; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; STACK S, 1982, SUICIDE LIFE-THREAT, V12, P67; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; WATNEY S, 1990, AIDS : INDIVIDUAL, CULTURAL AND POLICY DIMENSIONS, P19; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WINKELSTEIN W, 1989, JAMA-J AM MED ASSOC, V262, P1631, DOI 10.1001/jama.1989.03430120081021; [No title captured]	37	103	106	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					709	712						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355809				2022-12-28	WOS:A1992JN78000014
J	CLARK, SW; MEYER, DI				CLARK, SW; MEYER, DI			CENTRACTIN IS AN ACTIN HOMOLOG ASSOCIATED WITH THE CENTROSOME	NATURE			English	Article							GAMMA-TUBULIN; ASPERGILLUS-NIDULANS; BINDING PROTEINS; IDENTIFICATION; CONSTRUCTION; EXPRESSION; COMPONENT; RNA; TRANSLOCATION; MEMBRANE	ACTIN is one of the most ubiquitous, abundant and well-conserved proteins of eukaryotes, participating in many crucial cellular processes including the maintenance of cell shape, motility and cell division1,2. Actins from the most divergent sources still share amino-acid identities in excess of 70% (ref. 3). This may well explain why low-abundance homologues of actin have been difficult to isolate. Genes encoding distant relatives of actin in budding and fission yeast have now been cloned3,4. We report here the discovery of a vertebrate actin-like protein, which we name centractin. A full-length complementary DNA clone was isolated whose sequence reveals amino-acid identities with actin of over 50%, increasing to more than 70% when conservative amino-acid changes are considered. Northern analysis and western blotting indicate a ubiquitous tissue and species distribution. Morphological and biochemical criteria show that centractin is associated with centrosomes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; MOLEC BIOL INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; BUSH GL, 1991, J BIOL CHEM, V266, P13811; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOSTITESTU F, 1986, EMBO J, V5, P2545, DOI 10.1002/j.1460-2075.1986.tb04533.x; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARO B, 1980, BIOL CELLULAIRE, V39, P287; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; Sambrook J, 1989, MOL CLONING LABORATO; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	35	161	167	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					246	250		10.1038/359246a0	http://dx.doi.org/10.1038/359246a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1356230				2022-12-28	WOS:A1992JN94400065
J	COTTRELL, S; BICKNELL, D; KAKLAMANIS, L; BODMER, WF				COTTRELL, S; BICKNELL, D; KAKLAMANIS, L; BODMER, WF			MOLECULAR ANALYSIS OF APC MUTATIONS IN FAMILIAL ADENOMATOUS POLYPOSIS AND SPORADIC COLON CARCINOMAS	LANCET			English	Article							CELL-LINES; PRESYMPTOMATIC DIAGNOSIS; DNA MARKERS; GENE; IDENTIFICATION; CHROMOSOME-5Q21; ESTABLISHMENT; MISMATCHES; LOCUS; FAP	Mutations in the APC gene give rise to familial adenomatous polyposis (FAP) and also occur in many, perhaps most, sporadic colon cancers. By screening with single-strand conformation polymorphism analysis we identified several mutations in a small region of the APC gene in both FAP and sporadic cancers. These mutations were either point mutations or small deletions or insertions causing frameshifts, and all generated stop codons. One 5 base-pair deletion was found in a sporadic colon tumour, a colorectal cancer cell line derived from a sporadic colon tumour, and in four unrelated FAP patients. This mutation produces distinctive heteroduplex bands, which can be detected with a simple non-radioactive assay. Our findings suggest that highly localised short sequences, essentially runs that code for adenine and thymine, may account for up to 20% of all observed APC mutations.	IMPERIAL CANC RES FUND,CANC GENET LAB,POB 123,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,CANC IMMUNOL LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford; University of Oxford				Bodmer, Walter/0000-0001-6244-9792				BISHOP DT, 1990, HEREDITARY COLORECTA, P423; BODMER W, 1992, CANCER SURV, V13, P1; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BODMER WF, 1990, HEREDITARY COLORECTA, P37; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; Cottrel S., 1992, Human Molecular Genetics, V1, P352, DOI 10.1093/hmg/1.5.352-a; DAMICO D, 1992, CANCER RES, V52, P1996; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DREWINKO B, 1976, CANCER RES, V36, P467; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; GREENWALD BD, 1992, CANCER RES, V52, P741; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEIGHWAY J, 1991, NUCLEIC ACIDS RES, V19, P6966, DOI 10.1093/nar/19.24.6966; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KEEN J, 1991, TRENDS GENET, V7, P5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KRAUS C, 1992, HUM GENET, V88, P705, DOI 10.1007/BF02265305; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MCBAIN JA, 1984, CANCER RES, V44, P5813; MITELMAN F, 1991, CYTOGENET CELL GENET, V58, P1053, DOI 10.1159/000133721; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SUARDET L, 1992, CANCER RES, V52, P3705; TOPS CMJ, 1989, LANCET, V2, P1361; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	30	207	208	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					626	630		10.1016/0140-6736(92)92169-G	http://dx.doi.org/10.1016/0140-6736(92)92169-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355210				2022-12-28	WOS:A1992JM85100002
J	SAZAWAL, S; BLACK, RE				SAZAWAL, S; BLACK, RE			METAANALYSIS OF INTERVENTION TRIALS ON CASE-MANAGEMENT OF PNEUMONIA IN COMMUNITY SETTINGS	LANCET			English	Article							ACUTE RESPIRATORY-INFECTIONS; CHILDHOOD MORTALITY; MEASLES VACCINATION; CLINICAL-TRIALS; CHILDREN; BANGLADESH; REDUCTION; DISTRICT; PROGRAM; IMPACT	To appraise the effectiveness of the pneumonia case-management strategy in improving child survival, we have done a meta-analysis of six published intervention trials. The results of a seventh published study and two unpublished studies were also reviewed. The six published studies satisfied our criteria for methodological soundness. The reduction in mortality rate (control group minus intervention group) was estimated for each study, and for all the studies together. For total infant mortality, the overall reduction was 15.9 (95% confidence interval 10.6-21.1) deaths per 1000 livebirths; infant mortality due to acute lower respiratory infection was reduced by 10.7 (4.8-16.7) deaths/1000 livebirths. Mortality among children under 5 years was decreased by 36 deaths/1000 livebirths. The pooled estimates of relative risk are consistent with a 20% reduction in infant mortality and a 25% reduction in under-5 mortality. There was no clear association across the studies between the effect of the pneumonia case-management and extent of co-interventions such as immunisation and oral rehydration therapy. The consistency of findings of all the studies, despite differences in design and methods, shows that the case-management strategy has a substantial effect on infant and under-5 mortality, at least in settings with infant mortality rates of 90/1000 livebirths or more. It is important to find out the most efficient ways of implementing this strategy and integrating it into primary health care.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, 615 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University				Black, Robert/0000-0001-9926-7984				BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BRESLOW N, 1981, BIOMETRIKA, V68, P73, DOI 10.1093/biomet/68.1.73; BRESLOW NE, 1981, STATISTICAL METHODS, V2; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHEN LC, 1983, STUD FAMILY PLANN, V14, P199, DOI 10.2307/1966412; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; DATTA N, 1987, B WORLD HEALTH ORGAN, V65, P77; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FAUVEAU V, 1992, B WORLD HEALTH ORGAN, V70, P109; Greenland S, 1982, Stat Med, V1, P217, DOI 10.1002/sim.4780010304; HOLT EA, 1990, PEDIATRICS, V85, P188; KHAN AJ, 1990, B WORLD HEALTH ORGAN, V68, P577; KOENIG MA, IN PRESS CHILD HLTH; Leowski J, 1986, World Health Stat Q, V39, P138; MCCORD C, 1978, TROP DOCT, V8, P220, DOI 10.1177/004947557800800420; MTANGO FDE, 1986, T ROY SOC TROP MED H, V80, P851, DOI 10.1016/0035-9203(86)90241-5; OBERLE MW, 1980, INT J EPIDEMIOL, V9, P341, DOI 10.1093/ije/9.4.341; PANDEY MR, 1991, LANCET, V338, P993, DOI 10.1016/0140-6736(91)91847-N; PANDEY MR, 1989, ANN TROP PAEDIATR, V9, P212, DOI 10.1080/02724936.1989.11748635; REISCH JS, 1989, PEDIATRICS, V84, P815; Roesin R, 1990, Bull Int Union Tuberc Lung Dis, V65, P23; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; VANBALEN H, 1981, LANCET, V1, P764; 1988, CASE MANAGEMENT ACUT; 1988, LANCET, V2, P145	29	128	129	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1992	340	8818					528	533		10.1016/0140-6736(92)91720-S	http://dx.doi.org/10.1016/0140-6736(92)91720-S			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354286	hybrid			2022-12-28	WOS:A1992JL23400013
J	JARRETT, RJ				JARRETT, RJ			IN DEFENSE OF INSULIN - A CRITIQUE OF SYNDROME-X	LANCET			English	Editorial Material							CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; FAT DISTRIBUTION; SERUM-INSULIN; HYPERINSULINEMIA; HYPERTENSION; RESISTANCE; OBESITY; GLUCOSE; WOMEN				JARRETT, RJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT PUBL HLTH MED,LONDON SE1 9RT,ENGLAND.							ALBERTI KGG, 1989, DIABETES S1, V39, pA92; Asch Steven, 1991, Annals of Epidemiology, V1, P231; BURKE GL, 1986, METABOLISM, V35, P441, DOI 10.1016/0026-0495(86)90135-6; CAMBIEN F, 1987, DIABETES METAB, V13, P365; CHRISTLIEB AR, 1985, HYPERTENSION, V7, P54; COLLINS VR, 1990, J CLIN EPIDEMIOL, V43, P1369, DOI 10.1016/0895-4356(90)90104-W; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FOLSOM AR, 1989, AM J EPIDEMIOL, V130, P911, DOI 10.1093/oxfordjournals.aje.a115424; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; HALL JE, 1992, HYPERTENSION S1, V19, P45; JARRETT RJ, 1988, DIABETOLOGIA, V31, P71, DOI 10.1007/BF00395550; KANAI H, 1990, HYPERTENSION, V16, P484, DOI 10.1161/01.HYP.16.5.484; LANDIN K, 1989, METABOLISM, V38, P572, DOI 10.1016/0026-0495(89)90219-9; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SEIDELL JC, 1989, AM J EPIDEMIOL, V130, P53, DOI 10.1093/oxfordjournals.aje.a115322; UUSITUPA M, 1987, DIABETES RES CLIN EX, V4, P19; WEINSIER RL, 1986, INT J OBESITY, V10, P11; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WINOCOUR PH, 1991, Q J MED, V79, P539	22	107	109	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					469	471		10.1016/0140-6736(92)91781-3	http://dx.doi.org/10.1016/0140-6736(92)91781-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354794				2022-12-28	WOS:A1992JJ87700014
J	TONNESEN, H; PETERSEN, KR; HOJGAARD, L; STOKHOLM, KH; NIELSEN, HJ; KNIGGE, U; KEHLET, H				TONNESEN, H; PETERSEN, KR; HOJGAARD, L; STOKHOLM, KH; NIELSEN, HJ; KNIGGE, U; KEHLET, H			POSTOPERATIVE MORBIDITY AMONG SYMPTOM-FREE ALCOHOL MISUSERS	LANCET			English	Article							DELAYED-HYPERSENSITIVITY; ETHANOL; DYSFUNCTION; WITHDRAWAL; SURGERY; INJURY	Retrospective studies suggest that there is an increased postoperative morbidity among alcohol misusers. We have prospectively studied the risk of alcohol intake among patients undergoing surgery. We investigated 15 symptom-free subjects who required colorectal surgery and who were drinking at least 60 g of alcohol per day. These patients were matched for sex, nutrition, age, weight, cardiovascular and pulmonary disease, diagnosis, anaesthesia, and surgery to 15 control subjects who were consuming below 25 g of alcohol daily. Those drinking at least 60 g of alcohol per day developed more postoperative complications than controls (67% vs 20%, p < 0.05) and hospital stay was prolonged (20 vs 12 days, p < 0.05). Preoperatively, alcohol misusers had reduced left ventricular ejection fraction (median, 54% vs 68%, p<0.01). Delayed hypersensitivity responses were smaller in the alcohol group before (53 mm2 vs 78 mm2, p < 0.05) and after (18 mm2 vs 55 mm2, p < 0.01) surgery. Alcohol misusers had longer bleeding times during the first postoperative week (p < 0.01). Surgical stress responses, as assessed by changes in plasma cortisol and catecholamines, were higher among alcoholics (p < 0.05). Postoperative morbidity is increased in symptom-free alcohol misusers. The mechanism is probably subclinical cardiac insufficiency, immunosuppression, and decreased haemostatic function. Preoperative alcohol consumption may be a more important risk factor than previously thought.	UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT CLIN PHYSIOL NUCL MED,DK-2650 HVIDOVRE,DENMARK; UNIV COPENHAGEN,PANUM INST,DEPT MED PHYSIOL C,DK-2200 COPENHAGEN,DENMARK	University of Copenhagen; University of Copenhagen	TONNESEN, H (corresponding author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT SURG GASTROENTEROL,DK-2650 HVIDOVRE,DENMARK.		Højgaard, Liselotte/AAK-8329-2020	Tonnesen, Hanne/0000-0002-7161-3416; Kehlet, Henrik/0000-0002-2209-1711				BENJOHATHAN N, 1976, ENDOCRINOLOGY, V98, P1447; BRAUTBAR N, 1987, ALCOHOL CLIN EXP RES, V11, P118, DOI 10.1111/j.1530-0277.1987.tb01274.x; CREGLER LL, 1989, CLIN CARDIOL, V12, P122, DOI 10.1002/clc.4960120302; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRIBALDO RS, 1985, AM J CARDIOL, V56, P825, DOI 10.1016/0002-9149(85)91159-2; HJORTSO NC, 1986, ACTA CHIR SCAND, V152, P175; KATZ AM, 1985, J MOL CELL CARDIOL, V17, P11, DOI 10.1016/0022-2828(85)90004-5; KAWAKAMI M, 1990, J TRAUMA, V30, P27, DOI 10.1097/00005373-199001000-00004; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KRANTZ T, 1990, Ugeskrift for Laeger, V152, P1168; LINNOILA M, 1987, ANN INTERN MED, V107, P875, DOI 10.7326/0003-4819-107-6-875; MACLEAN LD, 1988, SURG GYNECOL OBSTET, V166, P285; MARVING J, 1985, CIRCULATION, V72, P502, DOI 10.1161/01.CIR.72.3.502; MIKHAILIDIS DP, 1986, BRIT MED J, V293, P715, DOI 10.1136/bmj.293.6549.715; MORGAN MY, 1988, P NUTR SOC, V47, P85, DOI 10.1079/PNS19880017; NEIMAN J, 1988, RES EXP MED, V188, P175, DOI 10.1007/BF01852318; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Simms J M, 1982, Clin Nutr, V1, P71, DOI 10.1016/0261-5614(82)90007-3; SMITH AJ, 1990, ALCOHOL CLIN EXP RES, V14, P497, DOI 10.1111/j.1530-0277.1990.tb01187.x; SUN GY, 1985, ALCOHOL CLIN EXP RES, V9, P164, DOI 10.1111/j.1530-0277.1985.tb05543.x; TIERNAN JM, 1985, INT J BIOCHEM, V17, P793, DOI 10.1016/0020-711X(85)90266-6; TONNESEN H, 1988, SCAND J UROL NEPHROL, V22, P175, DOI 10.1080/00365599.1988.11690408; TONNESEN H, 1987, DIS COLON RECTUM, V30, P549, DOI 10.1007/BF02554788; TONNESEN H, 1987, Ugeskrift for Laeger, V149, P285; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701	25	127	128	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					334	337						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353805				2022-12-28	WOS:A1992JH12500004
J	KHABBAZ, RF; ROWE, T; MURPHEYCORB, M; HENEINE, WM; SCHABLE, CA; GEORGE, JR; PAU, CP; PAREKH, BS; LAIRMORE, MD; CURRAN, JW; KAPLAN, JE; SCHOCHETMAN, G; FOLKS, TM				KHABBAZ, RF; ROWE, T; MURPHEYCORB, M; HENEINE, WM; SCHABLE, CA; GEORGE, JR; PAU, CP; PAREKH, BS; LAIRMORE, MD; CURRAN, JW; KAPLAN, JE; SCHOCHETMAN, G; FOLKS, TM			SIMIAN IMMUNODEFICIENCY VIRUS NEEDLESTICK ACCIDENT IN A LABORATORY WORKER	LANCET			English	Note								The macaque monkey infected with simian immunodeficiency virus (SIV) is an animal model of the acquired immunodeficiency syndrome. We investigated a laboratory worker who was exposed by needlestick accident to blood from an SIV-infected macaque. Seroreactivity to SIV developed within 3 months of exposure, with antibody titres peaking from the third to the fifth month and declining thereafter. Polymerase chain reaction for SIV sequences and cultures of peripheral-blood mononuclear cells failed to show infection. Inoculation of an SIV-negative monkey with blood from the worker did not cause infection. Animal-care and laboratory workers should adhere strictly to recommended procedures to avoid accidental exposures when working with SIV-infected animals or specimens.	TULANE UNIV,DELTA REG PRIMATE RES CTR,COVINGTON,LA 70433; OHIO STATE UNIV,DEPT VET PATHOBIOL,COLUMBUS,OH 43210; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Tulane University; University System of Ohio; Ohio State University; Centers for Disease Control & Prevention - USA	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,RETROVIRUS DIS BRANCH,MS-G03,ATLANTA,GA 30333, USA.			PAREKH, BHARAT/0000-0002-1088-4263				ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; MCLURE HM, 1989, VET IMMUNOL IMMUNOP, V21, P13; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; SHEN L, 1991, SCIENCE, V252, P440, DOI 10.1126/science.1708168; VILLINGER F, 1991, J VIROL, V65, P1855, DOI 10.1128/JVI.65.4.1855-1862.1991; 1988, MMWR, V37, P693	9	42	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					271	273		10.1016/0140-6736(92)92358-M	http://dx.doi.org/10.1016/0140-6736(92)92358-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353193				2022-12-28	WOS:A1992JG66500005
J	WESTGATE, J; HARRIS, M; CURNOW, JSH; GREENE, KR				WESTGATE, J; HARRIS, M; CURNOW, JSH; GREENE, KR			RANDOMIZED TRIAL OF CARDIOTOCOGRAPHY ALONE OR WITH ST WAVE-FORM ANALYSIS FOR INTRAPARTUM MONITORING	LANCET			English	Article							FETAL ELECTROCARDIOGRAM; BIRTH ASPHYXIA; BLOOD; SURVEILLANCE; DIAGNOSIS; LABOR	It is possible to record the fetal electrocardiographic waveform (ECG) from the scalp electrode used in labour for detection of fetal heart rate. Animal and observational studies of changes in the ST waveform of the ECG during hypoxia suggest that a combination of heart rate and ST waveform analysis might improve the predictive value of intrapartum monitoring. In a randomised trial, we have studied intervention rates and neonatal outcome for high-risk labours monitored either by conventional cardiotocography (CTG) or by ST waveform analysis plus CTG. 1200 women with pregnancy of at least 34 weeks' gestation were assigned to the groups when the decision to apply a fetal scalp electrode was made. Neonatal outcome was assessed by umbilical-cord blood gas analysis, Apgar scores, resuscitation needed, and postnatal course. All recordings were retrospectively viewed by an observer unaware of clinical details to check adherence to the trial protocol. The addition of ST waveform monitoring to CTG substantially reduced the proportion of deliveries for fetal distress (ST + CTG 27/615 vs CTG 58/606; p < 0.001). The groups did not differ in rate of operative delivery for other reasons, incidence of asphyxia at birth, or neonatal outcome. Metabolic acidosis and low 5 min Apgar scores were less common in the ST + CTG than the CTG group, but not significantly so. The only case of birth asphyxia in the ST + CTG group was identified by both heart rate and ST changes. The review of recordings showed that the reduction in intervention rate was among cases with CTG patterns classified as normal or intermediate, whereas there was no difference in intervention rates among cases with abnormal recordings. Our findings confirm that ST waveform analysis discriminates CTG changes in labour and that our protocol for interpretation is safe. Further randomised studies are warranted.			WESTGATE, J (corresponding author), PLYMOUTH GEN HOSP,DEPT OBSTET & BIOMED ENGN,PERINATAL RES GRP,FREEDOM FIELDS,PLYMOUTH PL4 7JJ,ENGLAND.							CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CLARK SL, 1985, AM J OBSTET GYNECOL, V153, P717, DOI 10.1016/0002-9378(85)90330-8; ENNIS M, 1990, BRIT MED J, V300, P1365, DOI 10.1136/bmj.300.6736.1365; GARDNER MJ, 1989, CONFIDENCE INTERVAL; GILSTRAP LC, 1989, AM J OBSTET GYNECOL, V161, P825, DOI 10.1016/0002-9378(89)90410-9; GREENE KR, 1982, AM J OBSTET GYNECOL, V144, P950, DOI 10.1016/0002-9378(82)90190-9; GREENE KR, 1987, BAILLIERE CLIN OB GY, V1, P131, DOI 10.1016/S0950-3552(87)80027-5; HAVERKAMP AD, 1979, AM J OBSTET GYNECOL, V134, P399, DOI 10.1016/S0002-9378(16)33082-4; HOKEGARD KH, 1979, ACTA PHYSIOL SCAND, V105, P195, DOI 10.1111/j.1748-1716.1979.tb06331.x; JOHANSON RB, 1992, BRIT J OBSTET GYNAEC, V99, P167, DOI 10.1111/j.1471-0528.1992.tb14482.x; LAGERCRANTZ H, 1977, PEDIATR RES, V11, P889, DOI 10.1203/00006450-197708000-00007; LINDECRANTZ KG, 1988, J BIOMED ENG, V10, P351, DOI 10.1016/0141-5425(88)90067-2; LOW JA, 1988, AM J OBSTET GYNECOL, V159, P1235, DOI 10.1016/0002-9378(88)90456-5; MACLACHLAN NA, 1992, BRIT J OBSTET GYNAEC, V99, P26, DOI 10.1111/j.1471-0528.1992.tb14387.x; MURPHY KW, 1992, BRIT J OBSTET GYNAEC, V99, P32, DOI 10.1111/j.1471-0528.1992.tb14388.x; MURPHY KW, 1990, BRIT J OBSTET GYNAEC, V97, P470, DOI 10.1111/j.1471-0528.1990.tb02515.x; NEWBOLD S, 1991, BRIT J OBSTET GYNAEC, V98, P173, DOI 10.1111/j.1471-0528.1991.tb13364.x; ROSEN KG, 1991, J PERINAT MED, V19, P221, DOI 10.1515/jpme.1991.19.3.221; ROSEN KG, 1989, CLIN PHYS PHYSIOL M, V10, P51, DOI 10.1088/0143-0815/10/4B/008; ROSEN KG, 1991, NESTLE NUTRITION WOR, P95; SIGGAARD.O, 1971, SCAND J CLIN LAB INV, V27, P239, DOI 10.3109/00365517109080214; WESTGATE J, 1990, CLIN PHYS PHYSIOL M, V11, P297, DOI 10.1088/0143-0815/11/4/002; WHEBLE AM, 1989, BRIT J OBSTET GYNAEC, V96, P1140, DOI 10.1111/j.1471-0528.1989.tb03188.x; WIDMARK C, 1991, J DEV PHYSIOL, V15, P161	24	57	58	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					194	198		10.1016/0140-6736(92)90465-F	http://dx.doi.org/10.1016/0140-6736(92)90465-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353134				2022-12-28	WOS:A1992JE75800002
J	LOCOCO, F; DIVERIO, D; PANDOLFI, PP; BIONDI, A; ROSSI, V; AVVISATI, G; RAMBALDI, A; ARCESE, W; PETTI, MC; MELONI, G; MANDELLI, F; GRIGNANI, F; MASERA, G; BARBUI, T; PELICCI, PG				LOCOCO, F; DIVERIO, D; PANDOLFI, PP; BIONDI, A; ROSSI, V; AVVISATI, G; RAMBALDI, A; ARCESE, W; PETTI, MC; MELONI, G; MANDELLI, F; GRIGNANI, F; MASERA, G; BARBUI, T; PELICCI, PG			MOLECULAR EVALUATION OF RESIDUAL DISEASE AS A PREDICTOR OF RELAPSE IN ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Note							LEUKEMIA	Acute promyelocytic leukaemia (APL) is characterised by a unique fusion transcript, PML/RARalpha. We tested for this transcript in 35 APL patients who were in apparent remission after various treatments. 11 of 13 patients who tested positive 4 months after achieving remission were in relapse 1-4 months later. All 22 patients who tested negative at 4 months were disease-free after a further 3 months to five years. The test may therefore prove useful in determining the need for additional treatment during clinical remission.	IST MARIO NEGRI,BERGAMO,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,I-06100 PERUGIA,ITALY; UNIV MILAN,PEDIAT CLIN,I-20122 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Perugia; University of Milan	LOCOCO, F (corresponding author), UNIV LA SAPIENZA,DEPT HUMAN BIOPATHOL,VIA BENEVENTO 6,I-00161 ROME,ITALY.		Biondi, Andrea/K-9997-2016; Rambaldi, Alessandro/M-6172-2019; Rambaldi, Alessandro/P-2603-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Biondi, Andrea/AAX-1865-2020	Rambaldi, Alessandro/0000-0002-3739-7502; Rambaldi, Alessandro/0000-0002-3739-7502; Biondi, Andrea/0000-0002-6757-6173; , Xavier/0000-0002-8083-2127; ARCESE, WILLIAM/0000-0001-5697-366X; Avvisati, Giuseppe/0000-0002-5027-5868				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BIONDI A, 1992, BLOOD, V80, P492; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; ROWLEY JD, 1977, LANCET, V1, P549; Sambrook J, 1989, MOL CLONING LABORATO	6	206	208	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1437	1438		10.1016/0140-6736(92)92625-P	http://dx.doi.org/10.1016/0140-6736(92)92625-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360562				2022-12-28	WOS:A1992KC28400006
J	BRYDON, WG; FERGUSON, A				BRYDON, WG; FERGUSON, A			HEMOGLOBIN IN GUT LAVAGE FLUID AS A MEASURE OF GASTROINTESTINAL BLOOD-LOSS	LANCET			English	Note							DISEASE	To detect and measure occult gastrointestinal bleeding, we have measured haemoglobin concentrations (by HemoQuant) in the clear fluid obtained after whole-gut lavage. In subjects with healthy gastrointestinal tracts, lavage-fluid haemoglobin concentrations were 0.5-5.1 mg/L, equivalent to daily blood loss of 0.1-1.1 mL. High concentrations were found for patients with colorectal cancer, severe diverticular disease, and rectal varices, in seven of sixteen patients with active inflammatory bowel disease, and in four patients with iron-deficiency anaemia thought to be due to gastrointestinal bleeding. In these four patients, estimated blood loss ranged from 2.6-24.5 mL per day. This method could have various research and clinical applications.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh								CAMERON AD, 1960, GUT, V1, P177, DOI 10.1136/gut.1.2.177; GASPARI MM, 1988, J IMMUNOL METHODS, V110, P85, DOI 10.1016/0022-1759(88)90086-5; HARDCASTLE JD, 1989, FAECAL OCCULT BLOOD; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; OMAHONY S, 1990, GUT, V31, P1341, DOI 10.1136/gut.31.12.1341; OMAHONY S, 1991, SCAND J GASTROENTERO, V26, P940, DOI 10.3109/00365529108996246; SALLAM J, 1992, LANCET, V339, P179; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061	9	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1381	1382		10.1016/0140-6736(92)92562-T	http://dx.doi.org/10.1016/0140-6736(92)92562-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360092				2022-12-28	WOS:A1992KB20200006
J	TAI, YT; BUT, PPH; YOUNG, K; LAU, CP				TAI, YT; BUT, PPH; YOUNG, K; LAU, CP			CARDIOTOXICITY AFTER ACCIDENTAL HERB-INDUCED ACONITE POISONING	LANCET			English	Note								Aconitine and its related alkaloids are known cardiotoxins with no therapeutic role in modern western medicine. The rootstocks of Aconitum plants, which contain aconite alkaloids, have been common components of Chinese herbal recipes. We have documented life-threatening intoxication in 17 Chinese subjects after accidental herb-induced aconite poisoning. All patients developed symptoms of aconite toxicity within 2 h of herb ingestion. Most developed tachyarrhythmias, including ventricular tachycardia and fibrillation from which 2 patients died. Toxicological evaluation revealed that aconites from the Aconitum rootstocks were the only plausible casual factor for intoxication. These cases point to the need for strict surveillance of herbal substances with low safety margins.	UNIV HONG KONG,DEPT MED,HONG KONG,HONG KONG; CHINESE UNIV HONG KONG,CHINESE MED MAT RES CTR,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT ANAESTHESIA & INTENS CARE,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT BIOL,SHA TIN,HONG KONG	University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong								BISSET NG, 1981, J ETHNOPHARMACOL, V4, P247, DOI 10.1016/0378-8741(81)90001-5; CHANG HM, 1987, PHARM APPLICATIONS C, V1; CHANG HM, 1987, PHARM APPLICATIONS C, V2; FATOVICH DM, 1992, ANN EMERG MED, V21, P309, DOI 10.1016/S0196-0644(05)80894-7; FIDDES FS, 1958, BRIT MED J, V2, P779, DOI 10.1136/bmj.2.5099.779; Hartung EF, 1930, J AMER MED ASSOC, V95, P1265, DOI 10.1001/jama.1930.27210170005010c; KAPOOR SC, 1969, INDIAN HEART J, V25, P329; PEPPER K, 1967, PFLUGGERS ARCH, V296, P328; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P1538; 1990, PHARMACOPOEIA PEOPLE, V1, P26; 1983, BRIT HERBAL PHARMACO, P12	11	148	153	3	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1254	1256		10.1016/0140-6736(92)92951-B	http://dx.doi.org/10.1016/0140-6736(92)92951-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359321				2022-12-28	WOS:A1992JZ23700005
J	JANKNEGT, RA; BAETEN, CGMI; WEIL, EHJ; SPAANS, F				JANKNEGT, RA; BAETEN, CGMI; WEIL, EHJ; SPAANS, F			ELECTRICALLY STIMULATED GRACILIS SPHINCTER FOR TREATMENT OF BLADDER SPHINCTER INCONTINENCE	LANCET			English	Note							MUSCLE	Correction of total urinary incontinence due to sphincter damage is done with an artificial sphincter prosthesis or urinary diversion. In this pilot study we used graciloplasty around the bladder neck followed by electrical stimulation of this muscle with an implanted stimulator, which could be switched off and on by a magnet. Stimulus variables could be changed externally. With the stimulator on, urethral pressures of about 50 cm H2O were obtained. Of three patients who underwent the procedure, two became continent and one improved but remained incontinent. Dynamic graciloplasty can restore urinary incontinence.	ACAD HOSP MAASTRICHT,DEPT UROL,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT GEN SURG,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT CLIN NEUROPHYSIOL,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)								ACKER MA, 1986, BIOMECHANICAL CARDIA, P19; BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; BOBECHKO WP, 1979, ORTHOP CLIN N AM, V10, P927; CHACHQUES JC, 1986, BIOMECHANICAL CARDIA, P59; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; Mortimer JT, 1981, HDB PHYSL NERVOUS SY, VII, P155; MUNSAT TL, 1976, ARCH NEUROL-CHICAGO, V33, P608, DOI 10.1001/archneur.1976.00500090014004	8	37	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1129	1130		10.1016/0140-6736(92)93153-E	http://dx.doi.org/10.1016/0140-6736(92)93153-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359213				2022-12-28	WOS:A1992JX13400006
J	DEMORAES, JC; PERKINS, BA; CAMARGO, MCC; HIDALGO, NTR; BARBOSA, HA; SACCHI, CT; GRAL, IML; GATTAS, VL; VASCONCELOS, HD; PLIKAYTIS, BD; WENGER, JD; BROOME, CV				DEMORAES, JC; PERKINS, BA; CAMARGO, MCC; HIDALGO, NTR; BARBOSA, HA; SACCHI, CT; GRAL, IML; GATTAS, VL; VASCONCELOS, HD; PLIKAYTIS, BD; WENGER, JD; BROOME, CV			PROTECTIVE EFFICACY OF A SEROGROUP-B MENINGOCOCCAL VACCINE IN SAO-PAULO, BRAZIL	LANCET			English	Article							DISEASE	Serogroup B Neisseria meningitidis is the most common cause of epidemic meningococcal disease in developed countries. Until recently no vaccine has been available for prevention of infection with this organism. In an attempt to control epidemic serogroup B meningococcal disease in greater Sao Paulo, Brazil, during 1989 and 1990, a Cuban-produced outer-membrane-protein-based serogroup B meningococcal vaccine was given to about 2.4 million children aged from 3 months to 6 years. We have done a case-control study to estimate the efficacy of the vaccine in greater Sao Paulo. Microbiologically confirmed cases of serogroup B meningococcal disease were identified through hospital-based surveillance. Controls were matched by neighbourhood and age. Vaccination status was confirmed by inspection of vaccination cards. Between June, 1990, and June, 1991, 112 patients and 409 matched controls with confirmed vaccine status were enrolled. Estimated vaccine efficacy varied by age: 48 months or older = 74% (95% CI 16 to 92%), 24 to 47 months = 47% (-72 to 84%), and less than 24 months = -37% (< - 100 to 73%). Our results suggest that the Cuban-produced vaccine may be effective for prevention of serogroup B meningococcal disease in older children and adults.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,BLDG 1,ROOM 4409,ATLANTA,GA 30333; CTR DIS CONTROL,OFF DIRECTOR,ATLANTA,GA 30333; SAO PAULO STATE DEPT HLTH,CTR EPIDEMIOL SURVEILLANCE,SAO PAULO,BRAZIL; SAO PAULO DEPT HLTH,ADOLFO LUTZ INST,SAO PAULO,BRAZIL	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Universidade Estadual Paulista; Instituto Adolfo Lutz			MORAES, JOSE C/H-6788-2012; Gattas, Vera Lucia/B-7956-2018	Gattas, Vera Lucia/0000-0001-5032-4570; Tavares Sacchi, Claudio/0000-0002-5686-7979				BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; Frasch CE, 1983, MED TROP, V43, P177; FRASCH CE, 1983, MED MICROBIOLOGY, V2, P115; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; NOVO MV, 1991, ENFERMEDAD MENINGOCO; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PELTOLA H, 1983, REV INFECT DIS, V5, P71; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; SIERRA VG, 1991, 7TH P INT PATH NEISS; ZOLLINGER W D, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P211; 1989, MMWR, V38, P205; 1985, MMWR, V34, P255; 1989, MMWR, V38, P219	18	279	308	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1074	1078						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357461				2022-12-28	WOS:A1992JV77500011
J	GROWDON, JH				GROWDON, JH			TREATMENT FOR ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEGENERATION; ADULT; BRAIN				GROWDON, JH (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GROWDON JH, 1983, MED RES REV, V3, P237, DOI 10.1002/med.2610030303; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; KOLIATSOS VE, 1991, ANN NEUROL, V30, P831, DOI 10.1002/ana.410300613; NITSCH RM, IN PRESS SCIENCE; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; TUSZYNSKI MH, 1991, ANN NEUROL, V30, P625, DOI 10.1002/ana.410300502; 1989, NEW ENGL J MED, V321, P1364	11	43	43	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1306	1308		10.1056/NEJM199210293271810	http://dx.doi.org/10.1056/NEJM199210293271810			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1357552				2022-12-28	WOS:A1992JV25900010
J	CHOI, DW				CHOI, DW			BENCH TO BEDSIDE - THE GLUTAMATE CONNECTION	SCIENCE			English	Editorial Material							MOLECULAR-CLONING; NMDA RECEPTOR; NITRIC-OXIDE; ACID; ANIRACETAM; ENCEPHALOPATHY; NEUROTOXICITY; MODULATION; ISCHEMIA; CHANNEL				CHOI, DW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110, USA.							ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHENG B, 1991, NEURON, V7, P1; CHOI DW, 1990, J NEUROSCI, V10, P2493; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Hory-Lee F., 1992, Society for Neuroscience Abstracts, V18, P46; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISAACSON JS, 1991, P NATL ACAD SCI USA, V88, P10936, DOI 10.1073/pnas.88.23.10936; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCNAMARA JO, 1992, J NEUROSCI, V12, P1555; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OLNEY JW, 1976, NATURE, V264, P659, DOI 10.1038/264659a0; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; PELLEGRINIGIAMP.DE, 1992, FIDIA S EXCITATORY A, P35; PERL TM, 1990, NEW ENGL J MED, V322, P1775, DOI 10.1056/NEJM199006213222504; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; SUN W, 1992, P NATL ACAD SCI USA, V89, P1143; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANG CM, 1991, SCIENCE, V254, P288, DOI 10.1126/science.1681589; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; YAMADA K A, 1991, Society for Neuroscience Abstracts, V17, P896	39	169	221	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					241	243		10.1126/science.1357748	http://dx.doi.org/10.1126/science.1357748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357748				2022-12-28	WOS:A1992JR86000019
J	GARBERS, DL				GARBERS, DL			GUANYLYL CYCLASE RECEPTORS AND THEIR ENDOCRINE, PARACRINE, AND AUTOCRINE LIGANDS	CELL			English	Review							NATRIURETIC-PEPTIDE RECEPTOR; RAT-KIDNEY; ATRIAL; PROTEIN; EXPRESSION; ACTIVATION; SEQUENCE; SUBUNITS; DOMAINS; SYSTEM		UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GARBERS, DL (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.							ANTUNESRODRIGUES J, 1992, P NATL ACAD SCI USA, V89, P6828, DOI 10.1073/pnas.89.15.6828; BEUVE A, 1992, J MOL BIOL, V225, P933, DOI 10.1016/0022-2836(92)90093-Y; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHINKERS M, 1992, IN PRESS J BIOL CHEM; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; GOLDBERG ND, 1977, ANNU REV BIOCHEM, V46, P823, DOI 10.1146/annurev.bi.46.070177.004135; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LAROSE L, 1991, BIOCHEMISTRY-US, V30, P8990, DOI 10.1021/bi00101a012; LUO JH, 1992, J BIOL CHEM, V267, P9645; MARALA RB, 1991, FEBS LETT, V281, P73, DOI 10.1016/0014-5793(91)80361-6; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; POTTER LR, 1992, J BIOL CHEM, V267, P14531; RITTER D, 1991, J CLIN INVEST, V87, P208, DOI 10.1172/JCI114973; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHIEBINGER RJ, 1992, AM J PHYSIOL, V262, pH78, DOI 10.1152/ajpheart.1992.262.1.H78; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V24, P2847; VESELY DL, 1991, BIOCHEM BIOPH RES CO, V179, P695, DOI 10.1016/0006-291X(91)91428-F; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; ZWILLER J, 1985, J BIOL CHEM, V260, P1350	45	274	277	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					1	4						4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356629				2022-12-28	WOS:A1992JQ62300001
J	NICOLAIDES, KH; SNIJDERS, RJM; GOSDEN, CM; BERRY, C; CAMPBELL, S				NICOLAIDES, KH; SNIJDERS, RJM; GOSDEN, CM; BERRY, C; CAMPBELL, S			ULTRASONOGRAPHICALLY DETECTABLE MARKERS OF FETAL CHROMOSOMAL-ABNORMALITIES	LANCET			English	Article							DOWNS-SYNDROME; AGE	Screening for fetal chromosomal abnormalities on the basis of maternal age has not resulted in a substantial fall in the Proportion of infants born with an abnormal karyotype. Most fetuses with major chromosomal abnormalities have defects that can be recognised on detailed ultrasonographic examination. Therefore, provided the cardinal signs of each chromosomal syndrome are recognised, it is possible that screening by ultrasound examination could have a greater impact. We karyotyped 2086 fetuses after ultrasonographic examination had revealed fetal malformations, growth retardation, or both. Chromosomal abnormalities were detected in 301 (14%) cases and were more common among fetuses with multisystem malformations (29%) than among those with isolated defects (2%). The commonest chromosomal abnormality was trisomy 18, followed by trisomy 21, triploidy, Turner's syndrome, unbalanced chromosomal rearrangements, and trisomy 13. Trisomy 18 was associated with strawberry-shaped head, choroid plexus cysts, facial cleft, micrognathia, heart defects, exomphalos, malformations of hands and feet, and growth retardation. In trisomy 21, the associated defects were subtle and included nuchal oedema, macroglossia, atrioventricular septal defects, mild hydronephrosis, clinodactyly, and sandal gap. The frequency of autosomal abnormalities increased with maternal age, but if fetal karyotyping had been restricted to mothers older than 35 years, large proportions of chromosomally abnormal fetuses would not have been diagnosed prenatally (64-97%). Our findings provide guidelines as to which defects to search for in screening studies for the detection of chromosomal abnormalities.	GUYS HOSP,SE THAMES REG GENET CTR,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Guy's & St Thomas' NHS Foundation Trust; University of Edinburgh	NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,HARRIS BIRTHRIGHT RES CTR FETAL MED,DENMARK HILL,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711; Snijders, Rosalinde/0000-0003-1809-7886				AZAR G B, 1991, Fetal Diagnosis and Therapy, V6, P46; BENACERRAF BR, 1990, OBSTET GYNECOL, V976, P59; BERRY S M, 1990, Fetal Diagnosis and Therapy, V5, P92; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; DRIFE JO, 1991, 18TH P STUDY GROUP R; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; HSU LYF, 1986, GENETIC DISORDERS FE, P115; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; NICOLAIDES K H, 1992, Fetal Diagnosis and Therapy, V7, P1; NICOLAIDES K H, 1990, Fetal Diagnosis and Therapy, V5, P5; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P123, DOI 10.1159/000263659; NICOLAIDES KH, 1986, LANCET, V1, P283; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P132, DOI 10.1159/000263660; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P102, DOI 10.1159/000263657; NICOLAIDES KH, IN PRESS FETAL DIAGN; NYBERG DA, 1989, J ULTRAS MED, V8, P299; RODECK CH, 1984, 11TH P STUD GROUP RO; Thorpe-Beeston G, 1989, FETAL THER, V4, P21; THORPEBEESTON JG, 1990, BRIT J RADIOL, V63, P783, DOI 10.1259/0007-1285-63-754-783; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; YOUINGS S, 1991, PRENATAL DIAG, V11, P419, DOI 10.1002/pd.1970110703; ZEITUNE M, 1991, PRENATAL DIAG, V11, P847, DOI 10.1002/pd.1970111106	22	228	246	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					704	707		10.1016/0140-6736(92)92240-G	http://dx.doi.org/10.1016/0140-6736(92)92240-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355807				2022-12-28	WOS:A1992JN78000012
J	ROCKEN, M; URBAN, JF; SHEVACH, EM				ROCKEN, M; URBAN, JF; SHEVACH, EM			INFECTION BREAKS T-CELL TOLERANCE	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; STIMULATORY FACTOR-I; TRANSGENIC MICE; CLONAL-DELETION; MONOCLONAL-ANTIBODY; SELF-TOLERANCE; RECEPTOR; ANERGY; INDUCTION; REACTIVITY	CLONAL deletion or clonal anergy establish tolerance in T cells that bear potentially autoreactive antigen receptors1-15. Here we report that concomitant infection with the nematode Nippostrongylus brasiliensis breaks an established T-cell tolerance induced by injection of mice with Staphylococcus enterotoxin B (SEB)16,17. CD4+ T cells from SEB-tolerant mice did not produce either interleukin-2 or interleukin-4 when challenged in vitro with SEB. N. brasiliensis infection of SEB-primed animals resulted in a normal expansion of SEB-tolerant CD4+V-beta-8+ T cells in vivo as well as an equivalent increase of SEB-reactive, interleukin-4-producing CD4+V-beta-8+ T cells both in SEB-tolerant and in normal animals. Thus, infection with N. brasiliensis circumvented the tolerance established with SEB. Activation of anergic, potentially autoreactive CD4+ T cells by infectious agents seems to be a major pathway for the initiation of autoimmune diseases15. Our results suggest that infectious agents may break tolerance in potentially autoreactive CD4+ T cells by activation of alternative reaction pathways.	USDA ARS, BELTSVILLE AGR RES CTR, INST LIVESTOCK & POULTRY SCI, HELMINTH DIS LAB, BELTSVILLE, MD 20705 USA	United States Department of Agriculture (USDA)	ROCKEN, M (corresponding author), NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA.			Urban, Joseph/0000-0002-1590-8869; Rocken, Martin/0000-0003-3795-7001				BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; HULI J, 1989, J IMMUNOL, V142, P800; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROCKEN M, 1992, J IMMUNOL, V148, P47; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SMITH H, 1989, SCIENCE, V245, P749, DOI 10.1126/science.2788921; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	29	147	147	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					79	82		10.1038/359079a0	http://dx.doi.org/10.1038/359079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1355854				2022-12-28	WOS:A1992JL66200059
J	GOBBI, G; BOUQUET, F; GRECO, L; LAMBERTINI, A; TASSINARI, CA; VENTURA, A; ZANIBONI, MG				GOBBI, G; BOUQUET, F; GRECO, L; LAMBERTINI, A; TASSINARI, CA; VENTURA, A; ZANIBONI, MG			CELIAC-DISEASE, EPILEPSY, AND CEREBRAL CALCIFICATIONS	LANCET			English	Article							STURGE-WEBER SYNDROME; CELIAC-DISEASE; FACIAL NEVUS	There have been anecdotal reports of an association between coeliac disease and epilepsy with cerebral calcifications that resemble those of the Sturge-Weber syndrome. A series of patients who had epilepsy with calcifications, in whom coeliac disease (CD) was incidentally observed, prompted us to study this association. 43 patients (15 male, age range 4.6-30.7 years) were selected from two series. 31 patients with cerebral calcifications of unexplained origin and epilepsy (series A) underwent intestinal biopsy. 12 patients with CD and epilepsy (series B) underwent computed tomography. Antibodies to gluten, folic acid serum concentrations, were measured, and HLA typing was done in most patients. 24 of the series A patients were identified as having CD on the basis of a flat intestinal mucosa (15/22 with a high concentration of serum antigluten), and 5 series B patients showed cerebral calcifications, giving a total of 29 cases with the combination of CD, epilepsy, and cerebral calcifications (CEC). In 27 of these CEC patients, calcifications were located in the parieto-occipital regions. Only 2 of the series A patients had gastrointestinal symptoms at the time of intestinal biopsy; most patients had recurrent diarrhoea, anaemia, and other symptoms suggestive of CD in the first 3 years of life. The epilepsy in CEC patients was poorly responsive to antiepileptic drugs. Gluten-free diet beneficially affected the course of epilepsy only when started soon after epilepsy onset. Cases of "atypical Sturge-Weber syndrome" (characterised by serpiginous cerebral calcifications and epilepsy without facial port-wine naevus) should be reviewed, and CD should be ruled out in all cases of epilepsy and cerebral calcifications of unexplained origin.	UNIV TRIESTE,DIV NEUROPSICHIAT INFANTILE,I-34100 TRIESTE,ITALY; UNIV TRIESTE,PEDIAT CLIN,I-34100 TRIESTE,ITALY; NAPLES UNIV,FAC MED & CHIRURG 2,PEDIAT CLIN,I-80138 NAPLES,ITALY; OSPED MAGGIORE BOLOGNA,DIV PEDIAT,BOLOGNA,ITALY; UNIV BOLOGNA,OSPED BELLARIA,CATTEDRA NEUROL,DIV NEUROL 2,I-40126 BOLOGNA,ITALY	University of Trieste; University of Trieste; University of Naples Federico II; AUSL di Bologna; University of Bologna	GOBBI, G (corresponding author), SERV NEUROPSYCHIAT INFANTILE,USL 9,VIA AMENDOLA 2,I-42100 REGGIO EMILIA,ITALY.			Ventura, Alessandro/0000-0002-4657-1760; Tassinari, Carlo Alberto/0000-0002-4183-5165				ALEXANDER GL, 1972, HDB CLIN NEUROLOGY, P223; AMBROSETTO P, 1983, CHILD BRAIN, V10, P387; [Anonymous], 1981, EPILEPSIA, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389; Auricchio S, 1988, GASTROENTEROL INT, V1, P25; BATTISTELLA PA, 1986, RIV ITAL PED, V12, P417; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CHAPMAN RWG, 1978, BRIT MED J, V2, P250, DOI 10.1136/bmj.2.6132.250; COPPER BT, 1978, BMJ, V1, P537; CORAZZA GR, 1985, GUT, V26, P1210, DOI 10.1136/gut.26.11.1210; CORBEEL L, 1985, EUR J PEDIATR, V143, P284, DOI 10.1007/BF00442302; DELGIUDICE E, 1984, NEUROPEDIATRICS, V15, P218, DOI 10.1055/s-2008-1052371; DELLACELLA G, 1991, MED SURG PEDIATR, V13, P427; DEMARCHI M, 1983, GUT, V24, P706, DOI 10.1136/gut.24.8.706; DUNNILL MS, 1972, J CLIN PATHOL, V25, P243, DOI 10.1136/jcp.25.3.243; Garwicz S, 1976, Pediatr Radiol, V5, P5, DOI 10.1007/BF00988654; GIROUD M, 1990, REV NEUROL, V4, P288; GOBBI G, 1988, NEUROLOGY, V38, P9103; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; ITO M, 1990, BRAIN DEV-JPN, V12, P473, DOI 10.1016/S0387-7604(12)80210-5; JASPER HH, 1958, ELECTROENCEPHALOGRAP, V10, P370, DOI DOI 10.1016/0013-4694(58)90053-1; LAIDLOW JM, 1977, GUT, V18, pA943; LOGAN RFA, 1983, BMJ-BRIT MED J, V286, P95, DOI 10.1136/bmj.286.6359.95; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1991, LANCET, V338, P724, DOI 10.1016/0140-6736(91)91445-Z; MAKI Y, 1979, CHILD BRAIN, V5, P51; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; MOLTENI N, 1988, AM J GASTROENTEROL, V83, P992; NAMAGUCHI Y, 1975, AM J ROENTGENOL, V123, P27; REYNOLDS EH, 1973, LANCET, V1, P1376; SAMMARITANO M, 1988, Neurology, V38, P239; TALY AB, 1987, NEUROLOGY, V37, P1063, DOI 10.1212/WNL.37.6.1063; TOSI R, 1983, CLIN IMMUNOL IMMUNOP, V28, P395, DOI 10.1016/0090-1229(83)90106-X; VENTURA A, 1991, ACTA PAEDIATR SCAND, V80, P552; YOUNG LW, 1977, AM J DIS CHILD, V131, P1283, DOI 10.1001/archpedi.1977.02120240101022; ZANIBONI MG, 1989, 1ST JOINT M BRIT SOC, P54	36	280	283	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					439	443						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354781				2022-12-28	WOS:A1992JJ87700001
J	LIANG, P; PARDEE, AB				LIANG, P; PARDEE, AB			DIFFERENTIAL DISPLAY OF EUKARYOTIC MESSENGER-RNA BY MEANS OF THE POLYMERASE CHAIN-REACTION	SCIENCE			English	Article							CELL-CYCLE; MOLECULAR-CLONING; CDNA SEQUENCES; KINASE; TUMOR; EXPRESSION; CANDIDATE; GENES; G1	Effective methods are needed to identify and isolate those genes that are differentially expressed in various cells or under altered conditions. This report describes a method to separate and clone individual messenger RNAs (mRNAs) by means of the polymerase chain reaction. The key element is to use a set of oligonucleotide primers, one being anchored to the polyadenylate tail of a subset of mRNAs, the other being short and arbitrary in sequence so that it anneals at different positions relative to the first primer. The mRNA subpopulations defined by these primer pairs were amplified after reverse transcription and resolved on a DNA sequencing gel. When multiple primer sets were used, reproducible patterns of amplified complementary DNA fragments were obtained that showed strong dependence on sequence specificity of either primer.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	LIANG, P (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Alberts B., 1989, MOL BIOL CELL; BAND V, 1990, CANCER RES, V50, P7351; Bothwell A., 1990, METHODS CLONING ANAL; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHAN AS, 1991, NUCLEIC ACIDS RES, V19, P1715, DOI 10.1093/nar/19.7.1715; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIANG P, UNPUB; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SU JY, 1991, NUCLEIC ACIDS RES, V19, P823, DOI 10.1093/nar/19.4.823; VARMUS H, 1989, ONCOGENES MOL ORIGIN, P3; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	21	4592	5472	1	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					967	971		10.1126/science.1354393	http://dx.doi.org/10.1126/science.1354393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1354393				2022-12-28	WOS:A1992JH82700036
J	OKSENHENDLER, E; AUTRAN, B; GOROCHOV, G; DAGAY, MF; SELIGMANN, M; CLAUVEL, JP				OKSENHENDLER, E; AUTRAN, B; GOROCHOV, G; DAGAY, MF; SELIGMANN, M; CLAUVEL, JP			CD8 LYMPHOCYTOSIS AND PSEUDOTUMORAL SPLENOMEGALY IN HIV-INFECTION	LANCET			English	Note							DISEASE; AIDS	Three patients infected with human immunodeficiency virus (HIV) presented with pseudotumoral splenomegaly, CD8 lymphocytosis (3.5-5.1 x 10(9)/l), and hypergammaglobulinaemia. Spleen and bone marrow showed diffuse CD8 lymphocyte and plasma-cell infiltration. Amplification of the T-cell-receptor gamma chain gene did not reveal any clonal T-cell population. Phenotypic analysis showed a predominance of CD8/CD57 suppressor T cells with expression of activation markers (DR and CD38). No cytotoxic T lymphocytes specific for HIV could be detected. The three patients shared the HLA haplotype A1, B8, DR3. The association with this haplotype suggests a genetically determined host immune response to HIV.	HOP ST LOUIS, MOLEC HAEMATOL LAB, F-75010 PARIS, FRANCE; HOP ST LOUIS, DEPT PATHOL, F-75010 PARIS, FRANCE; HOP LA PITIE SALPETRIERE, IMMUNOL LAB, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	OKSENHENDLER, E (corresponding author), HOP ST LOUIS, DEPT IMMUNOPATHOL & HAEMATOL, SERV IMMUNOPATHOL & HEMATOL, F-75010 PARIS, FRANCE.		Gorochov, Guy/P-2911-2017					CALVO CF, 1984, J IMMUNOL, V132, P2345; ITESCU S, 1989, LANCET, V2, P466; ITESCU S, 1990, ANN INTERN MED, V112, P3, DOI 10.7326/0003-4819-112-1-3; JOLY P, 1989, J IMMUNOL, V143, P2193; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; MACINTYRE EA, 1990, J CLIN INVEST, V86, P2125, DOI 10.1172/JCI114951; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; STEEL CM, 1988, LANCET, V1, P1185	10	19	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					207	208		10.1016/0140-6736(92)90471-E	http://dx.doi.org/10.1016/0140-6736(92)90471-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353138				2022-12-28	WOS:A1992JE75800006
J	MOFENSON, LM; MOYE, J; BETHEL, J; HIRSCHHORN, R; JORDAN, C; NUGENT, R				MOFENSON, LM; MOYE, J; BETHEL, J; HIRSCHHORN, R; JORDAN, C; NUGENT, R			PROPHYLACTIC INTRAVENOUS IMMUNOGLOBULIN IN HIV-INFECTED CHILDREN WITH CD4+ COUNTS OF 0.20X10(9)/L OR MORE - EFFECT ON VIRAL, OPPORTUNISTIC, AND BACTERIAL-INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; VIRUS	Objective.-To evaluate the efficacy of intravenous immunoglobulin (IVIG) for prevention of viral, opportunistic, and minor bacterial infections in children infected with human immunodeficiency virus (HIV). Design.-Randomized, double-blind, placebo-controlled, outpatient clinical trial comparing subjects treated with 400 mg of IVIG per kilogram of body weight every 28 days with those given albumin placebo. Setting.-Twenty-eight clinical centers in mainland United States and Puerto Rico. Patients.-Three hundred seventy-six children infected with human immunodeficiency virus with clinical or immunologic evidence of HIV disease, 313 of whom had entry CD4+ counts of at least 0.20 X 10(9)/L (greater-than-or-equal-to 200/mm3). Main Outcome Measures.-The incidence of laboratory-proven and clinically diagnosed viral, opportunistic, and bacterial infections. Main Results.-Viral infections and minor bacterial infections contributed more frequently to morbidity in children with entry CD4+ counts of at least 0.20 X 10(9)/L (together over five times as frequent) than did serious bacterial infection, the primary outcome measure of the trial. Opportunistic infections occurred at a similar rate as laboratory-proven serious bacterial infections. In this group of children, IVIG was significantly associated with a decrease in the rate of viral infections and minor bacterial infections per 100 patient-years (36.0 vs 54.0 episodes of viral infection per 100 patient-years, IVIG vs placebo, P=.01; and 115.1 vs 159.7 episodes of minor bacterial infection per 100 patient-years, IVIG vs placebo, P=.02), as well as a decrease in the rate of serious bacterial infections per 100 patient-years (26.4 vs 48.2 episodes per 100 patient-years; P=.002). There was no apparent difference in the rate of opportunistic infections between treatment arms. Conclusions.-Beneficial effect of IVIG was seen across multiple infectious outcome measures, with reductions in serious and minor viral and bacterial infections observed in children with entry CD4+ counts of at least 0.20 X 10(9)/L.	WESTAT CORP,ROCKVILLE,MD	Westat	MOFENSON, LM (corresponding author), NICHHD,CTR RES MOTHERS & CHILDREN,6120 EXECUT BLVD,ROOM 450,BETHESDA,MD 20892, USA.		Mofenson, Lynne/P-9631-2019; Pahwa, Savita/AAA-4900-2019	Mofenson, Lynne/0000-0002-2818-9808; Pahwa, Savita/0000-0002-4470-4216				AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; CHANDWANI S, 1990, J PEDIATR-US, V117, P251, DOI 10.1016/S0022-3476(05)80539-6; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HSU H, 1991, 7 INT C AIDS FLOR; HUGHES WT, 1991, PEDIATR INFECT DIS J, V10, P152, DOI 10.1097/00006454-199102000-00015; JANNER D, 1990, PEDIATR INFECT DIS J, V9, P434, DOI 10.1097/00006454-199006000-00013; JURA E, 1989, PEDIATR INFECT DIS J, V8, P586, DOI 10.1097/00006454-198909000-00003; KOHL S, 1991, REV INFECT DIS, V13, P108; KRASINSKI K, 1988, PEDIATR INFECT DIS J, V7, P323, DOI 10.1097/00006454-198805000-00006; LANE HC, 1985, ANNU REV IMMUNOL, V3, P477, DOI 10.1146/annurev.iy.03.040185.002401; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MARKOWITZ LE, 1988, J INFECT DIS, V158, P480; MAROLDA J, 1991, PEDIATR PULM, V10, P231, DOI 10.1002/ppul.1950100402; MESTER JC, 1991, J INFECT DIS, V163, P263, DOI 10.1093/infdis/163.2.263; MILLER RG, 1974, BIOMETRIKA, V61, P1; MOFENSON L, 1990, 30TH INT C ANT AG CH; MOFENSON LM, 1992, MAY AM PED SOC SOC P; MOFENSON LM, 1991, PEDIATRIC AIDS CHALL, P633; NADEL S, 1991, PEDIATR INFECT DIS J, V10, P542, DOI 10.1097/00006454-199107000-00014; PAHWA S, 1986, DIAGN CLIN IMMUNOL, V4, P24; PRINCIPI N, 1991, PEDIATRICS, V88, P566; RINALDO C, 1991, J INFECT DIS, V164, P638, DOI 10.1093/infdis/164.4.638; ROILIDES E, 1991, PEDIATR INFECT DIS J, V10, P813, DOI 10.1097/00006454-199111000-00004; ROILIDES E, 1991, J PEDIATR-US, V118, P724, DOI 10.1016/S0022-3476(05)80033-2; ROILIDES E, 1990, ANTIMICROB AGENTS CH, V34, P1672, DOI 10.1128/AAC.34.9.1672; ROILIDES E, 1990, 30TH INT C ANT AG CH; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; YARCHOAN R, 1990, ANN INTERN MED, V113, P607; 1987, MMWR, V36, P225; 1991, NEW ENGL J MED, V325, P73; 1987, MMWR S, V36, P1	34	86	86	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					483	488		10.1001/jama.268.4.483	http://dx.doi.org/10.1001/jama.268.4.483			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1352363				2022-12-28	WOS:A1992JD47200022
J	CAMERON, PU; FREUDENTHAL, PS; BARKER, JM; GEZELTER, S; INABA, K; STEINMAN, RM				CAMERON, PU; FREUDENTHAL, PS; BARKER, JM; GEZELTER, S; INABA, K; STEINMAN, RM			DENDRITIC CELLS EXPOSED TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMIT A VIGOROUS CYTOPATHIC INFECTION TO CD4+ T-CELLS	SCIENCE			English	Article							HUMAN PERIPHERAL-BLOOD; LYMPHOCYTES-T; LYMPH-NODES; HTLV-III/LAV; AIDS; LYMPHADENOPATHY; EXPRESSION; HIV-1; RETROVIRUS; ANTIGEN	The paucity of virus-laden CD4+ cells in individuals infected with human immunodeficiency virus type-1 (HIV-1) contrasts with the greatly reduced numbers and function of these lymphocytes. A pathway is described whereby dendritic cells carry HIV-1 to uninfected T cells, amplifying the cytopathic effects of small amounts of virus. After exposure to HIV-1, dendritic cells continue to present superantigens and antigens, forming clusters with T cells that are driven to replicate. Infection of the dendritic cells cannot be detected, but the clustered T cells form syncytia, release virions, and die. Carriage of HIV-1 by dendritic cells may facilitate the lysis and loss of antigen specific CD4+ T cells in acquired immunodeficiency syndrome.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University			Cameron, Paul/H-3474-2011; Steinman, Ralph/F-7729-2012	Cameron, Paul Urquhart/0000-0002-1906-6945	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00102] Funding Source: Medline; NIAID NIH HHS [AI 24775] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARMSTRONG JA, 1984, LANCET, V2, P370; BHARDWAJ N, 1992, J EXP MED, V175, P267, DOI 10.1084/jem.175.1.267; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1992, CLIN EXP IMMUNOL, V88, P226, DOI 10.1111/j.1365-2249.1992.tb03066.x; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLECHNER ER, 1988, CELL IMMUNOL, V111, P183, DOI 10.1016/0008-8749(88)90062-7; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; INABA K, 1987, J EXP MED, V166, P182, DOI 10.1084/jem.166.1.182; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; LANGHOFF E, 1989, J EXP MED, V169, P315, DOI 10.1084/jem.169.1.315; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LEVY JA, 1988, NATURE, V333, P519, DOI 10.1038/333519a0; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MACATONIA SE, 1989, IMMUNOLOGY, V67, P285; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MCELRATH MJ, 1991, J CLIN INVEST, V87, P27, DOI 10.1172/JCI114981; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; PATTERSON S, 1991, IMMUNOLOGY, V72, P361; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TENNERRACZ K, 1988, NEW ENGL J MED, V318, P49, DOI 10.1056/NEJM198801073180113; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	34	559	571	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					383	386		10.1126/science.1352913	http://dx.doi.org/10.1126/science.1352913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1352913				2022-12-28	WOS:A1992JD67400033
J	VIOLARIS, AG; LINNEMEIER, TJ; CAMPBELL, S; ROTHBAUM, DA; CUMBERLAND, DC				VIOLARIS, AG; LINNEMEIER, TJ; CAMPBELL, S; ROTHBAUM, DA; CUMBERLAND, DC			INTRAVASCULAR ULTRASOUND IMAGING COMBINED WITH CORONARY ANGIOPLASTY	LANCET			English	Note							INVITRO	A novel catheter combining ultrasound imaging and coronary balloon angioplasty was used in the treatment of 69 coronary-artery lesions in 51 patients. The ultrasound transducer enables real-time cross-sectional imaging and qualitative and quantitative assessment of the vessel wall before and after angioplasty. The combination catheter successfully dilated 67 lesions. There was a characteristic three-layered appearance, representing intima, media, and adventitia, in 60 cases. Intravascular imaging provided information on the vessel wall unobtainable by standard contrast angiogaphy in 28 cases and influenced our management in 6 cases.	NO GEN HOSP,CARDIAC UNIT,HERRIES RD,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; ST VINCENT HOSP,INDIANA HEART INST,INDIANAPOLIS,IN	Northern General Hospital								GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; NISHIMURA RA, 1990, J AM COLL CARDIOL, V16, P145, DOI 10.1016/0735-1097(90)90472-2; POTKIN BN, 1988, AM J CARDIOL, V62, P41, DOI 10.1016/0002-9149(88)91362-8; TOBIS JM, 1991, CIRCULATION, V83, P913, DOI 10.1161/01.CIR.83.3.913; Yock P G, 1989, J Am Soc Echocardiogr, V2, P296	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1571	1572		10.1016/0140-6736(92)91834-U	http://dx.doi.org/10.1016/0140-6736(92)91834-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351552				2022-12-28	WOS:A1992JB20200006
J	CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; RITTER, JM				CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; RITTER, JM			IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION OF FOREARM RESISTANCE VESSELS IN HYPERCHOLESTEROLEMIA	LANCET			English	Article							NITRIC-OXIDE; CORONARY-ARTERIES; RELAXING FACTOR; ACETYLCHOLINE; RELEASE; RELAXATION; AORTA	Endothelium-dependent vasodilation in response to acetylcholine is impaired in the coronary microvasculature of hypercholesterolaemic subjects. Outside the coronary circulation, however, it has been suggested that hypercholesterolaemia results in a functional abnormality of vascular smooth muscle rather than in endothelial dysfunction. We examined vasodilator responses to acetylcholine, methacholine, and the endothelium-independent vasodilator sodium nitroprusside in the forearm resistance vessels of 12 men with primary hypercholesterolaemia and 12 normocholesterolaemic male controls. Endothelium-dependent vasodilation in response to acetylcholine was impaired in hypercholesterolaemic patients compared with controls: at the highest dose of drug (15 mug per min) mean blood flow in the forearms of the hypercholesterolaemic group was only 52% (95% CI 31-88%) of that in the control group. Responses to sodium nitroprusside and to methacholine in the two study groups were not significantly different. These results indicate that endothelial dysfunction in hypercholesterolaemic subjects is generalised and extends to vascular beds outside the coronary circulation. Selective impairment to acetylcholine suggests that, at a molecular level, the defect is limited to a specific pathway.	ST THOMAS HOSP,DEPT ENDOCRINOL,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT CHEM PATHOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT CLIN PHARMACOL,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	CHOWIENCZYK, PJ (corresponding author), ST THOMAS HOSP,DEPT CLIN PHARMACOL,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.			Chowienczyk, Phil/0000-0003-4507-038X; Watts, Gerald/0000-0003-2276-1524				BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; BRAYDEN JE, 1985, CIRC RES, V56, P163; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; KATO T, 1990, HYPERTENSION, V15, P475, DOI 10.1161/01.HYP.15.5.475; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEILD TO, 1990, J PHYSIOL-LONDON, V420, P247, DOI 10.1113/jphysiol.1990.sp017910; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RALEVIC V, 1992, BRIT J PHARMACOL, V106, P650, DOI 10.1111/j.1476-5381.1992.tb14390.x; RUBANYI GM, 1987, J PHARMACOL EXP THER, V240, P802; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; VALLANCE P, 1989, LANCET, V2, P997; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1	15	441	446	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1430	1432		10.1016/0140-6736(92)92621-L	http://dx.doi.org/10.1016/0140-6736(92)92621-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360559				2022-12-28	WOS:A1992KC28400003
J	POLLOCK, RA; JAY, G; BIEBERICH, CJ				POLLOCK, RA; JAY, G; BIEBERICH, CJ			ALTERING THE BOUNDARIES OF HOX3.1 EXPRESSION - EVIDENCE FOR ANTIPODAL GENE-REGULATION	CELL			English	Article							CENTRAL NERVOUS-SYSTEM; TRANSGENIC MICE; HOMEODOMAIN PROTEIN; DROSOPHILA EMBRYOS; SUBMUCOSAL CYSTS; AUTO-REGULATION; RETINOIC ACID; HOMEOBOX; MOUSE; HOX-3.1	To investigate the function of region-specific patterns of mouse homeobox gene expression during embryogenesis, we programmed a minimal change in the distribution of Hox3.1 transcripts along the antero-posterior body axis in transgenic mice. Regulatory sequences from Hox1.4, a gene normally expressed more anteriorly than Hox3.1, were chosen to direct expression of a Hox3.1 transgene. Offspring of independent transgenic lines expressed the transgene more anteriorly than the Hox3.1 gene. Rather than predicted posterior transformations, we observed anterior transformations of vertebrae in newborn mice. Transgenic mice also developed profound gastrointestinal tissue malformations, which may provide a molecular explanation for human developmental disorders often involving these same two regions. Paradoxically, vertebral transformations in the transgenic mice were strikingly similar to those reported in mice homozygous for a null mutation of the Hox3.1 gene. This observation suggests that Hox genes may be regulated antipodally, with over- or underexpression resulting in similar phenotypes.			POLLOCK, RA (corresponding author), AMER RED CROSS, JEROME H HOLLAND LAB, ROCKVILLE, MD 20855 USA.		Jay, Gregory/C-6346-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD027943] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07522, HD27943] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKAM M, 1987, DEVELOPMENT, V101, P1; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEARDMORE H E, 1958, Pediatr Clin North Am, P457; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIEBERICH C, 1987, MOL CELL BIOL, V7, P4003, DOI 10.1128/MCB.7.11.4003; BIEBERICH CJ, 1991, ANN NY ACAD SCI, V642, P346; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; Danforth CH, 1930, AM J PHYS ANTHROPOL, V14, P463, DOI 10.1002/ajpa.1330140311; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; FERGUSONSMITH AC, 1989, GENOMICS, V5, P250, DOI 10.1016/0888-7543(89)90054-2; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GORDON JW, 1990, J IN VITRO FERTIL EM, V7, P223, DOI 10.1007/BF01129523; GORDON JW, 1990, BIOL REPROD, V42, P869, DOI 10.1095/biolreprod42.6.869; GORDON JW, 1990, DEV BIOL, V137, P349, DOI 10.1016/0012-1606(90)90259-L; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; Green EL, 1941, GENETICS, V26, P192; GREEN EL, 1953, SCIENCE, V117, P81, DOI 10.1126/science.117.3030.81; GREGG BC, 1983, J EMBRYOL EXP MORPH, V73, P135; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUNEBERG H, 1950, J GENET, V50, P112, DOI 10.1007/BF02986799; IGNATIUS JA, 1970, GASTROENTEROLOGY, V59, P610; INOUYE M, 1976, Congenital Anomalies, V16, P171; IWANAGA T, 1975, CANCER, V36, P606, DOI 10.1002/1097-0142(197508)36:2<606::AID-CNCR2820360243>3.0.CO;2-V; JAMES R, 1991, J BIOL CHEM, V266, P3246; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCLETCHIE NGB, 1954, SURG GYNECOL OBSTET, V99, P135; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MOCHIZUKI Y, 1989, Stomach and Intestine (Tokyo), V24, P1057; NIIZAWA M, 1992, GASTROINTEST RADIOL, V17, P9, DOI 10.1007/BF01888497; PILLAY I, 1976, CANCER, V38, P915, DOI 10.1002/1097-0142(197608)38:2<915::AID-CNCR2820380239>3.0.CO;2-V; Ptashne M., 1986, A GENETIC SWITCH; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; Rotterdam H., 1989, PATHOLOGY STOMACH DU; RUBIO CA, 1989, PATHOL RES PRACT, V184, P418, DOI 10.1016/S0344-0338(89)80037-8; RUSSELL LB, 1956, J EXP ZOOL, V131, P329, DOI 10.1002/jez.1401310308; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHUGHART K, 1991, DEVELOPMENT, V112, P807; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHASHIKANT C S, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P207; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; Struthers J, 1874, J Anat Physiol, V9, P17; Thorington R.W. Jr, 1989, P125; Thorington R.W. Jr., 1972, Nemouria, VNo. 8, P1; THURSTON SE, 1984, CLIN PEDIATR, V23, P652, DOI 10.1177/000992288402301111; TOTH LE, 1987, P NATL ACAD SCI USA, V84, P6790, DOI 10.1073/pnas.84.19.6790; Washburn S, 1952, AM J PHYS ANTHROPOL, V10, P251; WEBER W, 1950, J GENET, V50, P174, DOI 10.1007/BF02986801; WESTERFIELD M, 1992, GENE DEV, V6, P591, DOI 10.1101/gad.6.4.591; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIECZOREK RL, 1984, AM J GASTROENTEROL, V79, P597; WILLIS RA, 1962, BORDERLAND EMBRYOLOG; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; YAMAGIWA H, 1979, ACTA PATHOL JAPON, V29, P347; YASUDA Y, 1986, TERATOLOGY, V34, P37, DOI 10.1002/tera.1420340106; YOUNG WS, 1991, FOCUS, V13, P46; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	83	133	139	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					911	923		10.1016/0092-8674(92)90388-S	http://dx.doi.org/10.1016/0092-8674(92)90388-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1360875				2022-12-28	WOS:A1992KB99000005
J	CELERMAJER, DS; SORENSEN, KE; GOOCH, VM; SPIEGELHALTER, DJ; MILLER, OI; SULLIVAN, ID; LLOYD, JK; DEANFIELD, JE				CELERMAJER, DS; SORENSEN, KE; GOOCH, VM; SPIEGELHALTER, DJ; MILLER, OI; SULLIVAN, ID; LLOYD, JK; DEANFIELD, JE			NONINVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADULTS AT RISK OF ATHEROSCLEROSIS	LANCET			English	Article							CORONARY-ARTERY DISEASE; CAROTID-ARTERY; MEN; ACETYLCHOLINE; FLOW; RELAXATION; SMOKING; CHOLESTEROL; REGRESSION; THICKNESS	Endothelial dysfunction is an early event in experimental studies of atherogenesis, preceding formation of plaques. We have devised a non-invasive method for testing endothelial function, to find out whether abnormalities are present in symptom-free children and young adults at high risk of atherosclerosis. With high-resolution ultrasound, we measured the diameter of the superficial femoral and brachial arteries at rest, during reactive hyperaemia (with increased flow causing endothelium-dependent dilatation), and after sublingual glyceryl trinitrate (GTN; causing endothelium-independent dilatation) in 100 subjects-50 controls without vascular risk factors (aged 8-57 years), 20 cigarette smokers (aged 17-62 years), 10 children with familial hypercholesterolaemia (FH; aged 8-16 years), and 20 patients with established coronary artery disease (CAD). Adequate scans were obtained in all but 6 cases. Flow-mediated dilatation was observed in arteries from all control subjects. Dilatation was inversely related to baseline vessel diameter (r=-0.81, p<0.0001); in arteries of 6.0 mm or less, mean dilatation was 10 (SE 2)%. In smokers, FH children, and adults with CAD, flow-mediated dilatation was much reduced or absent (p<0.001 for comparison with each relevant control group). Dilatation in response to GTN was present in all groups. Endothelial dysfunction is present in children and adults with risk factors for atherosclerosis, such as smoking and hypercholesterolaemia, before anatomical evidence of plaque formation in the arteries studied. This may be an important early event in atherogenesis.	HOSP SICK CHILDREN,MED UNIT,LONDON WC1N 3JH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Biostatistics Unit	CELERMAJER, DS (corresponding author), HOSP SICK CHILDREN,CARDIOTHORAC UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Tanaka, Gohichi/A-1684-2010; Deanfield, John E/C-5178-2008	Deanfield, John/0000-0001-8806-6052				ANDERSON EA, 1989, CIRCULATION, V79, P93, DOI 10.1161/01.CIR.79.1.93; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CHAVEAU M, 1985, CARDIOVASC RES, V19, P700; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; KWITEROVICH PO, 1990, PEDIATR CLIN N AM, V37, P1489; LAURENT S, 1990, AM J PHYSIOL, V258, pH1004, DOI 10.1152/ajpheart.1990.258.4.H1004; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MCLENACHAN JM, 1990, CIRCULATION, V82, P1169, DOI 10.1161/01.CIR.82.4.1169; NABEL EG, 1990, J AM COLL CARDIOL, V16, P349, DOI 10.1016/0735-1097(90)90584-C; OLSSON AG, 1991, CIRCULATION, V83, P698, DOI 10.1161/01.CIR.83.2.698; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RENEMAN RS, 1986, ULTRASOUND MED BIOL, V12, P465, DOI 10.1016/0301-5629(86)90218-8; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1115; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; STARY HC, 1989, ARTERIOSCLEROSIS, V99, pI19; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x	29	3825	4394	3	170	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1111	1115		10.1016/0140-6736(92)93147-F	http://dx.doi.org/10.1016/0140-6736(92)93147-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359209	Bronze			2022-12-28	WOS:A1992JX13400001
J	GARNER, P; KRAMER, MS; CHALMERS, I				GARNER, P; KRAMER, MS; CHALMERS, I			MIGHT EFFORTS TO INCREASE BIRTH-WEIGHT IN UNDERNOURISHED WOMEN DO MORE HARM THAN GOOD	LANCET			English	Editorial Material							LOW BIRTH-WEIGHT; INFANT-MORTALITY; GESTATIONAL-AGE; DETERMINANTS; PREGNANCY; PRETERM; RISK		MCGILL UNIV,FAC MED,DEPT PEDIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,FAC MED,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3A 2T5,QUEBEC,CANADA; RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	McGill University; McGill University; Radcliffe Infirmary; University of Oxford	GARNER, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH POLICY UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941; Osmond, Clive/0000-0002-9054-4655; Fall, Caroline/0000-0003-4402-5552				BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; BREMS S, 1989, 1988 1989 M ADV GROU; CHALMERS I, 1979, LANCET, V2, P1063; CNATTINGIUS S, 1988, BMJ-BRIT MED J, V297, P258, DOI 10.1136/bmj.297.6643.258; Fleming AF, 1985, BR J OBSTET GYNAE S5, V92, P32; HABICHT JP, 1973, NUTR REP INT, V7, P533; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P100; Kramer M S, 1990, Paediatr Perinat Epidemiol, V4, P381, DOI 10.1111/j.1365-3016.1990.tb00661.x; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KRAMER MS, IN PRESS OXFORD DATA; LOMAS J, 1989, EFFECTIVE CARE PREGN, P1182; LUMLEY J, 1992, OXFORD DATABASE PERI; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; NAEYE RL, 1979, AM J OBSTET GYNECOL, V135, P3; PUFFER RR, 1987, SCI PUBLICATION PAN, V504; SAMMSVAUGHAN ME, 1990, J TROP PEDIATRICS, V36, P171, DOI 10.1093/tropej/36.4.171; TAFFEL S, 1986, DHHS PHS861922 NAT C; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VICTORA CG, 1987, INT J EPIDEMIOL, V16, P239, DOI 10.1093/ije/16.2.239; Villar J, 1982, Obstet Gynecol Surv, V37, P499, DOI 10.1097/00006254-198208000-00001; VILLAR J, 1984, PEDIATRICS, V74, P783; 1985, REPORT COMMITTEE STU; 1990, GESTATIONAL WEIGHT G	24	43	43	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1021	1023		10.1016/0140-6736(92)93022-F	http://dx.doi.org/10.1016/0140-6736(92)93022-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357412				2022-12-28	WOS:A1992JV01400014
J	PEETERS, M; GERSHYDAMET, GM; FRANSEN, K; KOFFI, K; COULIBALY, M; DELAPORTE, E; PIOT, P; VANDERGROEN, G				PEETERS, M; GERSHYDAMET, GM; FRANSEN, K; KOFFI, K; COULIBALY, M; DELAPORTE, E; PIOT, P; VANDERGROEN, G			VIROLOGICAL AND POLYMERASE CHAIN-REACTION STUDIES OF HIV-1 HIV-2 DUAL INFECTION IN COTE-DIVOIRE	LANCET			English	Note							IVORY-COAST; ABIDJAN; AIDS	Dual serological reactivity to the human immunodeficiency virus (HIV) types 1 and 2 is common in Cote d'Ivoire. To assess whether dual infection is the reason for dual seropositivity we sought HIV-1 and HIV-2 proviral DNA in primary uncultured peripheral blood mononuclear cells from selected seropositive patients in Cote d'Ivoire with the polymerase chain reaction (PCR). PCR on primary lymphocytes in 36 dually seropositive samples revealed the presence of both HIV-1 and HIV-2 proviral DNA in 12 cases and the presence of HIV-1 only in 24 cases. In 18 of these 36 samples a virus was isolated and identified by PCR. HIV-1 was isolated from the 9 specimens with only HIV-1 proviral DNA in the primary lymphocytes. Among dually PCR-positive samples, 2 viral isolates reacted with both HIV-1 and HIV-2 primers; and only HIV-2 (n = 1) or HIV-1 (n = 6) strains were isolated from the other samples. The findings show that surveys based on serology may overestimate the prevalence of mixed infections in areas where both HIV-1 and HIV-2 occur.	INST PASTEUR,ABIDJAN,COTE IVOIRE; INST MED & EPIDEMIOL AFRICAINES,INSERM,U13,PARIS,FRANCE; CHU TREICHVILLE,ABIDJAN,COTE IVOIRE	Institut National de la Sante et de la Recherche Medicale (Inserm)	PEETERS, M (corresponding author), INST TROP MED PRINCE LEOPOLD,WHO,COLLABORATING CTR AIDS,NATL ST 455,B-2000 ANTWERP,BELGIUM.		Delaporte, Eric/J-5397-2018	Delaporte, Eric/0000-0002-1822-9853				DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; EVANS LA, 1988, LANCET, V2, P1389; LEONARD G, 1991, 6TH INT C AIDS AFR D; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEPIN JM, 1991, 7 INT C AIDS FLOR; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RAYFIELD M, 1991, 6TH INT C AIDS DAK	9	65	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					339	340		10.1016/0140-6736(92)91407-Y	http://dx.doi.org/10.1016/0140-6736(92)91407-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353807				2022-12-28	WOS:A1992JH12500006
J	DUSHEIKO, GM; HOBBS, KEF; DICK, R; BURROUGHS, AK				DUSHEIKO, GM; HOBBS, KEF; DICK, R; BURROUGHS, AK			TREATMENT OF SMALL HEPATOCELLULAR CARCINOMAS	LANCET			English	Review							INTRAARTERIAL ADRIAMYCIN; LIVER-TRANSPLANTATION; LIPIODOL; CIRRHOSIS; INJECTION; CHEMOEMBOLIZATION; CHEMOTHERAPY; HYPERPLASIA; DIAGNOSIS; VIRUS	There is growing interest in screening to detect symptomless hepatocellular carcinoma (HCC), which should be easier to treat than symptomatic tumours. Combined alpha-fetoprotein and ultrasound monitoring can be detect HCCs of 1 cm, and Lipiodol retention can be detected in tumours smaller than 1 cm. A number of treatment options are available. Surgical resection may be curative in selected patients with a single small tumour, but the cirrhotic patient is left with a diseased liver and the risk of tumour recurrence or death from underlying liver dysfunction. Orthotopic liver transplantation is a rational treatment for patients with decompensating cirrhosis and a small HCC, but it is expensive and necessitates immunosuppression. A variety of targeted or local therapies, either individually or in combination, can be used to treat HCC. These include percutaneous alcohol injection into an HCC, which may be an alternative to surgical resection. Tumour necrosis can be seen after targeted Lipiodol chemotherapy or radiotherapy. Transcatheter arterial embolisation selectively embolises the feeding artery, and can be combined with Lipiodol chemotherapy. Small tumours are thus amenable to treatment, even in patients who cannot have surgery. Screening and treatment for symptomless HCC seems justified, unless controlled trials teach us differently.	ROYAL FREE HOSP & MED SCH, DEPT SURG, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP & MED SCH, DEPT RADIOL, LONDON NW3 2QG, ENGLAND	University of London; University College London; University of London; University College London	DUSHEIKO, GM (corresponding author), ROYAL FREE HOSP & MED SCH, DEPT MED, POND ST, LONDON NW3 2QG, ENGLAND.		Dusheiko, Geoffrey M/C-7677-2010; Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				BEASLEY RP, 1981, LANCET, V2, P1129; BRETAGNE JF, 1988, RADIOLOGY, V168, P547, DOI 10.1148/radiology.168.2.2839867; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; COTTONE M, 1989, GASTROENTEROLOGY, V96, P1566, DOI 10.1016/0016-5085(89)90528-3; ENGSTROM PF, 1990, CANCER, V65, P2641, DOI 10.1002/1097-0142(19900615)65:12<2641::AID-CNCR2820651207>3.0.CO;2-R; FRANCO D, 1990, GASTROENTEROLOGY, V98, P733, DOI 10.1016/0016-5085(90)90296-D; FURUTA T, 1990, HEPATO-GASTROENTEROL, V37, P494; GANDOLFI L, 1989, HEPATO-GASTROENTEROL, V36, P352; HAMASAKI K, 1992, BIOCHEM BIOPH RES CO, V183, P904, DOI 10.1016/0006-291X(92)90569-7; IGIDBASHIAN VN, 1989, SEMIN LIVER DIS, V9, P16, DOI 10.1055/s-2008-1040494; IMAOKA S, 1988, CANCER CHEMOTH PHARM, V23, P126; JACKSON JE, 1989, CLIN RADIOL, V40, P538, DOI 10.1016/S0009-9260(89)80281-8; JOHNSON PJ, 1991, J HEPATOL, V13, P120, DOI 10.1016/0168-8278(91)90873-A; KALAYCI C, 1990, J HEPATOL, V11, P349, DOI 10.1016/0168-8278(90)90220-L; KANEMATSU T, 1989, HEPATOLOGY, V10, P98, DOI 10.1002/hep.1840100119; KHAN KN, 1991, CANCER RES, V51, P5667; KONDO F, 1990, HEPATOLOGY, V12, P592, DOI 10.1002/hep.1840120324; KONDO S, 1991, AM J GASTROENTEROL, V86, P779; KONNO T, 1984, CANCER, V54, P2367, DOI 10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F; KUDO M, 1992, RADIOLOGY, V182, P155, DOI 10.1148/radiology.182.1.1309216; KURODA C, 1991, CANCER, V67, P81, DOI 10.1002/1097-0142(19910101)67:1<81::AID-CNCR2820670116>3.0.CO;2-H; LAI CL, 1989, BRIT J CANCER, V60, P928, DOI 10.1038/bjc.1989.392; MARAJ R, 1988, BRIT J SURG, V75, P335, DOI 10.1002/bjs.1800750413; McMahon B J, 1990, Prog Liver Dis, V9, P643; Nakakurna K., 1979, NICHIDOKU IHO, V24, P675; Novell J R, 1991, HPB Surg, V4, P223, DOI 10.1155/1991/34537; NOVELL R, 1991, POSTGRAD MED J, V67, P393, DOI 10.1136/pgmj.67.786.393; NOVELL R, 1991, ADV AP BIOT, V13, P317; OKUDA K, 1990, HEPATO-GASTROENTEROL, V37, P159; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; PARK C, 1990, LIVER, V10, P72; PENN I, 1991, SURGERY, V110, P726; SAMUEL D, 1991, LANCET, V337, P813, DOI 10.1016/0140-6736(91)92515-4; SHEU JC, 1987, RADIOLOGY, V163, P43, DOI 10.1148/radiology.163.1.3029806; SHIRABE K, 1991, HEPATOLOGY, V14, P802, DOI 10.1002/hep.1840140510; STONE MJ, 1989, TRANSPLANTATION, V48, P344, DOI 10.1097/00007890-198908000-00031; TAKAYAMA T, 1990, LANCET, V336, P1150, DOI 10.1016/0140-6736(90)92768-D; TAKAYASU K, 1990, AM J ROENTGENOL, V155, P49, DOI 10.2214/ajr.155.1.1693808; TANG ZY, 1989, CANCER, V64, P536, DOI 10.1002/1097-0142(19890715)64:2<536::AID-CNCR2820640230>3.0.CO;2-X; TSAI SL, 1990, HEPATOLOGY, V11, P481, DOI 10.1002/hep.1840110321; VETTER D, 1991, HEPATOLOGY, V13, P427, DOI 10.1002/hep.1840130308; 1991, LANCET, V337, P333; 1989, ANN SURG, V211, P277	44	98	100	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					285	288		10.1016/0140-6736(92)92367-O	http://dx.doi.org/10.1016/0140-6736(92)92367-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353202				2022-12-28	WOS:A1992JG66500014
J	RUBENS, RD; TOWLSON, KE; RAMIREZ, AJ; COLTART, S; SLEVIN, ML; TERRELL, C; TIMOTHY, AR				RUBENS, RD; TOWLSON, KE; RAMIREZ, AJ; COLTART, S; SLEVIN, ML; TERRELL, C; TIMOTHY, AR			APPROPRIATE CHEMOTHERAPY FOR PALLIATING ADVANCED CANCER	BRITISH MEDICAL JOURNAL			English	Article									KENT & CANTERBURY HOSP,DEPT RADIOTHERAPY,CANTERBURY CT1 3NG,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,LONDON EC1,ENGLAND; ST ELIZABETHS HOSPICE,IPSWICH IP3 8LX,SUFFOLK,ENGLAND; ST THOMAS HOSP,DEPT RADIOTHERAPY,LONDON SE1 7EW,ENGLAND	University of Kent; Guy's & St Thomas' NHS Foundation Trust	RUBENS, RD (corresponding author), GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND.							BLACKLEDGE G, 1989, BRIT J CANCER, V59, P650, DOI 10.1038/bjc.1989.132; Holland JC, 1989, HDB PSYCHOONCOLOGY P; PINEDO HM, 1990, CANCER CHEMOTHERAPY; RUBENS RD, 1990, EUR J CANCER, V26, P1023; SLEVIN ML, 1988, BRIT MED J, V297, P669, DOI 10.1136/bmj.297.6649.669; 1989, WORKING PATIENTS	6	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					35	40		10.1136/bmj.304.6818.35	http://dx.doi.org/10.1136/bmj.304.6818.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1370911	Green Published, Bronze			2022-12-28	WOS:A1992GY90900034
J	FOULKES, NS; MELLSTROM, B; BENUSIGLIO, E; SASSONECORSI, P				FOULKES, NS; MELLSTROM, B; BENUSIGLIO, E; SASSONECORSI, P			DEVELOPMENTAL SWITCH OF CREM - FUNCTION DURING SPERMATOGENESIS - FROM ANTAGONIST TO ACTIVATOR	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; MOUSE; EXPRESSION; GENE	MAMMALIAN spermatogenesis consists of a series of complex developmental processes controlled by the pituitary-hypothalamic axis 1. This flow of biochemical information is directly regulated by the adenylate cyclase signal transduction pathway 2. We have previously described the CREM (cyclic AMP-responsive element modulator) gene which generates, by cell-specific splicing, alternative antagonists of the cAMP transcriptional response 3. Here we report the expression of a novel CREM isoform (CREM-tau) in adult testis. CREM-tau differs from the previously characterized CREM antagonists by the coordinate insertion of two glutamine-rich domains that confer transcriptional activation function. During spermatogenesis there was an abrupt switch in CREM expression. In premeiotic germ cells CREM is expressed at low amounts in the antagonist form. Subsequently, from the pachytene spermatocyte stage onwards, a splicing event generates exclusively the CREM-tau activator, which accumulates in extremely high amounts. This splicing-dependent reversal in CREM function represents an important example of developmental modulation in gene expression.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Sassone-Corsi, Paolo/H-6182-2011; Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DYM M, 1983, HISTOLOGY CELL TISSU, P1000; EWING LL, 1989, ANN NY ACAD SCI, V564, P1; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOUTIER R, 1976, LABORATORY ANIMAL ST, P5; Santen R. J., 1987, ENDOCRINOL METAB, P821; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4	20	451	456	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					80	84		10.1038/355080a0	http://dx.doi.org/10.1038/355080a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1370576				2022-12-28	WOS:A1992GY22800056
J	CHRISTENSEN, J				CHRISTENSEN, J			PATHOPHYSIOLOGY OF THE IRRITABLE-BOWEL-SYNDROME	LANCET			English	Article							MYOELECTRICAL ACTIVITY; COLONIC MOTOR; SYMPTOMS; DIAGNOSIS; MOTILITY; DISEASE				CHRISTENSEN, J (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.							ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7; BARKER LF, 1928, AM J MED SCI, V178, P606; Bockus HL, 1928, AM J MED SCI, V176, P813, DOI 10.1097/00000441-192812000-00006; CHAUDHARY NA, 1962, Q J MED, V31, P307; DINAN TG, 1990, J PSYCHOSOM RES, V34, P575, DOI 10.1016/0022-3999(90)90032-Y; ESLER MD, 1973, NEW ENGL J MED, V288, P16, DOI 10.1056/NEJM197301042880104; HISLOP IG, 1971, GUT, V12, P452, DOI 10.1136/gut.12.6.452; Hurst AF, 1935, LANCET, V1, P1483; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JORDAN SM, 1929, JAMA-J AM MED ASSOC, V93, P592; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KELLOW JE, 1992, SCAND J GASTROENTERO, V27, P53, DOI 10.3109/00365529209011167; KENDALL GPN, 1990, GUT, V31, P1062, DOI 10.1136/gut.31.9.1062; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; KUMAR D, 1985, LANCET, V2, P973; KUMAR D, 1990, DIGESTION, V45, P80, DOI 10.1159/000200227; LATIMER P, 1981, GASTROENTEROLOGY, V80, P893; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MCALLISTER C, 1990, BIOMED PHARMACOTHER, V44, P399, DOI 10.1016/0753-3322(90)90043-9; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; Ryle JA, 1928, LANCET, V2, P1115; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; SNAPE WJ, 1977, GASTROENTEROLOGY, V72, P383; SNAPE WJ, 1978, GASTROENTEROLOGY, V75, P373; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; THOMPSON WG, 1979, IRRITABLE GUT FUNCTI; TROTMAN IF, 1986, LANCET, V2, P364; TROTMAN IF, 1988, GUT, V29, P218, DOI 10.1136/gut.29.2.218; White BV, 1940, ANN INTERN MED, V14, P854, DOI 10.7326/0003-4819-14-5-854; White WH, 1905, LANCET, V2, P1229; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0	35	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1444	1447						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360568				2022-12-28	WOS:A1992KC28400012
J	SHAW, RW				SHAW, RW			TREATMENT OF ENDOMETRIOSIS	LANCET			English	Article							HORMONE AGONIST; FOLLOW-UP; DANAZOL; WOMEN; BUSERELIN; DENSITY; LHRH				SHAW, RW (corresponding author), UNIV WALES COLL MED, DEPT OBSTET & GYNAECOL, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.							ANDREWS WC, 1974, AM J OBSTET GYNECOL, V118, P643, DOI 10.1016/S0002-9378(16)33739-5; [Anonymous], 1992, Fertil Steril, V57, P514; [Anonymous], 1985, Fertil Steril, V43, P351; BARBIERI RL, 1982, FERTIL STERIL, V37, P737; BERGQUIST C, 1982, CLIN ENDOCRINOL, V17, P91, DOI 10.1111/j.1365-2265.1982.tb02638.x; BUTTRAM VC, 1985, FERTIL STERIL, V43, P353; DAWOOD MY, 1990, PROG CLIN BIOL RES, V323, P253; DMOWSKI WP, 1981, AM J OBSTET GYNECOL, V141, P377, DOI 10.1016/0002-9378(81)90598-6; DMOWSKI WP, 1983, FERTIL STERIL, V39, P49; DMOWSKI WP, 1982, OBSTET GYNECOL, V59, P408; DMOWSKI WP, 1975, OBSTET GYNECOL, V46, P147; DOBERL A, 1984, ACTA OBSTET GYN SCAN, P51; DONNEZ J, 1992, BRIT J OBSTET GYNAEC, V99, P31, DOI 10.1111/j.1471-0528.1992.tb13537.x; FEDELE L, 1989, FERTIL STERIL, V51, P781; GREENBLATT RB, 1979, FERTIL STERIL, V32, P518; HENDERSON AF, 1990, ADV REP END, V1, P131; HENZL MR, 1988, NEW ENGL J MED, V318, P485, DOI 10.1056/NEJM198802253180805; JELLY RJ, 1986, BR J CLIN PRACT S, V41, P64; KAUPPILA A, 1985, FERTIL STERIL, V44, P466; KAUPPILA A, 1979, PROSTAGLANDINS, V18, P655, DOI 10.1016/0090-6980(79)90033-9; LEMAY A, 1984, FERTIL STERIL, V41, P863; MATTA WH, 1988, CLIN ENDOCRINOL, V29, P45, DOI 10.1111/j.1365-2265.1988.tb00248.x; NOBLE AD, 1980, BRIT J OBSTET GYNAEC, V87, P726, DOI 10.1111/j.1471-0528.1980.tb04607.x; SANDOW J, 1983, CLIN ENDOCRINOL, V18, P571, DOI 10.1111/j.1365-2265.1983.tb00595.x; SCHMOCK E, 1985, FERTIL STERIL, V44, P583; SCHWEPPE KW, 1984, AM J OBSTET GYNECOL, V148, P1024, DOI 10.1016/0002-9378(84)90546-5; SHAW RW, 1983, BRIT MED J, V287, P1667, DOI 10.1136/bmj.287.6406.1667; SHAW RW, 1992, FERTIL STERIL, V58, P265; STEINGOLD KA, 1987, OBSTET GYNECOL, V69, P403; SUTTON C, 1990, ADV REP END, V1, P209; Telimaa S, 1987, Gynecol Endocrinol, V1, P13, DOI 10.3109/09513598709082692; TUMMON IS, 1988, FERTIL STERIL, V49, P792; YLIKORKALA O, 1983, ACTA OBSTET GYN SCAN, P105	33	69	70	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1992	340	8830					1267	1271		10.1016/0140-6736(92)92960-N	http://dx.doi.org/10.1016/0140-6736(92)92960-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359330				2022-12-28	WOS:A1992JZ23700014
J	VERHOEVEN, WMA; TUINIER, S; SIJBEN, NAS; VANDENBERG, YWHM; DEWITTEVANDERSCHOOT, EPPM; PEPPLINKHUIZEN, L; VANNIEUWENHUIZEN, O				VERHOEVEN, WMA; TUINIER, S; SIJBEN, NAS; VANDENBERG, YWHM; DEWITTEVANDERSCHOOT, EPPM; PEPPLINKHUIZEN, L; VANNIEUWENHUIZEN, O			ELTOPRAZINE IN MENTALLY-RETARDED SELF-INJURING PATIENTS	LANCET			English	Letter									ST AUGUSTINUS INST MENTAL RETARDAT,GENNEP,NETHERLANDS; ERASMUS UNIV,PATHOPHYSIOL BEHAV SECT,3000 DR ROTTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,DEPT CHILD NEUROL,3511 GV UTRECHT,NETHERLANDS	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center	VERHOEVEN, WMA (corresponding author), VINCENT VAN GOGH INST PSYCHIAT,POB 5,5800 AA VENRAY,NETHERLANDS.							DEVRIES MH, 1991, EUR J CLIN PHARMACOL, V41, P485, DOI 10.1007/BF00626375; Markowitz P I, 1990, J Clin Psychopharmacol, V10, P299; PRIMEAU F, 1987, CAN J PSYCHIAT, V32, P699, DOI 10.1177/070674378703200813; RASMUSSEN D L, 1990, Drug Metabolism and Drug Interactions, V8, P159; VANPRAAG HM, 1991, PSYCHOL MED, V21, P15, DOI 10.1017/S0033291700014604	5	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1037	1038		10.1016/0140-6736(92)93050-W	http://dx.doi.org/10.1016/0140-6736(92)93050-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV014	1357425				2022-12-28	WOS:A1992JV01400035
J	SUDLOW, MF; CAMPBELL, IA; ANGEL, JH; BENTLEY, DP; FENNERTY, AG; PRESCOTT, RJ; ROUTLEDGE, PA				SUDLOW, MF; CAMPBELL, IA; ANGEL, JH; BENTLEY, DP; FENNERTY, AG; PRESCOTT, RJ; ROUTLEDGE, PA			OPTIMUM DURATION OF ANTICOAGULATION FOR DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM	LANCET			English	Article							VENOUS THROMBOEMBOLISM; THERAPY; HEPARIN	The optimum duration of anticoagulation therapy for deep-vein thrombosis (DVT) and pulmonary embolism (PE) is not clear. We have carried out a multicentre comparison of 4 weeks' and 3 months' anticoagulation in patients admitted to hospital with acute DVT, PE, or both. Of 712 patients enrolled, 358 were assigned 4 weeks' treatment and 354 3 months'. Objective confirmation of the diagnosis was obtained in 71%. PE caused or contributed to death in 7 patients (3 treated for 4 weeks, 4 for 3 months). Adverse effects were uncommon, although 1 patient (4-week group) died of haemorrhage. The numbers of patients whose thromboembolism failed to resolve on treatment was lower in the 3-month group than in the 4-week group (13 [3.7%] vs 24 [6.7%], p = 0.10) as was the number who had recurrences (14 [4.0%] vs 28 [7.8%], p = 0.04). Among patients with postoperative DVT or PE the rate of treatment failure and recurrence was low (2.6%) and there was little difference between the treatment groups. By contrast, among medical patients the rate was 12.8%, with a clear difference in favour of 3 months' treatment. If venous thromboembolism arises after surgery, 4 weeks of anticoagulation should be adequate. In other settings, patients with new DVT, PE, or both, who do not have a persisting underlying cause or risk factor should receive anticoagulants for 3 months.	SULLY HOSP,CARDIFF CF6 2YA,WALES									BARRITT DW, 1960, LANCET, V1, P1309; COON WW, 1973, SURGERY, V73, P823; FENNERTY A, 1988, BMJ-BRIT MED J, V297, P1285, DOI 10.1136/bmj.297.6659.1285; FENNERTY AG, 1987, CLIN LAB HAEMATOL, V9, P17; GALLUS A, 1986, LANCET, V2, P1293; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; LAGERSTEDT CI, 1985, LANCET, V2, P515; LEVINE MN, 1985, DRUGS, V30, P444, DOI 10.2165/00003495-198530050-00004; MOSER KM, 1990, AM REV RESPIR DIS, V141, P235, DOI 10.1164/ajrccm/141.1.235; OSULLIVAN EF, 1972, MED J AUSTRALIA, V2, P1104, DOI 10.5694/j.1326-5377.1972.tb103752.x; RASKOB GE, 1990, Q J MED, V280, P787; 1990, J CLIN PATHOL, V43, P177; 1988, LANCET, V1, P275	16	290	300	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					873	876						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357297				2022-12-28	WOS:A1992JT32700004
J	MADERAZO, EG; SUN, H; JAY, GT				MADERAZO, EG; SUN, H; JAY, GT			SIMPLIFICATION OF ANTIBIOTIC DOSE ADJUSTMENTS IN RENAL-INSUFFICIENCY - THE DREM SYSTEM	LANCET			English	Article							DOSING GUIDELINES; DRUG-THERAPY; GENTAMICIN; PHARMACOKINETICS; FAILURE; ADULTS; AGENTS	Many clinicians, unassisted by reference books, are unable to make the required dose adjustment of antibiotics needed when a patient has renal insufficiency. We describe the DREM (dosing in renopathy by easy-to-use multipliers) system, which simplifies the understanding and the process of dose adjustment. DREM is a two-step process: Cockcroft and Gault estimation of creatinine clearance (CLcr) from age, sex, and serum creatinine and calculation of the adjusted dose or dosing interval by multipliers. If the normal dose is multiplied by the dose multiplier (CLcr/100) and the dosing interval by the interval multiplier (100/CLcr), the adjusted dose and interval, respectively, are obtained. Theoretical trough concentrations calculated with the DREM system correlated closely (r=0.9) with actual concentrations obtained from doses calculated by the Hull and Sarubbi method in 23 patients. With DREM, gentamicin or tobramycin trough concentrations above 2 mug/ml were less likely to occur. The DREM system is a simple and easily remembered method for dose adjustments of certain anti-infective agents in renal insufficiency. Dose estimates with this method are reasonably accurate and compare favourably with other standard methods of correction.	HARTFORD HOSP,DEPT MED,ANTIBIOT MANAGEMENT PROGRAM,HARTFORD,CT 06115; HARTFORD HOSP,DEPT MED,DIV INFECT DIS,HARTFORD,CT 06115; HARTFORD HOSP,DEPT PHARM SERV,CTR DRUG INFORMAT,HARTFORD,CT 06115; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH PHARM,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH MED,STORRS,CT 06268; UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06268	Hartford Hospital; Hartford Hospital; Hartford Hospital; University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	MADERAZO, EG (corresponding author), HARTFORD HOSP,MED RES LAB,HARTFORD,CT 06115, USA.							BENNETT WM, 1980, ANN INTERN MED, V93, P62, DOI 10.7326/0003-4819-93-1-62; BENNETT WM, 1980, ANN INTERN MED, V93, P286, DOI 10.7326/0003-4819-111-3-286; BOUCHER BA, 1992, REV INFECT DIS, V14, P458; BRATER DC, 1984, PHARMACOKINETIC BASI, P111; CHOW MSS, 1986, DRUG INTELL CLIN PHA, V9, P385; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAHLGREN JG, 1975, ANTIMICROB AGENTS CH, V8, P58, DOI 10.1128/AAC.8.1.58; GAMBERTOGLIO JG, 1984, PHARMACOKINETIC BASI, P149; GIBSON TP, 1986, APPLIED PHARMACOKINE, P83; HULL JH, 1976, ANN INTERN MED, V85, P183, DOI 10.7326/0003-4819-85-2-183; MATZKE GR, 1984, ANTIMICROB AGENTS CH, V25, P433, DOI 10.1128/AAC.25.4.433; MAWER GE, 1974, BRIT J CLIN PHARMACO, V1, P45, DOI 10.1111/j.1365-2125.1974.tb00205.x; NORRIS S, 1990, PRINCIPLES PRACTICE, P434; PATEL IH, 1984, ANTIMICROB AGENTS CH, V25, P438, DOI 10.1128/AAC.25.4.438; SANFORD JP, 1991, GUIDE ANTIMICROBIAL; 1991, PHYSICIANS DESK REFE	16	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					767	770		10.1016/0140-6736(92)92302-V	http://dx.doi.org/10.1016/0140-6736(92)92302-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356185				2022-12-28	WOS:A1992JP86900011
J	COUTURIER, E; BROSSARD, Y; LARSEN, C; LARSEN, M; DUMAZAUBRUN, C; PARISLLADO, J; GILLOT, R; HENRION, R; BREART, G; BRUNET, JB				COUTURIER, E; BROSSARD, Y; LARSEN, C; LARSEN, M; DUMAZAUBRUN, C; PARISLLADO, J; GILLOT, R; HENRION, R; BREART, G; BRUNET, JB			HIV-INFECTION AT OUTCOME OF PREGNANCY IN THE PARIS AREA, FRANCE	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; NEWBORNS; WOMEN	The prevalence of H IV infection in women at end of pregnancy, irrespective of outcome, was determined in a comprehensive survey of both women and medical centres during successive 4-week periods in four areas of the Paris region, France. Blood samples were tested anonymously for antibodies to human immunodeficiency virus (HIV)-1 and HIV-2. Of the 11 593 blood samples 0.40% (95% confidence interval [CI] 0.28-0.51) were positive for HIV-1 and 0-02% (95% binomial interval [BI] 0.002-0.065) for HIV-2. Seroprevalence was higher among women with ectopic pregnancy (2%) (95% BI 0.24-7.04); the rate in women having an elective or therapeutic abortion was more than twice that in those delivering babies (0.70% vs O.28%, p<0.05, relative risk 2.54, 95% CI 1.36-4.75). Studies with neonatal HIV seroprevalence as a surrogate for HIV prevalence in pregnant women would underestimate prevalence in these women.	CLIN UNIV PORT ROYAL,PARIS,FRANCE; HOP ST ANTOINE,CTR PERINATOL HAEMATOL,F-75571 PARIS 12,FRANCE; INSERM,U149,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	COUTURIER, E (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE VAL DOSNE,F-94410 ST MAURICE,FRANCE.							ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; FAUR B, 1985, COLLECTIONS INSEE D, V106, P109; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; IPPOLITO G, 1991, J ACQ IMMUN DEF SYND, V4, P402; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P1289, DOI 10.1001/jama.261.9.1289; TAPPIN DM, 1991, LANCET, V337, P1565; 1991, B EPIDEMIOL HEBDOMAD, V32, P131; 1991, LANCET, V337, P253	8	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					707	709		10.1016/0140-6736(92)92241-7	http://dx.doi.org/10.1016/0140-6736(92)92241-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355808				2022-12-28	WOS:A1992JN78000013
J	KOVACS, JA				KOVACS, JA			EFFICACY OF ATOVAQUONE IN TREATMENT OF TOXOPLASMOSIS IN PATIENTS WITH AIDS	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ENCEPHALITIS; THERAPY; COMBINATION; INVITRO; GONDII; 566C80	Atovaquone (formerly 566C80) is a hydroxynaphthoquinone with potent activity against Toxoplasma in vitro and in laboratory animals. Eight patients with AIDS and presumed or biopsy confirmed toxoplasmosis who were intolerant of or had not responded to standard therapies were treated with oral atovaquone 750 mg four times a day. Seven patients showed radiographic improvement; the other remained radiographically stable. Six patients died 6-60 weeks after enrolment with no clinical (six) or necropsy (three) evidence of recurrent toxoplasmosis; two patients relapsed at 1 0 and 32 weeks. Toxicity was mild: only one patient required temporary discontinuation of drug due to a rash. Atovaquone is a well-tolerated drug that appears to be an effective alternative for patients with toxoplasmosis who are intolerant of standard therapies.			KOVACS, JA (corresponding author), NCI,DEPT CRIT CARE MED,BLDG 10,ROOM 7D43,BETHESDA,MD 20892, USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; CHANG HR, 1988, ANTIMICROB AGENTS CH, V32, P524, DOI 10.1128/AAC.32.4.524; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; FERNANDEZMARTIN J, 1991, ANTIMICROB AGENTS CH, V35, P2049, DOI 10.1128/AAC.35.10.2049; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; KATLAMA C, 1991, 7 INT C AIDS; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; REMINGTON JS, 1991, LANCET, V338, P1142, DOI 10.1016/0140-6736(91)91997-9	10	124	125	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					637	638		10.1016/0140-6736(92)92172-C	http://dx.doi.org/10.1016/0140-6736(92)92172-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355212				2022-12-28	WOS:A1992JM85100005
J	MEYAARD, L; OTTO, SA; JONKER, RR; MIJNSTER, MJ; KEET, RPM; MIEDEMA, F				MEYAARD, L; OTTO, SA; JONKER, RR; MIJNSTER, MJ; KEET, RPM; MIEDEMA, F			PROGRAMMED DEATH OF T-CELLS IN HIV-1 INFECTION	SCIENCE			English	Article							AIDS-RELATED COMPLEX; DNA FRAGMENTATION; HOMOSEXUAL MEN; SELECTIVE LOSS; IMMUNE-SYSTEM; APOPTOSIS; LYMPHOCYTES; EXPRESSION; INDUCTION; RECEPTOR	In human immunodeficiency virus (HIV) infection, functional defects and deletion of antigen-reactive T cells are more frequent than can be explained by direct viral infection. On culturing, both CD4+ and CD8+ T cells from asymptomatic HIV-infected individuals died as a result of programmed cell death (apoptosis). Apoptosis was enhanced by activation with CD3 antibodies. Programmed cell death, associated with impaired T cell reactivity, may thus be responsible for the deletion of reactive T cells that contributes to HIV-induced immunodeficiency.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB, DEPT CLIN VIROIMMUNOL,PLESMANLAAN 125, AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPTL & CLIN IMMUNOL LAB, 1066 CX AMSTERDAM, NETHERLANDS; TNO, INST APPL RADIOBIOL & IMMUNOL, DEPT MOLEC PATHOL, 2280 HV RIJSWIJK, NETHERLANDS; NETHERLANDS INST BRAIN RES, 1095 KJ AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT INFECT DIS, AMSTERDAM, NETHERLANDS	University of Amsterdam; Netherlands Organization Applied Science Research; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)				Keet, Rene/0000-0001-9959-6032; Meyaard, Linde/0000-0003-0707-4793				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CEFAI D, 1990, J CLIN INVEST, V86, P2117, DOI 10.1172/JCI114950; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; GRUTERS RA, 1990, EUR J IMMUNOL, V20, P1039, DOI 10.1002/eji.1830200514; JONKER RR, UNPUB; KEKOW J, 1991, J CLIN INVEST, V87, P1010, DOI 10.1172/JCI115059; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; MEYAARD L, UNPUB; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PRINCE HE, 1991, CELL IMMUNOL, V134, P276, DOI 10.1016/0008-8749(91)90302-R; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SALAZARGONZALEZ JF, 1985, J IMMUNOL, V135, P1778; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STITES DP, 1989, CLIN IMMUNOL IMMUNOP, V52, P96, DOI 10.1016/0090-1229(89)90196-7; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	33	905	934	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					217	219		10.1126/science.1352911	http://dx.doi.org/10.1126/science.1352911			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1352911				2022-12-28	WOS:A1992JC58500030
J	HARRIS, HJ; SCOTCHER, D; CRAUFURD, D; WALLACE, A; HARRIS, R				HARRIS, HJ; SCOTCHER, D; CRAUFURD, D; WALLACE, A; HARRIS, R			CYSTIC-FIBROSIS CARRIER SCREENING AT 1ST DIAGNOSIS OF PREGNANCY IN GENERAL-PRACTICE	LANCET			English	Letter									ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	HARRIS, HJ (corresponding author), BROOKLANDS MED PRACTICE,MANCHESTER,ENGLAND.		Craufurd, David/G-5277-2013					WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504	1	12	12	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1539	1539		10.1016/0140-6736(92)91303-P	http://dx.doi.org/10.1016/0140-6736(92)91303-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351208				2022-12-28	WOS:A1992HZ17500034
J	MARIOTTI, S; SANSONI, P; BARBESINO, G; CATUREGLI, P; MONTI, D; COSSARIZZA, A; GIACOMELLI, T; PASSERI, G; FAGIOLO, U; PINCHERA, A; FRANCESCHI, C				MARIOTTI, S; SANSONI, P; BARBESINO, G; CATUREGLI, P; MONTI, D; COSSARIZZA, A; GIACOMELLI, T; PASSERI, G; FAGIOLO, U; PINCHERA, A; FRANCESCHI, C			THYROID AND OTHER ORGAN-SPECIFIC AUTOANTIBODIES IN HEALTHY CENTENARIANS	LANCET			English	Note								To investigate the prevalence of thyroid autoantibodies in very old subjects, we assayed sera from 34 healthy centenarians (7 men, 27 women; age range 100-108 years) for these antibodies. There was a clear age-dependent increase in prevalence of thyroid autoantibodies in sera from 549 control subjects aged 7-85 years, prevalence in 40 subjects aged 70-85 being significantly greater (p<0.001, chi-2) than that in 436 subjects aged less than 50. By contrast, prevalence of thyroid autoantibodies in centenarians was not significantly different from that in controls aged less than 50. Cytofluorimetric analysis of peripheral blood lymphocytes showed a striking age-dependent decrease in total and CD5+ B cells (without changes in their ratio), which reached its nadir in centenarians. The age-dependent increase in prevalence of thyroid autoantibodies in the elderly is not seen after the ninth decade of life. What relation this characteristic has to derangement of circulating B cells is unknown.	UNIV MODENA,INST GEN PATHOL,I-41100 MODENA,ITALY; UNIV PARMA,INST GEN CLIN MED,I-43100 PARMA,ITALY; UNIV PADUA,INST INTERNAL MED,I-35100 PADUA,ITALY	Universita di Modena e Reggio Emilia; University of Parma; University of Padua	MARIOTTI, S (corresponding author), UNIV PISA,IST ENDOCRINOL,VIALE TIRRENO 64,I-56018 TIRRENIA,ITALY.		Monti, Daniela/G-9556-2012; Mariotti, Stefano/AAN-1948-2020; Franceschi, Claudio/L-4484-2017	Monti, Daniela/0000-0001-8651-8123; Franceschi, Claudio/0000-0001-9841-6386; Cossarizza, Andrea/0000-0002-5381-1558; Passeri, Giovanni/0000-0002-4039-1160				COSSARIZZA A, 1991, BLOOD, V77, P1263; FRANCESCHI C, 1991, ANN NY ACAD SCI, V261, P428; HACKETT E, 1960, LANCET, V2, P402; HIJMANS W, 1984, MECH AGEING DEV, V26, P83, DOI 10.1016/0047-6374(84)90167-2; HOOPER B, 1972, CLIN EXP IMMUNOL, V12, P79; KASAIAN MT, 1991, P SOC EXP BIOL MED, V197, P226; MARIOTTI S, 1990, J CLIN ENDOCR METAB, V71, P661, DOI 10.1210/jcem-71-3-661; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; ROBUSCHI G, 1987, ENDOCR REV, V8, P142, DOI 10.1210/edrv-8-2-142; Tomer Y, 1988, Autoimmunity, V1, P141, DOI 10.3109/08916938809001927	10	189	192	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1506	1508		10.1016/0140-6736(92)91265-A	http://dx.doi.org/10.1016/0140-6736(92)91265-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351187				2022-12-28	WOS:A1992HZ17500005
J	WEBSTER, ADB; BARNES, DE; ARLETT, CF; LEHMANN, AR; LINDAHL, T				WEBSTER, ADB; BARNES, DE; ARLETT, CF; LEHMANN, AR; LINDAHL, T			GROWTH-RETARDATION AND IMMUNODEFICIENCY IN A PATIENT WITH MUTATIONS IN THE DNA LIGASE-I GENE	LANCET			English	Note							BLOOMS SYNDROME; 46BR; CELLS; DEFECT; REPAIR	DNA ligases are required for the replication, repair, and recombination of DNA. A cell line derived from a young woman with growth retardation, sun sensitivity, and immunodeficiencies, who died aged 19 with lymphoma, showed two different miscoding mutations at the DNA ligase I locus on chromosome 19, one in each allele. One of the mutations was inherited from the mother and has also been detected in two healthy brothers. The patient had features similar to those of Bloom's syndrome (BS), but cell lines from BS patients do not have mutations in the DNA ligase I gene. This patient seems to represent a distinct genetic entity.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS,HERTS,ENGLAND; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND	University of Sussex	WEBSTER, ADB (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,MRC,CTR CLIN RES,IMMUNODEFICIENCY DIS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.							BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BLOOM D, 1966, J PEDIATR-US, V68, P103, DOI 10.1016/S0022-3476(66)80426-2; BRIDGES BA, 1982, ATAXIA TELANGIECTASI; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; HUTTEROTH TH, 1975, J CLIN INVEST, V56, P1, DOI 10.1172/JCI108058; LEHMANN AR, 1988, CANCER RES, V48, P6343; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; WEBSTER D, 1982, ATAXIA TELANGIECTASI, P379	10	78	80	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1508	1509		10.1016/0140-6736(92)91266-B	http://dx.doi.org/10.1016/0140-6736(92)91266-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351188				2022-12-28	WOS:A1992HZ17500006
J	PINOLROMA, S; DREYFUSS, G				PINOLROMA, S; DREYFUSS, G			SHUTTLING OF PRE-MESSENGER-RNA BINDING-PROTEINS BETWEEN NUCLEUS AND CYTOPLASM	NATURE			English	Article							RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; NASCENT TRANSCRIPTS; COMPLEXES; CELLS; VISUALIZATION; EXPORT; HNRNP	RNA polymerase II transcripts, heterogeneous nuclear RNAs (hnRNAs), associate in the nucleus with specific proteins that bind premessenger RNA (hnRNP proteins) 1,2 and with small nuclear ribonucleoprotein particles (snRNPs) 3-5. These hnRNA-hnRNP-snRNP complexes assemble on nascent transcripts and hnRNA is processed to mRNA in them 6-8. HnRNP proteins have been localized to the nucleoplasm 9-13 and their functions were presumed to be limited to nuclear events in mRNA biogenesis. It was proposed that an exchange of hnRNP for mRNA-binding proteins accompanies transport of mRNA from the nucleus to the cytoplasm 1,14. We show here that several of the abundant hnRNP proteins, including A1, shuttle between the nucleus and the cytoplasm. HnRNP proteins may thus also have cytoplasmic functions. Furthermore, when in the cytoplasm, A1 is bound to mRNA and RNA polymerase II transcription is necessary before it can return to the nucleus. We propose that the cytoplasmic ribonucleoprotein complex of mRNA with hnRNP proteins is the substrate of nuclear-cytoplasmic transport of mRNA.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ADAM SA, 1986, J VIROL, V57, P614, DOI 10.1128/JVI.57.2.614-622.1986; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; EGYHAZI E, 1982, EUR J BIOCHEM, V122, P445; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HURWITZ J, 1962, P NATL ACAD SCI USA, V48, P1222, DOI 10.1073/pnas.48.7.1222; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LESER GP, 1984, J BIOL CHEM, V259, P1827; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MARTIN TE, 1981, CELL NUCLEUS, V9, P119; MEHLIN H, 1991, EXP CELL RES, V193, P72, DOI 10.1016/0014-4827(91)90539-7; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; STEITZ JA, 1988, FUNCTIONS ABUNDANT S; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; TAMM I, 1978, ADV VIRUS RES, V22, P188; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465	31	775	784	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					730	732		10.1038/355730a0	http://dx.doi.org/10.1038/355730a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1371331				2022-12-28	WOS:A1992HE60400065
J	SILVER, RA; TRAYNELIS, SF; CULLCANDY, SG				SILVER, RA; TRAYNELIS, SF; CULLCANDY, SG			RAPID-TIME-COURSE MINIATURE AND EVOKED EXCITATORY CURRENTS AT CEREBELLAR SYNAPSES INSITU	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; PATCH-CLAMP; POSTSYNAPTIC CURRENTS; SYNAPTIC CURRENTS; NEURONS; GLUTAMATE; RECEPTORS; ACTIVATION; CELLS	NEUROTRANSMISSION from mossy fibre terminals onto cerebellar granule cells is almost certainly mediated by L-glutamate 1,2. By taking advantage of the small soma size, limited number of processes and short dendrite length of granule cells, we have obtained high-resolution recordings of spontaneous miniature excitatory postsynaptic currents (m.e.p.s.cs) and evoked currents in thin cerebellar slices 3. Miniature currents have a similar time-course and pharmacology to evoked currents and consist of an exceptionally fast non-NMDA (N-methyl-D-aspartate) component (measured rise-time, 200-mu-s; estimated pre-filtered rise-time < 100-mu-s; decay time constant, tau = 1.0 ms), followed by 50 pS NMDA channel openings that are directly resolvable. We could find no evidence for the recent proposal that miniature currents in granule cells are mediated solely by NMDA channels with a novel time course 4. The non-NMDA receptor component of m.e.p.s.cs has a skewed amplitude distribution, which suggests potential complications for quantal analysis. The difference in time course between the m.e.p.s.cs reported here and other synaptic currents in the brain 5-8 could reflect differences in synaptic function or electrotonic filtering; the relative contribution of these possibilities has vet to be established.			SILVER, RA (corresponding author), UNIV LONDON UNIV COLL,DEPT PHARMACOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Cull-Candy, Stuart G/0000-0002-0831-8326; Silver, Robin/0000-0002-5480-6638	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORNSTEIN JC, 1978, J PHYSIOL-LONDON, V282, P375, DOI 10.1113/jphysiol.1978.sp012470; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FINKEL AS, 1983, J PHYSIOL-LONDON, V342, P615, DOI 10.1113/jphysiol.1983.sp014872; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GIBB AJ, 1991, P ROY SOC B-BIOL SCI, V243, P39, DOI 10.1098/rspb.1991.0007; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; JAKAB RL, 1988, ANAT EMBRYOL, V179, P81, DOI 10.1007/BF00305102; JI ZQ, 1991, J COMP NEUROL, V307, P296, DOI 10.1002/cne.903070210; Katz B., 1969, RELEASE NEURAL TRANS; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MACGREGOR RJ, 1987, NEURAL BRAIN MODELLI; NELSON PG, 1986, J PHYSIOL-LONDON, V372, P169, DOI 10.1113/jphysiol.1986.sp016003; RALL W, 1969, BIOPHYS J, V9, P1483, DOI 10.1016/S0006-3495(69)86467-2; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P707, DOI 10.1113/jphysiol.1990.sp018236; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; STERN P, IN PRESS J PHYSL; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	32	322	322	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					163	166		10.1038/355163a0	http://dx.doi.org/10.1038/355163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370344				2022-12-28	WOS:A1992GY62900059
J	PHILLIPS, AN; ELFORD, J; SABIN, C; BOFILL, M; JANOSSY, G; LEE, CA				PHILLIPS, AN; ELFORD, J; SABIN, C; BOFILL, M; JANOSSY, G; LEE, CA			IMMUNODEFICIENCY AND THE RISK OF DEATH IN HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILIC COHORT; NATURAL-HISTORY; VIRUS-INFECTION; AIDS; COUNTS; PROGRESSION; PREDICTORS; MARKERS; TYPE-1; FOLLOW	Objective.-To describe the rate of development of immunodeficiency in human immunodeficiency virus (HIV) infection and to relate this to the risk of death. Design.-Inception cohort followed up for up to 12 years from HIV seroconversion until January 1, 1992. Setting.-A regional hemophilia center based in a major teaching hospital. Patients.-All 111 patients with hemophilia who seroconverted to HIV-1 between 1979 and 1985 were registered at the center. Patients have been closely followed up clinically and immunologically. Outcome Measures.-Development of immunodeficiency, defined by a CD4 lymphocyte count falling beneath 0.20 and 0.05 x 10(9)/L, and death. Results.-Kaplan-Meier estimates suggest that almost half (46%; 95% confidence interval [CI], 26% to 66%) of patients alive 12 years after seroconversion will have a CD4 lymphocyte count that has remained above 0.05 x 10(9)/L. Thirty-five percent (95% CI, 22% to 48%) remain above 0.20 x 10(9)/L. Thirty-seven patients died of HIV-related causes, and there was a 52% probability (95% CI, 35% to 69%) of HIV-related mortality by 12 years from seroconversion. Mortality risk was closely associated with severe immunodeficiency. There was only a 15% chance (95% CI, 6% to 25%) of HIV-related death occurring before a CD4 count of below 0.05 x 10(9)/L had been reached. There was an average of one HIV-related death per 96.7 patient-years of observation before the CD4 count had fallen below 0.05 x 10(9)/L, as compared with one death per 2.5 patient-years of observation after the CD4 count had fallen below this level (P<.0001). Conclusions.-In patients with HIV infection who are closely followed up, the risk of death is low before the CD4 lymphocyte count has fallen to 0.05 x 10(9)/L, a count many patients remain above up to 12 years after seroconversion.	UNIV LONDON ROYAL FREE HOSP,DEPT PUBL HLTH & PRIMARY CARE,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,DEPT IMMUNOL,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,CTR HAEMOPHILIA,LONDON,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London	PHILLIPS, AN (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				CAMPANA D, 1987, J IMMUNOL, V138, P648; ESTEBAN JI, 1990, LANCET, V335, P1419; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; EYSTER ME, 1992, 7TH INT C AIDS AMST; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LANGHON BE, 1991, J INFECT DIS, V164, P244; LEE C, 1992, BRIT J HAEMATOL, V81, P133, DOI 10.1111/j.1365-2141.1992.tb08191.x; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, 1992, J ACQ IMMUN DEF SYND, V5, P148; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; TEDDER RS, 1991, BRIT MED J, V302, P1299, DOI 10.1136/bmj.302.6788.1299; WAYNE WF, 1988, CYTOMETRY, V3, P23; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; [No title captured]	25	70	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2662	2666		10.1001/jama.268.19.2662	http://dx.doi.org/10.1001/jama.268.19.2662			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1359163				2022-12-28	WOS:A1992JX68000027
J	[Anonymous]				[Anonymous]			POLIOVACCINE AND AIDS ORIGIN LINK VERY UNLIKELY	LANCET			English	Editorial Material																		CURTIS T, 1992, ROLLING STONE M 0319; KYLE WS, 1992, LANCET, V339, P600, DOI 10.1016/0140-6736(92)90876-5	2	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1992	340	8827					1090	1091						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357471				2022-12-28	WOS:A1992JV77500017
J	PATHY, MSJ; BAYER, A; HARDING, K; DIBBLE, A				PATHY, MSJ; BAYER, A; HARDING, K; DIBBLE, A			RANDOMIZED TRIAL OF CASE FINDING AND SURVEILLANCE OF ELDERLY PEOPLE AT HOME	LANCET			English	Article							GENERAL-PRACTICE; HEALTH CHECK; ATTENDERS; CARE	Health screening for old people who live at home has been the subject of debate for 30 years or so. It has come to the fore again in the UK with the new emphasis on annual assessments by general practitioners (GPs) of those aged 75 or more. Screening in the elderly has implications for manpower. How can it best be done? We describe here a randomised, controlled study of case finding and surveillance in patients aged 65 and over in a general practice in South Wales. Problem identification was by a postal questionnaire, focusing on function, that was sent at random to 369 eligible patients with subsequent verification and intervention by a specially appointed nurse. The 356 controls had no questionnaires and no contact with that nurse. The study lasted 3 years, and end-points included mortality, self-ratings of quality of life, and health status, and use of all services (GP contacts, hospital admission, home help, and so on). Mortality was significantly lower in the intervention group (18%) than in the controls (24%) (difference 6.0% [95% CI 0.1-11.9%], p < 0.05). Total number of hospital admissions did not differ between intervention and control groups, but duration of hospital stay of patients aged 65 to 74 years was significantly shorter in the intervention group (difference 4.6 days [95% CI 1.6-7.6], p < 0.01). An increase i n visits to a G P was largely offset by a lower number of home visits by a GP. Quality-of-life measures revealed no between-group differences, but self-rated health status was superior in the intervention group. We conclude that the use of a postal screening questionnaire with selective follow-up and intervention can favourably influence outcome and use of health care resources by elderly people living at home.	UNIV WALES COLL MED, CARDIFF ROYAL INFIRM, DEPT GERIATR MED, CARDIFF CF4 4XN, S GLAM, WALES; SURGERY, CARDIFF, WALES	Cardiff Royal Infirmary; Cardiff University			Bayer, Antony/H-4434-2019; Bayer, Antony/H-4376-2019; Harding, Keith/J-5605-2013	Bayer, Antony/0000-0002-7514-248X; Harding, Keith/0000-0003-0048-3279				ANDERSON WF, 1955, LANCET, V2, P239; Barber J H, 1980, J R Coll Gen Pract, V30, P49; BOWNS I, 1991, BRIT J GEN PRACT, V41, P100; BUCKLEY EG, 1988, BMJ-BRIT MED J, V296, P1144, DOI 10.1136/bmj.296.6630.1144-a; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; EBRAHIM S, 1984, BRIT MED J, V289, P1273, DOI 10.1136/bmj.289.6454.1273; FORD G, 1985, J ROY COLL GEN PRACT, V35, P244; FREER CB, 1985, J ROY COLL GEN PRACT, V35, P288; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; Hunt SM, 1986, MEASURING HLTH STATU; KIRK H, 1982, DAN MED BULL, V29, P138; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; TAYLOR RC, 1983, J ROY COLL GEN PRACT, V33, P699; TAYLOR RC, 1987, 35 ROYAL COLL GEN PR; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; Townsend P., 1979, POVERTY UK; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; WILLIAMS EI, 1984, BRIT MED J, V288, P119, DOI 10.1136/bmj.288.6411.119; WILLIAMSON J, 1964, LANCET, V1, P1117; WILLIAMSON J, 1981, HLTH CARE ELDERLY	24	121	121	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1992	340	8824					890	893		10.1016/0140-6736(92)93294-W	http://dx.doi.org/10.1016/0140-6736(92)93294-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357306				2022-12-28	WOS:A1992JT32700013
J	GREGORY, R; TATTERSALL, RB				GREGORY, R; TATTERSALL, RB			ARE DIABETIC PREPREGNANCY CLINICS WORTH WHILE	LANCET			English	Editorial Material							CONGENITAL-MALFORMATIONS; WOMEN; MANAGEMENT; MOTHERS; INFANTS; CONCEPTION; ANOMALIES; BABIES; RISK; CARE		UNIV NOTTINGHAM HOSP,DIABET UNIT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BRYCE FC, 1991, DIABETIC MED, V8, P382, DOI 10.1111/j.1464-5491.1991.tb01614.x; CULLIMORE J, 1990, J OBSTET GYNAECOL, V10, P171; DAMM P, 1989, AM J OBSTET GYNECOL, V161, P1163, DOI 10.1016/0002-9378(89)90656-X; DRURY MI, 1989, DIABETIC MED, V6, P291, DOI 10.1111/j.1464-5491.1989.tb01167.x; FURHMAN K, 1983, DIABETES CARE, V6, P219; Greene MF, 1989, DIABETES COMPLICATIN, P147; GREGORY R, 1992, J ROY COLL PHYS LOND, V26, P162; Heller S R, 1984, Diabet Med, V1, P199; JOVANOVIC L, 1981, AM J MED, V71, P921, DOI 10.1016/0002-9343(81)90301-6; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; Lawrence RD, 1942, Q J MED, V11, P45; LESLIE RDG, 1978, LANCET, V2, P958; LOWY C, 1986, DIABETIC MED, V3, P458, DOI 10.1111/j.1464-5491.1986.tb00791.x; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; MIODOVNIK M, 1988, DIABETES CARE, V11, P714; MOLSTEDPEDERSEN L, 1985, DIABETES ANN, V1, P238; OAKLEY WG, 1968, CLIN DIABETES ITS BI, P643; ROSENN B, 1991, OBSTET GYNECOL, V77, P846; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; STEEL JM, 1980, DIABETES CARE, V3, P371, DOI 10.2337/diacare.3.2.371; TCHOBROUTSKY C, 1971, DIABETES METAB, V17, P287; YLINEN K, 1984, BRIT MED J, V289, P345, DOI 10.1136/bmj.289.6441.345; 1990, DIABETES CARE, V14, P994	25	15	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					656	658		10.1016/0140-6736(92)92181-E	http://dx.doi.org/10.1016/0140-6736(92)92181-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355220				2022-12-28	WOS:A1992JM85100013
J	SIBLEY, LD; BOOTHROYD, JC				SIBLEY, LD; BOOTHROYD, JC			VIRULENT-STRAINS OF TOXOPLASMA-GONDII COMPRISE A SINGLE CLONAL LINEAGE	NATURE			English	Article							CONGENITAL TOXOPLASMOSIS; DIAGNOSIS; ENCEPHALITIS	THE protozoan Toxoplasma gondii is a prevalent parasite in wild and domestic animals worldwide, being transmitted through the food chain by carnivorous feeding and scavenging1. Toxoplasma normally divides asexually to yield a haploid form that can infect virtually any vertebrate but it also has a well defined sexual cycle that occurs exclusively in cats1. Toxoplasma has become important as an often fatal opportunistic pathogen in patients with AIDS2,3, although the 15-85% of adult human populations that are chronically infected with T. gondii are typically asymptomatic4-7. Infections in immunocompromised hosts have variable outcomes. For example, only 30 to 50% of AIDS patients that are chronically infected with the parasite develop toxoplasmic encephalitis2,3 and only about half of acute maternal infections result in congenital disease of the newborn8. T. gondii strains differ in their virulence in animals1, but the extent to which different strains are related has not been determined. Here we analyse 28 strains from a variety of hosts on five continents and find that the ten virulent strains have an essentially identical genotype, whereas the nonvirulent strains are moderately polymorphic. These data strongly suggest that virulent strains of T. gondii originated from a single lineage which has remained genetically homogeneous despite being globally widespread, and despite the ability of this organism to reproduce sexually.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University			Sibley, L. David/C-4616-2008	Boothroyd, John C./0000-0001-9719-745X				APT WB, 1985, PARASITOL TODAY, V1, P44; BOOTHROYD JC, IN PRESS NATO ASI SE; BUELOW R, 1991, J IMMUNOL, V147, P3496; BURG JL, 1988, J IMMUNOL, V141, P3584; DANNEMANN BR, 1989, HOSP PRACT, V24, P139; DARDE ML, 1988, AM J TROP MED HYG, V39, P551, DOI 10.4269/ajtmh.1988.39.551; DARDE ML, IN PRESS J PARASIT; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Dubey J.P., 1977, P101; FELDMAN HA, 1965, AM J EPIDEMIOL, V81, P385, DOI 10.1093/oxfordjournals.aje.a120524; GROVER CM, 1990, J CLIN MICROBIOL, V28, P2297, DOI 10.1128/JCM.28.10.2297-2301.1990; Hughes H.P.A., 1985, Parasitology Today, V1, P41, DOI 10.1016/0169-4758(85)90112-7; KASPER LH, 1985, J CLIN INVEST, V75, P1570, DOI 10.1172/JCI111862; KIEHN TE, 1985, J CLIN MICROBIOL, V21, P168, DOI 10.1128/JCM.21.2.168-173.1985; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; PFEFFERKORN ER, 1977, J PARASITOL, V63, P158, DOI 10.2307/3280129; Sabin AB, 1941, J AMER MED ASSOC, V116, P801, DOI 10.1001/jama.1941.02820090001001; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SELANDER RK, 1980, SCIENCE, V210, P545, DOI 10.1126/science.6999623; SIBLEY LD, 1992, MOL BIOCHEM PARASIT, V51, P291, DOI 10.1016/0166-6851(92)90079-Y; SIBLEY LD, IN PRESS GENETICS; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5	24	563	605	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					82	85		10.1038/359082a0	http://dx.doi.org/10.1038/359082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1355855				2022-12-28	WOS:A1992JL66200060
J	LACKRITZ, EM; CAMPBELL, CC; RUEBUSH, TK; HIGHTOWER, AW; WAKUBE, W; STEKETEE, RW; WERE, JBO				LACKRITZ, EM; CAMPBELL, CC; RUEBUSH, TK; HIGHTOWER, AW; WAKUBE, W; STEKETEE, RW; WERE, JBO			EFFECT OF BLOOD-TRANSFUSION ON SURVIVAL AMONG CHILDREN IN A KENYAN HOSPITAL	LANCET			English	Article							HIV; KINSHASA; ZAIRE; SEROPOSITIVITY; TRANSMISSION; INFECTION; AFRICA; TRENDS	In Africa, blood transfusions are frequently given to treat severe paediatric anaemia. Because of the risk of HIV transmission, identification of when transfusion will reduce the risk of death for severely anaemic children has become increasingly important. For all children admitted to a Kenyan hospital from October, 1989, to October, 1990, we collected data on clinical presentation, haemoglobin (Hb), receipt of transfusion, and in-hospital survival. Of 2433 admissions, 29% (684) had severe anaemia (Hb<5.0 g/dl), and 20% (483) received blood transfusions. Based on laboratory criteria only, children with Hb<3.9 g/dl who were transfused had lower mortality than those with Hb<3.9 g/dl who were not transfused, but this finding applied only to children transfused on the day of admission (odds ratio [OR] 0.30; 95% CI 0.14, 0.61) or the day after admission (OR 0.37; 95% CI 0.14, 1.00). Based on a combination of laboratory and clinical criteria, children with clinical signs of respiratory distress and Hb<4.7 g/dl who were transfused had lower mortality than those who were not (OR 0.19; 95% CI 0.09, 0.41). Among children without respiratory distress, there was no association between receipt of transfusion and mortality, irrespective of admission Hb. The frequency of blood transfusion can be reduced and survival enhanced by targeting blood to those children with severe anaemia and clinical signs of respiratory distress, and by using transfusion early in the course of hospitalisation.	KENYA GOVT MED RES CTR, NAIROBI, KENYA	Kenya Medical Research Institute	LACKRITZ, EM (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV PARASIT DIS, MALARIA BRANCH, MS F-12, ATLANTA, GA 30333 USA.			Lackritz, Eve/0000-0002-5397-7291				[Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; COLEBUNDERS RL, 1989, EUR J CLIN MICROBIOL, V8, P505, DOI 10.1007/BF01967468; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; DORWARD JA, 1989, TROP DOCT, V19, P155, DOI 10.1177/004947558901900404; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; JAGER H, 1990, AIDS, V4, P571, DOI 10.1097/00002030-199006000-00012; KREISS J, 1990, AIDS, P16; LEPAGE P, 1988, INFECT CONT HOSP EP, V9, P200, DOI 10.1086/645833; MABEY DCW, 1988, BRIT MED J, V296, P83, DOI 10.1136/bmj.296.6615.83; MANN JM, 1987, AIDS SAFETY BLOOD BL, P47; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; Pape G L, 1989, Trop Doct, V19, P46; SCHMUTZHARD E, 1988, T ROY SOC TROP MED H, V82, P220, DOI 10.1016/0035-9203(88)90416-6; SHAFFER N, 1990, AIDS, V4, P1231, DOI 10.1097/00002030-199012000-00008; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P13; TORREY BB, 1990, 53 CTR INT RES STAFF; 1989, GUIDELINES APPROPRIA; 1989, INDICATIONS BLOOD TR; 1984, WHO TECH REP SER, V711, P176; 1968, WHO TECH REP SER, V405	20	229	229	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1992	340	8818					524	528		10.1016/0140-6736(92)91719-O	http://dx.doi.org/10.1016/0140-6736(92)91719-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354285				2022-12-28	WOS:A1992JL23400012
J	REGLAND, B; GOTTFRIES, CG				REGLAND, B; GOTTFRIES, CG			THE ROLE OF AMYLOID BETA-PROTEIN IN ALZHEIMER-DISEASE	LANCET			English	Article							PRECURSOR PROTEIN; MESSENGER-RNA; HEAT-SHOCK; PLAQUES; DEPOSITION; INHIBITORS; PLATELETS; INDUCTION; TANGLES; GENE	Deposition of amyloid beta-protein in the brain has been regarded as the central event in Alzheimer's disease; however, amyloid beta-protein precursor is an endogenous protein, probably with neurotrophic functions. An alternative hypothesis is that amyloid beta-protein is involved in the disease process secondarily, as a protective reactant when brain cells are injured. Insufficiency of amyloid beta-protein precursor, whether because of a genetic defect or in relation to the action of environmental factors, then allows development of Alzheimer changes.	MOLNDAL CTY HOSP,DEPT NEUROCHEM,S-43180 MOLNDAL,SWEDEN		REGLAND, B (corresponding author), MOLNDAL CTY HOSP,DEPT PSYCHIAT,S-43180 MOLNDAL,SWEDEN.							ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ALLSOP D, 1988, P NATL ACAD SCI USA, V85, P2790, DOI 10.1073/pnas.85.8.2790; BUSH AI, 1990, J BIOL CHEM, V265, P15977; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; DELAERE P, 1990, NEUROSCI LETT, V116, P87, DOI 10.1016/0304-3940(90)90391-L; DICKSON DW, 1989, ACTA NEUROPATHOL, V78, P572, DOI 10.1007/BF00691284; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWABATA S, 1991, NATURE, V354, P476, DOI 10.1038/354476a0; KAWABATA S, 1992, NATURE, V356, P23, DOI 10.1038/356023b0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P156; KORENBERG JR, 1990, AM J HUM GENET, V47, P236; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; PATTERSON PH, 1985, J PHYSIOLOGY PARIS, V80, P207; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTSON M, 1992, NATURE, V356, P103, DOI 10.1038/356103a0; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SELKOE DJ, 1991, SCI AM           NOV, P40; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	31	63	63	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					467	469		10.1016/0140-6736(92)91780-C	http://dx.doi.org/10.1016/0140-6736(92)91780-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354793				2022-12-28	WOS:A1992JJ87700013
J	ALDER, J; LU, B; VALTORTA, F; GREENGARD, P; POO, MM				ALDER, J; LU, B; VALTORTA, F; GREENGARD, P; POO, MM			CALCIUM-DEPENDENT TRANSMITTER SECRETION RECONSTITUTED IN XENOPUS OOCYTES - REQUIREMENT FOR SYNAPTOPHYSIN	SCIENCE			English	Article							SYNAPTIC VESICLE PROTEIN; MEMBRANE-PROTEIN; MESSENGER-RNA; NEUROMUSCULAR-JUNCTION; LAEVIS OOCYTES; AMINO-ACIDS; RAT-BRAIN; GLUTAMINE; RELEASE; NEUROTRANSMITTER	Calcium-dependent glutamate secretion was reconstituted in Xenopus oocytes by injecting the oocyte with total rat cerebellar messenger RNA (mRNA). Co-injection of total mRNA with antisense oligonucleotides to synaptophysin message decreased the expression of synaptophysin in the oocyte and reduced the calcium-dependent secretion. A similar effect on secretion was observed for oocytes injected with total mRNA together with an antibody to rat synaptophysin. These results indicate that synaptophysin is necessary for transmitter secretion and that the oocyte expression system may be useful for dissecting the molecular events associated with the secretory process.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; UNIV MILAN,NATL RES COUNCIL,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20129 MILAN,ITALY	Columbia University; Rockefeller University; University of Milan			Flavia, Valtorta/F-3450-2012; Lu, Bai/A-4018-2012	Flavia, Valtorta/0000-0001-9556-4746; Alder, Janet/0000-0002-5694-4946; Lu, Bai/0000-0001-5418-9759	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 39327] Funding Source: Medline; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BLAKELY RD, 1991, J NEUROCHEM, V56, P860, DOI 10.1111/j.1471-4159.1991.tb02002.x; BRADFORD HF, 1978, J NEUROCHEM, V30, P1453, DOI 10.1111/j.1471-4159.1978.tb10477.x; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CAVELLI A, 1991, EMBO J, V10, P1671; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P10507, DOI 10.1093/nar/15.24.10507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN D, 1990, BRAIN RES, V509, P1, DOI 10.1016/0006-8993(90)90301-Q; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1991, EMBO J, V10, P1275; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON PA, 1989, J BIOL CHEM, V264, P1258; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; JOHNSTON PA, 1990, J BIOL CHEM, V264, P7849; KNAUS P, 1990, FEBS LETT, V261, P358, DOI 10.1016/0014-5793(90)80591-6; KUSHNER L, 1989, METHODS NEUROSCIENCE, V1, P3; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MCMAHON HT, 1990, J NEUROCHEM, V54, P373, DOI 10.1111/j.1471-4159.1990.tb01883.x; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SHUTTLEWORTH J, 1988, GENE, V72, P267, DOI 10.1016/0378-1119(88)90152-7; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SZERB JC, 1985, J NEUROCHEM, V44, P1724, DOI 10.1111/j.1471-4159.1985.tb07160.x; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; VALTORTA F, 1988, J CELL BIOL, V107, P2717, DOI 10.1083/jcb.107.6.2717; VALTORTA F, UNPUB; WARD HK, 1983, J NEUROCHEM, V40, P855, DOI 10.1111/j.1471-4159.1983.tb08058.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YOUNG AB, 1974, BRAIN RES, V73, P1, DOI 10.1016/0006-8993(74)91002-6; 1990, PROMEGA PROTOCOLS AP, P116	42	123	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					657	661		10.1126/science.1353905	http://dx.doi.org/10.1126/science.1353905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1353905				2022-12-28	WOS:A1992JF85200033
J	GOLDFARB, DS				GOLDFARB, DS			ARE THE CYTOSOLIC COMPONENTS OF THE NUCLEAR, ER, AND MITOCHONDRIAL IMPORT APPARATUS FUNCTIONALLY RELATED	CELL			English	Review							PROTEIN IMPORT; BINDING; TRANSLOCATION; PORE; IDENTIFICATION; TRANSPORT; ENVELOPE; STEPS				GOLDFARB, DS (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FORBES DJ, 1992, IN PRESS ANN REV CEL, V8; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MEIER UT, 1992, CELL, V70, P127; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473	24	37	37	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					185	188		10.1016/0092-8674(92)90094-S	http://dx.doi.org/10.1016/0092-8674(92)90094-S			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1353417				2022-12-28	WOS:A1992JE75700003
J	WARKENTIN, TE; MOORE, JC; MORGAN, DG				WARKENTIN, TE; MOORE, JC; MORGAN, DG			AORTIC-STENOSIS AND BLEEDING GASTROINTESTINAL ANGIODYSPLASIA - IS ACQUIRED VONWILLEBRANDS DISEASE THE LINK	LANCET			English	Article							INDUCED PLATELET-AGGREGATION; VASCULAR ECTASIAS; PLASMA; MULTIMERS; DEFECTS	An association between aortic stenosis and haemorrhage from gastrointestinal angiodysplasia has been recognised for many years, but no explanation for this link has been found. Remarkably, aortic valve replacement, rather than bowel resection, corrects the bleeding. Aortic stenosis can be complicated by acquired von Willebrand's disease type II(A) (vWD-II(A)), which is corrected after valve replacement, and gastrointestinal angiodysplasia is a common site of bleeding in older patients with acquired or congenital vWD. Could the stenotic aortic valve lead to an acquired, reversible deficiency of the largest multimers of plasma von Willebrand factor (equivalent to vWD-II(A)) and thus explain the association with gastrointestinal haemorrhage?	HAMILTON CIVIC HOSP, HENDERSON DIV, DEPT MED, HAMILTON, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University	WARKENTIN, TE (corresponding author), HAMILTON CIVIC HOSP, DIV GEN, DEPT LAB MED, 237 BARTON ST E, HAMILTON L8L 2X2, ONTARIO, CANADA.							ALAM M, 1991, AM HEART J, V121, P608, DOI 10.1016/0002-8703(91)90739-5; BANERJEE AK, 1990, BRIT J CLIN PRACT, V44, P326; BOLEY SJ, 1977, GASTROENTEROLOGY, V72, P650; CAPPELL MS, 1986, ANN INTERN MED, V105, P54, DOI 10.7326/0003-4819-105-1-54; GILL JC, 1986, BLOOD, V67, P758; GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415; GRALNICK HR, 1988, AM J MED, V85, P806; GREENSTEIN RJ, 1986, AM J SURG, V151, P347, DOI 10.1016/0002-9610(86)90465-4; HEYDE EC, 1958, NEW ENGL J MED, V259, P196; KING RM, 1987, ANN THORAC SURG, V44, P514, DOI 10.1016/S0003-4975(10)62112-1; MARCUARD SP, 1988, J CLIN GASTROENTEROL, V10, P482, DOI 10.1097/00004836-198810000-00003; MATHUSVLIEGEN EMH, 1989, INT J COLORECTAL DIS, V4, P20, DOI 10.1007/BF01648545; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; OBRIEN JR, 1990, LANCET, V335, P711, DOI 10.1016/0140-6736(90)90815-M; RAMSAY DM, 1976, LANCET, V2, P275; ROSBOROUGH TK, 1978, AM J MED, V65, P96, DOI 10.1016/0002-9343(78)90698-8; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; STEWART AK, 1990, POSTGRAD MED J, V66, P560, DOI 10.1136/pgmj.66.777.560; WEINSTEIN M, 1988, BLOOD, V71, P1648, DOI 10.1182/blood.V71.6.1648.1648; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WOODLOCK TJ, 1988, AM J HEMATOL, V27, P125, DOI 10.1002/ajh.2830270211	21	208	217	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1992	340	8810					35	37		10.1016/0140-6736(92)92434-H	http://dx.doi.org/10.1016/0140-6736(92)92434-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351610				2022-12-28	WOS:A1992JC35400014
J	SCHULTZ, JE; KLUMPP, S; BENZ, R; SCHURHOFFGOETERS, WJC; SCHMID, A				SCHULTZ, JE; KLUMPP, S; BENZ, R; SCHURHOFFGOETERS, WJC; SCHMID, A			REGULATION OF ADENYLYL CYCLASE FROM PARAMECIUM BY AN INTRINSIC POTASSIUM CONDUCTANCE	SCIENCE			English	Article							EXCITABLE CILIARY MEMBRANE; DEPENDENT CALCIUM CHANNELS; CYCLIC-AMP LEVELS; GUANYLATE-CYCLASE; TETRAURELIA INVIVO; IONIC REGULATION; PROTEINS; PURIFICATION; SEPARATION; MUTATION	Hyperpolarization of the cell membrane of Paramecium stimulates adenosine 3',5'monophosphate (cAMP) formation. Manipulations of the K+ resting conductance of the ciliate by adaptation in different buffers affected excitability of the cAMP generating system. Blockade of K+ channels inhibited hyperpolarization-stimulated cAMP formation. A mutant of Paramecium that is unable to control its K+ resting conductance had a defect in cAMP formation. Purified adenylyl cyclase, when incorporated into an artificial lipid bilayer membrane, revealed properties of a voltage-independent K+ channel. This indicates that the adenylyl cyclase of Paramecium has a secondary function as carrier of the K+ resting conductance. A hyperpolarization-activated K+ efflux appears to directly regulate adenylyl cyclase activity in vivo.	UNIV WURZBURG, INST BIOTECHNOL, W-8700 WURZBURG, GERMANY	University of Wurzburg	SCHULTZ, JE (corresponding author), UNIV TUBINGEN, INST PHARMAZEUT, MORGENSTELLE 8, W-7400 TUBINGEN 1, GERMANY.			Benz, Roland/0000-0002-9510-9265				BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BOHEIM G, 1982, TRANSPORT BIOMEMBRAN, P87; BONINI NM, 1986, CELL MOTIL CYTOSKEL, V6, P2256; DELAAGE MA, 1978, MOL BIOL PHARM CYCLI, P155; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EHRLICH BE, 1984, SCIENCE, V225, P427, DOI 10.1126/science.6330895; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HINRICHSEN RD, 1984, J PHYSIOL-LONDON, V351, P397, DOI 10.1113/jphysiol.1984.sp015252; KLUMPP S, 1984, FEBS LETT, V171, P95, DOI 10.1016/0014-5793(84)80466-4; KLUMPP S, UNPUB; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MACHEMER H, 1989, J PROTOZOOL, V36, P463, DOI 10.1111/j.1550-7408.1989.tb01082.x; Machemer H., 1988, P185; MACHEMERROHNISCH S, 1989, EUR J PROTISTOL, V25, P45, DOI 10.1016/S0932-4739(89)80077-X; MAJIMA T, 1980, BIOPHYS CHEM, V11, P101, DOI 10.1016/0301-4622(80)85012-5; Naitoh Y., 1982, P1; OKA T, 1986, J EXP BIOL, V126, P111; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; PRESTON RR, 1990, J MEMBRANE BIOL, V115, P61, DOI 10.1007/BF01869106; RICHARD EA, 1985, J NEUROGENET, V2, P239, DOI 10.3109/01677068509102321; SCHONEFELD U, 1986, J PROTOZOOL, V33, P222, DOI 10.1111/j.1550-7408.1986.tb05595.x; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SCHULTZ JE, 1984, FEBS LETT, V167, P113, DOI 10.1016/0014-5793(84)80843-1; SCHULTZ JE, 1991, METHOD ENZYMOL, V195, P466; SIAMI Y, 1990, J MEMBRANE BIOL, V112, P79; SIAMI Y, 1987, ANNU REV GENET, V21, P47; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sonneborn T. M., 1970, Methods Cell Physiol., V4, P241, DOI 10.1016/S0091-679X(08)61758-6; THIELE J, 1982, EUR J CELL BIOL, V28, P3; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227	35	138	139	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1992	255	5044					600	603		10.1126/science.1371017	http://dx.doi.org/10.1126/science.1371017			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1371017				2022-12-28	WOS:A1992HB53100044
J	PARMENTIER, M; LIBERT, F; SCHURMANS, S; SCHIFFMANN, S; LEFORT, A; EGGERICKX, D; LEDENT, C; MOLLEREAU, C; GERARD, C; PERRET, J; GROOTEGOED, A; VASSART, G				PARMENTIER, M; LIBERT, F; SCHURMANS, S; SCHIFFMANN, S; LEFORT, A; EGGERICKX, D; LEDENT, C; MOLLEREAU, C; GERARD, C; PERRET, J; GROOTEGOED, A; VASSART, G			EXPRESSION OF MEMBERS OF THE PUTATIVE OLFACTORY RECEPTOR GENE FAMILY IN MAMMALIAN GERM-CELLS	NATURE			English	Article							CLONING	A SERIES of genomic and complementary DNA clones encoding new putative members of G protein-coupled receptors were isolated using homology cloning and low-stringency polymerase chain reaction 1,2. Among the unidentified receptors ('orphan receptors'), a human genomic clone (HGMP07) was characterized by the presence of its transcripts in the testis and by its belonging to a large subfamily of genes sharing extensive sequence similarities. Sequence comparison demonstrated that this gene subfamily is the human counterpart of the putative rat olfactory receptors cloned recently 3. Another 48 members of the family were cloned. Northern blotting further demonstrated the presence of olfactory receptor transcripts in germ cells. Our finding suggests that a common receptor gene family encodes olfactory receptors and sperm cell receptors that could be involved in chemotaxis during fertilization.	UNIV LIBRE BRUXELLES,SERV GENET,B-1070 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,RECH NEUROPEPTIDES LAB,B-1070 BRUSSELS,BELGIUM; CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,F-31077 TOULOUSE,FRANCE; ERASMUS UNIV ROTTERDAM,FAC MED,DEPT ENDOCRINOL & REPROD,3000 DR ROTTERDAM,NETHERLANDS	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Centre National de la Recherche Scientifique (CNRS); Erasmus University Rotterdam	PARMENTIER, M (corresponding author), UNIV LIBRE BRUXELLES,INST RECH INTERDISCIPLINAIRE BIOL HUMAINE & NUCL,CAMPUS ERASME,B-1070 BRUSSELS,BELGIUM.			Mollereau, Catherine/0000-0003-1543-5624; Parmentier, Marc/0000-0001-8081-4685; Schiffmann, Serge/0000-0002-0118-9816				BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Libert F, 1991, CURR OPIN CELL BIOL, V3, P218, DOI 10.1016/0955-0674(91)90142-L; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; RAIT D, 1991, P NATL ACAD SCI USA, V88, P2840; Sambrook J., 1989, MOL CLONING; THEMMEN APN, 1991, MOL CELL ENDOCRINOL, V78, pR7, DOI 10.1016/0303-7207(91)90130-K; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VILLANUEVADIAZ C, 1990, FERTIL STERIL, V54, P1180	12	338	376	4	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					453	455		10.1038/355453a0	http://dx.doi.org/10.1038/355453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1370859				2022-12-28	WOS:A1992HB53000071
J	GREENWALD, I; RUBIN, GM				GREENWALD, I; RUBIN, GM			MAKING A DIFFERENCE - THE ROLE OF CELL-CELL INTERACTIONS IN ESTABLISHING SEPARATE IDENTITIES FOR EQUIVALENT CELLS	CELL			English	Review							EPIDERMAL GROWTH-FACTOR; DEVELOPING DROSOPHILA RETINA; ELEGANS VULVAR INDUCTION; CAENORHABDITIS-ELEGANS; C-ELEGANS; NOTCH LOCUS; SEVENLESS PROTEIN; TYROSINE KINASE; LATERAL INHIBITION; HOMOLOGOUS GENES		HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	GREENWALD, I (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Rubin, Gerald/0000-0001-8762-8703				AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERGUSON EL, 1985, GENETICS, V110, P17; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, CELL, V63, P1113, DOI 10.1016/0092-8674(90)90403-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, IN PRESS GENES DEV; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; HEDGECOCK EM, 1990, NEURON, V2, P61; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LAWRENCE PA, 1966, J CELL SCI, V1, P475; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VAESSIN H, 1987, EMBO J, V6, P3433; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	95	404	417	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					271	281		10.1016/0092-8674(92)90470-W	http://dx.doi.org/10.1016/0092-8674(92)90470-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1365402				2022-12-28	WOS:A1992HB35300008
J	TOBIAS, JS				TOBIAS, JS			CLINICAL-PRACTICE OF RADIOTHERAPY	LANCET			English	Article							CELL LUNG-CANCER; RANDOMIZED TRIAL; RADIATION; THERAPY; CARCINOMA; TUMORS; SCHEDULES; HEAD				TOBIAS, JS (corresponding author), UNIV COLL HOSP LONDON,DEPT RADIOTHERAPY & ONCOL,GOWER ST,LONDON WC1E 6AU,ENGLAND.							ARRIAGADA R, 1985, INT J RADIAT ONCOL, V11, P1461, DOI 10.1016/0360-3016(85)90333-5; BLOOM HJG, 1982, BRIT J UROL, V54, P136, DOI 10.1111/j.1464-410X.1982.tb13537.x; BLOOM HJG, 1986, CANCER CHILDREN CLIN, P197; BUXTON EJ, 1990, CANCER CHEMOTHER PHA, V26, P59; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DUNCAN W, 1987, INT J RADIAT ONCOL, V13, P171, DOI 10.1016/0360-3016(87)90124-6; ERRINGTON RD, 1991, BRIT MED J, V302, P1045, DOI 10.1136/bmj.302.6784.1045; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GUPTA NK, 1987, CLIN RADIOL, V38, P575, DOI 10.1016/S0009-9260(87)80327-6; Hellman S., 1989, CANCER PRINCIPLES PR, P247; HETZEL MR, 1985, THORAX, V40, P341, DOI 10.1136/thx.40.5.341; HORIOT JC, 1990, EUR J CANCER, V26, P779, DOI 10.1016/0277-5379(90)90150-R; HORWICH A, 1990, RADIOTHER ONCOL, V19, P353, DOI 10.1016/0167-8140(90)90036-V; KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LIVESEY EA, 1990, BRIT J CANCER, V61, P622, DOI 10.1038/bjc.1990.138; PEREZ CA, 1986, GYNECOL ONCOL, V23, P127, DOI 10.1016/0090-8258(86)90216-7; PETERMAN SB, 1985, NEURORADIOLOGY, V27, P202, DOI 10.1007/BF00344488; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; ROWELL NP, 1991, BLOOD REV, V5, P84, DOI 10.1016/0268-960X(91)90039-F; SAUNDERS MI, 1989, INT J RADIAT ONCOL, V17, P1287, DOI 10.1016/0360-3016(89)90538-5; Sheline G E, 1986, Clin Neurosurg, V33, P563; SUIT HD, 1985, CANCER-AM CANCER SOC, V55, P2659, DOI 10.1002/1097-0142(19850601)55:11<2659::AID-CNCR2820551122>3.0.CO;2-Q; TAIT DM, 1990, EUR J CANCER, V26, P750, DOI 10.1016/0277-5379(90)90135-G; TANNOCK IF, 1989, RADIOTHER ONCOL, V16, P81; Tobias J, 1990, NEUROONCOLOGY PRIMAR, P164; TOBIAS JS, 1991, EUR J CANCER, V27, P1350, DOI 10.1016/0277-5379(91)90007-Z; WILLIAMS SF, 1990, SEMIN ONCOL, V17, P88; 1991, REPORT MEDICAL MANPO; IN PRESS BR J CANCER	31	21	23	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					159	163		10.1016/0140-6736(92)90219-S	http://dx.doi.org/10.1016/0140-6736(92)90219-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1370338				2022-12-28	WOS:A1992GZ96800012
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			TRAPPED BY AN INCIDENTAL FINDING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NEW ENGLAND MED CTR HOSP,BOSTON,MA 02111	Tufts Medical Center	PAUKER, SG (corresponding author), TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111, USA.							COPELAND PM, 1983, ANN INTERN MED, V98, P940, DOI 10.7326/0003-4819-98-6-940; EISENBERG JM, 1983, MED DECIS MAKING, V3, P155, DOI 10.1177/0272989X8300300203; Griner P F, 1981, Ann Intern Med, V94, P557; HAGEN MD, 1989, HOSP PRACT, V24, P25; HAMER MM, 1987, RADIOLOGY, V164, P263, DOI 10.1148/radiology.164.1.3588916; HORTON R, 1991, TXB INTERNAL MED, P2369; KASSIRER JP, 1988, HOSP PRACT, V23, P21; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MOLITCH ME, 1990, ANN INTERN MED, V112, P925, DOI 10.7326/0003-4819-112-12-925; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PEREZ CA, 1989, CANCER PRINCIPLES PR, P1023; ROSEN PJ, 1991, TXB INTERNAL MED, P1147; SCHABERG DA, 1991, TXB INTERNAL MED, P800; SPRATT JS, 1990, CANCER, V66, P1351, DOI 10.1002/1097-0142(19900915)66:14+<1351::AID-CNCR2820661410>3.0.CO;2-E	16	15	17	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					40	43		10.1056/NEJM199201023260107	http://dx.doi.org/10.1056/NEJM199201023260107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1370063				2022-12-28	WOS:A1992GX31500007
J	GRANT, SGN; ODELL, TJ; KARL, KA; STEIN, PL; SORIANO, P; KANDEL, ER				GRANT, SGN; ODELL, TJ; KARL, KA; STEIN, PL; SORIANO, P; KANDEL, ER			IMPAIRED LONG-TERM POTENTIATION, SPATIAL-LEARNING, AND HIPPOCAMPAL DEVELOPMENT IN FYN MUTANT MICE	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; ASPARTATE RECEPTOR ANTAGONIST; RAT-BRAIN; SYNAPTIC TRANSMISSION; NITRIC-OXIDE; C-SRC; SELECTIVE IMPAIRMENT; KINASE-ACTIVITY; PDGF RECEPTOR; GROWTH-FACTOR	Mice with mutations in four nonreceptor tyrosine kinase genes, fyn, src, yes, and abl, were used to study the role of these kinases in long-term potentiation (LTP) and in the relation of LTP to spatial learning and memory. All four kinases were expressed in the hippocampus. Mutations in src, yes, and abl did not interfere with either the induction or the maintenance of LTP. However, in fyn mutants, LTP was blunted even though synaptic transmission and two short-term forms of synaptic plasticity, paired-pulse facilitation and post-tetanic potentiation, were normal. In parallel with the blunting of LTP, fyn mutants showed impaired spatial learning, consistent with a functional link between LTP and learning. Although fyn is expressed at mature synapses, its lack of expression during development resulted in an increased number of granule cells in the dentate gyrus and of pyramidal cells in the CA3 region. Thus, a common tyrosine kinase pathway may regulate the growth of neurons in the developing hippocampus and the strength of synaptic plasticity in the mature hippocampus.	BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	GRANT, SGN (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Grant, Seth/0000-0001-8732-8735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702] Funding Source: Medline; NICHD NIH HHS [HD24875] Funding Source: Medline; NIMH NIH HHS [MH45923] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOSS BD, 1987, BRAIN RES, V406, P280, DOI 10.1016/0006-8993(87)90793-1; BROWN TH, 1991, LONG TERM POTENTIATI, P357; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CUDMORE SB, 1991, J NEUROCHEM, V57, P1240, DOI 10.1111/j.1471-4159.1991.tb08285.x; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; ESPINO PC, 1990, ONCOGENE, V5, P283; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GURD JW, 1982, J NEUROCHEM, V39, P1117, DOI 10.1111/j.1471-4159.1982.tb11504.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANNIG G, 1991, ONCOGENE, V6, P361; HARVEY J, 1992, NEUROSCI LETT, V139, P197, DOI 10.1016/0304-3940(92)90551-H; HEISENBERG M, 1989, PROGR ZOOLOGY, P3; HSI ED, 1989, J BIOL CHEM, V264, P10836; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNOVSKY MJ, 1969, HISTOCHEM CYTOCHEM, V112, P219; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPP HP, 1989, EXPERIENTIA, V45, P845, DOI 10.1007/BF01954059; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORRIS RGM, 1985, COLD SPRING HARB SYM, V50, P161; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, UNPUB; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SORIANO P, UNPUB; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; UPCHURCH M, 1989, BEHAV NEUROSCI, V103, P1251, DOI 10.1037/0735-7044.103.6.1251; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WOOLSEY TA, 1971, BRAIN RES, V26, P259; ZHAO YH, 1991, ONCOGENE, V6, P1725	69	950	973	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1903	1910		10.1126/science.1361685	http://dx.doi.org/10.1126/science.1361685			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1361685				2022-12-28	WOS:A1992KD08800022
J	DURANDZALESKI, I; BONNET, F; ROCHANT, H; BIERLING, P; LEMAIRE, F				DURANDZALESKI, I; BONNET, F; ROCHANT, H; BIERLING, P; LEMAIRE, F			USEFULNESS OF CONSENSUS CONFERENCES - THE CASE OF ALBUMIN	LANCET			English	Article							PRACTICE GUIDELINES; MEDICINE; TRIAL	The usefulness of consensus conferences has been questioned. We have assessed the impact of a 1989 consensus conference about the treatment of hypovolaemia on prescribing practice at our hospital. Data available from the blood bank enabled us to follow albumin use and costs by department between 1987 and 1991. Medical journals, direct mail, and meetings were used to disseminate the recommendations of the consensus conference, which were that the only indications for albumin are massive haemorrhage, plasmapheresis, massive hypoalbuminaemia, and volume expansion in pregnancy; for hypovolaemia caused by septic shock or vasoplegia, fluid gelatins and crystalloids should be used. In the year after the conference, and in subsequent years, albumin use and costs were 40% lower than before the conference, even though total medical expenditure continued to rise and numbers of patients admitted did not change. We believe that consensus conferences can be a useful means of improving medical practice. The features that ensured success in this programme were the small number of prescribers, the homogeneous setting, and the frequent restatement of the recommendations.	HOP HENRI MONDOR,SURG INTENS CARE UNIT,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,DEPT HAEMATOL,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,MED INTENS CARE UNIT,F-94010 CRETEIL,FRANCE; CDTS,VAL DE MARNE,CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	DURANDZALESKI, I (corresponding author), HOP HENRI MONDOR,DEPT PUBL HLTH,51 AVE MARECHAL DE LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							BLACKBURN GL, 1992, CRIT CARE MED, V20, P157; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CONSEILLER C, 1983, COMPENSATION PERTES, P49; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GROOTENDORST AF, 1988, INTENS CARE MED, V14, P554, DOI 10.1007/BF00263529; KANOUSE, 1989, CHANGING MED PRACTIS; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; PERRIER JF, 1989, ANN FR ANESTH, V8, P204, DOI 10.1016/S0750-7658(89)80105-4; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; Stocking B, 1992, Qual Health Care, V1, P56, DOI 10.1136/qshc.1.1.56; THOMAS J, 1991, JAMA-J AM MED ASSOC, V65, P2202; 1989, REAN SOINS INTENS ME, V5, P295; 1985, JAMA-J AM MED ASSOC, V253, P551	15	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1388	1390		10.1016/0140-6736(92)92568-Z	http://dx.doi.org/10.1016/0140-6736(92)92568-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360098				2022-12-28	WOS:A1992KB20200012
J	REARDON, W; ROSS, RJM; SWEENEY, MG; LUXON, LM; PEMBREY, ME; HARDING, AE; TREMBATH, RC				REARDON, W; ROSS, RJM; SWEENEY, MG; LUXON, LM; PEMBREY, ME; HARDING, AE; TREMBATH, RC			DIABETES-MELLITUS ASSOCIATED WITH A PATHOGENIC POINT MUTATION IN MITOCHONDRIAL-DNA	LANCET			English	Article							MYOPATHY; GENE; FEATURES; ACIDOSIS; DISEASE; MELAS	Family studies of diabetes mellitus (DM) show that patients are more likely to have affected mothers than affected fathers. Since the inheritance of mitochondrial (mtDNA), unlike nuclear DNA, is exclusively maternal, could it be that defect(s) in mtDNA account for some cases of DM? Such defects have been associated with rare neurological syndromes, in some of which DM has been an accompanying feature. We have looked for glucose intolerance and for a previously known point mutation of mtDNA in a family, some of whose members have a multisystem disorder with DM but not neurological involvement. DNA samples were obtained from fourteen family members. The point mutation (affecting position 3243 in the tRNA leucine mitochondrial gene) was found in all three diabetic patients and post mortem tissues in the proband; it was also found in seven offspring of female patients. It was not found in the two children of the male proband. The contribution of this mutation to DM in general is not known but clinicians ought to be aware of the possibility, especially in families with multisystem disease and maternal transmission.	ST BARTHOLOMEWS HOSP, DEPT ENDOCRINOL, LONDON EC1, ENGLAND; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON WC1, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROOTOL, LONDON WC1, ENGLAND	University of London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	REARDON, W (corresponding author), INST CHILD HLTH, MOTHERCARE UNIT CLIN GENET & FETAL MED, LONDON WC1N 1EH, ENGLAND.		Ross, Richard/B-2672-2012	Ross, Richard/0000-0001-9222-9678; Trembath, Richard/0000-0003-0550-3400				ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408; EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7; HAMMANS SR, 1991, BRIT J HOSP MED, V46, P20; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; PENROSE LS, 1945, P AM DIABETES ASSOC, V5, P163; PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915; POULTON J, 1989, LANCET, V1, P236; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VULIER C, 1991, NATURE, V354, P155; 1985, TECH REP SER WHO, V727	17	366	379	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1376	1379		10.1016/0140-6736(92)92560-3	http://dx.doi.org/10.1016/0140-6736(92)92560-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360090				2022-12-28	WOS:A1992KB20200004
J	MARTIN, BC; WARRAM, JH; KROLEWSKI, AS; BERGMAN, RN; SOELDNER, JS; KAHN, CR				MARTIN, BC; WARRAM, JH; KROLEWSKI, AS; BERGMAN, RN; SOELDNER, JS; KAHN, CR			ROLE OF GLUCOSE AND INSULIN RESISTANCE IN DEVELOPMENT OF TYPE-2 DIABETES-MELLITUS - RESULTS OF A 25-YEAR FOLLOW-UP-STUDY	LANCET			English	Article							BETA-CELL; FAT DISTRIBUTION; PIMA-INDIANS; SENSITIVITY; MUSCLE; NIDDM; TRANSPORTERS; TOLERANCE; INVIVO; RISK	Type 2 diabetes mellitus is characterised by resistance of peripheral tissues to insulin and a relative deficiency of insulin secretion. To find out which is the earliest or primary determinant of disease, we used a minimum model of glucose disposal and insulin secretion based on intravenous glucose tolerance tests to estimate insulin sensitivity (S(I)), glucose effectiveness (ie, insulin-independent glucose removal rate, S(G)), and first-phase and second-phase beta-cell responsiveness in normoglycaemic offspring of couples who both had type 2 diabetes. 155 subjects from 86 families were followed-up for 6-25 years. More than 10 years before the development of diabetes, subjects who developed the disease had lower values of both S(I) (mean 3.2 [SD 2.4] vs 8.1 [6.7] 10(-3) l min-1 pmol-1 insulin; p < 0.0001) and S(G) (1.6 [0.9] vs 2.3 [1.2] 10(-2) min-1, p < 0.0001) than did those who remained normoglycaemic). For the subjects with both S(I) and SG below the group median, the cumulative incidence of type 2 diabetes during the 25 years was 76% (95% confidence interval 54-99). By contrast, no subject with both S(I) and S(G) above the median developed the disease. Subjects with low S(I)/high S(G) or high S(I)/low S(G) had intermediate risks. Insulin secretion, especially first phase, tended to be increased rather than decreased in this prediabetic phase and was appropriate for the level of insulin resistance. The development of type 2 diabetes is preceded by and predicted by defects in both insulin-dependent and insulin- independent glucose uptake; the defects are detectable when the patients are normoglycaemic and in most cases more than a decade before diagnosis of disease.	HARVARD UNIV,SCH PUBL HLTH,JOSLIN DIABET CTR 1 JOSLIN PL,DEPT EPIDEMIOL,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV ZURICH,INST SOCIAL & PREVENT MED,CH-8006 ZURICH,SWITZERLAND; UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,LOS ANGELES,CA 90033	Harvard University; Harvard T.H. Chan School of Public Health; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Zurich; University of Southern California			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Bergman, Richard/0000-0003-1539-4471	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029867, R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33201, DK-36836, DK-29867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1985, J CLIN INVEST, V76, P1782, DOI 10.1172/JCI112169; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGMAN RN, 1989, DIABETES, V38, P1512, DOI 10.2337/diabetes.38.12.1512; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; BERGMAN RN, 1981, J CLIN INVEST, V68, P1456, DOI 10.1172/JCI110398; BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FREYMOND D, 1988, J CLIN INVEST, V82, P1503, DOI 10.1172/JCI113758; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HANSEN IL, 1985, DIABETES, V34, P751, DOI 10.2337/diabetes.34.8.751; Hoffman WS, 1937, J BIOL CHEM, V120, P51; JOHNSTON C, 1990, DIABETIC MED, V7, P119, DOI 10.1111/j.1464-5491.1990.tb01345.x; KADISH AH, 1968, CLIN CHEM, V14, P116; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LEE ET, 1980, STATISTICAL METHODS; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MENEILLY GS, 1989, J CLIN ENDOCR METAB, V63, P566; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; ROBERTSON RP, 1989, DIABETES, V38, P1501, DOI 10.2337/diabetes.38.12.1501; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P286; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; 1979, DIABETES, V28, P1039	31	951	975	1	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					925	929		10.1016/0140-6736(92)92814-V	http://dx.doi.org/10.1016/0140-6736(92)92814-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357346				2022-12-28	WOS:A1992JT82300001
J	TURNER, TJ; ADAMS, ME; DUNLAP, K				TURNER, TJ; ADAMS, ME; DUNLAP, K			CALCIUM CHANNELS COUPLED TO GLUTAMATE RELEASE IDENTIFIED BY OMEGA-AGA-IVA	SCIENCE			English	Article							CA2+ CHANNELS; CONOTOXIN GVIA; NERVE-ENDINGS; NEURONS; SYNAPTOSOMES; CURRENTS; BLOCKING; PEPTIDE	Presynaptic calcium channels are crucial elements of neuronal excitation-secretion coupling. In mammalian brain, they have been difficult to characterize because most presynaptic terminals are too small to probe with electrodes, and available pharmacological tools such as dihydropyridines and omega-conotoxin are largely ineffective. Subsecond measurements of synaptosomal glutamate release have now been used to assess presynaptic calcium channel activity in order to study the action of peptide toxins from the venom of the funnel web spider Agelenopsis aperta, which is known to inhibit dihydropyridine and omega-conotoxin-resistant neuronal calcium currents. A presynaptic calcium channel important in glutamate release is shown to be omega-Aga-IVA sensitive and omega-conotoxin resistant.	UNIV CALIF RIVERSIDE, DEPT ENTOMOL, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT NEUROSCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	TURNER, TJ (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA.		Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113; Turner, Timothy/0000-0001-9770-2647				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; HOFMANN F, 1990, N-S ARCH PHARMACOL, V341, P200; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LINDGREN CA, 1989, J PHYSIOL-LONDON, V414, P201, DOI 10.1113/jphysiol.1989.sp017684; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; Mintz I. M., 1992, Society for Neuroscience Abstracts, V18, P9; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; RIVIER J, 1987, J BIOL CHEM, V262, P1194; STANLEY EF, 1991, J NEUROSCI, V11, P985; SUSZKIW JB, 1989, J NEUROCHEM, V52, P1260, DOI 10.1111/j.1471-4159.1989.tb01874.x; TURNER T J, 1991, Society for Neuroscience Abstracts, V17, P577; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026; TURNER TJ, 1992, J CELL BIOCHEM, V16, P225; TURNER TJ, UNPUB; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; VENEMA VJ, 1992, J BIOL CHEM, V267, P2610	28	289	291	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					310	313		10.1126/science.1357749	http://dx.doi.org/10.1126/science.1357749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357749				2022-12-28	WOS:A1992JR86000038
J	CHESSELLS, JM; BAILEY, C; WHEELER, K; RICHARDS, SM				CHESSELLS, JM; BAILEY, C; WHEELER, K; RICHARDS, SM			BONE-MARROW TRANSPLANTATION FOR HIGH-RISK CHILDHOOD LYMPHOBLASTIC-LEUKEMIA IN 1ST REMISSION - EXPERIENCE IN MRC UKALL-X	LANCET			English	Article							LEUKEMIA; CHILDREN; ADULTS; GROWTH	Bone marrow transplantation (BMT) has been recommended for children with high-risk acute lymphoblastic leukaemia (ALL) in first remission. The recent MRC UKALL X trial was designed to facilitate a non-randomised comparison between BMT and chemotherapy in children deemed to be at high risk of treatment failure. 198 children aged 1-15 had a presenting leucocyte count of more than 100 x 10(9)/l. All received induction and early intensification therapy. Children with an HLA-compatible sibling donor were eligible for BMT in first remission. All other children received cranial irradiation at 24Gy, late intensification, and two years of continuous treatment. 183 children achieved a stable remission of whom 111 were HLA typed; these tended to be older and to have T-cell ALL. A donor was identified in 41 cases, of whom 34 proceeded to BMT at a median time of 17 weeks; there was no difference in distribution of age, sex, or leucocyte count between the groups receiving BMT and chemotherapy. Comparison of the 144 children who were in remission at 17 weeks and received chemotherapy with the 34 proceeding to BMT showed no significant difference in event-free survival at five years (69% for BMT and 52% for chemotherapy). There were significantly more treatment-related deaths in the marrow transplant group (6 vs 4) and more relapses in the chemotherapy group (59 vs 4). There was no significant difference in event-free survival between children who were HLA typed and had a donor and those without a donor, although there were fewer relapses among the former. BMT can be evaluated in the context of a multicentre trial for paediatric ALL but the number of children with donors is too small to make a significant impact on overall survival. However, marrow transplantation was associated with a much lower relapse rate than that with the UK ALL protocol, and with better definition of higher risk patients BMT may be of benefit in some children with high-risk ALL in first remission.	SEACROFT HOSP,REG PAEDIAT ONCOL UNIT,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND; RADCLIFFE INFIRM,CLIN TRIALS SERV UNIT,OXFORD OX2 6HE,ENGLAND; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; University College London	CHESSELLS, JM (corresponding author), HOSP SICK CHILDREN,DEPT HAEMATOL & ONCOL,LONDON WC1N 1EH,ENGLAND.							BLOOMFIELD CD, 1986, BLOOD, V67, P415; BORDIGONI P, 1989, J CLIN ONCOL, V7, P747, DOI 10.1200/JCO.1989.7.6.747; CHESSELLS JM, 1986, LANCET, V1, P1239; CHESSELLS JM, 1986, CLIN HAEMATOL, V15, P727; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; LEIPER AD, 1986, ARCH DIS CHILD, V61, P1007, DOI 10.1136/adc.61.10.1007; LEIPER AD, 1987, BRIT J HAEMATOL, V67, P419, DOI 10.1111/j.1365-2141.1987.tb06163.x; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; MCCARTHY DM, 1988, BONE MARROW TRANSPL, V3, P315; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SANDERS JE, 1986, BLOOD, V68, P1129	12	55	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					565	568		10.1016/0140-6736(92)92103-M	http://dx.doi.org/10.1016/0140-6736(92)92103-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355153				2022-12-28	WOS:A1992JM33400002
J	SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K				SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K			MODULATION OF MULTIDRUG-RESISTANT MULTIPLE-MYELOMA BY CYCLOSPORINE	LANCET			English	Article							ACUTE MYELOCYTIC-LEUKEMIA; PLASMA-CELL MYELOMA; P-GLYCOPROTEIN; DRUG-RESISTANCE; MDR1 GENE; ACCUMULATION; EXPRESSION; CANCER; ANTHRACYCLINES; DOXORUBICIN	Resistance to chemotherapy in refractory multiple myeloma is frequently associated with expression of multidrug resistance (MDR). In resistant cells, intracellular accumulation of doxorubicin and vincristine does not occur because the MDR-1 gene product, a membrane glycoprotein (PgP), is an energy-dependent efflux pump. Cyclosporin is one of several non-cytotoxic drugs that can block the function of PgP. In a prospective study, we assessed the possibility that cyclosporin could be used clinically to modulate MDR. We studied 21 patients with multiple myeloma; disease had progressed during primary chemotherapy in 6 and was resistant to VAD (vincristine, doxorubicin, dexamethasone) in 15, The patients received cyclosporin by continuous infusion during VAD treatment; there were three cyclosporin dosage groups (5, 7.5, 10 mg/kg daily). Serum cyclosporin concentrations adequate for MDR modulation were reached in all patients receiving 7.5 or 10 mg/kg daily. 47% (7) of the VAD-refractory patients and 48% (10) of the whole group responded to VAD. Before treatment, MDR-1 expression was present in 12 patients. After VAD plus cyclosporin, no MDR-1-positive plasma cells were present in 6 of 8 patients tested. The response rate in MDR-1-positive patients was 58% compared with 33% in all our patients. Toxic effects were mild and reversible and did not include nephrotoxic or serious cardiovascular side-effects. 12 months after the start of treatment, survival was 85%, and disease-free survival at a median of 9 months after the response was 65%. Thus, in multiple myeloma clinical resistance to VAD can be circumvented by cyclosporin, which enables the cytotoxic drugs to eliminate resistant myeloma cells.	EUROPEAN ORG RES TREATMENT CANC,CTR DATA,DEPT HAEMATOL,BRUSSELS,BELGIUM; WESTMINSTER & CHARING CROSS MED SCH,DEPT HAEMATOL,LONDON,ENGLAND; INST APPL IMMUNOL & RADIOBIOL,DEPT HAEMATOL,RIJSWIJK,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HAEMATOL,3511 GV UTRECHT,NETHERLANDS; HOP HOTEL DIEU,DEPT HAEMATOL,F-75181 PARIS 04,FRANCE	European Organisation for Research & Treatment of Cancer; Imperial College London; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	SONNEVELD, P (corresponding author), ERASMUS UNIV,HOSP DIJKZIGT,DEPT HAEMATOL,ROOM L407,DR MOLEWARTERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1985, ARCH INTERN MED, V145, P2073, DOI 10.1001/archinte.145.11.2073; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BELCH A, 1988, BRIT J CANCER, V57, P94, DOI 10.1038/bjc.1988.17; BUZAID AC, 1988, J CLIN ONCOL, V6, P889, DOI 10.1200/JCO.1988.6.5.889; DALTON WS, 1989, BLOOD, V73, P747; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; EPSTEIN J, 1989, BLOOD, V74, P913; GORE ME, 1989, LANCET, V2, P879; GOSLAND MP, 1991, P AM ASSOC CANC RES, P82; GROGAN T, 1990, LAB INVEST, V63, P815; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; KYLE RA, 1986, PROG HEMATOL, V14, P257; NOOTER K, 1990, INT J CANCER, V45, P263, DOI 10.1002/ijc.2910450210; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; SALMON SE, 1991, BLOOD, V78, P44; SALMON SE, 1989, J NATL CANCER I, V81, P696, DOI 10.1093/jnci/81.9.696; SONNEVELD P, 1990, BRIT J HAEMATOL, V75, P208, DOI 10.1111/j.1365-2141.1990.tb02650.x; SPETH PAJ, 1986, J CHROMATOGR, V377, P415, DOI 10.1016/S0378-4347(00)80803-8; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANKALKEN CK, 1991, EUR J CANCER, V27, P739, DOI 10.1016/0277-5379(91)90178-G	23	369	378	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					255	259		10.1016/0140-6736(92)92353-H	http://dx.doi.org/10.1016/0140-6736(92)92353-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353189				2022-12-28	WOS:A1992JG66500001
J	LIPSCHIK, GY; GILL, VJ; LUNDGREN, JD; ANDRAWIS, VA; NELSON, NA; NIELSEN, JO; OGNIBENE, FP; KOVACS, JA				LIPSCHIK, GY; GILL, VJ; LUNDGREN, JD; ANDRAWIS, VA; NELSON, NA; NIELSEN, JO; OGNIBENE, FP; KOVACS, JA			IMPROVED DIAGNOSIS OF PNEUMOCYSTIS-CARINII INFECTION BY POLYMERASE CHAIN-REACTION ON INDUCED SPUTUM AND BLOOD	LANCET			English	Article							AEROSOLIZED PENTAMIDINE; BRONCHOALVEOLAR LAVAGE; MONOCLONAL-ANTIBODIES; PNEUMONIA; DNA; STAIN	Detection of Pneumocystis carinii by the polymerase chain reaction (PCR) may facilitate non-invasive diagnosis of P carinii pneumonia and study of its epidemiology. We have compared the sensitivity and specificity of two PCR methods with those of conventional staining for detection of P carinii in induced sputum, bronchoalveolar lavage fluid (BAL), and blood. Of 71 sputum samples, 17 were from patients with microbiologically confirmed P carinii pneumonia. A nested PCR method correctly identified the presence of P carinii in all 17 (100% sensitive, 95% confidence interval [CI] 81-100%) and found no organisms in 50 of 54 microbiologically negative samples (93% specific, 95% CI 82-98%). PCR with a single primer pair was 71 % sensitive (44-90%) and 94% specific (85-99%). The sensitivity of conventional staining methods (direct and indirect fluorescence antibody and toluidine-blue-O tests) was significantly less (38-53%) than that of nested PCR (p<0.05). In BAL, neither PCR method was significantly better than the conventional staining methods. P carinii was detected in BAL or sputum from 10 immunocompromised patients without microbiological evidence of P carinii pneumonia, which suggests that symptom-free carriers or subclinical infection can exist. P carinii was detected by nested PCR in blood from 2 of 3 patients with disseminated pneumocystosis but in only 1 of 11 patients with P carinii infection restricted to the lungs. Nested PCR on induced sputum is more sensitive than conventional staining methods for the diagnosis of P carinii pneumonia and provides a non-invasive method of detecting disseminated disease.	NIH,WARREN G MAGNUSON CLIN CTR,MICROBIOL LAB,BETHESDA,MD 20892; UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT INFECT DIS,DK-2650 HVIDOVRE,DENMARK	National Institutes of Health (NIH) - USA; University of Copenhagen	LIPSCHIK, GY (corresponding author), NIH,DEPT CRIT CARE MED,WARREN G MAGNUSON CLIN CTR,BLDG 10,ROOM 7D43,BETHESDA,MD 20892, USA.		Kovacs, Joseph/AAU-6105-2021; Lundgren, Jens/AAE-6876-2019	Kovacs, Joseph/0000-0002-5191-9880; Lundgren, Jens/0000-0001-8901-7850				ARMITAGE P, 1971, STATISTICAL METHODS, P126; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; ESTERLY JA, 1968, AM REV RESPIR DIS, V97, P935; GILL VJ, 1987, J CLIN MICROBIOL, V25, P1837, DOI 10.1128/JCM.25.10.1837-1840.1987; GOSEY LL, 1985, J CLIN MICROBIOL, V22, P803, DOI 10.1128/JCM.22.5.803-807.1985; GRYZAN S, 1988, AM REV RESPIR DIS, V137, P1268, DOI 10.1164/ajrccm/137.6.1268; HARDY WD, 1989, AM J MED, V87, P329, DOI 10.1016/S0002-9343(89)80159-7; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEVINE SJ, 1991, AM REV RESPIR DIS, V144, P760, DOI 10.1164/ajrccm/144.4.760; MEUISSEN JH, 1977, J INFECT DIS, V136, P43; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OBRIEN RF, 1989, CHEST, V95, P136, DOI 10.1378/chest.95.1.136; OGNIBENE FP, 1984, AM REV RESPIR DIS, V129, P929; RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SPARLING TG, 1989, ANN INTERN MED, V111, P442, DOI 10.7326/0003-4819-111-5-442; WAKEFIELD AE, 1991, LANCET, V337, P1378, DOI 10.1016/0140-6736(91)93062-E; WAKEFIELD AE, 1990, LANCET, V336, P451, DOI 10.1016/0140-6736(90)92008-6; WOODWARD SC, 1961, B JOHNS HOPKINS HOSP, V109, P148; ZAMAN MK, 1988, ANN INTERN MED, V109, P7, DOI 10.7326/0003-4819-109-1-7	23	156	167	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					203	206		10.1016/0140-6736(92)90469-J	http://dx.doi.org/10.1016/0140-6736(92)90469-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353136				2022-12-28	WOS:A1992JE75800004
J	TAYLORROBINSON, D; GILROY, CB; THOMAS, BJ; KEAT, ACS				TAYLORROBINSON, D; GILROY, CB; THOMAS, BJ; KEAT, ACS			DETECTION OF CHLAMYDIA-TRACHOMATIS DNA IN JOINTS OF REACTIVE ARTHRITIS PATIENTS BY POLYMERASE CHAIN-REACTION	LANCET			English	Note								In 1986, Chlamydia trachomatis elementary bodies were found by direct immunofluorescence (DIF) in synovial-fluid cell deposits and synovial-membrane biopsy samples from five of eight patients with sexually acquired reactive arthritis (SARA) but in none of eight controls with other types of arthritis. Cells from the original slides (stored at 4-degrees-C) have now been examined by a polymerase chain reaction (PCR) that amplifies DNA for the major outer membrane protein of C trachomatis. Chlamydial DNA was found in samples from four DIF-positive patients, one DIF-negative patient, and one DIF-negative control. Overall, there was 80% concordance for DIF and PCR results. This study supports our previous finding of chlamydiae in joints in reactive arthritis.	ST MARYS HOSP,LONDON,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT RHEUMATOL,LONDON SW1P 2AP,ENGLAND	Imperial College London; Imperial College London	TAYLORROBINSON, D (corresponding author), CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							GILROY CB, 1992, J CLIN PATHOL, V45, P531, DOI 10.1136/jcp.45.6.531; HAMMER M, 1992, CLIN EXP RHEUMATOL, V10, P63; KEAT A, 1987, LANCET, V1, P72; KEAT AC, 1978, BRIT MED J, V1, P605, DOI 10.1136/bmj.1.6113.605; PALMER HM, 1991, J CLIN PATHOL, V44, P321, DOI 10.1136/jcp.44.4.321; RAHMAN M U, 1990, Arthritis and Rheumatism, V33, pS25; SCHUMACHER HR, 1988, ARTHRITIS RHEUM, V31, P937; TAYLORROBINSON D, 1988, ANN RHEUM DIS, V47, P295, DOI 10.1136/ard.47.4.295; WONG M L, 1986, Proceedings of the University of Otago Medical School, V64, P77; WORDSWORTH BP, 1990, BRIT J RHEUMATOL, V29, P208	10	202	205	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					81	82		10.1016/0140-6736(92)90399-N	http://dx.doi.org/10.1016/0140-6736(92)90399-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352016				2022-12-28	WOS:A1992JC58200006
J	EUVRARD, S; VERSCHOORE, M; TOURAINE, JL; DUREAU, G; COCHAT, P; CZERNIELEWSKI, J; THIVOLET, J				EUVRARD, S; VERSCHOORE, M; TOURAINE, JL; DUREAU, G; COCHAT, P; CZERNIELEWSKI, J; THIVOLET, J			TOPICAL RETINOIDS FOR WARTS AND KERATOSES IN TRANSPLANT RECIPIENTS	LANCET			English	Letter							SKIN-CANCER		CIRD GALDERMA,SOPHIA ANTIPOLIS,FRANCE; HOP CARDIOVASC,LYONS,FRANCE; HOP EDOUARD HERRIOT,PAEDIAT NEPHROL UNIT,F-69374 LYONS 08,FRANCE; HOP EDOUARD HERRIOT,TRANSPLANT UNIT,F-69374 LYONS 08,FRANCE	Galderma R&D SNC; CHU Lyon; CHU Lyon; CHU Lyon	EUVRARD, S (corresponding author), HOP EDOUARD HERRIOT,DERMATOL CLIN,F-69437 LYONS,FRANCE.							BARR BBB, 1989, LANCET, V1, P124; HALLIDAY GM, 1989, IMMUNOLOGY, V67, P298; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; KELLY JW, 1991, LANCET, V338, P1407, DOI 10.1016/0140-6736(91)92292-A; SHUTTLEWORTH D, 1988, Q J MED, V68, P717	5	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					48	49		10.1016/0140-6736(92)92459-S	http://dx.doi.org/10.1016/0140-6736(92)92459-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351617				2022-12-28	WOS:A1992JC35400027
J	SORRENTINO, BP; BRANDT, SJ; BODINE, D; GOTTESMAN, M; PASTAN, I; CLINE, A; NIENHUIS, AW				SORRENTINO, BP; BRANDT, SJ; BODINE, D; GOTTESMAN, M; PASTAN, I; CLINE, A; NIENHUIS, AW			SELECTION OF DRUG-RESISTANT BONE-MARROW CELLS INVIVO AFTER RETROVIRAL TRANSFER OF HUMAN MDR1	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; GENE-TRANSFER; MULTIDRUG RESISTANCE; EXPRESSION; RECIPIENTS; LINE	Experiments were performed to determine if retroviral-mediated transfer of the human multidrug resistance 1 gene (MDR1) into murine bone marrow cells would confer drug resistance to the cells and whether the MDR1 gene could be used as a dominant selectable marker in vivo. When mice transplanted with bone marrow cells containing a transferred MDR1 gene were treated with the cytotoxic drug taxol, a substantial enrichment for transduced bone marrow cells was observed. This demonstration of positive selection establishes the ability to amplify clones of transduced hematopoietic cells in vivo and suggests possible applications in human therapy.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; NCI,DIV CANC BIOL & DIAG,CELL BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SORRENTINO, BP (corresponding author), NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; COREY CA, 1990, BLOOD, V75, P337; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLETCHER FA, 1991, J EXP MED, V174, P837, DOI 10.1084/jem.174.4.837; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCLACHLIN JR, 1990, J NATL CANCER I, V82, P1260, DOI 10.1093/jnci/82.15.1260; MICKISCH GH, 1991, CANCER RES, V51, P5417; MICKISCH GH, 1992, BLOOD, V79, P1087; MICKISCH GH, 1991, P NATL ACAD SCI USA, V88, P547, DOI 10.1073/pnas.88.2.547; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247	17	477	501	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					99	103		10.1126/science.1352414	http://dx.doi.org/10.1126/science.1352414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1352414				2022-12-28	WOS:A1992JC16500040
J	MILDVAN, D; MACHADO, SG; WILETS, I; GROSSBERG, SE				MILDVAN, D; MACHADO, SG; WILETS, I; GROSSBERG, SE			ENDOGENOUS INTERFERON AND TRIGLYCERIDE CONCENTRATIONS TO ASSESS RESPONSE TO ZIDOVUDINE IN AIDS AND ADVANCED AIDS-RELATED COMPLEX	LANCET			English	Article							TUMOR NECROSIS FACTOR; GAMMA	To improve evaluation of new antiretroviral drugs in the acquired immunodeficiency syndrome (AIDS), sensitive biological markers that accurately predict response to treatment are needed. Two possible markers are endogenous interferon (E-IFN), which is a cytokine involved in the pathophysiology of AIDS, and serum triglycerides (TG), which are raised, in patients with AIDS, possibly reflecting enhanced cytokine activity. E-IFN, TG, body-mass index, CD4 count, and HIV p24 were measured in 19 patients (15 with AIDS, 4 with AIDS-related complex), who were part of the phase II licensing trial of zidovudine (ZDV). 10 received ZDV and 9 received placebo. Rapid, significant, and sustained declines from initial values in E-IFN and TG concentrations were observed in ZDV patients but not in placebo patients. Baseline values of E-IFN and TG concentrations after 4 months on ZDV treatment were both important contributors to long-term survival. The findings suggest that these indicators of abnormal cytokine expression may be useful measures of not only disease severity but also efficacy of antiretroviral therapy in AIDS.	BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,NEW YORK,NY 10003; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; NIAID,DIV AIDS,BIOSTAT RES BRANCH,BETHESDA,MD 20892; MED COLL WISCONSIN,DEPT MICROBIOL,MILWAUKEE,WI 53226	Harvard University; Beth Israel Deaconess Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Medical College of Wisconsin	MILDVAN, D (corresponding author), BETH ISRAEL MED CTR,DIV INFECT DIS,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							BUIMOVICIKLEIN E, 1986, AIDS RES HUM RETROV, V2, P99, DOI 10.1089/aid.1.1986.2.99; COX DR, 1972, J R STAT SOC B, V34, P187; CRONK CE, 1982, AM J CLIN NUTR, V35, P347, DOI 10.1093/ajcn/35.2.347; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOUJARD C, 1991, 7 INT C AIDS FLOR; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; Jameson P, 1981, Methods Enzymol, V78, P357; KROWN SE, 1991, J ACQ IMMUN DEF SYND, V4, P871; LAGAKOS SW, 1991, 31ST INT C ANT AG CH; LAU AS, 1989, J CLIN INVEST, V84, P738, DOI 10.1172/JCI114231; LINDEMAN RH, 1980, INTRO BIVARIATE MULT, P63; LUCERO MA, 1982, EUR J CANCER CLIN ON, V18, P243, DOI 10.1016/0277-5379(82)90043-8; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; PREBLE OT, 1984, ANN NY ACAD SCI, V437, P65, DOI 10.1111/j.1749-6632.1984.tb37123.x; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; SCHILLER JH, 1990, J CLIN INVEST, V86, P1211, DOI 10.1172/JCI114827; TRACEY KJ, 1989, CANCER CELL-MON REV, V1, P62	19	88	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					453	456		10.1016/0140-6736(92)91058-G	http://dx.doi.org/10.1016/0140-6736(92)91058-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1371323				2022-12-28	WOS:A1992HE93200004
J	HEADY, JA; MORRIS, JN; OLIVER, MF				HEADY, JA; MORRIS, JN; OLIVER, MF			WHO CLOFIBRATE CHOLESTEROL TRIAL - CLARIFICATIONS	LANCET			English	Letter									UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; WYNN INST METAB RES, LONDON NW8 9SQ, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	HEADY, JA (corresponding author), ROYAL FREE HOSP, LONDON NW3 2QG, ENGLAND.							DURRINGTON PN, 1992, BMJ-BRIT MED J, V305, P420, DOI 10.1136/bmj.305.6850.420-d; HEADY JA, 1980, LANCET, V2, P379; MULDOON M, 1990, BMJ-BRIT MED J, V301, P9; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431	7	57	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	1992	340	8832					1405	1406		10.1016/0140-6736(92)92588-7	http://dx.doi.org/10.1016/0140-6736(92)92588-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360101				2022-12-28	WOS:A1992KB20200022
J	KOBAYASHI, Y; TAKAKI, H				KOBAYASHI, Y; TAKAKI, H			GEOGRAPHIC-DISTRIBUTION OF PHYSICIANS IN JAPAN	LANCET			English	Article							CARE	In the 1970s, Japan's physician manpower policy was to increase the number of medical students and medical schools to ease the difficulties caused by shortage of doctors and their maldistribution. 34 medical schools were established during this time, which eventually doubled the number of newly certificated physicians from about 4000 to about 8000 per year by the mid 1980s. To examine the success of this policy, we analysed the numbers of physicians in relation to the population in all municipal bodies (n=3268) in Japan. Between 1980 and 1990, the number of practising physicians increased by about 37%, and the ratio of physicians per 100 000 population increased from 127 to 165 throughout the country. However, analyses by the Lorenz curve and the Gini coefficient indicated that the inequality in physician distribution did not improve. While municipal bodies with a population over 30 000 gained proportionally more physicians, most communities with fewer than 10 000 residents showed little gain. Our findings have important implications for policy changes now being considered by the government to plan the future supply of physician manpower in Japan. A policy that will alleviate physician maldistribution also needs to be devised.	TEIKYO UNIV,SCH MED,DEPT HYG,ITABASHI KU,TOKYO 173,JAPAN	Teikyo University	KOBAYASHI, Y (corresponding author), TEIKYO UNIV,SCH MED,DEPT PUBL HLTH,2-11-1 KAGA,ITABASHI KU,TOKYO 173,JAPAN.							FRENZEN PD, 1991, AM J PUBLIC HEALTH, V81, P1141, DOI 10.2105/AJPH.81.9.1141; HAMU S, 1992, SHAKAI HOKEN JUNPO, V1761, P6; IGLEHART JK, 1988, NEW ENGL J MED, V319, P807, DOI 10.1056/NEJM198809223191234; IKEGAMI N, 1991, HEALTH AFFAIR, V10, P87, DOI 10.1377/hlthaff.10.3.87; Morrow J S, 1977, Inquiry, V14, P278; NEWHOUSE JP, 1982, JAMA-J AM MED ASSOC, V247, P2392, DOI 10.1001/jama.247.17.2392; NEWHOUSE JP, 1990, ANNU REV PUBL HEALTH, V11, P207, DOI 10.1146/annurev.pu.11.050190.001231; ROSENTHAL M, 1990, POLITICAL DYNAMICS P; TODARO MP, 1989, EC DEV 3RD WORLD, P143; Yang B M, 1989, Asia Pac J Public Health, V3, P68, DOI 10.1177/101053958900300110; 1991, KOKUMIN EISEI NO DOK; 1992, ISHI SHIKAISHI YAKUZ; 1990, KINMUI NO MIRAI NI K; 1987, FINANCING DELIVERING, P73; 1972, JPN MED J, V2533, P99; 1986, CONSIDERING NUMBER P; 1969, JPN MED J, V2347, P103; 1992, 1980 1990 POPULATION	18	119	121	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1391	1393		10.1016/0140-6736(92)92569-2	http://dx.doi.org/10.1016/0140-6736(92)92569-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB202	1360099				2022-12-28	WOS:A1992KB20200013
J	[Anonymous]				[Anonymous]			SURFACTANT FOR BABIES	LANCET			English	Editorial Material																		CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; CROWLEY P, 1991, OXFORD DATABASE PERI; CUMMINGS JJ, 1992, AM REV RESPIR DIS, V145, P999, DOI 10.1164/ajrccm/145.5.999; MUGFORD M, 1991, ARCH DIS CHILD-FETAL, V66, P757, DOI 10.1136/adc.66.7_Spec_No.757; SOLA A, 1992, LANCET, V340, P1363	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1387	1387						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360097				2022-12-28	WOS:A1992KB20200011
J	MISHRA, M; BISWAS, UK; JHA, DN; KHAN, AB				MISHRA, M; BISWAS, UK; JHA, DN; KHAN, AB			AMPHOTERICIN VERSUS PENTAMIDINE IN ANTIMONY-UNRESPONSIVE KALA-AZAR	LANCET			English	Note								We compared the efficacy of amphotericin B and pentamidine isethionate in a prospective randomised trial in 120 uncomplicated and parasitologically confirmed cases of antimony-unresponsive kala-azar. Doses were twenty intramuscular injections of pentamidine 4 mg/kg on alternate days or fourteen definitive doses of amphotericin 0.5 mg/kg infused in 5% dextrose on alternate days. 48 (80%) patients given pentamidine showed initial cure and 46 (77%) showed definitive cure compared with 60 (100%) and 59 (98%) cases, respectively, on amphotericin (p < 0.001). Amphotericin also brought about quicker abatement of fever and more complete spleen regression.	DARBHANGA MED COLL & HOSP,DEPT PATHOL,DARBHANGA 846003,BIHAR,INDIA		MISHRA, M (corresponding author), DARBHANGA MED COLL & HOSP,DEPT MED,DARBHANGA 846003,BIHAR,INDIA.							BENETTE JE, 1991, GOODMAN GILMANS PHAR, P1165; BERMAN JD, 1988, REV INFECT DIS, V10, P560; CHUNGE CN, 1984, E AFR MED J, V61, P120; MISHRA M, 1991, LANCET, V337, P926, DOI 10.1016/0140-6736(91)90268-T; PRATA ALUIZIO, 1963, TRANS ROY SOC TROP MED AND HYG, V57, P266, DOI 10.1016/0035-9203(63)90183-4; 1984, WHO TECH REP SER, V701, P104	6	109	112	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1256	1257		10.1016/0140-6736(92)92952-C	http://dx.doi.org/10.1016/0140-6736(92)92952-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359322				2022-12-28	WOS:A1992JZ23700006
J	FOWKES, FGR; LENG, GC; DONNAN, PT; DEARY, IJ; RIEMERSMA, RA; HOUSLEY, E				FOWKES, FGR; LENG, GC; DONNAN, PT; DEARY, IJ; RIEMERSMA, RA; HOUSLEY, E			SERUM-CHOLESTEROL, TRIGLYCERIDES, AND AGGRESSION IN THE GENERAL-POPULATION	LANCET			English	Article							RISK; DISEASE; HEALTH; MEN	A higher than expected number of violent deaths and suicides in coronary prevention trials has provoked interest in the possibility that low serum cholesterol concentrations are associated in the general population with personality characteristics predisposing to aggressive and suicidal behaviour. We have investigated this possibility in the Edinburgh Artery Study. We measured serum lipid concentrations in blood samples taken from fasting subjects and assessed personality characteristics on the Bedford Foulds Personality Deviance Scales in a random sample of 1592 men and women aged 55-74 years, selected from age-sex registers of ten general practices in Edinburgh. Serum cholesterol concentration was not significantly associated with aggression in men, but it was associated in multivariate analysis (though not univariate analysis) with denigratory attitudes towards others among women. However, serum triglyceride concentration was related, especially in men, to hostile acts (r = 0.13, p < 0.001) and domineering attitude (r = 0.12, p < 0.001) independently of age, total and HDL cholesterol, cigarette smoking, and alcohol consumption. Subjects taking part in prevention trials have higher triglyceride concentrations than the general population and the relation between serum triglyceride concentration and aggression merits further investigation.	UNIV EDINBURGH, DEPT PSYCHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, CARDIOVASC RES UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	FOWKES, FGR (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PUBL HLTH SCI, WOLFSON UNIT PREVENT PERIPHERAL VASC DIS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; Donnan, Peter/0000-0001-7828-0610				BEDFORD A, 1978, PERSONALITY DEVIANCE; BOLTONSMITH C, 1991, INT J EPIDEMIOL, V20, P95, DOI 10.1093/ije/20.1.95; Brown MS, 1990, PHARMACOL BASIS THER, P874; BRUNNER E, 1992, LANCET, V339, P1001; Caine TM, 1967, MANUAL HOSTILITY DIR; CHAIT A, 1981, DIABETES CARE, V4, P343, DOI 10.2337/diacare.4.3.343; DAYTON S, 1969, CIRCULATION S2, V39, P1; DIXON WJ, 1989, BMDP STATISTICAL SOF; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEILMAN KM, 1974, ARCH NEUROL-CHICAGO, V31, P67, DOI 10.1001/archneur.1974.00490370093018; KROMHOUT D, 1992, LANCET, V340, P317, DOI 10.1016/0140-6736(92)92415-C; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATHEW NT, 1976, EUR NEUROL, V14, P370, DOI 10.1159/000114761; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; VIKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; VIKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27; ZUCKERMAN M, 1991, PSYCHOBIOLOGY PERSON, P205; 1930, ANN REPORTS REGISTRA; 1990, SCOTTISH HLTH STATIS; 1986, SPSSX USERS GUIDE	30	76	77	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					995	998		10.1016/0140-6736(92)93009-C	http://dx.doi.org/10.1016/0140-6736(92)93009-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357449				2022-12-28	WOS:A1992JV01400003
J	OCONNOR, BJ; AIKMAN, SL; BARNES, PJ				OCONNOR, BJ; AIKMAN, SL; BARNES, PJ			TOLERANCE TO THE NONBRONCHODILATOR EFFECTS OF INHALED BETA-2-AGONISTS IN ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL RESPONSIVENESS; ADENOSINE 5'-MONOPHOSPHATE; SODIUM CROMOGLYCATE; IPRATROPIUM BROMIDE; BETA-AGONISTS; SALBUTAMOL; HISTAMINE; BRONCHOCONSTRICTION; TERBUTALINE; PROVOCATION	Background. Tolerance to the direct bronchodilator effects of beta2-agonists does not appear to occur in asthma. However, it is not known whether this is true for the nonbronchodilator effects of these agents, which protect the airways against bronchoconstrictive stimuli. Methods. We investigated whether tolerance develops to the protective effect of inhaled terbutaline on airway responsiveness to the bronchoconstrictors methacholine (which acts directly on airway smooth muscle) and AMP (which acts indirectly by stimulating the release of mediators from mast cells) during sustained treatment with terbutaline. In a randomized, double-blind, crossover study, 12 patients with mild asthma each inhaled a single dose of terbutaline (500 mug) or placebo before a challenge with a series of doubling doses of inhaled methacholine or AMP, before and after treatment for seven days with 500 mug of terbutaline four times daily or placebo. Results. Before the seven days of treatment with terbutaline, a single dose of terbutaline reduced airway responsiveness to methacholine by 2.7 doubling doses (95 percent confidence interval, 1.9 to 3.5), but it had an even greater protective effect against AMP, reducing airway responsiveness by 3.8 doubling doses (95 percent confidence interval, 2.7 to 4.9; P<0.001). After seven days of treatment with terbutaline, the protective effect of terbutaline against methacholine decreased to 2.2 doubling doses (95 percent confidence interval, 1.3 to 3.0; P = 0.04), and that against AMP decreased even more, to 1.7 doubling doses (95 percent confidence interval, 1.1 to 2.4; P<0.001). By contrast, the bronchodilator response to terbutaline was unchanged during seven days of treatment with this agent. Conclusions. We observed tolerance to the nonbronchodilator actions of the inhaled beta2-agonist terbutaline in patients with mild asthma, an effect that may be more pronounced in mast cells than in bronchial smooth muscle. This property of beta-agonists may constitute a drawback to their regular use in patients with asthma.	NATL HEART & LUNG INST, DEPT THORAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND	Imperial College London				Barnes, Peter/0000-0002-5122-4018	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045947] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45947] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1987, STATISTICAL METHODS; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; KALINER M, 1989, J ALLERGY CLIN IMMUN, V83, P510, DOI 10.1016/0091-6749(89)90031-6; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; OCONNOR BJ, 1991, THORAX, V46, pP745; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1989, EUR RESPIR J, V2, P210; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; TATTERSFIELD AE, 1985, B EUR PHYSIOPATH RES, V21, pS1; VANDERHEIJDEN PJCM, 1984, EUR J RESPIR DIS, V65, P128; VATHENEN AS, 1988, LANCET, V1, P554	23	313	316	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1204	1208		10.1056/NEJM199210223271704	http://dx.doi.org/10.1056/NEJM199210223271704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1357551	Bronze			2022-12-28	WOS:A1992JU39300004
J	WILKINSON, JRW; ROBERTS, JA; BRADDING, P; HOLGATE, ST; HOWARTH, PH				WILKINSON, JRW; ROBERTS, JA; BRADDING, P; HOLGATE, ST; HOWARTH, PH			PARADOXICAL BRONCHOCONSTRICTION IN ASTHMATIC-PATIENTS AFTER SALMETEROL BY METERED DOSE INHALER	BRITISH MEDICAL JOURNAL			English	Article							BRONCHOSPASM				WILKINSON, JRW (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED 1,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.			Howarth, Peter/0000-0003-0619-7927; Bradding, Peter/0000-0001-8403-0319				BRYANT DH, 1976, BRIT MED J, V1, P1319, DOI 10.1136/bmj.1.6021.1319; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; YARBROUGH J, 1985, ANN ALLERGY, V55, P25; 1991, CURRENT PROBLEMS JUN	5	39	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1992	305	6859					931	932		10.1136/bmj.305.6859.931	http://dx.doi.org/10.1136/bmj.305.6859.931			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU649	1360855	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JU64900023
J	KASPER, W; GEIBEL, A; TIEDE, N; JUST, H				KASPER, W; GEIBEL, A; TIEDE, N; JUST, H			PATENT FORAMEN OVALE IN PATIENTS WITH HEMODYNAMICALLY SIGNIFICANT PULMONARY-EMBOLISM	LANCET			English	Article							PARADOXICAL EMBOLISM; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSIS; LIFE; PREVALENCE; HYPOXEMIA; STROKE	The prevalence of a patent foramen ovale is about 1 in 4. In cases with venous thromboembolism and raised right heart pressures, a patent foramen ovale may permit paradoxical emboli, which could complicate the course of patients with pulmonary embolism. Echocardiography enables detection of a patent foramen ovale in life. We have studied 85 patients who presented with haemodynamically significant pulmonary embolism as judged by clinical, echocardiographic, or haemodynamic indices and who had an echocardiographic evaluation for patent foramen ovale. 33 patients (39%) had a patent foramen ovale. Clinical symptoms suggestive of paradoxical embolism were more likely in patients with than in those without a patent foramen ovale (39% vs 6%, p=0.00034), with new neurological deficits occurring in 11 patients (9 vs 2, p=0.005) and a vascular occlusion in 8(7 vs 1, p=0.0096). Arterial oxygen tension was lower in patients with a patent foramen ovale (mean 55 [SD 14] vs 62 [16] mm Hg, p=0.038). Mortality was not different between the two groups (27% vs 19%). Cardiopulmonary complications in terms of resuscitation, intubation, or the use of catecholamines were more frequently observed in patients with a patent foramen ovale (48% vs 23%, p=0.028). Patients with a patent foramen ovale and haemodynamically significant pulmonary embolism are more likely to have arterial hypoxaemia and vascular occlusions, possibly due to paradoxical emboli.			KASPER, W (corresponding author), UNIV FREIBURG,MED CLIN 3,HUGSTETTERSTR 55,W-7800 FREIBURG,GERMANY.							BARNARD SP, 1991, EUR J CARDIO-THORAC, V5, P105, DOI 10.1016/1010-7940(91)90008-8; BILLER J, 1986, NEUROLOGY, V36, P1356, DOI 10.1212/WNL.36.10.1356; COME PC, 1985, DIAGNOSTIC CARDIOLOG, P281; CROSS SJ, 1992, BRIT MED J, V304, P481, DOI 10.1136/bmj.304.6825.481; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DALONZO GE, 1983, AM REV RESPIR DIS, V128, P170, DOI 10.1164/arrd.1983.128.1.170; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HALE GS, 1979, AUST NZ J MED, V9, P953; HIGGINS JR, 1984, AM HEART J, V107, P375, DOI 10.1016/0002-8703(84)90388-0; HOFMANN T, 1990, LANCET, V336, P1421; JARDIN F, 1979, CIRCULATION, V59, P909, DOI 10.1161/01.CIR.59.5.909; JOHNSON BI, 1951, J CLIN PATHOL, V4, P316, DOI 10.1136/jcp.4.3.316; KASPER W, 1989, HERZ, V14, P82; KASPER W, 1986, AM HEART J, V112, P1284, DOI 10.1016/0002-8703(86)90361-3; KRONIK G, 1989, EUR HEART J, V10, P1046; LANG I, 1988, EUR HEART J, V9, P678, DOI 10.1093/oxfordjournals.eurheartj.a062561; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEONARD RCF, 1982, EUR HEART J, V3, P362, DOI 10.1093/oxfordjournals.eurheartj.a061319; LOSCALZO J, 1986, AM HEART J, V112, P141, DOI 10.1016/0002-8703(86)90692-7; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MCNEIL BJ, 1980, J NUCL MED, V21, P319; MEISTER SG, 1972, AM J MED, V53, P292, DOI 10.1016/0002-9343(72)90171-4; MOON RE, 1989, LANCET, V1, P513; NELLESSEN U, 1985, J AM COLL CARDIOL, V5, P1002, DOI 10.1016/S0735-1097(85)80449-6; SEWARD JB, 1984, MAYO CLIN PROC, V59, P221, DOI 10.1016/S0025-6196(12)61253-1; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; Thompson T, 1930, Q J MED, V23, P135, DOI 10.1093/qjmed/os-23.90.135; WEBSTER MWI, 1988, LANCET, V2, P11; WILSON JE, 1971, J CLIN INVEST, V50, P481, DOI 10.1172/JCI106516	29	109	113	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					561	564		10.1016/0140-6736(92)92102-L	http://dx.doi.org/10.1016/0140-6736(92)92102-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355152				2022-12-28	WOS:A1992JM33400001
J	CHOY, DSJ; ALTMAN, P				CHOY, DSJ; ALTMAN, P			THE CARDIOVASCULAR-SYSTEM OF BAROSAURUS - AN EDUCATED GUESS	LANCET			English	Article									COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP CTR,INVEST CARDIOL LAB,NEW YORK,NY 10032	Columbia University; Mount Sinai St. Luke's; Mount Sinai West								GOETZ R H, 1955, S Afr Med J, V29, P773; GOETZ RH, 1960, CIRC RES, V8, P1049, DOI 10.1161/01.RES.8.5.1049; LILLYWHITE HB, 1991, NAT HIST, V100, P33	3	18	18	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					534	536		10.1016/0140-6736(92)91722-K	http://dx.doi.org/10.1016/0140-6736(92)91722-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354287	hybrid			2022-12-28	WOS:A1992JL23400014
J	GOLDBLUM, RM; PELLEY, RP; ODONELL, AA; PYRON, D; HEGGERS, JP				GOLDBLUM, RM; PELLEY, RP; ODONELL, AA; PYRON, D; HEGGERS, JP			ANTIBODIES TO SILICONE ELASTOMERS AND REACTIONS TO VENTRICULOPERITONEAL SHUNTS	LANCET			English	Article							MALFUNCTION; IMPLANTS	Silicone elastomers used to make medical implants and prostheses are generally believed to be biologically inert. However, we have seen two patients who showed severe, apparently immune-mediated, reactions to ventriculoperitoneal (VP) shunts. We used an enzyme-linked immunosorbent assay in which Silastic tubing served as the solid-phase antigen to test serum from the two patients, five other VP shunt patients without inflammatory reactions, and nine healthy adults. IgG binding to Silastic tubing was consistently higher in the two patients than in the healthy or patient controls. The IgG seemed to be binding specifically, since IgG Fab fragments also bound to the tubing, and preincubation of serum with Silastic or silylated proteins removed most of the activity. These findings show that specific immune reactivity to elastomers of polydimethylsiloxane can develop in human beings.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT FAMILY MED,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT SURG & MICROBIOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	GOLDBLUM, RM (corresponding author), UNIV TEXAS,MED BRANCH,DEPT PEDIAT,GALVESTON,TX 77550, USA.							BALDWIN CM, 1983, ANN PLAS SURG, V10, P270, DOI 10.1097/00000637-198304000-00002; BOWMAN BH, 1980, J BIOL CHEM, V255, P9484; FRISCH EE, 1983, BIOMATERIALS RECONST, P73; GOWER DJ, 1984, J NEUROSURG, V61, P1079, DOI 10.3171/jns.1984.61.6.1079; HEGGERS JP, 1983, ANN PLAS SURG, V11, P38, DOI 10.1097/00000637-198307000-00006; KIRCHER T, 1980, HUM PATHOL, V11, P240, DOI 10.1016/S0046-8177(80)80005-0; KOSSOVSKY N, 1987, J BIOMED MATER RES, V21, P1125, DOI 10.1002/jbm.820210906; PEIMER CA, 1986, J HAND SURG-AM, V11A, P624, DOI 10.1016/S0363-5023(86)80002-8; SNOW RB, 1989, SURG NEUROL, V31, P209, DOI 10.1016/0090-3019(89)90119-5; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WARREN KS, 1976, ANN NY ACAD SCI, V278, P7, DOI 10.1111/j.1749-6632.1976.tb47011.x	11	191	198	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					510	513		10.1016/0140-6736(92)91710-P	http://dx.doi.org/10.1016/0140-6736(92)91710-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354277				2022-12-28	WOS:A1992JL23400004
J	LEWIS, G; DAVID, A; ANDREASSON, S; ALLEBECK, P				LEWIS, G; DAVID, A; ANDREASSON, S; ALLEBECK, P			SCHIZOPHRENIA AND CITY LIFE	LANCET			English	Article							PSYCHOSIS; AREAS	Prevalence of schizophrenia and rates of first admission to hospital for this disorder are higher in most modem industrialised cities, and in urban compared with rural areas. The "geographical drift" hypothesis (ie, most schizophrenics tend to drift into city areas because of their illness or its prodrome) has remained largely unchallenged. We have investigated the association between place of upbringing and the incidence of schizophrenia with data from a cohort of 49 191 male Swedish conscripts linked to the Swedish National Register of Psychiatric Care. The incidence of schizophrenia was 1.65 times higher (95% confidence interval 1.19-2.28) among men brought up in cities than in those who had had a rural upbringing. The association persisted despite adjustment for other factors associated with city life such as cannabis use, parental divorce, and family history of psychiatric disorder. This finding cannot be explained by the widely held notion that people with schizophrenia drift into cities at the beginning of their illness. We conclude that undetermined environmental factors found in cities increase the risk of schizophrenia.	INST PSYCHIAT, DEPT PSYCHOL MED, LONDON SE5 8AF, ENGLAND; KAROLINSKA INST, HUDDINGE UNIV HOSP, DEPT COMMUNITY MED, S-14186 HUDDINGE, SWEDEN	University of London; King's College London; Karolinska Institutet	LEWIS, G (corresponding author), INST PSYCHIAT, EPIDEMIOL & GEN PRACTICE SECT, DENMARK HILL, LONDON SE5 8AF, ENGLAND.		Lewis, Glyn/E-9944-2012; David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019	Lewis, Glyn/0000-0001-5205-8245; David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; ANDREASSON S, 1990, THESIS KAROLINSKA I; ASTRUP C, 1961, PSYCHIAT QUART, V34, P116; BACHRACH LL, 1977, HOSP COMMUNITY PSYCH, V28, P669; BLAZER D, 1985, ARCH GEN PSYCHIAT, V42, P651; BOOK JA, 1953, ACTA GENET STATIST M, V4, P394; BROWN GW, 1968, J HEALTH SOC BEHAV, V9, P203; BROWN GW, 1981, PSYCHOL MED, V11, P581, DOI 10.1017/S0033291700052880; DUNHAM WH, 1965, COMMUNITY SCHIZOPHRE; EATON WW, 1985, EPIDEMIOL REV, V7, P105, DOI 10.1093/oxfordjournals.epirev.a036278; EATON WW, 1974, J HEALTH SOC BEHAV, V15, P289, DOI 10.2307/2137089; Field JH, 1976, EPIDEMIOLOGY HEAD IN; Gerard DL, 1953, PSYCHIAT QUART, V27, P90, DOI 10.1007/BF01562478; GIGGS JA, 1987, BRIT J PSYCHIAT, V151, P627, DOI 10.1192/bjp.151.5.627; HARE EH, 1956, J MENT SCI, V102, P349, DOI 10.1192/bjp.102.427.349; HARE EH, 1956, J MENT SCI, V102, P753, DOI 10.1192/bjp.102.429.753; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; KRISTJANSSON E, 1986, NORD PSYKIATR TIDSSK, V43, P229; MACHON RA, 1983, BRIT J PSYCHIAT, V143, P383, DOI 10.1192/bjp.143.4.383; Otto U, 1976, Acta Psychiatr Scand Suppl, V264, P1; ROTH D, 1986, HOSP COMMUNITY PSYCH, V37, P712; RUTTER M, 1981, AM J ORTHOPSYCHIAT, V51, P610, DOI 10.1111/j.1939-0025.1981.tb01407.x; SHEPHERD M, 1989, PSYCHOL MED S, V15; TAKEI N, 1992, SCHIZOPHR RES, V6, P102, DOI 10.1016/0920-9964(92)90114-K; THORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475, DOI 10.1192/bjp.158.4.475; TORREY EF, 1990, SCHIZOPHRENIA BULL, V16, P591, DOI 10.1093/schbul/16.4.591; TORREY EF, 1988, SCHIZOPHRENIA BULL, V14, P223, DOI 10.1093/schbul/14.2.223; VONKORFF M, 1985, J NERV MENT DIS, V173, P577; WIDERLOV B, 1989, ACTA PSYCHIAT SCAND, V80, P40, DOI 10.1111/j.1600-0447.1989.tb01298.x; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; 1974, GLOSSARY MENTAL DISO	31	249	252	2	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1992	340	8812					137	140		10.1016/0140-6736(92)93213-7	http://dx.doi.org/10.1016/0140-6736(92)93213-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352565				2022-12-28	WOS:A1992JE38200002
J	NURMOHAMED, MT; ROSENDAAL, FR; BULLER, HR; DEKKER, E; HOMMES, DW; VANDENBROUCKE, JP; BRIET, E				NURMOHAMED, MT; ROSENDAAL, FR; BULLER, HR; DEKKER, E; HOMMES, DW; VANDENBROUCKE, JP; BRIET, E			LOW-MOLECULAR-WEIGHT HEPARIN VERSUS STANDARD HEPARIN IN GENERAL AND ORTHOPEDIC-SURGERY - A METAANALYSIS	LANCET			English	Article							DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; TOTAL HIP-REPLACEMENT; UNFRACTIONATED HEPARIN; VENOUS THROMBOSIS; DOUBLE-BLIND; KABI 2165; POSTOPERATIVE THROMBOSIS; PULMONARY-EMBOLISM; MULTICENTER TRIAL	Low-molecular-weight heparins (LMWHs) have theoretical advantages over standard heparin as postoperative thromboprophylactic agents. We conducted a meta-analysis of studies reported between 1984 and April, 1991, in which LMWHs were compared with standard heparin for postoperative prophylaxis. We included only randomised studies (reported in English, French, or German) in which investigators compared currently recommended doses of the agents and used adequate screening techniques for deep vein thrombosis. For all surgical studies the relative risk (LMWH versus standard heparin) for deep vein thrombosis was 0.74 (95% CI 0.65-0.86), for pulmonary embolism 0.43 (95% CI 0.26-0.72), and for major bleeding 0.98 (95% CI 0.69-1.40). Comparable relative risks were observed for the general and orthopaedic surgery studies separately. When the analysis for the general surgery studies was limited to those of strong methodology, assessed by eight criteria defined in advance, the benefit/risk ratio was less favourable-relative risk for deep vein thrombosis 0.91 (95% CI 0.68-1.23), for major bleeding 1.32 (95% CI 0.69-2.56). There is at present no convincing evidence that in general surgery patients LMWHs, compared with standard heparin, generate a clinically important improvement in the benefit to risk ratio. However, LMWHs may be preferable for orthopaedic surgery patients, in view of the larger absolute risk reduction for venous thrombosis.	LEIDEN UNIV HOSP,DEPT HAEMATOL,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	NURMOHAMED, MT (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLAMMAT RES,F4-131,1105 AZ AMSTERDAM,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716; Nurmohamed, Michael/0000-0002-6274-1934				ADOLF J, 1989, DEUT MED WOCHENSCHR, V114, P48, DOI 10.1055/s-2008-1066550; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; Barre J, 1987, J Mal Vasc, V12 Suppl B, P90; BAUMGARTNER A, 1989, VASA-J VASCULAR DIS, V18, P152; BERGQVIST D, 1988, BRIT J SURG, V75, P888, DOI 10.1002/bjs.1800750920; BERGQVIST D, 1986, BRIT J SURG, V73, P204, DOI 10.1002/bjs.1800730316; BLUM A, 1989, THROMB HAEMOSTASIS, V62, P126; BORSTAD E, 1988, ACTA OBSTET GYN SCAN, V67, P99, DOI 10.3109/00016348809004178; BREYER HG, 1987, THROMB HAEMOSTAS S, V7, P23; BRIEL RC, 1988, GEBURTSH FRAUENHEILK, V48, P160, DOI 10.1055/s-2008-1035716; BULLER HR, 1991, THROMB HAEMOSTASIS, V66, P133; CADE J, 1989, THROMB HAEMOSTASIS, V62, P42; CAEN JP, 1988, THROMB HAEMOSTASIS, V59, P216; CARTER C, 1987, HEMOSTASIS THROMBOSI, P1185; CATANIA G, 1988, INT J CLIN PHARM TH, V26, P304; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COLDITZ GA, 1986, LANCET, V2, P143; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAHAN M, 1989, THROMB HAEMOSTASIS, V62, P519; DECHAVANNE M, 1989, HAEMOSTASIS, V1, P5; ENCKE A, 1988, BRIT J SURG, V75, P1058; ERIKSSON BI, 1989, THROMB HAEMOSTASIS, V62, P470; ESTOPPEY D, 1989, THROMB HAEMOSTASIS, V62, P356; FRICKER JP, 1988, EUR J CLIN INVEST, V18, P561, DOI 10.1111/j.1365-2362.1988.tb01268.x; HAAS S, 1987, DRUG RES, V37, P839; HARTL P, 1990, THROMB RES, V57, P577, DOI 10.1016/0049-3848(90)90074-M; HEILMANN L, 1989, GEBURTSH FRAUENHEILK, V49, P803, DOI 10.1055/s-2008-1036089; HOFFMANN R, 1987, HELV CHIR ACTA, V54, P521; KAKKAR VV, 1985, BRIT J SURG, V72, P786, DOI 10.1002/bjs.1800721006; KOLLER M, 1986, THROMB HAEMOSTASIS, V56, P243; KORNINGER C, 1987, THROMB HAEMOSTASIS, V62, P187; LASSEN MR, 1989, ARCH ORTHOP TRAUM SU, V108, P10, DOI 10.1007/BF00934150; LASSEN MR, 1988, BRIT J SURG, V75, P686, DOI 10.1002/bjs.1800750720; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEIZOROVICZ A, 1989, THROMB HAEMOSTASIS, V62, P521; LEYVRAZ PF, 1990, DEEP VEIN THROMBOSIS, P105; LIGHT RS, 1984, SUMMING SCI REV RESE, P66; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONREAL M, 1989, J TRAUMA, V29, P873, DOI 10.1097/00005373-198906000-00028; ONARHEIM H, 1986, ACTA CHIR SCAND, V152, P593; PINI M, 1989, INT ANGIOL, V8, P134; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; SALCUNI PF, 1988, CURR THER RES CLIN E, V43, P824; SALZMAN EW, 1980, J CLIN INVEST, V65, P64, DOI 10.1172/JCI109661; SAMAMA M, 1988, BRIT J SURG, V75, P128, DOI 10.1002/bjs.1800750213; SASAHARA AA, 1986, BRIT J SURG, V73, P697, DOI 10.1002/bjs.1800730906; SCHMITZHUEBNER U, 1984, KLIN WOCHENSCHR, V62, P349, DOI 10.1007/BF01716253; STEINER RA, 1989, ARCH GYNECOL OBSTET, V244, P141, DOI 10.1007/BF00931291; TENCATE H, 1984, CLIN CHEM, V30, P860; VERARDI S, 1989, CURR THER RES CLIN E, V46, P366; VERARDI S, 1988, INT ANGIOL, V7, P19; VONVOIGT J, 1986, ZENT BL CHIR, V111, P1296; WELZEL D, 1989, THROMB HAEMOSTASIS, V62, P523; WELZEL D, 1988, ARZNEIMITTEL-FORSCH, V38-1, P120; 1986, JAMA-J AM MED ASSOC, V256, P744	56	560	571	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					152	156		10.1016/0140-6736(92)93223-A	http://dx.doi.org/10.1016/0140-6736(92)93223-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352573				2022-12-28	WOS:A1992JE38200011
J	BURMAN, LG; CHRISTENSEN, P; CHRISTENSEN, K; FRYKLUND, B; HELGESSON, AM; SVENNINGSEN, NW; TULLUS, K				BURMAN, LG; CHRISTENSEN, P; CHRISTENSEN, K; FRYKLUND, B; HELGESSON, AM; SVENNINGSEN, NW; TULLUS, K			PREVENTION OF EXCESS NEONATAL MORBIDITY ASSOCIATED WITH GROUP-B STREPTOCOCCI BY VAGINAL CHLORHEXIDINE DISINFECTION DURING LABOR	LANCET			English	Article							DOSE PENICILLIN PROPHYLAXIS; ROUTINE CORD CARE; NEWBORN-INFANTS; CONTROLLED TRIAL; COLONIZATION; DISEASE; EPIDEMIOLOGY	Streptococcus agalactiae transmitted to infants from the vagina during birth is an important cause of invasive neonatal infection. We have done a prospective, randomised, double-blind, placebo-controlled, multi-centre study of chlorhexidine prophylaxis to prevent neonatal disease due to vaginal transmission of S agalactiae. On arrival in the delivery room, swabs were taken for culture from the vaginas of 4483 women who were expecting a full-term single birth. Vaginal flushing was then done with either 60 ml chlorhexidine diacetate (2 g/l) (2238 women) or saline placebo (2245) and this procedure was repeated every 6 h until delivery. The rate of admission of babies to special-care neonatal units within 48 h of delivery was the primary end point. For babies born to placebo-treated women, maternal carriage of S agalactiae was associated with a significant increase in the rate of admission compared with non-colonised mothers (5.4 vs 2.4%; RR 2.31, 95% Cl 1.39-3.86; p=0.002). Chlorhexidine reduced the admission rate for infants born of carrier mothers to 2.8% (RR 1.95, 95% Cl 0.94-4.03), and for infants born to all mothers to 2.0% (RR 1.48, 95% Cl 1.01-2.16; p=0.04). Maternal S agalactiae colonisation is associated with excess early neonatal morbidity, apparently related to aspiration of the organism, that can be reduced with chlorhexidine disinfection of the vagina during labour.	UNIV LUND HOSP, DEPT PAEDIAT, S-22185 LUND, SWEDEN; CENT HOSP KRISTIANSTAD, DEPT BACTERIOL, KRISTIANSTAD, SWEDEN; KAROLINSKA INST, ST GORANS CHILDRENS HOSP, DEPT PAEDIAT, S-11281 STOCKHOLM, SWEDEN	Lund University; Skane University Hospital; Karolinska Institutet	BURMAN, LG (corresponding author), NATL BACTERIOL LAB, S-10521 STOCKHOLM, SWEDEN.		Tullus, Kjell/C-6589-2008					BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1990, J INFECT DIS, V161, P917, DOI 10.1093/infdis/161.5.917; BAKER CJ, 1990, INFECT DIS, P743; BERGQVISTKARLSSON A, 1988, CONTACT DERMATITIS, V18, P84, DOI 10.1111/j.1600-0536.1988.tb02745.x; BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; BYGDEMAN S, 1984, INFECT CONT HOSP EP, V5, P275, DOI 10.1017/S019594170006032X; CASE DE, 1977, J CLIN PERIODONTOL, V4, P66, DOI 10.1111/j.1600-051X.1977.tb00052.x; CASSELL GH, 1988, PEDIATR INFECT DIS J, V7, P535; CHRISTENSEN KK, 1985, EUR J OBSTET GYN R B, V19, P231, DOI 10.1016/0028-2243(85)90034-6; CHRISTENSEN KK, 1982, INT ARCH ALLER A IMM, V67, P7, DOI 10.1159/000232980; CHRISTENSEN KK, 1983, EUR J OBSTET GYN R B, V16, P157, DOI 10.1016/0028-2243(83)90095-3; CHRISTENSEN KK, 1987, 10TH INT LANC S STRE; DYKES AK, 1983, EUR J OBSTET GYN R B, V16, P167, DOI 10.1016/0028-2243(83)90096-5; GASTRIN B, 1968, ACTA PATHOL MIC SC, V74, P371; HJALMARSON O, 1981, ACTA PAEDIATR SCAND, V70, P773, DOI 10.1111/j.1651-2227.1981.tb06228.x; JOHNSSON J, 1987, ACTA PAEDIATR SCAND, V76, P675, DOI 10.1111/j.1651-2227.1987.tb10544.x; MADOFF LC, 1991, INFECT IMMUN, V59, P204, DOI 10.1128/IAI.59.1.204-210.1991; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; PYATI SP, 1982, PEDIATR RES, V16, P1019; SEEBERG S, 1984, J HOSP INFECT, V5, P121, DOI 10.1016/0195-6701(84)90116-6; SIEGEL JD, 1982, LANCET, V1, P1426; SIEGEL JD, 1980, NEW ENGL J MED, V303, P769, DOI 10.1056/NEJM198010023031401; STRAYPEDERSEN B, 1992, 1ST EUR C INF DIS OB; TERES FO, 1987, PEDIATR INFECT DIS J, V6, P874, DOI 10.1097/00006454-198709000-00026; WESSELS MR, 1990, J CLIN INVEST, V86, P1428, DOI 10.1172/JCI114858; 1976, LAKARTIDNINGEN, V73, P300	26	78	79	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1992	340	8811					65	69		10.1016/0140-6736(92)90393-H	http://dx.doi.org/10.1016/0140-6736(92)90393-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352011				2022-12-28	WOS:A1992JC58200001
J	MADDEN, BP; HODSON, ME; TSANG, V; RADLEYSMITH, R; KHAGHANI, A; YACOUB, MY				MADDEN, BP; HODSON, ME; TSANG, V; RADLEYSMITH, R; KHAGHANI, A; YACOUB, MY			INTERMEDIATE-TERM RESULTS OF HEART-LUNG TRANSPLANTATION FOR CYSTIC-FIBROSIS	LANCET			English	Article							ADULTS	Between September, 1984, and March, 1991, 79 patients underwent heart-lung transplantation for end-stage cystic fibrosis at the Harefield Hospital. Short-term outcome has already been reported, and we now present intermediate-term results. The overall actuarial patient survival was 69% at 1 year, 52% at 2 years, and 49% at 3 years. 17 patients had diabetes mellitus with a survival of 62% to 1 year and 51% to 2 years. 23 patients had one or more other possible high-risk factors, and survival of these patients was 64% at 1 year and 57% at 2 years, compared with 71% and 49%, respectively, in the low-risk group (n=56). Pseudomonas aeruginosa infection was the most common respiratory infection encountered postoperatively. 92% of patients had at least one episode of acute rejection during the first 3 postoperative months. Lung function was greatly improved after transplantation, the mean forced expiratory volume in 1 s and forced vital capacity increasing from 22% and 35% predicted, respectively, preoperatively to 68% and 70% predicted, respectively, by the sixth postoperative month. This improvement was maintained at 1, 2, and 3 years after transplantation. Lymphoproliferative disorders (4 patients) were successfully treated. Obliterative bronchiolitis developed in 17 patients and the cumulative probability of getting this complication at 1, 2, and 3 years postoperatively was 17%, 23%, and 48%, respectively. Overall, 7 patients were retransplanted. There was no coronary artery disease in the 37 patients who underwent coronary angiography at 1 year, 14 at 2 years, and 9 at 3 years after surgery. 58 patients donated their hearts for subsequent "domino" heart transplantation. Our 5 1/2-year experience with heart-lung transplantation is encouraging but the shortage of donor organs and the complication of obliterative bronchiolitis are the two main obstacles to be overcome.	HAREFIELD HOSP,UXBRIDGE UB9 6JH,MIDDX,ENGLAND; ROYAL BROMPTON HOSP,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital; Imperial College London								ALAJMO F, 1989, ANN THORAC SURG, V48, P536, DOI 10.1016/S0003-4975(10)66857-9; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; HODSON ME, 1989, BRIT MED J, V298, P471, DOI 10.1136/bmj.298.6672.471; HODSON ME, 1991, EUR RESPIR J, V4, P524; NIELSEN OH, 1982, ACTA PAEDIATR SC   S, V301, P107; PATTERSON GA, 1989, PEDIATR PULM, V4, P56; PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCOTT J, 1988, LANCET, V2, P1962; SMYTH RL, 1991, THORAX, V46, P213, DOI 10.1136/thx.46.3.213; WOOD A, 1989, AM REV RESPIR DIS, V140, P1645, DOI 10.1164/ajrccm/140.6.1645; YACOUB MH, 1990, J HEART TRANSPLANT, V9, P459; YACOUB MH, 1990, TRANSPLANT REV, P1; 1988, BRIT MED J, V297, P1599; 1990, RECOMMENDATIONS CARE	15	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1583	1587		10.1016/0140-6736(92)91842-V	http://dx.doi.org/10.1016/0140-6736(92)91842-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351559				2022-12-28	WOS:A1992JB20200013
J	WEBER, R; BRYAN, RT; OWEN, RL; WILCOX, CM; GORELKIN, L; VISVESVARA, GS; JURANEK, DD; ADDISS, DG; SPENCER, HC; HIGHTOWER, AW; STEWART, JM; ROBERTS, JM; WAHLQUIST, SP; HORSBURGH, CR; CASTRO, KG; TAUXE, RV; VUGIA, DJ; GLASS, RI; THOMPSON, SE; SCHWARTZ, DA; KOZARSKY, PE; STEINBERG, JP; SHULMAN, JA; DISMUKES, RM; DUPUIS, MH; NICKERSON, JF; RIMLAND, D; HOGAN, SE; JOHNSON, A; ELLIOTT, N				WEBER, R; BRYAN, RT; OWEN, RL; WILCOX, CM; GORELKIN, L; VISVESVARA, GS; JURANEK, DD; ADDISS, DG; SPENCER, HC; HIGHTOWER, AW; STEWART, JM; ROBERTS, JM; WAHLQUIST, SP; HORSBURGH, CR; CASTRO, KG; TAUXE, RV; VUGIA, DJ; GLASS, RI; THOMPSON, SE; SCHWARTZ, DA; KOZARSKY, PE; STEINBERG, JP; SHULMAN, JA; DISMUKES, RM; DUPUIS, MH; NICKERSON, JF; RIMLAND, D; HOGAN, SE; JOHNSON, A; ELLIOTT, N			IMPROVED LIGHT-MICROSCOPIC DETECTION OF MICROSPORIDIA SPORES IN STOOL AND DUODENAL ASPIRATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS PATIENTS; INTESTINAL MICROSPORIDIOSIS; ENTEROCYTOZOON-BIENEUSI; NOSEMATOSIS; DIAGNOSIS; ENCEPHALITOZOONOSIS; DIARRHEA; CORNEA	Background. The diagnosis of infection with Enterocytozoon bieneusi, a microsporidian organism that causes chronic diarrhea in patients infected with the human immunodeficiency virus (HIV), has depended on invasive procedures. We have developed a new method to detect microsporidia spores in feces and duodenal aspirates. Methods. Stool was obtained from four HIV-infected patients with biopsy-confirmed intestinal microsporidiosis. Slides prepared from unconcentrated, formalin-fixed stool specimens were stained with a new chromotrope-based technique and examined by light microscopy. Methods of stool concentration were also compared. The technique was then evaluated by examining 215 specimens from 134 HIV-infected persons with or without diarrhea. In addition, duodenal aspirates from 10 patients with unexplained chronic diarrhea were examined by light microscopy after staining according to the new and the traditional techniques. Results. E. bieneusi spores were found in all unconcentrated stool specimens from the four patients with microsporidiosis. The use of various methods of stool concentration did not improve the detection of microsporidia spores. In the prospective study, microsporidiosis was detected in samples from 6 of 27 patients with chronic diarrhea, but in none of those from 42 patients with acute diarrhea or 65 patients without diarrhea. The presence of microsporidia spores in stool specimens and duodenal aspirates allowed the successful prediction of the presence of microsporidia in small-bowel biopsy specimens from all four patients who subsequently underwent endoscopy. Conclusions. E. bieneusi is an important cause of chronic diarrhea in HIV-infected persons. This new diagnostic technique serves as a practical, noninvasive means to detect microsporidia spores in stool specimens and is also applicable to the examination of duodenal aspirates.	CTR DIS CONTROL,DIV PARASIT DIS,PARASIT DIS BRANCH,MAILSTOP F13,1600 CLIFTON RD,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,SCI RESOURCES PROGRAM,PATHOL BRANCH,ATLANTA,GA 30333; VET AFFAIRS MED CTR,CELL BIOL & AGING SECT,SAN FRANCISCO,CA; EMORY UNIV,GRADY MEM HOSP,SCH MED,DEPT INTERNAL MED,DIV GASTROENTEROL,ATLANTA,GA 30322; EMORY UNIV,CRAWFORD LONG HOSP,SCH MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,VET AFFAIRS MED CTR,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System			Castro, Kenneth G/P-1882-2018; Schwartz, David A./AAX-7306-2021; Weber, Rainer/D-5175-2012	Castro, Kenneth G/0000-0001-7964-6354; Schwartz, David A./0000-0002-7486-8545; 				ASHTON N, 1973, BRIT J OPHTHALMOL, V57, P669, DOI 10.1136/bjo.57.9.669; BERGQUIST NR, 1984, BRIT MED J, V288, P902, DOI 10.1136/bmj.288.6421.902; Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; Bryan R T, 1991, Prog Clin Parasitol, V2, P1; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CALI A, 1991, J PROTOZOOL, V38, P215; CANNING EU, 1990, T ROY SOC TROP MED H, V84, P181, DOI 10.1016/0035-9203(90)90247-C; CANNING EU, 1986, MICROSPORIDIA VERTEB; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; CURRY A, 1988, J CLIN PATHOL, V41, P477, DOI 10.1136/jcp.41.4.477-b; DAVIS RM, 1990, OPHTHALMOLOGY, V97, P953; DIDIER ES, 1991, J INFECT DIS, V163, P617, DOI 10.1093/infdis/163.3.617; DOBBINS WO, 1985, GASTROENTEROLOGY, V88, P738, DOI 10.1016/0016-5085(85)90145-3; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; GOURLEY WK, 1988, LAB INVEST, V58, pA35; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; JOUVENAZ DP, 1981, J INVERTEBR PATHOL, V37, P319, DOI 10.1016/0022-2011(81)90093-8; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LEDFORD DK, 1985, ANN INTERN MED, V102, P628, DOI 10.7326/0003-4819-102-5-628; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; MARGILETH AM, 1973, ARCH PATHOL, V95, P145; MATSUBAYASHI H, 1959, ARCH PATHOL, V67, P181; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN JM, 1990, LANCET, V336, P1127, DOI 10.1016/0140-6736(90)92600-M; Palk G, 1974, MANUAL CLIN MICROBIO, P930; PINNOLIS M, 1981, ARCH OPHTHALMOL-CHIC, V99, P1044, DOI 10.1001/archopht.1981.03930011044012; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; Sheather A. L., 1923, Journal of Comparative Pathology and Therapeutics, V36, P266; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; ULLRICH R, 1989, ANN INTERN MED, V111, P954, DOI 10.7326/0003-4819-111-11-954_1; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; 1990, MMWR, V39, P188	38	468	486	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					161	166		10.1056/NEJM199201163260304	http://dx.doi.org/10.1056/NEJM199201163260304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1370122	Bronze			2022-12-28	WOS:A1992GZ21300004
J	LOWEL, S; SINGER, W				LOWEL, S; SINGER, W			SELECTION OF INTRINSIC HORIZONTAL CONNECTIONS IN THE VISUAL-CORTEX BY CORRELATED NEURONAL-ACTIVITY	SCIENCE			English	Article							CAT STRIATE CORTEX; FLUORESCENT LATEX MICROSPHERES; OCULAR DOMINANCE; POSTNATAL-DEVELOPMENT; INHIBITION; ASSOCIATION; PROJECTIONS; EXPERIENCE; AREA-18; COLUMNS	In the visual cortex of the brain, long-ranging tangentially oriented axon collaterals interconnect regularly spaced clusters of cells. These connections develop after birth and attain their specificity by pruning. To test whether there is selective stabilization of connections between those cells that exhibit correlated activity, kittens were raised with artificially induced strabismus (eye deviation) to eliminate the correlation between signals from the two eyes. In area 17, cell clusters were driven almost exclusively from either the right or the left eye and tangential intracortical fibers preferentially connected cell groups activated by the same eye. Thus, circuit selection depends on visual experience, and the selection criterion is the correlation of activity.			LOWEL, S (corresponding author), MAX PLANCK INST HIRNFORSCH,DEUTSCHORDEN STR 46,W-6000 FRANKFURT 71,GERMANY.		Singer, Wolf/D-6874-2012					ANDERSON PA, 1988, J NEUROSCI, V8, P2183; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; Damasio A. R., 1990, SEMIN NEUROSCI, V2, P287; Duke-Elder S, 1973, SYSTEM OPHTHALMOLOGY, V6; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; EYSEL UT, 1987, EXP BRAIN RES, V68, P606; FISKEN RA, 1975, PHILOS T ROY SOC B, V272, P487, DOI 10.1098/rstb.1975.0099; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1985, VISION RES, V25, P365, DOI 10.1016/0042-6989(85)90061-6; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; INNOCENTI GM, 1979, NATURE, V280, P231, DOI 10.1038/280231a0; INNOCENTI GM, 1981, SCIENCE, V212, P824, DOI 10.1126/science.7221566; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KONIG P, 1990, SOC NEUR ABSTR, V16; LOWEL S, 1988, EXP BRAIN RES, V71, P33; LOWEL S, 1987, EXP BRAIN RES, V68, P661; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; LOWEL S, 1991, J PHYSIOL-LONDON, V438, pP157; LUHMANN HJ, 1986, EXP BRAIN RES, V63, P443; LUHMANN HJ, 1990, EUR J NEUROSCI, V2, P344, DOI 10.1111/j.1460-9568.1990.tb00426.x; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MATSUBARA JA, 1987, J NEUROSCI, V7, P1428; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; NELSON JI, 1975, J THEOR BIOL, V49, P1, DOI 10.1016/S0022-5193(75)80020-8; PRICE DJ, 1986, DEV BRAIN RES, V24, P31, DOI 10.1016/0165-3806(86)90170-7; PRICE DJ, 1985, NATURE, V316, P721, DOI 10.1038/316721a0; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; SHATZ CJ, 1977, BRAIN RES, V131, P103, DOI 10.1016/0006-8993(77)90031-2; SINGER W, 1976, EXP BRAIN RES, V26, P171; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; SWINDALE NV, 1981, NATURE, V290, P332, DOI 10.1038/290332a0; Von Noorden GK., 1990, BINOCULAR VISION OCU; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0	40	403	408	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					209	212		10.1126/science.1372754	http://dx.doi.org/10.1126/science.1372754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1372754				2022-12-28	WOS:A1992GY70400040
J	BRANCA, F; ROBINS, SP; FERROLUZZI, A; GOLDEN, MHN				BRANCA, F; ROBINS, SP; FERROLUZZI, A; GOLDEN, MHN			BONE TURNOVER IN MALNOURISHED CHILDREN	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; URINARY-EXCRETION; COLLAGEN; GROWTH; MALNUTRITION; CROSSLINKS; MARKERS; AGE	Pyridinoline (PYD) and deoxypyridinoline (DPD) are cross-linking aminoacids of collagen that are located mainly in bone and cartilage. When bone matrix is resorbed these cross-links are quantitatively excreted in the urine and therefore represent specific markers. We have measured the urinary excretion rate of PYD and DPD in 46 severely malnourished boys to assess their skeletal turnover and to relate this to their subsequent rate of growth. The children were aged 13 months (SD 6), and height-for-age was -3.6 (1.6) Z-score, and weight-for-height was -2.4 (0.8) Z-score. PYD excretion when malnourished and after "recovery" was 11.2 (4.6) nmol h-1m-2 and 32.2 (10.8) nmol h-1m-2 and DPD excretion was 2.6 (1.3) nmol h-1m-2 and 7.5 (3.0) nmol h-1m-2, respectively. The ratio of the two cross-links did not change with recovery. These data show that cartilage and bone turnover is much lower in the malnourished than in the recovered child. There was no difference in the degree of depression of turnover between the children with marasmus, marasmic-kwashiorkor, or kwashiorkor. The rate of height gain during recovery was significantly related to cross-link excretion, age, and weight-for-height on admission. These three factors accounted for 44% of the variance in the height velocity of the children. PYD and DPD excretion rate could be used to assess therapeutic interventions designed to alleviate stunting.	UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA; IST NAZL NUTR,ROME,ITALY; ROWETT RES INST,BUCKSBURN AB2 9SB,ABERDEEN,SCOTLAND	University West Indies Mona Jamaica; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); University of Aberdeen	GOLDEN, MHN (corresponding author), UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND.		Golden, Michael/AAB-8989-2020	Golden, Michael/0000-0002-4039-7538	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAMAGUNA AI, 1986, PEDIATR RADIOL, V16, P40, DOI 10.1007/BF02387503; BAUMGARTNER RN, 1986, AM J CLIN NUTR, V43, P711, DOI 10.1093/ajcn/43.5.711; BEARDSWORTH LJ, 1990, J BONE MINER RES, V5, P671; BLACK D, 1988, ANAL BIOCHEM, V169, P197, DOI 10.1016/0003-2697(88)90274-6; BROWN KH, 1982, AM J CLIN NUTR, V36, P303; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; DELMAS PD, 1991, J BONE MINER RES, V6, P639; EASTELL R, 1990, 3RD P INT S OST AALB, P469; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; GARN SM, 1981, AM J ROENTGENOL, V137, P231, DOI 10.2214/ajr.137.2.231; GOLDEN M, 1977, AM J CLIN NUTR, V30, P1345, DOI 10.1093/ajcn/30.8.1345; GOLDEN MHN, 1981, TRACE ELEMENT METABO, V4, P69; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HEIKENS GT, 1989, EUR J CLIN NUTR, V43, P145; Himes J H, 1978, World Rev Nutr Diet, V28, P143; JACKSON AA, 1987, OXFORD TXB MED; LAMPL M, 1978, ANN HUM BIOL, V5, P219, DOI 10.1080/03014467800002841; PICOU D, 1966, CLIN SCI, V30, P345; PICOU D, 1965, CLIN SCI, V29, P517; PRUDHON C, 1991, CR ACAD SCI III-VIE, V313, P233; ROBINS SP, 1988, BAILLIERE CLIN RHEUM, V2, P1, DOI 10.1016/S0950-3579(88)80003-7; ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x; TROTTER M, 1970, AM J PHYS ANTHROPOL, V33, P313, DOI 10.1002/ajpa.1330330305; WALKER SP, 1988, EUR J CLIN NUTR, V42, P395; Wellcome Trust Working Party, 1970, LANCET, V2, P302; WHITEHEAD RG, 1965, LANCET, V2, P567; WILKINSON L, 1990, SYSTAT SYSTEM STATIS	28	61	61	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1493	1496		10.1016/0140-6736(92)92754-4	http://dx.doi.org/10.1016/0140-6736(92)92754-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361595				2022-12-28	WOS:A1992KD06900003
J	FINN, R				FINN, R			BOSTOCK,JOHN, HAY-FEVER, AND THE MECHANISM OF ALLERGY	LANCET			English	Editorial Material											FINN, R (corresponding author), ROYAL LIVERPOOL UNIV HOSP,MED UNIT,LIVERPOOL L7 8XP,ENGLAND.							[Anonymous], LANCET; Blackley CH., 1873, EXPT RES CAUSES NATU; Bostock J, 1819, Med Chir Trans, V10, P161; Bostock J, 1828, Med Chir Trans, V14, P437; Bostock J, 1813, Med Chir Trans, V4, P53; BOSTOCK J, BEST MEANS OBVIATING; BOSTOCK J, 1846, LANCET, V2, P222; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P430; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; SEARS MR, 1990, ASTHMA INFLAMMATORY, P15	15	21	22	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1453	1455						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360571				2022-12-28	WOS:A1992KC28400015
J	ADAM, R; BISMUTH, H; DIAMOND, T; DUCOT, B; MORINO, M; ASTARCIOGLU, I; JOHANN, M; AZOULAY, D; CHICHE, L; BAO, YM; CASTAING, D				ADAM, R; BISMUTH, H; DIAMOND, T; DUCOT, B; MORINO, M; ASTARCIOGLU, I; JOHANN, M; AZOULAY, D; CHICHE, L; BAO, YM; CASTAING, D			EFFECT OF EXTENDED COLD ISCHEMIA WITH UW SOLUTION ON GRAFT FUNCTION AFTER LIVER-TRANSPLANTATION	LANCET			English	Article							EURO-COLLINS SOLUTIONS; HYDROXYETHYL STARCH; PRESERVATION; STORAGE; METABOLISM; 24-HOUR; P-31	Studies in animals on the use of UW solution in liver transplantation have shown an inverse relation between cold ischaemia time (CIT) and graft function. There are few clinical data on this relation in human beings. We have investigated the effect of extended cold ischaemia in a prospective study. We assessed early graft function and subsequent outcome for 306 consecutive elective liver transplantations; for analyses, grafts were grouped according to CIT (< 12 h group A, greater-than-or-equal-to 12 h group B), since a preliminary study identified 12 h as a significant cut-off point. Initial graft function was better in group A than group B, as shown by maximum alanine aminotransferase activity (mean 623 [805] vs 946 [1148], p=0.02), bile production on days 1-3 (p<0.05), maximum serum bilirubin by day 10 (206 [166] vs 244 [163] mumol/l, p=0.04), and frequencies of primary non-function (1 [0.4%] vs 4 [7%], p=0.006) and hepatocyte necrosis on routine biopsy sample after reperfusion (18% vs 31%, p=0.04). Long-term outcome was also better in group A than group B; graft and patient survival rates were higher and fewer retransplantations were needed. These findings suggest that cold ischaemia in UW solution for longer than 12 h is a risk factor for graft function and patient survival. We recommend that the limit of the safe CIT be reconsidered.	HOP BICETRE,INSERM,U292,F-94270 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	ADAM, R (corresponding author), HOP PAUL BROUSSE,HEPATOBILIARY SURG & LIVER TRANSPLANT RES UNIT,F-94800 VILLEJUIF,FRANCE.		Azoulay, Daniel/Q-7887-2018; Morino, Mario/AAI-6437-2020	CHICHE, LAURENCE/0000-0001-9081-4750; Morino, Mario/0000-0003-4540-1409				ADAM R, 1990, TRANSPLANT P, V22, P499; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; BISMUTH H, 1984, SURGERY, V95, P367; BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723; COFER JB, 1990, TRANSPLANTATION, V49, P1088, DOI 10.1097/00007890-199006000-00012; FURUKAWA H, 1991, TRANSPLANT P, V23, P1550; HOWARD TK, 1990, TRANSPLANTATION, V49, P103, DOI 10.1097/00007890-199001000-00023; JAMIESON NV, 1988, TRANSPLANTATION, V46, P512, DOI 10.1097/00007890-198810000-00009; JAMIESON NV, 1989, TRANSPLANT P, V21, P1292; KALAYOGLU M, 1988, LANCET, V1, P617; MORINO M, 1992, CLIN TRANSPLANT, V6, P97; NEDELEC JF, 1990, TRANSPLANT P, V22, P492; NEDELEC JF, 1989, TRANSPLANT P, V21, P1327; OLTHOFF KM, 1990, TRANSPLANTATION, V49, P284, DOI 10.1097/00007890-199002000-00012; SANCHEZURDAZPAL L, 1992, HEPATOLOGY, V16, P49, DOI 10.1002/hep.1840160110; STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343; STRATTA RJ, 1990, TRANSPLANTATION, V50, P438, DOI 10.1097/00007890-199009000-00015; TODO S, 1989, JAMA-J AM MED ASSOC, V261, P711, DOI 10.1001/jama.261.5.711; TODO S, 1989, CLIN TRANSPLANT, V3, P253; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002	20	179	182	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1373	1376		10.1016/0140-6736(92)92559-X	http://dx.doi.org/10.1016/0140-6736(92)92559-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360089				2022-12-28	WOS:A1992KB20200003
J	YOSHINAGA, SK; PETERSON, CL; HERSKOWITZ, I; YAMAMOTO, KR				YOSHINAGA, SK; PETERSON, CL; HERSKOWITZ, I; YAMAMOTO, KR			ROLES OF SWI1, SWI2, AND SWI3 PROTEINS FOR TRANSCRIPTIONAL ENHANCEMENT BY STEROID-RECEPTORS	SCIENCE			English	Article							TUMOR VIRUS PROMOTER; MAMMALIAN GLUCOCORTICOID RECEPTOR; DEHYDROGENASE-II ISOZYME; YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; PREINITIATION COMPLEX; INVITRO TRANSCRIPTION; UPSTREAM ACTIVATION; CHROMATIN STRUCTURE	The SWI1, SWI2, and SWI3 proteins, which are required for regulated transcription of numerous yeast genes, were found also to be essential for rat glucocorticoid receptor function in yeast; the receptor failed to activate transcription in strains with mutations in the SWI1, SWI2, or SWI3 genes. Certain mutations in genes encoding components of chromatin, identified as suppressors of swi mutations, partially relieved the SWI- requirement for receptor function. Immunoprecipitation of glucocorticoid receptor derivatives from wild-type (SWI+) yeast extracts coprecipitated the SWI3 protein; such receptor-SWI3 complexes were not detected in swi1- or swi2- mutant strains, implying that a complex of multiple SWI proteins may associate with the receptor. Prior incubation of a Drosophila embryo transcription extract with the yeast SWI3-specific antibody inhibited receptor function in vitro whereas the antibody had no effect if added after initiation complex formation. Thus, positive regulation by the glucocorticoid receptor in vivo and in vitro appears to require its interaction, at an early step, with one or more SWI proteins.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GUARENTE L, 1992, TRENDS GENET, V8, P27, DOI 10.1016/0168-9525(92)90021-U; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; IMAI E, UNPUB; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, UNPUB; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MOAZED D, COMMUNICATION; NASMYTH K, COMMUNICATION; NEIGEBORN L, 1984, GENETICS, V108, P845; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PERLMANN T, 1991, MOL CELL BIOL, V11, P5259, DOI 10.1128/MCB.11.10.5259; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PICARD D, 1990, GENE, V86, P257, DOI 10.1016/0378-1119(90)90287-2; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAGUCHI AKW, 1987, GENETICS, V116, P531; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WINSTON F, IN PRESS TRENDS GENE; WOOLFORD J, 1986, MOL CELL BIOL, V6, P674; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; YOSHINAGA SK, 1991, MOL ENDOCRINOL, V5, P844, DOI 10.1210/mend-5-6-844; YOSHINAGA SK, UNPUB; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	74	434	439	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1598	1604		10.1126/science.1360703	http://dx.doi.org/10.1126/science.1360703			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360703				2022-12-28	WOS:A1992KA89600021
J	CHATELAIN, P; MEIER, B; DELASERNA, F; MOLES, V; PANDE, AK; VERINE, V; URBAN, P				CHATELAIN, P; MEIER, B; DELASERNA, F; MOLES, V; PANDE, AK; VERINE, V; URBAN, P			SUCCESS WITH CORONARY ANGIOPLASTY AS SEEN AT DEMONSTRATIONS OF PROCEDURE	LANCET			English	Article							NATIONAL-HEART; OCCLUSION; REGISTRY; STENTS; LUNG	To assess the real-life results of coronary angioplasty, unidentified participants made notes on 104 cases demonstrated live at twelve international angioplasty courses in 1991. The initially planned procedure was successful in 73% with crossover to another device in 20% for an ultimate success rate of 93%. Interventions lasted an hour on average and two devices on average were used per artery tackled. Rates of success and of complication necessitating reintervention were, for balloon angioplasty (57 cases) 81% and 19%, for directional atherectomy (16 cases) 75% and 0%, for the Rotablator (12 cases) 42% and 42%, for stent implantation (10 cases) 100% and 0%, for excimer laser angioplasty (6 cases) 17% and 33%, and for Rotacs recanalisation (3 cases) 67% and 0%, respectively. The complications were occlusions (threatened, acute, or delayed) and they were usually treated by balloon angioplasty or a stent. No death or myocardial infarction was reported. The observer attending the demonstration tended to take a less favourable view of the outcome than the clinician doing the procedure and in general the results of coronary angioplasty seemed inferior to those reported in journals. Interventions done before an audience will be unusually stressful but this will be outweighed by the fact that difficult cases with a low probability of success are rarely tackled during live courses. This survey suggests that conventional balloon angioplasty, complemented by stent implantation in selected cases, is the treatment of choice.	UNIV GENEVA,HOP CANTONAL,CTR CARDIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			DE LA SERNA, JAVIER/B-1735-2012	DE LA SERNA, JAVIER/0000-0003-3904-1101				DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ERBEL R, 1986, CATHETER CARDIO DIAG, V12, P116, DOI 10.1002/ccd.1810120211; FOURRIER JL, 1989, J AM COLL CARDIOL, V14, P1278, DOI 10.1016/0735-1097(89)90428-2; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; HINOHARA T, 1990, CIRCULATION, V81, P79; HOLMES DR, 1990, TXB INTERVENTIONAL C, P223; KALTENBACH M, 1989, J INTERVEN CARDIOL, V2, P137; LITVACK F, 1989, LANCET, V1, P102; Meany T B, 1991, J Invasive Cardiol, V3, P19; MEIER B, 1992, JAMA-J AM MED ASSOC, V268, P741, DOI 10.1001/jama.268.6.741; SANBORN TA, 1991, J AM COLL CARDIOL, V17, P94, DOI 10.1016/0735-1097(91)90709-I; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHATZ RA, 1989, CIRCULATION, V79, P445, DOI 10.1161/01.CIR.79.2.445; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL E J, 1992, Journal of the American College of Cardiology, V19, p138A; UMANS V, 1992, EUR HEART J, V13, P918, DOI 10.1093/oxfordjournals.eurheartj.a060293; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C	18	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1202	1205		10.1016/0140-6736(92)92900-Z	http://dx.doi.org/10.1016/0140-6736(92)92900-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359269				2022-12-28	WOS:A1992JY38600012
J	YUSUF, S; PEPINE, CJ; GARCES, C; POULEUR, H; SALEM, D; KOSTIS, J; BENEDICT, C; ROUSSEAU, M; BOURASSA, M; PITT, B				YUSUF, S; PEPINE, CJ; GARCES, C; POULEUR, H; SALEM, D; KOSTIS, J; BENEDICT, C; ROUSSEAU, M; BOURASSA, M; PITT, B			EFFECT OF ENALAPRIL ON MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA IN PATIENTS WITH LOW EJECTION FRACTIONS	LANCET			English	Article							CORONARY HEART-DISEASE; CONVERTING ENZYME-INHIBITION; RANDOMIZED CLINICAL-TRIALS; BLOOD-PRESSURE; PRIMARY-PREVENTION; ANGIOTENSIN-II; FAILURE; STROKE; RISK; HYPERTENSION	An association between raised renin levels and myocardial infarction has been reported. We studied the effects of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, on the development of myocardial infarction and unstable angina in 6797 patients with ejection fractions less-than-or-equal-to 0.35 enrolled into the two Studies of Left Ventricular Dysfunction (SOLVD) trials. Patients were randomly assigned to placebo (n = 3401) or enalapril (n = 3396) at doses of 2.5-20 mg per day in two concurrent double-blind trials with the same protocol. Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial (n = 4228). Follow-up averaged 40 months. In each trial there were significant reductions in the number of patients developing myocardial infarction (treatment trial: 158 placebo vs 127 enalapril, p < 0.02; prevention trial: 204 vs 161 p < 0.01) or unstable angina (240 vs 187 p < 0.001; 355 vs 312, p < 0.05). Combined, there were 362 placebo group patients with myocardial infarction compared with 288 in the enalapril group (risk reduction 23%, 95% Cl 11-34%; p < 0.001). 595 placebo group patients developed unstable angina compared with 499 in the enalapril group (risk reduction 20%, 95% Cl 9-29%, p < 0.001). There was also a reduction in cardiac deaths (711 placebo, 615 enalapril; p < 0.003), so that the reduction in the combined endpoint of deaths, myocardial infarction, and unstable angina was highly significant (20% risk reduction, 95% CI 14-26%; p < 0.0001). Enalapril treatment significantly reduced myocardial infarction, unstable angina, and cardiac mortality in patients with low ejection fractions.	NHLBI, BETHESDA, MD 20892 USA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UNIV TEXAS, MED CTR, HOUSTON, TX 77025 USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; ROBERT WOOD JOHNSON MED CTR, NEW BRUNSWICK, NJ USA; UNIV CATHOLIQUE LOUVAIN, B-1348 LOUVAIN, BELGIUM; MONTREAL HEART INST, MONTREAL H1T 1C8, QUEBEC, CANADA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida; University of North Carolina; University of North Carolina Chapel Hill; Tufts Medical Center; University of Texas System; University of Michigan System; University of Michigan; Rutgers State University New Brunswick; Rutgers State University Medical Center; Universite Catholique Louvain; Universite de Montreal				Bourassa, Martial G./0000-0002-4439-8650; Yusuf, Salim/0000-0003-4776-5601				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; [Anonymous], 1990, Am J Cardiol, V66, P315; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; CLELAND JGF, 1991, J AM COLL CARDIOL, V17, P733, DOI 10.1016/S0735-1097(10)80192-5; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; DZAU VJ, 1989, BRIT J CLIN PHARMACO, V28, pS183, DOI 10.1111/j.1365-2125.1989.tb03594.x; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GAVRAS H, 1971, LANCET, V2, P19; GAVRAS I, 1987, ANGIOTENSIN CONVERTI, P93; GIBBS JSR, 1989, BRIT HEART J, V62, P112; KATZ AM, 1990, J MOL CELL CARDIOL, V22, P739, DOI 10.1016/0022-2828(90)90086-H; KIOWSKI W, 1991, AM HEART J, V122, P1382, DOI 10.1016/0002-8703(91)90581-2; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; ONTKEAN MT, 1992, J AM COLL CARDIOL  S, V19, P768; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWELL JS, 1991, CLIN RES, V39, pA287; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1990, CIRCULATION, V42, P455; 1985, PROG CARDIOVASC DIS, V27, P335	27	625	636	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1173	1178		10.1016/0140-6736(92)92889-N	http://dx.doi.org/10.1016/0140-6736(92)92889-N			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359258	Green Submitted			2022-12-28	WOS:A1992JY38600001
J	LAHTINEN, R; LAAKSO, M; PALVA, I; VIRKKUNEN, P; ELOMAA, I				LAHTINEN, R; LAAKSO, M; PALVA, I; VIRKKUNEN, P; ELOMAA, I			RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL OF CLODRONATE IN MULTIPLE-MYELOMA	LANCET			English	Article							DICHLOROMETHYLENE DIPHOSPHONATE; BONE METASTASES; PAGETS-DISEASE; HYPERCALCEMIA; MALIGNANCY; CL2MDP	Osteolytic lesions and pathological fractures are common in multiple myeloma. Because clodronate inhibits osteoclastic resorption, we did a randomised, controlled trial in 350 patients from 23 hospitals. All patients received standard melphalan-prednisolone, and were randomised to receive clodronate 2.4 g daily or placebo for 24 months. The proportion of patients with progression of osteolytic bone lesions was twice as high in the placebo group (n = 168 at baseline) than in the clodronate group (n = 168 at baseline) in an intention-to-treat analysis (24 vs 12%, p = 0.026). Progression of vertebral fractures was lower in the clodronate group, but the difference was not significant (30 vs 40%). Serum calcium and urinary calcium excretion decreased significantly in both groups, but the changes were greater in the clodronate group. The percentage of patients feeling no pain increased more in the clodronate group (from 24 to 54%, p < 0.001) than in the placebo group (from 29 to 44%, p < 0.01). Side-effects were similar in both groups. We conclude that clodronate is an effective and safe adjunct in the management of multiple myeloma. The drug delays osteolytic bone lesions, reduces the degree of hypercalcaemia and hypercalciuria, and decreases pain.	KUOPIO UNIV HOSP,DEPT MED,SF-70210 KUOPIO,FINLAND; HATANPAA HOSP,TAMPERE,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT RADIOTHERAPY,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT ONCOL,SF-00100 HELSINKI 10,FINLAND	Kuopio University Hospital; University of Eastern Finland; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital								BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909; BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397; BICKERSTAFF DR, 1991, BONE, V12, P17, DOI 10.1016/8756-3282(91)90049-O; CHAPUY MC, 1980, J CLIN INVEST, V65, P1243, DOI 10.1172/JCI109780; CHAPUY MC, 1983, METAB BONE DIS RELAT, V4, P325; DELMAS PD, 1982, METAB BONE DIS RELAT, V4, P163, DOI 10.1016/0221-8747(82)90013-3; DOUGLAS DL, 1980, ARTHRITIS RHEUM, V23, P1185, DOI 10.1002/art.1780231017; DOUGLAS DL, 1980, LANCET, V1, P1043; DURIE BMG, 1979, RECENT ADV HAEMATOLO, V2, P243; ELOMAA I, 1983, LANCET, V1, P146; JACOBS TP, 1981, ANN INTERN MED, V94, P312, DOI 10.7326/0003-4819-94-3-312; KANIS JA, 1980, METAB BONE DIS RELAT, V2, P151, DOI 10.1016/0221-8747(80)90022-3; KANIS JA, 1991, BONE, V12, pS13, DOI 10.1016/8756-3282(91)90061-M; Krisyin Kanis J.A., 1990, PROG BASIC CLIN PHAR, V4, P89; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; LUZZANI M, 1990, INT J CLIN PHARM RES, V4, P243; MERLINI G, 1990, HEMATOL ONCOL, V8, P23, DOI 10.1002/hon.2900080104; MEUNIER PJ, 1980, ARTHRITIS RHEUM-US, V23, P1095, DOI 10.1002/art.1780231005; MORTON AR, 1988, BRIT J CANCER, V58, P556, DOI 10.1038/bjc.1988.257; MUNDY GR, 1987, BONE, V8, pS9; PATERSON AD, 1983, BRIT J HAEMATOL, V54, P121, DOI 10.1111/j.1365-2141.1983.tb02074.x; PERCIVAL RC, 1985, BRIT J CANCER, V51, P665, DOI 10.1038/bjc.1985.100; SIRIS ES, 1980, NEW ENGL J MED, V302, P310, DOI 10.1056/NEJM198002073020602; SPIRO TP, 1980, CALCIFIED TISSUE INT, V31, P66; URWIN GH, 1987, BONE S1, V8, P43; WITTE RS, 1987, ARCH INTERN MED, V147, P937, DOI 10.1001/archinte.147.5.937	27	320	324	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1049	1052		10.1016/0140-6736(92)93075-X	http://dx.doi.org/10.1016/0140-6736(92)93075-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357451				2022-12-28	WOS:A1992JV77500001
J	WALRAVENS, PA; CHAKAR, A; MOKNI, R; DENISE, J; LEMONNIER, D				WALRAVENS, PA; CHAKAR, A; MOKNI, R; DENISE, J; LEMONNIER, D			ZINC SUPPLEMENTS IN BREAST-FED INFANTS	LANCET			English	Article							CHILDREN	Among breastfed infants, growth faltering in comparison with reference growth curves is common in both developing and developed countries. We performed a zinc supplementation trial in Paris, France, to find out whether such growth faltering is due to nutritional zinc deficiency. 57 breastfed infants aged 4-9 (mean 5.7) months were randomly assigned to receive either 5 mg zinc daily or a placebo for 3 months. Most of the infants were from low-income immigrant families and the majority were of African origin. Before supplementation there were no significant differences between the zinc and placebo groups in weight, length, or corresponding Z-scores for age. After 3 months' supplementation, the length for-age Z-score had increased in the zinc group and fallen in the placebo group (+0.21 vs -0.13, p=0.029). This difference was due mainly to greater linear growth of boys in the zinc than in the placebo group (6.0 vs 4.6 cm, p=0.02). Weight gain was also significantly greater with zinc supplementation (1.64 vs 1.28 kg, p=0.047). Among infants breastfed for longer than 4 months, decreases in growth velocity result partly from inadequate zinc intake.	INSERM,U1,F-75005 PARIS,FRANCE; CTR PROTECT MATERNELLE & INFANTILE,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								BUTTE NF, 1992, AM J CLIN NUTR, V55, P1109, DOI 10.1093/ajcn/55.6.1109; DEWEY KG, 1991, J PEDIATR-US, V119, P538, DOI 10.1016/S0022-3476(05)82401-1; DEWEY KG, 1992, PEDIATRICS, V89, P1035; FAVIER AE, 1992, BIOL TRACE ELEM RES, V32, P383, DOI 10.1007/BF02784624; GOLDEN MHN, 1981, AM J CLIN NUTR, V34, P900, DOI 10.1093/ajcn/34.5.900; GUIGLIANO R, 1984, BR J NUTR, V52, P545; HIJAZI SS, 1989, ACTA PAEDIATR SCAND, V78, P23, DOI 10.1111/j.1651-2227.1989.tb10881.x; KREBS NF, 1985, AM J CLIN NUTR, V41, P571; KREBS NF, 1983, AJDC, V138, P270; KREBS NF, 1991, AM J CLIN NUTR, V53, P54; PRENTICE AM, 1988, LANCET, V2, P1066, DOI 10.1016/S0140-6736(88)90077-3; SALMENPERA L, 1985, PEDIATR RES, V19, P307, DOI 10.1203/00006450-198503000-00011; SIMMER K, 1990, BRIT J NUTR, V63, P91, DOI 10.1079/BJN19900094; STRUFF JE, 1989, J PEDIATR, V115, P959; WALRAVENS PA, 1989, PEDIATRICS, V83, P532; [No title captured]; DHEW PHS781650 PUBL	17	89	91	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					683	685		10.1016/0140-6736(92)92229-9	http://dx.doi.org/10.1016/0140-6736(92)92229-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355797				2022-12-28	WOS:A1992JN78000001
J	SIMEONE, A; ACAMPORA, D; GULISANO, M; STORNAIUOLO, A; BONCINELLI, E				SIMEONE, A; ACAMPORA, D; GULISANO, M; STORNAIUOLO, A; BONCINELLI, E			NESTED EXPRESSION DOMAINS OF 4 HOMEOBOX GENES IN DEVELOPING ROSTRAL BRAIN	NATURE			English	Article							DROSOPHILA HEAD DEVELOPMENT; ORTHODENTICLE GENE; NERVOUS-SYSTEM; HOMEODOMAIN; FOREBRAIN; EMBRYO; MOUSE	INSIGHT into the genetic control of the identity of specific regions along the body axis of vertebrates1 has resulted primarily from the study of vertebrate homologues of regulatory genes operating in the Drosophila trunk2, but little is known about the development of most anterior regions of the body either in flies3,4 or vertebrates. Three Drosophila genes have been identified that are important in controlling the development of the head5-8, two of which, empty spiracles5 and orthodenticle8, have been cloned and shown to contain a homeobox9-11. We previously cloned and characterized Emx1 and Emx2, two mouse genes related to empty spiracles that are expressed in restricted regions of the developing forebrain, including the presumptive cerebral cortex and olfactory bulbs12. Here we report the identification of Otx1 and Otx2, which are related to orthodenticle7,8. We have compared the expression domains of the four genes in the developing rostral brain of mouse embryos at a developmental stage, day 10 post coitum, when they are all expressed. Otx2 is expressed in every dorsal and most ventral regions of telencephalon, diencephalon and mesencephalon. The Otx1 expression domain is similar to that of Otx2, but contained within it. The Emx2 expression domain is comprised of dorsal telencephalon and small diencephalic regions, both dorsally and ventrally. Finally, Emx1 expression is exclusively confined to the dorsal telencephalon. Thus at the time when regional specification of major brain regions takes place, the expression domains of the four genes seem to be continuous regions contained within each other in the sequence Emx1 < Emx2 < Otx1 < Otx2.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Acampora, Dario/C-2156-2013; Simeone, Antonio/ABG-5269-2020; Gulisano, Massimo/F-6609-2012	Simeone, Antonio/0000-0003-2693-9836; Gulisano, Massimo/0000-0001-8654-1745				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINKELSTEIN R, 1991, DEVELOPMENT, V112, P899; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; HOLLAND P, 1992, BIOESSAYS, V14, P267, DOI 10.1002/bies.950140412; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; SAKAI Y, 1987, ANAT REC, V218, P450, DOI 10.1002/ar.1092180414; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; WILKINSON D, 1990, POSTIMPLANTATION MOU	24	701	717	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					687	690		10.1038/358687a0	http://dx.doi.org/10.1038/358687a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1353865				2022-12-28	WOS:A1992JJ88200060
J	AABY, P				AABY, P			INFLUENCE OF CROSS-SEX TRANSMISSION ON MEASLES MORTALITY IN RURAL SENEGAL	LANCET			English	Article							INTENSIVE EXPOSURE; CHILD-MORTALITY; INFECTION; PATTERN	Previous studies of measles mortality in West Africa have shown a significantly higher case-fatality rate (CFR) among girls than among boys. This study aimed to find out whether the male/female difference in CFR is related to different risks for boys and girls of being infected as secondary rather than index cases and of transmission from someone of the same or the opposite sex. The study was conducted in Niakhar, a rural area of Senegal (population 24 000). All cases of measles reported between March, 1983, and December, 1986, were investigated to determine source of infection and pattern of transmission. For each case, the closest source of infection was judged the most likely. Death was attributed to measles if it occurred within 6 weeks of the onset of rash. Girls had a higher measles CFR than boys (53 deaths/722 cases [7.3%] vs 45/778 [5.8%]); the relative risk of death was 1.30 (95% confidence interval [CI] 0.89-1.90). Secondary cases infected by a child of the opposite sex had a 2.44 (1.48-4.02) times higher risk of death than did secondary cases infected by a child of the same sex. The risk of cross-sex transmission of infection was significantly greater for female than for male secondary cases (1.26 [1.09-1.47]). When this difference in risk of exposure to infection from the opposite sex was taken into account, the difference in risk of death between girls and boys disappeared (1.06 [0.66-1.69]). Within families, the CFR was higher in huts with 1 boy and 1 girl affected than in huts of either 2 boys or 2 girls affected (relative risk 2.16 [0.99-4.70]). Measles infection contracted from a person of the opposite sex is more severe. Variation in exposure may be an important determinant of sex differences in case fatality.	ORSTOM,UNITE RECH POPULAT & SANTE,DAKAR,SENEGAL; STATENS SERUM INST,DEPT EPIDEMIOL,DK-2300 COPENHAGEN,DENMARK	Institut de Recherche pour le Developpement (IRD); Statens Serum Institut				Aaby, Peter/0000-0001-8331-1389				AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5; AABY P, 1991, J INFECTION, V22, P287, DOI 10.1016/S0163-4453(05)80014-3; AABY P, 1988, REV INFECT DIS, V10, P478; AABY P, 1991, ANN TROP PAEDIATR, V11, P397, DOI 10.1080/02724936.1991.11747537; AABY P, 1991, INT J EPIDEMIOL, V20, P504, DOI 10.1093/ije/20.2.504; AABY P, 1984, REV INFECT DIS, V6, P239; AABY P, 1990, BRIT MED J, V301, P143, DOI 10.1136/bmj.301.6744.143; AABY P, 1986, REV INFECT DIS, V8, P138; AABY P, 1983, ANTHR SOC, V7, P47; ARGUES P, 1988, DOUZE ANS MORTALITE; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BHUIYA A, 1984, SOC SCI MED, V24, P439; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; Garenne M. L, 1982, THESIS U PENNSYLVANI; MCGREGOR I A, 1964, West Afr Med J, V13, P251; MONASTIRI H, 1961, Tunis Med, V39, P179; PISON G, 1992, BRIT MED J, V304, P284, DOI 10.1136/bmj.304.6822.284; Rothman K, 1986, MODERN EPIDEMIOLOGY; 1991, WKLY EPIDEMIOL REC, V66, P249; IN PRESS WKLY EPIDEM	20	30	31	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					388	391		10.1016/0140-6736(92)91470-S	http://dx.doi.org/10.1016/0140-6736(92)91470-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353555				2022-12-28	WOS:A1992JJ44900003
J	KAYE, SB; LEWIS, CR; PAUL, J; DUNCAN, ID; GORDON, HK; KITCHENER, HC; CRUICKSHANK, DJ; ATKINSON, RJ; SOUKOP, M; RANKIN, EM; CASSIDY, J; DAVIS, JA; REED, NS; CRAWFORD, SM; MACLEAN, A; SWAPP, GA; SARKAR, TK; KENNEDY, JH; SYMONDS, RP				KAYE, SB; LEWIS, CR; PAUL, J; DUNCAN, ID; GORDON, HK; KITCHENER, HC; CRUICKSHANK, DJ; ATKINSON, RJ; SOUKOP, M; RANKIN, EM; CASSIDY, J; DAVIS, JA; REED, NS; CRAWFORD, SM; MACLEAN, A; SWAPP, GA; SARKAR, TK; KENNEDY, JH; SYMONDS, RP			RANDOMIZED STUDY OF 2 DOSES OF CISPLATIN WITH CYCLOPHOSPHAMIDE IN EPITHELIAL OVARIAN-CANCER	LANCET			English	Article							COMBINATION CHEMOTHERAPY; CARCINOMA; CARBOPLATIN; REGIMENS; TRIAL	Cisplatin is generally accepted to be the most active cytotoxic agent for the treatment of ovarian cancer but the optimum dose remains unclear. We have performed a randomised trial to assess the importance of cisplatin dose in the treatment of advanced epithelial ovarian cancer. Patients were randomly assigned treatment with 50 mg/m2 (low dose) or 100 mg/m2 (high dose) cisplatin plus 750 mg/m2 cyclophosphamide, for a maximum of six cycles with intervals of 3 weeks. We planned to recruit 300 patients, but an interim analysis on the first 165 indicated a highly significant survival difference (p = 0.0008). Recruitment was therefore stopped and the trial patients were followed-up for 12 months longer. The relative progression rate (high-dose/low-dose) after 12 months' extra follow-up was 0.55 (95% confidence interval 0.37-0.81, p = 0.003) and the relative death rate 0.53 (0.34-0.81, p = 0.003). Overall median survival was 69 weeks in the low-dose group and 114 weeks in the high-dose group. Residual disease extent before chemotherapy had an important influence-patients with lesions of less than 2 cm did best; if given high-dose cisplatin their median survival was 3 years. 56 low-dose and 45 high-dose patients completed six cycles of chemotherapy; 15 and 9 patients, respectively, were withdrawn early because of progressive disease and treatment was stopped in 6 and 25, respectively, because of unacceptable side-effects or patient refusal. Toxic effects were significantly greater in the high-dose group, especially those on the nervous system and ears, alopecia, vomiting, and anaemia. Although the higher dose of cisplatin clearly leads to better results in terms of survival, its overall clinical benefit in the management of ovarian cancer will depend on further improvements in measures to alleviate toxic effects.	GLASGOW ROYAL INFIRM, GLASGOW G4 0SF, SCOTLAND; STOBHILL GEN HOSP, GLASGOW G21 3UW, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DUNDEE DD1 9SY, SCOTLAND; ABERDEEN ROYAL INFIRM, ABERDEEN AB9 2ZB, SCOTLAND; BELFAST CITY HOSP, BELFAST BT9 7AD, ANTRIM, NORTH IRELAND; AIREDALE HOSP, W YORKSHIRE, ENGLAND	University of Glasgow; University of Dundee; University of Aberdeen; Belfast City Hospital	KAYE, SB (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP, BEATSON ONCOL CTR, GLASGOW G11 6NT, SCOTLAND.			Paul, James/0000-0001-7367-5816				AAPRO MS, 1991, EUR J CANCER, V27, P356, DOI 10.1016/0277-5379(91)90545-O; BLAND M, 1987, INTRO MED STATISTICS; COX DR, 1972, J R STAT SOC B, V34, P187; DEMBO AJ, 1986, J CLIN ONCOL, V4, P1573, DOI 10.1200/JCO.1986.4.11.1573; DIRE F, 1990, CANCER CHEMOTH PHARM, V25, P355, DOI 10.1007/BF00686237; EHRLICH CE, 1983, CLIN OBSTET GYNAECOL, V10, P325; EINHORN L, 1990, P AN M AM SOC CLIN, V9, P132; HAMERS FD, 1990, P AN M AM SOC CLIN, V9, P140; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMBERT HE, 1985, BRIT MED J, V290, P889, DOI 10.1136/bmj.290.6472.889; LEVIN L, 1987, J CLIN ONCOL, V5, P756, DOI 10.1200/JCO.1987.5.5.756; MANGIONI C, 1989, J NATL CANCER I, V81, P1464, DOI 10.1093/jnci/81.19.1464; MCGUIRE WP, 1989, J NATL CANCER I, V81, P1438, DOI 10.1093/jnci/81.19.1438; MCGUIRE WP, 1992, P AN M AM SOC CLIN, V11, P226; MOLLMAN JE, 1988, CANCER, V61, P2192, DOI 10.1002/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; NGAN HYS, 1989, CHEMOTHERAPY, V35, P221, DOI 10.1159/000238673; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RANKIN EM, 1992, BRIT J CANCER, V65, P275, DOI 10.1038/bjc.1992.55; SAMSON MK, 1984, CANCER, V53, P1029, DOI 10.1002/1097-0142(19840301)53:5<1029::AID-CNCR2820530503>3.0.CO;2-Z; STEWART LA, 1991, BRIT MED J, V303, P884; VANDERHOOP RG, 1990, NEW ENGL J MED, V322, P89, DOI 10.1056/NEJM199001113220204; 1979, HDB REPORTING RESULT	24	198	200	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1992	340	8815					329	333		10.1016/0140-6736(92)91404-V	http://dx.doi.org/10.1016/0140-6736(92)91404-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353804				2022-12-28	WOS:A1992JH12500003
J	MENNIE, ME; GILFILLAN, A; COMPTON, M; CURTIS, L; LISTON, WA; PULLEN, I; WHYTE, DA; BROCK, DJH				MENNIE, ME; GILFILLAN, A; COMPTON, M; CURTIS, L; LISTON, WA; PULLEN, I; WHYTE, DA; BROCK, DJH			PRENATAL SCREENING FOR CYSTIC-FIBROSIS	LANCET			English	Article							IDENTIFICATION; GENE	Screening for carriers of CF (cystic fibrosis) is now possible but the best way of delivering such a service is unknown. In one model 4348 women attending antenatal clinics in an Edinburgh maternity hospital were invited to participate in a trial of prenatal screening. Mouthwash samples were tested for six CF alleles (85% of mutant genes) and when a woman was found to be a CF carrier her partner was also tested. Heterozygous couples were offered prenatal diagnosis. 609 (14%) women declined to enter the trial and another 574 (13%) were not screened, usually because of late booking. Among the remaining 3165 women there were 111 carriers of a CF gene (1 in 29). 4 of these 111 had carrier partners and these couples opted for prenatal diagnosis, the 1 pregnancy with an affected fetus being terminated. The psychological impact of screening was assessed by the general health questionnaire. There was a significant increase in stress at the time of the test result among women identified as carriers. However, this disappeared when their male partners tested normal and did not reappear later in the pregnancy. By providing time for couples to discuss the possibility of screening and by offering the test at a point (the antenatal booking clinic) at which most pregnant women are seen, this approach has advantages, provided that counselling is readily available.	UNIV EDINBURGH,HUMAN GENET UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHIAT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT NURSING STUDIES,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh								BROCK DJH, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92013-R; FERRIE RM, 1991, AM J HUM GENET, V49, pA993; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; KEREM B, 1989, SCIENCE, V345, P1073; MARI JD, 1985, PSYCHOL MED, V15, P651; MCINTOSH I, 1989, LANCET, V2, P1404; MENNIE ME, 1992, J MED GENET, V29, P308, DOI 10.1136/jmg.29.5.308; MODELL B, 1990, J MED GENET, V27, P475, DOI 10.1136/jmg.27.8.475; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHAPIRO DA, 1989, NEW YORK STATE J MED, V89, P317; SHARP DJ, 1988, PSYCHOL MED, V18, P503, DOI 10.1017/S0033291700008047; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1989, PRENATAL DIAGNOSIS G	16	121	123	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					214	216		10.1016/0140-6736(92)90476-J	http://dx.doi.org/10.1016/0140-6736(92)90476-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353143				2022-12-28	WOS:A1992JE75800011
J	PALERMO, G; JORIS, H; DEVROEY, P; VANSTEIRTEGHEM, AC				PALERMO, G; JORIS, H; DEVROEY, P; VANSTEIRTEGHEM, AC			PREGNANCIES AFTER INTRACYTOPLASMIC INJECTION OF SINGLE SPERMATOZOON INTO AN OOCYTE	LANCET			English	Note							EMBRYOS; SPERM; ZONA	Intracytoplasmic sperm injection (ICSI) is a promising assisted-fertilisation technique that may benefit women who have not become pregnant by in-vitro fertilisation (IVF) or subzonal insemination (SUZI) of oocytes. We have used ICSI to treat couples with infertility because of severely impaired sperm characteristics, and in whom IVF and SUZI had failed. Direct injection of a single spermatozoon into the ooplasm was done in 47 metaphase-II oocytes: 38 oocytes remained intact after injection, 31 became fertilised, and 15 embryos were replaced in utero. Four pregnancies occurred after eight treatment cycles-two singleton and one twin pregnancy, and a preclinical abortion. Two healthy boys have been delivered from the singleton pregnancies and a healthy boy and girl from the twin pregnancy.			PALERMO, G (corresponding author), VRIJE UNIV BRUSSELS,ACAD ZIEKENHUIS,CTR REPROD MED,LAARBEEKLAAN 101,B-1090 BRUSSELS,BELGIUM.							COHEN J, 1988, LANCET, V2, P162; IRITANI A, 1991, MOL REPROD DEV, V28, P199, DOI 10.1002/mrd.1080280214; LANZENDORF SE, 1988, FERTIL STERIL, V49, P835; NG SC, 1991, FERTIL STERIL, V56, P1117; NG SC, 1988, LANCET, V2, P790; PALERMO G, 1991, MOL REPROD DEV, V30, P339, DOI 10.1002/mrd.1080300408; PALERMO G, 1992, HUM REPROD, V7, P248, DOI 10.1093/oxfordjournals.humrep.a137626; VANSTEIRTEGHEM AC, 1987, HUM REPROD, V2, P593, DOI 10.1093/oxfordjournals.humrep.a136595; VEECK LL, 1990, 45TH P ANN M AM FERT	9	2452	2593	7	130	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					17	18		10.1016/0140-6736(92)92425-F	http://dx.doi.org/10.1016/0140-6736(92)92425-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351601				2022-12-28	WOS:A1992JC35400005
J	GAO, YJ; THOMAS, JO; CHOW, RL; LEE, GH; COWAN, NJ				GAO, YJ; THOMAS, JO; CHOW, RL; LEE, GH; COWAN, NJ			A CYTOPLASMIC CHAPERONIN THAT CATALYZES BETA-ACTIN FOLDING	CELL			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; TCP-1; CELLS; GROE; ARCHAEBACTERIA; MITOCHONDRIA; PURIFICATION	We have isolated a cytoplasmic chaperonin based on its ability to catalyze the folding of denatured beta-actin. The cytoplasmic chaperonin is organized as a multisubunit toroid and requires Mg2+ and ATP for activity. The folding reaction proceeds via the rapid ATP-independent formation of a binary complex, followed by a slower ATP-dependent release of the native product. Electron microscopic observations reveal a striking structural change that occurs upon addition of Mg2+ and ATP. The eukaryotic cytoplasm thus contains a chaperonin that is functionally analagous to its prokaryotic, mitochondrial, and chloroplastic counter parts.			GAO, YJ (corresponding author), NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016, USA.							AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUTCHISON EG, 1989, EMBO J, V8, P1484; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MILLER SG, 1990, J MOL BIOL, V214, P407, DOI 10.1016/0022-2836(90)90190-W; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHI Y, 1992, IN PRESS MOL CELL BI; SILVER LM, 1979, P NATL ACAD SCI USA, V77, P6077; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRENT JT, 1992, NATURE, V354, P490; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; ZILLIG W, 1987, ANN NY ACAD SCI, V503, P78, DOI 10.1111/j.1749-6632.1987.tb40599.x	40	427	439	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					1043	1050		10.1016/0092-8674(92)90622-J	http://dx.doi.org/10.1016/0092-8674(92)90622-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1351421	hybrid			2022-12-28	WOS:A1992HY79200015
J	MILLER, B; SARANTIS, M; TRAYNELIS, SF; ATTWELL, D				MILLER, B; SARANTIS, M; TRAYNELIS, SF; ATTWELL, D			POTENTIATION OF NMDA RECEPTOR CURRENTS BY ARACHIDONIC-ACID	NATURE			English	Article							LONG-TERM POTENTIATION; METHYL-D-ASPARTATE; PROTEIN KINASE-C; NORDIHYDROGUAIARETIC ACID; STRIATAL NEURONS; GLUTAMATE UPTAKE; 2ND MESSENGERS; DENTATE GYRUS; FATTY-ACIDS; RAT	ARACHIDONIC acid is released by phospholipase A2 when activation of N-methyl-D-aspartate (NMDA) receptors by neurotransmitter glutamate raises the calcium concentration in neurons 1,2, for example during the initiation of long-term potentiation and during brain anoxia 3,4. Here we investigate the effect of arachidonic acid on glutamate-gated ion channels by whole-cell clamping isolated cerebellar granule cells. Arachidonic acid potentiates, and makes more transient, the current through NMDA receptor channels, and slightly reduces the current through non-NMDA receptor channels. Potentiation of the NMDA receptor current results from an increase in channel open probability, with no change in open channel current. We observe potentiation even with saturating levels of agonist at the glutamate- and glycine-binding sites on these channels; it does not result from conversion of arachidonic acid to lipoxygenase or cyclooxygenase derivatives, or from activation of protein kinase C. Arachidonic acid may act by binding to a site on the NMDA receptor, or by modifying the receptor's lipid environment. Our results suggest that arachidonic acid released by activation of NMDA (or other) receptors will potentiate NMDA receptor currents, and thus amplify increases in intracellular calcium concentration caused by glutamate. This may explain why inhibition of phospholipase A2 blocks the induction of long-term potentiation 5.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	MILLER, B (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND.		Attwell, David/ABE-6750-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DAVIES J, 1982, COMP BIOCHEM PHYS C, V72, P211, DOI 10.1016/0306-4492(82)90086-7; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; GOPPELTSTRUEBE M, 1986, PROSTAGLANDINS, V32, P373, DOI 10.1016/0090-6980(86)90006-7; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKADA D, 1989, NEUROSCI LETT, V100, P141, DOI 10.1016/0304-3940(89)90674-5; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SPROSEN TS, 1990, EUR J PHARMACOL, V179, P477, DOI 10.1016/0014-2999(90)90193-A; WEAST RC, 1971, CRC HDB CHEM PHYSICS, pF47; WILLIAMS JH, 1988, NEUROSCI LETT, V88, P81, DOI 10.1016/0304-3940(88)90319-9	26	419	432	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					722	725		10.1038/355722a0	http://dx.doi.org/10.1038/355722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1371330				2022-12-28	WOS:A1992HE60400062
J	ZANETTI, M				ZANETTI, M			ANTIGENIZED ANTIBODIES	NATURE			English	Article							RESHAPING HUMAN-ANTIBODIES; 3-DIMENSIONAL STRUCTURE; INTERNAL IMAGE; PROTEIN; PEPTIDE; EPITOPE; MUTAGENESIS; MOLECULES; VACCINES; LIBRARY		UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92103	University of California System; University of California San Diego	ZANETTI, M (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103, USA.							ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ATASSI MZ, 1980, MOL CELL BIOCHEM, V32, P21; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CO MS, 1991, P NATL ACAD SCI USA, V88, P2869, DOI 10.1073/pnas.88.7.2869; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GEYSEN HM, 1985, IMMUNOL TODAY, V6, P364, DOI 10.1016/0167-5699(85)90096-9; HOFFMAN SL, 1991, SCIENCE, V252, P520, DOI 10.1126/science.2020852; JENNINGS PA, 1989, PROTEIN ENG, V2, P365, DOI 10.1093/protein/2.5.365; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KABAT EA, 1987, PROTEINS IMMUNOLOGIC; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWAJIMA G, 1988, BIO-TECHNOL, V6, P1080, DOI 10.1038/nbt0988-1080; LERNER RA, 1983, SCI AM, V248, P66, DOI 10.1038/scientificamerican0283-66; NEWMARK P, 1983, NATURE, V305, P9, DOI 10.1038/305009a0; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; NOVOTNY J, 1975, NATURE, V258, P641, DOI 10.1038/258641a0; OLLIER P, 1985, EMBO J, V4, P3681, DOI 10.1002/j.1460-2075.1985.tb04135.x; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SPANGLER BD, 1991, J IMMUNOL, V146, P1591; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; VAN CV, 1988, J EXP, V167, P1841; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; ZANETTI M, 1991, ANTIIDOTYPIC VACCINE, P123	30	44	64	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					476	477		10.1038/355476a0	http://dx.doi.org/10.1038/355476a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1370860				2022-12-28	WOS:A1992HB53000079
J	TAKAHASHI, H; NAKAGAWA, Y; PENDLETON, CD; HOUGHTEN, RA; YOKOMURO, K; GERMAIN, RN; BERZOFSKY, JA				TAKAHASHI, H; NAKAGAWA, Y; PENDLETON, CD; HOUGHTEN, RA; YOKOMURO, K; GERMAIN, RN; BERZOFSKY, JA			INDUCTION OF BROADLY CROSS-REACTIVE CYTOTOXIC T-CELLS RECOGNIZING AN HIV-1 ENVELOPE DETERMINANT	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODIES; NEUTRALIZATION; CHIMPANZEES; INFECTION; PEPTIDES; MOLECULE; GP160; LYMPHOCYTES; RECOGNITION	An immunodominant determinant for cytotoxic T lymphocytes (CTLs) exists in the hypervariable portion of human immunodeficiency virus-1 (HIV-1) gp160. Three mouse CTL lines (specific for isolates MN, RF, and IIIB) were examined for recognition of homologous determinants from distinct isolates. Only MN-elicited CTLs showed extensive interisolate cross-reactivity. Residue 325 played a critical role in specificity, with MN-elicited CTLs responding to peptides with an aromatic or cyclic residue and IIIB-induced cells recognizing peptides with an aliphatic residue at this position. CTL populations with broad specificities were generated by restimulation of IIIB-gp160 primed cells with MN-type peptides that have an aliphatic substitution at 325. This represents an approach to synthetic vaccines that can generate broadly cross-reactive CTLs capable of effector function against a wide range of HIV isolates.	TORREY PINES INST MOLEC STUDIES,SAN DIEGO,CA 92121; NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892; NCI,METAB BRANCH,MOLEC IMMUNOGENET & VACCINE RES SECT,BETHESDA,MD 20892	Torrey Pines Institute for Molecular Studies, California; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAKAHASHI, H (corresponding author), NIPPON MED COLL,DEPT MICROBIOL & IMMUNOL,1-1-5 SENDAGI,BUNKYO KU,TOKYO 113,JAPAN.		Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ALEXANDER MA, 1991, J EXP MED, V173, P849, DOI 10.1084/jem.173.4.849; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; CLERICI M, 1991, EUR J IMMUNOL, V21, P1345, DOI 10.1002/eji.1830210603; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1991, J IMMUNOL, V146, P2214; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MYERS G, 1989, HUMAN RETROVIRUSES A; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TAKAHASHI H, 1989, J EXP MED, V170, P2023, DOI 10.1084/jem.170.6.2023; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; Takahashi H., UNPUB; VANBLEEK GM, 1990, NATURE, V348, P213; ZAGURY D, 1988, NATURE, V332, P728, DOI 10.1038/332728a0	28	147	154	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					333	336		10.1126/science.1372448	http://dx.doi.org/10.1126/science.1372448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1372448				2022-12-28	WOS:A1992GZ69500043
J	SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C				SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C			RED-BLOOD-CELL TRANSFUSION IN WARM-TYPE AUTOIMMUNE HEMOLYTIC-ANEMIA	LANCET			English	Article							HEMOLYTIC-ANEMIA; AUTOANTIBODIES	Blood transfusions are regarded as hazardous in patients with warm-type autoimmune haemolytic anaemia (AIHA) because of potential intensification of haemolysis and a presumed high incidence of alloimmunisation. We have retrospectively analysed data of 79 multitransfused patients (74 adults, 5 children) with detectable warm autoantibodies and transitory or persisting haemolytic anaemia. All patients had received blood transfusions on at least two occasions. Patients were reexamined at least twice within the first 6 months of transfusion (duration of follow-up 6 months-12 years). 53 patients had received blood transfusions because of decompensated AIHA, all of whom presented with detectable autoantibodies against red blood cells. None of these patients had transfusion-related alloimmunisation or a definite increase in haemolysis, even when the transfused red cells were serologically incompatible because of free serum autoantibodies. The other 26 patients had no signs of AIHA at presentation (negative direct and indirect antiglobulin test), but received blood transfusions for anaemia due to various other causes. 23 of these 26 patients went on to develop alloantibodies as well as autoantibodies upon transfusion, and 3 patients developed autoantibodies alone. Our findings do not support the generally accepted notion that transfusion therapy should be avoided in AIHA patients. Rather, they indicate that the incidence of alloimmunisation as well as adverse haemolytic transfusion reactions are less common in AIHA patients than in other multitransfused patients.	UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY; UNIV GIESSEN,DEPT INTERNAL MED,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen; Justus Liebig University Giessen	MUELLERECKHARDT, C (corresponding author), UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY.							BELL CA, 1973, AM J CLIN PATHOL, V60, P903; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CROOKSTON JH, 1975, ARCH INTERN MED, V135, P1314, DOI 10.1001/archinte.135.10.1314; HABIBI B, 1974, AM J MED, V56, P61, DOI 10.1016/0002-9343(74)90751-7; ISSITT P, 1985, APPLIED BLOOD GROUP; LEDDY JP, 1970, J IMMUNOL, V105, P677; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Petz LD, 1980, ACQUIRED IMMUNE HEMO; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROSENFIELD RE, 1976, SEMIN HEMATOL, V13, P311; SALAMA A, 1987, BRIT J HAEMATOL, V65, P67, DOI 10.1111/j.1365-2141.1987.tb06137.x; SALAMA A, 1984, TRANSFUSION, V24, P188, DOI 10.1046/j.1537-2995.1984.24384225018.x; WALLHERMFECHTEL MA, 1984, TRANSFUSION, V24, P482, DOI 10.1046/j.1537-2995.1984.24685066805.x	13	53	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1515	1517		10.1016/0140-6736(92)92766-9	http://dx.doi.org/10.1016/0140-6736(92)92766-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361607				2022-12-28	WOS:A1992KD06900015
J	WEBER, FH; MCCALLUM, RW				WEBER, FH; MCCALLUM, RW			CLINICAL APPROACHES TO IRRITABLE-BOWEL-SYNDROME	LANCET			English	Article							DOUBLE-BLIND; DISORDERS; PLACEBO; DIAGNOSIS; MOTILITY; TRANSIT		UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA 22908	University of Virginia								BYRNE S, 1987, J CLIN PSYCHIAT, V48, P388; CAMILLERI M, 1989, AM J PHYSIOL, V257, pG284, DOI 10.1152/ajpgi.1989.257.2.G284; CHAUDHARY NA, 1962, Q J MED, V31, P307; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; FIELDING JF, 1981, DIGESTION, V22, P155, DOI 10.1159/000198627; Froguel E., 1990, J GASTROINTEST MOTIL, V2, P176; GREENBAUM DS, 1987, DIGEST DIS SCI, V32, P257, DOI 10.1007/BF01297051; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HARVEY RF, 1983, LANCET, V1, P632; HASLER W, 1992, Gastroenterology, V102, pA457; KEELING PWN, 1975, J IRISH COLL PHYS S, V4, P91; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KREVSKY B, 1992, DIGEST DIS SCI, V37, P919, DOI 10.1007/BF01300391; LAVO B, 1987, SCAND J GASTROENTERO, V22, P77, DOI 10.3109/00365528709091003; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MATHIAS JR, 1989, DIGEST DIS SCI, V34, P761, DOI 10.1007/BF01540350; MAXTON DG, 1991, GUT, V32, P662, DOI 10.1136/gut.32.6.662; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; PASSARETTI S, 1989, ALIMENT PHARM THERAP, V3, P267; PASSARETTI S, 1987, PROG MED, V43, P121; PRIOR A, 1987, GUT, V28, P1510, DOI 10.1136/gut.28.11.1510; RITSEMA GH, 1991, CLIN RADIOL, V43, P113, DOI 10.1016/S0009-9260(05)81589-2; SASAKI D, 1986, GASTROINTEST ENDOSC, V32, P185, DOI 10.1016/S0016-5107(86)71801-4; SCHAFFSTEIN W, 1990, CURR THER RES CLIN E, V47, P136; SCIARRETTA G, 1987, GUT, V28, P970, DOI 10.1136/gut.28.8.970; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; STAFANINI GF, 1992, AM J GASTROENTEROL, V87, P55; STEADMAN C J, 1990, Gastroenterology, V98, pA394; SUTBBS JB, 1991, J NUCL MED, V32, P1375; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1987, LANCET, V2, P1144; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VANOUTRYVE M, 1991, J CLIN GASTROENTEROL, V13, P49; WALSH P, 1986, BR J CLIN PRACT, V40, P292; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1485, DOI 10.1016/0016-5085(90)91079-L; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423	39	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1447	1452		10.1016/0140-6736(92)92632-P	http://dx.doi.org/10.1016/0140-6736(92)92632-P			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360569				2022-12-28	WOS:A1992KC28400013
J	SUN, XF; CARSTENSEN, JM; ZHANG, H; STAL, O; WINGREN, S; HATSCHEK, T; NORDENSKJOLD, B				SUN, XF; CARSTENSEN, JM; ZHANG, H; STAL, O; WINGREN, S; HATSCHEK, T; NORDENSKJOLD, B			PROGNOSTIC-SIGNIFICANCE OF CYTOPLASMIC-P53 ONCOPROTEIN IN COLORECTAL ADENOCARCINOMA	LANCET			English	Article							P53 EXPRESSION; BREAST-CANCER; ONCOGENE; TUMORS	Mutation of p53, a tumour-suppressor protein, leads to overexpression of the protein and loss of its tumour-suppressive properties. In some tumours (eg, breast) p53 expression is related to well-known prognostic factors, but findings in colorectal tumours are equivocal. We have used the polyclonal antibody CM1 to investigate nuclear and cytoplasmic p53 expression in colorectal tumours and to assess their relations with prognosis. Of 293 colorectal adenocarcinomas, 71 (24%) showed p53 expression in the nucleus alone, 30 (10%) showed p53 in the cytoplasm alone, and 43 (15%) showed both nuclear and cytoplasmic expression. Nuclear p53 expression showed no relation with survival or Dukes' stage of the tumour. However, the frequency of cytoplasmic expression increased with advancing Dukes' stage (chi2 for trend 11.18, 1 df, p=0.0008) and cytoplasmic expression was associated with poor survival (rate ratio 2.3 [95% Cl 1.6-3.3], p<0.0001). Among tumours of Dukes' stage A-C, cytoplasmic expression showed prognostic value independent of nuclear staining, grade of differentiation, and Dukes' stage (2.3 [1.4-3.7], p=0.0021). We conclude that cytoplasmic expression of p53 may be a useful biological indicator of prognosis in colorectal adenocarcinoma.	LINKOPING UNIV HOSP,DEPT PATHOL,S-58185 LINKOPING,SWEDEN	Linkoping University	SUN, XF (corresponding author), LINKOPING UNIV HOSP,DEPT ONCOL,S-58185 LINKOPING,SWEDEN.			Carstensen, John/0000-0003-2256-8089				ARMITAGE P, 1987, STATISTICAL METHODS; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; COSSMAN J, 1991, J NATL CANCER I, V83, P980, DOI 10.1093/jnci/83.14.980; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIDOFF AM, 1991, SURGERY, V110, P259; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARRIS AL, 1990, J PATHOL, V162, P5, DOI 10.1002/path.1711620103; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; PURDIE CA, 1991, AM J PATHOL, V138, P807; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REMVIKOS Y, 1990, INT J CANCER, V45, P450, DOI 10.1002/ijc.2910450313; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1991, ADV ONCOL, V7, P3	20	234	237	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1369	1373		10.1016/0140-6736(92)92558-W	http://dx.doi.org/10.1016/0140-6736(92)92558-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360088				2022-12-28	WOS:A1992KB20200002
J	KATAGIRI, H; ASANO, T; ISHIHARA, H; INUKAI, K; ANAI, M; MIYAZAKI, J; TSUKUDA, K; KIKUCHI, M; YAZAKI, Y; OKA, Y				KATAGIRI, H; ASANO, T; ISHIHARA, H; INUKAI, K; ANAI, M; MIYAZAKI, J; TSUKUDA, K; KIKUCHI, M; YAZAKI, Y; OKA, Y			NONSENSE MUTATION OF GLUCOKINASE GENE IN LATE-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note								A nonsense mutation at codon 186 in exon 5 of the gene for glucokinase, an enzyme important for glucose-induced insulin secretion, was identified in a Japanese patient with late-onset non-insulin-dependent diabetes mellitus (NIDDM). All affected members of her family were heterozygous for the mutation and had late-onset NIDDM or impaired glucose tolerance, whereas unaffected members showed normal glucose tolerance. The early insulin response to oral glucose was impaired in affected relatives, but was normal in those unaffected. These findings suggest that the glucokinase mutation raises the set-point of pancreatic beta cells for glucose-induced insulin secretion, leading to abnormal glucose tolerance in some patients with late-onset NIDDM.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT DIS RELATED GENE REGULAT RES SANDOZ,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,TOKYO,JAPAN	University of Tokyo; Novartis; Sandoz; University of Tokyo; Asahi Life Foundation			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; KOSAKA K, 1980, DIABETOLOGIA, V18, P23, DOI 10.1007/BF01228297; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; MATCHINSKY FM, 1990, DIABETES, V39, P647; SELTZER HS, 1967, J CLIN INVEST, V46, P323, DOI 10.1172/JCI105534; TANIZAWA Y, 1991, P NATL ACAD SCI USA, V88, P7294, DOI 10.1073/pnas.88.16.7294; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0	10	70	71	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1316	1317		10.1016/0140-6736(92)92494-Z	http://dx.doi.org/10.1016/0140-6736(92)92494-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360036				2022-12-28	WOS:A1992KA26200005
J	SCHOLEFIELD, JH; HICKSON, WGE; SMITH, JHF; ROGERS, K; SHARP, F				SCHOLEFIELD, JH; HICKSON, WGE; SMITH, JHF; ROGERS, K; SHARP, F			ANAL INTRAEPITHELIAL NEOPLASIA - PART OF A MULTIFOCAL DISEASE PROCESS	LANCET			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN-REACTION; PREVALENCE; CERVIX; WARTS; WOMEN	Invasive carcinomas of the anogenital epithelium share a common aetiological facto-human papillomavirus (HPV) type 16. Although genital intraepithelial neoplasia may be multifocal, there have been no studies of the prevalence of anal intraepithelial neoplasia in women with intraepithelial neoplasia of the genital tract. We tested the hypothesis that women with high-grade cervical intraepithelial neoplasia are at higher risk of disease in the anus than are control women of similar age with no history of anogenital neoplasia. 29 (19%) of 152 women with cervical intraepithelial neoplasia grade III had histological evidence of anal intraepithelial neoplasia. Of the 29 patients, 11 had grade III anal lesions; 2 of those women had concomitant invasive anal squamous-cell carcinomas. Only 7% (8/115) women with high-grade lesions of the cervix alone had evidence of anal intraepithelial neoplasia; by contrast, 57% (21/37) of those with more than one focus of intraepithelial neoplasia (cervix plus vulva, vagina, or both) had anal lesions. HPV 16 DNA was identified in 18 (51%) of 35 anal biopsy samples in the study group. No evidence of anal intraepithelial neoplasia was found in the control group (50 women), although 2 patients had grade I cervical lesions. HPV 16 DNA was identified in 12 (24%) of biopsy samples from the cervix and 7 (14%) from the anus in the control group; all 7 women with anal HPV16 had concomitant cervical infection. The role of anal examination in the assessment of women with any focus of genital intraepithelial neoplasia requires further investigation.	NO GEN HOSP,CTR CLIN SCI,DEPT GYNAECOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT HISTOPATHOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	Northern General Hospital; Northern General Hospital	SCHOLEFIELD, JH (corresponding author), NO GEN HOSP,CTR CLIN SCI,DEPT SURG,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							Bancroft J.D., 1996, THEORY PRACTICE HIST, VVolume 6; CAMPION MJ, 1986, LANCET, V2, P237; CORNELISSEN MTE, 1989, J GEN VIROL, V70, P2555, DOI 10.1099/0022-1317-70-10-2555; GOORNEY BP, 1987, GENITOURIN MED, V63, P216; HAUSEN HZ, 1987, MED ONCOL TUMOR PHAR, V4, P187; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1991, THESIS U LIVERPOOL; SHARP F, 1991, TEXT ATLAS INTEGRATE, P186; SONNEX C, 1991, BRIT MED J, V303, P1243, DOI 10.1136/bmj.303.6812.1243; WATERHOUSE J, 1982, CANCER INCIDENCE 5 C, P675; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	16	98	101	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1271	1273		10.1016/0140-6736(92)92961-E	http://dx.doi.org/10.1016/0140-6736(92)92961-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359331				2022-12-28	WOS:A1992JZ23700015
J	EMSON, HE				EMSON, HE			A RIGHT TO REPRODUCE	LANCET			English	Editorial Material											EMSON, HE (corresponding author), ROYAL UNIV HOSP SASKATOON,DEPT PATHOL,SASKATOON S7N 0X0,SASKATCHEWAN,CANADA.							[Anonymous], 1992, LANCET, V339, P1515; EMSON HE, 1992, J APPL PHILOS, V9, P3	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1083	1083		10.1016/0140-6736(92)93089-6	http://dx.doi.org/10.1016/0140-6736(92)93089-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357463				2022-12-28	WOS:A1992JV77500013
J	GARZON, MC; MUBITA, M; KACHINKA, L				GARZON, MC; MUBITA, M; KACHINKA, L			LEVAMISOLE TREATMENT IN HIV-INFECTED ZAMBIAN CHILDREN	LANCET			English	Letter									ARTHUR DAVISON CHILDRENS HOSP, NDOLA, ZAMBIA									BORUT TC, 1980, J PEDIATR-US, V97, P567, DOI 10.1016/S0022-3476(80)80010-2; MARKINK RG, 1986, NEW ENGL J MED, V315, P1549; SZABO M, 1974, THER HUNG, V17, P173	3	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1992	340	8827					1099	1100		10.1016/0140-6736(92)93121-3	http://dx.doi.org/10.1016/0140-6736(92)93121-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357488				2022-12-28	WOS:A1992JV77500039
J	WALT, RP; COTTRELL, J; MANN, SG; FREEMANTLE, NP; LANGMAN, MJS				WALT, RP; COTTRELL, J; MANN, SG; FREEMANTLE, NP; LANGMAN, MJS			CONTINUOUS INTRAVENOUS FAMOTIDINE FOR HEMORRHAGE FROM PEPTIC-ULCER	LANCET			English	Article							GASTROINTESTINAL HEMORRHAGE; PLATELET-AGGREGATION; CONTROLLED TRIAL; INTRAGASTRIC PH; CIMETIDINE; ACID	Peptic ulcer bleeding often stops spontaneously but rebleeding may be catastrophic. Emergency surgery carries risks so safe medical therapies are needed. Since platelet function and plasma coagulation are both pH sensitive and since pepsin lyses clot at low pH the maintenance of gastric pH close to neutrality might influence rebleeding rates. Previous trials with H-2 antagonists have been inadequate although a 1985 meta-analysis did support an important clinical effect. We report here a large multicentre trial of famotidine in ulcer bleeding. 1005 patients admitted to one of sixty-seven hospitals in the UK or Eire with haemorrhage from peptic ulcer with endoscopic signs of oozing, black slough, fresh clot or visible vessel were randomly allocated to famotidine (10 mg bolus followed by 3.2 mg/h intravenously) or matching placebo for 72 h. This famotidine regimen had previously been shown to maintain pH near 7 in such patients. 497 patients received famotidine and 508 placebo. The treatment groups were similar in respect of age, sex, ulcer site, and signs and severity of bleeding. Case fatality (6.2% famotidine vs 5.0% placebo), rebleeding (23.9% vs 25.5% placebo), and surgery (15.5% vs 17.1% placebo) rates were not significantly different between the two groups. This trial suggests that potent inhibition of gastric secretion does not influence the natural history of peptic ulcer haemorrhage.	MERCK SHARPE & DOHME LTD, DEPT MED, HODDESDON, HERTS, ENGLAND	Merck & Company	WALT, RP (corresponding author), QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND.							ALLAN R, 1976, Q J MED, V45, P533; BARER D, 1983, NEW ENGL J MED, V308, P1571, DOI 10.1056/NEJM198306303082606; BARKHAM P, 1953, J APPL PHYSIOL, V6, P1; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DAWSON J, 1982, BRIT MED J, V285, P476, DOI 10.1136/bmj.285.6340.476; FULLARTON GM, 1991, ALIMENT PHARM THERAP, V5, P77; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; HAN P, 1974, BRIT J HAEMATOL, V26, P373, DOI 10.1111/j.1365-2141.1974.tb00479.x; HOARE AM, 1979, LANCET, V2, P671; LOW J, 1980, THROMB RES, V17, P819, DOI 10.1016/0049-3848(80)90247-9; MEREDITH CG, 1980, AUST NZ J MED, V25, P92; MERKI HS, 1988, GUT, V29, P453, DOI 10.1136/gut.29.4.453; PATCHETT SE, 1989, GUT, V30, P1704, DOI 10.1136/gut.30.12.1704; PICKARD RG, 1979, BRIT MED J, V1, P661, DOI 10.1136/bmj.1.6164.661-a; REYNOLDS J R, 1987, Alimentary Pharmacology and Therapeutics, V1, P23; TERES J, 1980, DIGEST DIS SCI, V25, P92, DOI 10.1007/BF01308303; ZUCKERMAN G, 1984, AM J MED, V76, P361, DOI 10.1016/0002-9343(84)90652-1	18	107	109	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1992	340	8827					1058	1062		10.1016/0140-6736(92)93078-2	http://dx.doi.org/10.1016/0140-6736(92)93078-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357453				2022-12-28	WOS:A1992JV77500003
J	LUFKIN, T; MARK, M; HART, CP; DOLLE, P; LEMEUR, M; CHAMBON, P				LUFKIN, T; MARK, M; HART, CP; DOLLE, P; LEMEUR, M; CHAMBON, P			HOMEOTIC TRANSFORMATION OF THE OCCIPITAL BONES OF THE SKULL BY ECTOPIC EXPRESSION OF A HOMEOBOX GENE	NATURE			English	Article							VERTEBRAL COLUMN; DROSOPHILA; DISRUPTION; DEFECTS; HOX-1.1; MICE	MURINE Hox genes have been postulated to play a role in patterning of the embryonic body plan1-3. Gene disruption studies have suggested that for a given Hox complex, patterning of cell identity along the antero-posterior axis is directed by the more 'posterior' (having a more posterior rostral boundary of expression) Hox proteins expressed in a given cell4-6. This supports the 'posterior prevalence' model2, which also predicts that ectopic expression of a given Hox gene would result in altered structure only in regions anterior to its normal domain of expression. To test this model further, we have expressed the Hox-4.2 gene more rostrally than its normal mesoderm anterior boundary of expression, which is at the level of the first cervical somites. This ectopic expression results in a homeotic transformation of the occipital bones towards a more posterior phenotype into structures that resemble cervical vertebrae, whereas it has no effect in regions that normally express Hox-4.2. These results are similar to the homeotic posteriorization phenomenon generated in Drosophila by ectopic expression of genes of the homeotic complex HOM-C (refs 7-10; reviewed in ref. 3).	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dolle, Pascal/A-8037-2010; Lufkin, Thomas/AAG-7476-2019; Lufkin, Thomas/B-5352-2011	Dolle, Pascal/0000-0002-9294-9090; Lufkin, Thomas/0000-0002-7902-4771; Lufkin, Thomas/0000-0002-7902-4771; Hart, Charles/0000-0003-4440-726X				BAGNALL KM, 1988, DEVELOPMENT, V103, P69; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; de Beer G.R, 1971, DEV VERTEBRATE SKULL; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; EVANS FRANCIS GAYNOR, 1939, ANN NEW YORK ACAD SCI, V39, P29, DOI 10.1111/j.1749-6632.1939.tb55370.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FERGUSON MWJ, 1978, J ANAT, V125, P555; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gruss P, 1991, CURR OPIN GENET DEV, V1, P204, DOI 10.1016/S0959-437X(05)80071-1; HOGAN B, 1986, MANIPULATING MOUSE E; JENKINS FA, 1969, ANAT REC, V164, P173, DOI 10.1002/ar.1091640205; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KURIORA MA, 1988, CELL, V55, P477; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NODEN DM, 1988, DEVELOPMENT, V103, P121; PIVETEAU J, 1954, TRAITE ZOOLOGIE, V12; Remak R., 1855, UNTERSUCHUNGEN ENTWI; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; VERBOUT AJ, 1985, ADV ANAT EMBRYOL CEL, V90, P1; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	31	247	252	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					835	841		10.1038/359835a0	http://dx.doi.org/10.1038/359835a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1359423				2022-12-28	WOS:A1992JV77700066
J	SWALES, JD				SWALES, JD			THE LEICESTER ANTIVACCINATION MOVEMENT	LANCET			English	Article											SWALES, JD (corresponding author), UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT MED,CLIN SCI BLDG,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND.							BIGGS JT, 1912, SANITATION VERSUS VA; BOND FT, 1897, J SAN I, V18, P438; 1886, LANCET, V1, P1086; 1884, LANCET, V2, P504; 1886, LANCET, V1, P1090; 1901, LANCET, V2, P1141	6	20	22	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1019	1021		10.1016/0140-6736(92)93021-E	http://dx.doi.org/10.1016/0140-6736(92)93021-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357411				2022-12-28	WOS:A1992JV01400013
J	BEUTLER, E				BEUTLER, E			CLADRIBINE (2-CHLORODEOXYADENOSINE)	LANCET			English	Article							HAIRY-CELL LEUKEMIA; ADENOSINE-DEAMINASE DEFICIENCY; HUMAN-LYMPHOCYTES; TOXICITY; PENTOSTATIN; 2-CHLORO-2'-DEOXYADENOSINE; NUCLEOSIDE; METABOLISM; INTERFERON; ALPHA				BEUTLER, E (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, SBR3, 10666 N TORREY PINES RD, LA JOLLA, CA 92307 USA.				NCRR NIH HHS [RR00833] Funding Source: Medline; FDA HHS [FD-R-000280] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); FDA HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEUTLER E, 1991, LEUKEMIA LYMPHOMA, V5, P1, DOI 10.3109/10428199109068099; CARRERA CJ, 1990, J CLIN INVEST, V86, P1480, DOI 10.1172/JCI114865; CARRERA CJ, 1990, BLOOD S, V76, pA260; CARSON DA, 1984, P NATL ACAD SCI-BIOL, V81, P2232, DOI 10.1073/pnas.81.7.2232; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; CARSON DA, 1983, BLOOD, V62, P737; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CARSON DA, 1982, BLOOD, V60, pA161; CASSILETH PA, 1991, J CLIN ONCOL, V9, P243, DOI 10.1200/JCO.1991.9.2.243; DIMOPOULOS MA, IN PRESS ANN INTERN; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; ESTEY EH, 1992, BLOOD, V79, P882; GOLOMB H, 1990, P AN M AM SOC CLIN, V6, P215; HO AD, 1989, J CLIN ONCOL, V7, P1533, DOI 10.1200/JCO.1989.7.10.1533; HOFFMAN M, 1992, P AN M AM SOC CLIN, V11, P271; JULIUSSON G, 1992, BLOOD, V79, P888; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; KAHN J, 1991, P AN M AM SOC CLIN, V10, P34; KAY AC, 1992, J CLIN ONCOL, V10, P371, DOI 10.1200/JCO.1992.10.3.371; KRAUT EH, 1989, J CLIN ONCOL, V7, P168, DOI 10.1200/JCO.1989.7.2.168; LAURIA F, 1991, BLOOD S, V78, pA34; LILIEMARK J, 1992, J CLIN ONCOL, V10, P1514, DOI 10.1200/JCO.1992.10.10.1514; LILIEMARK J, 1991, CANCER RES, V51, P5570; PETZER AL, 1991, BLOOD, V78, P2583; PIRO LD, 1992, P AN M AM SOC CLIN, V11, P259; QUESADA JR, 1986, BLOOD, V68, P493, DOI 10.1182/blood.V68.2.493.493; RAI K, 1987, P AN M AM SOC CLIN, V6, P159; RISCOE MK, 1989, BLOOD REV, V3, P162, DOI 10.1016/0268-960X(89)90013-1; SANTANA VM, 1992, J CLIN ONCOL, V10, P364, DOI 10.1200/JCO.1992.10.3.364; SAVEN A, 1992, BLOOD, V80, P587; SAVEN A, 1992, BLOOD, V79, P1111; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394; SAVEN A, 1992, P AN M AM SOC CLIN, V11, P261; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; TALLMAN M, 1991, BLOOD S, V79, pA34	36	314	343	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					952	956		10.1016/0140-6736(92)92826-2	http://dx.doi.org/10.1016/0140-6736(92)92826-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357355				2022-12-28	WOS:A1992JT82300012
J	THOMAS, SJ; MACLENNAN, R				THOMAS, SJ; MACLENNAN, R			SLAKED LIME AND BETEL NUT CANCER IN PAPUA-NEW-GUINEA	LANCET			English	Note							TOBACCO	Oral squamous cell cancer is the most common malignant tumour in Papua New Guinea. We have found that oral cancer in this region is concentrated at the corner of the mouth and cheek, by striking contrast with western populations, and corresponds precisely with the site of application of lime in 77% of 169 cases. Powdered slaked lime applied to the chewed Areca nut with Piper betle inflorescence at the comer of the mouth causes the mean pH to rise to 10, at which reactive oxygen species are generated from betel quid ingredients in vitro. Reactive oxygen species, together with sustained lime-induced cell proliferation, suggest a possible mechanism of carcinogenesis for this tumour.			THOMAS, SJ (corresponding author), QUEENSLAND INST MED RES,300 HERSTON RD,BRISBANE 4029,AUSTRALIA.							COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COOKE RA, 1969, CANCER, V24, P397, DOI 10.1002/1097-0142(196908)24:2<397::AID-CNCR2820240223>3.0.CO;2-6; Henderson BE, 1979, NATL CANCER I MONOGR, V53, P67; LANGDON JD, 1985, MALIGNANT TUMOURS OR, P3; MOORE C, 1967, AM J SURG, V114, P510, DOI 10.1016/0002-9610(67)90008-6; NAIR UJ, 1990, CARCINOGENESIS, V11, P2145, DOI 10.1093/carcin/11.12.2145; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; SCRIMGEOUR EM, 1983, BRIT MED J, V286, P1414, DOI 10.1136/bmj.286.6375.1414; STICH HF, 1989, MUTAT RES, V214, P47, DOI 10.1016/0027-5107(89)90197-8	9	106	110	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					577	578		10.1016/0140-6736(92)92109-S	http://dx.doi.org/10.1016/0140-6736(92)92109-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355157				2022-12-28	WOS:A1992JM33400006
J	SEGREDO, V; CALDWELL, JE; MATTHAY, MA; SHARMA, ML; GRUENKE, LD; MILLER, RD				SEGREDO, V; CALDWELL, JE; MATTHAY, MA; SHARMA, ML; GRUENKE, LD; MILLER, RD			PERSISTENT PARALYSIS IN CRITICALLY ILL PATIENTS AFTER LONG-TERM ADMINISTRATION OF VECURONIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORG NC 45; RENAL-FAILURE; BLOCKING ACTIONS; PHARMACOKINETICS; PANCURONIUM; BROMIDE; CAT; 3-DESACETYLVECURONIUM; PHARMACODYNAMICS; PHARMACOLOGY	Background. The muscle relaxant vecuronium is sometimes administered to facilitate mechanical ventilation. Neuromuscular paralysis lasting up to seven days may occur after the termination of long-term administration (i.e., more than two days) of vecuronium in critically ill patients. We investigated the role of clinical factors and plasma concentrations of vecuronium and its metabolite in causing this prolonged neuromuscular blockade. Methods. We studied 16 critically ill adult patients (8 women and 8 men) who had received vecuronium to facilitate mechanical ventilation for at least two consecutive days. Clinical factors and plasma concentrations of vecuronium and 3-desacetylvecuronium, the active metabolite of vecuronium, were compared in patients with and without prolonged neuromuscular blockade. In addition, we performed detailed pharmacokinetic studies in the patients without prolonged neuromuscular blockade. Results. Seven of the 16 patients had prolonged neuromuscular blockade, lasting from six hours to more than seven days, after the termination of vecuronium therapy. These seven patients, six of whom were women, had higher plasma magnesium concentrations and lower arterial blood pH values than the nine patients without prolonged neuromuscular blockade. They also had higher plasma concentrations of 3-desacetylvecuronium and a higher frequency of renal failure (seven of seven patients vs. four of nine patients, P<0.03). In the patients without prolonged neuromuscular blockade, the mean (+/-SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5+/-1.0 ml per kilogram of body weight per minute, 299+/-154 minutes, and 1.1+/-0.6 liters per kilogram, respectively. Conclusions. Prolonged neuromuscular blockade after the termination of long-term treatment with vecuronium is associated with metabolic acidosis, elevated plasma magnesium concentrations, female sex, and probably more important, the presence of renal failure and high plasma concentrations of 3-desacetylvecuronium.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026403] Funding Source: NIH RePORTER; NIGMS NIH HHS [R0I GM 26403-0648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDEN JR, 1988, ANESTHESIOLOGY, V68, P771, DOI 10.1097/00000542-198805000-00016; BENCINI AF, 1985, BRIT J ANAESTH, V57, P782, DOI 10.1093/bja/57.8.782; BENCINI AF, 1985, BRIT J ANAESTH, V57, P789, DOI 10.1093/bja/57.8.789; CANNON JE, 1987, ANESTHESIOLOGY, V67, P503, DOI 10.1097/00000542-198710000-00010; COURSIN DB, 1989, ANESTH ANALG, V69, P518; DANON MJ, 1991, MUSCLE NERVE, V14, P1131, DOI 10.1002/mus.880141115; DARRAH WC, 1989, CRIT CARE MED, V17, P1297, DOI 10.1097/00003246-198912000-00010; DIXON WJ, 1985, BMDP STATISTICAL SOF, P237; FAHEY MR, 1981, BRIT J ANAESTH, V53, P1049, DOI 10.1093/bja/53.10.1049; FUNK DI, 1980, ACTA ANAESTH SCAND, V24, P119, DOI 10.1111/j.1399-6576.1980.tb01518.x; FURUTA T, 1988, J CHROMATOGR-BIOMED, V427, P41, DOI 10.1016/0378-4347(88)80103-8; GIBALDI M, 1975, PHARMACOKINETICS, P27; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; LEBRAULT C, 1985, ANESTHESIOLOGY, V62, P601, DOI 10.1097/00000542-198505000-00010; LYNAM DP, 1988, ANESTHESIOLOGY, V69, P227, DOI 10.1097/00000542-198808000-00012; MARSHALL IG, 1983, BRIT J ANAESTH, V55, P703, DOI 10.1093/bja/55.8.703; MATTHAY MA, 1989, TXB PULMONARY DISEAS, V2, P1055; MEISTELMAN C, 1986, EUR J ANAESTH, V3, P153; MILLER RD, 1984, ANESTHESIOLOGY, V61, P444, DOI 10.1097/00000542-198410000-00014; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; ONO K, 1988, ANESTHESIOLOGY, V68, P357, DOI 10.1097/00000542-198803000-00006; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SEGREDO V, 1991, ANESTHESIOLOGY, V74, P1052, DOI 10.1097/00000542-199106000-00013; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHEARER ES, 1991, BRIT J ANAESTH, V67, P569, DOI 10.1093/bja/67.5.569; SMITH CL, 1987, ANAESTHESIA, V42, P387, DOI 10.1111/j.1365-2044.1987.tb03980.x; SMITH CL, 1987, ANAESTHESIA, V42, P925; UPTON RA, 1982, ANESTH ANALG, V61, P313; VIBYMOGENSEN J, 1982, BRIT J ANAESTH, V54, P209, DOI 10.1093/bja/54.2.209; WASER PG, 1987, BRIT J ANAESTH, V59, P1044, DOI 10.1093/bja/59.8.1044; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176	33	336	342	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					524	528		10.1056/NEJM199208203270804	http://dx.doi.org/10.1056/NEJM199208203270804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1353252	Bronze			2022-12-28	WOS:A1992JJ45700004
J	LUNNISS, PJ; ARMSTRONG, P; BARKER, PG; REZNEK, RH; PHILLIPS, RKS				LUNNISS, PJ; ARMSTRONG, P; BARKER, PG; REZNEK, RH; PHILLIPS, RKS			MAGNETIC-RESONANCE-IMAGING OF ANAL FISTULAS	LANCET			English	Note							IN-ANO	Success of surgery for an anal fistula depends on accurate assessment of the fistula; however, such assessment is technically difficult. We have done a prospective study that determined the accuracy of magnetic resonance imaging (MRI) in demonstrating the course of fistulae, by comparing MRI scan interpretations with subsequent operative findings. 16 patients (mean [range] age 42 [24-66] years) had MRI followed by surgery within a mean of 22 (1-101) days. MRI scan interpretations agreed precisely with independently documented operative findings in 14 of 16 patients. MRI is an accurate method of delineating anal fistulae, and should be considered for patients with difficult fistulae that recur despite skilled attention because it demonstrates abnormalities that might otherwise be missed.	ST MARKS HOSP,CITY RD,LONDON EC1V 2PS,ENGLAND; LONDON CLIN,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,PROF SURG UNIT,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND	Imperial College London; University of London; University College London; University of London; Queen Mary University London; University of London; Queen Mary University London								COEN S, 1991, BRIT J SURG, V78, P445; KUIJPERS HC, 1985, DIS COLON RECTUM, V28, P103, DOI 10.1007/BF02552656; LAW PJ, 1989, BRIT J SURG, V76, P752, DOI 10.1002/bjs.1800760737; PARKS AG, 1976, BRIT J SURG, V63, P1, DOI 10.1002/bjs.1800630102; POMMERI F, 1988, RADIOL MED, V75, P632; SAINIO P, 1984, ANN CHIR GYNAECOL FE, V73, P219; SEOWCHOEN F, 1991, BRIT J SURG, V78, P539; SHOULER PJ, 1986, INT J COLORECTAL DIS, V1, P113, DOI 10.1007/BF01648418	8	141	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					394	396		10.1016/0140-6736(92)91472-K	http://dx.doi.org/10.1016/0140-6736(92)91472-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353557				2022-12-28	WOS:A1992JJ44900005
J	DUNN, MJ; CRISP, SJ; ROSE, ML; TAYLOR, PM; YACOUB, MH				DUNN, MJ; CRISP, SJ; ROSE, ML; TAYLOR, PM; YACOUB, MH			ANTIENDOTHELIAL ANTIBODIES AND CORONARY-ARTERY DISEASE AFTER CARDIAC TRANSPLANTATION	LANCET			English	Article								Accelerated coronary artery disease is the most serious complication after cardiac transplantation. The disease has a multifactorial aetiology, with little agreement about the relative importance of the various risk factors. We have investigated the frequency of anti-endothelial antibodies against human umbilical vein endothelial cells by one-dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis and western blotting. Peptide-specific anti-endothelial antibodies were found in 15/21 heart transplant recipients with accelerated coronary artery disease, and 1/20 transplant patients who had not developed the disease. Positive immunofluorescence of patients' serum on frozen sections of coronary vessels confirmed the endothelial specificity of antibodies. These results provide evidence of an immune aetiology for transplant-associated coronary artery disease and could have important implications for its diagnosis and therapy.			DUNN, MJ (corresponding author), NATL HEART & LUNG INST,DEPT CARDIOTHORAC SURG,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							AUCHINCLOSS H, 1990, TRANSPLANT REV, V4, P14; Banner N R, 1987, Clin Transpl, P17; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN MJ, 1991, TRANSPLANTATION, V51, P806, DOI 10.1097/00007890-199104000-00014; GAO S, 1990, SEMINARS THORACIC CA, P241; HEURKENS AHM, 1991, J IMMUNOL METHODS, V141, P33, DOI 10.1016/0022-1759(91)90207-V; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAGE C, IN PRESS AM J PATHOL; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALOMON RN, 1991, AM J PATHOL, V138, P791; SIMMONS J, 1991, 2D PAGE 91, P46; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827	15	171	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1566	1570		10.1016/0140-6736(92)91832-S	http://dx.doi.org/10.1016/0140-6736(92)91832-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351550				2022-12-28	WOS:A1992JB20200004
J	NIKONOWICZ, EP; PARDI, A				NIKONOWICZ, EP; PARDI, A			3-DIMENSIONAL HETERONUCLEAR NMR-STUDIES OF RNA	NATURE			English	Article							RIBOSOMAL-RNA; SPECTROSCOPY; PROTEINS; ASSIGNMENT; OLIGORIBONUCLEOTIDE; INTERLEUKIN-1-BETA; RESONANCES; SEQUENCE; C-13; DNA	MULTIDIMENSIONAL heteronuclear NMR has revolutionized solution structure determinations of proteins 1-3. But this technique has not been applied to nucleic acids because of difficulties in the synthesis of isotopically (C-13 and/or N-15) labeLled molecules. Here we report the application of three-dimensional heteronuclear NMR to the study of a uniformly C-13/N-15 or N-15-labelled RNA duplex of defined sequence. These experiments simplify resonance assignment and the analysis of proton-proton nuclear Overhauser effects 4 (and therefore distance information) in the molecule. Our results show that it is now possible to determine the structures of larger and more complex RNAs using multidimensional heteronuclear NMR.			NIKONOWICZ, EP (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; CECH TC, 1989, MOL BIOL RNA; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; FERSHT A, 1985, ENZYME STRUCTURE MEC, P389; FESIK SW, 1990, J AM CHEM SOC, V112, P886, DOI 10.1021/ja00158a069; FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; LORE GM, 1991, SCIENCE, V252, P1390; LUCIA JS, 1991, BIOCHEMISTRY-US, V30, P8242; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PATEL DJ, 1987, Q REV BIOPHYS, V20, P35, DOI 10.1017/S0033583500004224; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SIMON ES, 1990, J ORG CHEM, V55, P1834, DOI 10.1021/jo00293a030; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	25	105	106	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					184	186		10.1038/355184a0	http://dx.doi.org/10.1038/355184a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370345				2022-12-28	WOS:A1992GY62900066
J	PRESS, RI; PEEBLES, CL; KUMAGAI, Y; OCHS, RL; TAN, EM				PRESS, RI; PEEBLES, CL; KUMAGAI, Y; OCHS, RL; TAN, EM			ANTINUCLEAR AUTOANTIBODIES IN WOMEN WITH SILICONE BREAST IMPLANTS	LANCET			English	Article							HUMAN ADJUVANT DISEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; AUGMENTATION MAMMOPLASTY; AUTOIMMUNE-DISEASE; RHEUMATIC DISEASES; SJOGRENS SYNDROME; SCLERODERMA; ANTIBODIES; SCLEROSIS	Clinical syndromes resembling autoimmune diseases have been reported in women who have had breast augmentation procedures. To see whether there is a humoral immune response in these diseases that is similar to the immune response in their idiopathic counterparts, we assessed the immunological specificity of antinuclear antibodies (ANAs) and certain epidemiological features in 24 patients, all of whom (with 1 exception) had received silicone gel breast implants. ANA specificities were identified by indirect immunofluorescence, immunodiffusion, western blot analysis, and immunoprecipitation of radiolabelled intracellular proteins. Of 11 patients who had symptoms and signs that met criteria for defined autoimmune diseases, 7 had scleroderma or subsets of this disorder and the others had systemic lupus erythematosus, rheumatoid arthritis, or overlapping autoimmune diseases. High ANA titres were present in 10 of these 11 patients and the ANA specificities were similar to those found in the idiopathic forms of the corresponding autoimmune diseases. Trauma, with resultant rupture of implants, accelerated onset of symptoms. 13 other patients had autoimmune disorders of a less clearly defined nature and low titres of ANAs whose specificities could not be identified. ANAs are associated with the development of autoimmune complications in women with silicone breast implants. Further studies are needed to see whether this relation is one of cause and effect and whether ANAs might be early serological markers preceding development of autoimmune symptoms.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, WM KECK AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA; IMAICHI HOSP, TOCHIGI 32112, JAPAN	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032063, R01AR032063] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIAMS NIH HHS [AR32063] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; ARNETT F C, 1987, Arthritis and Rheumatism, V30, pS17; BALDWIN CM, 1983, ANN PLAS SURG, V10, P270, DOI 10.1097/00000637-198304000-00002; BALLOU SP, 1986, MANUAL CLIN LABORATO, P740; BLACK CM, 1983, LANCET, V1, P53; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; BYRON MA, 1984, BRIT J RHEUMATOL, V23, P227; CHAN EKL, 1992, MANUAL CLIN LABORATO, P755; ENDO LP, 1987, SEMIN ARTHRITIS RHEU, V17, P112, DOI 10.1016/0049-0172(87)90033-3; FOCK KM, 1984, J RHEUMATOL, V11, P98; FRITZLER MJ, 1985, CLIN IMMUNOL IMMUNOP, V36, P120, DOI 10.1016/0090-1229(85)90045-5; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HAUSTEIN UF, 1985, INT J DERMATOL, V24, P147, DOI 10.1111/j.1365-4362.1985.tb05745.x; HOCHBERG MC, 1981, EPIDEMIOL REV, V3, P27, DOI 10.1093/oxfordjournals.epirev.a036238; KAISER W, 1990, ANN RHEUM DIS, V49, P937, DOI 10.1136/ard.49.11.937; KASAKAWAR, 1987, MIXED CONNECTIVE TIS, P41; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; MARIK PE, 1990, S AFR MED J, V77, P212; MEDSGER TA, 1985, EPIDEMIOLOGY RHEUMAT; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; MIYOSHI K, 1964, IJISHIMPO, V2122, P9; OKANO Y, 1984, ANN RHEUM DIS, V43, P520, DOI 10.1136/ard.43.3.520; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; ROM WN, 1983, CHEST, V83, P515, DOI 10.1378/chest.83.3.515; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; VANVENROOIJ WJ, 1991, J IMMUNOL METHODS, V140, P181, DOI 10.1016/0022-1759(91)90369-Q; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WEINER SR, 1986, PLAST RECONSTR SURG, V77, P185, DOI 10.1097/00006534-198602000-00001; WELSH KT, 1988, SYSTEMIC SCLEROSIS S; WILSON MR, 1986, MANUAL CLIN LABORATO, P750	34	143	143	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1992	340	8831					1304	1307		10.1016/0140-6736(92)92491-W	http://dx.doi.org/10.1016/0140-6736(92)92491-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360033	Bronze			2022-12-28	WOS:A1992KA26200002
J	SHELTON, JD; ANGLE, MA; JACOBSTEIN, RA				SHELTON, JD; ANGLE, MA; JACOBSTEIN, RA			MEDICAL BARRIERS TO ACCESS TO FAMILY-PLANNING	LANCET			English	Editorial Material							NURSE-MIDWIVES; PHYSICIANS		UNIV N CAROLINA,PROGRAM INT TRAINING HLTH,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	SHELTON, JD (corresponding author), US AGCY INT DEV,OFF POPULAT,WASHINGTON,DC 20523, USA.							AFFANDI B, 1987, STUD FAMILY PLANN, V18, P302, DOI 10.2307/1966859; BIRDSALL N, 1987, FAM PLANN PERSPECT, V19, P14, DOI 10.2307/2135361; BRUCE J, 1990, STUD FAMILY PLANN, V21, P61, DOI 10.2307/1966669; EREN N, 1983, STUD FAMILY PLANN, V14, P43, DOI 10.2307/1965401; HARLAP S, 1991, PREVENTING PREGNANCY; Hatcher RA, 1990, CONTRACEPTIVE TECHNO; ROSENFIELD AG, 1972, AM J OBSTET GYNECOL, V114, P942, DOI 10.1016/0002-9378(72)90103-2; SATYAPAN S, 1983, STUD FAMILY PLANN, V14, P115, DOI 10.2307/1966065; SHERRIS JD, 1985, POPUL REP J, V13, P773; 1991, LANCET, V338, P856; 1989, CONTRACEPTION REPROD	11	92	92	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1334	1336		10.1016/0140-6736(92)92505-A	http://dx.doi.org/10.1016/0140-6736(92)92505-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KA262	1360046	Bronze			2022-12-28	WOS:A1992KA26200015
J	ROSEVEAR, SK; HOLT, DW; LEE, TD; FORD, WCL; WARDLE, PG; HULL, MGR				ROSEVEAR, SK; HOLT, DW; LEE, TD; FORD, WCL; WARDLE, PG; HULL, MGR			SMOKING AND DECREASED FERTILIZATION RATES INVITRO	LANCET			English	Note							CIGARETTE-SMOKING; COTININE; NICOTINE; DISPOSITION; FLUID	To examine possible mechanisms for the association between cigarette smoking and reduced fertility, we have measured the concentration of the nicotine metabolite cotinine in ovarian follicular fluid collected at the time of oocyte recovery during treatment for in-vitro fertilisation. In a group of women in whom follicular fluid cotinine could not be detected (limit of accurate measurement 20 ng/ml) 116 oocytes were collected, of which 84 became fertilised (72%), whereas among women with cotinine concentration greater than 20 ng/ml 20/45 (44%) oocytes did so (p < 0.01). The median fertilisation rates for individuals (range 1-8 eggs each) in the high and low cotinine groups were 57% and 75%, respectively (p < 0.05). These findings suggest that infertile women should be advised to stop or reduce smoking generally, and especially before treatment by in-vitro fertilisation.	ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, ANALYT UNIT, LONDON SW17 0RE, ENGLAND	St Georges University London	ROSEVEAR, SK (corresponding author), UNIV BRISTOL, ST MICHAELS HOSP, DEPT OBSTET & GYNAECOL, BRISTOL BS2 8EG, ENGLAND.							BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BARBIERI RL, 1986, FERTIL STERIL, V46, P232; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; HANSEL MC, 1986, ANN CLIN BIOCHEM, V23, P596, DOI 10.1177/000456328602300518; HOWE G, 1985, BRIT MED J, V290, P1697, DOI 10.1136/bmj.290.6483.1697; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; MCLACHLAN JA, 1976, FERTIL STERIL, V27, P1204; ROSENBERG J, 1980, CLIN PHARMACOL THER, V28, P517, DOI 10.1038/clpt.1980.196; WARDLE PG, 1986, HUM REPROD, V1, P455, DOI 10.1093/oxfordjournals.humrep.a136454; WEISS T, 1989, HUM REPROD, V4, P482, DOI 10.1093/oxfordjournals.humrep.a136931	11	79	81	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1195	1196		10.1016/0140-6736(92)92895-M	http://dx.doi.org/10.1016/0140-6736(92)92895-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359264				2022-12-28	WOS:A1992JY38600007
J	HERRERO, I; MIRASPORTUGAL, MT; SANCHEZPRIETO, J				HERRERO, I; MIRASPORTUGAL, MT; SANCHEZPRIETO, J			POSITIVE FEEDBACK OF GLUTAMATE EXOCYTOSIS BY METABOTROPIC PRESYNAPTIC RECEPTOR STIMULATION	NATURE			English	Article							PROTEIN-KINASE-C; ISOLATED NERVE-TERMINALS; LONG-TERM POTENTIATION; RAT CEREBROCORTICAL SYNAPTOSOMES; AMINO-ACID RECEPTORS; DIRECT ACTIVATION; DENTATE GYRUS; RELEASE; CA-2+; 4-AMINOPYRIDINE	GLUTAMATE is important in several forms of synaptic plasticity such as long-term potentiation, and in neuronal cell degeneration1,2. Glutamate activates several types of receptors, including a metabotropic receptor that is sensitive to trans-1-amino-cyclo-penthyl-1,3-dicarboxylate, coupled to G protein(s) and linked to inositol phospholipid metabolism3-6. The activation of the metabotropic receptor in neurons generates inositol 1,4,5-trisphosphate, which causes the release of Ca2+ from intracellular stores and diacylglycerol, which activates protein kinase C7-9. In nerve terminals, the activation of presynaptic protein kinase C with phorbol esters enhances glutamate release10. But the presynaptic receptor involved in this protein kinase C-mediated increase in the release of glutamate has not yet been identified. Here we demonstrate the presence of a presynaptic glutamate receptor of the metabotropic type that mediates an enhancement of glutamate exocytosis in cerebrocortical nerve terminals. Interestingly, this potentiation of glutamate release is observed only in the presence of arachidonic acid, which may reflect that this positive feedback control of glutamate exocytosis operates in concert with other pre- or postsynaptic events of the glutamatergic neurotransmission that generate arachidonic acid. This presynaptic glutamate receptor may have a physiological role in the maintenance of long-term potentiation where there is an increase in glutamate release mediated by postsynaptically generated arachidonic acid11.	UNIV COMPLUTENSE MADRID, FAC VET, DEPT BIOQUIM, E-28040 MADRID, SPAIN	Complutense University of Madrid			Miras-Portugal, Maria Teresa/L-7137-2014	Sanchez-Prieto, Jose/0000-0002-8513-3501				BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1988, NEUROLOGY NEUROBIOLO, V35, P3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERRERO I, 1991, J NEUROCHEM, V57, P718, DOI 10.1111/j.1471-4159.1991.tb03805.x; HERRERO I, 1991, NEUROSCI LETT, V126, P41, DOI 10.1016/0304-3940(91)90366-2; HERRERO I, 1992, FEBS LETT, V296, P317, DOI 10.1016/0014-5793(92)80312-5; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MANZONI OJJ, 1990, NEUROSCI LETT, V109, P146, DOI 10.1016/0304-3940(90)90553-L; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; MURPHY SN, 1988, P NATL ACAD SCI USA, V85, P8737, DOI 10.1073/pnas.85.22.8737; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NICOLETTI F, 1988, NEUROPHARMACOLOGY, V27, P551, DOI 10.1016/0028-3908(88)90174-8; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; RUBIO I, 1991, J NEUROCHEM, V57, P1159, DOI 10.1111/j.1471-4159.1991.tb08274.x; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP D D, 1990, Society for Neuroscience Abstracts, V16, P618; SCHOEPP DD, 1989, J NEUROCHEM, V53, P273, DOI 10.1111/j.1471-4159.1989.tb07324.x; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VERHAGE M, 1989, J NEUROCHEM, V53, P1188, DOI 10.1111/j.1471-4159.1989.tb07413.x	34	355	374	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					163	166		10.1038/360163a0	http://dx.doi.org/10.1038/360163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1359425				2022-12-28	WOS:A1992JX75200061
J	[Anonymous]				[Anonymous]			ANOTHER MILESTONE IN THE HUMAN GENOME RACE	LANCET			English	Editorial Material																		GOODFELLOW PN, 1992, NATURE, V359, P777, DOI 10.1038/359777a0; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; 1992, LANCET, V340, P905	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1090	1090						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357470				2022-12-28	WOS:A1992JV77500016
J	JULIUSSON, G; ELMHORNROSENBORG, A; LILIEMARK, J				JULIUSSON, G; ELMHORNROSENBORG, A; LILIEMARK, J			RESPONSE TO 2-CHLORODEOXYADENOSINE IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA RESISTANT TO FLUDARABINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							2-CHLORO-2'-DEOXYADENOSINE	Background. Patients with untreated B-cell chronic lymphocytic leukemia have a high rate of complete remission when given the halogenated nucleoside analogue fludarabine. However, patients in whom the disease has proved refractory to primary treatment have a reduced life expectancy and a dismal outcome. Methods. We treated four consecutive patients who had unsatisfactory responses to second-line or subsequent treatment with fludarabine with another halogenated nucleoside analogue, 2-chlorodeoxyadenosine. Results. One patient with progressing lymphocytosis, anemia, and thrombocytopenia despite 10 courses of fludarabine entered a complete remission when treated with 2-chlorodeoxyadenosine. Two patients who had less-than-partial remissions after six courses of fludarabine had good partial remissions when treated with 2-chlorodeoxyadenosine. One patient with Coombs-positive hemolytic anemia who had no response to three courses of fludarabine had a partial remission, with resolution of hypogammaglobulinemia, when treated with 2-chlorodeoxyadenosine. Conclusions. There was no evidence of cross-resistance between fludarabine and 2-chlorodeoxyadenosine despite their similar structures. 2-Chlorodeoxyadenosine may induce a complete remission in chronic lymphocytic leukemia that is highly resistant to chemotherapy, and it deserves wider clinical evaluation in patients with this condition.	HUDDINGE HOSP,DEPT PATHOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital	JULIUSSON, G (corresponding author), HUDDINGE HOSP,DEPT MED,DIV CLIN HEMATOL & ONCOL,S-14186 HUDDINGE,SWEDEN.							BEUTLER E, 1991, LEUKEMIA LYMPHOMA, V5, P1, DOI 10.3109/10428199109068099; BEUTLER E, IN PRESS LANCET; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; CARSON DA, 1984, P NATL ACAD SCI-BIOL, V81, P2232, DOI 10.1073/pnas.81.7.2232; CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; CHESON BD, 1991, LEUKEMIA LYMPHOMA, V5, P119, DOI 10.3109/10428199109103391; CHUNDURU S K, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P17; GREVER MR, 1986, BLOOD S, V68, pA223; JULIUSSON G, 1992, BLOOD, V79, P888; JULIUSSON G, 1985, BLOOD, V65, P134; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; JULIUSSON G, 1991, 5TH INT WORKSH CCL S; KEATING MJ, 1990, SEMIN ONCOL, V17, P49; KEMENA A, 1990, BLOOD S1, V76, pA288; LILIEMARK J, 1992, J CLIN ONCOL, V10, P1514, DOI 10.1200/JCO.1992.10.10.1514; LILIEMARK J, 1991, CANCER RES, V51, P5570; LILIEMARK J, 1991, BLOOD S, V78, pA269; LJUNGMAN P, 1990, SCAND J INFECT DIS, V22, P601, DOI 10.3109/00365549009027103; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710	21	132	133	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1056	1061		10.1056/NEJM199210083271504	http://dx.doi.org/10.1056/NEJM199210083271504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1355853				2022-12-28	WOS:A1992JR32100004
J	SUHARYONO; SIMANJUNTAK, C; WITHAM, N; PUNJABI, N; HEPPNER, DG; LOSONSKY, G; TOTOSUDIRJO, H; RIFAI, AR; CLEMENS, J; LIM, YL; BURR, D; WASSERMAN, SS; KAPER, J; SORENSON, K; CRYZ, S; LEVINE, MM				SUHARYONO; SIMANJUNTAK, C; WITHAM, N; PUNJABI, N; HEPPNER, DG; LOSONSKY, G; TOTOSUDIRJO, H; RIFAI, AR; CLEMENS, J; LIM, YL; BURR, D; WASSERMAN, SS; KAPER, J; SORENSON, K; CRYZ, S; LEVINE, MM			SAFETY AND IMMUNOGENICITY OF SINGLE-DOSE LIVE ORAL CHOLERA VACCINE CVD 103-HGR IN 5-9-YEAR-OLD INDONESIAN CHILDREN	LANCET			English	Article							BOVINE ROTAVIRUS VACCINE; VIBRIO-CHOLERAE; ANTIBODY-RESPONSES; FIELD TRIAL; BANGLADESH; PROTECTION; RIT-4237; DURATION; IMMUNITY; STRAINS	Oral vaccines offer great promise as public-health measures to prevent disease in less-developed countries. CVD 103-HgR, a genetically engineered, attenuated, Vibrio cholerae O1 strain has proved effective in industrialised countries. We have assessed the safety, immunogenicity, and excretion of this live cholera vaccine in children in north Jakarta, Indonesia. 412 children aged 5-9 years received single doses of 5 x 10(6), 5 x 10(7), 5 x 10(8), 5 x 10(9), or 1 x 10(10) colony forming units (CFU) of CVD 103-HgR or placebo (5 x 10(8) inactivated Escherichia coli K-12) with buffer. All doses were well tolerated. The 5 x 10(8) CFU dose, which is highly immunogenic in subjects in industrialised countries (> 90% seroconversion), elicited seroconversions of vibriocidal antibody in only 16% of indonesian children. By contrast, a single 5 x 10(9) CFU dose of vaccine resulted in high rates (75% and 87%) of seroconversion with two different batches of vaccine. A batch prepared with a centrifugation step gave significantly higher geometric mean titres (16-fold increase over baseline) than did a batch in which there was a filtration step between fermentation and lyophilisation (10-fold increase over baseline). At a 5 x 10(9) CFU dose, CVD 103-HgR is well tolerated and highly immunogenic in Indonesian children and should therefore be further investigated for use as a one-dose live oral cholera vaccine in developing countries.	UNIV MARYLAND, SCH MED, CTR VACCINE DEV, 10 S PINE ST, BALTIMORE, MD 21201 USA; UNIV INDONESIA, DEPT PEDIAT, JAKARTA, INDONESIA; INFECT DIS HOSP, N JAKARTA, INDONESIA; SWISS SERUM & VACCINE INST, BERN, SWITZERLAND; NATL INST HLTH RES & DEV, JAKARTA, INDONESIA; USN, MED RES UNIT 2, JAKARTA, INDONESIA	University System of Maryland; University of Maryland Baltimore; University of Indonesia; National Institute of Health Research & Development - Indonesia; University of 19 November Kolaka				Kaper, James/0000-0003-0715-2907	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062528] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI62528] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAT P, 1972, GASTROENTEROLOGY, V62, P11; CLEMENS JD, 1987, J INFECT DIS, V155, P79, DOI 10.1093/infdis/155.1.79; CLEMENS JD, 1991, J INFECT DIS, V163, P1235, DOI 10.1093/infdis/163.6.1235; CLEMENTS ML, 1982, J INFECT DIS, V145, P465, DOI 10.1093/infdis/145.4.465; CRYZ SJ, 1990, VACCINE, V8, P577, DOI 10.1016/0264-410X(90)90012-B; DEMOL P, 1986, LANCET, V2, P108; FAGUNDESNETO U, 1984, J TROP PEDIATRICS, V30, P204, DOI 10.1093/tropej/30.4.204; GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236; GRACEY M, 1973, AM J CLIN NUTR, V26, P1170; HANLON P, 1987, LANCET, V1, P1342; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; KAPER JB, 1984, BIO-TECHNOL, V2, P345, DOI 10.1038/nbt0484-345; KAPER JB, 1990, RES MICROBIOL, V141, P901, DOI 10.1016/0923-2508(90)90128-D; KOTLOFF K, IN PRESS INFECT IMMU; LANATA CF, 1989, J INFECT DIS, V159, P452, DOI 10.1093/infdis/159.3.452; LANATA CF, 1992, VACCINE, V10, P273; LEVINE M M, 1988, Lancet, V2, P467; LEVINE MM, 1988, INFECT IMMUN, V56, P161, DOI 10.1128/IAI.56.1.161-167.1988; LEVINE MM, 1981, J INFECT DIS, V143, P818, DOI 10.1093/infdis/143.6.818; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LEVINE MM, 1985, J CLIN MICROBIOL, V21, P174, DOI 10.1128/JCM.21.2.174-179.1985; LEVINE MM, 1979, T ROY SOC TROP MED H, V73, P3, DOI 10.1016/0035-9203(79)90119-6; LEVINE MM, 1992, CHOLERA, V88, P285; LEVINE MM, IN PRESS VACCINE; LINDENBAUM J, 1966, BMJ-BRIT MED J, V2, P1616, DOI 10.1136/bmj.2.5530.1616; Mata L J, 1972, Am J Clin Nutr, V25, P118, DOI 10.1093/ajcn/25.10.1118; MIGASENA S, 1989, INFECT IMMUN, V57, P3261, DOI 10.1128/IAI.57.11.3261-3264.1989; MONTEFIORE DG, 1971, SCI PUBLICATION PAN, V226, P182; MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P777; MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P327; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; SACK DA, 1991, J INFECT DIS, V164, P407, DOI 10.1093/infdis/164.2.407; SANTOSHAM M, 1991, J INFECT DIS, V163, P483, DOI 10.1093/infdis/163.3.483; SPRINZ H, 1962, AM J CLIN PATHOL, V38, P43; SUAREHAWARATANA P, 1992, J INFECT DIS, V165, P1042, DOI 10.1093/infdis/165.6.1042; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837	36	120	120	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					689	694		10.1016/0140-6736(92)92231-4	http://dx.doi.org/10.1016/0140-6736(92)92231-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355798				2022-12-28	WOS:A1992JN78000003
J	MODAN, B				MODAN, B			DIET AND CANCER - CAUSAL RELATION OR JUST WISHFUL THINKING	LANCET			English	Editorial Material							BREAST-CANCER; COLON CANCER; FIBER; RISK; EPIDEMIOLOGY; ETIOLOGY				MODAN, B (corresponding author), CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL.							Baker S. R., 1990, ADV MOD ENV TOXICOL, V18, P1; Burkitt D P, 1972, Lancet, V2, P1408; CARROLL KK, 1968, CAN MED ASSOC J, V98, P590; EIGHANY NA, 1990, EPIDEMIOLOGY, V1, P107; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; GRAHAM S, 1979, AM J EPIDEMIOL, V109, P1; HILL MJ, 1974, CANCER, V34, P815, DOI 10.1002/1097-0142(197409)34:3+<815::AID-CNCR2820340705>3.0.CO;2-6; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HOWELL MA, 1974, BRIT J CANCER, V29, P328, DOI 10.1038/bjc.1974.75; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Kritchevsky D, 1986, Prog Clin Biol Res, V222, P495; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; MODAN B, 1975, J NATL CANCER I, V55, P15, DOI 10.1093/jnci/55.1.15; PHILLIPS RL, 1975, CANCER RES, V35, P3513; RUSSELL R, 1916, NOTES CAUSATION CANC; SLATTERY ML, 1988, J NATL CANCER I, V80, P1474, DOI 10.1093/jnci/80.18.1474; SNOW J, 1945, SNOW CHOLERA; TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3; WYNDER EL, 1991, CANCER-AM CANCER SOC, V67, P746, DOI 10.1002/1097-0142(19910201)67:3<746::AID-CNCR2820670336>3.0.CO;2-1; 1987, REGULATING PESTICIDE	21	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					162	164		10.1016/0140-6736(92)93227-E	http://dx.doi.org/10.1016/0140-6736(92)93227-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352577				2022-12-28	WOS:A1992JE38200015
J	OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; HUIBREGTSE, K; VANDENBROUCKE, JP; TYTGAT, GNJ				OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; HUIBREGTSE, K; VANDENBROUCKE, JP; TYTGAT, GNJ			EVALUATION OF ENDOSCOPY FOR EARLY DETECTION OF GASTRIC-STUMP CANCER	LANCET			English	Article							SURGERY; LESIONS; COHORT	The value of endoscopic surveillance of postgastrectomy patients for the early detection of gastric-stump cancer is controversial. Using data from an Amsterdam postgastrectomy cohort of 2633 patients, we have done a retrospective analysis of the effect on mortality from gastric cancer of endoscopic surveillance in these patients. Between 1976 and 1982, 504 symptom-free patients from the Amsterdam cohort participated in an endoscopic surveillance programme. All patients were followed up until 1988. Relative to the general Dutch population, risk of death from gastric cancer was less among patients who took part in surveillance than among those who did not participate. However, differences were small and similar differences existed for risk of death from lung and colorectal cancers, suggesting the presence of selection. Our study seems to confirm that large-scale surveillance of postgastrectomy patients is not justified.	UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2333 AA LEIDEN,NETHERLANDS; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Johns Hopkins University	OFFERHAUS, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				CAYGILL CPJ, 1986, LANCET, V1, P929; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; CRAANEN ME, 1991, DIGEST DIS SCI, V36, P1529, DOI 10.1007/BF01296393; LOGAN RFA, 1983, LANCET, V2, P667; OFFERHAUS GJA, 1989, CANCER, V64, P698, DOI 10.1002/1097-0142(19890801)64:3<698::AID-CNCR2820640322>3.0.CO;2-D; SAVALGI RS, 1990, LANCET, V336, P413, DOI 10.1016/0140-6736(90)91954-9; SCHUMAN BM, 1986, GASTROINTEST ENDOSC, V32, P117, DOI 10.1016/S0016-5107(86)71773-2; SONNENBERG A, 1984, GASTROENTEROLOGY, V87, P489; TERSMETTE AC, 1991, AM J EPIDEMIOL, V134, P14, DOI 10.1093/oxfordjournals.aje.a115988; TERSMETTE AC, 1991, GASTROENTEROLOGY, V101, P148, DOI 10.1016/0016-5085(91)90471-V	11	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					33	35		10.1016/0140-6736(92)92433-G	http://dx.doi.org/10.1016/0140-6736(92)92433-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351609				2022-12-28	WOS:A1992JC35400013
J	JAMES, AA				JAMES, AA			MOSQUITO MOLECULAR-GENETICS - THE HANDS THAT FEED BITE BACK	SCIENCE			English	Editorial Material							ANOPHELES-GAMBIAE COMPLEX				JAMES, AA (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.			James, Anthony/0000-0001-5577-3308				COLUZZI M, 1977, NATURE, V266, P832, DOI 10.1038/266832a0; CRAMPTON JM, 1990, MOL INSECT SCI; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; KAUFMAN PD, 1991, NUCLEIC ACIDS RES, V19, P6336, DOI 10.1093/nar/19.22.6336; MORRIS AC, 1991, NUCLEIC ACIDS RES, V19, P5895, DOI 10.1093/nar/19.21.5895; PASKEWITZ SM, 1990, MED VET ENTOMOL, V4, P367, DOI 10.1111/j.1365-2915.1990.tb00453.x; ZHENG LB, 1991, P NATL ACAD SCI USA, V88, P11187, DOI 10.1073/pnas.88.24.11187; 1991, MOSQUITO MOL GENETIC	8	114	119	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					37	38		10.1126/science.1352413	http://dx.doi.org/10.1126/science.1352413			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1352413				2022-12-28	WOS:A1992JC16500023
J	WOODS, KL; FLETCHER, S; ROFFE, C; HAIDER, Y				WOODS, KL; FLETCHER, S; ROFFE, C; HAIDER, Y			INTRAVENOUS MAGNESIUM-SULFATE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE 2ND LEICESTER-INTRAVENOUS-MAGNESIUM-INTERVENTION-TRIAL (LIMIT-2)	LANCET			English	Article							SULFATE; ARRHYTHMIAS; INFUSION; PLACEBO; IONS	The cardiovascular actions of the magnesium ion at pharmacological concentrations include coronary and systemic vasodilatation, platelet inhibition, and antiarrhythmic effects. Magnesium has also been reported to protect myocardial tissue in experimental models of ischaemia and reperfusion. Several small clinical trials in suspected acute myocardial infarction have suggested that early mortality can be reduced by intravenous infusion of magnesium salts in the acute phase, but none has been of sufficient size to be conclusive. We therefore conducted a randomised, double blind, placebo controlled study in 2316 patients with suspected acute myocardial infarction who received either intravenous magnesium sulphate (8 mmol over 5 min followed by 65 mmol over 24 h) or physiological saline. The primary outcome measure was 28-day mortality, which was ascertained in 99.3% of patients. The groups were well balanced for prognostic factors. By intention-to-treat analysis mortality from all causes was 7.8% in the magnesium group and 10.3% in the placebo group (2p=0.04), a relative reduction of 24% (95% confidence interval 1-43%). Within the coronary care unit the incidence of left ventricular failure was reduced by 25% (7-39%) in the magnesium group (2p=0.009). There was no significant difference between the groups in the incidence of heart block or the use of antiarrhythmic drugs, direct-current cardioversion, or temporary pacing. Myocardial infarction was confirmed in 65% of each group, with closely similar rises in cardiac enzymes. The side-effects of magnesium treatment were transient flushing, related to speed of injection of the loading dose, and an increased incidence of sinus bradycardia (2p=0.02). Exploratory subgroup analyses of 28-day mortality did not indicate any effect modification by thrombolysis or aspirin, or by previous treatment with beta blockers, calcium antagonists, or diuretics. Intravenous magnesium sulphate is a simple, safe, and widely applicable treatment. Its efficacy in reducing early mortality of myocardial infarction is comparable to, but independent of, that of thrombolytic or antiplatelet therapy.	LEICESTER ROYAL INFIRM, CORONARY CARE UNIT, LEICESTER LE2 7LX, ENGLAND; UNIV LEICESTER, DEPT PHARMACOL & THERAPEUT, LEICESTER LE1 7RH, ENGLAND	University of Leicester; University of Leicester			Roffe, Christine/AAT-5611-2020	Roffe, Christine/0000-0002-5259-6649				ABRAHAM AS, 1987, ARCH INTERN MED, V147, P753, DOI 10.1001/archinte.147.4.753; ADAMS JH, 1979, THROMB HAEMOSTASIS, V42, P603; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BOHMAN VR, 1990, OBSTET GYNECOL, V76, P984; BORCHGREVINK PC, 1989, AM J PHYSIOL, V256, pH195, DOI 10.1152/ajpheart.1989.256.1.H195; CEREMUZYNSKI L, 1989, AM HEART J, V118, P1333, DOI 10.1016/0002-8703(89)90027-6; DEMETS DL, 1980, BIOMETRIKA, V67, P651; FELDSTEDT M, 1988, European Heart Journal, V9, P226; FERRARI R, 1986, J MOL CELL CARDIOL, V18, P487, DOI 10.1016/S0022-2828(86)80914-2; HAVERKAMP W, 1988, EUR HEART J, V9, P228; HEARSE DJ, 1978, J THORAC CARDIOV SUR, V75, P877; ISERI LT, 1985, AM HEART J, V110, P789, DOI 10.1016/0002-8703(85)90458-2; KIMURA T, 1989, CIRCULATION, V79, P1118, DOI 10.1161/01.CIR.79.5.1118; KUGIYAMA K, 1988, J AM COLL CARDIOL, V12, P1177, DOI 10.1016/0735-1097(88)92597-1; KULICK DL, 1988, AM HEART J, V115, P367, DOI 10.1016/0002-8703(88)90483-8; MANTEL N, 1959, J NATL CANCER I, V22, P719; Morton B C, 1984, Magnesium, V3, P346; MROCZEK WJ, 1977, ANGIOLOGY, V28, P720; RASMUSSEN HS, 1986, LANCET, V1, P234; RASMUSSEN HS, 1987, CLIN CARDIOL, V10, P351, DOI 10.1002/clc.4960100610; RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P377, DOI 10.1002/clc.4960110604; ROGIERS P, 1989, AM HEART J, V117, P1278, DOI 10.1016/0002-8703(89)90406-7; SHECHTER M, 1990, AM J CARDIOL, V66, P271, DOI 10.1016/0002-9149(90)90834-N; SMITH LF, 1986, INT J CARDIOL, V12, P175, DOI 10.1016/0167-5273(86)90239-1; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TZIVONI D, 1990, AM J CARDIOL, V65, P1397, DOI 10.1016/0002-9149(90)91335-4; VIGORITO C, 1991, AM J CARDIOL, V67, P1435, DOI 10.1016/0002-9149(91)90478-4; WATSON KV, 1986, P NATL ACAD SCI USA, V83, P1075, DOI 10.1073/pnas.83.4.1075; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; WOODS KL, 1992, BRIT MED J, V304, P119, DOI 10.1136/bmj.304.6819.119-b; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x; 1991, LANCET, V338, P667	33	450	463	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1992	339	8809					1553	1558		10.1016/0140-6736(92)91828-V	http://dx.doi.org/10.1016/0140-6736(92)91828-V			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351547				2022-12-28	WOS:A1992JB20200001
J	SCHNEIDER, MME; HOEPELMAN, AIM; SCHATTENKERK, JKME; NIELSEN, TL; VANDERGRAAF, Y; FRISSEN, JPHJ; VANDERENDE, IME; KOLSTERS, AFP; BORLEFFS, JCC				SCHNEIDER, MME; HOEPELMAN, AIM; SCHATTENKERK, JKME; NIELSEN, TL; VANDERGRAAF, Y; FRISSEN, JPHJ; VANDERENDE, IME; KOLSTERS, AFP; BORLEFFS, JCC			A CONTROLLED TRIAL OF AEROSOLIZED PENTAMIDINE OR TRIMETHOPRIM SULFAMETHOXAZOLE AS PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED PENTAMIDINE; SECONDARY PROPHYLAXIS; HIV-INFECTION; PREVENTION; AIDS; CHEMOPROPHYLAXIS; AZIDOTHYMIDINE; COTRIMOXAZOLE; ZIDOVUDINE; PULMONARY	Background. Primary prophylaxis against Pneumocystis carinii pneumonia (PCP) is recommended for patients with human immunodeficiency virus (HIV) infection if their CD4 cell counts are below 200 per cubic millimeter (0.2 x 10(9) per liter). Either aerosolized pentamidine or trimethoprim-sulfamethoxazole (co-trimoxazole) is commonly prescribed for prophylaxis, but the relative efficacy and toxicity of these agents are unknown. Methods. We conducted a multicenter trial involving 215 HIV-infected patients with no history of PCP but with CD4 cell counts below 200 per cubic millimeter. The patients were randomly assigned to one of three regimens: aerosolized pentamidine once a month, 480 mg of trimethoprim-sulfamethoxazole once a day (80 mg of trimethoprim and 400 mg of sulfamethoxazole), or 960 mg of trimethoprim-sulfamethoxazole once a day (160 mg and 800 mg, respectively). The cumulative incidence of PCP was estimated by Kaplan-Meier survival analysis. Results. After a mean follow-up of 264 days, 6 of the 71 patients in the pentamidine group had a confirmed first episode of PCP (11 percent), whereas none of the 142 patients in the two trimethoprim-sulfamethoxazole groups had PCP (P = 0.002). However, adverse events that required discontinuation of the medication were much more frequent in the trimethoprim-sulfamethoxazole groups (1 7 and 18 patients) than in the pentamidine group (2 patients). The adverse reactions occurred significantly sooner in the group given 960 mg of trimethoprim-sulfamethoxazole than in the group given 480 mg (mean time, 16 vs. 57 days; P = 0.02). Conclusions. For patients with HIV infection, trimethoprim-sulfamethoxazole taken once a day is more effective as primary prophylaxis against PCP than aerosolized pentamidine administered once a month, although adverse drug reactions are more frequent with trimethoprim-sulfamethoxazole.	UGENE RES,UTRECHT,NETHERLANDS; UNIV HOSP ROTTERDAM,ROTTERDAM,NETHERLANDS; HVIDOVRE UNIV HOSP,KOBENHAVNS KOMMUNES,DEPT INFECT DIS,DK-2650 HVIDOVRE,DENMARK; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,AIDS UNIT,1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,DEPT CLIN MICROBIOL,3511 GV UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,INFECT DIS LAB,3511 GV UTRECHT,NETHERLANDS; UNIV UTRECHT,DEPT EPIDEMIOL,UTRECHT,NETHERLANDS; ONZE LIEVE VROUW HOSP,AMSTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Onze Lieve Vrouwe Gasthuis Hospital	SCHNEIDER, MME (corresponding author), UNIV HOSP UTRECHT,DEPT INTERNAL MED,IMMUNOL & INFECT DIS SECT,F02 126,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS.							ABD AG, 1988, CHEST, V94, P329, DOI 10.1378/chest.94.2.329; BRADBURNE RM, 1989, THORAX, V44, P591, DOI 10.1136/thx.44.7.591; BUHL R, 1989, LANCET, V2, P1294; CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FLANIGAN T, 1987, NEW ENGL J MED, V317, P1155; FREEDBERG KA, 1991, NEW ENGL J MED, V325, P735, DOI 10.1056/NEJM199109053251013; GIRARD PM, 1989, LANCET, V1, P1348; GLATT AE, 1988, NEW ENGL J MED, V318, P1439, DOI 10.1056/NEJM198806023182206; GOLDEN JA, 1989, LANCET, V1, P654; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KOVACS JA, 1989, J INFECT DIS, V160, P882, DOI 10.1093/infdis/160.5.882; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MACHER AM, 1987, NEW ENGL J MED, V316, P1092; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MILLER R, 1991, J ANTIMICROB CHEMOTH, V27, P153, DOI 10.1093/jac/27.2.153; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NORTHFELT DW, 1989, LANCET, V2, P1454, DOI 10.1016/S0140-6736(89)92060-6; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; STEIN DS, 1991, ANTIMICROB AGENTS CH, V35, P1705, DOI 10.1128/AAC.35.9.1705; TELZAK EE, 1990, REV INFECT DIS, V12, P380; VANDERVEN AJAM, 1991, LANCET, V338, P431, DOI 10.1016/0140-6736(91)91046-W; WORMSER GP, 1991, ARCH INTERN MED, V151, P688, DOI 10.1001/archinte.151.4.688; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T; 1989, JAMA-J AM MED ASSOC, V262, P335; 1986, MMWR MORB MORTAL WKL, V35, P17; 1987, MMWR MORB MORTAL SS1, V36, pS1; 1985, SAS STAT GUIDE PERSO; 1990, STATISTICS EPIDEMIOL; 1989, MMWR MORB MORTAL SS5, V38, P1	39	254	258	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1836	1841		10.1056/NEJM199212243272603	http://dx.doi.org/10.1056/NEJM199212243272603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1360145	Bronze			2022-12-28	WOS:A1992KD71400003
J	FRERICHS, RR; HTOON, MT; ESKES, N; LWIN, S				FRERICHS, RR; HTOON, MT; ESKES, N; LWIN, S			COMPARISON OF SALIVA AND SERUM FOR HIV SURVEILLANCE IN DEVELOPING-COUNTRIES	LANCET			English	Article							ANTIBODIES	Saliva has been proposed as a non-invasive alternative to serum for HIV antibody testing. In a field study in Myanmar (formerly Burma), we evaluated such an alternative to identify the frequency of HIV infection in a surveillance programme of high-risk and low-risk sentinel groups. Duplicate vials of saliva and serum were collected from 479 high-risk and 1039 low-risk subjects. One vial of each pair was analysed blind in two laboratories, one in the USA and the other in Myanmar. The US laboratory followed WHO confirmatory strategy III with three different enzyme-linked immunosorbent assays (ELISAs), while the laboratory in Myanmar followed strategy I with one ELISA. Serum testing in the US was the gold standard. The Cambridge ELISA with saliva was a more effective surveillance tool (sensitivity 90.5%, specificity 99.5-100%) for describing the frequency of subjects with HIV antibodies than the serum ELISA supplied to Myanmar by WHO (95.9% and 98.3%, respectively). Saliva is recommended as a safe and effective alternative to serum for HIV antibody testing with ELISA in surveillance programmes in developing countries.	SALIVA DIAGNOST SYST,VANCOUVER,WA; DEPT HLTH YANGON,AIDS PREVENT & CONTROL PROGRAMME,YANGON,MYANMAR; NATL HLTH LAB,YANGON,MYANMAR		FRERICHS, RR (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024, USA.							BARR CE, 1992, J AM DENT ASSOC, V123, P36; BEHETS FM, 1991, J ACQ IMMUN DEF SYND, V4, P183; COATES R, 1991, CAN J PUBLIC HEALTH, V82, P397; CROFTS N, 1991, AIDS, V5, P561, DOI 10.1097/00002030-199105000-00013; FOX PC, 1991, J AM DENT ASSOC, V122, P46, DOI 10.14219/jada.archive.1991.0331; FRERICHS RR, 1991, ANNU REV PUBL HEALTH, V12, P257, DOI 10.1146/annurev.pu.12.050191.001353; KLOKKE AH, 1991, AIDS, V5, P1391, DOI 10.1097/00002030-199111000-00022; MAJOR CJ, 1991, J INFECT DIS, V163, P699, DOI 10.1093/infdis/163.4.699; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; 1992, WHO WEEKLY EPID REC, V67, P145	10	63	64	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1496	1499		10.1016/0140-6736(92)92755-5	http://dx.doi.org/10.1016/0140-6736(92)92755-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361596				2022-12-28	WOS:A1992KD06900004
J	SCHOTT, GD				SCHOTT, GD			THE EXTENT OF MAN FROM VITRUVIUS TO MARFAN	LANCET			English	Article								It is frequently stated that patients with Marfan's syndrome have an arm span greater than height. This implies a characteristic different from the proportions in normal adult man, in whom span and height are often thought to be equal. Such equality of span and height, which allows man to be portrayed within a square, has been a widely held concept, immortalised by Leonardo da Vinci, that dates from the Roman Vitruvius. However, in the past two hundred years, anthropometry has shown that span exceeds height in 59-78% of normal adult white men. Thus not only is the classic concept of equality of span and height generally incorrect, but also a span greater than height cannot be considered characteristic of Marfan's syndrome. Paradoxically, in some affected individuals, Vitruvian equality of height and span may occur.			SCHOTT, GD (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND.							BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BONOMI J, 1880, PROPORTIONS HUMAN FI; BONOMI J, 1856, PROPORTIONS HUMAN FI, P12; CASSINIS U, 1934, CONTROLLO MED SPORT; DAVINCI L, 1939, LIT WORKS L DAVINCI, V1, P255; HANCOX J, 1992, BYROM COLLECTION REN; MAGID D, 1990, AM J ROENTGENOL, V155, P99, DOI 10.2214/ajr.155.1.2112876; MCKUSICK VA, 1972, HERITABLE DISORDERS, P69; NUKI G, 1991, DAVIDSONS PRINCIPLES, P807; PANOFSKY Erwin, 1970, MEANING VISUAL ARTS, P82; Pearson K., 1903, BIOMETRIKA, V2, P357; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; Schott G D, 1979, J Neurol Sci, V42, P321, DOI 10.1016/0022-510X(79)90165-5; SINCLAIR RJG, 1960, Q J MED, V29, P19; SMITH R, 1987, OXFORD TXB MED, V2; THOMPSON DW, 1952, GROWTH FORM, V1, P190; VANDERVAEL F, 1964, BIOMETRIE HUMAINE, P70; VITRUVIUS P, 1791, ARCHITECTURA, V1, P45; YOUNG I, 1991, BRIT MED J, V303, P1414, DOI 10.1136/bmj.303.6815.1414	19	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1518	1520		10.1016/0140-6736(92)92767-A	http://dx.doi.org/10.1016/0140-6736(92)92767-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KD069	1361608				2022-12-28	WOS:A1992KD06900016
J	ECKEL, RH				ECKEL, RH			INSULIN RESISTANCE - AN ADAPTATION FOR WEIGHT MAINTENANCE	LANCET			English	Article							LIPOPROTEIN-LIPASE; PIMA-INDIANS; OBESE WOMEN; GLUCOSE; GAIN; RESPONSIVENESS; SENSITIVITY; METABOLISM; REDUCTION; RECEPTOR	Insulin resistance can be physiological, but most often is associated with metabolic disorders such as obesity and non-insulin dependent diabetes mellitus. The reduction in insulin action seen in insulin-resistant states affects metabolic fuel partitioning in a way that would prevent additional weight gain. Despite the potential adverse effects of cardiovascular risk factors that accompany insulin resistance, reductions in insulin action may well be necessary to prevent additional weight gain in those in whom excessive food intake is coupled with inactivity.			ECKEL, RH (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL, DENVER, CO 80262 USA.							BIELINSKI R, 1985, AM J CLIN NUTR, V42, P69, DOI 10.1093/ajcn/42.1.69; BLOCH CA, 1987, J PEDIATR-US, V110, P481, DOI 10.1016/S0022-3476(87)80522-X; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; DONAHUE RP, 1987, LANCET, V1, P821; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1987, J CLIN INVEST, V80, P992, DOI 10.1172/JCI113193; FARESE RV, 1991, METABOLISM, V40, P214, DOI 10.1016/0026-0495(91)90178-Y; FLATT JP, 1987, AM J CLIN NUTR, V45, P296, DOI 10.1093/ajcn/45.1.296; HAFFNER SM, 1989, ARTERIOSCLEROSIS, V9, P928, DOI 10.1161/01.ATV.9.6.928; HOLLENBECK CB, 1984, DIABETES, V33, P460, DOI 10.2337/diabetes.33.5.460; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; KRAMER FM, 1989, INT J OBESITY, V13, P123; LEBLANC J, 1982, METABOLISM, V31, P453, DOI 10.1016/0026-0495(82)90233-5; NEWMAN WP, 1983, METABOLISM, V32, P590, DOI 10.1016/0026-0495(83)90029-X; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; RANDLE PJ, 1963, LANCET, V1, P785; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSSINI AA, 1985, JOSLINS DIABETES MEL, P834; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TURNER RC, 1983, DIABETOLOGIA, V24, P404; WIGAND JP, 1979, DIABETES, V28, P287, DOI 10.2337/diabetes.28.4.287; ZURLO F, 1990, AM J PHYSIOL, V259, pE650	26	154	156	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1992	340	8833					1452	1453		10.1016/0140-6736(92)92633-Q	http://dx.doi.org/10.1016/0140-6736(92)92633-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360570				2022-12-28	WOS:A1992KC28400014
J	ICHINOSE, M; NAKAJIMA, N; TAKAHASHI, T; YAMAUCHI, H; INOUE, H; TAKISHIMA, T				ICHINOSE, M; NAKAJIMA, N; TAKAHASHI, T; YAMAUCHI, H; INOUE, H; TAKISHIMA, T			PROTECTION AGAINST BRADYKININ-INDUCED BRONCHOCONSTRICTION IN ASTHMATIC-PATIENTS BY NEUROKININ RECEPTOR ANTAGONIST	LANCET			English	Article							SUBSTANCE-P; GUINEA-PIG; MULTIPLE TACHYKININS; SENSORY NERVES; SMOOTH-MUSCLE; AIRWAYS; NEUROPEPTIDES; CONTRACTION	Axon reflex mechanisms may be involved in the pathogenesis of asthma, but there has been no direct evidence that endogenous tachykinins cause bronchoconstriction in asthmatic subjects. We have studied the effect of a tachykinin receptor antagonist (FK-224) on bronchoconstriction induced by inhalation of bradykinin in asthmatic patients. In a double-blind, placebo-controlled, crossover trial, ten subjects with stable asthma were given FK-224 (4 mg) or placebo by inhalation 20 min before challenge with bradykinin (0-1250 mug/ml, five breaths of each concentration) given with 5 min intervals. Bradykinin caused dose-dependent bronchoconstriction in all subjects. FK-224 significantly opposed the bronchoconstrictor effect; the geometric mean of the cumulative concentration required to elicit a 35% fall in specific airway conductance was 5.3 mug/ml after placebo and 40 mug/ml after FK-224 (p < 0.001). Inhalation of bradykinin caused coughing in three subjects, which was inhibited by FK-224 in all three. Antagonism of the tachykinin receptor by FK-224 greatly inhibited both bronchoconstriction and coughing induced by bradykinin in asthmatic patients, suggesting that tachykinin release from the airway sensory nerves is involved in responses to bradykinin. Tachykinin receptor antagonists may be useful in the treatment of asthma.			ICHINOSE, M (corresponding author), TOHOKU UNIV, SCH MED, DEPT INTERNAL MED 1, 1-1 SEIRYO MACHI, AOBA KU, SENDAI, MIYAGI 980, JAPAN.			Inoue, Hiroshi/0000-0002-9969-2152				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1991, ANN NY ACAD SCI, V629, P359; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUNHILL MS, 1960, J CLIN PATHOL, V13, P27; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; HALL AK, 1989, BRIT J PHARMACOL, V97, P274, DOI 10.1111/j.1476-5381.1989.tb11951.x; HASHIMOTO M, 1992, J ANTIBIOT, V45, P1064, DOI 10.7164/antibiotics.45.1064; HAYASHI K, 1992, J ANTIBIOT, V45, P1055, DOI 10.7164/antibiotics.45.1055; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; ICHINOSE M, 1990, J PHARMACOL EXP THER, V253, P594; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; KAUFMAN MP, 1980, J APPL PHYSIOL, V48, P511, DOI 10.1152/jappl.1980.48.3.511; KOHROGI H, 1988, J CLIN INVEST, V82, P2063, DOI 10.1172/JCI113827; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; MAGGI CA, 1988, GEN PHARMACOL-VASC S, V19, P1, DOI 10.1016/0306-3623(88)90002-X; MARTLING CR, 1987, LIFE SCI, V40, P1633, DOI 10.1016/0024-3205(87)90130-5; MIROMOTO H, 1992, J PHARMACOL EXP THER, V262, P398; MURAI M, 1992, J PHARMACOL EXP THER, V262, P403; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; ROGERS DF, 1989, EUR J PHARMACOL, V174, P283, DOI 10.1016/0014-2999(89)90322-1; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SEKIZAWA K, 1987, J PHARMACOL EXP THER, V243, P1211; TANAKA DT, 1986, J APPL PHYSIOL, V60, P458, DOI 10.1152/jappl.1986.60.2.458	28	155	165	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1992	340	8830					1248	1251		10.1016/0140-6736(92)92948-F	http://dx.doi.org/10.1016/0140-6736(92)92948-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359319				2022-12-28	WOS:A1992JZ23700003
J	SKRABANEK, P				SKRABANEK, P			SMOKING AND STATISTICAL OVERKILL	LANCET			English	Editorial Material											SKRABANEK, P (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH,DUBLIN 2,IRELAND.							COWELL MJ, 1979, MORTALITY DIFFERENCE; OKAMOTO Y, 1992, BRIT MED J, V305, P403, DOI 10.1136/bmj.305.6850.403; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PETO R, 1985, NEW SCI         0124, P26; TAYLOR P, 1985, SMOKE RING, P302; 1991, SMOKING EPIDEMIC COU, V1, P3; 1992, LANCET, V339, P1600; 1992, LANCET, V340, P399; 1990, TOBACCO ALERT    JUL, P4; 1992, LANCET, V339, P1267; 1984, LANCET, V2, P1167	11	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1208	1209		10.1016/0140-6736(92)92902-R	http://dx.doi.org/10.1016/0140-6736(92)92902-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359271				2022-12-28	WOS:A1992JY38600014
J	CARME, B				CARME, B			PSEUDORESISTANT MALARIA IN TROPICAL COUNTRIES	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; CHEMOSENSITIVITY		FAC MED AMIENS,F-800054 AMIENS,FRANCE		CARME, B (corresponding author), CTR HOSP REG UNIV AMIENS,SERV PARASITOL,F-800054 AMIENS,FRANCE.							CARME B, 1991, LANCET, V338, P582, DOI 10.1016/0140-6736(91)91158-Q; CARME B, 1991, J INFECT DIS, V164, P828, DOI 10.1093/infdis/164.4.828; HOFFMAN SL, 1984, T ROY SOC TROP MED H, V78, P175, DOI 10.1016/0035-9203(84)90271-2; 1989, UN DIENSA STESA112 U; 1984, WHO TECH REP SER, V711	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					896	897		10.1016/0140-6736(92)93296-Y	http://dx.doi.org/10.1016/0140-6736(92)93296-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357307				2022-12-28	WOS:A1992JT32700015
J	BATES, I; BEDUADDO, G; RUTHERFORD, T; BEVAN, DH				BATES, I; BEDUADDO, G; RUTHERFORD, T; BEVAN, DH			SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES IN TROPICAL WEST AFRICA	LANCET			English	Note							BLOOD	Splenic lymphoma with villous lymphocytes (SLVL) is a monoclonal B-lymphoproliferative disorder characterised by splenomegaly and distinctive villous lymphocytes in the peripheral blood. It has not previously been reported from Africa, but we describe ten Ghanaian patients with SLVL seen at one hospital during a 4-year period. The clinical presentation is similar in Africa and in temperate regions, though the lymphocyte count is higher in African patients and the disorder predominantly affects middle-aged women rather than elderly men. It is likely that SLVL has previously been classified as splenic chronic lymphocytic leukaemia or hyper-reactive malarial splenomegaly.	KOMFO ANOKYE TEACHING HOSP,KUMASI,GHANA	Kwame Nkrumah University Science & Technology	BATES, I (corresponding author), ST GEORGE HOSP,SCH MED,DIV HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATES I, 1991, J CLIN PATHOL, V44, P605, DOI 10.1136/jcp.44.7.605; BATES I, 1991, LANCET, V337, P505, DOI 10.1016/0140-6736(91)91293-4; MELO JV, 1987, LEUKEMIA, V1, P294; SONNET J, 1966, TROP GEOGR MED, V18, P272; SPIRANO P, 1986, HEMATOLOGICA, V71, P25; 1990, BRIT J HAEMATOL, V75, P449	8	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					575	577		10.1016/0140-6736(92)92108-R	http://dx.doi.org/10.1016/0140-6736(92)92108-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355156				2022-12-28	WOS:A1992JM33400005
J	MATUCHANSKY, C; MESSING, B; JEEJEEBHOY, KN; BEAU, P; BELIAH, M; ALLARD, JP				MATUCHANSKY, C; MESSING, B; JEEJEEBHOY, KN; BEAU, P; BELIAH, M; ALLARD, JP			CYCLICAL PARENTERAL-NUTRITION	LANCET			English	Review							SUBSTRATE UTILIZATION; ENTERAL NUTRITION; ADULT PATIENTS; BONE-DISEASE; HYPERALIMENTATION; CATHETER; PROTEIN; HUMANS		ST LAZARE HOSP,CTR HOME PARENTERAL NUTR,PARIS,FRANCE; ST MICHAELS HOSP,GASTROENTEROL & NUTR UNIT,TORONTO M5B 1W8,ONTARIO,CANADA; ST MICHAELS HOSP,CTR HOME PARENTERAL NUTR,TORONTO M5B 1W8,ONTARIO,CANADA; JEAN BERNARD HOSP,CTR HOME PARENTERAL NUTR,POITIERS,FRANCE; ST LAZARE HOSP,GASTROENTEROL & NUTR SUPPORT UNIT,107 BIS RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE; JEAN BERNARD HOSP,GASTROENTEROL UNIT,POITIERS,FRANCE; TORONTO GEN HOSP,DEPT MED,TORONTO M5G 1L7,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	MATUCHANSKY, C (corresponding author), ST LAZARE HOSP,GASTROENTEROL & NUTR SUPPORT UNIT,107 BIS RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							BAPTISTA RJ, 1984, JPEN-PARENTER ENTER, V8, P708, DOI 10.1177/0148607184008006708; BEAU P, 1987, LANCET, V330, P1095; BEAU P, 1986, LANCET, V327, P1272; BERKELHAMMER CH, 1988, AM J CLIN NUTR, V48, P1482, DOI 10.1093/ajcn/48.6.1482; BYRNE WJ, 1981, GASTROENTEROLOGY, V80, P947; DETSKY AS, 1986, JPEN-PARENTER ENTER, V10, P49, DOI 10.1177/014860718601000149; DETSKY AS, 1991, NEW ENGL J MED, V325, P573, DOI 10.1056/NEJM199108223250808; DEVERNEJOUL MC, 1985, J CLIN ENDOCR METAB, V60, P109, DOI 10.1210/jcem-60-1-109; GOULET O, 1986, JPEN-PARENTER ENTER, V10, P284, DOI 10.1177/0148607186010003284; GOUTTEBEL MC, 1987, JPEN-PARENTER ENTER, V11, P475, DOI 10.1177/0148607187011005475; HOWARD L, 1989, JPEN-PARENTER ENTER, V13, P478, DOI 10.1177/0148607189013005478; HOWARD L, 1986, JPEN-PARENTER ENTER, V10, P416, DOI 10.1177/0148607186010004416; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; JUST B, 1991, AM J CLIN NUTR, V54, P560, DOI 10.1093/ajcn/54.3.560; JUST B, 1990, AM J CLIN NUTR, V51, P107, DOI 10.1093/ajcn/51.1.107; KENNEDY G, 1983, TOTAL PARENTERAL NUT, P87; LEREBOURS E, 1988, JPEN-PARENTER ENTER, V12, P360, DOI 10.1177/0148607188012004360; LIPKIN EW, 1988, AM J CLIN NUTR, V47, P515, DOI 10.1093/ajcn/47.3.515; MAINI B, 1976, J SURG RES, V20, P515, DOI 10.1016/0022-4804(76)90085-8; MARTINS FM, 1985, AM J CLIN NUTR, V42, P61, DOI 10.1093/ajcn/42.1.61; MATUCHANSKY C, 1985, AM J CLIN NUTR, V41, P727, DOI 10.1093/ajcn/41.4.727; MATUCHANSKY C, 1981, GASTROENTEROLOGY, V81, P433; MESSING B, 1992, NUTRITION, V8, P30; MESSING B, 1990, NUTRITION, V6, P190; MESSING B, 1989, CLIN NUTR, V8, P3, DOI 10.1016/0261-5614(89)90018-6; MESSING B, 1983, JPEN-PARENTER ENTER, V7, P21, DOI 10.1177/014860718300700121; MESSING B, 1990, CLIN NUTR, V9, P220, DOI 10.1016/0261-5614(90)90023-L; MESSING B, 1991, GASTROENTEROLOGY, V100, P1502, DOI 10.1016/0016-5085(91)90645-2; MESSING B, 1990, AM J CLIN NUTR, V52, P1094, DOI 10.1093/ajcn/52.6.1094; MILLWARD DJ, 1982, FED PROC, V41, P2686; MORICHAUBEAUCHANT M, 1982, AM J CLIN NUTR, V35, P997, DOI 10.1093/ajcn/35.5.997; MUGHAL M, 1986, LANCET, V2, P383; PUTET G, 1984, ARCH FR PEDIATR, V41, P111; SHIKE M, 1986, AM J CLIN NUTR, V44, P89, DOI 10.1093/ajcn/44.1.89; WAKEFIELD A, 1989, GASTROENTEROLOGY, V97, P1210, DOI 10.1016/0016-5085(89)91692-2; WOOD RJ, 1985, AM J CLIN NUTR, V41, P614, DOI 10.1093/ajcn/41.3.614	36	43	44	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					588	592		10.1016/0140-6736(92)92116-W	http://dx.doi.org/10.1016/0140-6736(92)92116-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355164				2022-12-28	WOS:A1992JM33400013
J	MCINTOSH, EDG; MENSER, MA				MCINTOSH, EDG; MENSER, MA			A 50-YEAR FOLLOW-UP OF CONGENITAL-RUBELLA	LANCET			English	Article							DIABETES-MELLITUS	50 patients with congenital rubella, born in 1939-43, were reviewed in 1967. Here we report their outcome in 1 991. Since 1 967, there have been 7 deaths (3 cardiovascular, 3 malignant disease, 1 AIDS). 40 had full clinical assessment. The prevalence of diabetes mellitus is similar to that in 1967: 4 of the 5 reported diabetic then, remain so, and there is 1 new case. 1 subject has malignant melanoma and 3 have died from cancer. Although the incidence of malignant disease is not increased, the death rate is (standardised mortality rate 6.0, 95% CI 1.24-17.57). Longer follow-up will be required to confirm this observation.	ROYAL ALEXANDRA HOSP CHILDREN,DEPT MED,POB 34,CAMPERDOWN,NSW 2050,AUSTRALIA									FINE PEM, 1985, BRIT MED J, V290, P509, DOI 10.1136/bmj.290.6467.509; FORREST JM, 1971, LANCET, V2, P332; Gregg NM, 1941, T OPHTHALMOL SOC AUS, V3, P35; GREGG NM, 1945, MED J AUSTRALIA, V2, P122; MENSER MA, 1978, LANCET, V1, P57; MENSER MA, 1967, LANCET, V2, P1347; 1991, LANCET, V337, P668	7	57	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					414	415		10.1016/0140-6736(92)91483-O	http://dx.doi.org/10.1016/0140-6736(92)91483-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353568				2022-12-28	WOS:A1992JJ44900016
J	STEHOUWER, CDA; NAUTA, JJP; ZELDENRUST, GC; HACKENG, WHL; DONKER, AJM; DENOTTOLANDER, GJH				STEHOUWER, CDA; NAUTA, JJP; ZELDENRUST, GC; HACKENG, WHL; DONKER, AJM; DENOTTOLANDER, GJH			URINARY ALBUMIN EXCRETION, CARDIOVASCULAR-DISEASE, AND ENDOTHELIAL DYSFUNCTION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							CORONARY HEART-DISEASE; VONWILLEBRAND-FACTOR; RISK-FACTORS; MICROALBUMINURIA PREDICTS; NEPHROPATHY; MORTALITY; PROTEINURIA; PLASMA; ABNORMALITIES; KIDNEY	Raised urinary albumin excretion (UAE) is associated with an increased risk of cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM). We have examined the role of endothelial dysfunction as a possible explanation for this association in 94 NIDDM patients by investigating UAE, new cardiovascular events, and plasma concentration of von Willebrand factor (vWF), an indicator of endothelial dysfunction. At baseline, 66 patients had normal UAE (< 15-mu-g/min), which remained normal in 33 (group 1) and increased in 33 (to median 31.5-mu-g/min, group 2). In 28 patients, baseline UAE was abnormal (67.1-mu-g/min, group 3). Follow-up ranged between 9 and 53 months. vWF did not change in group 1 (median 128% at baseline and 123% at follow-up), but increased in group 2 (from 116 to 219%, p < 0.0001) and group 3 (from 157 to 207%, p = 0.0005). Baseline level of and change in vWF were strongly related to the development of microalbuminuria (R2 = 0.60, p < 0.0001), but cardiovascular risk factors were not (R2 = 0.14). Raised baseline UAE was associated with an increased risk of new cardiovascular events only in patients with vWF concentrations above the median (relative risk 3.66, 95% Cl 1.3-11.9) and not in patients with lower vWF (0.19, 0.01-1.33). In addition, the cardiovascular risk associated with increased UAE was modified by low compared with high concentrations of serum high density lipoprotein cholesterol (2.86 [1.03-8.48] vs 0.15 [0.01-1.43]). Dysfunction of vascular endothelium may be a link between albuminuria and atherosclerotic cardiovascular disease in NIDDM.	BERGWEG HOSP,ENDOCRINOL LAB,ROTTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT THEORY MED EPIDEMIOL & BIOSTAT,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	STEHOUWER, CDA (corresponding author), BERGWEG HOSP,DEPT INTERNAL MED,ROTTERDAM,NETHERLANDS.		Stehouwer, Coen/AAB-3435-2021					BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BULPITT CJ, 1979, LANCET, V2, P134; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; ELLIS D, 1989, AM J KIDNEY DIS, V13, P321, DOI 10.1016/S0272-6386(89)80039-3; FITZGERALD AP, 1991, DIABETIC MED, V8, P475, DOI 10.1111/j.1464-5491.1991.tb01635.x; IWASHIMA Y, 1990, DIABETES, V39, P983, DOI 10.2337/diabetes.39.8.983; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; JANSSON JH, 1991, BRIT HEART J, V66, P351; Jarrett R J, 1984, Diabet Med, V1, P17; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, LANCET, V1, P461; KANWAR YS, 1984, LAB INVEST, V51, P7; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NISKANEN L, 1990, DIABETOLOGIA, V33, P237, DOI 10.1007/BF00404802; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHMITZ A, 1990, DIABETIC MED, V7, P521, DOI 10.1111/j.1464-5491.1990.tb01435.x; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; STEHHOUWER CDA, 1991, DIABETES, V40, P1746; STEHOUWER CDA, 1991, DIABETES, V40, P971, DOI 10.2337/diabetes.40.8.971; STEHOUWER CDA, 1992, DIABETOLOGIA, V35, P555, DOI 10.1007/BF00400484; STEHOUWER CDA, 1990, ARCH INTERN MED, V150, P373, DOI 10.1001/archinte.150.2.373; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIBERTI GC, 1986, CLIN ENDOCRINOL META, V15, P753, DOI 10.1016/S0300-595X(86)80073-1; VUKOVICH TC, 1989, J CLIN ENDOCR METAB, V69, P84, DOI 10.1210/jcem-69-1-84; YUDKIN JS, 1988, LANCET, V2, P530	29	523	532	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					319	323		10.1016/0140-6736(92)91401-S	http://dx.doi.org/10.1016/0140-6736(92)91401-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353802				2022-12-28	WOS:A1992JH12500001
J	AWGULEWITSCH, A; JACOBS, D				AWGULEWITSCH, A; JACOBS, D			DEFORMED AUTOREGULATORY ELEMENT FROM DROSOPHILA FUNCTIONS IN A CONSERVED MANNER IN TRANSGENIC MICE	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; DIFFERENTIAL EXPRESSION; HOMEOTIC GENES; HINDBRAIN; ORGANIZATION; HOX-1.4; DOMAINS; MURINE; REGION; HOX	THE striking similarities in the structure, organization and anterior-posterior expression patterns between the murine Hox gene system and the Drosophila homeotic gene complexes1,2, called HOM-C (ref. 3), may point to highly conserved mechanisms for specifying positional identities (reviewed in ref. 4). Strong support for this concept lies in the observation of conserved colinearity between the genomic order of the Hox/HOM genes and their unique successive expression domains along the anterior-posterior axes of both mouse and fly embryos1,2. These unique and precise expression patterns appear to be facilitated by multiple cis-regulatory elements (reviewed in ref. 5). One of the few elements characterized in detail is the autoregulatory enhancer of the homeotic gene Deformed (Dfd)6-9, which supports expression in subregions of posterior head segments of Drosophila embryos7. Here we present evidence that this enhancer is capable of conferring reporter gene expression to a discrete subregion of the hindbrain in transgenic mouse embryos. Remarkably, this anterior-posterior subregion lies within the common anterior expression domain of the Dfd cognate Hox genes in the postotic hindbrain10,11. Our results indicate that the Dfd autoregulatory enhancer is part of a highly conserved mechanism for establishing region-specific gene expression along the anterior-posterior axis of the embryo.			AWGULEWITSCH, A (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; AWGULEWITSCH A, 1991, METHODS NUCLEIC ACID, P359; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; Dessain S, 1991, CURR OPIN GENET DEV, V1, P275, DOI 10.1016/S0959-437X(05)80082-6; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOGAN B, 1986, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KEYNES R, 1990, NEURON, V2, P1; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; Maniatis T., 1982, MOL CLONING; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGinnis W, 1990, Adv Genet, V27, P363; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; RUGH R, 1990, MOUSE ITS REPRODUCTI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	33	71	71	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					341	344		10.1038/358341a0	http://dx.doi.org/10.1038/358341a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353608				2022-12-28	WOS:A1992JE68400067
J	FAHAL, IH; SALLOMI, DF; YAQOOB, M; BELL, GM				FAHAL, IH; SALLOMI, DF; YAQOOB, M; BELL, GM			ACUTE-RENAL-FAILURE AFTER ECSTASY	BRITISH MEDICAL JOURNAL			English	Letter							RHABDOMYOLYSIS				FAHAL, IH (corresponding author), ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L7 8XP,ENGLAND.		Fahal, Ibrahim/ABC-1366-2021	Fahal, Ibrahim/0000-0003-4897-6427				EKNOYAN G, 1986, AM J NEPHROL, V6, P117, DOI 10.1159/000167066; FOLEY RJ, 1984, SOUTHERN MED J, V77, P258, DOI 10.1097/00007611-198402000-00035; GINSBERG MD, 1970, ANN INTERN MED, V73, P81, DOI 10.7326/0003-4819-73-1-81; KENDRICK WC, 1977, ANN INTERN MED, V86, P381, DOI 10.7326/0003-4819-86-4-381; KOFFLER A, 1976, ANN INTERN MED, V85, P23, DOI 10.7326/0003-4819-85-1-23; SCANDLING J, 1982, SOUTHERN MED J, V75, P237, DOI 10.1097/00007611-198202000-00033	6	80	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					29	29		10.1136/bmj.305.6844.29	http://dx.doi.org/10.1136/bmj.305.6844.29			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1353389	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JC79900028
J	BLUM, M; GAUNT, SJ; CHO, KWY; STEINBEISSER, H; BLUMBERG, B; BITTNER, D; DEROBERTIS, EM				BLUM, M; GAUNT, SJ; CHO, KWY; STEINBEISSER, H; BLUMBERG, B; BITTNER, D; DEROBERTIS, EM			GASTRULATION IN THE MOUSE - THE ROLE OF THE HOMEOBOX GENE GOOSECOID	CELL			English	Article							MESODERM FORMATION; INSITU HYBRIDIZATION; CELL FATE; T-GENE; EMBRYOS; LOCALIZATION; EXPRESSION; POSITION; PROTEIN; PATTERN	Mouse goosecoid is a homeobox gene expressed briefly during early gastrulation. Its mRNA accumulates as a patch on the side of the epiblast at the site where the primitive streak is first formed. goosecoid-expressing cells are then found at the anterior end of the developing primitive streak, and finally in the anteriormost mesoderm at the tip of the early mouse gastrula, a region that gives rise to the head process. Treatment of early mouse embryos with activin results in goosecoid mRNA accumulation in the entire epiblast, suggesting that a localized signal induces goosecoid expression during development. Transplantation experiments indicate that the tip of the murine early gastrula is the equivalent of the organizer of the amphibian gastrula.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT MOLEC EMBRYOL,CAMBRIDGE CB2 4AT,ENGLAND	University of California System; University of California Los Angeles; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	BLUM, M (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 21502-07] Funding Source: Medline; NIGMS NIH HHS [GM-07185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA AR, 1989, NATURE, V341, P33; Baer v., 1828, ENTWICKLUNGSGESCHICH; Beddington R., 1983, DEVELOPMENT IN MAMMALS, V5, P1; Beddington R. S. P., 1986, EXPT APPROACHES MAMM, P121; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHO KWY, 1991, SEM DEV BIOL, V2, P393; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOGAN B, 1986, MANIPULATING MOUSE E; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLAGER HG, 1991, DEV BIOL, V145, P205, DOI 10.1016/0012-1606(91)90120-R; SMITH JC, 1989, DEVELOPMENT, V107, P149; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SNELL GEORGE D., 1966, P205; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Sobotta J, 1903, ARCH MIKRO ANAT ENTW, V61, P274, DOI 10.1007/BF02977924; Sobotta J., 1911, Archiv fuer Mikroskopische Anatomie Bonn, V78, DOI 10.1007/BF02978986; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEILER K, 1989, HOUSE MOUSE; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLISON K, 1990, TRENDS GENET, V6, P104, DOI 10.1016/0168-9525(90)90106-G; Wilmut I., 1990, TRENDS BIOTECHNOLOGY	42	347	360	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1097	1106		10.1016/0092-8674(92)90632-M	http://dx.doi.org/10.1016/0092-8674(92)90632-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1352187				2022-12-28	WOS:A1992JA43100005
J	RAVINE, D; WALKER, RG; GIBSON, RN; FORREST, SM; RICHARDS, RI; FRIEND, K; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; WALKER, RG; GIBSON, RN; FORREST, SM; RICHARDS, RI; FRIEND, K; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			PHENOTYPE AND GENOTYPE HETEROGENEITY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Article							LINKAGE HETEROGENEITY; GENETIC-HETEROGENEITY; CHROMOSOME-16; LOCUS; PKD1; DIAGNOSIS; FAMILIES; MARKER	It is now clear that mutations of at least two genetic loci can lead to autosomal dominant polycystic kidney disease (ADPKD). We have compared the clinical features of ADPKD caused by mutations at the PKD1 locus (linked to the alpha-globin complex on chromosome 16) with those of disease not linked to the locus (non-PKD1). We identified 18 families (285 affected members) with mutations at PKD1 and 5 families (49 affected individuals) in which involvement of this locus could be dismissed. Non-PKD1 patients lived longer than PKD1 patients (median survival 71.5 vs 56.0 years), had a lower risk of progressing to renal failure (odds ratio 0.35, 95% Cl 0.13-0.92), were less likely to have hypertension (odds ratio adjusted for age and family of origin 0.29, 0.11-0.80), were diagnosed at an older age (median 69.1 vs 44.8 years), and had fewer renal cysts at the time of diagnosis. Although most of the PKD1 families were ascertained through clinics treating patients with renal impairment, no non-PKD1 family was identified through this source. Non-PKD1 ADPKD has a much milder phenotype than that linked to PKD1. Partly as a result of this difference in severity, the reported prevalence of this genotype is probably an underestimate.	ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT NEPHROL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital	RAVINE, D (corresponding author), UNIV HOSP WALES,INST MED GENET,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.		Richards, Robert/ABE-6423-2020; Ravine, David/A-6797-2008					BACHNER L, 1990, HUM GENET, V85, P221; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BREUNING MH, 1990, NUCLEIC ACIDS RES, V18, P3106, DOI 10.1093/nar/18.10.3106-a; BREUNING MH, 1987, LANCET, V2, P1359; BREUNING MH, 1990, J MED GENET, V27, P603, DOI 10.1136/jmg.27.10.603; DISNEY APS, 1990, 13TH AUSTR NZ COMB D, P22; GAL A, 1989, CLIN GENET, V35, P13; HARRIS PC, 1991, LANCET, V338, P1484, DOI 10.1016/0140-6736(91)92300-Q; HYLAND VJ, 1990, HUM GENET, V84, P286; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIMBERLING WJ, 1990, KIDNEY INT, V37, P249; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, AM J HUM GENET, V42, P498; MANDICH P, 1990, AM J MED GENET, V35, P579, DOI 10.1002/ajmg.1320350426; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3122, DOI 10.1093/nar/16.7.3122; NAROD S, 1991, CLIN GENET, V39, P125; Norby S, 1989, Prog Clin Biol Res, V305, P83; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1987, HUM GENET, V76, P348, DOI 10.1007/BF00272443; ROMEO G, 1988, LANCET, V2, P8; SNIJDEWINT FGM, 1990, NUCLEIC ACIDS RES, V18, P3108, DOI 10.1093/nar/18.10.3108-a; THOMPSON AD, IN PRESS GENOMICS; TUFVESON G, NEPHROL DIAL TRANS S, V4, P5; WEEKS DE, 1989, AM J HUM GENET, V45, P819	28	170	174	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1330	1333		10.1016/0140-6736(92)92503-8	http://dx.doi.org/10.1016/0140-6736(92)92503-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360045				2022-12-28	WOS:A1992KA26200014
J	KATO, H; INOUE, O; KAWASAKI, T; FUJIWARA, H; WATANABE, T; TOSHIMA, H				KATO, H; INOUE, O; KAWASAKI, T; FUJIWARA, H; WATANABE, T; TOSHIMA, H			ADULT CORONARY-ARTERY DISEASE PROBABLY DUE TO CHILDHOOD KAWASAKI-DISEASE	LANCET			English	Note							ANEURYSMS	We have surveyed adult survivors of childhood Kawasaki disease (KD) who had coronary artery disease that could be ascribed to KD. In response to questionnaires sent to cardiologists throughout Japan, 21 patients (1 7 men, 4 women, aged 20-63 years) with coronary lesions and a definite (2) or suspected (19) history of KD were reported. 5 patients had presented with acute myocardial infarction, 6 previous myocardial infarction, 9 angina pectoris, and 1 dilated cardiomyopathy. 16 patients had obstructions in two or more coronary arteries. 3 had died and 18 were alive with serious sequelae (mitral regurgitation, arrhythmias, congestive heart failure). Childhood KD should be included in the differential diagnosis of coronary artery disease in young adults.	KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA 830,JAPAN; KAWASAKI DIS RES INFORMAT CTR,KAWASAKI,JAPAN; KYOTO UNIV,SCH MED,DEPT INTERNAL MED,KYOTO 606,JAPAN; AICHI MED SCH,DEPT INTERNAL MED,AICHI,JAPAN	Kurume University; Kyoto University; Aichi Medical University	KATO, H (corresponding author), KURUME UNIV,SCH MED,DEPT PEDIAT,67 ASAHI-MACHI,KURUME,FUKUOKA 830,JAPAN.							ISHIWATA S, 1992, AM J CARDIOL, V69, P692, DOI 10.1016/0002-9149(92)90168-X; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KATO H, 1986, J PEDIATR-US, V108, P923, DOI 10.1016/S0022-3476(86)80928-3; KATO H, 1975, J PEDIATR-US, V86, P892, DOI 10.1016/S0022-3476(75)80220-4; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; SAKAI Y, 1988, ANGIOLOGY, V39, P625, DOI 10.1177/000331978803900711	6	128	128	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1127	1129		10.1016/0140-6736(92)93152-D	http://dx.doi.org/10.1016/0140-6736(92)93152-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359212				2022-12-28	WOS:A1992JX13400005
J	KLEIJNEN, J; KNIPSCHILD, P				KLEIJNEN, J; KNIPSCHILD, P			GINKGO-BILOBA	LANCET			English	Article							DOUBLE-BLIND; EXTRACT; PLACEBO; DRUG; MULTICENTER				KLEIJNEN, J (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							BAUER U, 1984, ARZNEIMITTEL-FORSCH, V34-1, P716; BRAQUET P, 1991, J ETHNOPHARMACOL, V32, P135, DOI 10.1016/0378-8741(91)90111-P; BRAQUET P, 1989, GINKGOLIDES CHEM BIO, V2; BRAQUET P, 1988, GINKGOLIDES CHEM BIO, V1; BRUCHERT E, 1991, MUNCH MED WOCHENS S1, V133, pS9; CHUNG KF, 1987, LANCET, V1, P248; De Feudis F.V., 1991, GINKGO BILOBA EXTRAC, P68; DEFEUDIS FV, 1991, GINKGO BILOBA EXTRAC, P143; Eckmann F, 1990, Fortschr Med, V108, P557; HAGUENAUER JP, 1986, PRESSE MED, V15, P1569; HARTMANN A, 1991, MUNCHEN MED WOCHEN, V133, pS23; HOFFERBERTH B, 1989, ARZNEIMITTEL-FORSCH, V39-2, P918; HOFFERBERTH B, 1991, MUNCHEN MED WOCHEN, V133, pS30; JUNG F, 1990, ARZNEIMITTELFORSCH, V40-1, P589; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KLEIJNEN J, 1991, FOOD SUPPLEMENTS THE; KOLTRINGER P, 1989, PERFUSION, V1, P28; MEYER B, 1986, PRESSE MED, V15, P1562; MOREAU JP, 1986, PRESSE MED, V15, P1458; Nieder M., 1991, MUNCHEN MED WOCHEN, V133, pS61; PINCEMAIL J, 1989, EXPERIENTIA, V45, P708, DOI 10.1007/BF01974564; Rabinovici K, 1991, MUNCH MED WOCHENS S1, V133, pS15; ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4; SAUDREAU F, 1989, J MAL VASCUL, V14, P177; TAILLANDIER J, 1986, PRESSE MED, V15, P1583; VORBERG G, 1989, HERZ GEFASSE, V9, P936; Wesnes K., 1987, HUMAN PSYCHOPHARMACO, V2, P159, DOI [10.1002/hup.470020305, DOI 10.1002/HUP.470020305]	27	439	458	1	60	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1136	1139		10.1016/0140-6736(92)93158-J	http://dx.doi.org/10.1016/0140-6736(92)93158-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359218	Bronze			2022-12-28	WOS:A1992JX13400011
J	ISAACS, JD; WATTS, RA; HAZLEMAN, BL; HALE, G; KEOGAN, MT; COBBOLD, SP; WALDMANN, H				ISAACS, JD; WATTS, RA; HAZLEMAN, BL; HALE, G; KEOGAN, MT; COBBOLD, SP; WALDMANN, H			HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR RHEUMATOID-ARTHRITIS	LANCET			English	Article							T-CELLS; TRANSPLANTATION; COMPLEMENT; RESPONSES; TOLERANCE; REJECTION; ANTI-CD4	Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than conventional rodent antibodies, might overcome this problem. We therefore assessed in a phase 1 open study the potential of a "lymphocyte depleting" regimen of the humanised monoclonal antibody CAMPATH-1H in 8 patients with refractory rheumatoid arthritis. Apart from symptoms associated with first infusions of antibody, adverse effects were negligible. Significant clinical benefit was seen in 7 patients, lasting for eight months in 1. After one course of therapy, there was no measurable antiglobulin response, although 3 out of 4 patients have become sensitised on retreatment. Humanisation reduces the immunogenicity of rodent antibodies but anti-idiotype responses may still be seen on repeated therapy, even in patients sharing immunoglobulin allotype with the humanised antibody.	UNIV CAMBRIDGE,DEPT RHEUMATOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV CAMBRIDGE,DEPT CLIN IMMUNOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge; University of Cambridge	ISAACS, JD (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		waldmann, herman/W-8051-2019	Cobbold, Stephen/0000-0003-1206-4880; Keogan, Mary/0000-0002-2596-0660; Hale, Geoff/0000-0001-9473-423X; Waldmann, Herman/0000-0001-7519-6720; Isaacs, John/0000-0002-6103-7056	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENJAMIN RJ, 1986, J EXP MED, V163, P1539, DOI 10.1084/jem.163.6.1539; BRUGGEMANN M, 1989, J EXP MED, V170, P2153, DOI 10.1084/jem.170.6.2153; CHATENOUD L, 1992, CRITICAL ANAL MONOCL; COBBOLD SP, 1990, J IMMUNOL METHODS, V127, P19, DOI 10.1016/0022-1759(90)90335-S; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; EMMRICH J, 1991, LANCET, V338, P570, DOI 10.1016/0140-6736(91)91133-F; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; FRIEND PJ, 1989, TRANSPLANTATION, V48, P248, DOI 10.1097/00007890-198908000-00013; FRIEND PJ, 1991, TRANSPLANT P, V23, P2253; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Gorman S D, 1990, Semin Immunol, V2, P457; GUTSTEIN NL, 1986, J IMMUNOL, V137, P1121; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; HALE G, 1983, BLOOD, V62, P873; Isaacs J D, 1990, Semin Immunol, V2, P449; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; OH CS, 1988, TRANSPLANTATION, V45, P68, DOI 10.1097/00007890-198801000-00016; PRINZ J, 1991, LANCET, V338, P320, DOI 10.1016/0140-6736(91)90464-Z; PUTTICK AH, 1990, ANN RHEUM DIS, V49, P225, DOI 10.1136/ard.49.4.225; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WATTS RA, 1992, ANN RHEUM DIS, V51, P577, DOI 10.1136/ard.51.5.577	22	290	305	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					748	752		10.1016/0140-6736(92)92294-P	http://dx.doi.org/10.1016/0140-6736(92)92294-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356177				2022-12-28	WOS:A1992JP86900003
J	STEINETZ, BG; WHITAKER, PG; EDWARDS, JRG				STEINETZ, BG; WHITAKER, PG; EDWARDS, JRG			MATERNAL RELAXIN CONCENTRATIONS IN DIABETIC PREGNANCY	LANCET			English	Article							HUMAN CHORIONIC-GONADOTROPIN; INSULIN BINDING; RECEPTOR-BINDING; PORCINE RELAXIN; ADIPOCYTES; MOTHERS; RADIOIMMUNOASSAY; PROGESTERONE; INFANTS; WOMEN	Maternal serum concentrations of relaxin, an insulin homologue produced both by the corpus luteum of pregnancy and by the fetoplacental unit, are highest in the first trimester and fall to their lowest level in the third trimester. Relaxin is thought to influence carbohydrate metabolism in the uterus, and it has been suggested that serum concentrations of relaxin in diabetic women are higher than those of non-diabetic women. We show that maternal serum relaxin concentrations are significantly higher at each stage of pregnancy in insulin-dependent diabetic mothers than in non-diabetic mothers. This elevation in relaxin concentrations is not related to other indices of diabetic control. The physiological importance of the higher concentrations of relaxin in the serum of diabetic women-in particular, whether they contribute to the higher incidence of major anomalies in the fetuses of diabetic mothers-is yet to be determined.	UNIV NEWCASTLE UPON TYNE,CLEFT PALATE RES UNIT,1-4 CLAREMONT TERRACE,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,PRINCESS MARY MATERN HOSP,DEPT OBSTET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; NYU,MED CTR,EXPTL MED & SURG PRIMATES LAB,TUXEDO PK,NY	Newcastle University - UK; Newcastle University - UK; New York University								BELL RJ, 1989, FERTIL STERIL, V52, P85; BELL RJ, 1987, OBSTET GYNECOL, V69, P585; CRELIN ES, 1969, T NEW YORK ACAD SCI, V31, P1049, DOI 10.1111/j.2164-0947.1969.tb02024.x; EDWARDS JRG, 1988, LANCET, V1, P1428; HANING RV, 1985, OBSTET GYNECOL, V66, P42; JARRETT JC, 1984, AM J OBSTET GYNECOL, V149, P250, DOI 10.1016/0002-9378(84)90223-0; JOHNSON MR, 1991, J CLIN ENDOCR METAB, V72, P1042, DOI 10.1210/jcem-72-5-1042; LADENHEIM RG, 1984, ENDOCRINOLOGY, V115, P752, DOI 10.1210/endo-115-2-752; LOUMAYE E, 1978, GYNECOL OBSTET INVES, V9, P262, DOI 10.1159/000300993; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104; NEUFELD ND, 1978, J CLIN ENDOCR METAB, V47, P590, DOI 10.1210/jcem-47-3-590; OBYRNE EM, 1976, P SOC EXP BIOL MED, V152, P272, DOI 10.3181/00379727-152-39377; OBYRNE EM, 1978, J CLIN ENDOCR METAB, V47, P1106, DOI 10.1210/jcem-47-5-1106; OLEFSKY JM, 1982, ANN NY ACAD SCI, V380, P200, DOI 10.1111/j.1749-6632.1982.tb18043.x; PAGANO G, 1980, HORM METAB RES, V12, P177, DOI 10.1055/s-2007-996237; PAWLINA W, 1990, MOL CELL ENDOCRINOL, V72, P55, DOI 10.1016/0303-7207(90)90239-5; PEDERSEN J, 1980, PREGNANT DIABETIC HE; PEDERSEN O, 1981, J CLIN ENDOCR METAB, V53, P1160, DOI 10.1210/jcem-53-6-1160; QUAGLIARELLO J, 1980, J CLIN ENDOCR METAB, V51, P74, DOI 10.1210/jcem-51-1-74; QUAGLIARELLO J, 1979, AM J OBSTET GYNECOL, V135, P43; Sherwood O.D., 1988, P585; STEINETZ BG, IN PRESS ENDOCRINOLO; STEWART DR, 1990, J CLIN ENDOCR METAB, V70, P1771, DOI 10.1210/jcem-70-6-1771; STEWART MO, 1989, BRIT J OBSTET GYNAEC, V96, P415, DOI 10.1111/j.1471-0528.1989.tb02415.x; SUTTERDUB MT, 1973, HORM METAB RES, V5, P18, DOI 10.1055/s-0028-1093994; SUTTERDUB MT, 1984, J ENDOCRINOL, V102, P209, DOI 10.1677/joe.0.1020209; SZLACHTER BN, 1982, OBSTET GYNECOL, V59, P167; TOYODA N, 1985, ENDOCRINOLOGY, V116, P998, DOI 10.1210/endo-116-3-998; VASILENKO P, 1982, P SOC EXP BIOL MED, V169, P376; WEISS G, 1976, SCIENCE, V194, P948, DOI 10.1126/science.982052; WHITTAKER PG, 1990, OBSTET GYNECOL, V76, P223; WITT BR, 1990, FERTIL STERIL, V53, P1029	33	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					752	755		10.1016/0140-6736(92)92295-Q	http://dx.doi.org/10.1016/0140-6736(92)92295-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356178				2022-12-28	WOS:A1992JP86900004
J	WILSON, DI; GOODSHIP, JA; BURN, J; CROSS, IE; SCAMBLER, PJ				WILSON, DI; GOODSHIP, JA; BURN, J; CROSS, IE; SCAMBLER, PJ			DELETIONS WITHIN CHROMOSOME-22Q11 IN FAMILIAL CONGENITAL HEART-DISEASE	LANCET			English	Article							DIGEORGE SYNDROME	Because a locus on chromosome 22q11 is deleted in most individuals with DiGeorge and Shprintzen syndromes-conditions in which heart abnormalities are an important feature-we have looked for deletions in nine families with recurrent out flow-tract heart defects. In five families, chromosome 22 deletions were detected in all the living affected individuals studied and also in the clinically normal father of three affected children. The deletion was transmitted from parents to offspring and was associated with an increase in the severity of cardiac defects. No deletions were found in four families in which the parents were normal and affected siblings had anatomically identical defects. We propose that deletions within band q11 of chromosome 22 are an important cause of familial heart defects.	ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON,ENGLAND	Imperial College London	WILSON, DI (corresponding author), UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,ENGLAND.		Scambler, Peter/AAZ-6026-2020; Wilson, David/A-6264-2010; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Wilson, David/0000-0001-8779-2060; Scambler, Peter J/0000-0002-1487-4628; Burn, John/0000-0002-9823-2322				[Anonymous], 1985, INT SYSTEM HUMAN CYT; BURN J, 1990, AM J HUM GENET S, V47, pA121; CAREY AH, IN PRESS AM J HUM GE; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; CZEIZEL A, 1982, BRIT HEART J, V47, P290; DENNIS NR, 1981, J MED GENET, V18, P8, DOI 10.1136/jmg.18.1.8; DRISCOLL AD, 1992, AM J HUM GENET, V50, P924; LIPSON AH, 1991, J MED GENET, V28, P596, DOI 10.1136/jmg.28.9.596; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; WHITTEMORE R, 1982, AM J CARDIOL, V50, P641, DOI 10.1016/0002-9149(82)90334-4; WILSON DI, 1991, BRIT HEART J, V66, P308; WILSON DI, 1992, APR P BRIT PAED ASS; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L	14	158	162	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					573	575		10.1016/0140-6736(92)92107-Q	http://dx.doi.org/10.1016/0140-6736(92)92107-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355155				2022-12-28	WOS:A1992JM33400004
J	SHIELD, JPH; STROBEL, S; LEVINSKY, RJ; MORGAN, G				SHIELD, JPH; STROBEL, S; LEVINSKY, RJ; MORGAN, G			IMMUNODEFICIENCY PRESENTING AS HYPERGAMMAGLOBULINEMIA WITH IGG2 SUBCLASS DEFICIENCY	LANCET			English	Article							IGA DEFICIENCY	Recurrent bacterial infections, lymphadenopathy, and failure to thrive are unlikely to be attributed to immune deficiency if they occur in the presence of hypergammaglobulinaemia, and other explanations will usually be sought. We describe eight patients who presented with all these features in infancy or early childhood. Deficiencies of immunoglobulin and antibody production were initially discounted, and the children were referred for investigation of possible lymphoma, autoimmune disease, or chronic viral infection. The patients were later referred to us for more detailed immunological investigation, which revealed low levels of IgG2 and poor specific antibody production to common pathogens. Treatment with intravenous immunoglobulin resulted in resolution of signs and symptoms in all patients. Thus we have shown that hypergammaglobulinaemia does not preclude the presence of immunoglobulin/antibody deficiency. We suggest that investigation of children with high levels of IgG and features of immunodeficiency should include IgG subclass analysis.	INST CHILD HLTH,HOST DEF UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; HOSP SICK CHILDREN,LONDON WC1N 3JH,ENGLAND	Imperial College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Shield, Julian PH/D-6297-2014	Shield, Julian PH/0000-0003-2601-7575				Aucouturier P, 1986, Monogr Allergy, V20, P62; BIRD D, 1985, ARCH DIS CHILD, V60, P204, DOI 10.1136/adc.60.3.204; GOLDBLATT D, 1989, R SOC MED SER INT C, V143, P19; MORGAN G, 1988, ARCH DIS CHILD, V63, P579, DOI 10.1136/adc.63.6.579; MORGAN G, 1985, ARCH DIS CHILD, V63, P771; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; Rosen F S, 1989, Semin Immunol, V1, P87; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SHAKELFORD PG, 1990, PAEDIATR RES, V17, P16; 1991, NEW ENGL J MED, V325, P73	10	24	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					448	450						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354783				2022-12-28	WOS:A1992JJ87700003
J	RAMSDELL, F; FOWLKES, BJ				RAMSDELL, F; FOWLKES, BJ			MAINTENANCE OF INVIVO TOLERANCE BY PERSISTENCE OF ANTIGEN	SCIENCE			English	Article							T-CELL-RECEPTOR; MAMMARY-TUMOR VIRUS; TRANSGENIC MICE; CLONAL ANERGY; TRANSPLANTATION TOLERANCE; NEGATIVE SELECTION; DELETION; INDUCTION; INACTIVATION; ELIMINATION	T cells of the immune system respond only to foreign antigens because those cells with reactivity for self proteins are either deleted during their development or rendered nonresponsive (anergic). The maintenance of the nonresponsive state was found to require the continual exposure of the anergic T cells to antigen. When anergic T cells were removed from the self antigen by adoptive transfer to a mouse strain lacking the antigen or by in vitro culture, nonresponsiveness was reversed and the anergic cells returned to normal functional status.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALTERS SE, 1991, J EXP MED, V173, P491, DOI 10.1084/jem.173.2.491; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1991, P NATL ACAD SCI USA, V88, P6682, DOI 10.1073/pnas.88.15.6682; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RAMSDELL F, UNPUB; RELLAHAN BL, 1990, J EXP MED, V172, P1071; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; TEW JG, 1980, IMMUNOL REV, V53, P29; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WIETIES K, 1990, P NATL ACAD SCI USA, V87, P6604, DOI 10.1073/pnas.87.17.6604; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	30	212	222	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1130	1134		10.1126/science.257.5073.1130	http://dx.doi.org/10.1126/science.257.5073.1130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1354889				2022-12-28	WOS:A1992JJ88400037
J	PAMER, EG; WANG, CR; FLAHERTY, L; LINDAHL, KF; BEVAN, MJ				PAMER, EG; WANG, CR; FLAHERTY, L; LINDAHL, KF; BEVAN, MJ			H-2M3 PRESENTS A LISTERIA-MONOCYTOGENES PEPTIDE TO CYTOTOXIC LYMPHOCYTES-T	CELL			English	Article							CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; INTRACELLULAR GROWTH; CELL RECEPTOR; ANTIGEN; HEMOLYSIN; MOUSE; IMMUNITY; REGION; DELTA	We report evidence that a major histocompatibility complex-encoded nonclassic class I molecule presents a foreign peptide to cytotoxic T lymphocytes (CTL) during an infection. Mice immunized with virulent Listeria monocytogenes generate CD8+ CTL with alpha-beta receptors specific for a bacterial peptide presented by a conserved class I molecule encoded in the M region of the major histocompatibility complex. The Listeria peptide is digested by carboxypeptidase Y but resists aminopeptidase M, and only peptides with N-formyl methionine competitively block its presentation to CTL. Transfection with the H-2M3d ene enables a negative (H-2w17) cell line to present the bacterial peptide. One function, therefore, of H-2M3 is to present bacterial peptides to CTL during infection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; Wadsworth Center								ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BERCHE P, 1987, J IMMUNOL, V138, P2266; BISHOP DK, 1987, J IMMUNOL, V139, P2005; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BROCKE S, 1991, INFECT IMMUNON, V59, P4561; BROWN ML, 1992, J IMMUNOL, V148, P555; BRUNT LM, 1990, J IMMUNOL, V145, P3540; CONLAN JW, 1991, J EXP MED, V174, P741, DOI 10.1084/jem.174.3.741; DELIBERO G, 1986, J IMMUNOL, V137, P2688; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; HARTY JT, 1992, IN PRESS J EXP MED; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KUBO RT, 1989, J IMMUNOL, V142, P2736; LALANNE JL, 1982, NUCLEIC ACIDS RES, V10, P1039, DOI 10.1093/nar/10.3.1039; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINDAHL KF, 1980, J EXP MED, V152, P1583; LINDAHL KF, 1989, COLD SH Q B, V54, P563; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUCASLENARD J, 1971, ANNU REV BIOCHEM, V40, P409, DOI 10.1146/annurev.bi.40.070171.002205; LUKACS K, 1989, J IMMUNOL, V143, P3731; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Maniatis T., 1982, MOL CLONING; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NOGUEIRA N, 1976, J EXP MED, V143, P1402, DOI 10.1084/jem.143.6.1402; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; POTTER TA, 1987, J IMMUNOL, V138, P1270; RIKIHISA Y, 1980, INFECT IMMUN, V30, P231, DOI 10.1128/IAI.30.1.231-243.1980; ROETZSCHKE O, 1990, Nature (London), V348, P252; ROSEN H, 1989, J EXP MED, V170, P27, DOI 10.1084/jem.170.1.27; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; Wang C.-R., 1991, NATO ASI Series Series H Cell Biology, V59, P441; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WOLF PR, 1990, J EXP MED, V172, P1795, DOI 10.1084/jem.172.6.1795; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213	56	201	203	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					215	223		10.1016/0092-8674(92)90097-V	http://dx.doi.org/10.1016/0092-8674(92)90097-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1353418				2022-12-28	WOS:A1992JE75700006
J	PACKER, M				PACKER, M			PATHOPHYSIOLOGY OF CHRONIC HEART-FAILURE	LANCET			English	Article							ATRIAL-NATRIURETIC-FACTOR; TUMOR-NECROSIS-FACTOR; THERAPY; RAT; VASODILATION; MYOCARDIUM; REVERSAL; PROTEIN; PEPTIDE				PACKER, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV CIRCULATORY PHYSIOL, NEW YORK, NY 10032 USA.							ABASSI Z, 1990, AM J PHYSIOL, V259, pR84, DOI 10.1152/ajpregu.1990.259.1.R84; BELCH JJF, 1991, BRIT HEART J, V65, P245; BRISTOW MR, 1990, CIRCULATION, V82, P12; CAPASSO JM, 1990, AM J PHYSIOL, V259, pH1086, DOI 10.1152/ajpheart.1990.259.4.H1086; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; CONNELLY CM, 1991, CIRCULATION, V84, P387, DOI 10.1161/01.CIR.84.1.387; CREAGER MA, 1986, J AM COLL CARDIOL, V7, P758, DOI 10.1016/S0735-1097(86)80333-3; CREAGER MA, 1991, CIRCULATION, V83, P1873, DOI 10.1161/01.CIR.83.6.1873; DIBONA GF, 1991, AM J PHYSIOL, V260, pR298, DOI 10.1152/ajpregu.1991.260.2.R298; DONCK LV, 1991, J CARDIOVASC PHARM, V18, P1, DOI 10.1097/00005344-199107000-00001; EISKJAER H, 1991, AM J PHYSIOL, V260, pF883, DOI 10.1152/ajprenal.1991.260.6.F883; ELLENBOGEN KA, 1989, CIRCULATION, V79, P51, DOI 10.1161/01.CIR.79.1.51; FLORAS JS, 1990, CIRCULATION, V81, P1860, DOI 10.1161/01.CIR.81.6.1860; FORSTER C, 1990, J CARDIOVASC PHARM, V16, P708, DOI 10.1097/00005344-199011000-00004; GULICK T, 1989, P NATL ACAD SCI USA, V86, P6753, DOI 10.1073/pnas.86.17.6753; HAN J, 1992, Journal of the American College of Cardiology, V19, p207A; HIROOKA Y, 1990, CIRCULATION, V82, P147, DOI 10.1161/01.CIR.82.1.147; HIRSCH AT, 1987, CIRCULATION, V75, P36; HORN EM, 1988, CIRCULATION, V78, P1373, DOI 10.1161/01.CIR.78.6.1373; JALIL JE, 1989, CIRC RES, V65, P258, DOI 10.1161/01.RES.65.2.258; KENTISH JC, 1986, CIRC RES, V58, P755, DOI 10.1161/01.RES.58.6.755; KIMURA K, 1990, AM J PHYSIOL, V259, pF936, DOI 10.1152/ajprenal.1990.259.6.F936; KUBO SH, 1991, CIRCULATION, V84, P1589, DOI 10.1161/01.CIR.84.4.1589; LEFER AM, 1990, BLOOD VESSELS, V27, P162; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MARGULIES KB, 1990, CIRCULATION, V82, P2226, DOI 10.1161/01.CIR.82.6.2226; MOE GW, 1991, CIRCULATION, V83, P1780, DOI 10.1161/01.CIR.83.5.1780; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NEUMANN J, 1988, LANCET, V2, P936; PACKER M, 1988, CIRCULATION, V77, P64; PETTERSSON A, 1989, ACTA PHYSIOL SCAND, V135, P487, DOI 10.1111/j.1748-1716.1989.tb08607.x; PFEFFER MA, 1985, CIRCULATION, V72, P406, DOI 10.1161/01.CIR.72.2.406; SINOWAY L, 1987, AM J CARDIOL, V60, P107, DOI 10.1016/0002-9149(87)90995-7; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185	35	211	215	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1992	340	8811					88	92		10.1016/0140-6736(92)90405-R	http://dx.doi.org/10.1016/0140-6736(92)90405-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352022	hybrid			2022-12-28	WOS:A1992JC58200012
J	SHOJIKASAI, Y; YOSHIDA, A; SATO, K; HOSHINO, T; OGURA, A; KONDO, S; FUJIMOTO, Y; KUWAHARA, R; KATO, R; TAKAHASHI, M				SHOJIKASAI, Y; YOSHIDA, A; SATO, K; HOSHINO, T; OGURA, A; KONDO, S; FUJIMOTO, Y; KUWAHARA, R; KATO, R; TAKAHASHI, M			NEUROTRANSMITTER RELEASE FROM SYNAPTOTAGMIN-DEFICIENT CLONAL VARIANTS OF PC12 CELLS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; PHEOCHROMOCYTOMA CELLS; AFFINITY; BINDING	Synaptotagmin (p65) is an abundant synaptic vesicle protein of neurons and contains regions similar to the regulatory domain of protein kinase C. These domains are thought to be involved in calcium-dependent interaction with membrane phospholipids during exocytosis. To assess the functional role of synaptotagmin, synaptotagmin-deficient clonal variants of PC12 cells were isolated. All of the variant cells released catecholamine and adenosine triphosphate in response to elevated intracellular concentrations of calcium, which suggests that synaptotagmin is not essential for secretion of catecholamine and adenosine triphosphate from PC12 cells.			SHOJIKASAI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BAEGE EE, 1991, NEURON, V6, P21; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Bjerrum OJ., 1986, ELECTROPHORESIS 86, P315; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BURNSTOCK G, 1981, J PHYSIOL-LONDON, V313, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; Katz B., 1966, NERVE MUSCLE SYNAPSE; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; OGURA A, 1984, BRAIN RES, V301, P323, DOI 10.1016/0006-8993(84)91101-6; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO Y, 1988, J BIOL CHEM, V263, P6927; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SHOJIKASAI Y, UNPUB; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKAHASHI M, 1983, J BIOL CHEM, V258, P944; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; Yoshida A, UNPUB	32	173	176	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1820	1823		10.1126/science.256.5065.1820	http://dx.doi.org/10.1126/science.256.5065.1820			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1352065				2022-12-28	WOS:A1992JA43400037
J	BRAHAMS, D				BRAHAMS, D			MENINGITIS, SCHOOLS, AND PUBLIC ALARM	LANCET			English	Editorial Material																		1989, COMMUN DIS REP  0224	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1532	1532		10.1016/0140-6736(92)91287-I	http://dx.doi.org/10.1016/0140-6736(92)91287-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351199				2022-12-28	WOS:A1992HZ17500018
J	CHAUHAN, A; DILAWARI, JB; JAMEEL, S; KAUR, U; CHAWLA, YK; SHARMA, ML; GANGULY, NK				CHAUHAN, A; DILAWARI, JB; JAMEEL, S; KAUR, U; CHAWLA, YK; SHARMA, ML; GANGULY, NK			COMMON ETIOLOGIC AGENT FOR EPIDEMIC AND SPORADIC NON-A, NON-B HEPATITIS	LANCET			English	Note							TRANSMITTED NON-A	Enterovirus-like particles have been reported in the acute phase of both epidemic and sporadic non-A, non-B (NANB) hepatitis. To examine whether these particles were the causative agent in the two types of disease, 29 patients with acute viral hepatitis in a north Indian epidemic outbreak and 9 with sporadic acute disease were investigated. 25 (86%) of 29 patients with epidemic hepatitis and 5 (56%) of 9 with sporadic disease were diagnosed as having enterically-transmitted-NANB hepatitis by exclusion. Virus-like particles (VLP) of 30-34 nm were detected in stool of 1 patient with epidemic and 1 with sporadic hepatitis. The VLPs crossreacted serologically and a specific IgM response was seen in acute epidemic and sporadic serum samples. After inoculation with infected stool rhesus monkeys had a mild rise in liver enzymes, and bile samples contained VLPs. These results suggest that the aetiological agent in epidemic and sporadic disease is the same.	POSTGRAD INST MED EDUC & RES,DEPT HEPATOL,CHANDIGARH 160012,INDIA; POSTGRAD INST MED EDUC & RES,DEPT EXPTL MED,CHANDIGARH 160012,INDIA; INT CTR GENET ENGN & BIOTECHNOL,NEW DELHI,INDIA; PUNJAB UNIV,REG SOPHISTICATED INSTRUMENTAT CTR,CHANDIGARH,INDIA	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Panjab University			Bambery, Upjeet/G-7593-2011					Almeida J D, 1969, Adv Virus Res, V15, P307, DOI 10.1016/S0065-3527(08)60878-7; BALAYAN MS, 1987, SOVIET MED REV E, V2, P235; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1988, LANCET, V1, P819; DATTA R, 1987, J GASTROEN HEPATOL, V2, P333, DOI 10.1111/j.1440-1746.1987.tb00171.x; DOROSHENKO NV, 1989, VORP VIRUSOL, V45, P164; HUMPHREY CD, 1988, VIRAL HEPATITIS LIVE, P148; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005	9	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1509	1510		10.1016/0140-6736(92)91267-C	http://dx.doi.org/10.1016/0140-6736(92)91267-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351189				2022-12-28	WOS:A1992HZ17500007
J	STERN, LJ; WILEY, DC				STERN, LJ; WILEY, DC			THE HUMAN CLASS-II MHC PROTEIN HLA-DR1 ASSEMBLES AS EMPTY ALPHA-BETA-HETERODIMERS IN THE ABSENCE OF ANTIGENIC PEPTIDE	CELL			English	Article							B-CELL LINE; ENDOPLASMIC-RETICULUM; INVARIANT CHAIN; HISTOCOMPATIBILITY ANTIGENS; ENDOGENOUS ANTIGEN; T-CELLS; HLA-DR; MOLECULES; BINDING; IA	We have produced the human class II histocompatibility protein, HLA-DRI, as a soluble, secreted glycoprotein in insect cells infected with baculoviruses carrying truncated alpha and beta-subunit genes. The peptide-binding site is empty, and the empty molecules are fully competent to bind antigenic peptide. We used the empty molecules to measure an intrinsic rate for peptide association, and to investigate the role of peptide in stabilizing the class II structure. Peptide binding kinetics for the empty molecule are only 10-fold faster than for peptide exchange into an occupied site, suggesting that a conformational change may accompany peptide binding. The native alpha-beta-heterodimer assembles in the absence of antigenic peptide, but peptide binding stabilizes the empty heterodimer against aggregation and against SDS-induced denaturation.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	STERN, LJ (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUSCH R, 1990, J IMMUNOL METHODS, V134, P1, DOI 10.1016/0022-1759(90)90107-7; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARLOW E, 1988, ANTIBODIES LABORATOR; HOFMANN T, 1988, BIOCHEMISTRY-US, V27, P1140, DOI 10.1021/bi00404a010; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NYGARD NR, 1991, J EXP MED, V174, P243, DOI 10.1084/jem.174.1.243; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHACKELFORD DA, 1983, J IMMUNOL, V130, P274; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TIJSSEN P, 1985, LABORATORY TECHNIQUE, V15; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	69	299	330	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					465	477		10.1016/0092-8674(92)90184-E	http://dx.doi.org/10.1016/0092-8674(92)90184-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1371238				2022-12-28	WOS:A1992HD39800008
J	CHUCK, SL; LINGAPPA, VR				CHUCK, SL; LINGAPPA, VR			PAUSE TRANSFER - A TOPOGENIC SEQUENCE IN APOLIPOPROTEIN-B MEDIATES STOPPING AND RESTARTING OF TRANSLOCATION	CELL			English	Article							NEWLY SYNTHESIZED PROTEINS; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCE; MICROSOMAL-MEMBRANES; SECRETORY PROTEINS; MESSENGER-RNA; PRION PROTEIN; HEAT-SHOCK; PRE-GOLGI; DEGRADATION	Previously, we described the stepwise translocation of a large amino-terminal fragment of apolipoprotein B (apo Bl5) in which the nascent secretory chain translocates through a series of distinct, nonintegrated transmembrane intermediates with large domains exposed to the cytoplasm. Thus, apo B15 appears to stop and restart translocation at several points. We have identified a sequence of amino acids in apo B15 that confers this behavior on a heterologous chimeric protein. In addition, we dissect pausing into two distinct steps, stopping and restarting, thereby trapping otherwise transient intermediates. Finally, we demonstrate the function of a second "pause transfer" sequence over 200 amino acids downstream in apo B15 that restarts translocation posttranslationally, suggesting that multiple pause transfer sequences are involved in the biogenesis of apolipoprotein B.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHUCK, SL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FISHER WR, 1986, METHOD ENZYMOL, V128, P247; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PATERSON RG, 1987, CELL, V48, P441, DOI 10.1016/0092-8674(87)90195-4; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SABATINI DD, 1966, J MOL BIOL, V19, P503, DOI 10.1016/S0022-2836(66)80019-0; SATO R, 1990, J BIOL CHEM, V265, P11880; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SPIESS M, 1989, J BIOL CHEM, V264, P19117; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	53	111	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					9	21		10.1016/0092-8674(92)90202-N	http://dx.doi.org/10.1016/0092-8674(92)90202-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370657				2022-12-28	WOS:A1992GZ58300005
J	EISEMAN, E; BOLEN, JB				EISEMAN, E; BOLEN, JB			ENGAGEMENT OF THE HIGH-AFFINITY IGE RECEPTOR ACTIVATES SRC PROTEIN-RELATED TYROSINE KINASES	NATURE			English	Article							IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; HISTAMINE-RELEASE; MAST-CELLS; CD4; PHOSPHORYLATION; ASSOCIATION; ANTIGENS; BINDING; SUBUNIT	THE high-affinity IgE receptor (Fc-epsilon RI), which is expressed on the surface of mast cells and basophils, has a central role in immediate allergic responses. In the rat basophilic leukaemia cell line RBL-2H3, which is a model system for the analysis of Fc-epsilon-RI-mediated signal transduction, surface engagement of Fc-epsilon-RI induces histamine release and the tyrosine phosphorylation of several distinct proteins 1. Although the alpha, beta and gamma-subunits of Fc-epsilon-RI lack intrinsic tyrosine protein kinase (TPK) activity, a kinase that copurifies with Fc-epsilon-RI phosphorylates the beta and gamma-subunits of the receptor on tyrosine residues 2,3. We report here that in RBL-2H3 cells, p56lyn and pp60c-src are activated after Fc-epsilon-RI crosslinking, and p56lyn coimmunoprecipitates with Fc-epsilon-RI. In the mouse mast-cell line PT-18, another cell type used to study FC-epsilon-RI-mediated signalling, tyrosine phosphorylation of proteins is also an immediate consequence of receptor crosslinking. Notably, the only detectable src protein-related TPK in PT-18 cells is p62c-yes, and it is this TPK that is activated on Fc-epsilon-RI engagement and coimmunoprecipitates with the receptor. Therefore, it seems that different src protein-related TPKs can associate with the same receptor and become activated after receptor engagement.			EISEMAN, E (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							BANIYASH M, 1987, J IMMUNOL, V138, P2999; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; HEMPSTEAD BL, 1981, BIOCHEM BIOPH RES CO, V98, P815, DOI 10.1016/0006-291X(81)91184-0; HOLOWKA D, 1980, J RECEPTOR RES, V1, P41, DOI 10.3109/10799898009039254; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUI FT, 1980, J IMMUNOL, V124, P2728; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; PLUZNIK DH, 1982, EXP HEMATOL, V10, P211; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	22	492	506	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					78	80						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1370575				2022-12-28	WOS:A1992GY22800055
J	HARVEY, JM; HOWIE, AJ; LEE, SJ; NEWBOLD, KM; ADU, D; MICHAEL, J; BEEVERS, DG				HARVEY, JM; HOWIE, AJ; LEE, SJ; NEWBOLD, KM; ADU, D; MICHAEL, J; BEEVERS, DG			RENAL BIOPSY FINDINGS IN HYPERTENSIVE PATIENTS WITH PROTEINURIA	LANCET			English	Note								27 patients with hypertension and persistent proteinuria were investigated by renal biopsy. The 13 patients without structural glomerular abnormalities were younger and had less proteinuria than the other 14, but otherwise the two groups had similar clinical features. 6 of the 14 had diffuse glomerular abnormalities; the other 8 had segmental sclerosing lesions, which were mainly in the hilum of the glomeruli, as seen in states of glomerular overload. Glomeruli in all groups were larger than those in normotensive people. It is possible that hypertension causes glomerular enlargement, proteinuria, and segmental glomerular lesions because of loss of functioning glomeruli due to ischaemia.	DUDLEY RD GEN HOSP,DEPT MED,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,DEPT NEPHROL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								BULPITT CJ, 1986, J HYPERTENS, V4, P93, DOI 10.1097/00004872-198602000-00015; GIFFORD RW, 1969, MILBANK FUND Q, V47, P170, DOI 10.2307/3349261; GOSLING P, 1989, CLIN SCI, V76, P39, DOI 10.1042/cs0760039; HOWIE AJ, 1989, J PATHOL, V157, P141, DOI 10.1002/path.1711570209; KINCAIDSMITH PS, 1982, HYPERTENSION MECHANI, P94; NEWBOLD KM, 1990, J PATHOL, V162, P329, DOI 10.1002/path.1711620409; NEWBOLD KM, 1990, J PATHOL, V160, P255, DOI 10.1002/path.1711600312; TOBIAN L, 1987, AM J CARDIOL, V60, P421; TOMSON CRV, 1991, J HUM HYPERTENS, V5, P189; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35	10	83	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1435	1436		10.1016/0140-6736(92)92624-O	http://dx.doi.org/10.1016/0140-6736(92)92624-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360561				2022-12-28	WOS:A1992KC28400005
J	ETEMADI, A; FARID, R; STANFORD, JL				ETEMADI, A; FARID, R; STANFORD, JL			IMMUNOTHERAPY FOR DRUG-RESISTANT TUBERCULOSIS	LANCET			English	Letter									MASHAD UNIV MED SCI, MASHHAD, IRAN; UCL, SCH MED, DEPT MED MICROBIOL, DIV BACTERIOL, LONDON W1P 7LD, ENGLAND	Mashhad University Medical Science; University of London; University College London; UCL Medical School	ETEMADI, A (corresponding author), TAHLEGHANI PULM DIS HOSP, MASHHAD, IRAN.							STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9	1	48	49	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1360	1361		10.1016/0140-6736(92)92551-P	http://dx.doi.org/10.1016/0140-6736(92)92551-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360082				2022-12-28	WOS:A1992KA26200058
J	SUOMALAINEN, A; PAETAU, A; LEINONEN, H; MAJANDER, A; PELTONEN, L; SOMER, H				SUOMALAINEN, A; PAETAU, A; LEINONEN, H; MAJANDER, A; PELTONEN, L; SOMER, H			INHERITED IDIOPATHIC DILATED CARDIOMYOPATHY WITH MULTIPLE DELETIONS OF MITOCHONDRIAL-DNA	LANCET			English	Note							MUTATION	Idiopathic dilated cardiomyopathy (DCM) is often familial, but the pathogenetic mechanisms of DCM are unknown. We report a woman and her son who both died of DCM. The son's cardiac and skeletal muscles showed a high proportion of mitochondrial DNA (mtDNA) with multiple large deletions by Southern-blot hybridisation and polymerase chain reaction analyses. Amplification of the mother's cardiac mtDNA from 20-year-old paraffin-embedded sections showed that she also had deletions of mtDNA. These data suggest that a subgroup of inherited DCMs is associated with mtDNA mutations.	UNIV HELSINKI, DEPT PATHOL, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT MED 1, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT MED CHEM, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT NEUROL, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	SUOMALAINEN, A (corresponding author), NATL PUBL HLTH INST, DEPT HUMAN MOLEC GENET, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.			Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195				BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; HATTORI K, 1991, AM HEART J, V122, P866, DOI 10.1016/0002-8703(91)90542-P; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	10	139	140	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1992	340	8831					1319	1320		10.1016/0140-6736(92)92496-3	http://dx.doi.org/10.1016/0140-6736(92)92496-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360038				2022-12-28	WOS:A1992KA26200007
J	PREDEL, HG; YANG, ZH; VONSEGESSER, L; TURINA, M; BUHLER, FR; LUSCHER, TF				PREDEL, HG; YANG, ZH; VONSEGESSER, L; TURINA, M; BUHLER, FR; LUSCHER, TF			IMPLICATIONS OF PULSATILE STRETCH ON GROWTH OF SAPHENOUS-VEIN AND MAMMARY ARTERY SMOOTH-MUSCLE	LANCET			English	Note							CORONARY-BYPASS GRAFTS; PULSE PRESSURE; HYPERTENSION	Internal mammary artery (IMA) coronary bypass grafts have a higher patency than saphenous vein (SV) grafts. Intimal hyperplasia and occlusion of venous grafts result from smooth muscle proliferation. Mechanical factors, such as pulsatile stretch, are potential mediators of this process. Smooth muscle cells from IMA and SV were cultured on deformable membranes and exposed to pulsatile stretch (60 cycles/min). This stimulus increased H-3-thymidine incorporation into venous (a two-fold increase) but not arterial smooth muscle cells after 24 h. Smooth muscle cell numbers from SV, but not IMA, were increased (p < 0.05) after 6 days of stretch. Thus, pulsatile stretch stimulates smooth muscle cell proliferation in SV, but not IMA, and may contribute to venous bypass graft disease.	UNIV HOSP BASEL, DEPT MED, DIV CLIN PHARMACOL, CH-4031 BASEL, SWITZERLAND; UNIV HOSP BASEL, VASC RES LAB, CH-4031 BASEL, SWITZERLAND; UNIV HOSP ZURICH, DEPT CARDIOVASC SURG, CH-8091 ZURICH, SWITZERLAND; UNIV HOSP BASEL, DEPT RES, CH-4031 BASEL, SWITZERLAND	University of Basel; University of Basel; University of Zurich; University Zurich Hospital; University of Basel			Predel, Hans-Georg/AAO-6996-2020					ANGELINI GD, 1989, EUR HEART J, V10, P273, DOI 10.1093/oxfordjournals.eurheartj.a059476; BAUMBACH GL, 1991, HYPERTENSION, V18, P728, DOI 10.1161/01.HYP.18.6.728; CHRISTENSEN KL, 1991, HYPERTENSION, V18, P722, DOI 10.1161/01.HYP.18.6.722; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LUSCHER TF, 1991, CURR OPIN CARDIOL, V6, P868; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; MILLS I, 1990, BIOCHEM BIOPH RES CO, V171, P143, DOI 10.1016/0006-291X(90)91368-3; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SUMPIO B E, 1989, Journal of Vascular Surgery, V10, P570; YANG ZH, 1991, LANCET, V337, P939, DOI 10.1016/0140-6736(91)91571-B	10	128	136	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1992	340	8824					878	879						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357299				2022-12-28	WOS:A1992JT32700006
J	DERIJKE, YB; VOGELEZANG, CJM; VANBERKEL, TJC; PRINCEN, HMG; VERWEY, HF; VANDERLAARSE, A; BRUSCHKE, AVG				DERIJKE, YB; VOGELEZANG, CJM; VANBERKEL, TJC; PRINCEN, HMG; VERWEY, HF; VANDERLAARSE, A; BRUSCHKE, AVG			SUSCEPTIBILITY OF LOW-DENSITY LIPOPROTEINS TO OXIDATION IN CORONARY-BYPASS PATIENTS	LANCET			English	Letter									TNO,IVVO,2313 AD LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CARDIOL,2333 AA LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC)	DERIJKE, YB (corresponding author), LEIDEN UNIV,CTR BIOPHARMACEUT SCI,DIV BIOPHARMACEUT,SYLVIUS LAB,2300 RA LEIDEN,NETHERLANDS.		Van Berkel, Theo/ABD-7677-2021; de Rijke, Yolanda/AAQ-5497-2020; Princen, Hans MG/AID-9392-2022	Princen, Hans MG/0000-0002-7206-1596				PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V15, P554; REGNSTROM, 1992, LANCET, V339, P1183; STEINBERG D, 1989, NEW ENGL J MED, V320, P915	3	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					858	859		10.1016/0140-6736(92)92742-X	http://dx.doi.org/10.1016/0140-6736(92)92742-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357286				2022-12-28	WOS:A1992JR16800056
J	ZOUROS, E; FREEMAN, KR; BALL, AO; POGSON, GH				ZOUROS, E; FREEMAN, KR; BALL, AO; POGSON, GH			DIRECT EVIDENCE FOR EXTENSIVE PATERNAL MITOCHONDRIAL-DNA INHERITANCE IN THE MARINE MUSSEL MYTILUS	NATURE			English	Article							MATERNAL INHERITANCE; HETEROPLASMY; POPULATIONS; DROSOPHILA; MICE	INHERITANCE of Mitochondrial DNA in animals was thought to be strictly maternal1,2. Recently, evidence for incidental paternal mtDNA leakage was obtained in hybrid crosses of Drosophila3,4 and mice5. In mice, the frequency of paternal mtDNA contributions was estimated at 10(-4), Compared with maternal contributions. The common occurrence in the marine mussel Mytilus of heteroplasmic individuals with two or more types of highly diverged mtDNA molecules was interpreted as strong evidence for biparental mtDNA inheritance by some6, but not by others7. We report here results from pair-matings involving two species of mussels, Mytilus edulis and Mytilus trossulus. Extensive contribution of paternal mtDNA, amounting to several orders of magnitude higher than that inferred for Drosophila or mice, was observed in both intra- and interspecific crosses.	DALHOUSIE UNIV, MARINE GENE PROBE LAB, HALIFAX B3H 4J1, NS, CANADA; UNIV CRETE, DEPT BIOL, IRAKLION, GREECE; INST MARINE BIOL CRETE, IRAKLION, GREECE; FISHERIES & OCEANS CANADA, HALIFAX FISHERIES RES LAB, HALIFAX B3J 2S7, NS, CANADA	Dalhousie University; University of Crete; Fisheries & Oceans Canada	ZOUROS, E (corresponding author), DALHOUSIE UNIV, DEPT BIOL, HALIFAX B3H 4J1, NS, CANADA.							CHAPMAN RW, 1984, METHOD RAPID ISOLATI; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER C, 1990, P ROY SOC B-BIOL SCI, V242, P149, DOI 10.1098/rspb.1990.0118; GJETVAJ B, 1992, MOL BIOL EVOL, V9, P106; GYLLENSTEN U, 1985, J HERED, V76, P321, DOI 10.1093/oxfordjournals.jhered.a110103; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HOEH WR, 1991, SCIENCE, V251, P1488, DOI 10.1126/science.1672472; HOFFMANN RJ, 1992, GENETICS, V131, P397; KOEHLER CM, 1991, GENETICS, V129, P247; KOEHN RK, 1991, AQUACULTURE, V94, P125, DOI 10.1016/0044-8486(91)90114-M; KONDO R, 1990, GENETICS, V126, P657; LANSMAN RA, 1981, J MOL EVOL, V17, P214, DOI 10.1007/BF01732759; LANSMAN RA, 1983, P NATL ACAD SCI-BIOL, V80, P1969, DOI 10.1073/pnas.80.7.1969; LONGO FJ, 1969, J EXP ZOOL, V172, P97, DOI 10.1002/jez.1401720108; MAGOULAS A, IN PRESS MOL BIOL EV; MALLET AL, 1985, MAR BIOL, V87, P165, DOI 10.1007/BF00539424; MCDONALD JH, 1991, MAR BIOL, V111, P323, DOI 10.1007/BF01319403; MCDONALD JH, 1988, MAR BIOL, V99, P111, DOI 10.1007/BF00644984; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; SATTA Y, 1988, GENET RES, V52, P1, DOI 10.1017/S0016672300027245; WESTNEAT DF, 1988, NUCLEIC ACIDS RES, V16, P4161, DOI 10.1093/nar/16.9.4161	22	168	173	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					412	414		10.1038/359412a0	http://dx.doi.org/10.1038/359412a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1357555				2022-12-28	WOS:A1992JQ62400055
J	FIELDING, LP; HITTINGER, R; GRACE, RH; FRY, JS				FIELDING, LP; HITTINGER, R; GRACE, RH; FRY, JS			RANDOMIZED CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY BY PORTAL-VEIN PERFUSION AFTER CURATIVE RESECTION FOR COLORECTAL ADENOCARCINOMA	LANCET			English	Article							LARGE BOWEL-CANCER; CLINICAL-TRIAL; CARCINOMA; THERAPY; FLUOROURACIL; INFUSION; COLON; HEPARIN	About half the patients treated with curative resection for colorectal cancer do not survive long-term. Adjuvant chemotherapy given during and after surgery may prevent hepatic metastases and improve patient survival. In patients with colorectal cancer, we have done a multicentre, randomised controlled trial comparing five-year survival after intraportal infusion of fluorouracil (1 g per day) plus heparin (10 000 U per day) (130 patients) or heparin alone (123) during curative resection and for 7 days thereafter, or after resection alone (145). There was no reduction in liver metastasis or increased overall survival advantage in either active-treatment arm of the study. However, patients who had stage III, Dukes' C (lymph-node-positive) tumours resected and were treated with fluorouracil plus heparin had a significant (p<0.03) survival advantage of about 16% compared with surgery-only controls. Further study of intraportal infusion of chemotherapeutic agent as adjuvant treatment to surgery in patients with colorectal cancer appears worthwhile.	ST MARYS HOSP,ACAD SURG UNIT,LARGE BOWEL CANC PROJECT,LONDON,ENGLAND; ROYAL HOSP WOLVERHAMPTON,WOLVERHAMPTON,ENGLAND	Imperial College London								ARCHER SG, 1989, BRIT J SURG, V76, P545, DOI 10.1002/bjs.1800760607; BEART RW, 1990, ARCH SURG-CHICAGO, V125, P897; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; CORMAN ML, 1979, DIS COLON RECTUM, V22, P477, DOI 10.1007/BF02586935; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; FIELDING LP, 1986, LANCET, V2, P904; FINDLAY IG, 1983, GASTROENTEROLOGY, V85, P596; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FISHER ER, 1955, SURG GYNECOL OBSTET, V100, P102; GRAY BN, 1987, ADJUVANT THERAPY CAN, V5; HARDCASTLE JD, 1991, BRIT J SURG, V78, P45; Hermanek P, 1987, UICC TNM CLASSIFICAT; JAGELMAN DG, 1983, ROB SMITHS OPERATIVE, P270; METZGER U, 1987, WORLD J SURG, V11, P452, DOI 10.1007/BF01655809; METZGER U, 1989, P AN M AM SOC CLIN, V8, P407; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NAND S, 1990, AM J HEMATOL, V35, P45, DOI 10.1002/ajh.2830350111; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RYAN J, 1988, P AN M AM SOC CLIN, V7, P361; SILVERBERG E, 1989, CA, V39, P1; SYLVESTER DM, 1990, IMMUNOPHARM IMMUNOT, V12, P161, DOI 10.3109/08923979009019667; TAYLOR I, 1977, BRIT MED J, V2, P1320, DOI 10.1136/bmj.2.6098.1320; WEISS L, 1977, SEMIN ONCOL, V4, P5; WERELDSMA JCJ, 1990, CANCER, V65, P425, DOI 10.1002/1097-0142(19900201)65:3<425::AID-CNCR2820650309>3.0.CO;2-M; WHITE H, 1976, P ROY SOC MED, V69, P467, DOI 10.1177/003591577606900701; WOLMARK N, 1988, JNCI-J NATL CANCER I, V80, P30, DOI 10.1093/jnci/80.1.30; WOLMARK N, 1990, J CLIN ONCOL, V8, P1466, DOI 10.1200/JCO.1990.8.9.1466; WOOD S, 1971, PATHOBIOL ANN, P281; 1980, OFFICE POPULATIO DH1, V6	29	138	140	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					502	506		10.1016/0140-6736(92)91708-G	http://dx.doi.org/10.1016/0140-6736(92)91708-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354275				2022-12-28	WOS:A1992JL23400002
J	ZENZES, MT; WANG, P; CASPER, RF				ZENZES, MT; WANG, P; CASPER, RF			CHROMOSOME STATUS OF UNTRANSFERRED (SPARE) EMBRYOS AND PROBABILITY OF PREGNANCY AFTER INVITRO FERTILIZATION	LANCET			English	Article							FERTILIZATION	Many spontaneous abortions are associated with chromosomal abnormality of the fetus. In in-vitro fertilisation (IVF) the chromosome status of untransferred (''spare'') embryos and subsequent fate (pregnancy or not) of the transferred sibling embryos might be related. Since the spare and transferred embryos of a patient's cycle genetically are full siblings, the inherited chromosomal abnormalities in spare embryos have a 50% probability of also appearing in transferred embryos. We have tested whether chromosome analysis of spare embryos has predictive power for transferred embryos. 48 couples with a total of 437 embryos were selected because their spare embryos (1-4 per couple; 76 total) were successfully analysed for chromosome status. 16 patients became pregnant. These women produced a higher proportion of chromosomally normal spare embryos (9/24; 37.5%) than those who did not achieve pregnancy (1/52; 1.9%). The proportion of patients who had only normal embryos was significantly higher (p=0.012) in the pregnant group than in the non-pregnant group, and the proportion of patients who had only abnormal embryos was significantly higher (p=0.001) in the non-pregnant group. Patients with preclinical and clinical pregnancy losses had only chromosomally abnormal spare embryos; by contrast, 50% of spare embryos from patients with ectopic pregnancies were normal. The proportion of spare embryos that were normal (13%, 10/76), was similar to the livebirth rate of 11% per transferred embryo (19 infants from 171 transferred embryos). These results suggest that chromosome analysis of spare embryos may have predictive value for their transferred sibling embryos. We conclude that improving detection of chromosomally normal embryos for transfer should improve the success rate in IVF.	UNIV TORONTO, DEPT OBSTET & GYNAECOL, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto			Casper, Robert F./E-3775-2013	Casper, Robert F./0000-0002-6249-462X				Angell R R, 1988, J Reprod Fertil Suppl, V36, P73; BEIER H, 1991, GUIDELINES ESHRE ETH, V1, P21; BELSEY MA, 1980, LABORATORY MANUAL EX, P9; BRAUDE RR, 1986, HUMAN EMBRYO RES YES, P63; BREED ASPM, 1990, PRENATAL DIAG, V10, P101, DOI 10.1002/pd.1970100206; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; EIBEN B, 1990, AM J HUM GENET, V47, P656; GONEN Y, 1990, FERTIL STERIL, V53, P282; HARNDEN DG, 1985, CYTOGENET CELL GENET; HERTIG AT, 1949, AM J OBSTET GYNECOL, V58, P968, DOI 10.1016/0002-9378(49)90203-3; HOOK EB, IN PRESS PRENATAL DI; KLINE J, 1989, CONCEPTION BIRTH EPI, P81; LOPATA A, 1983, FERTIL STERIL, V40, P289; MILLER JF, 1980, LANCET, V2, P554; PLACHOT M, 1988, ANN NY ACAD SCI, V541, P384, DOI 10.1111/j.1749-6632.1988.tb22275.x; QUINN P, 1984, FERTIL STERIL, V41, P202; SUTTON HE, 1988, INTRO HUMAN GENETICS, P147; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; VANBLERKOM J, 1988, HUM REPROD, V3, P777, DOI 10.1093/oxfordjournals.humrep.a136783; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WRAMSBY H, 1987, HUM REPROD, V2, P233, DOI 10.1093/oxfordjournals.humrep.a136519; ZENZES MT, 1990, HUM REPROD, V5, P842, DOI 10.1093/oxfordjournals.humrep.a137195; ZENZES MT, 1992, FERTIL STERIL, V57, P143; ZENZES MT, 1992, HUM GENET, V88, P367, DOI 10.1007/BF00215667	24	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1992	340	8816					391	394		10.1016/0140-6736(92)91471-J	http://dx.doi.org/10.1016/0140-6736(92)91471-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353556				2022-12-28	WOS:A1992JJ44900004
J	CRAWLEY, J				CRAWLEY, J			THE INNOCENT RESEARCH WORKER	LANCET			English	Editorial Material											CRAWLEY, J (corresponding author), JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					356	357		10.1016/0140-6736(92)91416-6	http://dx.doi.org/10.1016/0140-6736(92)91416-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353816				2022-12-28	WOS:A1992JH12500015
J	BOTTGER, EC; TESKE, A; KIRSCHNER, P; BOST, S; CHANG, HR; BEER, V; HIRSCHEL, B				BOTTGER, EC; TESKE, A; KIRSCHNER, P; BOST, S; CHANG, HR; BEER, V; HIRSCHEL, B			DISSEMINATED MYCOBACTERIUM-GENAVENSE INFECTION IN PATIENTS WITH AIDS	LANCET			English	Article							TAQ POLYMERASE; DNA; IDENTIFICATION; RNA	We describe 18 patients with advanced HIV infection, most of whom had a chronic illness characterised by fever, diarrhoea, and massive loss of weight. Biopsy and necropsy samples revealed abundant acid-fast microorganisms in intestines, liver, spleen, lymph nodes, and many other tissues, which did not grow on solid media, although limited growth was observed in liquid blood cultures. Using primers complementary to bacterial 16S rRNA we amplified DNA sequences from tissue and leucocyte extracts and from blood-culture bottles. The sequences obtained were unique and suggest that the microorganism is a new member of the genus Mycobacterium, for which we propose the name "Mycobacterium genavense". Disseminated infection with "M genavense" should be considered in the differential diagnosis of HIV-infected patients with extreme immunosuppression, wasting, and fever.	HOP CANTONAL GENEVA,DIV INFECT DIS,CH-1211 GENEVA 4,SWITZERLAND; CHU VAUDOIS,MICROBIOL LAB,CH-1011 LAUSANNE,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT MED GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	BOTTGER, EC (corresponding author), MED HSCH HANNOVER,INST MED MIKROBIOL,W-3000 HANNOVER 61,GERMANY.		Böttger, Erik C./F-6175-2011; Teske, Andreas/AAQ-9577-2021					BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; BOTTGER EC, 1990, CLIN CHEM, V36, P1258; BRENNER DJ, 1980, MANUAL CLIN MICROBIO, P1; BRENNER DJ, 1983, ASM NEWS, V49, P58; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HIRSCHEL B, 1990, NEW ENGL J MED, V323, P109, DOI 10.1056/NEJM199007123230207; HIRSCHEL B, 1990, MED KLIN, V85, P268; JACOBSON MA, 1990, MED MANAGEMENT AIDS, P291; Maniatis T., 1982, MOL CLONING; MIDDLEBROOK G, 1977, AM REV RESPIR DIS, V115, P1066; RAND KH, 1990, MOL CELL PROBE, V4, P445, DOI 10.1016/0890-8508(90)90003-I; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROGALL T, 1990, INT J SYST BACTERIOL, V40, P323, DOI 10.1099/00207713-40-4-323; ROGALL T, 1990, J GEN MICROBIOL, V136, P1915, DOI 10.1099/00221287-136-9-1915; STAHL DA, 1990, J BACTERIOL, V172, P116, DOI 10.1128/JB.172.1.116-124.1990; Teske A, 1991, FEMS Microbiol Lett, V64, P231; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	19	217	219	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					76	80		10.1016/0140-6736(92)90397-L	http://dx.doi.org/10.1016/0140-6736(92)90397-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352014				2022-12-28	WOS:A1992JC58200004
J	RIDDELL, SR; WATANABE, KS; GOODRICH, JM; LI, CR; AGHA, ME; GREENBERG, PD				RIDDELL, SR; WATANABE, KS; GOODRICH, JM; LI, CR; AGHA, ME; GREENBERG, PD			RESTORATION OF VIRAL IMMUNITY IN IMMUNODEFICIENT HUMANS BY THE ADOPTIVE TRANSFER OF T-CELL CLONES	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CYTOMEGALO-VIRUS DISEASE; MARROW TRANSPLANTATION; INVIVO; REPLICATION; GENERATION; PNEUMONIA; MEMORY; DEATH; HOST	The adoptive transfer of antigen-specific T cells to establish immunity is an effective therapy for viral infections and tumors in animal models. The application of this approach to human disease would require the isolation and in vitro expansion of human antigen-specific T cells and evidence that such T cells persist and function in vivo after transfer. Cytomegalovirus-specific CD8+ cytotoxic T cell (CTL) clones could be isolated from bone marrow donors, propagated in vitro, and adoptively transferred to immunodeficient bone marrow transplant recipients. No toxicity developed and the clones provided persistent reconstitution of CD8+ cytomegalovirus-specific CTL responses.	UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIDDELL, SR (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Agha, Mounzer/AAC-2520-2022; Wilson, Matthew H/K-3193-2013	Agha, Mounzer/0000-0002-2275-7544	NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORYSIEWICZ LK, 1983, EUR J IMMUNOL, V13, P804, DOI 10.1002/eji.1830131005; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRYNE JA, 1984, J VIROL, V51, P682; CHEEVER MA, 1986, J EXP MED, V163, P1100, DOI 10.1084/jem.163.5.1100; FAUCI AS, 1985, ANN INTERN MED, V102, P800, DOI 10.7326/0003-4819-102-6-800; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; GREENBERG PD, 1991, ADV IMMUNOL, V9, P280; GREENBERG PD, 1985, J IMMUNOL, V133, P3401; HOWES EL, 1979, NATURE, V277, P67, DOI 10.1038/277067a0; LAUBSCHER A, 1988, J IMMUNOL METHODS, V110, P69, DOI 10.1016/0022-1759(88)90084-1; Li C, UNPUB; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MACHER AM, 1983, NEW ENGL J MED, V309, P1454; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MEYERS JD, 1987, INFECTIONS TRANSPLAN, P17; MUTTER W, 1988, J EXP MED, V167, P1645, DOI 10.1084/jem.167.5.1645; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PETERSON PK, 1980, MEDICINE, V59, P283, DOI 10.1097/00005792-198007000-00004; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; QUINNAN GV, 1982, NEW ENGL J MED, V307, P6; REDDEHASE MJ, 1985, J VIROL, V55, P264, DOI 10.1128/JVI.55.2.264-273.1985; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL S, UNPUB; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; SCHRIER RD, 1986, J VIROL, V59, P127, DOI 10.1128/JVI.59.1.127-131.1986; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WALKER BD, 1988, NATURE, V336, P484; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0	32	1044	1153	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					238	241						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1352912				2022-12-28	WOS:A1992JC58500038
J	SWEDBERG, K				SWEDBERG, K			MRC TRIAL OF TREATING HYPERTENSION IN OLDER ADULTS	BRITISH MEDICAL JOURNAL			English	Letter											SWEDBERG, K (corresponding author), OSTRA HOSP,DEPT MED,S-41685 GOTHENBURG,SWEDEN.							DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; 1992, BMJ, V304, P405	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1630	1631		10.1136/bmj.304.6842.1630-b	http://dx.doi.org/10.1136/bmj.304.6842.1630-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1352715	Green Published			2022-12-28	WOS:A1992JA43600045
J	TUOMILEHTO, J				TUOMILEHTO, J			MRC TRIAL OF TREATING HYPERTENSION IN OLDER ADULTS	BRITISH MEDICAL JOURNAL			English	Letter											TUOMILEHTO, J (corresponding author), NATL PUBL HLTH INST,SF-00510 HELSINKI,FINLAND.							ABLAD B, 1991, Journal of the American College of Cardiology, V17, p165A; ECKBERG DL, 1984, MED HYPOTHESES, V15, P421, DOI 10.1016/0306-9877(84)90158-0; HAYANO J, 1991, AM HEART J, V121, P1070, DOI 10.1016/0002-8703(91)90664-4; HJALMARSON A, 1991, CIRCULATION, V84, P101; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; PARKER GW, 1990, CIRC RES, V66, P259, DOI 10.1161/01.RES.66.2.259; WIKSTRAND J, 1991, CIRCULATION, V84, P93; WIKSTRAND J, 1991, HYPERTENSION, V17, P579, DOI 10.1161/01.HYP.17.4.579; 1991, LANCET, V338, P727; 1992, BMJ, V304, P405	10	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1631	1631		10.1136/bmj.304.6842.1631-a	http://dx.doi.org/10.1136/bmj.304.6842.1631-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1352716	Green Published			2022-12-28	WOS:A1992JA43600047
J	BEAR, CE; LI, CH; KARTNER, N; BRIDGES, RJ; JENSEN, TJ; RAMJEESINGH, M; RIORDAN, JR				BEAR, CE; LI, CH; KARTNER, N; BRIDGES, RJ; JENSEN, TJ; RAMJEESINGH, M; RIORDAN, JR			PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)	CELL			English	Article							LIPID BILAYER-MEMBRANES; CHLORIDE CHANNEL; ACETYLCHOLINE-RECEPTOR; ESCHERICHIA-COLI; CELL LINE; PLANAR; PROTEINS; GENE; BACTERIORHODOPSIN; RENATURATION	Circumstantial evidence has accumulated suggesting that CFTR is a regulated low-conductance CI- channel. To test this postulate directly, we have purified to homogeneity a recombinant CFTR protein from a high-level baculovirus-infected insect cell line. Evidence of purity included one- and two-dimensional gel electrophoresis, N-terminal peptide sequence, and quantitative amino acid analysis. Reconstitution into proteoliposomes at less than one molecule per vesicle was accomplished by established procedures. Nystatin and ergosterol were included in these vesicles, so that nystatin conductance could serve as a quantitative marker of vesicle fusion with a planar lipid bilayer. Upon incorporation, purified CFTR exhibited regulated chloride channel activity, providing evidence that the protein itself is the channel. This activity exhibited the basic biophysical and regulatory properties of the type of CI- channel found exclusively in CFTR-expressing cell types and believed to underlie cAMP-evoked secretion in epithelial cells.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Alabama System; University of Alabama Birmingham	BEAR, CE (corresponding author), UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Dottin R P, 1979, Methods Enzymol, V68, P513; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; FLEM K, 1991, OCT N AM CYST C DALL; FURMAN RE, 1986, P NATL ACAD SCI USA, V83, P488, DOI 10.1073/pnas.83.2.488; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1985, P NATL ACAD SCI USA, V82, P240, DOI 10.1073/pnas.82.1.240; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1985, BIOCHIM BIOPHYS ACTA, V822, P127, DOI 10.1016/0304-4157(85)90005-X; LONDON E, 1982, J BIOL CHEM, V257, P7003; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MONTAL M, 1984, BIOPHYS J, V45, P165, DOI 10.1016/S0006-3495(84)84145-4; NOWAK R, 1991, J NIH RES, V3, P30; REINHARDT R, 1987, J MEMBRANE BIOL, V95, P47, DOI 10.1007/BF01869629; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1991, ADV EXP MED BIOL, V290, P19; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARIBANSOHRABY S, 1984, NATURE, V308, P80, DOI 10.1038/308080a0; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SHEPPARD DN, 1992, FASEB J, V6, pA537; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2	44	830	852	0	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					809	818		10.1016/0092-8674(92)90155-6	http://dx.doi.org/10.1016/0092-8674(92)90155-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1371239				2022-12-28	WOS:A1992HF44000020
J	VERRALL, S; HALL, ZW				VERRALL, S; HALL, ZW			THE N-TERMINAL DOMAINS OF ACETYLCHOLINE-RECEPTOR SUBUNITS CONTAIN RECOGNITION SIGNALS FOR THE INITIAL STEPS OF RECEPTOR ASSEMBLY	CELL			English	Article							ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; BINDING-SITES; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; DELTA-SUBUNIT; ION CHANNELS; MUSCLE; MUTAGENESIS; SELECTION	Ligand-gated ion channels are oligomeric membrane proteins in which homologous subunits specifically recognize one another and assemble around an aqueous pore. To identity domains responsible for the specificity of subunit association, we used a dominant-negative assay in which truncated subunits of the mouse muscle acetylcholine receptor (AChR) were coexpressed with the four wild-type subunits in transfected COS cells. Fragments of the alpha, delta, and gamma-subunits consisting solely of the extracellular N-terminal domain blocked surface expression of the AChR and the formation of alpha-delta-heterodimers, an early step in the assembly pathway of the AChR. Immunoprecipitation and sucrose gradient sedimentation experiments showed that an N-terminal fragment of the alpha-subunit forms a specific complex with the intact delta-subunit. Thus the extracellular N-terminal domain of the alpha, delta, and gamma-subunits contains the information necessary for specific subunit association.			VERRALL, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA.							BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOWDING AJ, 1987, BIOCHEMISTRY-US, V26, P6372, DOI 10.1021/bi00394a010; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1988, J BIOL CHEM, V263, P12878; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KARLIN A, 1980, CELL SURF REV, V6, P191; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RALSTON E, 1989, J CELL BIOL, V109, P2345, DOI 10.1083/jcb.109.5.2345; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	43	134	135	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					23	31		10.1016/0092-8674(92)90203-O	http://dx.doi.org/10.1016/0092-8674(92)90203-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370654				2022-12-28	WOS:A1992GZ58300006
J	TRAVIS, SPL; MCGRATH, JA; TURNBULL, AJ; SCHOFIELD, OM; CHAN, O; OCONNOR, AF; MAYOU, B; EADY, RAJ; THOMPSON, RPH				TRAVIS, SPL; MCGRATH, JA; TURNBULL, AJ; SCHOFIELD, OM; CHAN, O; OCONNOR, AF; MAYOU, B; EADY, RAJ; THOMPSON, RPH			ORAL AND GASTROINTESTINAL MANIFESTATIONS OF EPIDERMOLYSIS-BULLOSA	LANCET			English	Note							MONOCLONAL-ANTIBODY; DIAGNOSIS	The mouth, oesophagus, and anus are often involved in dystrophic and junctional epidermolysis bullosa, but the frequency is unknown. Among 246 patients with epidermolysis bullosa, dysphagia developed in 76% of those with recessive dystrophic, in 20% of those with dominant dystrophic, in 15% of those with junctional, and in 2% of those with simplex forms. Lingual adhesions or microstomia occurred in dystrophic epidermolysis bullosa only, but were eight times more common in recessive than in dominant subtypes. These lesions are provoked by the trauma of eating and further reduce food intake, which exacerbates constipation caused by anal blisters and results in malnutrition. Management requires specialised multidisciplinary care.	ST THOMAS HOSP,GASTROINTESTINAL LAB,LONDON SE1,ENGLAND; ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT RADIOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT OTOLARYNGOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT PLAST SURG,LONDON SE1,ENGLAND		TRAVIS, SPL (corresponding author), RADCLIFFE INFIRM,GASTROENTEROL UNIT,OXFORD OX2 6HE,ENGLAND.		McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Travis, Simon/0000-0002-2690-4361				COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FEURLE GE, 1984, GASTROENTEROLOGY, V87, P1376; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FOX T, 1879, LANCET, V1, P765; GRYBOSKI JD, 1988, ARCH DERMATOL, V124, P746, DOI 10.1001/archderm.124.5.746; HEAGERTY AHM, 1986, LANCET, V1, P860; HEAGERTY AHM, 1986, BRIT J DERMATOL, V115, P125, DOI 10.1111/j.1365-2133.1986.tb05707.x; NOWAK AJ, 1988, ARCH DERMATOL, V124, P742, DOI 10.1001/archderm.124.5.742; PEARSON RW, 1988, ARCH DERMATOL, V124, P718, DOI 10.1001/archderm.124.5.718; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P374, DOI 10.1111/1523-1747.ep12265460; TIDMAN MJ, 1988, CLIN EXP DERMATOL, V13, P279, DOI 10.1111/j.1365-2230.1988.tb00702.x	12	34	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1505	1506		10.1016/0140-6736(92)92759-9	http://dx.doi.org/10.1016/0140-6736(92)92759-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361600				2022-12-28	WOS:A1992KD06900008
J	ARIYOSHI, K; HARWOOD, E; CHIENGSONGPOPOV, R; WEBER, J				ARIYOSHI, K; HARWOOD, E; CHIENGSONGPOPOV, R; WEBER, J			IS CLEARANCE OF HIV-1 VIREMIA AT SEROCONVERSION MEDIATED BY NEUTRALIZING ANTIBODIES	LANCET			English	Note							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION; GAG	The mechanism of clearance of human immunodeficiency virus-1 (HIV-1) viraemia is not fully understood. In two patients with acute HIV-1 infection, initial high titres of free infectious virus in plasma declined rapidly to undetectable levels within 4-8 weeks, an event that was coincident with seroconversion. Neutralising antibodies directed against the first autologous isolates taken during the viraemic periods could not be detected in either patient around the time of disappearance of plasma virus. In the absence of functional neutralising antibody, it is unlikely that humoral factors are responsible for the suppression of primary viraemia in early HIV infection.			ARIYOSHI, K (corresponding author), ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED & COMMUNICABLE DIS,PRAED ST,LONDON W2 1NY,ENGLAND.							ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; CHEINGSONGPOPOV R, 1991, BMJ-BRIT MED J, V302, P23, DOI 10.1136/bmj.302.6767.23; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0	7	55	55	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1257	1258		10.1016/0140-6736(92)92953-D	http://dx.doi.org/10.1016/0140-6736(92)92953-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359323				2022-12-28	WOS:A1992JZ23700007
J	JOHAL, GS; BRIGGS, SP				JOHAL, GS; BRIGGS, SP			REDUCTASE-ACTIVITY ENCODED BY THE HM1 DISEASE RESISTANCE GENE IN MAIZE	SCIENCE			English	Article							HELMINTHOSPORIUM-CARBONUM; HC-TOXIN; DETOXIFICATION	The HM1 gene in maize controls both race-specific resistance to the fungus Cochliobolus carbonum race 1 and expression of the NADPH (reduced form of nicotinamide adenine dinucleotide phosphate)-dependent HC toxin reductase (HCTR), which inactivates HC toxin, a cyclic tetrapeptide produced by the fungus to permit infection. Several HM1 alleles were generated and cloned by transposon-induced mutagenesis. The sequence of wild-type HM1 shares homology with dihydroflavonol-4-reductase genes from maize, petunia, and snapdragon. Sequence homology is greatest in the betaalphabeta-dinucleotide binding fold that is conserved among NADPH- and NADH (reduced form of nicotinamide adenine dinucleotide)dependent reductases and dehydrogenases. This indicates that HM1 encodes HCTR.			JOHAL, GS (corresponding author), PIONEER HI BRED INT INC,DEPT BIOTECHNOL RES,JOHNSTON,IA 50131, USA.		Johal, Guri/F-5056-2017	Johal, Guri/0000-0001-8101-8410				ANZAI H, 1989, MOL GEN GENET, V219, P492, DOI 10.1007/BF00259626; ATHMA P, 1991, GENETICS, V128, P163; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; BEAVIS WD, 1991, THEOR APPL GENET, V82, P636, DOI 10.1007/BF00226803; BELD M, 1989, PLANT MOL BIOL, V13, P491, DOI 10.1007/BF00027309; BRIGGS SP, 1987, CURR TOP PLANT BIOCH, V6, P59; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONE KC, 1988, PLANT TRANSPOSABLE E; DELLAPORTA SL, 1983, PLANT MOL BIOL REP, V1, P18; GROSS ML, 1982, TETRAHEDRON LETT, V23, P5381; HENRY RJ, 1991, PLANT MOL BIOL REP, V9, P139; JOHAL GS, 1990, MAIZE GENETICS COOPE, V64, P37; JOHAL GS, UNPUB; KAWAI M, 1983, BIOCHEM BIOPH RES CO, V111, P398, DOI 10.1016/0006-291X(83)90319-4; LIESCH JM, 1982, TETRAHEDRON, V38, P45, DOI 10.1016/0040-4020(82)85043-6; MEELEY RB, 1992, PLANT CELL, V4, P71, DOI 10.1105/tpc.4.1.71; MEELEY RB, 1991, PLANT PHYSIOL, V97, P1080, DOI 10.1104/pp.97.3.1080; MEYEROWITZ EM, 1982, CELL, V28, P165, DOI 10.1016/0092-8674(82)90386-5; MIAO VPW, 1992, APPL ENVIRON MICROB, V58, P801, DOI 10.1128/AEM.58.3.801-808.1992; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PERHAM RN, 1991, BIOESSAYS, V13, P515, DOI 10.1002/bies.950131005; RASMUSSEN JB, 1988, PHYSIOL MOL PLANT P, V32, P283, DOI 10.1016/S0885-5765(88)80023-7; ROBERTSON D, COMMUNICATION; SCHEFFER RP, 1965, PHYTOPATHOLOGY, V55, P1037; SHAH D M, 1983, Journal of Molecular and Applied Genetics, V2, P111; SISCO P, COMMUNICATION; WALTON JD, 1982, BIOCHEM BIOPH RES CO, V107, P785, DOI 10.1016/0006-291X(82)90592-7; WOLF SJ, 1991, PLANT SCI, V70, P127; YODER OC, 1980, ANNU REV PHYTOPATHOL, V18, P103, DOI 10.1146/annurev.py.18.090180.000535	31	342	440	5	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					985	987		10.1126/science.1359642	http://dx.doi.org/10.1126/science.1359642			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359642				2022-12-28	WOS:A1992JW79600032
J	BRAHAMS, D				BRAHAMS, D			CAUTIONARY TALES FROM GYNECOLOGY AND OBSTETRICS	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					720	721		10.1016/0140-6736(92)92251-A	http://dx.doi.org/10.1016/0140-6736(92)92251-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355812				2022-12-28	WOS:A1992JN78000017
J	MALONE, RE; BULLARD, S; LUNDQUIST, S; KIM, S; TARKOWSKI, T				MALONE, RE; BULLARD, S; LUNDQUIST, S; KIM, S; TARKOWSKI, T			A MEIOTIC GENE CONVERSION GRADIENT OPPOSITE TO THE DIRECTION OF TRANSCRIPTION	NATURE			English	Article							INITIATION SITE; SACCHAROMYCES-CEREVISIAE; ARG4 LOCUS; DECREASING GRADIENTS; YEAST; RECOMBINATION; REPLACEMENT; SEQUENCES; SIDES	GENETIC recombination involves classical crossing-over and gene conversion (aberrant segregation). In fungi that produce an ascus containing four spores, a gene conversion event is manifested as 3:1 or 1:3 (or more rarely 4:0 or 0:4) segregations, in contrast to the normal mendelian 2:2 segregation1,2. Polarity is one of the properties of gene conversion; in almost all cases the frequency of conversion exhibits a gradient across the gene monitored1. The frequency of conversion is usually independent of the specific allele used as a marker, but dependent on its location. An interpretation of conversion polarity is that it is caused by the existence of specific initiation sites for meiotic recombination, located at the high end of the polarity gradient. Here we show that the polarity gradient for the HIS2 gene of Saccharomyces cerevisiae is high at the 3' end of the gene, implying that the promoter of HIS2 is not the initiation site.			MALONE, RE (corresponding author), UNIV IOWA, DEPT BIOL, IOWA CITY, IA 52242 USA.							DICAPRIO L, 1976, GENETICS, V84, P697; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; WHITE MA, 1992, CURR GENET, V21, P109, DOI 10.1007/BF00318468; WHITE MA, 1991, P NATL ACAD SCI USA, V88, P9755, DOI 10.1073/pnas.88.21.9755	11	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 10	1992	359	6391					154	155		10.1038/359154a0	http://dx.doi.org/10.1038/359154a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1355857				2022-12-28	WOS:A1992JM49400055
J	STADTMAN, ER				STADTMAN, ER			PROTEIN OXIDATION AND AGING	SCIENCE			English	Article							MIXED-FUNCTION OXIDATION; METAL-CATALYZED OXIDATION; RED BLOOD-CELLS; GLUTAMINE-SYNTHETASE; OXYGEN RADICALS; NONENZYMATIC GLYCOSYLATION; CYSTEINE PROTEINASE; DENATURED PROTEINS; OXIDIZED PROTEINS; DEGRADATION	A number of systems that generate oxygen free radicals catalyze the oxidative modification of proteins. Such modifications mark enzymes for degradation by cytosolic neutral alkaline proteases. Protein oxidation contributes to the pool of damaged enzymes, which increases in size during aging and in various pathological states. The age-related increase in amounts of oxidized protein may reflect the age-dependent accumulation of unrepaired DNA damage that, in a random manner, affects the concentrations or activities of numerous factors that govern the rates of protein oxidation and the degradation of oxidized protein.			STADTMAN, ER (corresponding author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AMES BN, 1991, OXIDATIVE DAMAGE & REPAIR, P181; AMICI A, 1989, J BIOL CHEM, V264, P3341; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BERLETT BS, 1991, FASEB J, V5, pA1524; BERLETT BS, UNPUB; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; CERAMI A, 1986, TRENDS PHARMACOL SCI, V7, P271, DOI 10.1016/0165-6147(86)90350-0; CERAMI A, 1986, J CELL BIOCHEM, V30, P111, DOI 10.1002/jcb.240300203; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; CREETH JM, 1983, BIOCHEM J, V211, P323, DOI 10.1042/bj2110323; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DAVIES KJA, 1984, CELLULAR MOL ASPECTS, P15; DAVIES KJA, 1988, FREE RADIC BIOL MED, V5, P217; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; FARBER JM, 1982, FED PROC, V41, P865; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; FULKS RM, 1985, BIOCHIM BIOPHYS ACTA, V843, P214, DOI 10.1016/0304-4165(85)90142-4; GARLAND D, 1988, OXYGEN RADICALS BIOL, P347; GARRISON WM, 1984, RADIAT RES, V16, P267; GERSHON H, 1970, NATURE, V227, P1214, DOI 10.1038/2271214a0; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P247, DOI 10.1016/S0065-3233(08)60066-2; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; OLIVER CN, 1981, METABOLIC INTERCONVE, P259; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; POSTON MJ, 1988, FED PROC, V46, P1979; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; RIVETT AJ, 1985, ARCH BIOCHEM BIOPHYS, V243, P624, DOI 10.1016/0003-9861(85)90540-5; ROTHSTEIN M, 1985, MOL BIOL AGING, P193; SAHAKIAN JA, 1991, FASEB J, V5, pA1177; Schauenstein E., 1979, CIBA F S, V67, P225; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STARKE PE, 1987, FASEB J, V1, P36, DOI 10.1096/fasebj.1.1.2886388; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; SWALLOW AJ, 1960, RAD CHEM ORGANIC COM, P211; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1992, Z NATURFORSCH C, V89, P4544; UCHIDA K, UNPUB; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243	58	1563	1636	4	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1220	1224		10.1126/science.1355616	http://dx.doi.org/10.1126/science.1355616			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1355616	Green Submitted			2022-12-28	WOS:A1992JL05000017
J	JOFFE, BI; PANZ, VR; WING, JR; RAAL, FJ; SEFTEL, HC				JOFFE, BI; PANZ, VR; WING, JR; RAAL, FJ; SEFTEL, HC			PATHOGENESIS OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS IN THE BLACK-POPULATION OF SOUTHERN AFRICA	LANCET			English	Review							BETA-CELL; SECRETION; NIDDM; PATTERNS; RATHER	Non-insulin-dependent diabetes mellitus (NIDDM) is an important health problem in the black population of southern Africa. Whether the primary cause of NIDDM is insulin secretory dysfunction or peripheral insulin resistance is unknown. In westernised populations it is believed that insulin resistance and hyperinsulinaemia occur in the early stages of disease, followed later by progressive impairment of insulin secretion. However, we suggest that in the southern African black population a decrease in the mass of functioning beta cells is an important event, making these people vulnerable to the deleterious effects of insulin resistance induced by obesity and other factors. These abnormalities are, in turn, associated with insulin receptor down-regulation. An accelerated decline in beta-cell function then follows in susceptible individuals, ultimately producing striking insulinopenia. Insulinopenic NIDDM in black southern Africans may partly explain why this population has a comparatively low incidence of macrovascular complications and also predicts a short-lived therapeutic response to oral sulphonylureas in most patients.	UNIV WITWATERSRAND,SCH MED,DEPT MED,DIV ENDOCRINOL,JOHANNESBURG 2193,SOUTH AFRICA	University of Witwatersrand	JOFFE, BI (corresponding author), UNIV WITWATERSRAND,SCH MED,CARBOHYDRATE & LIPID METAB RES GRP,JOHANNESBURG 2193,SOUTH AFRICA.		Raal, FJ/ABD-5111-2021	Raal, FJ/0000-0002-9170-7938				ASMAL AC, 1975, S AFR MED J, V49, P810; BELL GI, 1991, DIABETES, V40, P413, DOI 10.2337/diabetes.40.4.413; CLARK A, 1989, DIABETIC MED, V6, P561, DOI 10.1111/j.1464-5491.1989.tb01228.x; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; GILL GV, 1991, Q J MED, V81, P829; GREENFIELD MS, 1982, DIABETES, V31, P307, DOI 10.2337/diabetes.31.4.307; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; JACKSON WPU, 1972, POSTGRAD MED J, V48, P391, DOI 10.1136/pgmj.48.561.391; JOFFE BI, 1975, AM J CLIN NUTR, V28, P616, DOI 10.1093/ajcn/28.6.616; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; MCLARTY DG, 1991, PRACTICAL DIABETES D, V3, P3; NAIDOO C, 1987, DIABETES RES CLIN EX, V4, P35; NISKANEN LK, 1990, DIABETES CARE, V13, P41, DOI 10.2337/diacare.13.1.41; OLEFSKY JM, 1982, AM J PHYSIOL, V243, P15; ORAHILLY SP, 1986, LANCET, V2, P360; PANZ VR, 1992, DIABETES CARE, V15, P277, DOI 10.2337/diacare.15.2.277; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; REDDY SSK, 1988, DIABETIC MED, V5, P621, DOI 10.1111/j.1464-5491.1988.tb01069.x; RUBENSTEIN AH, 1969, BMJ-BRIT MED J, V1, P748, DOI 10.1136/bmj.1.5646.748; SEFTEL HC, 1978, EPIDEMIOLOGY DIABETE; SHAPIRO ET, 1985, THESIS U WITWATERSRA; SHERWIN RS, 1974, J CLIN INVEST, V53, P1481, DOI 10.1172/JCI107697; SHIRES R, 1985, S AFR MED J, V67, P845; SHIRES R, 1978, S AFR MED J, V53, P446; TURNER RC, 1976, LANCET, V1, P1272; WARD WK, 1984, DIABETES CARE, V7, P491, DOI 10.2337/diacare.7.5.491; WICKS ACB, 1973, BRIT MED J, V1, P773, DOI 10.1136/bmj.1.5856.773; WING JR, IN PRESS DIABETIC ME; 1985, WHO TECH REP SER, P727	32	46	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					460	462		10.1016/0140-6736(92)91777-6	http://dx.doi.org/10.1016/0140-6736(92)91777-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354791				2022-12-28	WOS:A1992JJ87700011
J	SEIDELIN, PH; JONES, GA; BOON, NA				SEIDELIN, PH; JONES, GA; BOON, NA			EFFECTS OF DUAL-CHAMBER PACING IN HYPERTROPHIC CARDIOMYOPATHY WITHOUT OBSTRUCTION	LANCET			English	Letter									CITY HOSP EDINBURGH,DEPT MED,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT CARDIOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	SEIDELIN, PH (corresponding author), VICTORIA INFIRM,DEPT MED & CARDIOL,GLASGOW G42 9TY,SCOTLAND.							HARIZI RC, 1988, ARCH INTERN MED, V148, P99, DOI 10.1001/archinte.148.1.99; JEANRENAUDD, 1992, LANCET, V339, P1318; LAWSON JWR, 1987, AM J MED SCI, V294, P191, DOI 10.1097/00000441-198709000-00011; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; YAMAGUCHI H, 1979, AM J CARDIOL, V44, P401, DOI 10.1016/0002-9149(79)90388-6	5	5	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					369	369		10.1016/0140-6736(92)91443-C	http://dx.doi.org/10.1016/0140-6736(92)91443-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353826				2022-12-28	WOS:A1992JH12500026
J	GETZOFF, ED; CABELLI, DE; FISHER, CL; PARGE, HE; VIEZZOLI, MS; BANCI, L; HALLEWELL, RA				GETZOFF, ED; CABELLI, DE; FISHER, CL; PARGE, HE; VIEZZOLI, MS; BANCI, L; HALLEWELL, RA			FASTER SUPEROXIDE-DISMUTASE MUTANTS DESIGNED BY ENHANCING ELECTROSTATIC GUIDANCE	NATURE			English	Article							PULSE RADIOLYSIS; COPPER; ENZYME; SIMULATION; MECHANISM; DIFFUSION; SUBSTRATE; SEQUENCE; PROTEIN; SITE	THE enzyme Cu, Zn superoxide dismutase (SOD) protects against oxidative damage by dismuting the superoxide radical O2.- to molecular oxygen and hydrogen peroxide1-3 at the active-site Cu ion4,5 in a reaction that is rate-limited by diffusion3,6 and enhanced by electrostatic guidance7-10. SOD has evolved to be one of the fastest enzymes known (V(max) approximately 2 x 10(9) M-1 s-1)6,11. The new crystal structures of human SOD12 show that amino-acid site chains that are implicated in electrostatic guidance8 (Glu 132, Glu 133 and Lys 136) form a hydrogen-bonding network. Here we show that site-specific mutants that increase local positive charge while maintaining this orienting network (Glu --> Gln) have faster reaction rates and increased ionic-strength dependence, matching brownian dynamics simulations incorporating electrostatic terms. Increased positive charge alone is insufficient: one charge reversal (Glu --> Lys) mutant is slower than the equivalent charge neutralization (Glu --> Gln) mutant, showing that the newly introduced positive charge disrupts the orienting network. Thus, electrostatically facilitated diffusion rates can be increased by design, provided the detailed structural integrity of the active-site electrostatic network is maintained.	BROOKHAVEN NATL LAB, DEPT CHEM, LONG ISL, NY 11973 USA; UNIV FLORENCE, DEPT CHEM, I-50121 FLORENCE, ITALY; CHIRON CORP, EMERYVILLE, CA 94608 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; University of Florence; Novartis	GETZOFF, ED (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.			BANCI, LUCIA/0000-0003-0562-5774				ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ALLISON SA, 1988, BIOPOLYMERS, V27, P251, DOI 10.1002/bip.360270207; ARGESE E, 1987, BIOCHEMISTRY-US, V26, P3224, DOI 10.1021/bi00385a043; BANCI L, 1990, INORG CHEM, V29, P2398, DOI 10.1021/ic00338a004; BEYER WF, 1987, J BIOL CHEM, V262, P11182; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CUDD A, 1982, J BIOL CHEM, V257, P1443; DAVIS ME, 1991, J COMPUT CHEM, V12, P909, DOI 10.1002/jcc.540120718; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; KLUG D, 1972, J BIOL CHEM, V247, P4839; Koppenol W.H., 1981, OXYGEN OXYRADICALS C, P671; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; PARGE HE, IN PRESS P NATN ACAD; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; SHEN J, 1991, CHEM PHYS, V158, P191, DOI 10.1016/0301-0104(91)87066-5; SINES JJ, 1990, BIOCHEMISTRY-US, V29, P9403, DOI 10.1021/bi00492a014; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TAINER JA, 1991, STUDY ENZYMES, V2, P499; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	32	363	367	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					347	351		10.1038/358347a0	http://dx.doi.org/10.1038/358347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353610				2022-12-28	WOS:A1992JE68400069
J	GORE, SM; JONES, G; THOMPSON, SG				GORE, SM; JONES, G; THOMPSON, SG			THE LANCETS STATISTICAL REVIEW PROCESS - AREAS FOR IMPROVEMENT BY AUTHORS	LANCET			English	Article							CLINICAL-TRIALS; MEDICAL JOURNALS	The Lancet now incorporates statistical review of submitted papers which remain candidates for publication after conventional review. We summarise here criticisms noted by the statistical reviewers for 191 such papers received between November, 1990, and June, 1991. Only 54% of papers were deemed acceptable or acceptable after revision; the others were either recommended for rejection (14%) or for more substantial revision and re-review (32%). Descriptions of methods and of results were found inadequate in about half of the papers; about one-quarter of papers had inadequate abstracts and conclusions. Major errors of inference were made in 48 papers and went hand in hand with major criticisms of analysis or design in those papers. The natural focus of statistical review is whether conclusions drawn are justified by study design and statistical analysis. In this, there is room for improvement by authors.	DEPT HLTH LONDON,LONDON,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,5 SHAFTESBURY RD,CAMBRIDGE CB2 2BW,ENGLAND.							ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/bmj.292.6523.810; GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355; GARDNER MJ, 1989, BRIT MED J; GORE SM, 1982, BRIT MED J, P38; GORE SM, 1991, J R STATIST SOC A, V154, P259; MATTHEWS JNS, 1990, BRIT MED J, V300, P680, DOI 10.1136/bmj.300.6725.680-a; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; POCOCK SJ, 1985, BMJ-BRIT MED J, V290, P39, DOI 10.1136/bmj.290.6461.39; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; SCHOR S, 1966, JAMA-J AM MED ASSOC, V195, P145; 1990, LANCET, V337, P84	16	62	65	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					100	102		10.1016/0140-6736(92)90409-V	http://dx.doi.org/10.1016/0140-6736(92)90409-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1351973				2022-12-28	WOS:A1992JC58200015
J	WATANABEFUKUNAGA, R; BRANNAN, CI; COPELAND, NG; JENKINS, NA; NAGATA, S				WATANABEFUKUNAGA, R; BRANNAN, CI; COPELAND, NG; JENKINS, NA; NAGATA, S			LYMPHOPROLIFERATION DISORDER IN MICE EXPLAINED BY DEFECTS IN FAS ANTIGEN THAT MEDIATES APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; LPR LPR MICE; GENE; RECEPTOR; GLD; LYMPHADENOPATHY; TOLERANCE; INDUCTION; LYMPHOCYTES; ENVIRONMENT	Fas antigen is a cell-surface protein that mediates apoptosis. It is expressed in various tissues including the thymus and has structural homology with a number of cell-surface receptors, including tumour necrosis factor receptor and nerve growth factor receptor. Mice carrying the lymphoproliferation (lpr) mutation have defects in the Fas antigen gene. The lpr mice develop lymphadenopathy and suffer from a systemic lupus erythematosus-like autoimmune disease, indicating an important role for Fas antigen in the negative selection of autoreactive T cells in the thymus.	OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN PL, 1991, REV IMMUNOL, V9, P243; FRIZZERA G, 1989, LEUKEMIA, V3, P1; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZUI S, 1984, J IMMUNOL, V133, P227; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; KATAGIRI T, 1988, J EXP MED, V167, P741, DOI 10.1084/jem.167.3.741; KIMURA M, 1991, EUR J IMMUNOL, V21, P63, DOI 10.1002/eji.1830210111; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MATSUMOTO K, 1991, J EXP MED, V173, P127, DOI 10.1084/jem.173.1.127; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUNTZ JD, 1990, J EXP MED, V172, P1805, DOI 10.1084/jem.172.6.1805; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; OHTEKI T, 1990, J EXP MED, V172, P7, DOI 10.1084/jem.172.1.7; PERKINS DL, 1990, J IMMUNOL, V145, P549; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANEWIJK WA, 1991, REV IMMUNOL, V9, P591; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAG.R, IN PRESS J IMMUN; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHOU T, 1991, J IMMUNOL, V147, P466	34	2577	2674	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					314	317		10.1038/356314a0	http://dx.doi.org/10.1038/356314a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1372394				2022-12-28	WOS:A1992HK79400054
J	SWAIN, A; COFFIN, JM				SWAIN, A; COFFIN, JM			MECHANISM OF TRANSDUCTION BY RETROVIRUSES	SCIENCE			English	Article							SINGLE REPLICATION CYCLE; ROUS-SARCOMA VIRUS; MUTATIONAL HOTSPOTS; BROAD-SPECTRUM; SHUTTLE VECTOR; ONCOGENE; RNA; POLYADENYLATION; HYPERMUTATIONS; SEQUENCE	Retroviruses can capture cellular sequences and express them as oncogenes. Capture has been proposed to be a consequence of the inefficiency of polyadenylation of the viral genome that allows the packaging of cellular sequences flanking the integrated provirus in virions; after transfer into virions, these sequences could be incorporated into the viral genome by illegitimate recombination during reverse transcription. As a test for this hypothesis, a tissue culture system was developed that mimics the transduction process and allows the analysis and quantitation of capture events in a single step. In this model transduction of sequences adjacent to a provirus depends on the formation of readthrough transcripts and their transmission in virions and leads to various recombinant structures whose formation is independent of sequence similarity at the crossover site. Thus, all events in the transduction process can be attributed to the action of reverse transcriptase on readthrough transcripts without involving deletions of cellular DNA.	TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,136 HARRISON AVE,BOSTON,MA 02111	Tufts University					NCI NIH HHS [R35 CA 44385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; DOGGETT DL, 1989, J VIROL, V63, P2108, DOI 10.1128/JVI.63.5.2108-2117.1989; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOLDFARB MP, 1981, J VIROL, V38, P136, DOI 10.1128/JVI.38.1.136-150.1981; HERMAN SA, 1986, J VIROL, V60, P497, DOI 10.1128/JVI.60.2.497-505.1986; HERMAN SA, 1987, SCIENCE, V236, P845, DOI 10.1126/science.3033828; HUANG CC, 1986, CELL, V44, P935, DOI 10.1016/0092-8674(86)90016-4; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Maniatis T., 1982, MOL CLONING; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; RAINES MA, 1988, J VIROL, V62, P2437, DOI 10.1128/JVI.62.7.2437-2443.1988; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SWAIN A, 1989, J VIROL, V63, P3301, DOI 10.1128/JVI.63.8.3301-3306.1989; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; Weiss R, 1985, RNA TUMOR VIRUSES	22	118	120	3	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					841	845		10.1126/science.1371365	http://dx.doi.org/10.1126/science.1371365			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1371365				2022-12-28	WOS:A1992HD54800035
J	CULOTTA, E; KOSHLAND, DE				CULOTTA, E; KOSHLAND, DE			NO NEWS IS GOOD-NEWS	SCIENCE			English	Article																		GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913	1	682	728	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1862	1865		10.1126/science.1361684	http://dx.doi.org/10.1126/science.1361684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1361684				2022-12-28	WOS:A1992KD08800002
J	JEGALIAN, BG; DEROBERTIS, EM				JEGALIAN, BG; DEROBERTIS, EM			HOMEOTIC TRANSFORMATIONS IN THE MOUSE INDUCED BY OVEREXPRESSION OF A HUMAN HOX3.3 TRANSGENE	CELL			English	Article							HUMAN HOMEOBOX GENES; SPINAL-CORD; DROSOPHILA; EXPRESSION; ANTENNAPEDIA; MURINE; ORGANIZATION; PROTEIN; SEQUENCE; HOX-1.1	A permanent transgenic mouse line was generated carrying 40 copies of the human Hox3.3 gene. The resulting mice express large amounts of Hox3.3 protein in posterior regions of the embryo where this homeodomain protein is normally not expressed. The transgene causes homeotic transformations of the skeleton, in particular the appearance of an extra pair of ribs in the lumbar region, transformation of the shape of posterior ribs into that of more anterior ones, and the joining of an additional pair of ribs to the sternum. The phenotype of this line resembles that obtained by the targeted loss-of-function mutation of Hox3.1 (Le Mouellic et al., 1992). In transient assays, the human Hox3.3 transgene leads to the formation of additional ribs in more posterior vertebrae as well.			JEGALIAN, BG (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.			De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD 21502-07] Funding Source: Medline; NIGMS NIH HHS [GM 08042-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acampora D, 1991, Oxf Surv Eukaryot Genes, V7, P1; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; COLETTA PL, 1991, MECH DEVELOP, V35, P129, DOI 10.1016/0925-4773(91)90063-C; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ESTIBEIRO JP, 1990, POSTIMPLANTATION MAM, P173; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILMAN M, 1989, CURRENT PROTOCOLS MO, P471; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Green EL, 1941, GENETICS, V26, P192; GREEN MC, 1989, GENETIC VARIANTS STR; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HOGAN BLM, 1988, MANIPULATING MOUSE E; JEGALIAN BJ, 1992, IN PRESS MECH DEV; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KESSEL M, 1992, DEVELOPMENT, V115, P4487; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; OJEDA JL, 1970, STAIN TECHNOL, V45, P137; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	46	159	163	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					901	910		10.1016/0092-8674(92)90387-R	http://dx.doi.org/10.1016/0092-8674(92)90387-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1360874				2022-12-28	WOS:A1992KB99000004
J	THOMAS, JE; GIBSON, GR; DARBOE, MK; DALE, A; WEAVER, LT				THOMAS, JE; GIBSON, GR; DARBOE, MK; DALE, A; WEAVER, LT			ISOLATION OF HELICOBACTER-PYLORI FROM HUMAN FECES	LANCET			English	Note							INFECTION; CHILDHOOD	Helicobacter pylori is arguably the commonest chronic infection in man. However, its route of transmission is unknown. We have isolated viable H pylori from the faeces of an infected individual from The Gambia. The organism was cultured on selective media after concentration of faecal bacteria by centrifugation in a buffer equilibrated with a microaerophilic gas mixture. Growth characteristics, microscopic appearances, and enzyme activities were the same as those of a typical gastric isolate of H pylori. Protein preparations derived from the new isolate and the typical strain were antigenically similar, and had very similar electrophoretic profiles (including two major protein bands of 62 and 26 kDa, corresponding to the urease enzyme subunits). With the same technique, organisms with the colony morphology, growth requirements, enzyme activities, and microscopic appearances of H pylori were isolated from the faeces of 9 of 23 randomly selected childen aged 3-27 months from a Gambian village with a high prevalence of H pylori infection in early life. Faecal-oral transmission is probably important in the spread of infection in such communities.	MRC,DUNN NUTR CTR,BANJUL,SENEGAMBIA		THOMAS, JE (corresponding author), MRC,DUNN NUTR CTR,MILTON RD,CAMBRIDGE CB4 1XJ,ENGLAND.		Gibson, Glenn R/A-9595-2009					COSTAS M, 1991, SCAND J GASTROENTERO, V26, P20, DOI 10.3109/00365529109093204; HOLCOMBE C, 1992, AM J GASTROENTEROL, V87, P28; KLEIN PD, 1991, LANCET, V337, P1503, DOI 10.1016/0140-6736(91)93196-G; KLEIN PD, 1989, CAMPYLOBACTER PYLORI, P83; MAPSTONE NP, 1992, IRISH J MED SCI S10, V161, P29; MARSHALL B J, 1984, Microbios Letters, V25, P83; MILLER L, 1988, J BIOL CHEM, V263, P5668; SHAMES B, 1989, J CLIN MICROBIOL, V27, P2849, DOI 10.1128/JCM.27.12.2849-2850.1989; THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641, DOI 10.1128/JCM.28.12.2641-2646.1990; THOMAS JE, 1991, GUT, V32, pA1231	10	421	441	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1194	1195		10.1016/0140-6736(92)92894-L	http://dx.doi.org/10.1016/0140-6736(92)92894-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359263				2022-12-28	WOS:A1992JY38600006
J	BARKUN, JS; BARKUN, AN; SAMPALIS, JS; FRIED, G; TAYLOR, B; WEXLER, MJ; GORESKY, CA; MEAKINS, JL				BARKUN, JS; BARKUN, AN; SAMPALIS, JS; FRIED, G; TAYLOR, B; WEXLER, MJ; GORESKY, CA; MEAKINS, JL			RANDOMIZED CONTROLLED TRIAL OF LAPAROSCOPIC VERSUS MINI CHOLECYSTECTOMY	LANCET			English	Article							SURGERY; CHOICE	Laparoscopic cholecystectomy (LC) has gained wide acceptance for treatment of cholelithiasis in preference to open cholecystectomy, though it has not been formally compared with mini cholecystectomy (MC). We have compared these two techniques in a randomised trial. 70 patients with ultrasound-proven cholelithiasis were randomly allocated LC (38) or MC (32); 37 and 25, respectively, underwent the assigned procedure. The mean hospital stay (including 1 preoperative day) was significantly shorter in the LC than the MC group (median 3 [interquartile range 2-3] vs 4 [3-5], p=0.001) as was duration of convalescence (mean 11.9 [SD 9.1] vs 20.2 [16.5] days, p = 0.04). The rate of return to normal activities was 1.77 times greater in the LC group than in the MC group (95% confidence interval 1.01-3.11, p=0.03). In regression analysis, the type of cholecystectomy done was the only variable significantly associated with the duration of convalescence. Although there was significant postoperative improvement in all of three quality of life scores in both groups, LC patients improved more quickly than did MC patients. This randomised trial shows the superior effectiveness of LC over MC in treating cholelithiasis.	ROYAL VICTORIA HOSP,DEPT SURG,ROOM S1034,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV TORONTO,DEPT SURG,TORONTO M5S 1A1,ONTARIO,CANADA; MCGILL UNIV,DIV GASTROENTEROL,MONTREAL H3A 2T5,QUEBEC,CANADA; MONTREAL GEN HOSP,DIV EPIDEMIOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DIV BIOSTAT,MONTREAL H3G 1A4,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; University of Toronto; McGill University; McGill University; McGill University				Fried, Gerald/0000-0001-6434-0555				ARMSTRONG PJ, 1990, BRIT J SURG, V77, P746, DOI 10.1002/bjs.1800770709; BARKUN A N, 1992, Clinical and Investigative Medicine, V15, pA44; CAMERON JL, 1991, ANN SURG, V213, P1; CHESLYNCURTIS S, 1991, BRIT J SURG, V78, P143, DOI 10.1002/bjs.1800780206; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; EYPASCH E, 1990, THEOR SURG, V5, P3; FRAZEE RC, 1991, ANN SURG, V213, P651, DOI 10.1097/00000658-199106000-00016; GADACZ TR, 1991, AM J SURG, V161, P336, DOI 10.1016/0002-9610(91)90591-Z; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; LEDET WP, 1990, ARCH SURG-CHICAGO, V125, P1434; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; NEUGEBAUER E, 1991, BRIT J SURG, V78, P150, DOI 10.1002/bjs.1800780207; OLSEN DO, 1991, AM J SURG, V161, P339, DOI 10.1016/0002-9610(91)90592-2; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; PATERSONBROWN S, 1991, BRIT J SURG, V78, P131, DOI 10.1002/bjs.1800780203; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SALTZSTEIN EC, 1992, SURG GYNECOL OBSTET, V174, P173; SCHIRMER BD, 1991, ANN SURG, V213, P665, DOI 10.1097/00000658-199106000-00018; STEINMETZ O K, 1991, Clinical and Investigative Medicine, V14, pA51; STREINER DL, 1989, HLTH MEASUREMENT SCA, P23; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; WALSH TN, 1992, BRIT J SURG, V79, P4, DOI 10.1002/bjs.1800790103; 1991, LANCET, V338, P789; 1991, NEW ENGL J MED, V324, P1073	28	349	356	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1116	1119		10.1016/0140-6736(92)93148-G	http://dx.doi.org/10.1016/0140-6736(92)93148-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359210	Bronze			2022-12-28	WOS:A1992JX13400002
J	MATSUMURA, Y; TARIN, D				MATSUMURA, Y; TARIN, D			SIGNIFICANCE OF CD44 GENE-PRODUCTS FOR CANCER-DIAGNOSIS AND DISEASE EVALUATION	LANCET			English	Article							CELLS	With increasing emphasis on the early detection of cancer, the search is on for reliable markers that will be clinically helpful in the diagnosis of small tumours and in the assessment of their metastatic potential. This report presents evidence that an abnormal pattern of activity of the CD44 gene is a promising candidate for both of these purposes in various types of malignancy. By a mechanism known as alternative splicing this gene can produce different messenger RNA molecules (transcripts) which are detectable, after amplification, as separate bands in electrophoretic gels. In neoplasia many abnormal variant transcripts are produced. A previous finding in animal experiments, that one such variant might be important in metastasis, prompted our study of human tumour tissue, benign and malignant, and of corresponding normal tissues. We studied tumour tissue from 34 patients with neoplastic disease (mostly breast or colon cancer) and normal or non-malignant diseased breast or colonic tissue from 11 patients and peripheral blood leucocytes from 4 healthy volunteers. CD44 gene activity was studied by amplifying messenger RNA with the polymerase chain reaction (PCR) followed by electrophoresis and blot hybridisation. In malignant tissues there was gross overproduction of each of 9 or more alternatively-spliced large molecular variants in all samples, whereas in the control samples only the standard product was routinely detected with occasional minimal quantities of one or two small variants. Furthermore, the band pattern permitted differentiation between the 23 cases with metastatic tumours of the breast or colon and the 8 with no detectable metastases. Calibration studies seeding blood with tumour cells showed that the technique can detect as few as 10 tumour cells among 10(7) leucocytes (1 ml of blood). Analysis of CD44 splice variants may prove to have applications not just to the early detection of metastatic potential in surgical biopsy specimens but also, if our findings are confirmed, in readily available bodily fluids, to the early diagnosis of cancer in screening programmes, to the assessment of remaining disease in the body and to the early detection of recurrences.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND	University of Oxford			Matsumura, Yasuhiro/N-4472-2016					BIRCH M, 1991, CANCER RES, V51, P6660; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROST P, 1992, LANCET, V339, P1458, DOI 10.1016/0140-6736(92)92040-M; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HOFMANN M, 1991, CANCER RES, V51, P5292; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859	11	452	480	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1053	1058		10.1016/0140-6736(92)93077-Z	http://dx.doi.org/10.1016/0140-6736(92)93077-Z			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357452				2022-12-28	WOS:A1992JV77500002
J	KALLIONIEMI, A; KALLIONIEMI, OP; SUDAR, D; RUTOVITZ, D; GRAY, JW; WALDMAN, F; PINKEL, D				KALLIONIEMI, A; KALLIONIEMI, OP; SUDAR, D; RUTOVITZ, D; GRAY, JW; WALDMAN, F; PINKEL, D			COMPARATIVE GENOMIC HYBRIDIZATION FOR MOLECULAR CYTOGENETIC ANALYSIS OF SOLID TUMORS	SCIENCE			English	Article							BREAST-CANCER; AMPLIFICATION; PROGRESSION	Comparative genomic hybridization produces a map of DNA sequence copy number as a function of chromosomal location throughout the entire genome. Differentially labeled test DNA and normal reference DNA are hybridized simultaneously to normal chromosome spreads. The hybridization is detected with two different fluorochromes. Regions of gain or loss of DNA sequences, such as deletions, duplications, or amplifications, are seen as changes in the ratio of the intensities of the two fluorochromes along the target chromosomes. Analysis of tumor cell lines and primary bladder tumors identified 16 different regions of amplification, many in loci not previously known to be amplified.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	KALLIONIEMI, A (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT LAB MED,DIV MOLEC CYTOMETRY,SAN FRANCISCO,CA 94143, USA.		Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Kallioniemi, Anne/0000-0003-3552-8158; Sudar, Damir/0000-0002-2510-7272	NATIONAL CANCER INSTITUTE [R01CA047537, P01CA044768, U01CA047537, R01CA045919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 45919, CA 47537, CA 44768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SAKAMOTO M, COMMUNICATION; SATO T, 1990, CANCER RES, V50, P7184; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; TEYSSIER JR, 1989, CANCER GENET CYTOGEN, V37, P103, DOI 10.1016/0165-4608(89)90080-0	11	2596	2844	1	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					818	821		10.1126/science.1359641	http://dx.doi.org/10.1126/science.1359641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1359641				2022-12-28	WOS:A1992JV69200044
J	MIETTINEN, OS; FLEGEL, KM				MIETTINEN, OS; FLEGEL, KM			MEDICAL CURRICULUM AND LICENSING - STILL IN NEED OF RADICAL REVISION	LANCET			English	Editorial Material									ROYAL VICTORIA HOSP,DIV GEN INTERNAL MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3A 2T5,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University	MIETTINEN, OS (corresponding author), ROYAL VICTORIA HOSP,DEPT MED,ROOM A421,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA.								0	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					956	957		10.1016/0140-6736(92)92827-3	http://dx.doi.org/10.1016/0140-6736(92)92827-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357356				2022-12-28	WOS:A1992JT82300013
J	FARQUHARSON, J; COCKBURN, F; PATRICK, WA; JAMIESON, EC; LOGAN, RW				FARQUHARSON, J; COCKBURN, F; PATRICK, WA; JAMIESON, EC; LOGAN, RW			INFANT CEREBRAL-CORTEX PHOSPHOLIPID FATTY-ACID COMPOSITION AND DIET	LANCET			English	Article							MEMBRANE PHOSPHOLIPIDS; HUMAN-BRAIN; LINOLENATE; RATS	It has not been established whether nutrition in early infancy affects subsequent neurodevelopment and function. If there is an effect, it seems probable that the essential fatty acids and their metabolites, the major constituents of brain structure, will be the most susceptible to dietary influence. We determined the phospholipid fatty-acid composition of cerebral cortex grey matter obtained from 20 term and 2 preterm infants who had died of "cot deaths" and related results to the milk diet the infants had received. Tissues were analysed by gas chromotography. The mean weight percentage of docosahexaenoic acid was significantly greater (p < 0.02) in 5 breast-milk-fed infants (9.7%) than in 5 age-comparable formula-milk-fed infants (7.6%). In these formula-fed babies, the overall percentage of long-chain polyunsaturated fatty acids was maintained by increased incorporation of the major n-6 series fatty acids. In 1 formula-fed preterm infant, in whom the lowest concentration of cortical docosahexaenoic acid was found, the compensatory effect was only partial with both n-9 series eicosatrienoic acid or Mead acid and docosatrienoic acid also detected in the phospholipid. Supplementation of formula milks for term infants with docosahexaenoic acid and those for preterm infants with both docosahexaenoic and arachidonic acid could prove beneficial to subsequent neurodevelopment.	UNIV GLASGOW,DEPT CHILD HLTH,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND; ROYAL HOSP SICK CHILDREN,DEPT PATHOL,GLASGOW G3 8SJ,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow								ANDERSON GJ, 1990, PEDIATR RES, V27, P89, DOI 10.1203/00006450-199001000-00023; ANDING RH, 1986, LIPIDS, V21, P697, DOI 10.1007/BF02537243; CARLSON SE, 1986, J NUTR, V116, P718, DOI 10.1093/jn/116.5.718; CLANDININ M T, 1981, Progress in Lipid Research, V20, P901, DOI 10.1016/0163-7827(81)90168-5; CLANDININ MT, 1980, EARLY HUM DEV, V4, P121, DOI 10.1016/0378-3782(80)90015-8; Crawford M A, 1977, Adv Exp Med Biol, V83, P135; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARANT I, 1990, JPEN-PARENTER ENTER, V14, P42, DOI 10.1177/014860719001400142; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MARTINEZ M, 1974, PEDIATR RES, V8, P93, DOI 10.1203/00006450-197402000-00005; OBRIEN JS, 1965, J LIPID RES, V6, P545; SVENNERHOLM L, 1973, BRAIN RES, V50, P341, DOI 10.1016/0006-8993(73)90735-X; YAMAMOTO N, 1987, J LIPID RES, V28, P144; 1991, ACTA PAEDIATR SCAND, V80, P887; 1977, DHSS12 REP	15	453	478	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					810	813		10.1016/0140-6736(92)92684-8	http://dx.doi.org/10.1016/0140-6736(92)92684-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357244				2022-12-28	WOS:A1992JR16800003
J	NICHOLL, JP; BRAZIER, JE; MILNER, PC; WESTLAKE, L; KOHLER, B; WILLIAMS, BT; ROSS, B; FROST, E; JOHNSON, AG				NICHOLL, JP; BRAZIER, JE; MILNER, PC; WESTLAKE, L; KOHLER, B; WILLIAMS, BT; ROSS, B; FROST, E; JOHNSON, AG			RANDOMIZED CONTROLLED TRIAL OF COST-EFFECTIVENESS OF LITHOTRIPSY AND OPEN CHOLECYSTECTOMY AS TREATMENTS FOR GALLBLADDER STONES	LANCET			English	Article							SHOCK-WAVE LITHOTRIPSY; EXTRACORPOREAL	Inpatient extracorporeal shockwave lithotripsy for treatment of gallbladder stones has not previously been compared with open cholecystectomy in terms of cost-effectiveness. In a randomised controlled trial, 163 patients, stratified by gallstone bulk (over 4 cm3 or not), were randomised to lithotripsy or cholecystectomy (38 large-bulk and 27 small-bulk cholecystectomy; 37 large-bulk and 61 small-bulk lithotripsy) and followed up for 1 year. Both treatments gave significant health gains in terms of a reduction in episodes of biliary pain, improved perceived health status, and symptom relief, but few differences between treatments were found. There was some evidence that biliary-pain episodes were less severe after cholecystectomy. Cholecystectomy patients also had greater improvements in mean health gain for three related symptoms: vomiting, feeling sick, and fatty-food upset. However, there were no differences between groups in perceived health status. Among lithotripsy patients, health gain was not related to stone clearance. Lithotripsy was more expensive than cholecystectomy, principally because of the costs of the inpatient stay and adjuvant bile-salt therapy. Conventional lithotripsy appears at least as cost-effective as cholecystectomy for patients with small-bulk stones but less cost-effective for those with large-bulk stones. To some extent treatment choice can be guided by patient preference.	ROYAL HALLAMSHIRE HOSP,DEPT RADIOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT SURG,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield	NICHOLL, JP (corresponding author), SHEFFIELD UNIV,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,BEECH HILL RD,SHEFFIELD S10 2BX,ENGLAND.		Nicholl, Jon/B-8257-2008; brazier, john e/B-1936-2008	Brazier, John/0000-0001-8645-4780				Bardsley M J, 1992, Qual Health Care, V1, P10, DOI 10.1136/qshc.1.1.10; CHARIG CR, 1986, BRIT MED J, V292, P879, DOI 10.1136/bmj.292.6524.879; DARZI A, 1989, BRIT MED J, V299, P302, DOI 10.1136/bmj.299.6694.302; EFFRON A, 1983, AM STAT, V37, P36; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; Hunt SM, 1986, MEASURING HLTH STATU; MANLY BF, 1991, RANDOMISATION MONTE; MATHEWS JNS, 1990, BRIT MED J, V300, P230; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MILNER DC, 1989, J LITHOTRIPSY STONE, V1, P122; ROSS BR, 1991, LITHOTRIPSY RELATED, P103; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SACKMANN M, 1991, LITHOTRIPSY RELATED, P49; SACKMANN M, 1991, 4TH INT S BIL STON T; SAUERBRUCH T, 1986, NEW ENGL J MED, V314, P818, DOI 10.1056/NEJM198603273141304	15	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					801	807		10.1016/0140-6736(92)92682-6	http://dx.doi.org/10.1016/0140-6736(92)92682-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357242				2022-12-28	WOS:A1992JR16800001
J	MANDEL, MA; BOWMAN, JL; KEMPIN, SA; MA, H; MEYEROWITZ, EM; YANOFSKY, MF				MANDEL, MA; BOWMAN, JL; KEMPIN, SA; MA, H; MEYEROWITZ, EM; YANOFSKY, MF			MANIPULATION OF FLOWER STRUCTURE IN TRANSGENIC TOBACCO	CELL			English	Article							MOSAIC VIRUS-35S PROMOTER; ARABIDOPSIS-THALIANA; FLORAL DEVELOPMENT; ANTIRRHINUM-MAJUS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; GENETIC INTERACTIONS; HOMEOTIC GENES; MORPHOGENESIS; EXPRESSION	Genetic studies suggest that three homeotic functions, designated A, B, and C, act alone and together to specify the fate of floral organ primordia in distantly related dicotyledonous plant species. To test the genetic model, we have generated transgenic tobacco plants that ectopically express the AGAMOUS gene from Brassica napus, which is necessary for the C function. Flowers on the resulting plants showed homeotic transformations of sepals into carpels and petals into stamens. These phenotypes are consistent with predictions from the genetic model, show that expression of AGAMOUS is sufficient to provide ectopic C function, and demonstrate that the structure of flowers can be manipulated in a predictable manner by altering the expression of a single regulatory gene. Furthermore, the generation of the predicted transformations by ectopic expression of the Brassica gene in transgenic tobacco indicates that gene functions are interchangable between phylogenetically distant species.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California San Diego; California Institute of Technology	MANDEL, MA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Ma, Hong/W-5251-2018; Meyerowitz, Elliot M/A-7118-2009	Ma, Hong/0000-0001-8717-4422; Bowman, John/0000-0001-7347-3691	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45697, 5T32-GM07616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; DUBOIS E, 1987, GENE, V55, P265, DOI 10.1016/0378-1119(87)90286-1; EVANS PT, 1989, DEV BIOL, V136, P273, DOI 10.1016/0012-1606(89)90148-6; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HICKS GS, 1970, CAN J BOTANY, V48, P133, DOI 10.1139/b70-017; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KOLTUNOW AM, 1990, PLANT CELL, V2, P1201, DOI 10.1105/tpc.2.12.1201; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1987, ANNU REV GENET, V21, P93, DOI 10.1146/annurev.genet.21.1.93; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pruitt RE, 1987, GENETIC REGULATION D, P327; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	36	194	216	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					133	143		10.1016/0092-8674(92)90272-E	http://dx.doi.org/10.1016/0092-8674(92)90272-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356631				2022-12-28	WOS:A1992JQ62300013
J	WEST, JB; MATHIEUCOSTELLO, O				WEST, JB; MATHIEUCOSTELLO, O			STRESS FAILURE OF PULMONARY CAPILLARIES - ROLE IN LUNG AND HEART-DISEASE	LANCET			English	Review							OPERATION EVEREST-II; BASEMENT-MEMBRANES; HIGH-ALTITUDE; SEA-LEVEL; GOODPASTURES-SYNDROME; IV COLLAGEN; EDEMA; PRESSURES; EXERCISE; ULTRASTRUCTURE	Pulmonary capillaries have extremely thin walls to allow rapid exchange of respiratory gases across them. Recently it has been shown that the wall stresses become very large when the capillary pressure is raised, and in anaesthetised rabbits, ultrastructural damage to the walls is seen at pressures of 40 mm Hg and above. The changes include breaks in the capillary endothelial layer, alveolar epithelial layer, and sometimes all layers of the wall. The strength of the thin part of the capillary wall can be attributed to the type IV collagen in the extracellular matrix. Stress failure of pulmonary capillaries results in a high-permeability form of oedema, or even frank haemorrhage, and is apparently the mechanism of neurogenic pulmonary oedema and high-altitude pulmonary oedema. It also explains the exercise-induced pulmonary haemorrhage that occurs in all racehorses. Several features of mitral stenosis are consistent with stress failure. Overinflation of the lung also leads to stress failure, a common cause of increased capillary permeability in the intensive care environment. Stress failure also occurs if the type IV collagen of the capillary wall is weakened by autoantibodies as in Goodpasture's syndrome. Neutrophil elastase degrades type IV collagen and this may be the starting point of the breakdown of alveolar walls that is characteristic of emphysema. Stress failure of pulmonary capillaries is a hitherto overlooked and potentially important factor in lung and heart disease.			WEST, JB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED 0623,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NHLBI NIH HHS [HL17331-17] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHATTACHARYA J, 1982, J APPL PHYSIOL, V52, P634, DOI 10.1152/jappl.1982.52.3.634; BOREN HG, 1962, AM REV RESPIR DIS, V85, P328; CAMERON GR, 1949, J PATHOL BACTERIOL, V61, P375, DOI 10.1002/path.1700610309; CROUCH EC, 1991, LUNG SCI F, P421; DEMPSEY JA, 1984, J PHYSIOL-LONDON, V355, P161, DOI 10.1113/jphysiol.1984.sp015412; DONALD KJ, 1975, AM J MED, V59, P642, DOI 10.1016/0002-9343(75)90225-9; DREYFUSS D, 1991, ADULT RESPIRATORY DI, P433; Erickson B K, 1990, Equine Vet J Suppl, P47; FISHER RF, 1976, PROC R SOC SER B-BIO, V193, P335, DOI 10.1098/rspb.1976.0051; FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123; GEHR P, 1978, RESP PHYSIOL, V32, P121, DOI 10.1016/0034-5687(78)90104-4; GLAZIER JB, 1969, J APPL PHYSIOL, V26, P65, DOI 10.1152/jappl.1969.26.1.65; GROVES BM, 1987, J APPL PHYSIOL, V63, P521, DOI 10.1152/jappl.1987.63.2.521; HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364; HOUSTON CS, 1960, NEW ENGL J MED, V263, P478, DOI 10.1056/NEJM196009082631003; HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759; Hultgren HN., 1969, BIOMEDICINE HIGH TER, P131; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JONES JH, 1992, FASEB J, V6, pA2020; KAY JM, 1983, HUM PATHOL, V14, P451, DOI 10.1016/S0046-8177(83)80292-5; KAY JM, 1973, J PATHOL, V111, P239, DOI 10.1002/path.1711110404; MINNEAR FL, 1981, MICROVASC RES, V22, P345, DOI 10.1016/0026-2862(81)90102-3; MINNEAR FL, 1987, J APPL PHYSIOL, V63, P335, DOI 10.1152/jappl.1987.63.1.335; MOOI W, 1978, J PATHOL, V126, P189, DOI 10.1002/path.1711260402; OCALLAGHAN MW, 1987, EQUINE VET J, V19, P428, DOI 10.1111/j.2042-3306.1987.tb02636.x; PARKER JC, 1984, J APPL PHYSIOL, V57, P1809, DOI 10.1152/jappl.1984.57.6.1809; PIETRA GG, 1969, SCIENCE, V166, P1643, DOI 10.1126/science.166.3913.1643; PIPOLY DJ, 1987, BIOCHEMISTRY-US, V26, P5748, DOI 10.1021/bi00392a025; REEVES JT, 1990, RESP PHYSIOL, V80, P147, DOI 10.1016/0034-5687(90)90078-D; SARNOFF SJ, 1981, J APPL PHYSIOL, V5, P367; SCHOENE RB, 1986, JAMA-J AM MED ASSOC, V256, P63, DOI 10.1001/jama.256.1.63; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573; WAGNER PD, 1986, J APPL PHYSIOL, V61, P260, DOI 10.1152/jappl.1986.61.1.260; WELLING LW, 1972, J CLIN INVEST, V51, P1063, DOI 10.1172/JCI106898; WEST J B, 1991, American Review of Respiratory Disease, V143, pA569; WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731; WHITWELL KE, 1984, EQUINE VET J, V16, P499, DOI 10.1111/j.2042-3306.1984.tb02000.x; WIESLANDER J, 1985, ANN NY ACAD SCI, V460, P363, DOI 10.1111/j.1749-6632.1985.tb51183.x; WILLIAMSON JR, 1971, AM J PATHOL, V63, P359; YOUNES M, 1987, J APPL PHYSIOL, V62, P344, DOI 10.1152/jappl.1987.62.1.344; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	42	179	186	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					762	767		10.1016/0140-6736(92)92301-U	http://dx.doi.org/10.1016/0140-6736(92)92301-U			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356184				2022-12-28	WOS:A1992JP86900010
J	FARLOW, M; GHETTI, B; BENSON, MD; FARROW, JS; VANNOSTRAND, WE; WAGNER, SL				FARLOW, M; GHETTI, B; BENSON, MD; FARROW, JS; VANNOSTRAND, WE; WAGNER, SL			LOW CEREBROSPINAL-FLUID CONCENTRATIONS OF SOLUBLE AMYLOID BETA-PROTEIN PRECURSOR IN HEREDITARY ALZHEIMERS-DISEASE	LANCET			English	Note							CEREBRAL-HEMORRHAGE; MUTATION	In Alzheimer's disease, deposits of amyloid beta-protein are apparently derived from intracellular processing of a large precursor protein. We have measured concentrations of this precursor in cerebrospinal fluid (CSF) from six members of a family affected by presenile Alzheimer's disease associated with a point mutation of the precursor gene. One gene carrier with clinical signs of the disorder had low CSF concentrations of the precursor, similar to those of three patients with sporadic Alzheimer's disease subsequently confirmed at necropsy. Two symptom-free gene carriers had CSF precursor concentrations similar to those of non-demented controls, though the value was lower in one, who had deficits revealed on neuropsychological testing, than in the other. These findings suggest that low concentrations of soluble amyloid precursor proteins in the CSF reflect the process that results in amyloid plaque formation and vascular deposition in Alzheimer's disease.	SALK INST BIOTECHNOL IND ASSOCIATES INC,505 COAST BLVD S,LA JOLLA,CA 92037; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	Salk Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Irvine					NIA NIH HHS [P30 AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		GHETTI B, 1992, BRAIN RES, V571, P133, DOI 10.1016/0006-8993(92)90519-F; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRUBB A, 1984, NEW ENGL J MED, V311, P1547, DOI 10.1056/NEJM198412133112406; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2251; VANNOSTRAND WE, IN PRESS ANN NEUROL	10	57	61	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					453	454		10.1016/0140-6736(92)91771-Y	http://dx.doi.org/10.1016/0140-6736(92)91771-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354785				2022-12-28	WOS:A1992JJ87700005
J	GEORGE, JR; OU, CY; PAREKH, B; BRATTEGAARD, K; BROWN, V; BOATENG, E; DECOCK, KM				GEORGE, JR; OU, CY; PAREKH, B; BRATTEGAARD, K; BROWN, V; BOATENG, E; DECOCK, KM			PREVALENCE OF HIV-1 AND HIV-2 MIXED INFECTIONS IN COTE-DIVOIRE	LANCET			English	Note							POLYMERASE CHAIN-REACTION; WESTERN BLOTS; DNA	We have investigated the cause of dual serological reactivity to human immunodeficiency virus (HIV) types 1 and 2, a common occurrence in West Africa. Serum specimens from 111 individuals from cote d'Ivoire classified by commercial western blot as HIV-1 (n = 15), HIV-2 (32), and dually reactive (64) were further tested by more specific serological tests (a synthetic peptide enzyme immunoassay [Pepti-LAV 1/2] and western blots prepared from antigen in which oligomeric forms of the transmembrane protein were disrupted by trichloroacetic acid [WB-TCA]). Peripheral blood mononuclear cells were tested for HIV-1 and HIV-2 with the polymerase chain reaction (PCR) and virus culture. Of 104 samples that were concordant by both WB-TCA and Pepti-LAV, 82 (79%) were confirmed by PCR results. Virus culture was concordant with serology for specimens (35/38) in which any virus was detected. Our findings indicate that mixed HIV-1/HIV-2 infections are common in Cote d'Ivoire, and suggest that natural infection by one HIV type does not prevent heterologous infection.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,INT ACT,ATLANTA,GA 30333; PROJECT RETROCI,ABIDJAN,COTE IVOIRE	Centers for Disease Control & Prevention - USA	GEORGE, JR (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,LAB INVEST BRANCH,ATLANTA,GA 30333, USA.		Brown, Verity/X-6637-2019	Brown, Verity/0000-0001-5762-1797; PAREKH, BHARAT/0000-0002-1088-4263				DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1991, AIDS, V5, pS21; GUERN ML, 1992, P NATL ACAD SCI USA, V89, P363; JACKSON J, 1990, ARCH PATHOL LAB MED, V144, P249; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; 1989, MMWR, V38, P17	10	82	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					337	339		10.1016/0140-6736(92)91406-X	http://dx.doi.org/10.1016/0140-6736(92)91406-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353806				2022-12-28	WOS:A1992JH12500005
J	SORLIE, P; ROGOT, E; ANDERSON, R; JOHNSON, NJ; BACKLUND, E				SORLIE, P; ROGOT, E; ANDERSON, R; JOHNSON, NJ; BACKLUND, E			BLACK-WHITE MORTALITY DIFFERENCES BY FAMILY INCOME	LANCET			English	Article							NATIONAL-DEATH-INDEX; UNITED-STATES; EXCESS MORTALITY; RISK-FACTORS; DISEASE; HEALTH; RACE	Death rates among US black men and women under 75 years of age are higher than for their white counterparts. The explanation for this excess risk, though attributed to socioeconomic factors, remains unclear. We calculated mortality rates by family income for blacks and whites in a respresentative sample of the US population (National Longitudinal Mortality Study). For persons aged less than 65 years of age, mortality rates are lower in those with higher family income for both blacks and whites, and both men and women. However, at each level of income, blacks have higher mortality than whites. Higher levels of family income are also associated with lower death rates from cardiovascular disease, cancer, and deaths from causes other than cardiovascular disease or cancer. After adjustment for income, blacks have higher death rates from each of these three general causes. For subjects below 65 years, the mortality gradient by income is larger than the gradient by race. The differences in mortality rates by race not accounted for by income may be due to other differences such as access to health care, type or quality of medical care, or behavioural risk factors that disadvantage black populations.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, EPIDEMIOL SECT, WINSTON SALEM, NC 27103 USA; US BUR CENSUS, SUITLAND, MD USA	Wake Forest University; Wake Forest Baptist Medical Center	SORLIE, P (corresponding author), NHLBI, FED BLDG, ROOM 3A10, BETHESDA, MD 20892 USA.							[Anonymous], 1990, JAMA-J AM MED ASSOC, V263, P2344; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; DAYAL H, 1986, J CHRON DIS, V39, P877, DOI 10.1016/0021-9681(86)90036-6; Durkheim E, 1897, SUICIDE ETUDE SOCIOL; FARLEY R, 1971, SOC BIOL, V18, P341, DOI 10.1080/19485565.1971.9987941; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; Kaplan G.A., 1987, AM J PREVENTIVE ME S, V3, P125; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; LEE AJ, 1990, BRIT J ADDICT, V85, P1165; MANTON KG, 1987, MILBANK Q         S1, V65, P125; MASSEY DS, 1988, AM J SOCIOL, V94, P592, DOI 10.1086/229031; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; ROGOT E, 1988, NIH882896 PUB; ROMANO PS, 1991, AM J PUBLIC HEALTH, V81, P1415, DOI 10.2105/AJPH.81.11.1415; Satariano W A, 1986, Am J Prev Med, V2, P1; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SORLIE PD, 1990, AM J EPIDEMIOL, V132, P983, DOI 10.1093/oxfordjournals.aje.a115741; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SUTTON GF, 1971, SOC BIOL, V18, P369, DOI 10.1080/19485565.1971.9987944; TAEUBER KE, 1965, SCI AM, V213, P12, DOI 10.1038/scientificamerican0865-12; WALDRON I, 1989, AM J PREV MED, V5, P142, DOI 10.1016/S0749-3797(18)31095-X; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; 1989, DHHS PHS891232 PUBL; 1991, LANCET, V338, P1116; 1970, MONTHLY VITAL STATIS, V18; 1985, REPORT SECRETARY TAS; 1978, 40 S BUR CENS TECHN; 1990, DHSS PHS901148 NAT C	33	121	122	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1992	340	8815					346	350		10.1016/0140-6736(92)91413-3	http://dx.doi.org/10.1016/0140-6736(92)91413-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353813				2022-12-28	WOS:A1992JH12500012
J	SLYPER, AH				SLYPER, AH			A FRESH LOOK AT THE ATHEROGENIC REMNANT HYPOTHESIS	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; HIGH-DENSITY LIPOPROTEIN; POSTPRANDIAL LIPEMIA; MYOCARDIAL-INFARCTION; METABOLISM; CHOLESTEROL; ASSOCIATION; MEN				SLYPER, AH (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53209, USA.							ALBERS JJ, 1989, CLIN LAB MED, V9, P137, DOI 10.1016/S0272-2712(18)30646-2; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; DEGENNES JL, 1981, DIABETES METAB, V7, P161; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAMSTEN A, 1986, ATHEROSCLEROSIS, V59, P223, DOI 10.1016/0021-9150(86)90051-1; JONES HB, 1951, AM J MED, V11, P358, DOI 10.1016/0002-9343(51)90171-4; KAMEDA K, 1984, ATHEROSCLEROSIS, V5, P241; KRAUSS RM, 1987, LANCET, V2, P62; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MERRILL JR, 1989, ARTERIOSCLEROSIS, V9, P217, DOI 10.1161/01.ATV.9.2.217; MOORJANI S, 1986, METABOLISM, V35, P311, DOI 10.1016/0026-0495(86)90146-0; NIKKILA EA, 1971, ACTA MED SCAND, V190, P49; PATSCH JR, 1990, CIRCULATION, V82, P284; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; SIMPSON HS, 1990, ATHEROSCLEROSIS, V85, P193, DOI 10.1016/0021-9150(90)90111-U; SNIDERMAN A, 1991, ATHEROSCLEROSIS, V89, P109, DOI 10.1016/0021-9150(91)90050-D; SNIDERMAN AD, 1990, ARTERIOSCLEROSIS, V10, P665, DOI 10.1161/01.ATV.10.5.665; STEINER G, 1987, CIRCULATION, V75, P124, DOI 10.1161/01.CIR.75.1.124; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1984, J BIOL CHEM, V259, P9587; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	26	61	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					289	291		10.1016/0140-6736(92)92368-P	http://dx.doi.org/10.1016/0140-6736(92)92368-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353203				2022-12-28	WOS:A1992JG66500015
J	BRAHAMS, D				BRAHAMS, D			TOBACCO LITIGATION (USA, UK, AND AUSTRALIA)	LANCET			English	Editorial Material																		1992, ASH B           0616; 1992, TIMES           0625; 1992, LANCET, V339, P1406	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					230	231		10.1016/0140-6736(92)90487-N	http://dx.doi.org/10.1016/0140-6736(92)90487-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353147				2022-12-28	WOS:A1992JE75800016
J	SHEEHAN, MP; RUSTIN, MHA; ATHERTON, DJ; BUCKLEY, C; HARRIS, DJ; BROSTOFF, J; OSTLERE, L; DAWSON, A				SHEEHAN, MP; RUSTIN, MHA; ATHERTON, DJ; BUCKLEY, C; HARRIS, DJ; BROSTOFF, J; OSTLERE, L; DAWSON, A			EFFICACY OF TRADITIONAL CHINESE HERBAL THERAPY IN ADULT ATOPIC-DERMATITIS	LANCET			English	Article							ECZEMA	There has been considerable interest in traditional Chinese herbal therapy (TCHT) as a new treatment for atopic dermatitis. To establish the efficacy and safety of this treatment, a daily decoction of a formula containing ten herbs that has been found to be beneficial in open studies was tested in a double-blind placebo-controlled study. 40 adult patients with longstanding, refractory, widespread, atopic dermatitis were randomised into two groups to receive 2 months' treatment of either the active formulation of herbs (TCHT) or placebo herbs, followed by a crossover to the other treatment after a 4-week washout period. The main outcome measures were extent and severity of erythema and surface damage as judged by standardised body scores. The patients' own assessments of the overall response to treatment were also sought. The geometric mean score for erythema at the end of active treatment was 12.6 (95% confidence interval [CI] 5.9 to 22.0) and at the end of the placebo phase was 113 (65 to 180). The geometric mean score for surface damage was 11.3 (5.8 to 21.8) and 111.0 (68 to 182), respectively. The 95% CI for the mean geometric ratio for the two values with active treatment was 0.04 to 0.22 for erythema (p<0.0005) and 0.04 to 0.27 for surface damage (p<0.0005). Of the 31 patients who completed the study and expressed a preference, 20 preferred that phase of the trial in which they received TCHT whereas 4 patients preferred placebo (p<0.02). There was a subjective improvement in itching (p<0.001) and sleep (p<0.078) during the TCHT treatment phase. No side-effects were reported by the patients although many commented on the unpalatability of the decoction. TCHT seems to benefit patients with atopic dermatitis. Palatability of the treatment needs to be improved and its safety assured.	UNIV LONDON ROYAL FREE HOSP, DEPT DERMATOL, POND ST, LONDON NW3 2QG, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, DEPT IMMUNOL, LONDON, ENGLAND; HOSP SICK CHILDREN, DEPT DERMATOL, LONDON WC1N 3JH, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								ARMITAGE P, 1987, STATISTICAL METHODS; ATHERTON D, 1990, LANCET, V336, P1254, DOI 10.1016/0140-6736(90)92871-E; CARLSSON C, 1990, LANCET, V336, P1068, DOI 10.1016/0140-6736(90)92538-S; CHANG HM, 1987, PHARM APPLICATIONS C, V2, P1; CHANG HM, 1987, PHARM APPLICATIONS C, V1, P1; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; DAVIES EG, 1990, LANCET, V336, P177; EDWARDS CRW, 1991, NEW ENGL J MED, V325, P1242, DOI 10.1056/NEJM199110243251709; FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; FINLAY A, 1991, BR J DERMATOL S, V38, P16; GALLOWAY JH, 1991, LANCET, V337, P566, DOI 10.1016/0140-6736(91)91364-Z; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HEDDLE RJ, 1984, BRIT MED J, V289, P651, DOI 10.1136/bmj.289.6446.651; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; MORISON WL, 1978, BRIT J DERMATOL, V98, P25, DOI 10.1111/j.1365-2133.1978.tb07329.x; POPOCK SJ, 1983, CLIN TRIALS PRACTICA, P222; SASAKI H, 1989, PLANTA MED, P458; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; STEWART PM, 1987, LANCET, V2, P821; TEELUCKSINGH S, 1990, LANCET, V335, P1060, DOI 10.1016/0140-6736(90)92633-S; WESTON CFM, 1987, BRIT MED J, V295, P183, DOI 10.1136/bmj.295.6591.183; WU G, 1989, CHIN J INTEGR TRAD C, V9, P57	23	203	206	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1992	340	8810					13	17		10.1016/0140-6736(92)92424-E	http://dx.doi.org/10.1016/0140-6736(92)92424-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351600				2022-12-28	WOS:A1992JC35400004
J	MARX, A; KIRCHNER, T; GREINER, A; MULLERHERMELINK, HK; SCHALKE, B; OSBORN, M				MARX, A; KIRCHNER, T; GREINER, A; MULLERHERMELINK, HK; SCHALKE, B; OSBORN, M			NEUROFILAMENT EPITOPES IN THYMOMA AND ANTIAXONAL AUTOANTIBODIES IN MYASTHENIA-GRAVIS	LANCET			English	Note							EPITHELIAL-CELLS	Expression by neoplastic thymic epithelial cells of acetylcholine-receptor (AChR) epitopes is associated with the presence of AChR autoantibodies and the development of myasthenia gravis. We studied thymic tumours from patients with and without myasthenia gravis for the expression of neurofilament epitopes by immunohistochemistry with four monoclonal antibodies. There was very little antibody binding in control samples (healthy thymus, or thymitis) or in medullary and mixed thymomas, but neurofilament epitopes were strongly expressed in all cortical thymomas and thymic carcinomas. In addition, the frequency of serum autoantibodies against axons was significantly higher among myasthenic patients with thymic epithelial tumours than among age-matched controls (7/10 vs 3/50; p < 0.01).	UNIV WURZBURG,DEPT NEUROL,W-8700 WURZBURG,GERMANY; MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	University of Wurzburg; Max Planck Society	MARX, A (corresponding author), UNIV WURZBURG,INST PATHOL,JOSEF SCHNEIDER STR 2,W-8700 WURZBURG,GERMANY.							DARDENNE M, 1987, AM J PATHOL, V126, P194; GILHUS NE, 1984, J NEUROIMMUNOL, V7, P55, DOI 10.1016/S0165-5728(84)80006-5; KIRCHNER T, 1987, LANCET, V1, P218; KIRCHNER T, 1988, AM J PATHOL, V130, P268; Kirchner Thomas, 1989, PROGR SURGICAL PATHO, P167; MARX A, 1990, LAB INVEST, V62, P279; MARX A, 1989, AM J PATHOL, V134, P864; MOLL R, 1987, MORPHOLOGICAL TUMOUR, P79; MULLER KMI, 1989, J NEUROL SCI, V93, P263, DOI 10.1016/0022-510X(89)90196-2	9	27	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					707	708		10.1016/0140-6736(92)90601-X	http://dx.doi.org/10.1016/0140-6736(92)90601-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1372058				2022-12-28	WOS:A1992HK32000006
J	HAMBLIN, TJ				HAMBLIN, TJ			INDOMETHACIN, RANITIDINE, AND INTERLEUKIN-2 IN MELANOMA	LANCET			English	Letter											HAMBLIN, TJ (corresponding author), ROYAL BOURNEMOUTH HOSP,BOURNEMOUTH BH7 7DW,ENGLAND.							1992, LANCET, V340, P397	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1044	1044		10.1016/0140-6736(92)93065-U	http://dx.doi.org/10.1016/0140-6736(92)93065-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357439				2022-12-28	WOS:A1992JV01400050
J	ROGSTAD, KE; WHITE, DJ; AHMEDJUSHUF, IH				ROGSTAD, KE; WHITE, DJ; AHMEDJUSHUF, IH			EFFICACY OF LIGNOCAINE ANALGESIA DURING TREATMENT TO THE CERVIX	LANCET			English	Note							TRIAL	There is no consensus amongst physicians about the need for analgesia when a woman undergoes ablative therapy of the cervix. Many doctors believe that the discomfort felt during such procedures is insubstantial. By means of a randomised double-blind placebo-controlled trial, we have shown that patients experience considerable pain during cold-coagulation treatment of the cervix. We found that intracervical lignocaine leads to a significant (p < 0.01) reduction in this pain.			ROGSTAD, KE (corresponding author), CITY HOSP,DEPT GENITOURINARY MED,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.							BOAG FC, 1991, GENITOURIN MED, V67, P481; DODSON ME, 1985, CURRENT TOPICS ANAES, P38; Duncan I D, 1983, Clin Obstet Gynecol, V26, P996, DOI 10.1097/00003081-198312000-00022; Huskisson E., 1983, PAIN MEASUREMENT ASS, P33; JOHNSON N, 1989, BRIT J OBSTET GYNAEC, V96, P1410, DOI 10.1111/j.1471-0528.1989.tb06304.x; LEE ETC, 1986, BRIT J OBSTET GYNAEC, V93, P967, DOI 10.1111/j.1471-0528.1986.tb08017.x; MARTEAU TM, 1990, BRIT J OBSTET GYNAEC, V97, P589; 1989, LANCET, V2, P83	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					942	942		10.1016/0140-6736(92)92820-6	http://dx.doi.org/10.1016/0140-6736(92)92820-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357350				2022-12-28	WOS:A1992JT82300006
J	FRESKGARD, PO; BERGENHEM, N; JONSSON, BH; SVENSSON, M; CARLSSON, U				FRESKGARD, PO; BERGENHEM, N; JONSSON, BH; SVENSSON, M; CARLSSON, U			ISOMERASE AND CHAPERONE ACTIVITY OF PROLYL ISOMERASE IN THE FOLDING OF CARBONIC-ANHYDRASE	SCIENCE			English	Article							CIS-TRANS ISOMERASE; BINDING; CYCLOPHILIN; AGGREGATION; CATALYSIS; PROTEINS; MODELS; SITE	Several proteins have been discovered that either catalyze slow protein-folding reactions or assist folding in the cell. Prolyl isomerase, which has been shown to accelerate rate-limiting cis-trans peptidyl-proline isomerization steps in the folding pathway, can also participate in the protein-folding process as a chaperone. This function is exerted on an early folding intermediate of carbonic anhydrase, which is thereby prevented from aggregating, whereas the isomerase activity is performed later in the folding process.	LINKOPING UNIV,DEPT CHEM,INST FYS MATTEKN K,S-58183 LINKOPING,SWEDEN; UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN	Linkoping University; Umea University			Freskgård, Per-Ola/AAY-4194-2021					BERGENHEM N, 1989, INT J PEPT PROT RES, V33, P140; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARLSSON U, 1975, EUR J BIOCHEM, V52, P25, DOI 10.1111/j.1432-1033.1975.tb03969.x; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; DRAKENBERG T, 1972, J PHYS CHEM-US, V76, P2178, DOI 10.1021/j100659a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRESKGARD PO, 1991, FEBS LETT, V289, P117, DOI 10.1016/0014-5793(91)80922-P; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HENDERSON LE, 1973, ANAL BIOCHEM, V51, P288, DOI 10.1016/0003-2697(73)90477-6; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V9, P11; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; WOLFENDEN R, 1991, CHEMTRACTS BIOCH MOL, V2, P52	26	187	200	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					466	468		10.1126/science.1357751	http://dx.doi.org/10.1126/science.1357751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1357751				2022-12-28	WOS:A1992JT77500036
J	NAJARIAN, JS; CHAVERS, BM; MCHUGH, LE; MATAS, AJ				NAJARIAN, JS; CHAVERS, BM; MCHUGH, LE; MATAS, AJ			20 YEARS OR MORE OF FOLLOW-UP OF LIVING KIDNEY DONORS	LANCET			English	Article							TERM RENAL-FUNCTION; UNILATERAL NEPHRECTOMY; HYPERTENSION	The perioperative and long-term risks for living kidney donors are of concern. We have studied donors at the University of Minnesota 20 years or more (mean 23.7) after donation by comparing renal function, blood pressure, and proteinuria in donors with siblings. In 57 donors (mean age 61 [SE 1]), mean serum creatinine is 1.1 (0.01) mg/dl, blood urea nitrogen 17 (0.5) mg/dl, creatinine clearance 82 (2) ml/min, and blood pressure 134 (2)/80 (1) mm Hg. 32% of the donors are taking antihypertensive drugs and 23% have proteinuria. The 65 siblings (mean age 58 [1.3]) do not significantly differ from the donors in any of these variables: 1.1 (0.03) mg/dl, 17 (1.2) mg/dl, 89 (3.3) ml/min, and 130 (3)/80 (1.5) mm Hg, respectively. 44% of the siblings are taking antihypertensives and 22% have proteinuria. To assess perioperative mortality, we surveyed all members of the American Society of Transplant Surgeons about donor mortality at their institutions. We documented 17 perioperative deaths in the USA and Canada after living donation, and estimate mortality to be 0.03%. We conclude that perioperative mortality in the USA and Canada after living-donor nephrectomy is low. In long-term follow-up of our living donors, we found no evidence of progressive renal deterioration or other serious disorders.	UNIV MINNESOTA,DEPT SURG,BOX 328,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			matas, arthur/ABE-1018-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK013083] Funding Source: NIH RePORTER; NIDDK NIH HHS [5P01-DK 13083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen B, 1968, Scand J Urol Nephrol, V2, P91, DOI 10.3109/00365596809136977; ANDERSON CF, 1985, MAYO CLIN PROC, V60, P367, DOI 10.1016/S0025-6196(12)60845-3; ANDERSON RG, 1991, J UROLOGY, V145, P11, DOI 10.1016/S0022-5347(17)38232-0; BAY WH, 1987, ANN INTERN MED, V106, P719, DOI 10.7326/0003-4819-106-5-719; BENNETT AH, 1974, SURG GYNECOL OBSTET, V139, P894; BONER G, 1973, AM J MED, V55, P169, DOI 10.1016/0002-9343(73)90165-4; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; CHANUBIN M, 1932, ARCH INTERN MED, V49, P767; Cho Y W, 1989, Clin Transpl, P325; DOWIE M, 1988, WE HAVE DONOR BOLD N, P52; DUNN JF, 1986, ANN SURG, V203, P637, DOI 10.1097/00000658-198606000-00008; HAKIM RM, 1984, KIDNEY INT, V25, P930, DOI 10.1038/ki.1984.112; KJELLSTRAND CM, 1972, TRANSPLANTATION, P418; LADEFOGED J, 1992, LANCET, V339, P124, DOI 10.1016/0140-6736(92)91034-6; LEARY FJ, 1973, J UROLOGY, V109, P947, DOI 10.1016/S0022-5347(17)60589-5; MILLER IJ, 1985, AM J MED, V79, P201, DOI 10.1016/0002-9343(85)90010-5; RINGDEN O, 1978, TRANSPLANTATION, V25, P221, DOI 10.1097/00007890-197804000-00013; ROBERTS J, 1975, VITAL HLTH STATIS 11, V203; ROBITAILLE P, 1985, LANCET, V1, P1297; SHIMAMURA T, 1975, AM J PATHOL, V79, P95; SMITH MJV, 1973, J UROLOGY, V110, P158, DOI 10.1016/S0022-5347(17)60146-0; SPITAL A, 1988, TRANSPLANTATION, V45, P819; STARZL TE, 1987, TRANSPLANT P, V19, P174; TALSETH T, 1986, KIDNEY INT, V29, P1072, DOI 10.1038/ki.1986.109; TAPSON JS, 1986, NEPHRON, V42, P262, DOI 10.1159/000183678; UEHLING DT, 1974, J UROLOGY, V111, P745, DOI 10.1016/S0022-5347(17)60061-2; VINCENTI F, 1983, TRANSPLANTATION, V36, P626, DOI 10.1097/00007890-198336060-00006; WATNICK TJ, 1988, TRANSPLANTATION, V45, P59; WEILAND D, 1984, TRANSPL P, V16, P5; WILLIAMS SL, 1986, ANN INTERN MED, V105, P1, DOI 10.7326/0003-4819-105-1-1; 1991, UNOS UPDATE, V17; 1991, USRDS1991 NIH NAT I; 1985, HYPERTENSION, V7, P457	33	497	506	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					807	810		10.1016/0140-6736(92)92683-7	http://dx.doi.org/10.1016/0140-6736(92)92683-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357243				2022-12-28	WOS:A1992JR16800002
J	HACHINSKI, V				HACHINSKI, V			PREVENTABLE SENILITY - A CALL FOR ACTION AGAINST THE VASCULAR DEMENTIAS	LANCET			English	Review							MULTI-INFARCT DEMENTIA; CEREBRAL BLOOD-FLOW; MULTIINFARCT DEMENTIA; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; PREVALENCE				HACHINSKI, V (corresponding author), UNIV WESTERN ONTARIO,UNIV HOSP,DEPT CLIN NEUROL SCI,339 WINDERMERE RD,LONDON N6A 5A5,ONTARIO,CANADA.							ALZHEIMER A, 1899, NEUROL ZENTRALBLATT, V18, P95; [Anonymous], ALZHEIMERS DIS; BARNETT HJM, 1992, CEREBRAL ISCHEMIA AD; BORSTIN DJ, CITED INDIRECTLY; BROWN WD, 1991, ALZ DIS ASSOC DIS, V5, P131, DOI 10.1097/00002093-199100520-00010; BRUST JCM, 1988, ARCH NEUROL-CHICAGO, V45, P799, DOI 10.1001/archneur.1988.00520310117026; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; DIAZ F, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P9; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FEHER EP, 1992, ARCH NEUROL-CHICAGO, V49, P87, DOI 10.1001/archneur.1992.00530250091022; FEIN G, 1990, ARCH GEN PSYCHIAT, V47, P220; Fisher C, 1968, CEREBRAL VASCULAR DI, P232; FORSTL H, 1991, INT J GERIATR PSYCH, V6, P757; FRACKOWIAK RSJ, 1981, BRAIN, V104, P753, DOI 10.1093/brain/104.4.753; HACHINSKI J, 1978, ALZHEIMERS DISEASE S, P97; HACHINSKI V, 1991, J NEUROL SCI, V103, P1, DOI 10.1016/0022-510X(91)90274-B; HACHINSKI V, 1987, ARCH NEUROL-CHICAGO, V44, P42; HACHINSKI VC, 1974, LANCET, V2, P207; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KASE CS, 1991, ALZ DIS ASSOC DIS, V5, P71, DOI 10.1097/00002093-199100520-00004; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYER JS, 1989, J AM GERIATR SOC, V37, P549, DOI 10.1111/j.1532-5415.1989.tb05688.x; MUNOZ DG, 1991, ALZ DIS ASSOC DIS, V5, P77, DOI 10.1097/00002093-199100520-00005; NARITOMI H, 1991, ALZ DIS ASSOC DIS, V5, P103, DOI 10.1097/00002093-199100520-00007; NORRIS JW, 1991, PREVENTION STROKE; POGUE FC, 1966, ORDEAL HOPE; ROGER J, 1991, DO IT LETS GET OFF O, P404; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; VALENTINE AR, 1980, J NEUROL NEUROSUR PS, V43, P139, DOI 10.1136/jnnp.43.2.139; WADE JPH, 1987, ARCH NEUROL-CHICAGO, V44, P24, DOI 10.1001/archneur.1987.00520130016010; 1976, ECONOMIST       0814, P14	34	195	202	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					645	648						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JM851	1355217				2022-12-28	WOS:A1992JM85100010
J	PELTOLA, H; KILPI, T; ANTTILA, M				PELTOLA, H; KILPI, T; ANTTILA, M			RAPID DISAPPEARANCE OF HAEMOPHILUS-INFLUENZAE TYPE-B MENINGITIS AFTER ROUTINE CHILDHOOD IMMUNIZATION WITH CONJUGATE VACCINES	LANCET			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; MEMBRANE-PROTEIN; FIELD TRIAL; EFFICACY; INFANTS; CHILDREN; FINLAND; AGE	Mortality from meningitis caused by Haemophilus influenzae type b (Hib), a disease that affects mainly infants and young children, can reach 5% in industrialised countries and ten times that in non-industrialised countries. To determine the efficacy of vaccination against Hib, we carried out a retrospective survey of the incidence of Hib meningitis over five decades in the Greater Helsinki area of Finland, where all children with bacterial meningitis are treated in one of three centres. Except for a meningococcal epidemic in the early 1970s, Hib was the leading cause of childhood bacterial meningitis until the Hib conjugate vaccines changed the picture profoundly. In 1986-87 the polysaccharide-diphtheria toxoid conjugate (PRP-D) was given experimentally to 50% of infants. In 1988-89 all infants were vaccinated, 50% with PRP-D, 50% with another conjugate vaccine, the oligosaccharide-CRM197 protein conjugate (HbOC). Since 1990 a third conjugate vaccine, the polysaccharide-tetanus toxoid (PRP-T), has been administered routinely to all infants. The vaccines were administered at age 3-6 months, with a booster dose at 14-18 months. In the first 5 years of the Hib vaccination programme the number of cases of Hib meningitis in children aged 0-4 years fell sharply, from 30 in 1986 (the first year of the programme) to none in 1991. The decline contrasts sharply with the rising trend up to the mid 1980s. Vaccination seems to be the only explanation for the observed change in the epidemiology of Hib meningitis.	AURORA CITY HOSP,HELSINKI,FINLAND; NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND	Finland National Institute for Health & Welfare	PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,11 STENBACKINKATU,SF-00290 HELSINKI 29,FINLAND.							ANDERSON PW, 1989, J IMMUNOL, V142, P2464; BIJLMER HA, 1991, VACCINE, V9, pS5, DOI 10.1016/0264-410X(91)90172-3; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; ESKOLA J, 1991, VACCINE, V9, pS14, DOI 10.1016/0264-410X(91)90174-5; FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009; FORSSELL P, 1967, LEIRAKSEN JULKAISUJA, V17, P137; GORDON LK, 1984, MODERN APPROACHES VA, P393; KAUHTIO J, 1958, Ann Paediatr Fenn, V4, P42; KAYHTY H, 1991, AM J DIS CHILD, V145, P223; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KOSKINIEMI M, 1978, ACTA PAEDIATR SCAND, V67, P17, DOI 10.1111/j.1651-2227.1978.tb16271.x; MAKELA PH, 1977, J INFECT DIS, V136, pS43; MARBURG S, 1986, J AM CHEM SOC, V108, P5282, DOI 10.1021/ja00277a037; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; PELTOLA H, 1989, LANCET, V1, P1281; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; 1990, MORBID MORTAL WKLY R, V39, P924	25	284	291	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					592	594		10.1016/0140-6736(92)92117-X	http://dx.doi.org/10.1016/0140-6736(92)92117-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355165				2022-12-28	WOS:A1992JM33400014
J	FISHERHOCH, SP; PEREZORONOZ, GI; JACKSON, EL; HERMANN, LM; BROWN, BG				FISHERHOCH, SP; PEREZORONOZ, GI; JACKSON, EL; HERMANN, LM; BROWN, BG			FILOVIRUS CLEARANCE IN NONHUMAN-PRIMATES	LANCET			English	Article							EBOLA; MONKEYS; VIRUS	There has been concern in the USA and Europe about filovirus outbreaks in recently imported monkeys, and possible transmission to human beings. Healthy monkeys have been found to have low-titre immunofluorescence antibody (IFA) to Asian filoviruses (Reston and Pennsylvania viruses) as well as to the African filoviruses that caused fulminating human outbreaks in the 1970s (Ebola [Zaire] and Sudan viruses). We have assessed whether such monkeys are a risk to man. We studied 42 non-human primates; 31 were experimentally infected with African and Asian filoviruses, 6 were infected during a documented Reston filovirus outbreak, and 5 had serological evidence suggestive of recent filovirus infection. During the first 15 days after infection, virus could be routinely recovered from serum or biopsy or necropsy tissue, and Asian filovirus RNA could be detected by polymerase chain reaction. 20 to 600 days after challenge, filovirus could no longer be recovered nor viral RNA detected in 141 serum, liver, spleen, or kidney specimens. Animals surviving filovirus infection develop high-titre, cross-reacting filovirus-specific antibody 14 to 21 days after infection, and this coincides with virus clearance. Healthy monkeys with low-titre filovirus antibody may be regarded as uninfected.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,ANIM RESOURCES BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1978, Bull World Health Organ, V56, P271; FISHERHOCH SP, IN PRESS J INFECT DI; HENRICKSON RV, 1983, LANCET, V2, P388; HEYMANN DL, 1980, J INFECT DIS, V142, P372, DOI 10.1093/infdis/142.3.372; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON BK, 1982, T ROY SOC TROP MED H, V76, P307, DOI 10.1016/0035-9203(82)90175-4; MARTINI G A, 1971, P1; MIRANDA MEG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91199-5; SANCHEZ A, 1992, J GEN VIROL, V73, P347, DOI 10.1099/0022-1317-73-2-347; STEGALL MD, 1989, TRANSPLANTATION, V48, P944, DOI 10.1097/00007890-198912000-00009; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407; 1990, MMWR, V39, P296; 1978, B WEHO, V56, P247; 1992, WEEKLY EPIDEMIOL REP, V67, P142; 1989, MMWR, V38, P831; 1990, MMWR, V39, P22	16	29	29	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					451	453		10.1016/0140-6736(92)91770-9	http://dx.doi.org/10.1016/0140-6736(92)91770-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354784				2022-12-28	WOS:A1992JJ87700004
J	SPITERI, MA; KLENERMAN, P; SHEPPARD, MN; PADLEY, S; CLARK, TJK; NEWMANTAYLOR, A				SPITERI, MA; KLENERMAN, P; SHEPPARD, MN; PADLEY, S; CLARK, TJK; NEWMANTAYLOR, A			SEASONAL CRYPTOGENIC ORGANIZING PNEUMONIA WITH BIOCHEMICAL CHOLESTASIS - A NEW CLINICAL ENTITY	LANCET			English	Article							OBLITERANS-ORGANIZING PNEUMONIA; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE	The term crytogenic organising pneumonia has been used for the combination of dyspnoea, cough, pleuritic pain, widespread shadows on chest radiographs, and histological evidence of intra-alveolar organisation with buds of granulation tissue within the alveoli. We report 12 patients with seasonal recurrence of this disorder for between 3 and 11 years. In all 12 patients, symptoms recurred between late February and early May every year, tending to increase in severity each year, and resolved between June and January. Chest radiography and computed tomography showed bilateral consolidation. Lung biopsy samples showed intra-alveolar buds of granulation tissue. There were many neutrophils within the lumina of medium-sized airways and terminal bronchioles showed evidence of obstruction by granulation tissue. Functionally, the predominant defect was restrictive and only 2 patients (life-long non-smokers) had airflow limitation. All 12 patients had very high activities of liver enzymes, suggesting intrahepatic cholestasis, but no other evidence of liver disease. Cultures of blood, sputum, lung tissue, and bronchoalveolar lavage fluid, viral screening, and complement fixation tests were consistently negative. In all patients all abnormalities responded rapidly to oral steroid therapy. These findings suggest a seasonal syndrome of organising pneumonia and biochemical abnormalities indicative of intrahepatic cholestasis. No aetiological factor has been identified, but the nature and periodicity of the illness point to an inhaled agent present in the environment for a limited period every year.	ROYAL BROMPTON HOSP,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	Royal Brompton Hospital; Imperial College London			Sheppard, Mary N/AAB-3364-2019	Sheppard, Mary N/0000-0003-2724-3881; klenerman, paul/0000-0003-4307-9161				BELSEY R, 1960, BRIT J DIS CHEST, V54, P342, DOI 10.1016/S0007-0971(60)80068-X; BONKOWSKY HL, 1975, JAMA-J AM MED ASSOC, V1284, P233; CORDIER JF, 1989, CHEST, V96, P999, DOI 10.1378/chest.96.5.999; DAVISON AG, 1983, Q J MED, V207, P382; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; FORCE MLG, 1987, AM REV RESPIR DIS, V133, P705; HASLAM P L, 1987, European Journal of Respiratory Diseases Supplement, V71, P120; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; Laennec Rene-Theophile-Hyacinthe, 1826, TRAITE AUSCULTATION, V1; MCCARTHY D S, 1973, Clinical Allergy, V3, P339, DOI 10.1111/j.1365-2222.1973.tb01341.x; MCLOUD TC, 1986, RADIOLOGY, V159, P1; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; NEVILLE E, 1975, POSTGRAD MED J, V51, P361, DOI 10.1136/pgmj.51.596.361; Nishimura K, 1989, Rinsho Hoshasen, V34, P127; PEYROL S, 1990, AM J PATHOL, V137, P155; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; RUDD RM, 1981, AM REV RESPIR DIS, V124, P1; SULAVIK SB, 1989, CHEST, V96, P967, DOI 10.1378/chest.96.5.967; TESCHLER H, 1991, American Review of Respiratory Disease, V143, pA53; WOODHEAD MA, 1987, LANCET, V1, P671	20	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					281	284		10.1016/0140-6736(92)92366-N	http://dx.doi.org/10.1016/0140-6736(92)92366-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353201				2022-12-28	WOS:A1992JG66500013
J	KAELBLING, M; BURK, RD; ATKIN, NB; JOHNSON, AB; KLINGER, HP				KAELBLING, M; BURK, RD; ATKIN, NB; JOHNSON, AB; KLINGER, HP			LOSS OF HETEROZYGOSITY ON CHROMOSOME-17P AND MUTANT P53 IN HPV-NEGATIVE CERVICAL CARCINOMAS	LANCET			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; LUNG-CANCER; SUPPRESSION; MUTATIONS	Inactivation of the protein product of the wild-type tumour suppressor gene p53 through complexing of the protein with the E6 oncoprotein of human papillomaviruses (HPV) in HPV-infected cells is thought to be important in the aetiology of cervical carcinoma. Mutations of p53 have also been reported in HPV-negative carcinomas, and we now demonstrate loss of heterozygosity (LOH) of chromosome region 17p13 (in which p53 is located) in such tumours. Immunocytochemical staining with monoclonal antimutant-p53 antibody revealed that the carcinomas with LOH on 17p and completely lacking HPV DNA sequences had mutant p53. Thus the LOH had apparently resulted in the loss of the wild-type allele. Consequently, in both HPV-positive and HPV-negative tumours there is loss of function of wild-type p53, in the former because the protein product of the p53 gene complexes with that of the viral E6 gene, in the latter because the protein is altered, presumably as a result of a direct alteration of the p53 gene but possibly because of other posttranslational changes. That this mutant allele of the tumour suppressor gene may sometimes behave like an oncogene is suggested by the presence of more than the expected number of copies of the remaining chromosome 17 homologue in some carcinomas.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; MT VERNON HOSP,DEPT CANC RES,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA051395] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330, CA 51395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1988, CYTOGENET CELL GENET, V47, P106, DOI 10.1159/000132521; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CROOK T, 1991, ONCOGENE, V6, P873; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KAELBLING M, 1986, CYTOGENET CELL GENET, V41, P65, DOI 10.1159/000132206; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	12	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					140	142		10.1016/0140-6736(92)93214-8	http://dx.doi.org/10.1016/0140-6736(92)93214-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352566				2022-12-28	WOS:A1992JE38200003
J	MAYER, RJ; LANDON, M; LASZLO, L; LENNOX, G; LOWE, J				MAYER, RJ; LANDON, M; LASZLO, L; LENNOX, G; LOWE, J			PROTEIN PROCESSING IN LYSOSOMES - THE NEW THERAPEUTIC TARGET IN NEURODEGENERATIVE DISEASE	LANCET			English	Review							ALZHEIMERS-DISEASE; CULTURED-CELLS; UBIQUITIN; SCRAPIE; SYSTEM; FIBROBLASTS; BRAINS; IMMUNOREACTIVITY; ACCUMULATE; NEURITES	A little recognised feature of neurons is their large complement of lysosomes. Studies of the accumulation of the abnormal isoform of the prion protein (PrPSC) in the prion encephalopathies and the formation of beta/A4 protein from its precursor in Alzheimer's disease suggest that generation of these key proteins takes place in lysosome-related organelles. The release of hydrolytic enzymes from lysosomes may be a primary cause of neuronal damage. Although molecular genetic approaches have identified protein mutations central to the main neurodegenerative disease, cell biological observations are now beginning to unravel the intracellular pathways involved in the molecular pathogenesis of neurodegeneration: as a result, it is now appropriate to consider therapeutic manipulation of the lysosomal system as an approach to treatment.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT NEUROL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	MAYER, RJ (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT BIOCHEM,NOTTINGHAM NG7 2UH,ENGLAND.		László, Lajos/AAG-2098-2020	László, Lajos/0000-0002-2114-9109; Lowe, James/0000-0002-9856-1599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CHAING HL, 1989, SCIENCE, V246, P282; COLE GM, 1987, NEUROSCI LETT, V79, P207, DOI 10.1016/0304-3940(87)90698-7; DAVIS JQ, 1986, J BIOL CHEM, V261, P5368; DICKSON DW, 1990, LAB INVEST, V63, P87; DICKSON DW, 1990, ACTA NEUROPATHOL, V79, P486, DOI 10.1007/BF00296107; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HOLZMANN E, 1989, LYSOSOMES; HSAIO KK, 1990, SCIENCE, V250, P1587; IRONSIDE JW, 1992, NEUROPATHOL APPL NEU, V18, P295; KAWAI M, 1992, AM J PATHOL, V140, P947; LASZLO L, 1991, J PATHOL, V164, P203; LASZLO L, 1991, FEBS LETT, V279, P175, DOI 10.1016/0014-5793(91)80142-P; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LOWE J, 1990, J PATHOL, V162, P61, DOI 10.1002/path.1711620112; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; LOWE J, 1990, NEUROPATH APPL NEURO, V16, P281, DOI 10.1111/j.1365-2990.1990.tb01263.x; LOWE J, IN PRESS J PATHOL; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MIGHELI A, 1991, NEUROSCI LETT, V121, P55, DOI 10.1016/0304-3940(91)90648-D; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; SUENAGA T, 1990, ANN NEUROL, V28, P174, DOI 10.1002/ana.410280210; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; WRIGHT AF, 1991, NATURE, V349, P653, DOI 10.1038/349653a0	35	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					156	159		10.1016/0140-6736(92)93224-B	http://dx.doi.org/10.1016/0140-6736(92)93224-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352574				2022-12-28	WOS:A1992JE38200012
J	DEWAEGH, SM; LEE, VMY; BRADY, ST				DEWAEGH, SM; LEE, VMY; BRADY, ST			LOCAL MODULATION OF NEUROFILAMENT PHOSPHORYLATION, AXONAL CALIBER, AND SLOW AXONAL-TRANSPORT BY MYELINATING SCHWANN-CELLS	CELL			English	Article							HEREDITARY HYPERTROPHIC NEUROPATHY; MONOCLONAL-ANTIBODIES DISTINGUISH; MOTOR NEURON DISEASE; TREMBLER MOUSE; MAMMALIAN NEUROFILAMENTS; CYTOSKELETAL PROTEINS; STRUCTURAL PROTEINS; GENE-EXPRESSION; GANGLION-CELLS; SCIATIC-NERVE	Studies in Trembler and control mice demonstrated that myelinating Schwann cells exert a profound influence on axons. Extensive contacts between myelin and axons have been considered structural. However, demyelination decreases neurofilament phosphorylation, slow axonal transport, and axonal diameter, as well as significantly increasing neurofilament density. In control sciatic nerves with grafted Trembler nerve segments, these changes were spatially restricted: they were confined to axon segments without normal myelination. Adjacent regions of the same axons had normal diameters, neurofilament phosphorylation, cytoskeletal organization, and axonal transport rates. Close intercellular contacts between myelinating Schwann cells and axons modulate a kinase-phosphatase system acting on neurofilaments and possibly other substrates. Myelination by Schwann cells sculpts the axon-altering functional architecture, electrical properties, and neuronal morphologies.	UNIV PENN,SCH MED,DEPT PATHOL,MED LAB,PHILADELPHIA,PA 19104	University of Pennsylvania	DEWAEGH, SM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.				NINDS NIH HHS [NS23868, NS23320, NS18616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023868, R01NS023320, R01NS018616, R01NS023868] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; BERTHOLD CH, 1982, AXOPLASMIC TRANSPORT, P40; BIZZI A, 1986, ACTA NEUROPATHOL, V71, P154, DOI 10.1007/BF00687978; Brady ST, 1982, AXOPLASMIC TRANSPORT, P206; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDEN MJ, 1987, NEUROCHEM PATHOL, V7, P189; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P15; CZOSNEK H, 1980, J CELL BIOL, V85, P726, DOI 10.1083/jcb.85.3.726; DEWAEGH S, 1990, J NEUROSCI, V10, P1855; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; Griffin JW, 1988, INTRINSIC DETERMINAN, P403; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J NEUROSCI, V5, P2920; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; JOHNSON GVW, 1988, BRAIN RES, V456, P95, DOI 10.1016/0006-8993(88)90350-2; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasec R, 1988, INTRINSIC DETERMINAN, P1; LASEK RJ, 1983, COLD SPRING HARB SYM, V48, P731, DOI 10.1101/SQB.1983.048.01.076; LEE VMY, 1986, J NEUROSCI, V6, P2179; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; LOW PA, 1976, J NEUROL SCI, V30, P343, DOI 10.1016/0022-510X(76)90139-8; LOW PA, 1976, J NEUROL SCI, V30, P327, DOI 10.1016/0022-510X(76)90138-6; LOW PA, 1975, J NEUROL SCI, V26, P565, DOI 10.1016/0022-510X(75)90057-X; MCQUARRIE IG, 1986, J NEUROSCI, V6, P1593; MEDORI R, 1988, J NEUROSCI, V8, P1814; MEDORI R, 1988, NEUROLOGY, V38, P59; MONACO S, 1989, NEUROPATHOLOGY, V48, P26; NIXON RA, 1986, J BIOL CHEM, V261, P6298; OBLINGER MM, 1988, J NEUROSCI, V8, P1747; OBLINGER MM, 1987, J NEUROSCI, V7, P453; PAGGI P, 1987, J NEUROSCI, V7, P2397; PARHAD I, 1987, AXONAL TRANSPORT, P473; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; SCHMIDT ML, 1987, LAB INVEST, V56, P282; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; TASHIRO T, 1987, AXONAL TRANSPORT, P201; TOYOSHIMA I, 1989, J NEUROL SCI, V89, P269, DOI 10.1016/0022-510X(89)90028-2; TRAPP BD, 1990, ANN NY ACAD SCI, V605, P29, DOI 10.1111/j.1749-6632.1990.tb42378.x; WATSON DF, 1989, J NEUROCHEM, V53, P1818, DOI 10.1111/j.1471-4159.1989.tb09248.x; WILLARD M, 1983, CELL, V35, P551, DOI 10.1016/0092-8674(83)90189-7; WONG J, 1987, METAB BRAIN DIS, V2, P291, DOI 10.1007/BF00999699	55	649	652	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					451	463		10.1016/0092-8674(92)90183-D	http://dx.doi.org/10.1016/0092-8674(92)90183-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1371237				2022-12-28	WOS:A1992HD39800007
J	SMITH, CH; ATKINSON, B; MORRIS, RW; HAYES, N; FOREMAN, JC; LEE, TH				SMITH, CH; ATKINSON, B; MORRIS, RW; HAYES, N; FOREMAN, JC; LEE, TH			CUTANEOUS RESPONSES TO VASOACTIVE INTESTINAL POLYPEPTIDE IN CHRONIC IDIOPATHIC URTICARIA	LANCET			English	Note							GENE-RELATED PEPTIDE; HUMAN-SKIN; SUBSTANCE-P	Cutaneous wheal and flare responses to increasing concentrations of calcitonin gene-related peptide, substance P, neurokinin A, vasoactive intestinal polypeptide (VIP), compound 48/80, and phosphate-buffered saline were measured in 10 patients with chronic idiopathic urticaria and 10 healthy controls. A significant increase in VIP-induced wheal, but not flare or cutaneous blood flow, was seen in urticarial patients compared with controls (p < 0.001). No significant differences in responses to other tested compounds were found between these groups. These data point to an increased sensitivity of microvasculature to VIP in patients with chronic idiopathic urticaria.	GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND; GUYS HOSP,DEPT PUBL HLTH MED,LONDON SE1 9RT,ENGLAND; UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London			Lee, Tak/AAA-9526-2020; Smith, Catherine H./G-5268-2012	Lee, Tak/0000-0002-7554-4059; Smith, Catherine H./0000-0001-9918-1144; Morris, Richard/0000-0001-7240-4563				ANAND P, 1983, BRIT J PHARMACOL, V78, P665, DOI 10.1111/j.1476-5381.1983.tb09418.x; BJORKLUND H, 1986, CELL TISSUE RES, V243, P51; CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; FOREMAN JC, 1987, INT ARCH ALLER A IMM, V82, P366, DOI 10.1159/000234229; HERNANZ A, 1989, INT ARCH ALLER A IMM, V90, P198, DOI 10.1159/000235024; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; TOREBJORK HE, 1974, BRAIN RES, V67, P387, DOI 10.1016/0006-8993(74)90489-2; WALLENGREN J, 1987, ARCH DERMATOL RES, V279, P512, DOI 10.1007/BF00413281; 1991, LANCET, V337, P886	10	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					91	93		10.1016/0140-6736(92)91000-X	http://dx.doi.org/10.1016/0140-6736(92)91000-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1370236				2022-12-28	WOS:A1992GZ15600004
J	MCKENNA, R; XIA, D; WILLINGMANN, P; ILAG, LL; KRISHNASWAMY, S; ROSSMANN, MG; OLSON, NH; BAKER, TS; INCARDONA, NL				MCKENNA, R; XIA, D; WILLINGMANN, P; ILAG, LL; KRISHNASWAMY, S; ROSSMANN, MG; OLSON, NH; BAKER, TS; INCARDONA, NL			ATOMIC-STRUCTURE OF SINGLE-STRANDED-DNA BACTERIOPHAGE-PHI-X174 AND ITS FUNCTIONAL IMPLICATIONS	NATURE			English	Article							CELL-WALL LIPOPOLYSACCHARIDE; TOBACCO MOSAIC-VIRUS; BUSHY STUNT VIRUS; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; ANTIVIRAL AGENTS; PROTEIN; PHI-X174; ECLIPSE	The mechanism of DNA ejection, viral assembly and evolution are related to the structure of bacteriophage PHI-X174. The F protein forms a T = 1 capsid whose major folding motif is the eight-stranded antiparallel-beta-barrel found in many other icosahedral viruses. Groups of 5 G proteins form 12 dominating spikes that enclose a hydrophilic channel containing some diffuse electron density. Each G protein is a tight-beta-barrel with its strands running radially outwards and with a topology similar to that of the F protein. The 12 'pilot' H proteins per virion may be partially located in the putative ion channel. The small, basic J protein is associated with the DNA and is situated in an interior cleft of the F protein. Tentatively, there are three regions of partially ordered DNA structure, accounting for about 12% of the total genome.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Tennessee System; University of Tennessee Health Science Center				, Timothy/0000-0001-6543-8968	NIGMS NIH HHS [R37 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; AOYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P7285, DOI 10.1073/pnas.78.12.7285; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P4855, DOI 10.1021/bi00234a004; BLOOMER AC, 1978, NATURE, V276, P362, DOI 10.1038/276362a0; BROWN DT, 1971, J VIROL, V7, P836, DOI 10.1128/JVI.7.6.836-846.1971; BURGESS AB, 1969, P NATL ACAD SCI USA, V64, P613, DOI 10.1073/pnas.64.2.613; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHAPMAN MS, 1991, J MOL BIOL, V217, P455, DOI 10.1016/0022-2836(91)90749-V; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; Cohen S S, 1979, Adv Virus Res, V24, P331, DOI 10.1016/S0065-3527(08)60397-8; DONIGER J, 1969, VIROLOGY, V39, P389, DOI 10.1016/0042-6822(69)90086-5; DOWELL CE, 1981, VIROLOGY, V114, P252, DOI 10.1016/0042-6822(81)90271-3; EDGELL MH, 1969, J MOL BIOL, V42, P547, DOI 10.1016/0022-2836(69)90242-3; EIGNER J, 1963, J MOL BIOL, V6, P61, DOI 10.1016/S0022-2836(63)80082-0; FEIGE U, 1976, BIOCHEM BIOPH RES CO, V71, P566, DOI 10.1016/0006-291X(76)90824-X; FUJISAWA H, 1977, J VIROL, V23, P439, DOI 10.1128/JVI.23.2.439-442.1977; GIBSON TJ, 1990, J MOL BIOL, V212, P7, DOI 10.1016/0022-2836(90)90298-Z; GODSON GN, 1978, SINGLE STRANDED DNA, P51; GODSON GN, 1978, SINGLE STRANDED DNA, P103; HALL CE, 1959, J MOL BIOL, V1, P192, DOI 10.1016/S0022-2836(59)80050-4; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; HUBER R, 1983, BIOPOLYMERS, V22, P261, DOI 10.1002/bip.360220136; INCARDONA NL, 1974, J VIROL, V14, P469, DOI 10.1128/JVI.14.3.469-478.1974; INCARDONA NL, 1973, J VIROL, V11, P775, DOI 10.1128/JVI.11.5.775-782.1973; INCARDONA NL, 1985, J MOL BIOL, V181, P479, DOI 10.1016/0022-2836(85)90421-8; JAZWINSKI SM, 1975, VIROLOGY, V66, P268, DOI 10.1016/0042-6822(75)90197-X; JAZWINSKI SM, 1975, VIROLOGY, V66, P294, DOI 10.1016/0042-6822(75)90199-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LAU PCK, 1985, GENE, V40, P273, DOI 10.1016/0378-1119(85)90050-2; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; MANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P2041, DOI 10.1080/00021369.1982.10865381; MATTHEWS BW, 1985, METHOD ENZYMOL, V115, P397; MUKAI R, 1979, P NATL ACAD SCI USA, V76, P4877, DOI 10.1073/pnas.76.10.4877; NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490; NEWBOLD JE, 1970, J VIROL, V5, P427, DOI 10.1128/JVI.5.4.427-431.1970; NEWBOLD JE, 1970, J MOL BIOL, V49, P49, DOI 10.1016/0022-2836(70)90375-X; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; ROSSMANN MG, 1988, P NATL ACAD SCI USA, V85, P4625, DOI 10.1073/pnas.85.13.4625; ROSSMANN MG, IN PRESS J APPL CRYS; Saenger W., 1984, PRINCIPLES NUCL ACID, P51; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SHAW DC, 1978, NATURE, V272, P510, DOI 10.1038/272510a0; SIDEN EJ, 1974, J MOL BIOL, V89, P1, DOI 10.1016/0022-2836(74)90159-4; Sinsheimer R L, 1968, Prog Nucleic Acid Res Mol Biol, V8, P115; SINSHEIMER RL, 1959, J MOL BIOL, V1, P37, DOI 10.1016/S0022-2836(59)80005-X; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; SMITH TJ, 1990, J APPL CRYSTALLOGR, V23, P141; Stauffacher C.V., 1987, CRYSTALLOGRAPHY MOL, P293; STOUTHAMER AH, 1963, VIROLOGY, V20, P246, DOI 10.1016/0042-6822(63)90112-0; THOMAS WJ, 1961, VIROLOGY, V15, P1; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WEISBEEK PJ, 1972, VIROLOGY, V48, P456, DOI 10.1016/0042-6822(72)90056-6; WEISBEEK PJ, 1973, VIROLOGY, V52, P408, DOI 10.1016/0042-6822(73)90335-8; WILLINGMANN P, 1990, J MOL BIOL, V212, P345, DOI 10.1016/0022-2836(90)90129-A; YAZAKI K, 1981, J VIROL METHODS, V2, P159	67	196	200	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					137	143		10.1038/355137a0	http://dx.doi.org/10.1038/355137a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370343	Green Accepted			2022-12-28	WOS:A1992GY62900049
J	MURPHY, M				MURPHY, M			THE MOLECULAR PATHOGENESIS OF ALZHEIMERS-DISEASE - CLINICAL PROSPECTS	LANCET			English	Review							AMYLOID PRECURSOR PROTEIN; PAIRED HELICAL FILAMENTS; DOWNS-SYNDROME; SECRETED FORM; BETA-PROTEIN; MUTATION; TAU; BRAINS; FRAGMENT; TANGLES				MURPHY, M (corresponding author), QUEEN MARYS UNIV HOSP,DEPT PSYCHIAT,ROEHAMPTON LANE,LONDON SW15 5PN,ENGLAND.							CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; FARLOW M, 1992, LANCET, V340, P453, DOI 10.1016/0140-6736(92)91771-Y; George Hyslop P. St., 1990, NATURE, V347, P194; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HANGER DP, 1991, BIOCHEM J, V275, P99, DOI 10.1042/bj2750099; HARDY J, 1992, NATURE, V359, P268, DOI 10.1038/359268a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HSAIO K, 1990, SCIENCE, V250, P1557; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWABATA S, 1991, NATURE, V354, P476, DOI 10.1038/354476a0; KAWABATA S, 1992, NATURE, V356, P256; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MAYER RJ, 1992, LANCET, V340, P156, DOI 10.1016/0140-6736(92)93224-B; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; NIETO A, 1990, NEUROSCIENCE, V37, P163, DOI 10.1016/0306-4522(90)90201-E; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; REFOLO LM, 1991, J NEUROSCI, V11, P3888; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIER AF, 1992, NATURE, V356, P804; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1991, NATURE, V350, P564, DOI 10.1038/350564a0; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V89, P2551; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805; VITEK MP, 1988, MOL BRAIN RES, V4, P121, DOI 10.1016/0169-328X(88)90004-6; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	47	23	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1512	1515		10.1016/0140-6736(92)92765-8	http://dx.doi.org/10.1016/0140-6736(92)92765-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361606				2022-12-28	WOS:A1992KD06900014
J	DAVIES, JA; GALLIVAN, S; SPENCER, JAD				DAVIES, JA; GALLIVAN, S; SPENCER, JAD			RANDOMIZED CONTROLLED TRIAL OF DOPPLER ULTRASOUND SCREENING OF PLACENTAL PERFUSION DURING PREGNANCY	LANCET			English	Article							INTRAUTERINE GROWTH-RETARDATION; HIGH-RISK PREGNANCIES; UTEROPLACENTAL BLOOD-FLOW; WAVE-FORM ANALYSIS; UMBILICAL ARTERY; VELOCITY WAVEFORMS; INDEXES; VARIABILITY; PREDICTION; UTERINE	We have done a randomised controlled trial to assess the effect on primary management and outcome of routine doppler ultrasound examinations of the umbilical and uterine arteries during pregnancy. Over 9 months, 2600 women with singleton pregnancies were recruited from a general obstetric population. Of 2475 women who delivered in hospital after 20 weeks' gestation, 1246 had been allocated at random to receive standard antenatal care with routine doppler examinations. The first doppler ultrasound was done at 19-22 weeks' gestation, and thereafter examinations were monthly if the pregnancy was considered high risk (192) or once at 32 weeks if considered low risk (1054). The control group of 1229 women received standard, antenatal care without doppler ultrasonography. The study groups did not differ in number of antenatal admissions or cardiotocographs, gestational age at delivery, method of delivery, frequency of deliveries with fetal distress, or need for resuscitation or admission to the neonatal intensive care unit. More perinatal deaths occurred in the doppler group (17 vs 7, relative risk 2.4, 95% Cl 1.00-5.76), but only 1 of 11 normally formed stillbirths and none of the 4 normally formed neonatal deaths after 24 weeks' gestation had an abnormal umbilical-artery doppler examination. We did not demonstrate any improvement in neonatal outcome by routine doppler ultrasound screening of a general obstetric population.	QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON,ENGLAND; UNIV LONDON UNIV COLL,DEPT STAT SCI,CLIN OPERAT RES UNIT,LONDON WC1E 6BT,ENGLAND	Imperial College London; University of London; University College London								BEATTIE RB, 1989, BRIT MED J, V298, P631, DOI 10.1136/bmj.298.6674.631; BEWLEY S, 1991, BRIT J OBSTET GYNAEC, V98, P871, DOI 10.1111/j.1471-0528.1991.tb13508.x; CAMPBELL S, 1986, OBSTET GYNECOL, V68, P649; DAVIES JA, 1990, OBSTET GYNECOL, V76, P366; HANRETTY KP, 1989, BRIT J OBSTET GYNAEC, V96, P1163, DOI 10.1111/j.1471-0528.1989.tb03191.x; MCPARLAND P, 1988, PLACENTA, V9, P427, DOI 10.1016/0143-4004(88)90055-0; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; MEHALEK KE, 1988, OBSTET GYNECOL, V72, P603; NEILSON JP, 1991, OXFORD DATA BASE PER; NEWNHAM JP, 1991, BRIT J OBSTET GYNAEC, V98, P956, DOI 10.1111/j.1471-0528.1991.tb15332.x; NEWNHAM JP, 1990, AM J OBSTET GYNECOL, V162, P403, DOI 10.1016/0002-9378(90)90396-O; OMTZIGT AWJ, 1990, THESIS U UTRECHT; PEARCE JM, 1988, BRIT J OBSTET GYNAEC, V95, P248, DOI 10.1111/j.1471-0528.1988.tb06865.x; PEARCE JM, 1991, FETAL MONITORING, P78; REUWER PJHM, 1987, LANCET, V2, P415; SCHULMAN H, 1989, AM J OBSTET GYNECOL, V160, P192, DOI 10.1016/0002-9378(89)90118-X; SPENCER JAD, 1991, J ULTRAS MED, V10, P37; SPENCER JAD, 1989, FETAL MED REV, V1, P105; SPENCER JAD, 1988, J ULTRAS MED, V8, P197; STEEL SA, 1990, LANCET, V335, P1548, DOI 10.1016/0140-6736(90)91376-L; TRUDINGER BJ, 1987, LANCET, V1, P188; TYRRELL SN, 1990, BRIT J OBSTET GYNAEC, V97, P909, DOI 10.1111/j.1471-0528.1990.tb02446.x	22	74	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1299	1303		10.1016/0140-6736(92)92490-7	http://dx.doi.org/10.1016/0140-6736(92)92490-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360032				2022-12-28	WOS:A1992KA26200001
J	RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA				RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA			AMBULATORY OXYGEN IN CHRONIC HEART-FAILURE	LANCET			English	Note							OBSTRUCTIVE AIRWAYS DISEASE; PORTABLE OXYGEN; EXERCISE CAPACITY	Ambulatory oxygen therapy may be of benefit in bicycle exercise tests. We have assessed the effects of ambulatory oxygen during walk tests in 12 patients with chronic heart failure. In 6 min walks with the patient breathing air, mean (SD) arterial oxygen saturation (SaO2) fell from 94.4 (3.7)% at rest to 90.1 (6.1)% (p = 0.014) on exercise. 2 l/min oxygen increased resting SaO2 from 93.7 (4.0)% (air cylinder) to 96.5 (3.0)% (p < 0.001) with no effect on minimum SaO2, distance, or breathlessness. During endurance walks, 4 l/min oxygen increased minimum SaO2 from 90.4 (5.6)% to 93.5 (4.7)% (p = 0.011) but also had no effect on breathlessness or distance. Ambulatory oxygen in currently available cylinders cannot be recommended for patients with chronic heart failure.	LONDON CHEST HOSP,DEPT THORAC MED,BONNER RD,LONDON E2 9JX,ENGLAND; LONDON CHEST HOSP,DEPT CARDIOL,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COCKROFT AL, 1989, Q J MED, V268, P669; DAVIDSON AC, 1988, THORAX, V43, P965, DOI 10.1136/thx.43.12.965; DAVIES S W, 1992, Pharmaceutical Medicine (London), V5, P239; DAVIES SW, 1991, BRIT HEART J, V65, P179; LEGGETT RJE, 1977, BRIT MED J, V2, P84, DOI 10.1136/bmj.2.6079.84; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; LOCK SH, 1991, RESP MED, V85, P407, DOI 10.1016/S0954-6111(06)80186-1; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; WATERHOUSE JC, 1983, THORAX, V38, P302, DOI 10.1136/thx.38.4.302	10	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1192	1193		10.1016/0140-6736(92)92893-K	http://dx.doi.org/10.1016/0140-6736(92)92893-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359262				2022-12-28	WOS:A1992JY38600005
J	TAKAHAMA, Y; SHORES, EW; SINGER, A				TAKAHAMA, Y; SHORES, EW; SINGER, A			NEGATIVE SELECTION OF PRECURSOR THYMOCYTES BEFORE THEIR DIFFERENTIATION INTO CD4+CD8+ CELLS	SCIENCE			English	Article							RECEPTOR TRANSGENIC MICE; BETA-T-CELL; IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; CLONAL ELIMINATION; CD4+8+ THYMOCYTES; ANTIGEN RECEPTOR; INVIVO; INTERMEDIATE; GENERATION	Thymic selection of the developing T cell repertoire is thought to occur at the CD4+CD8+ stage of differentiation and to be determined by the specificity of the T cell receptors (TCRs) that CD4+CD8+ thymocytes express. However, TCR signals can inhibit the differentiation of precursor thymocytes into CD4+CDB+ cells, which suggests that selection might occur earlier than thought. Indeed, in a negatively selecting male thymus, CD4-CD8(lo) precursor thymocytes that express a transgenic TCR to male antigen are developmentally arrested as a consequence of antigen encounter and fail to become CD4+CD8+. Thus, negative selection can occur before the CD4+CD8+ stage of differentiation.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Takahama, Yousuke/A-5863-2010	Takahama, Yousuke/0000-0002-4992-9174				BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; Maniatis T., 1982, MOL CLONING; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TAKAHAMA Y, UNPUB; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THEILER K, 1989, HOUSE MOUSE; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	31	108	109	2	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					653	656		10.1126/science.1357752	http://dx.doi.org/10.1126/science.1357752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1357752				2022-12-28	WOS:A1992JU74500058
J	MOSS, SF; LEGON, S; BISHOP, AE; POLAK, JM; CALAM, J				MOSS, SF; LEGON, S; BISHOP, AE; POLAK, JM; CALAM, J			EFFECT OF HELICOBACTER-PYLORI ON GASTRIC SOMATOSTATIN IN DUODENAL-ULCER DISEASE	LANCET			English	Article							CAMPYLOBACTER PYLORI; GENE-EXPRESSION; ACID SECRETION; ANTRAL GASTRIN; G-CELL; SEQUENCE; BASAL	Infection of the gastric antrum by Helicobacter pylori is associated with recurrent duodenal ulcer disease but the mechanism of ulcerogenesis is unclear. Since pathways inhibiting gastric secretion are defective in patients with duodenal ulcers, we investigated whether H pylori interferes with the normal gastric inhibition that is mediated by somatostatin. We studied 28 patients with active duodenal ulcers in whom H pylori was eradicated successfully. In 18 patients, we measured the density of antral somatostatin-immunoreactive cells and in a further 10 subjects, the amount of somatostatin mRNA before and after eradication of H pylori was determined. After eradication, the median density of somatostatin-immunoreactive cells increased significantly from 9 (range 3-47) to 19 (6-57) cells per mm muscularis mucosa (p=0.025). The median somatostatin mRNA/rRNA ratio increased from 50 (25-160) to 95 (40-180) (p=0.01). The number of gastrin cells and quantity of gastrin mRNA did not change significantly. Our results suggest that in duodenal ulcer disease, gastric secretory function is disinhibited through the suppression Of mucosal somatostatin.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London	MOSS, SF (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAIR AJ, 1987, J CLIN INVEST, V79, P582, DOI 10.1172/JCI112850; BRAND SJ, 1988, J CLIN INVEST, V82, P1059, DOI 10.1172/JCI113662; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER RG, 1985, GUT, V26, P232, DOI 10.1136/gut.26.3.232; DOCKRAY GJ, 1991, GASTROENTEROLOGY, V100, P1187; GOLODNER E H, 1992, Gastroenterology, V102, pA630; GRAHAM D Y, 1991, Gastroenterology, V100, pA75; HOWARD A, 1992, BIOCHEM BIOPH RES CO, V183, P499, DOI 10.1016/0006-291X(92)90510-R; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; KANEKO H, 1992, DIGEST DIS SCI, V37, P409, DOI 10.1007/BF01307736; KING W W, 1992, Gastroenterology, V102, pA646; KIRKPATRICK PM, 1980, GASTROENTEROLOGY, V79, P4; LEVI S, 1989, BRIT MED J, V299, P1504, DOI 10.1136/bmj.299.6714.1504; LEVI S, 1989, LANCET, V1, P1167; MALAGELADA JR, 1977, GASTROENTEROLOGY, V73, P989; MCCOLL KEL, 1989, LANCET, V2, P499; MOSS S, 1992, GUT, V33, P289, DOI 10.1136/gut.33.3.289; MOSS SF, 1992, GUT, V33, pS28; SHEN LP, 1982, P NATL ACAD SCI-BIOL, V79, P4575, DOI 10.1073/pnas.79.15.4575; SOLCIA E, 1988, DIGESTION, V41, P185, DOI 10.1159/000199786; TARNASKY P R, 1991, Gastroenterology, V100, pA845; WALSH JH, 1975, J CLIN INVEST, V55, P462, DOI 10.1172/JCI107952; WU V, 1991, GASTROENTEROLOGY, V101, P1552, DOI 10.1016/0016-5085(91)90391-W	23	276	280	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					930	932		10.1016/0140-6736(92)92816-X	http://dx.doi.org/10.1016/0140-6736(92)92816-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357347				2022-12-28	WOS:A1992JT82300002
J	MCCRIRRICK, A; KESTIN, I				MCCRIRRICK, A; KESTIN, I			HEMODYNAMIC-EFFECTS OF TRACHEAL COMPARED WITH INTRAVENOUS ADRENALINE	LANCET			English	Article							ENDOTRACHEAL EPINEPHRINE; CLINICAL-TRIALS; CARDIAC-ARREST	If intravenous access is not available during cardiopulmonary resuscitation, tracheal administration of adrenaline 0.02 mg/kg, twice the intravenous dose, is recommended. In a randomised crossover study we investigated the haemodynamic effects of low doses of tracheal versus intravenous adrenaline. 12 anaesthetised patients having a hip replaced received one dose of adrenaline intravenously (0.1 mug/kg) and the other tracheally (0.5 mug/kg). There was a mean increase in systolic arterial pressure of 40.5 mm Hg (range 16-81) after the intravenous injection, with little effect on heart rate. Tracheal adrenaline had no effect on arterial pressure or heart rate. Thus low doses of tracheal adrenaline have no haemodynamic effects. We believe that the recommended tracheal dose of twice the intravenous dose is likely to be ineffective for the treatment of cardiac arrest. Animal studies suggest that a tracheal dose at least ten times the intravenous dose is required.	DERRIFORD HOSP, DEPT ANAESTHET, PLYMOUTH, DEVON, ENGLAND	Derriford Hospital								BRAY BM, 1987, ANAESTHESIA, V42, P1188, DOI 10.1111/j.1365-2044.1987.tb05226.x; CRESPO SG, 1991, ANN EMERG MED, V20, P230, DOI 10.1016/S0196-0644(05)80928-X; DAY SJ, 1989, BMJ-BRIT MED J, V299, P663, DOI 10.1136/bmj.299.6700.663; GREENBERG MI, 1979, JACEP-J AM COLL EMER, V8, P500, DOI 10.1016/S0361-1124(79)80294-4; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; ORLOWSKI JP, 1990, RESUSCITATION, V19, P103, DOI 10.1016/0300-9572(90)90033-B; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P114; QUINTON DN, 1987, LANCET, V1, P828; RALSTON SH, 1985, ANN EMERG MED, V14, P1044, DOI 10.1016/S0196-0644(85)80916-1; REDDING JS, 1967, ANESTH ANAL CURR RES, V46, P253; ROBERTS JR, 1979, JACEP-J AM COLL EMER, V8, P53, DOI 10.1016/S0361-1124(79)80036-2; SENN SJ, 1990, STAT MED, V9, P1287, DOI 10.1002/sim.4780091108; 1986, JAMA-J AM MED ASSOC, V255, P2938; 1986, JAMA-J AM MED ASSOC, V255, P2973; 1989, BMJ, V299, P446; 1986, JAMA-J AM MED ASSOC, V255, P2964	16	29	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1992	340	8824					868	870		10.1016/0140-6736(92)93283-S	http://dx.doi.org/10.1016/0140-6736(92)93283-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357295				2022-12-28	WOS:A1992JT32700002
J	MIZUKAMI, Y; MA, H				MIZUKAMI, Y; MA, H			ECTOPIC EXPRESSION OF THE FLORAL HOMEOTIC GENE AGAMOUS IN TRANSGENIC ARABIDOPSIS PLANTS ALTERS FLORAL ORGAN IDENTITY	CELL			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; THALIANA; TRANSFORMATION; MORPHOGENESIS; SEQUENCES; PRODUCT	The Arabidopsis floral homeotic gene AGAMOUS (AG) is required for development of the reproductive organs (stamens and carpels). In ag mutants, the loss of AG function leads to the conversion of these organs to the perianth organs (petals and sepals). In contrast, mutations in another floral homeotic gene, APETALA2 (AP2), result in the replacement of the perianth organs by the reproductive organs. On the basis of these observations, it has been proposed that AG and AP2 act in an antagonistic fashion. To test this hypothesis, we have studied the effects of ectopically expressed AG in transgenic Arabidopsis plants. The flowers of the transgenic plants exhibit a range of phenotypes mirroring those of ap2 mutants. These experiments provide direct evidence of the proposed antagonism between AG and AP2 functions, and the results strongly suggest that AG does indeed inhibit AP2 function.			MIZUKAMI, Y (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Ma, Hong/W-5251-2018	Ma, Hong/0000-0001-8717-4422				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MATZKE MA, 1990, DEV GENET, V11, P214, DOI 10.1002/dvg.1020110307; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; Pruitt RE, 1987, GENETIC REGULATION D, P327; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	355	387	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					119	131		10.1016/0092-8674(92)90271-D	http://dx.doi.org/10.1016/0092-8674(92)90271-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356630				2022-12-28	WOS:A1992JQ62300012
J	BOUMPAS, DT; AUSTIN, HA; VAUGHN, EM; KLIPPEL, JH; STEINBERG, AD; YARBORO, CH; BALOW, JE				BOUMPAS, DT; AUSTIN, HA; VAUGHN, EM; KLIPPEL, JH; STEINBERG, AD; YARBORO, CH; BALOW, JE			CONTROLLED TRIAL OF PULSE METHYLPREDNISOLONE VERSUS 2 REGIMENS OF PULSE CYCLOPHOSPHAMIDE IN SEVERE LUPUS NEPHRITIS	LANCET			English	Article							INTRAVENOUS CYCLOPHOSPHAMIDE; THERAPY; ERYTHEMATOSUS; PREDNISONE; DRUGS	Pulse cyclophosphamide is more effective than prednisone alone in preventing renal failure in lupus nephritis. We undertook a randomised, controlled trial to find out whether pulse methylprednisolone could equal pulse cyclophosphamide in preserving renal function in patients with lupus nephritis, and whether there was a difference between long and short courses of pulse cyclophosphamide in preventing exacerbations. 65 patients (60 female, 5 male; median [range] age 29 [10-48] years) with severe lupus nephritis were assigned randomly to monthly pulse methylprednisolone for 6 months (25 patients), monthly pulse cyclophosphamide for 6 months (20), or monthly cyclophosphamide for 6 months followed by quarterly pulse cyclophosphamide for 2 additional years (20). Patients treated with pulse methylprednisolone had a higher probability of doubling serum creatinine than those treated with long-course cyclophosphamide (p<0.04). Risk of doubling creatinine was not significantly different between short and long course cyclophosphamide. However, patients treated with short-course cyclophosphamide had a higher probability of exacerbations than those treated with long-course cyclophosphamide (p<0.01). An extended course of pulse cyclophosphamide is more effective than 6 months of pulse methylprednisolone in preserving renal function in patients with severe lupus nephritis. Addition of a quarterly maintenance regimen to monthly pulse cyclophosphamide reduces the rate of exacerbations.	NIAMSD,CTR CLIN,DEPT NURSING,BETHESDA,MD; NIAMSD,ARTHRIT & RHEUMATISM BRANCH,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	BOUMPAS, DT (corresponding author), NIDDK,KIDNEY DIS SECT,BLDG 10,ROOM 3N-112,BETHESDA,MD 20892, USA.							AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALLOU SP, 1985, J RHEUMATOL, V12, P944; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BENEDETTI J, 1981, BMDP STATISTICAL SOF, P557; BOUMPAS DT, 1991, Q J MED, V81, P975, DOI 10.1093/qjmed/81.3.975; BOUMPAS DT, 1990, ANN INTERN MED, V112, P674, DOI 10.7326/0003-4819-112-9-674; BOUMPAS DT, 1992, CURRENT THERAPY ALLE, P95; CAMERON JS, 1989, PEDIATR NEPHROL, V3, P350, DOI 10.1007/BF00858546; CATHCART ES, 1976, LANCET, V1, P163; Churg J, 1982, RENAL DIS CLASSIFICA, P127; DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102; DOSA S, 1978, POSTGRAD MED J, V54, P628, DOI 10.1136/pgmj.54.635.628; FELSON DT, 1984, NEW ENGL J MED, V311, P1528, DOI 10.1056/NEJM198412133112402; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; HOUSSIAU FA, 1991, LUPUS, V1, P31, DOI 10.1177/096120339100100106; ISENBERG DA, 1982, ANN RHEUM DIS, V41, P347, DOI 10.1136/ard.41.4.347; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIMBERLY RP, 1981, AM J MED, V70, P817, DOI 10.1016/0002-9343(81)90538-6; LEHMAN TJA, 1989, J PEDIATR-US, V114, P1055, DOI 10.1016/S0022-3476(89)80463-9; LIEBLING MR, 1982, J RHEUMATOL, V9, P543; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; PONTICELLI C, 1987, CLIN NEPHROL, V28, P263; PONTICELLI C, 1990, DRUGS, V40, P19, DOI 10.2165/00003495-199040010-00003; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	27	656	693	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					741	745		10.1016/0140-6736(92)92292-N	http://dx.doi.org/10.1016/0140-6736(92)92292-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356175	Green Submitted			2022-12-28	WOS:A1992JP86900001
J	ROWE, WJ				ROWE, WJ			EXTRAORDINARY UNREMITTING ENDURANCE EXERCISE AND PERMANENT INJURY TO NORMAL HEART	LANCET			English	Article							MYOCARDIAL NECROSIS; SERUM MAGNESIUM; VARIANT ANGINA; CATECHOLAMINES; PATHOGENESIS; ISCHEMIA; DAMAGE; SPASM	This hypothesis is that permanent cardiac injury could develop in some endurance athletes despite the absence of coronary atherosclerosis and ventricular hypertrophy. The proposed mechanism by which this injury could arise involves two physiological "vicious cycles". The first vicious cycle would occur between severe ischaemia and high catecholamines, the second would be between coronary vasospasm (induced by high catecholamines) and endothelial injury. The likelihood of the injury becoming permanent might increase if there is insufficient time between bouts of endurance exercise for regression of ischaemia and endothelial repair. Furthermore, magnesium ion deficiency, which can be induced by exercise, could exacerbate these vicious cycles and also contribute to catecholamine-induced thrombogenesis. In addition to ischaemia, there are several mechanisms, including the effect of free fatty acids liberated by the lipolytic effect of high catecholamines, that could cause direct myocardial injury.										ASTRAND PO, 1986, TXB WORK PHYSL PHYSL, P685; Badimon L., 1992, THROMBOSIS CARDIOVAS, P17; BELLER GA, 1975, AVIAT SPACE ENVIR MD, V46, P709; BENNET WC, 1935, TARAHUMARA INDIAN TR, P113; CHILIAN WM, 1986, CIRC RES, V58, P68, DOI 10.1161/01.RES.58.1.68; DEARMAN J, 1983, J SPORT MED PHYS FIT, V23, P30; EATON SB, 1988, PALEOLITHIC PRESCRIP, P32; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ESCOURROU P, 1984, J APPL PHYSIOL, V57, P1507, DOI 10.1152/jappl.1984.57.5.1507; FACTOR SM, 1985, PROG CARDIOVASC DIS, V27, P395, DOI 10.1016/0033-0620(85)90002-7; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GEFT IL, 1982, CIRCULATION, V66, P1150, DOI 10.1161/01.CIR.66.6.1150; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; GOTO K, 1990, AM J CARDIOL, V65, P709, DOI 10.1016/0002-9149(90)91375-G; GREEN LH, 1976, ANN INTERN MED, V84, P704, DOI 10.7326/0003-4819-84-6-704; HIRAMATSU K, 1984, CLIN EXP PHARMACOL P, V11, P171, DOI 10.1111/j.1440-1681.1984.tb00254.x; KNOCHEL JP, 1961, AM J MED, V30, P299, DOI 10.1016/0002-9343(61)90101-2; KONDO T, 1987, CARDIOVASC RES, V21, P248, DOI 10.1093/cvr/21.4.248; LAKS MM, 1991, CATECHOLAMINES HEART, P103; MAJUMDER S, 1991, CATECHOLAMINES HEART, P267; MARON MB, 1977, EUR J APPL PHYSIOL O, V36, P231, DOI 10.1007/BF00423048; MCKECHNIE JK, 1979, S AFR MED J, V56, P261; PRASAD DM, 1980, SCIENCE, V208, P198; PREVITALI M, 1989, AM HEART J, V117, P92, DOI 10.1016/0002-8703(89)90661-3; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; ROWE WJ, 1991, CHEST, V99, P1306, DOI 10.1378/chest.99.5.1306; RYZEN E, 1990, J AM COLL NUTR, V9, P114; SCHWARTZ SM, 1975, AM J PATHOL, V81, P15; SEELIG MS, 1974, AM J CLIN NUTR, V27, P59, DOI 10.1093/ajcn/27.1.59; STENDIGLINDBERG G, 1987, J AM COLL NUTR, V6, P35; TODD GL, 1985, J MOL CELL CARDIOL, V17, P647, DOI 10.1016/S0022-2828(85)80064-X; WENGER NK, 1974, HEART ARTERIES VEINS, P1546; YASUE H, 1978, CIRCULATION, V58, P56, DOI 10.1161/01.CIR.58.1.56	33	56	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					712	714		10.1016/0140-6736(92)92243-9	http://dx.doi.org/10.1016/0140-6736(92)92243-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355810				2022-12-28	WOS:A1992JN78000015
J	KUSIN, JA; KARDJATI, S; HOUTKOOPER, JM; RENQVIST, UH				KUSIN, JA; KARDJATI, S; HOUTKOOPER, JM; RENQVIST, UH			ENERGY SUPPLEMENTATION DURING PREGNANCY AND POSTNATAL-GROWTH	LANCET			English	Article							WEIGHT; BIRTH	The effect of improving maternal nutrition during pregnancy on growth of the child has not been assessed, since previous studies supplemented the diets of children as well as mothers. In a controlled randomised trial in Madura, East Java, pregnant women received a high (HE) or low (LE) energy supplement that provided 1950 kJ (465 kcal) or 218 kJ (52 kcal), respectively, in the last trimester of pregnancy. The effect of this intervention on the children's growth was assessed longitudinally for the first 5 years of life. Only the children of mothers who had complied for at least 90 days were included. Infants entered the study at birth and their growth was measured at 4-week intervals until 12 months old; thereafter they were measured every 3 months. Growth curves were calculated from a mathematical model, based on the best fit of actual measurements and the age-related growth velocity. Up to the age of 24 months, HE children were significantly heavier than LE children (p<0.05). HE children were also taller throughout the first 5 years (p<0.005 from 15 to 48 months, p<0.05 at both 3-12 and 60 months), Weight-for-height by age was similar in both groups, but stunting (height-for-age) was less prevalent in HE children. In a community characterised by chronic energy deficiency among women of reproductive age, energy supplementation of women for the last 90 days of pregnancy was effective in the promotion of postnatal growth and reduction in malnutrition of preschool children.	AIRLANGGA UNIV, SCH MED, NUTR LABS, SURABAYA, INDONESIA; HOUTKOOPER SOFTWARE ENGN, AMSTEL, NETHERLANDS	Airlangga University	KUSIN, JA (corresponding author), ROYAL TROP INST, NUTR SECT, 63 MAURITSKADE, 1092 AD AMSTERDAM, NETHERLANDS.							BEATON GH, 1982, AM J CLIN NUTR, V35, P864, DOI 10.1093/ajcn/35.4.864; DELGADO HL, 1982, EARLY HUM DEV, V6, P273, DOI 10.1016/0378-3782(82)90121-9; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; GRANT JP, 1991, STATE WORLDS CHILDRE; KARDJATI S, 1978, TROP GEOGR MED, V30, P359; KARDJATI S, 1988, BRIT J OBSTET GYNAEC, V95, P783, DOI 10.1111/j.1471-0528.1988.tb06553.x; KARLBERG J, 1987, ACTA PAEDIATR SCAND, V76, P478, DOI 10.1111/j.1651-2227.1987.tb10503.x; KELLER W, 1988, LINEAR GROWTH RETARD, P17; Lechtig A., 1980, Maternal nutrition during pregnancy and lactation, P285; LECHTIG A, 1981, MATERNAL NUTRITION P, P131; MARTORELL R, 1980, NUTR REP INT, V21, P447; MORA J. O., 1981, Nutrition Research, V1, P213, DOI 10.1016/S0271-5317(81)80021-8; MUELLER WH, 1984, EARLY HUM DEV, V10, P127, DOI 10.1016/0378-3782(84)90119-1; ROCHE AF, 1989, AM J CLIN NUTR, V49, P599, DOI 10.1093/ajcn/49.4.599; RUSH D, 1983, NUTRITION PREGNANCY, P65; WOHLLEB JC, 1983, ARCH LATINOAM NUTR, V33, P642	16	84	84	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1992	340	8820					623	626		10.1016/0140-6736(92)92168-F	http://dx.doi.org/10.1016/0140-6736(92)92168-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355209				2022-12-28	WOS:A1992JM85100001
J	FRY, J				FRY, J			THE MOUSE AND THE ELEPHANT - CAN PRIMARY CARE SAVE THE US HEALTH SYSTEM	LANCET			English	Editorial Material																			0	0	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					594	595		10.1016/0140-6736(92)92118-Y	http://dx.doi.org/10.1016/0140-6736(92)92118-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355166				2022-12-28	WOS:A1992JM33400015
J	TOMKINS, CM				TOMKINS, CM			HIV TRANSMISSION AND THE LAW	LANCET			English	Editorial Material							POLICY; AIDS				TOMKINS, CM (corresponding author), MED DEF UNION,LONDON,ENGLAND.							BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1951; KRASNIK A, 1989, SOC SCI MED, V29, P577, DOI 10.1016/0277-9536(89)90203-7; LANSDELL GT, 1991, MED J AUSTRALIA, V154, P61, DOI 10.5694/j.1326-5377.1991.tb112856.x; IN PRESS AUSTR HIV A	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					543	543		10.1016/0140-6736(92)91732-N	http://dx.doi.org/10.1016/0140-6736(92)91732-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL234	1354289				2022-12-28	WOS:A1992JL23400017
J	WHITE, HD				WHITE, HD			THROMBOLYTIC THERAPY FOR PATIENTS WITH MYOCARDIAL-INFARCTION PRESENTING AFTER 6 HOURS	LANCET			English	Editorial Material							LEFT-VENTRICULAR VOLUME; CORONARY-OCCLUSION; REPERFUSION; MORTALITY; TRIAL				WHITE, HD (corresponding author), GREEN LANE HOSP, CARDIOVASC RES UNIT, AUCKLAND 3, NEW ZEALAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1991, LANCET, V337, P271; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; BROWN EJ, 1991, J AM COLL CARDIOL, V17, P1641, DOI 10.1016/0735-1097(91)90660-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1987, EUR HEART J, V8, P634; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; JEREMY RW, 1987, J AM COLL CARDIOL, V9, P989, DOI 10.1016/S0735-1097(87)80298-X; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; SAGER PT, 1988, J AM COLL CARDIOL, V12, P19, DOI 10.1016/0735-1097(88)90350-6; WHITE H, 1988, LANCET, V2, P914; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1991, 40TH AM COLL CARD AN	20	21	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					221	222		10.1016/0140-6736(92)90478-L	http://dx.doi.org/10.1016/0140-6736(92)90478-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353145				2022-12-28	WOS:A1992JE75800013
J	GOLDHABER, SZ; MANSON, JE; STAMPFER, MJ; LAMOTTE, F; ROSNER, B; BURING, JE; HENNEKENS, CH				GOLDHABER, SZ; MANSON, JE; STAMPFER, MJ; LAMOTTE, F; ROSNER, B; BURING, JE; HENNEKENS, CH			LOW-DOSE ASPIRIN AND SUBSEQUENT PERIPHERAL ARTERIAL-SURGERY IN THE PHYSICIANS HEALTH STUDY	LANCET			English	Article							INTERMITTENT CLAUDICATION; UNITED-STATES; DISEASE; MORTALITY; ANGINA; TRIAL	In the US Physicians' Health Study the early termination of the aspirin arm has provided the opportunity to test the hypothesis that low-dose aspirin (325 mg on alternate days) might affect the subsequent occurrence of peripheral arterial surgery. In the study, a randomised double-blind placebo-controlled trial among 22 071 healthy US male physicians aged 40-84, there were, during an average of 60.2 months of treatment and follow-up, 56 participants who underwent peripheral arterial surgery (20 aspirin, 36 placebo). The relative risk of peripheral artery surgery in the aspirin group was 0.54 (95% confidence intervals 0.30-0.95; p=0.03). These data indicate that chronic administration of low-dose aspirin to apparently healthy men reduced the need for peripheral arterial surgery.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PREVENT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	GOLDHABER, SZ (corresponding author), BRIGHAM & WOMENS HOSP, CHANNING LAB, 75 FRANCIS ST, ROOM A-313, BOSTON, MA 02115 USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, NEW ENGL J MED; GIANSANTE C, 1990, J INT MED RES, V18, P400, DOI 10.1177/030006059001800508; GILLUM RF, 1990, AM HEART J, V120, P1414, DOI 10.1016/0002-8703(90)90257-X; HESS H, 1985, LANCET, V1, P415; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MANSON JE, 1990, AM J MED, V89, P772, DOI 10.1016/0002-9343(90)90220-8; MCNAMARA TO, 1991, CIRCULATION, V83, P106; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; PICK R, 1979, J CLIN INVEST, V63, P158, DOI 10.1172/JCI109272; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; VERHAEGE R, 1992, THROMBOSIS CARDIOVAS, P436; 1989, NEW ENGL J MED, V3216, P129	13	111	119	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1992	340	8812					143	145		10.1016/0140-6736(92)93216-A	http://dx.doi.org/10.1016/0140-6736(92)93216-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352567				2022-12-28	WOS:A1992JE38200004
J	DUBOWITZ, LMS; BOUZA, H; HIRD, MF; JAEKEN, J				DUBOWITZ, LMS; BOUZA, H; HIRD, MF; JAEKEN, J			LOW CEREBROSPINAL-FLUID CONCENTRATION OF FREE GAMMA-AMINOBUTYRIC-ACID IN STARTLE DISEASE	LANCET			English	Note							HYPEREXPLEXIA	The pathophysiology of startle disease (hyperekplexia) is unknown. Hyperactivity of the brainstem reticular formation has been suggested as a cause. We report a newborn infant with classic features of startle disease in whom cerebrospinal fluid (CSF) concentrations of gamma-aminobutyric acid (GABA) were substantially lower than normal during the first weeks of life. She improved greatly on clonazepam treatment. We suggest that the signs of this disorder may be due to a genetic defect or to delayed maturation resulting in low CSF GABA.	UNIV ZIEKENHUIS GASTHUISBERG,DEPT PAEDIAT,LOUVAIN,BELGIUM	KU Leuven; University Hospital Leuven	DUBOWITZ, LMS (corresponding author), HAMMERSMITH HOSP,DEPT PAEDIAT & NEONATAL MED,DU CANE RD,LONDON W12 0HS,ENGLAND.							ANDERMANN F, 1988, BRAIN DEV-JPN, V10, P213, DOI 10.1016/S0387-7604(88)80001-9; CARCHON HA, 1991, CLIN CHIM ACTA, V201, P83, DOI 10.1016/0009-8981(91)90027-A; KIRSTEIN L, 1958, ACTA PSYCH NEUROL, V33, P471, DOI 10.1111/j.1600-0447.1958.tb03533.x; MARKAND ON, 1984, ARCH NEUROL-CHICAGO, V41, P71, DOI 10.1001/archneur.1984.04050130077028; MORLEY DJ, 1982, CLIN GENET, V21, P388; SHAHAR E, 1991, ACTA PAEDIATR SCAND, V80, P1073; SUHREN O, 1966, J NEUROL SCI, V3, P577, DOI 10.1016/0022-510X(66)90047-5; TOHIER C, 1991, ARCH DIS CHILD, V66, P460, DOI 10.1136/adc.66.4.460; VIGEVANO F, 1989, LANCET, V1, P216; WEINGER MB, 1987, ANESTHESIOLOGY, V66, P580, DOI 10.1097/00000542-198704000-00038	10	33	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					80	81		10.1016/0140-6736(92)90398-M	http://dx.doi.org/10.1016/0140-6736(92)90398-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352015				2022-12-28	WOS:A1992JC58200005
J	RABACCHI, S; BAILLY, Y; DELHAYEBOUCHAUD, N; MARIANI, J				RABACCHI, S; BAILLY, Y; DELHAYEBOUCHAUD, N; MARIANI, J			INVOLVEMENT OF THE N-METHYL D-ASPARTATE (NMDA) RECEPTOR IN SYNAPSE ELIMINATION DURING CEREBELLAR DEVELOPMENT	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; PURKINJE-CELLS; CLIMBING FIBERS; MULTIPLE INNERVATION; RAT CEREBELLUM; OLIVOCEREBELLAR RELATIONSHIPS; POSTNATAL-DEVELOPMENT; NERVOUS-SYSTEM; STRIATE CORTEX; VISUAL-CORTEX	In many instances, the establishment of highly specific neuronal connections during development results from the rearrangement of axonal projections through the trimming of exuberant collaterals or the elimination of functional synapses or both. Although the involvement of the N-methyl D-aspartate (NMDA) subtype of the glutamate receptor has been demonstrated in the shaping of axonal arbors, its participation in the process of selective stabilization of synapses remains an open issue. In this study, the effects of chronic in vivo application of D,L-2-amino-5-phosphonovaleric acid (D,L-APV), a selective antagonist of the NMDA receptor, on the synapse elimination process that takes place in the developing cerebellum of the rat have been analyzed. D,L-APV treatment prevented the regression of supernumerary climbing fiber synapses in 49 percent of the recorded Purkinje cells, while the inactive isomer L-APV was ineffective. Thus, activation of the NMDA receptor is a critical step in the regression of functional synapses during development.	UNIV PARIS 06,F-75230 PARIS 05,FRANCE; CNRS,INST NEUROSCI,NEUROBIOL DEV LAB,F-75005 PARIS,FRANCE	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)								ALKON DL, 1984, SCIENCE, V226, P1037, DOI 10.1126/science.6093258; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BEAR MF, 1990, J NEUROSCI, V10, P909; BENOIT P, 1984, DEV BRAIN RES, V14, P310, DOI 10.1016/0165-3806(84)90320-1; BENOIT P, 1987, DEV BRAIN RES, V34, P51, DOI 10.1016/0165-3806(87)90194-5; BENOIT P, 1975, BRAIN RES, V99, P354, DOI 10.1016/0006-8993(75)90036-0; BOURRAT F, 1984, DEV BRAIN RES, V16, P241, DOI 10.1016/0165-3806(84)90029-4; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1976, ARCH ITAL BIOL, V114, P49; CREPEL F, 1976, J NEUROBIOL, V7, P579, DOI 10.1002/neu.480070610; CREPEL F, 1981, DEV BRAIN RES, V1, P59, DOI 10.1016/0165-3806(81)90094-8; CREPEL F, 1976, J NEUROBIOL, V7, P567, DOI 10.1002/neu.480070609; CREPEL F, 1980, NATURE, V283, P482; DAVIES J, 1982, BRAIN RES, V235, P378, DOI 10.1016/0006-8993(82)91017-4; DELHAYEBOUCHAUD N, 1985, J COMP NEUROL, V232, P299, DOI 10.1002/cne.902320303; DUPONT JL, 1987, DEV BRAIN RES, V34, P59, DOI 10.1016/0165-3806(87)90195-7; FOX K, 1989, J NEUROSCI, V9, P2443; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; HAHN J, 1991, NATURE, V351, P568; HUSSAIN S, 1991, NEUROPHARMACOLOGY, V30, P1029, DOI 10.1016/0028-3908(91)90130-4; INNOCENTI GM, 1981, TRENDS NEUROSCI, V4, P142, DOI 10.1016/0166-2236(81)90047-3; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KRUPA M, 1990, EUR J NEUROSCI, V2, P312, DOI 10.1111/j.1460-9568.1990.tb00423.x; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARIANI J, 1982, J NEUROBIOL, V13, P119, DOI 10.1002/neu.480130204; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MARIANI J, 1981, J NEUROSCI, V1, P696, DOI 10.1523/JNEUROSCI.01-07-00696.1981; MARIANI J, 1981, J NEUROSCI, V1, P703, DOI 10.1523/JNEUROSCI.01-07-00703.1981; MARIANI J, 1987, NEWS PHYSIOL SCI, V2, P93; MARIANI J, 1990, DEV BRAIN RES, V57, P63, DOI 10.1016/0165-3806(90)90185-2; MARIANI J, 1983, PROG BRAIN RES, V58, P383, DOI 10.1016/S0079-6123(08)60041-2; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; SANDOVAL ME, 1978, NEUROSCIENCE, V3, P199, DOI 10.1016/0306-4522(78)90101-X; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; WIKLUND L, 1982, SCIENCE, V216, P78, DOI 10.1126/science.6121375; WOODWARD DJ, 1974, J NEUROBIOL, V5, P283, DOI 10.1002/neu.480050402	47	290	295	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1823	1825		10.1126/science.1352066	http://dx.doi.org/10.1126/science.1352066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1352066				2022-12-28	WOS:A1992JA43400038
J	LANE, EB; RUGG, EL; NAVSARIA, H; LEIGH, IM; HEAGERTY, AHM; ISHIDAYAMAMOTO, A; EADY, RAJ				LANE, EB; RUGG, EL; NAVSARIA, H; LEIGH, IM; HEAGERTY, AHM; ISHIDAYAMAMOTO, A; EADY, RAJ			A MUTATION IN THE CONSERVED HELIX TERMINATION PEPTIDE OF KERATIN-5 IN HEREDITARY SKIN BLISTERING	NATURE			English	Article							AMINO-ACID-SEQUENCE; INTERMEDIATE FILAMENTS; EPIDERMOLYSIS BULLOSA; EXPRESSION; CELLS; EPITHELIA; PATTERNS; ANTIBODY; PROTEINS; TUMORS	IN the hereditary blistering condition epidermolysis bullosa simplex, the skin blisters on trauma following rupture of epidermal basal cells. Clinical variations range from severely incapacitating, especially in early childhood, to mild forms that may not even present clinically. Dowling-Meara epidermolysis bullosa simplex is characterized by clusters of epidermal blisters and keratin clumping in the cytoplasm 1; recent reports describe potentially causal mutations in keratin 14 (refs 2, 3). Here we describe a 'complementary' mutation at the other end of the other keratin expressed by these cells (K5, coexpressed with K14), a change from a Glu to a Gly in the helix termination peptide, detected by altered antibody binding and confirmed by sequencing using the polymerase chain reaction. The two conserved helix boundary peptides are predicted to be essential for filament assembly, and the requirement for two complementary (type I and type II) keratins is absolute. Epidermolysis bullosa simplex diseases demonstrate the function of the keratin cytoskeleton in resisting compaction stresses which otherwise lead to cell lysis.	EXPTL DERMATOL LAB,LONDON E1 2BL,ENGLAND; IMPERIAL CANC RES FUND,SKIN TUMOUR LAB,LONDON E1 2BL,ENGLAND; N STAFFORDSHIRE ROYAL INFIRM,DEPT DERMATOL,STOKE ON TRENT ST4 7LN,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,INST DERMATOL,DEPT CELL PATHOL,LONDON SE1 7EH,ENGLAND	University of London; Queen Mary University London; Cancer Research UK; Keele University; University Hospital of North Staffordshire NHS Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	LANE, EB (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT ANAT & PHYSIOL,CANC RES CAMPAIGN,CELL STRUCT RES GRP,DUNDEE DD1 4HN,SCOTLAND.							ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BONIFAS JM, 1991, J INVEST DERMATOL, V96, pA550; CHAPMAN S J, 1985, European Journal of Cell Biology, V39, P352; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COOPER D, 1984, DIFFERENTIATION, V28, P30, DOI 10.1111/j.1432-0436.1984.tb00263.x; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; ECKERT RL, 1988, DNA-J MOLEC CELL BIO, V7, P337, DOI 10.1089/dna.1.1988.7.337; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; HATZFELD M, 1991, J CELL SCI, V99, P351; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; Lane E B, 1990, Semin Cancer Biol, V1, P165; LEIGH IM, 1984, BRIT J DERMATOL, V111, P527, DOI 10.1111/j.1365-2133.1984.tb06621.x; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MISCHKE D, 1990, AM J HUM GENET, V46, P548; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1988, VIRCHOWS ARCH B, V58, P105; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PURKIS PE, 1990, J CELL SCI, V97, P39; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Sambrook J, 1989, MOL CLONING LABORATO; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; TREVOR K T, 1990, New Biologist, V2, P1004; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F	29	356	361	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					244	246		10.1038/356244a0	http://dx.doi.org/10.1038/356244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1372711				2022-12-28	WOS:A1992HJ94400059
J	SHERIDAN, WP; BEGLEY, CG; JUTTNER, CA; SZER, J; TO, LB; MAHER, D; MCGRATH, KM; MORSTYN, G; FOX, RM				SHERIDAN, WP; BEGLEY, CG; JUTTNER, CA; SZER, J; TO, LB; MAHER, D; MCGRATH, KM; MORSTYN, G; FOX, RM			EFFECT OF PERIPHERAL-BLOOD PROGENITOR CELLS MOBILIZED BY FILGRASTIM (G-CSF) ON PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY	LANCET			English	Article							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; NON-LYMPHOBLASTIC LEUKEMIA; NEUTROPHIL RECOVERY; EARLY REMISSION; GRANULOCYTE; MALIGNANCIES; RECONSTITUTION; COLLECTION	The haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF; filgrastim) substantially shortens the period of severe neutropenia that follows high-dose chemotherapy and autologous bone-marrow infusion by stimulating granulopoiesis. Filgrastim also increases numbers of circulating progenitor cells. We have studied the ability of filgrastim to mobilise peripheral-blood progenitor cells and assessed their efficacy when infused after chemotherapy on recovery of neutrophil and platelet counts. 17 patients with non-myeloid malignant disorders received filgrastim (12-mu-g/kg daily for 6 days) by continuous subcutaneous infusion. Numbers of granulocyte-macrophage progenitors in peripheral-blood increased a median of 58-fold over pretreatment values, and numbers of erythroid progenitors increased a median of 24-fold. Three leucapheresis procedures collected a mean total of 33 (SEM 5.7) x 10(4) granulocyte-macrophage progenitors per kg body weight. After high-dose chemotherapy in 14 of the patients (busulphan and cyclophosphamide), these cells were used to augment autologous bone-marrow rescue and posttransplant filgrastim treatment. Platelet recovery was significantly faster in these patients than in controls who received the same treatment apart from the infusion of peripheral-blood progenitors; the platelet count reached 50 x 10(9)/l a median of 15 days after infusion of haemopoietic cells in the study patients compared with 39 days in controls (p = 0.0006). The accelerated neutrophil recovery associated with filgrastim treatment after chemotherapy was maintained. This method may be widely applicable to aid both neutrophil and platelet recovery after high-dose chemotherapy; it will allow investigation of peripheral-blood progenitor-cell allotransplantation.	ALFRED UNIV,CLIN HAEMATOL & BONE MARROW TRANSPLANTAT UNIT,ALFRED,NY 14802; LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIAGNOST HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL ADELAIDE HOSP,CLIN HAEMATOL & BONE MARROW TRANSPLANTAT UNIT,ADELAIDE,SA 5000,AUSTRALIA	State University of New York (SUNY) System; Alfred University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Adelaide Hospital	SHERIDAN, WP (corresponding author), ROYAL MELBOURNE HOSP,DEPT CLIN HAEMATOL & MED ONCOL,PARKVILLE,VIC 3050,AUSTRALIA.			Szer, Jeff/0000-0001-6783-2301; Sheridan, William/0000-0001-8320-1323				ANTMAN K, 1991, AUTOLOGOUS BONE MARR, P305; BLAZAR BR, 1989, BLOOD, V73, P849; DEVEREAUX S, 1989, BONE MARROW TRANSPL, V4, P49; DUHRSEN U, 1988, BLOOD, V72, P2074; FERRERO D, 1989, BLOOD, V73, P402; GABRILOVE JL, 1988, J CLIN INVEST, V82, P1454, DOI 10.1172/JCI113751; GIANNI AM, 1989, LANCET, V2, P580; GIANNI AM, 1990, BONE MARROW TRANSPL, V6, P143; GORIN NC, 1986, CLIN HAEMATOL, V15, P19, DOI 10.1016/S0308-2261(86)80004-2; HAAS R, 1990, EXP HEMATOL, V18, P94; HARA H, 1989, EXP HEMATOL, V17, P816; MCNIECE I, 1989, BLOOD, V74, P110; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1986, BLOOD, V67, P257; MOLINEUX G, 1990, BLOOD, V76, P2153; MORSTYN G, 1991, CANCER CHEMOTHERAPY, P307; NEMUNAITIS J, 1988, BLOOD, V72, P834; OFFIT K, 1990, BLOOD, V75, P1346; PETERS WP, 1991, AUTOLOGOUS BONE MARR, P313; PETZ LD, 1987, BLOOD, V70, P1331; SHERIDAN WP, 1989, MED J AUSTRALIA, V151, P379, DOI 10.5694/j.1326-5377.1989.tb101219.x; SHERIDAN WP, 1989, LANCET, V2, P891; SOCINSKI MA, 1988, LANCET, V1, P1194; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; TO LB, 1984, BRIT J HAEMATOL, V58, P399, DOI 10.1111/j.1365-2141.1984.tb03987.x; TO LB, 1990, BONE MARROW TRANSPL, V6, P109; TO LB, 1987, BONE MARROW TRANSPL, V2, P103	27	933	961	0	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					640	644		10.1016/0140-6736(92)90795-5	http://dx.doi.org/10.1016/0140-6736(92)90795-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1371817				2022-12-28	WOS:A1992HH74300004
J	MAHOWALD, AP				MAHOWALD, AP			GERM PLASM REVISITED AND ILLUMINATED	SCIENCE			English	Editorial Material							POLAR GRANULES; ANTEROPOSTERIOR POLARITY; DROSOPHILA EMBRYO; LOCALIZATION; GENE; VASA; EGG				MAHOWALD, AP (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.							BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BOSWELL RE, 1985, COMPREHENSIVE INSECT, V1, P387; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HAY B, 1990, DEVELOPMENT, V109, P425; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1971, J EXP ZOOL, V176, P345, DOI 10.1002/jez.1401760309; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MAHOWALD AP, 1971, DEV BIOL, V24, P37, DOI 10.1016/0012-1606(71)90045-5; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WARING GL, 1978, DEV BIOL, V6, P197	26	24	24	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1216	1217		10.1126/science.1372132	http://dx.doi.org/10.1126/science.1372132			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1372132				2022-12-28	WOS:A1992HG67700030
J	CONCATO, J; HORWITZ, RI; FEINSTEIN, AR; ELMORE, JG; SCHIFF, SF				CONCATO, J; HORWITZ, RI; FEINSTEIN, AR; ELMORE, JG; SCHIFF, SF			PROBLEMS OF COMORBIDITY IN MORTALITY AFTER PROSTATECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; BENIGN PROSTATIC HYPERPLASIA; TRANS-URETHRAL RESECTION; TRANSURETHRAL PROSTATECTOMY; CO-MORBIDITY; OUTCOMES; COMPLICATIONS; REOPERATION; IMMEDIATE; SEVERITY	Objective. - In recent studies of patients with benign prostatic hyperplasia (BPH), men undergoing transurethral resection of the prostate (TURP) had higher long-term mortality than men undergoing open prostatectomy. We tested the hypothesis that the higher mortality for patients undergoing TURP could have occurred if these patients were older and sicker at the time of surgery than patients undergoing open prostatectomy. Design and Setting. -Retrospective cohort study at Yale-New Haven (Conn) Hospital. Patients. - Two hundred fifty-two men who underwent TURP or open prostatectomy from 1979 through 1981 for the treatment of BPH. Main Outcome Measures. - Five-year mortality adjusted for age and severity of comorbid illness at the time of surgery. Results. - The crude 5-year mortality rates were 17.5% (22 of 126 patients) for the TURP group and 13.5% (17 of 126 patients) for the open group. At the time of surgery, however, patients in the TURP group were sicker and older than patients in the open group. As the detail and quality of the assessment of comorbidity increased, the adjusted risk of TURP decreased. Improved classifications of comorbidity in three different forms of statistical analysis did not show an effect of type of prostatectomy on long-term mortality (Mantel-Haenszel relative risk, 1.03; 95% confidence interval, 0.57 to 1.87). Conclusions. - These results suggest that TURP does not increase long-term mortality after surgery for the treatment of BPH. Inadequate accounting for severity of illness may also affect other statistical "adjustments" used in research concerned with patient outcomes.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT UROL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University								ACQUAVELLA JF, 1986, AM J IND MED, V9, P181, DOI 10.1002/ajim.4700090209; ANDERSEN TF, 1990, MED CARE, V28, P870, DOI 10.1097/00005650-199010000-00002; ARMITAGE P, 1971, STATISTICAL METHODS, P384; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P109; BYAR DP, 1980, BIOMETRICS, V36, P337, DOI 10.2307/2529989; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COX DR, 1972, J R STAT SOC B, V34, P187; FEINSTEIN AR, 1990, MEDICINE, V69, P1; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P184; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; HARRELL F, 1980, SUGI SUPPLEMENTAL LI, P437; HOWE GE, 1983, BENIGN PROSTATIC HYP, P806; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; KAPLAN MH, 1974, J CHRON DIS, V27, P387, DOI 10.1016/0021-9681(74)90017-4; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LURIE N, 1990, MED CARE, V28, P867, DOI 10.1097/00005650-199010000-00001; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; Mantel N, 1983, Stat Med, V2, P355; MCMAHON LF, 1988, J GEN INTERN MED, V3, P482, DOI 10.1007/BF02595926; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MELCHIOR J, 1974, J UROLOGY, V112, P634, DOI 10.1016/S0022-5347(17)59817-1; MUNOZ E, 1988, UROLOGY, V32, P380, DOI 10.1016/0090-4295(88)90251-8; OCONOR VJ, 1983, BENIGN PROSTATIC HYP, P868; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS NP, 1987, J UROLOGY, V137, P1184, DOI 10.1016/S0022-5347(17)44442-9; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SEJR T, 1991, SCAND J UROL NEPHROL, V25, P101, DOI 10.3109/00365599109024541; Singh M, 1973, Br J Urol, V45, P93, DOI 10.1111/j.1464-410X.1973.tb00050.x; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STIMSON JB, 1990, J GEN INTERN MED, V5, P153, DOI 10.1007/BF02600518; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; 1988, 1986 NATIONAL HLT 13, V197; 1989, INT CLASSIFICATION D; 1989, NATIONAL DEATH INDEX	38	126	126	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1077	1082		10.1001/jama.267.8.1077	http://dx.doi.org/10.1001/jama.267.8.1077			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE391	1370963				2022-12-28	WOS:A1992HE39100022
J	SOLA, A; KURLAT, I; POLLAK, A; DEVLIEGER, H; TAPIA, J; SAENZ, A; PEITERSEN, B; RAIVO, K; JARVENPAA, AL; LELOUP, M; LENOIR, S; DAGBJARTSSON, A; CUSSEN, G; SCHIMMEL, M; PAULTY, F; DARLOW, B; GROGAARD, J; TORRADO, A; JANUARIU, L; HO, N; JIMENEZ, JQ; HJALMARSON, O; BUCHER, HO; BERNER, M; COOKE, R; WEINDLING, M; WILKINSON, A; MERRITT, A				SOLA, A; KURLAT, I; POLLAK, A; DEVLIEGER, H; TAPIA, J; SAENZ, A; PEITERSEN, B; RAIVO, K; JARVENPAA, AL; LELOUP, M; LENOIR, S; DAGBJARTSSON, A; CUSSEN, G; SCHIMMEL, M; PAULTY, F; DARLOW, B; GROGAARD, J; TORRADO, A; JANUARIU, L; HO, N; JIMENEZ, JQ; HJALMARSON, O; BUCHER, HO; BERNER, M; COOKE, R; WEINDLING, M; WILKINSON, A; MERRITT, A			EARLY VERSUS DELAYED NEONATAL ADMINISTRATION OF A SYNTHETIC SURFACTANT - THE JUDGMENT OF OSIRIS	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; 30 WEEKS GESTATION; CONTROLLED TRIAL; INFANTS; PROPHYLAXIS; THERAPY; LESS	Although exogenous surfactants are of known efficacy in the prevention and treatment of respiratory distress syndrome (RDS), questions remain about the best regimens. During 1990-91, 6774 babies were recruited to an international multicentre trial to assess when administration of Exosurf, a synthetic surfactant should be started and how often it should be given. The clinical outcome is known for 6757 (99.7%) infants. 2690 babies, judged to be at high risk of RDS when less than 2 hours of age, were randomly allocated to either early administration or delayed selective administration; 96% versus 73% received surfactant, at median ages of 118 and 182 min. The risk of death or dependence on extra oxygen at the expected date of delivery was 16% (95% Cl 25% to 7%) lower among infants allocated early administration. Early administration was also associated with a 32% lower risk of pneumothorax. These 2690 infants were further randomised in a factorial design to either two doses of surfactant 12 hours apart, or the option of third and fourth doses at 12-36 hour intervals if signs of RDS persisted or recurred. 4067 other infants who later developed RDS were also recruited to this comparison, giving a total of 3376 infants allocated up-to-four doses (of whom, 45% received more than two) and 3381 allocated two doses. The outcome was similar in the two groups in respect of death, long-term oxygen dependence, and other major morbidity, even in secondary analyses restricted to infants who met the criteria for additional administration. There were more reports of poorly tolerated administration in the up-to-four doses group but no clear increase in serious morbidity, such as pulmonary haemorrhage. The OSIRIS trial suggests that early administration of surfactant to an estimated 32 babies, when compared with treatment of established RDS, would prevent 1 baby from dying and another from being dependent on extra oxygen long-term, but would entail the additional use of surfactant in 8 of these babies. It provides no evidence that a regimen including the option of third and fourth doses when signs of RDS persist or recur is clinically superior to a regimen of two doses.			SOLA, A (corresponding author), JP GARRAHAN, BUENOS AIRES, ARGENTINA.							CUMMINGS JJ, 1992, AM REV RESPIR DIS, V145, P999, DOI 10.1164/ajrccm/145.5.999; DUNN MS, 1991, PEDIATRICS, V87, P377; EGBERTS J, 1992, OXFORD DATABASE PERI; ENHORNING G, 1977, J APPL PHYSIOL, V43, P198, DOI 10.1152/jappl.1977.43.2.198; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; Halliday Henry L., 1992, P359; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; KONISHI M, 1990, P ROSS SPEC C HOT TO, P233; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MERRITT TA, 1991, J PEDIATR-US, V118, P581, DOI 10.1016/S0022-3476(05)83387-6; PRAMANIK AK, 1992, PEDIATR RES 2, V31; SOLL RF, 1992, OXFORD DATABASE PERI; Soll Roger F., 1992, P325; 1992, ONLINE J CURR C 1110	16	159	160	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	1992	340	8832					1363	1369						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360087				2022-12-28	WOS:A1992KB20200001
J	VANACKER, BAC; KOOMEN, GCM; KOOPMAN, MG; DEWAART, DR; ARISZ, L				VANACKER, BAC; KOOMEN, GCM; KOOPMAN, MG; DEWAART, DR; ARISZ, L			CREATININE CLEARANCE DURING CIMETIDINE ADMINISTRATION FOR MEASUREMENT OF GLOMERULAR-FILTRATION RATE	LANCET			English	Article							MARKER; PHARMACOKINETICS; IMPROVES	Creatinine clearance inaccurately estimates true glomerular filtration rate (GFR) because of tubular secretion of creatinine. We studied the ability of oral cimetidine, a blocker of tubular creatinine secretion, to improve the accuracy of measuring creatinine clearance. Clearances of inulin and endogenous creatinine were simultaneously measured in 16 patients with renal disease before administration of cimetidine and during 8 successive 3 h clearance periods with cimetidine 400 mg as priming dose followed by 200 mg every 3 h. At baseline, creatinine relative to inulin clearance (Cl(C)/Cl(I)) ranged from 1.14 to 2.27. With cimetidine, Cl(C)/Cl(I) approached unity in 8 patients (mean 1.02 [SD 0.03]), but considerably exceeded unity in 8 others (1.33 [0.14]). Plasma cimetidine/creatinine ratio was smaller in this second group, due to significantly higher renal clearance of cimetidine (333 [136] vs 165 [89] ml/min, p=0.01). In a further study, cimetidine dose and, consequently plasma cimetidine concentration, was increased in 6 additional patients who had incomplete inhibition previously. This increased dose completely inhibited tubular creatinine secretion in the third until the sixth hour, so that creatinine clearance equalled GFR. Provided an adequate dose of cimetidine is given, 24 h creatinine clearance during administration of drug measures GFR accurately in patients with renal disease. However, because of the maximum daily dose of cimetidine that is advised, short clearance times (3 h) are recommended.	UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN CHEM,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VANACKER, BAC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT MED,RENAL UNIT F4-215,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							BAUER JH, 1982, AM J KIDNEY DIS, V2, P337, DOI 10.1016/S0272-6386(82)80091-7; BERLYNE GM, 1964, LANCET, V2, P874; BRATER C, 1992, KIDNEY PHYSL PATHOPH, P3597; BROWN P, 1977, CLIN CHIM ACTA, V76, P103, DOI 10.1016/0009-8981(77)90123-1; BURGESS E, 1982, RENAL PHYSIOL BIOCH, V5, P27; CARRIE BJ, 1980, AM J MED, V69, P177, DOI 10.1016/0002-9343(80)90376-9; GIOVANNETTI S, 1991, NEPHRON, V59, P11, DOI 10.1159/000186510; GISCLON LG, 1988, DRUG METAB DISPOS, V16, P331; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; HOOD B, 1971, Scandinavian Journal of Urology and Nephrology, V5, P154, DOI 10.3109/00365597109133594; KOOPMAN MG, 1989, CLIN SCI, V77, P105, DOI 10.1042/cs0770105; LEVINSKY NG, 1959, AM J PHYSIOL, V196, P549, DOI 10.1152/ajplegacy.1959.196.3.549; Miller BF, 1938, J CLIN INVEST, V17, P31, DOI 10.1172/JCI100925; PETRI M, 1988, KIDNEY INT, V34, P832, DOI 10.1038/ki.1988.257; ROUBENOFF R, 1990, ANN INTERN MED, V113, P501, DOI 10.7326/0003-4819-113-7-501; Shannon JA, 1935, J CLIN INVEST, V14, P403, DOI 10.1172/JCI100691; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; SOMOGYI A, 1983, CLIN PHARMACOKINET, V8, P463, DOI 10.2165/00003088-198308060-00001; VANACKER BAC, 1992, J LAB CLIN MED, V120, P400; VANGINNEKEN CAM, 1989, CLIN PHARMACOKINET, V16, P38, DOI 10.2165/00003088-198916010-00003; WEBER JA, 1991, CLIN CHEM, V37, P695; ZIEMNIAK JA, 1981, CLIN CHEM, V27, P272	22	138	138	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1326	1329		10.1016/0140-6736(92)92502-7	http://dx.doi.org/10.1016/0140-6736(92)92502-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360044	Bronze			2022-12-28	WOS:A1992KA26200013
J	MOMBAERTS, P; CLARKE, AR; RUDNICKI, MA; IACOMINI, J; ITOHARA, S; LAFAILLE, JJ; WANG, LL; ICHIKAWA, Y; JAENISCH, R; HOOPER, ML; TONEGAWA, S				MOMBAERTS, P; CLARKE, AR; RUDNICKI, MA; IACOMINI, J; ITOHARA, S; LAFAILLE, JJ; WANG, LL; ICHIKAWA, Y; JAENISCH, R; HOOPER, ML; TONEGAWA, S			MUTATIONS IN T-CELL ANTIGEN RECEPTOR GENES ALPHA-BLOCK AND BETA-BLOCK THYMOCYTE DEVELOPMENT AT DIFFERENT STAGES	NATURE			English	Article							MOUSE PGK-1 GENE; TRANSGENIC MICE; EXPRESSION; CHAIN; ORGANIZATION; DIVERSITY; ANTIBODY; SEQUENCE; PROMOTER; MUTANT	Analysis of mice carrying mutant T-cell antigen receptor (TCR) genes indicates that TCR-beta gene rearrangement or expression is critical for the differentiation of CD4-CD8- thymocytes to CD4+CD8+ thymocytes, as well as for the expansion of the pool of CD4+CD8+ cells. TCR-alpha is irrelevant in these developmental processes. The development of gammadelta T cells does not depend on either TCR-alpha or TCR-beta.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV EDINBURGH,AFRC,CTR GENOME RES,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV EDINBURGH,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Edinburgh; Massachusetts Institute of Technology (MIT); University of Edinburgh			Itohara, Shigeyoshi/I-8769-2012; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Itohara, Shigeyoshi/0000-0002-2410-9989; Clarke, Alan/0000-0002-4281-426X				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HAAS W, 1992, CURR OPIN IMMUNOL, V4, P147, DOI 10.1016/0952-7915(92)90004-X; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; HOCKETT R D JR, 1989, New Biologist, V1, P266; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P293; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; SHORTMAN K, 1992, CURR OPIN IMMUNOL, V4, P140, DOI 10.1016/0952-7915(92)90003-W; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	29	968	983	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					225	231		10.1038/360225a0	http://dx.doi.org/10.1038/360225a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359428				2022-12-28	WOS:A1992JY96000041
J	SHATZ, CJ				SHATZ, CJ			DIVIDING UP THE NEOCORTEX	SCIENCE			English	Editorial Material							CAT STRIATE CORTEX; CORTICAL AREAS; CONNECTIONS; NEURONS; SEGMENTATION; SPECIFICITY; HINDBRAIN				SHATZ, CJ (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV NEUROBIOL, BERKELEY, CA 94720 USA.							BARBE MF, 1991, J NEUROSCI, V11, P519; BOLTZ J, 1990, NATURE, V346, P359; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; FISHELL CA, 1992, SOC NEUR ABSTR, V18, P926; Frantz G. D., 1992, Society for Neuroscience Abstracts, V18, P957; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; STERN CD, 1988, TRENDS NEUROSCI, V11, P190, DOI 10.1016/0166-2236(88)90120-8; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	27	31	32	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					237	238		10.1126/science.1357747	http://dx.doi.org/10.1126/science.1357747			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357747				2022-12-28	WOS:A1992JR86000016
J	ROBERTS, JD; POLANER, DM; LANG, P; ZAPOL, WM				ROBERTS, JD; POLANER, DM; LANG, P; ZAPOL, WM			INHALED NITRIC-OXIDE IN PERSISTENT PULMONARY-HYPERTENSION OF THE NEWBORN	LANCET			English	Note							RELAXING FACTOR	Nitric oxide (NO) has vasodilatory effects on the pulmonary vasculature in adults and animals. We examined the effects on systemic oxygenation and blood pressure of inhaling up to 80 parts per million by volume of NO at F(i)O2 0.9 for up to 30 minutes by 6 infants with persistent pulmonary hypertension of the newborn (PPHN). In all infants this treatment rapidly and significantly increased preductal oxygen saturation (SpO2); in 5 infants postductal SpO2 and oxygen tensions also increased. Inhalation of NO did not cause systemic hypotension or raise methaemoglobin. These data suggest that low levels of inhaled NO have an important role in the reversal of hypoxaemia due to PPHN.	MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROBERTS, JD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114, USA.		Polaner, David M/AAX-2514-2021	Polaner, David M/0000-0001-8716-6289	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042397] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CLUTTONBROCK J, 1967, BRIT J ANAESTH, V39, P388, DOI 10.1093/bja/39.5.388; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS J D JR, 1992, American Review of Respiratory Disease, V145, pA208	8	693	719	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					818	819		10.1016/0140-6736(92)92686-A	http://dx.doi.org/10.1016/0140-6736(92)92686-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357245				2022-12-28	WOS:A1992JR16800005
J	MCKEITH, I; FAIRBAIRN, A; PERRY, R; THOMPSON, P; PERRY, E				MCKEITH, I; FAIRBAIRN, A; PERRY, R; THOMPSON, P; PERRY, E			NEUROLEPTIC SENSITIVITY IN PATIENTS WITH SENILE DEMENTIA OF LEWY BODY TYPE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To determine the outcome of administration of neuroleptics to patients with senile dementia of Lewy body type confirmed at necropsy. Design-Retrospective analysis of clinical notes blind to neuropathological diagnosis. Setting-Specialist psychogeriatric assessment units referring cases for necropsy to a teaching hospital neuropathology service. Patients-41 elderly patients with diagnosis of either Alzheimer type dementia (n=21) or Lewy body type dementia (n=20) confirmed at necropsy. Main outcome measures-Clinical state including extrapyramidal features before and after neuroleptic treatment and survival analysis of patients showing severe neuroleptic sensitivity compared with the remainder in the group. Results-16 (80%) patients with Lewy body type dementia received neuroleptics, 13 (81%) of whom reacted adversely; in seven (54%) the reactions were severe. Survival analysis showed an increased mortality in the year after presentation to psychiatric services compared with patients with mild or no neuroleptic sensitivity (hazard ratio 2.70 (95% confidence interval 2.50-8.99); (chi-2=2.68, p=0.05). By contrast, only one (7%) of 14 patients with Alzheimer type dementia given neuroleptics showed severe neuroleptic sensitivity. Conclusions-Severe, and often fatal, neuroleptic sensitivity may occur in elderly patients with confusion, dementia, or behavioural disturbance. Its occurrence may indicate senile dementia of Lewy body type and this feature has been included in clinical diagnostic criteria for this type of dementia.	GATESHEAD MENTAL HLTH UNIT,OLD AGE PSYCHIAT,GATESHEAD,ENGLAND; NEWCASTLE GEN HOSP,MRC,NEUROCHEM PATHOL UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	MCKEITH, I (corresponding author), NEWCASTLE GEN HOSP,OLD AGE PSYCHIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.		McKeith, Ian/AAH-3382-2021	McKeith, Ian/0000-0002-9250-0568				ADOZZONIZIO G, 1991, INT J GERIATRIC PSYC, V6, P547; GILLEARD CJ, 1983, ACTA PSYCHIAT SCAND, V68, P419, DOI 10.1111/j.1600-0447.1983.tb00950.x; HANSEN L, 1990, NEUROLOGY, V40, P1; LENNOX G, 1989, J NEUROL NEUROSUR PS, V52, P1236, DOI 10.1136/jnnp.52.11.1236; MCKEITH IG, IN PRESS PSYCHOL MED; PERRY EK, 1991, ANN NY ACAD SCI, V640, P197; PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G; ZIMMER JG, 1984, AM J PUBLIC HEALTH, V74, P1118, DOI 10.2105/AJPH.74.10.1118	8	447	452	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					673	678		10.1136/bmj.305.6855.673	http://dx.doi.org/10.1136/bmj.305.6855.673			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1356550	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JP51100018
J	KOUDSTAAL, PJ; ALGRA, A; POP, GAM; KAPPELLE, LJ; VANLATUM, JC; VANGIJN, J				KOUDSTAAL, PJ; ALGRA, A; POP, GAM; KAPPELLE, LJ; VANLATUM, JC; VANGIJN, J			RISK OF CARDIAC EVENTS IN ATYPICAL TRANSIENT ISCHEMIC ATTACK OR MINOR STROKE	LANCET			English	Article							ISCHEMIC ATTACKS; INTEROBSERVER AGREEMENT; CEREBRAL-ISCHEMIA; DIAGNOSIS; SYMPTOMS	Proposed guidelines for the diagnosis of transient ischaemic attack (TIA) involve interpretation of symptoms, so it can be very difficult to distinguish a TIA from other disorders, such as migraine, epilepsy, syncope, or neurosis. Atypical cerebral and visual events may be classified as TIA. To see whether TIA or stroke patients with atypical cerebral or visual symptoms are at high or low risk of cardiac complications, we prospectively followed 572 patients (entered into the Dutch multicentre TIA trial) with a diagnosis of TIA or minor ischaemic stroke, but whose symptoms did not fully accord with internationally accepted criteria. We compared their outcome with that of 2555 other TIA or stroke patients in the trial, who had unequivocal symptoms; all patients were treated with aspirin. During mean follow-up of 2.6 years the risk of a major vascular event did not differ between the groups (14.5% in patients with atypical symptoms vs 15.1% of patients with typical attacks). Patients with atypical attacks had a lower risk of stroke (5.6% vs 9.4%, hazard ratio 0.6, 95% confidence interval 0.4-0.9) and a higher risk of a major cardiac event (8.4% vs 5.9%, 1.4, 1.0-2.0) than did patients with typical attacks. These differences could not be explained by differences in cardiac risk factors, and were independent of minor discrepancies in baseline characteristics between the groups. A heavy or tired feeling in one or two limbs was the only atypical symptom associated with cerebral rather than cardiac events (ratio cardiac/cerebral events 0.8). For all other atypical symptoms cardiac events were about twice as common as cerebral events (range 1.3-2.5). Our findings suggest that TIA or minor stroke patients with atypical symptoms may have symptomatic heart disease, especially cardiac arrhythmia.	HOLY HOSP VLAARDINGEN,DEPT CARDIOL,VLAARDINGEN,NETHERLANDS; UNIV UTRECHT,DEPT NEUROL,UTRECHT,NETHERLANDS	Utrecht University	KOUDSTAAL, PJ (corresponding author), UNIV HOSP ROTTERDAM DIJKZIGT,DEPT NEUROL,40 DR MOLEWATERPLEIN,3015 GD ROTTERDAM,NETHERLANDS.		van Gijn, Jan/A-9444-2008; Pop, Gheorghe/L-4582-2015					[Anonymous], 1988, Stroke, V19, P512; [Anonymous], 1975, STROKE, V6, P566; BAQUIS GD, 1985, STROKE, V16, P444, DOI 10.1161/01.STR.16.3.444; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; DEBONO DP, 1982, BRIT MED J, V284, P1437, DOI 10.1136/bmj.284.6327.1437; DENNIS MS, 1989, LANCET, V1, P185; FISHER CM, 1980, CAN J NEUROL SCI, V7, P9; GAUL JJ, 1986, STROKE, V17, P393, DOI 10.1161/01.STR.17.3.393; HEYDEN S, 1980, STROKE, V11, P252, DOI 10.1161/01.STR.11.3.252; JONAS S, 1977, ANN NEUROL, V1, P470, DOI 10.1002/ana.410010511; KOUDSTAAL PJ, 1991, CLIN NEUROL NEUROSUR, V93, P107, DOI 10.1016/0303-8467(91)90049-U; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; MUURONEN A, 1982, STROKE, V13, P24, DOI 10.1161/01.STR.13.1.24; Rai G S, 1982, Age Ageing, V11, P113, DOI 10.1093/ageing/11.2.113; REED RL, 1973, JAMA-J AM MED ASSOC, V223, P893, DOI 10.1001/jama.223.8.893; RUSSELL WRR, 1983, BRAIN, V296, P320; VANDURME JP, 1975, AM HEART J, V89, P538, DOI 10.1016/0002-8703(75)90164-7; VANMERODE T, 1985, STROKE, V16, P34, DOI 10.1161/01.STR.16.1.34; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; 1991, NEW ENGL J MED, V325, P1261; 1991, J NEUROL NEUROSUR PS, V54, P1044; 1988, BMJ, V296, P320	24	41	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					630	633		10.1016/0140-6736(92)92170-K	http://dx.doi.org/10.1016/0140-6736(92)92170-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355211				2022-12-28	WOS:A1992JM85100003
J	REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA				REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA			CARDIAC RESUSCITATION WITH PERCUTANEOUS CARDIOPULMONARY SUPPORT	LANCET			English	Note							ACUTE MYOCARDIAL-INFARCTION; BYPASS; SHOCK	Percutaneous cardiopulmonary support (CPS) was initiated in 9 patients to provide haemodynamic stability after failure of conventional resuscitation. 4 patients were in cardiogenic shock and 4 remained in asystole, with 1 in resistant ventricular fibrillation, after cardiac arrest. During CPS for those in cardiogenic shock, the mean intra-arterial pressures ranged from 65 to 100 mm Hg (mean 84), at flow rates of between 3 to 5 l/min (mean 3.9). 2 patients underwent technically successful coronary angioplasty. No patient in this group survived. In the cardiac arrest group, acceptable mean intra-arterial blood pressures were achieved (mean 95, range 90-100 mm Hg) at flow rates of between 2 to 3 l/min (mean 2.6). All 5 subjects underwent technically successful coronary angioplasty whilst on CPS. 4 survived. 2 were alive and well at 12 months follow-up, 1 of whom had returned to work; the third is alive and well at 4 months.			REES, MR (corresponding author), KILLINGBECK HOSP,REG CARDIOTHORAC CTR,CARDIAC RES UNIT,YORK RD,LEEDS LS14 6UQ,ENGLAND.		Rees, Michael/Y-4640-2019					AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; LITZIE AK, 1987, P AM ACAD CV PERFUSI, V8, P60; PROCTOR E., 1967, CARDIOVASC RES, V1, P189, DOI 10.1093/cvr/1.2.189; ROZENBAUM EA, 1988, CRIT CARE MED, V16, P583, DOI 10.1097/00003246-198806000-00003; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SHAWL FA, 1989, AM J CARDIOL, V64, P967, DOI 10.1016/0002-9149(89)90791-1; TOPOL E, 1988, ACUTE CORONARY INTER, P195	8	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					513	514		10.1016/0140-6736(92)91711-G	http://dx.doi.org/10.1016/0140-6736(92)91711-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354278				2022-12-28	WOS:A1992JL23400005
J	VELHO, G; FROGUEL, P; CLEMENT, K; PUEYO, ME; RAKOTOAMBININA, B; ZOUALI, H; PASSA, P; COHEN, D; ROBERT, JJ				VELHO, G; FROGUEL, P; CLEMENT, K; PUEYO, ME; RAKOTOAMBININA, B; ZOUALI, H; PASSA, P; COHEN, D; ROBERT, JJ			PRIMARY PANCREATIC BETA-CELL SECRETORY DEFECT CAUSED BY MUTATIONS IN GLUCOKINASE GENE IN KINDREDS OF MATURITY ONSET DIABETES OF THE YOUNG	LANCET			English	Article							INSULIN RELEASE; GLUCOSE; HUMANS	Maturity-onset diabetes of the young (MODY), characterised by non-insulin-dependent diabetes mellitus (NIDDM) with an early age of onset, is a genetically heterogeneous disorder. In most MODY kindreds described in France, chronic hyperglycaemia is caused by mutations in the gene encoding pancreatic beta-cell and liver glucokinase (GCK). We here report the beta-cell secretory profiles of nine patients from four GCK-linked MODY kindreds. First-phase insulin secretion assessed by an intravenous glucose test was comparable in patients and seven controls. However, beta-cell secretory response to continuous glucose stimulus during a hyperglycaemic glucose clamp was significantly reduced: mean plasma insulin values of 12 (SD 7) vs 40 (11) mU/l (p=0.0001) and mean plasma C-peptide values 1.20 (0.30) vs 2.61 (0.37) (p=0.0001).This secretory profile is different from those for NIDDM with late age of onset or MODY not linked to GCK. Fasting plasma insulin and C-peptide in patients were inappropriately low in relation to concomitant plasma glucose level. Furthermore, during a hyperinsulinaemic euglycaemic clamp, endogenous insulin secretion at euglycaemia (5 mmol/l) was suppressed in patients but not in controls. These results suggest that mutant GCK may lead to chronic hyperglycaemia by raising the threshold of circulating glucose level which induces insulin secretion. These data provide the first demonstration of a primary pancreatic secretory defect associated with a form of NIDDM.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,UNITE ENDOCRINOL & DIABETOL PEDIAT,INSERM,U30,F-75730 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	VELHO, G (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Velho, Gilberto/Q-6724-2017; Clément, karine/R-1120-2017; FROGUEL, Philippe/O-6799-2017	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784				ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222, DOI 10.1210/jcem-42-2-222; CALLESESCANDON J, 1987, DIABETES, V36, P1167, DOI 10.2337/diabetes.36.10.1167; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Efendic S, 1988, Adv Exp Med Biol, V246, P167; FAJANS S S, 1986, Diabetes Metabolism Reviews, V2, P347; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; LUZI L, 1989, AM J PHYSIOL, V257, pE241, DOI 10.1152/ajpendo.1989.257.2.E241; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NAIDOO C, 1986, DIABETES CARE, V9, P57, DOI 10.2337/diacare.9.1.57; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; STOFFEL M, 1992, IN PRESS P NATL ACAD, V89; TCHHOBROUTSKY G, 1991, DIABETOLOGIA, V34, P67; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1985, TECH REP SER WHO, V727	24	200	202	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					444	448		10.1016/0140-6736(92)91768-4	http://dx.doi.org/10.1016/0140-6736(92)91768-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354782				2022-12-28	WOS:A1992JJ87700002
J	COOKSON, WOCM; YOUNG, RP; SANDFORD, AJ; MOFFATT, MF; SHIRAKAWA, T; SHARP, PA; FAUX, JA; JULIER, C; LESOUEF, PN; NAKAMURA, Y; LATHROP, GM; HOPKIN, JM				COOKSON, WOCM; YOUNG, RP; SANDFORD, AJ; MOFFATT, MF; SHIRAKAWA, T; SHARP, PA; FAUX, JA; JULIER, C; LESOUEF, PN; NAKAMURA, Y; LATHROP, GM; HOPKIN, JM			MATERNAL INHERITANCE OF ATOPIC IGE RESPONSIVENESS ON CHROMOSOME-11Q	LANCET			English	Article							SERUM IGE; ALLERGY; RESPONSES; GENETICS; ASTHMA; TWINS	Atopy is a common familial state underlying allergic asthma and rhinitis. Lately, we have assigned a gene for atopy to chromosome 11 q by linkage to the marker D11S97. Since previous studies have suggested that the risk of atopy is higher for children of atopic mothers than for those of atopic fathers, we sought differences between maternal and paternal patterns of transmission at the 11q13 locus among pairs of siblings in families affected by atopy. When we defined atopy as the presence of a positive skinprick test (greater-than-or-equal-to 2 mm) to any of a panel of common allergens, a higher than normal concentration of total serum IgE, or a positive radioallergosorbent test for a specific IgE, we found that 125 (62%) of the sibling-pairs affected by atopy shared the maternal 11q13 allele and 78 (38%) did not. This distribution differs significantly from the expected 50/50 distribution (p=0.001). Of paternally derived alleles, 83 (46%) were shared and 96 (54%) were not (not significantly different from 50/50). The result was similar whatever definition of atopy was used and with other genetic markers on 11q. These findings show that transmission of atopy at the chromosome 11q locus is detectable only through the maternal line. The pattern of inheritance is consistent either with paternal genomic imprinting or with maternal modification of developing immune responses.	CTR ETUD POLYMORPHISME HUMAINE,PARIS,FRANCE; CHURCHILL HOSP,OLSER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Oxford; Japanese Foundation for Cancer Research	COOKSON, WOCM (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND.		JULIER, Cécile/M-9824-2017; Le Souef, Peter N/H-5256-2014; Cookson, William/HHC-1790-2022	JULIER, Cécile/0000-0002-1538-0240; Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; HALL JG, 1990, ARCH DIS CHILD-FETAL, V65, P1013, DOI 10.1136/adc.65.10_Spec_No.1013; HANSON B, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90337-9; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOLT PG, 1990, IMMUNOLOGY, V1, P3; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; PEAT JK, 1987, CLIN ALLERGY, V17, P271; RUIZ RGG, 1991, SCHWEIZ MED WSCH S40, V121, P129; SETTIPANE RA, 1989, ALLERGY PROC, V9, P555; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1970; SHIRAKAWA T, IN PRESS AM J EPIDEM; SOLTER D, 1988, ANNU REV GENET, V22, P127; TOKINO T, 1991, AM J HUM GENET, V48, P258; WAYE JS, 1987, HUM GENET, V77, P151, DOI 10.1007/BF00272383; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	29	297	309	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					381	384		10.1016/0140-6736(92)91468-N	http://dx.doi.org/10.1016/0140-6736(92)91468-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353553				2022-12-28	WOS:A1992JJ44900001
J	HERRERA, MG; NESTEL, P; ELAMIN, A; FAWZI, WW; MOHAMED, KA; WELD, L				HERRERA, MG; NESTEL, P; ELAMIN, A; FAWZI, WW; MOHAMED, KA; WELD, L			VITAMIN-A SUPPLEMENTATION AND CHILD SURVIVAL	LANCET			English	Article							SOUTHERN INDIA; MORTALITY; TRIAL; MEASLES	Previous studies of the effect of 6-monthly vitamin A supplementation on child mortality have given conflicting results. In other trials, more frequent doses of vitamin A have significantly reduced mortality among children at risk of vitamin A deficiency. We have done a double-blind, placebo controlled trial of vitamin A supplementation in the Sudan among 28 753 children aged 9-72 months at risk of vitamin A deficiency. Children were assigned to receive either 200 000 IU vitamin A and 40 IU vitamin E every 6 months (vitamin A group) or 40 IU vitamin E alone (placebo group). During the 18 months of follow-up, there were 120 deaths (8.4/1000) in the vitamin A group and 112 (7.9/1000) in the placebo group (relative risk 1.06, 95% confidence interval 0.82-1.37). Controlling for geographic site, round of observation, anthropometry, morbidity, dietary intake of vitamin A, sex, and all baseline differences between the two groups did not change the results. Children living in poor and unsanitary environments, younger children, and those sick, stunted, wasted, or consuming diets low in vitamin A were at a significantly higher risk of dying. The lack of an effect of large-dose vitamin A supplementation on mortality, despite a clear association between dietary vitamin A and mortality, underscores the need to identify factors that modify the efficacy of vitamin A supplements as a public health measure. Reducing poverty, improvements in sanitation, and access to adequate diets should remain the main goals to improve child survival.	MINIST HLTH SUDAN,DIV NUTR,KHARTOUM,SUDAN; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	HERRERA, MG (corresponding author), HARVARD UNIV,INST INT DEV,1 ELIOT ST,CAMBRIDGE,MA 02138, USA.		Elamin, Abdelaziz/AAA-2873-2022	Elamin, Abdelaziz/0000-0002-4454-1664; Weld, Leisa/0000-0001-6550-0135				[Anonymous], 1968, FOOD COMPOSITION TAB; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; GLOVER J, 1983, P NUTR SOC, V42, P19, DOI 10.1079/PNS19830004; GOPALAN C, 1991, 1ST P INT S NUTR F I; HAMILL PVV, DHEW PHS781650 PUBL; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; MUHILAL PD, 1988, AM J CLIN NUTR, V48, P1271; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; SINGER JD, 1991, PSYCHOL BULL, V110, P268, DOI 10.1037/0033-2909.110.2.268; Sommer A, 1983, Trans Am Ophthalmol Soc, V81, P825; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1983, LANCET, V2, P585; SUVAKUMAR B, 1972, BR J NUTR, V27, P299; SWAMINATHAN MC, 1970, AM J CLIN NUTR, V23, P119; UDOMKESMALEE E, 1992, AM J CLIN NUTR, V56, P50, DOI 10.1093/ajcn/56.1.50; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; 1976, AGR HDB, V81	19	107	110	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					267	271		10.1016/0140-6736(92)92357-L	http://dx.doi.org/10.1016/0140-6736(92)92357-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353192				2022-12-28	WOS:A1992JG66500004
J	LAURENCE, J; SIEGAL, FP; SCHATTNER, E; GELMAN, IH; MORSE, S				LAURENCE, J; SIEGAL, FP; SCHATTNER, E; GELMAN, IH; MORSE, S			ACQUIRED IMMUNODEFICIENCY WITHOUT EVIDENCE OF INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2	LANCET			English	Note								There have been three published cases of acquired immunodeficiency in which no evidence for infection with human immunodeficiency virus (HIV) types 1 and 2 was found. We have identified five other individuals, from the New York City area (four who have known risk factors for HIV infection), with profound CD4 depletion and clinical syndromes consistent with definitions of the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. None had evidence of HIV-1, 2 infection, as judged by multiple serologies over several years, standard viral co-cultures for HIV p24 Gag antigen, and proviral DNA amplification by polymerase chain reaction.	ROCKEFELLER UNIV,NEW YORK,NY 10021; LONG ISL JEWISH MED CTR,NEW HYDE PK,NY 11042; MT SINAI MED CTR,DEPT MICROBIOL,NEW YORK,NY 10029	Rockefeller University; Northwell Health; Icahn School of Medicine at Mount Sinai	LAURENCE, J (corresponding author), CORNELL UNIV,MED CTR,COLL MED,AIDS VIRUS RES LAB,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029119] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CASTRO A, 1992, LANCET, V339, P868, DOI 10.1016/0140-6736(92)90308-P; LAURENCE J, 1987, SCIENCE, V235, P1501, DOI 10.1126/science.2435004; SAFAI B, 7TH INT C AIDS FLOR; SORIANO VC, 1991, 7 INT C AIDS FLOR; 1987, MMWR, V36, pS1	6	85	87	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					273	274		10.1016/0140-6736(92)92359-N	http://dx.doi.org/10.1016/0140-6736(92)92359-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353194	hybrid			2022-12-28	WOS:A1992JG66500006
J	LIM, R; DYMOND, DS				LIM, R; DYMOND, DS			SHOULD ANTIANGINAL MEDICATION BE STOPPED FOR EXERCISE TESTING	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE				LIM, R (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CARDIOL,LONDON EC1A 7BE,ENGLAND.		Lim, Richard/J-7102-2012	Lim, Richard/0000-0002-4914-7244				ELAMIN MS, 1982, BRIT HEART J, V48, P311; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; HO WCS, 1985, AM J CARDIOL, V55, P258; JONES RH, 1981, CIRCULATION, V64, P586, DOI 10.1161/01.CIR.64.3.586; KRONE RJ, 1987, AM J CARDIOL, V60, P23, DOI 10.1016/0002-9149(87)90977-5; Lim R, 1991, Int J Card Imaging, V7, P125, DOI 10.1007/BF01798052; LIM R, 1992, AM J CARDIOL, V69, P733, DOI 10.1016/0002-9149(92)90496-L; LIM R, 1991, Journal of the American College of Cardiology, V17, p183A; STONE D, 1980, BRIT HEART J, V44, P208; WILCOX I, 1991, J AM COLL CARDIOL, V18, P677, DOI 10.1016/0735-1097(91)90789-C	10	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					161	162		10.1016/0140-6736(92)93226-D	http://dx.doi.org/10.1016/0140-6736(92)93226-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352576				2022-12-28	WOS:A1992JE38200014
J	WHORWELL, PJ; HOUGHTON, LA; TAYLOR, EE; MAXTON, DG				WHORWELL, PJ; HOUGHTON, LA; TAYLOR, EE; MAXTON, DG			PHYSIOLOGICAL-EFFECTS OF EMOTION - ASSESSMENT VIA HYPNOSIS	LANCET			English	Article							IRRITABLE-BOWEL-SYNDROME; HYPNOTHERAPY; STRESS; PERTURBATION; MOTILITY; MOTOR	Assessment of the physiological effects of physical and emotional stress has been hampered by a lack of suitable laboratory techniques. Since hypnosis can be used safely to induce specific emotional states of considerable intensity, we studied the effect on distal colonic motility of three hypnotically induced emotions (excitement, anger, and happiness) in 18 patients aged 20-48 years with irritable bowel syndrome. Colonic motility index was reduced by hypnosis on its own (mean change 19.1; 95% Cl 0.8, 37.3; p<0.05) and this change was accompanied by decreases in both pulse (12; 8, 15) and respiration (6; 4, 8) rates (p<0.001 for both). Anger and excitement increased the colonic motility index (50.8; 29.4, 72.2; and 30.4; 8.9, 51.9, respectively; p<0.01 for both), pulse rate (26; 22, 30; and 28; 24, 32; p<0.001 for both), and respiration rate (14; 12, 16; and 12; 10, 14; p<0.001 for both). Happiness further reduced colonic motility although not significantly from that observed during hypnosis alone. Changes in motility were mainly due to alterations in rate than in amplitude of contractions. Our results indicate that hypnosis may help in the investigation of the effects of emotion on physiological functions; this approach could be useful outside the gastrointestinal system. Our observation that hypnosis strikingly reduces fasting colonic motility may partly explain the beneficial effects of this form of therapy in functional bowel disorders.			WHORWELL, PJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT MED,MANCHESTER M20 8LR,LANCS,ENGLAND.			Houghton, Lesley/0000-0002-5351-0229; Whorwell, Peter/0000-0002-5220-8474				ALMY TP, 1949, GASTROENTEROLOGY, V12, P425, DOI 10.1016/S0016-5085(49)80125-9; CANN PA, 1983, GUT, V24, P236, DOI 10.1136/gut.24.3.236; FONE D, 1988, GASTROENTEROLOGY, V94, pA133; NARDUCCI F, 1985, DIGEST DIS SCI, V30, P40, DOI 10.1007/BF01318369; OBRIEN JD, 1985, GASTROENTEROLOGY, V88, P1520; PRIOR A, 1990, GUT, V31, P896, DOI 10.1136/gut.31.8.896; ROGERS J, 1989, GUT, V30, P642, DOI 10.1136/gut.30.5.642; STANGHELLINI V, 1983, GASTROENTEROLOGY, V85, P83; THOMPSON DG, 1983, GUT, V24, P277, DOI 10.1136/gut.24.4.277; THOMPSON DG, 1982, GASTROENTEROLOGY, V83, P1200; Waxman D., 1989, HARTLANDS MED DENTAL; WELGAN P, 1988, GASTROENTEROLOGY, V94, P1150, DOI 10.1016/0016-5085(88)90006-6; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4; WHORWELL PJ, 1991, BRIT J HOSP MED, V45, P27	15	103	104	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					69	72		10.1016/0140-6736(92)90394-I	http://dx.doi.org/10.1016/0140-6736(92)90394-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC582	1352012				2022-12-28	WOS:A1992JC58200002
J	HALL, P; BOICE, JD; BERG, G; BJELKENGREN, G; ERICSSON, UB; HALLQUIST, A; LIDBERG, M; LUNDELL, G; MATTSSON, A; TENNVALL, J; WIKLUND, K; HOLM, LE				HALL, P; BOICE, JD; BERG, G; BJELKENGREN, G; ERICSSON, UB; HALLQUIST, A; LIDBERG, M; LUNDELL, G; MATTSSON, A; TENNVALL, J; WIKLUND, K; HOLM, LE			LEUKEMIA INCIDENCE AFTER I-131 EXPOSURE	LANCET			English	Article							CANCER; MORTALITY; LEUKEMIA; RADIOTHERAPY; I-131; RISK	Leukaemia is one of the most prominent late effects of exposure to ionising radiation. We have studied the incidence of leukaemia among 46 988 Swedish patients exposed to iodine-131 (I-131) for diagnostic reasons or to treat hyperthyroidism or thyroid cancer. The observed number of leukaemias was compared with that expected based on incidence data from the general population. The mean absorbed dose to the bone marrow was estimated as 14 mGy (range 0.01-2.226). 195 leukaemias occurred more than 2 years after exposure, and the standardised incidence ratio (SIR) was 1.09 (95% confidence interval 0.94-1.25). Similar, but again not significantly, increased risks were seen for chronic lymphocytic leukaemia (CLL) (SIR=1.08), a malignant condition not found to be increased after irradiation, and for non-CLL (SIR=1.09). The risk of leukaemia did not vary by sex, age, time, or radiation dose from I-131. One reason for the absence of a radiation effect, other than chance, includes the possible lowering of risk when exposure is protracted over time as occurs with I-131. Excess leukaemia risks of more than 25% could thus be excluded with high assurance in this population of mainly adults. These results should be reassuring to patients exposed to I-131 in medical practice and to most individuals exposed to the fall-out from the Chernobyl accident.	KAROLINSKA HOSP,RADIUM HEMMET,CTR ONCOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC PREVENT,S-10401 STOCKHOLM,SWEDEN; SODER SJUKHUSET,DEPT HOSP PHYS,STOCKHOLM,SWEDEN; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892; SAHLGRENS UNIV HOSP,DEPT GEN ONCOL,S-41345 GOTHENBURG,SWEDEN; MALMO GEN HOSP,DEPT GEN ONCOL,S-21401 MALMO,SWEDEN; MALMO GEN HOSP,DEPT INTERNAL MED,S-21401 MALMO,SWEDEN; UMEA UNIV HOSP,DEPT GEN ONCOL,S-90185 UMEA,SWEDEN; UNIV LUND HOSP,DEPT GEN ONCOL,S-22185 LUND,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sodersjukhuset Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sahlgrenska University Hospital; Umea University; Lund University; Skane University Hospital	HALL, P (corresponding author), KAROLINSKA HOSP,RADIUM HEMMET,DEPT GEN ONCOL,S-10401 STOCKHOLM,SWEDEN.		Tennvall, Jan/F-8760-2014		DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051034] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-51034] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKIN M, 1990, OXFORD STATISTICAL S, V4; [Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1991, COMP DOS COEFF BAS I, V21, P493; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BRINCKER H, 1973, BRIT J CANCER, V28, P232, DOI 10.1038/bjc.1973.142; COLEMAN MP, 1989, IARC89006 INT AG RES; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; EDMONDS CJ, 1986, BRIT J RADIOL, V59, P45, DOI 10.1259/0007-1285-59-697-45; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HOFFMAN DA, 1984, RAD CARCINOGENESIS E, P273; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1989, JNCI-J NATL CANCER I, V81, P302, DOI 10.1093/jnci/81.4.302; INSKIP PD, 1990, RADIAT RES, V122, P107, DOI 10.2307/3577593; International Committee on Radiological Protection Publication 53, 1988, ANN ICRP, V18; LEWIS CA, 1988, BRIT J RADIOL, V61, P212, DOI 10.1259/0007-1285-61-723-212; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SAENGER EL, 1968, J AMER MED ASSOC, V205, P855, DOI 10.1001/jama.205.12.855; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; 1988, HLTH RISKS RADON OTH, V4	25	95	97	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					1	4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351599				2022-12-28	WOS:A1992JC35400001
J	PILGRIM, AJ; LLOYD, DK				PILGRIM, AJ; LLOYD, DK			MIGRAINE	LANCET			English	Letter											PILGRIM, AJ (corresponding author), GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND.							1991, NEW ENGL J MED, V325, P316	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					62	62						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351649				2022-12-28	WOS:A1992JC35400060
J	BURNET, NG; NYMAN, J; TURESSON, I; WURM, R; YARNOLD, JR; PEACOCK, JH				BURNET, NG; NYMAN, J; TURESSON, I; WURM, R; YARNOLD, JR; PEACOCK, JH			PREDICTION OF NORMAL-TISSUE TOLERANCE TO RADIOTHERAPY FROM INVITRO CELLULAR RADIATION SENSITIVITY	LANCET			English	Note							REPAIR CAPACITY; SURVIVAL-CURVE; TUMORS	The success of radiotherapy depends on the total radiation dose, which is limited by the tolerance of surrounding normal tissues. Since there is substantial variation among patients in normal-tissue radiosensitivity, we have tested the hypothesis that in-vitro cellular radiosensitivity is correlated with in-vivo normal-tissue responses. We exposed skin fibroblast cell lines from six radiation-treated patients to various doses of radiation and measured the proportions surviving. There was a strong relation between fibroblast sensitivity in vitro and normal-tissue reactions, especially acute effects. Assessment of radiosensitivity could lead to improved tumour cure rates by enabling radiation doses to be tailored to the individual.	SAHLGRENS UNIV HOSP,DEPT ONCOL,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital	BURNET, NG (corresponding author), INST CANC RES,RADIOTHERAPY RES UNIT,15 COTSWOLD RD,SUTTON SM2 5PX,SURREY,ENGLAND.		Burnet, Neil/L-1025-2019					AGREN A, 1990, INT J RADIAT ONCOL, V19, P1077, DOI 10.1016/0360-3016(90)90037-K; DEACON J, 1984, RADIOTHER ONCOL, V2, P317, DOI 10.1016/S0167-8140(84)80074-2; FERTIL B, 1988, RADIAT RES, V116, P74, DOI 10.2307/3577479; FUKS Z, 1991, INT J RADIAT ONCOL, V21, P537, DOI 10.1016/0360-3016(91)90668-T; STEEL GG, 1991, RADIOTHER ONCOL, V20, P71; SUTTON ML, 1986, RADIOTHERAPY CLIN PR, P1; TURESSON I, 1989, RADIOTHER ONCOL, V15, P169, DOI 10.1016/0167-8140(89)90131-X; TURESSON I, 1990, INT J RADIAT ONCOL, V19, P1569, DOI 10.1016/0360-3016(90)90374-S; TURESSON I, 1989, RADIOTHER ONCOL, V15, P217, DOI 10.1016/0167-8140(89)90089-3; WEST CML, 1991, BRIT J CANCER, V64, P197, DOI 10.1038/bjc.1991.270	10	138	139	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1570	1571		10.1016/0140-6736(92)91833-T	http://dx.doi.org/10.1016/0140-6736(92)91833-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351551				2022-12-28	WOS:A1992JB20200005
J	CARTMILL, RSV; THORNTON, JG				CARTMILL, RSV; THORNTON, JG			EFFECT OF PRESENTATION OF PARTOGRAM INFORMATION ON OBSTETRIC DECISION-MAKING	LANCET			English	Article								The way in which medical information is presented may affect doctors' decision-making. We have assessed whether changing the appearance of the same information on the partogram affects clinical decisions during labour. Sixteen junior obstetricians were asked about how they would manage six hypothetical cases of difficult labour. information was given by partogram, in which we varied either the relative scales of the x and y axes or whether the latent phase of labour had been included. Doctors were more likely to intervene and to intervene more actively if the progress of labour curve appeared flat and if the latent phase was included. The shape and point of origin of the partogram probably influence intervention rates in practice and may partly explain the low rates of caesarean section in some hospitals.	UNIV LEEDS,ST JAMES HOSP,INST EPIDEMIOL & HLTH SERV RES,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	Saint James's University Hospital; University of Leeds			Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; Friedman EA, 1978, LABOR CLIN EVALUATIO, V2nd; ODRISCOLL K, 1990, ACTIVE MANAGEMENT LA	4	39	39	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1520	1522		10.1016/0140-6736(92)91275-D	http://dx.doi.org/10.1016/0140-6736(92)91275-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351197				2022-12-28	WOS:A1992HZ17500015
J	KLUINNELEMANS, HC; JANSEN, JH; BREUKELMAN, H; WOLTHERS, BG; KLUIN, PM; KROON, HM; WILLEMZE, R				KLUINNELEMANS, HC; JANSEN, JH; BREUKELMAN, H; WOLTHERS, BG; KLUIN, PM; KROON, HM; WILLEMZE, R			RESPONSE TO INTERFERON-ALFA-2B IN A PATIENT WITH SYSTEMIC MASTOCYTOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HAIRY-CELL LEUKEMIA; BONE-MARROW; MALIGNANT MASTOCYTOSIS; MAST-CELLS; HISTAMINE; METABOLITES; BLOOD; URINE		LEIDEN UNIV,MED CTR,DEPT HEMATOL,2300 RA LEIDEN,NETHERLANDS; LEIDEN UNIV,MED CTR,DEPT DIAGNOST RADIOL,2300 RA LEIDEN,NETHERLANDS; LEIDEN UNIV,PATHOL LAB,2300 RA LEIDEN,NETHERLANDS; UNIV HOSP GRONINGEN,CENT CLIN CHEM LAB,GRONINGEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Groningen			Kluin-Nelemans, Johanna C/F-8658-2018; Jansen, J.H./H-8054-2014	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Jansen, J.H./0000-0001-9459-568X				BARDAWIL RG, 1987, LEUKEMIA, V1, P340; DESAI RG, 1991, J CLIN ONCOL, V9, P893, DOI 10.1200/JCO.1991.9.5.893; GRIESINGER F, 1987, BLUT, V55, P309; HORNY HP, 1990, BRIT J HAEMATOL, V76, P186, DOI 10.1111/j.1365-2141.1990.tb07870.x; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KEYZER JJ, 1981, CLIN CHIM ACTA, V113, P165, DOI 10.1016/0009-8981(81)90150-9; KEYZER JJ, 1982, CLIN CHIM ACTA, V121, P379, DOI 10.1016/0009-8981(82)90247-9; KEYZER JJ, 1984, AGENTS ACTIONS, V15, P189, DOI 10.1007/BF01972348; MCKINSTRY CS, 1987, RADIOLOGY, V162, P701, DOI 10.1148/radiology.162.3.3544034; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS45, DOI 10.1111/1523-1747.ep12469022; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS55, DOI 10.1111/1523-1747.ep12469049; MINER PB, 1991, J INVEST DERMATOL, V96, pS40, DOI 10.1111/1523-1747.ep12469015; PARDINI S, 1991, ACTA HAEMATOL-BASEL, V85, P220; PARKER RI, 1991, J INVEST DERMATOL, V96, pS52, DOI 10.1111/1523-1747.ep12469045; RATAIN MJ, 1987, BLOOD, V69, P872; RIMMER EF, 1987, LEUCOCYTE TYPING, V3, P729; STEINER R M, 1990, Magnetic Resonance Quarterly, V6, P17; SWIETER M, 1989, IMMUNOLOGY, V66, P606; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TORREY E, 1990, AM J HEMATOL, V34, P283, DOI 10.1002/ajh.2830340409; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TRAVIS WD, 1990, MEDICINE, V69, P34; VOGLER JB, 1988, RADIOLOGY, V168, P679, DOI 10.1148/radiology.168.3.3043546	24	197	200	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					619	623		10.1056/NEJM199202273260907	http://dx.doi.org/10.1056/NEJM199202273260907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1370856				2022-12-28	WOS:A1992HF63300007
J	WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM				WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM			ORDERING AND ADMINISTRATION OF SEDATIVES AND ANALGESICS DURING THE WITHHOLDING AND WITHDRAWAL OF LIFE-SUPPORT FROM CRITICALLY ILL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAZEPAM; MIDAZOLAM; DECISION	Objective. - To determine why and how sedatives and analgesics are ordered and administered during the withholding and withdrawal of life support from critically ill patients. Design. - Prospective case series. Setting. - Medical-surgical intensive care units at a county hospital and a university hospital. Patients. - Consecutive 1-year sample of 22 patients from whom life support was withheld or withdrawn in one intensive care unit at a county hospital and a random sample of 22 similar patients in the intensive care unit in the university hospital over the same period. Main Outcome Measures. - Physicians and nurses were interviewed to determine their reasons for ordering and administering drugs, and medical records were reviewed to document amounts of drugs ordered and administered. Results. - Drugs were given to 75% of patients during withholding and withdrawal of life support. Patients who did not receive medication were comatose and considered incapable of benefiting from sedation and analgesia. The median time until death following the initiation of the withholding or withdrawal of life support was 3.5 hours in the patients who received drugs and 1.3 hours in those patients who did not (P, not significant). Physicians ordered drugs to decrease pain in 88% of patients, to decrease anxiety in 85%, to decrease air hunger in 76%, to comfort families in 82%, and to hasten death in 39%; in no instance was hastening death the only reason cited. The amounts of benzodiazepines and opiates averaged 2.2 mg/h of diazepam and 3.3 mg/h of morphine sulfate in the 24 hours before withholding and withdrawal of life support and 9.8 mg/h and 11.2 mg/h in the 24 hours thereafter (P < .025 and P < .001, respectively). Conclusions. - Large doses of sedatives and analgesics were ordered primarily to relieve pain and suffering during the withholding and withdrawal of life support, and death was not hastened by drug administration.	SAN FRANCISCO GEN HOSP,ROOM 5K1,1001 POTRERO AVE,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SOCIAL WORK,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; BERGGREN L, 1987, ACTA ANAESTH SCAND, V31, P667, DOI 10.1111/j.1399-6576.1987.tb02643.x; CLOUSER KD, 1977, ANN INTERN MED, V87, P622, DOI 10.7326/0003-4819-87-5-622; FLAKE JW, 1985, ANESTH ANALG, V64, P897; FORRESTER A, 1980, ANESTHESIOLOGY, V53, P494; GEORGE KA, 1977, BRIT J CLIN PHARMACO, V4, P45, DOI 10.1111/j.1365-2125.1977.tb00665.x; GREENBLATT DJ, 1981, BR J PHARM S, V11, pS2; HAMMOND J, 1989, CRIT CARE MED, V17, P136, DOI 10.1097/00003246-198902000-00006; JAFFE JH, 1981, PHARM BASIS THERAPEU; JONSEN AR, 1983, ANN INTERN MED, V99, P261, DOI 10.7326/0003-4819-99-2-261; JONSEN AR, 1986, CLIN ETHICS, P120; KEATS AS, 1985, ANNU REV PHARMACOL, V25, P41, DOI 10.1146/annurev.pa.25.040185.000353; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; PORRO GB, 1988, GASTROINTEST ENDOSC, V34, P252, DOI 10.1016/S0016-5107(88)71323-1; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIL MH, 1988, CRIT CARE MED, V16, P636, DOI 10.1097/00003246-198806000-00015; WHITE PF, 1988, PLAST RECONSTR SURG, V81, P703, DOI 10.1097/00006534-198805000-00009; ZAWACKI B, 1989, CRIT CARE MED, V17, P198; 1986, AM REV RESPIR DIS, V134, P1327	22	170	170	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					949	953						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1370853				2022-12-28	WOS:A1992HD15500028
J	BENHAMOU, B; GARCIA, T; LEROUGE, T; VERGEZAC, A; GOFFLO, D; BIGOGNE, C; CHAMBON, P; GRONEMEYER, H				BENHAMOU, B; GARCIA, T; LEROUGE, T; VERGEZAC, A; GOFFLO, D; BIGOGNE, C; CHAMBON, P; GRONEMEYER, H			A SINGLE AMINO-ACID THAT DETERMINES THE SENSITIVITY OF PROGESTERONE RECEPTORS TO RU486	SCIENCE			English	Article							GLUCOCORTICOID RECEPTOR; COMPLEMENTARY-DNA; EXPRESSION; SEQUENCE; HORMONE; TRANSCRIPTION; DOMAINS; CLONING; RU-486; CDNA	The progesterone analog RU486, an abortifacient, inhibits the action of progestins in humans but not in chickens or hamsters. Substitution of cysteine at position 575 by glycine in the hormone binding domain (HBD) of the chicken progesterone receptor (cPR) generated a cPR that binds RU486 and whose activity is antagonized by that compound. In fact, all receptors that bind RU486 have a glycine at the corresponding position. The hamster PR, like cPR, has a cysteine. Only glycine-not methionine or leucine at position 575 allowed binding of RU486 to cPR. Substitution of this glycine by cysteine in the human PR (hPR) abrogated binding of RU486 but not that of an agonist. The corresponding mutation in the human glucocorticoid receptor resulted in a loss of binding of both dexamethasone and RU486. Examination of a series of 11-beta-substituted steroids showed that antagonism is not an intrinsic property of an antihormone, because one hPR antagonist acted as an agonist for a mutated hPR. The positioning of an aromatic 11-beta-substitution in the PR HRD appears to be critical for generating agonistic or antagonistic activity.	FAC MED STRASBOURG,INST CHIM BIOL,INSERM,UNITE BIOL MOLEC & GENIE GENET 184,CNRS,F-67085 STRASBOURG,FRANCE; ROUSSEL UCLAF,CTR RECH,DEPT ENDOCRINOL,F-93230 ROMAINVILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAGCHI MK, 1990, NATURE, V345, P457; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHAWNSHANG C, 1988, P NATL ACAD SCI USA, V85, P7211; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLOOSTERBOER HJ, 1988, J STEROID BIOCHEM, V31, P567, DOI 10.1016/0022-4731(88)90007-6; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; Moguilewsky M., 1985, ANTIPROGESTIN STEROI, P87; TEUTSCH G, 1985, ANTIPROGESTIN STEROI, P27; TEUTSCH G, 1984, ADRENAL STEROID ANTA, P66; ULLMANN A, 1990, SCI AM, V262, P18	24	138	142	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					206	209		10.1126/science.1372753	http://dx.doi.org/10.1126/science.1372753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1372753				2022-12-28	WOS:A1992GY70400039
J	TIMMONS, MJ				TIMMONS, MJ			MALIGNANT-MELANOMA EXCISION MARGINS - MAKING A CHOICE	LANCET			English	Editorial Material							RECURRENCE; WIDE				TIMMONS, MJ (corresponding author), ST LUKES HOSP,DEPT PLAST SURG,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.							ACKERMAN AB, 1983, HUM PATHOL, V14, P743, DOI 10.1016/S0046-8177(83)80298-6; Ames FC, 1992, CUTANEOUS MELANOMA, P287; BOULAY M, 1888, ARCH GEN MED, V2, P157; Butterworth T, 1934, J AMER MED ASSOC, V102, P739, DOI 10.1001/jama.1934.02750100005002; CASCINELLI N, 1980, EUR J CANCER, V16, P1079; DIETERICH P, 1887, ARCH KLIN CHIR BERLI, V35, P289; EVANS J, 1990, BRIT J PLAST SURG, V43, P426, DOI 10.1016/0007-1226(90)90007-M; FALLOWFIELD ME, 1990, HISTOPATHOLOGY, V17, P397, DOI 10.1111/j.1365-2559.1990.tb00758.x; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; GRIFFITHS RW, 1986, BRIT J SURG, V73, P349, DOI 10.1002/bjs.1800730507; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; Handley WS, 1907, LANCET, V1, P927; Handley WS, 1907, LANCET, V1, P996; KELLY JW, 1984, ANN SURG, V200, P759; Norris W., 1857, 8 CASES MELANOSIS PA; PACK GT, 1952, ANN SURG, V136, P905, DOI 10.1097/00000658-195212000-00001; RAMPEN F, 1981, EUR J CANCER, V17, P589, DOI 10.1016/0014-2964(81)90062-1; RAVEN RW, 1950, ANN ROY COLL SURG, V6, P28; TAYLOR BA, 1985, EUR J SURG ONCOL, V11, P7; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438	20	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1393	1395		10.1016/0140-6736(92)92570-6	http://dx.doi.org/10.1016/0140-6736(92)92570-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360100				2022-12-28	WOS:A1992KB20200014
J	CLEMENTS, JD; LESTER, RAJ; TONG, G; JAHR, CE; WESTBROOK, GL				CLEMENTS, JD; LESTER, RAJ; TONG, G; JAHR, CE; WESTBROOK, GL			THE TIME COURSE OF GLUTAMATE IN THE SYNAPTIC CLEFT	SCIENCE			English	Article							METHYL-D-ASPARTATE; CULTURED HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; CENTRAL NERVOUS-SYSTEM; KINETIC-ANALYSIS; RAT HIPPOCAMPUS; ACID RECEPTORS; BINDING-SITES; CURRENTS; ACETYLCHOLINE	The peak concentration and rate of clearance of neurotransmitter from the synaptic cleft are important determinants of synaptic function, yet the neurotransmitter concentration time course is unknown at synapses in the brain. The time course of free glutamate in the cleft was estimated by kinetic analysis of the displacement of a rapidly dissociating competitive antagonist from N-methyl-D-aspartate (NMDA) receptors during synaptic transmission. Glutamate peaked at 1.1 millimolar and decayed with a time constant of 1.2 milliseconds at cultured hippocampal synapses. This time course implies that transmitter saturates postsynaptic NMDA receptors. However, glutamate dissociates much more rapidly from alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Thus, the time course of free glutamate predicts that dissociation contributes to the decay of the AMPA receptor-mediated postsynaptic current.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	CLEMENTS, JD (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		yasin, raiesa/F-9500-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046613, R37MH046613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026494, R01NS021419, R29NS026494] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46613] Funding Source: Medline; NINDS NIH HHS [NS21419, NS26494] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTOL TM, 1991, BIOPHYS J, V59, P1209; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; BENVENISTE M, 1991, BRIT J PHARMACOL, V104, P207, DOI 10.1111/j.1476-5381.1991.tb12409.x; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; COLQUHOUN D, IN PRESS J PHYSL LON; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; EVANS RH, 1979, BRIT J PHARMACOL, V67, P591, DOI 10.1111/j.1476-5381.1979.tb08706.x; EVANS RH, 1978, BRAIN RES, V148, P536, DOI 10.1016/0006-8993(78)90744-8; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GAGE PW, 1975, J PHYSIOL-LONDON, V244, P385, DOI 10.1113/jphysiol.1975.sp010805; HARRIS KM, 1986, NEUROSCIENCE, V19, P857, DOI 10.1016/0306-4522(86)90304-0; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; LAND BR, 1984, P NATL ACAD SCI-BIOL, V81, P1594, DOI 10.1073/pnas.81.5.1594; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCLENNAN H, 1979, BRAIN RES, V169, P83, DOI 10.1016/0006-8993(79)90375-5; MONAGHAN DT, 1988, P NATL ACAD SCI USA, V85, P9836, DOI 10.1073/pnas.85.24.9836; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P1, DOI 10.1016/0306-4522(88)90123-6; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RIVEROS N, 1986, BRAIN RES, V386, P405, DOI 10.1016/0006-8993(86)90181-2; Salpeter MM, 1987, VERTEBRATE NEUROMUSC, V23, P1; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THEDINGA KH, 1989, NEUROSCI LETT, V104, P217, DOI 10.1016/0304-3940(89)90357-1; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	36	818	851	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1498	1501		10.1126/science.1359647	http://dx.doi.org/10.1126/science.1359647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1359647				2022-12-28	WOS:A1992JZ62500033
J	MANDEL, MA; GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF				MANDEL, MA; GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF			MOLECULAR CHARACTERIZATION OF THE ARABIDOPSIS FLORAL HOMEOTIC GENE APETALA1	NATURE			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; LINKAGE MAP; YEAST; THALIANA; SRF	THE first step in flower development is the transition of an inflorescence meristem into a floral meristem. Each floral meristem differentiates into a flower consisting of four organ types that occupy precisely defined positions within four concentric whorls. Genetic studies in Arabidopsis thaliana and Antirrhinum majus have identified early-acting genes that determine the identity of the floral meristem, and late-acting genes that determine floral organ identity1-5. In Arabidopsis, at least two genes, APETALA1 and LEAFY, are required for the transition of an inflorescence meristem into a floral meristem1. We have cloned the APETALA1 gene and here we show that it encodes a putative transcription factor that contains a MADS-domain2. APETALA1 RNA is uniformly expressed in young flower primordia, and later becomes localized to sepals and petals. Our results suggest that APETALA1 acts locally to specify the identity of the floral meristem, and to determine sepal and petal development.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								BOWMAN JL, 1991, DEVELOPMENT, V112, P1; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	23	909	1015	4	123	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					273	277						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359429				2022-12-28	WOS:A1992JY96000057
J	BRAHAMS, D				BRAHAMS, D			DELAYED DISCONNECTION OF DEAD BABY FROM VENTILATOR	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1154	1155		10.1016/0140-6736(92)93172-J	http://dx.doi.org/10.1016/0140-6736(92)93172-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359223				2022-12-28	WOS:A1992JX13400016
J	FUGHBERMAN, A; EPSTEIN, S				FUGHBERMAN, A; EPSTEIN, S			TAMOXIFEN - DISEASE PREVENTION OR DISEASE SUBSTITUTION	LANCET			English	Editorial Material							BONE-MINERAL CONTENT; BREAST-CANCER; ADJUVANT TAMOXIFEN; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR RISK; SERUM-LIPOPROTEINS; TRIAL; DENSITY; TUMORS		UNIV ILLINOIS,SCH PUBL HLTH,BOX 6998,CHICAGO,IL 60680; NATL WOMENS HLTH NETWORK,WASHINGTON,DC	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Fugh-Berman, Adriane/0000-0002-1717-7617				BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; BUSH TL, 1988, CLIN CHEM, V34, pB60; CHING CK, 1992, LANCET, V339, P940, DOI 10.1016/0140-6736(92)90991-B; FENDL KC, 1992, CANCER RES, V52, P235; FENTIMAN IS, 1989, BRIT J CANCER, V60, P262, DOI 10.1038/bjc.1989.266; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1990, J CLIN ONCOL, V8, P1019, DOI 10.1200/JCO.1990.8.6.1019; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GOTFREDSEN A, 1984, CANCER, V53, P853, DOI 10.1002/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M; JORDAN VC, 1992, J NATL CANCER I, V84, P231, DOI 10.1093/jnci/84.4.231; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; LOVE RR, 1988, BREAST CANCER RES TR, V12, P279; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOGUCHI M, 1987, BRIT J SURG, V74, P586, DOI 10.1002/bjs.1800740714; PAVLIDIS NA, 1992, CANCER, V69, P2961, DOI 10.1002/1097-0142(19920615)69:12&lt;2961::AID-CNCR2820691215&gt;3.0.CO;2-W; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; RALOFF J, 1992, SCI NEWS, V141, P266; ROSSNER S, 1984, ATHEROSCLEROSIS, V52, P339, DOI 10.1016/0021-9150(84)90064-9; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SHULTZ MM, 1985, YALE LAW J, V95, P219, DOI 10.2307/796352; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; WOLTER J, 1988, P AN M AM SOC CLIN, V7, P10; 1987, FDA ADVERSE REACTION	25	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1143	1145		10.1016/0140-6736(92)93161-F	http://dx.doi.org/10.1016/0140-6736(92)93161-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359220				2022-12-28	WOS:A1992JX13400013
J	THOROGOOD, M; COWEN, P; MANN, J; MURPHY, M; VESSEY, M				THOROGOOD, M; COWEN, P; MANN, J; MURPHY, M; VESSEY, M			FATAL MYOCARDIAL-INFARCTION AND USE OF PSYCHOTROPIC-DRUGS IN YOUNG-WOMEN	LANCET			English	Note								We have observed an unexpected 17-fold increase in risk of total myocardial infarction (relative risk 16.9, 95% confidence interval 3.9-72.8) associated with current use of psychotropic drugs. This incidental finding, in a case-control study of cardiovascular mortality in women aged 16-39 not designed to test any hypothesis about psychotropic drugs, should be treated cautiously. There is, however, evidence of a relation between psychiatric morbidity and cardiovascular disease and the association recorded here requires further investigation.	LITTLEMORE HOSP,MRC,PSYCHOPHARMACOL RES UNIT,OXFORD,ENGLAND; UNIV OTAGO,DEPT HUMAN NUTR,DUNEDIN,NEW ZEALAND; UK OFF POPULAT CENSUSES & SURVEYS,HLTH STAT UNIT,LONDON WC2,ENGLAND; UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Otago; University of Oxford	THOROGOOD, M (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Cowen, Philip/0000-0001-5518-6138				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; BRESLOW NE, STATISTICAL METHODS, V1; CARNEY RM, 1990, PSYCHOSOM MED, V52, P603, DOI 10.1097/00006842-199011000-00001; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; HAINES AP, 1987, BRIT MED J, V295, P297, DOI 10.1136/bmj.295.6593.297; TALBOTT E, 1981, AM J EPIDEMIOL, V114, P671, DOI 10.1093/oxfordjournals.aje.a113238; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, IN PRESS AM J EPIDEM; WEISSMAN MM, 1990, AM J PSYCHIAT, V147, P1504	10	69	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1067	1068		10.1016/0140-6736(92)93081-W	http://dx.doi.org/10.1016/0140-6736(92)93081-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357456				2022-12-28	WOS:A1992JV77500006
J	BOBAK, M; LEON, DA				BOBAK, M; LEON, DA			AIR-POLLUTION AND INFANT-MORTALITY IN THE CZECH REPUBLIC, 1986-88	LANCET			English	Article							RESPIRATORY HEALTH; PARTICLES; CHILDREN	An ecological study of infant mortality and air pollution was conducted in the Czech Republic. Routinely collected data on infant mortality and air pollution in the period 1986-88 were analysed for the 46 of the 85 districts in the republic for which both were available. The independent effects of total suspended particulates (TSP-10), sulphur dioxide (SO2), and oxides of nitrogen (NO(x)) adjusted for district socioeconomic characteristics, such as income, car ownership, and abortion rate, were estimated by logistic regression. We found weak positive associations between neonatal mortality and quintile of TSP-10 and SO2. Stronger adjusted effects were seen for postneonatal mortality, with a consistent increase in risk from the lowest to the highest TSP-10 quintile (p<0.001). Weaker and less consistent evidence of a positive association with NO(x) (p = 0.061) was observed. The strongest effects were seen for postneonatal respiratory mortality, which increased consistently from lowest to highest TSP-10 quintile (p = 0.013). There was also a suggestion of a positive association with SO2 (p = 0.062). The highest to lowest quintile risk ratios for postneonatal respiratory mortality were 2.41 (95% Cl 1.10-5.28) for TSP-10, 3.91 (0.90-16.9) for SO2, and 1.20 (0.37-3.91) NO(x). The specificity of the association between air pollution quintile (especially TSP-10) and postneonatal respiratory mortality is consistent with the known effects of air pollution on respiratory disease morbidity in children. These ecological associations require confirmation in an individually based study.	CHARLES UNIV, FAC MED 3, DEPT EPIDEMIOL, CS-11636 PRAGUE 1, CZECHOSLOVAKIA	Charles University Prague	BOBAK, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Bobak, Martin/0000-0002-2633-6851	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRESLOW NE, 1987, IARC SCI PUBL, V82; COLLINS JJ, 1971, AM J EPIDEMIOL, V93, P10, DOI 10.1093/oxfordjournals.aje.a121224; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; HOLLAND WW, 1979, AM J EPIDEMIOL, V110, P525, DOI 10.1093/oxfordjournals.aje.a112836; Lave LB, 1977, AIR POLLUTION HUMAN; Penna M L, 1991, Bull Pan Am Health Organ, V25, P47; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; READ C, 1991, AIR POLLUTION CHILD; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; 1987, AIR QUALITY GUIDELIN; 1990, ENV CZECH REPUBLIC; 1988, EGRET USERS MANUAL	12	137	140	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					1010	1014		10.1016/0140-6736(92)93017-H	http://dx.doi.org/10.1016/0140-6736(92)93017-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357409				2022-12-28	WOS:A1992JV01400011
J	HALLIDAY, JL; LUMLEY, J; SHEFFIELD, LJ; ROBINSON, HP; RENOU, P; CARLIN, JB				HALLIDAY, JL; LUMLEY, J; SHEFFIELD, LJ; ROBINSON, HP; RENOU, P; CARLIN, JB			IMPORTANCE OF COMPLETE FOLLOW-UP OF SPONTANEOUS FETAL LOSS AFTER AMNIOCENTESIS AND CHORION VILLUS SAMPLING	LANCET			English	Article							SPONTANEOUS-ABORTION; PREGNANCIES; RISK	Women who are the most difficult to trace after amniocentesis or chorion villus sampling are often those who have had an adverse pregnancy outcome. To calculate total fetal loss figures for use in prenatal counselling we have followed in a multicentre study 100% of women who had undergone these procedures. Early spontaneous loss (within three weeks of the procedure) and total spontaneous loss were much lower after amniocentesis (0.2% and 1.3%, respectively) than after chorion villus sampling (1.2% and 2.9%). Four spontaneous fetal losses among the 20 pregnancies that were the most difficult to follow-up increased the loss rate by 0.5% for chorion villus sampling. Risk of early fetal loss after chorion villus sampling was related to experience of the operator (relative risk [RR] 4.3, p = 0.003), and total fetal loss was lower in pregnancies tested at 10 weeks' or more gestational age compared with those tested before 10 weeks' (RR 0.4, p = 0.01). A table showing the frequency of each of the seven possible outcomes after amniocentesis and chorion villus sampling is useful in counselling those considering one or other test.	DEPT HLTH,PERINATAL DATA COLLECT UNIT,MELBOURNE,VIC,AUSTRALIA; MONASH MED CTR,FETAL DIAGNOST UNIT,CLAYTON,VIC,AUSTRALIA; ROYAL WOMENS HOSP,DEPT ULTRASOUND,CARLTON,VIC 3053,AUSTRALIA; ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Monash University; Royal Children's Hospital Melbourne	HALLIDAY, JL (corresponding author), MURDOCH INST RES BIRTH DEFECTS,PARKVILLE,VIC 3052,AUSTRALIA.		halliday, jane/T-1476-2019; Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463				[Anonymous], 1991, LANCET, V337, P1491; BRAMBATI B, 1991, PRENATAL DIAG, V11, P285, DOI 10.1002/pd.1970110503; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; COHENOVERBEEK TE, 1990, LANCET, V336, P27, DOI 10.1016/0140-6736(90)91528-I; DECOUFLE P, 1991, AM J EPIDEMIOL, V133, P83, DOI 10.1093/oxfordjournals.aje.a115806; GARDNER MJ, 1990, BMJ, P16; HALLIDAY J, 1990, LANCET, V335, P1156, DOI 10.1016/0140-6736(90)91157-6; HOLT VL, 1991, EPIDEMIOLOGY, V2, P375, DOI 10.1097/00001648-199109000-00012; JACKSON L, 1990, AM J HUM GENET S, V47, pA278; JACKSON LG, 1992, NEW ENGL J MED, V327, P594, DOI 10.1056/NEJM199208273270903; JAHODA MGJ, 1989, PRENATAL DIAG, V9, P621, DOI 10.1002/pd.1970090905; LESCHOT NJ, 1989, BRIT J OBSTET GYNAEC, V96, P663, DOI 10.1111/j.1471-0528.1989.tb03280.x; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; ROBERTSON H, 1986, RIGHTS WRONGS VALIDA; SILVER RK, 1990, AM J OBSTET GYNECOL, V163, P917, DOI 10.1016/0002-9378(90)91096-U; SMIDTJENSEN S, 1991, ULTRASOUND OBST GYN, V1, P86, DOI 10.1046/j.1469-0705.1991.01020086.x; VERJAAL M, 1981, PRENATAL DIAG, V1, P173, DOI 10.1002/pd.1970010303; WASS D, 1991, AUST NZ J OBSTET GYN, V3, P240; 1989, CONSULTATIVE COUNCIL; 1992, PRENAT DIAGN, V12, P385	20	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					886	890		10.1016/0140-6736(92)93293-V	http://dx.doi.org/10.1016/0140-6736(92)93293-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357305				2022-12-28	WOS:A1992JT32700012
J	CRAIG, PS; LIU, DS; MACPHERSON, CNL; SHI, DZ; REYNOLDS, D; BARNISH, G; GOTTSTEIN, B; WANG, ZR				CRAIG, PS; LIU, DS; MACPHERSON, CNL; SHI, DZ; REYNOLDS, D; BARNISH, G; GOTTSTEIN, B; WANG, ZR			A LARGE FOCUS OF ALVEOLAR ECHINOCOCCOSIS IN CENTRAL CHINA	LANCET			English	Article							HYDATID-DISEASE; CYSTIC ECHINOCOCCOSIS; MULTILOCULARIS; ALBENDAZOLE; INFECTION; POPULATION; REGION	Human alveolar echinococcosis (AE) is a rare and highly pathogenic helminthic zoonosis due to infection with the intermediate stage of the small fox tapeworm, Echinococcus multilocularis. Parasite transmission is restricted to northern latitudes, including central and north China, from where few clinical and no detailed community studies have been reported. In August, 1991, 65 (5%) of 1312 people residing in three rural communes of Zhang County, Gansu Province, China were diagnosed as having hepatic AE after mass ultrasound scanning with serological back-up. This represents one of the highest prevalence rates of AE ever recorded. It is also the first time that mass ultrasound scanning and serology have been used together in an AE endemic region. The region was selected one year earlier, when a preliminary serosurvey on 606 unselected people in the same locality resulted in an 8.8% serum antibody positive rate with a 76% rate of confirmation of hepatic AE in 37 individuals who could be followed up in 1991. Seropositivity rates varied for villages between 0 and 20.5%. Overall, females (7.8%) had a significantly greater risk of infection than males (2.5%), especially in the 31-50 age group, a difference which may be related to contact with dogs and dog faeces over many years. Age-specific prevalence of AE increased from 0% in the under-5-year group to 8.2% in those aged 31-50. The youngest case was 11 years and the mean age of diagnosis was 40 years. Adult tapeworms of E multilocularis were identified from the small intestines of 10% of domestic dogs. Sylvatic animal hosts of the parasite have not yet been identified. The high prevalence of human AE in this region of central China is most probably due to semi-domestic transmission of E multilocularis between wild rodents and dogs, together with the poverty and poor hygiene in these rural communities.	LANZHOU MED COLL, DEPT PARASITOL, LANZHOU, PEOPLES R CHINA; UNIV W INDIES, FAC MED, SCH VET MED, ST AUGUSTINE, TRINIDAD TOBAGO; UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, ENGLAND; UNIV ZURICH, INST PARASITOL, CH-8006 ZURICH, SWITZERLAND; PUBL HLTH BUR, Ganzhou, PEOPLES R CHINA	Lanzhou University; University West Indies Mona Jamaica; University West Indies Saint Augustine; Liverpool School of Tropical Medicine; University of Liverpool; University of Zurich	CRAIG, PS (corresponding author), UNIV SALFORD, DEPT BIOL SCI, SALFORD M5 4WT, LANCS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUER H, 1991, PARASITOL RES, V77, P430, DOI 10.1007/BF00931640; BCHIR A, 1991, ACTA TROP, V49, P149, DOI 10.1016/0001-706X(91)90062-O; BRESSONHADNI S, 1991, HEPATOLOGY, V13, P1061, DOI 10.1002/hep.1840130610; CHI P, 1990, TROP MED PARASITOL, V41, P157; COLTORTI E, 1988, T ROY SOC TROP MED H, V82, P607, DOI 10.1016/0035-9203(88)90527-5; CRAIG PS, 1991, PARASITOL TODAY, V7, P46, DOI 10.1016/0169-4758(91)90188-T; DIDIER D, 1985, RADIOLOGY, V154, P179, DOI 10.1148/radiology.154.1.3880602; GOTTSTEIN B, 1987, T ROY SOC TROP MED H, V81, P960, DOI 10.1016/0035-9203(87)90365-8; GOTTSTEIN B, 1985, LANCET, V1, P1097; GOTTSTEIN B, 1991, 15TH EXTR C CEL 50 Y, P831; GROVE DI, 1990, HIST HUMAN HELMINTHO, P343; Habluetzel A., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P15, DOI 10.1016/0035-9203(89)90597-X; HORTON RJ, 1989, T ROY SOC TROP MED H, V83, P97, DOI 10.1016/0035-9203(89)90724-4; JIANG C, 1991, CHIN END DIS B, V6, P82; JIANG CP, 1981, CHINESE MED J-PEKING, V94, P771; LU YQ, 1988, CHIN J ULTRASOUND ME, V4, P78; MACPHERSON CNL, 1987, LANCET, V2, P259; MATOSSIAN RM, 1977, B WORLD HEALTH ORGAN, V55, P499; PODOPRIGORA GI, UNPUB WHO GUIDELINES; Rausch R.L., 1986, P44; RAUSCH RL, 1990, ANN TROP MED PARASIT, V84, P239, DOI 10.1080/00034983.1990.11812463; ROGAN MT, 1991, T ROY SOC TROP MED H, V85, P773, DOI 10.1016/0035-9203(91)90451-4; Schantz P.M., 1986, P69; SCHANTZ PM, 1991, PARASITOL TODAY, V7, P35, DOI 10.1016/0169-4758(91)90185-Q; STEHRGREEN JK, 1988, AM J TROP MED HYG, V38, P380, DOI 10.4269/ajtmh.1988.38.380; TODOROV T, 1988, T ROY SOC TROP MED H, V82, P453, DOI 10.1016/0035-9203(88)90161-7; Vuitton D, 1990, Hepatology, V12, P617, DOI 10.1002/hep.1840120329; WATSONJONES DL, 1988, ANN TROP MED PARASIT, V82, P343, DOI 10.1080/00034983.1988.11812256; WEN H, 1990, CHIN MED J, V70, P47; WILSON JF, 1987, AM J TROP MED HYG, V37, P162, DOI 10.4269/ajtmh.1987.37.162; WILSON JF, 1980, AM J TROP MED HYG, V29, P1340, DOI 10.4269/ajtmh.1980.29.1340; YAO P, 1965, CHINESE J SURG, V13, P461; 1987, LANCET, V1, P21; 1981, GUIDELINES ECHINOCOC	34	147	157	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1992	340	8823					826	831		10.1016/0140-6736(92)92693-A	http://dx.doi.org/10.1016/0140-6736(92)92693-A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357252				2022-12-28	WOS:A1992JR16800012
J	KINSELLA, JP; NEISH, SR; SHAFFER, E; ABMAN, SH				KINSELLA, JP; NEISH, SR; SHAFFER, E; ABMAN, SH			LOW-DOSE INHALATIONAL NITRIC-OXIDE IN PERSISTENT PULMONARY-HYPERTENSION OF THE NEWBORN	LANCET			English	Note								We studied the effects of inhaled nitric oxide (NO) in 9 newborn infants with severe persistent pulmonary hypertension (PPHN) who were candidates for extracorporeal membrane oxygenation treatment. With low doses of NO (10-20 ppm) all showed rapid improvement in oxygenation without reduction of systemic blood pressure. In 6 infants treated with inhaled NO for 24 h, clinical improvement was sustained at 6 ppm.	CHILDRENS HOSP,DEPT PEDIAT,DIV CARDIOL,DENVER,CO 80218; CHILDRENS HOSP,DEPT PEDIAT,DIV PULM MED,DENVER,CO 80218; UNIV COLORADO,SCH MED,DENVER,CO 80202	Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KINSELLA, JP (corresponding author), CHILDRENS HOSP,DEPT PEDIAT,DIV NEONATOL,BOX B-070,1056 E 19TH AVE,DENVER,CO 80218, USA.		Neish, Steven/AAJ-7974-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041012, R29HL041012, P50HL046481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41012, HL-01932, HL-46481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KINSELLA JP, 1992, J PEDIATR SURG, V27, P44, DOI 10.1016/0022-3468(92)90102-D; KINSELLA JP, AM J PHYSL, V32; LEVIN DL, 1976, J PEDIATR-US, V89, P626, DOI 10.1016/S0022-3476(76)80405-2; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1991, CIRCULATION S2, V84, pA1279	8	592	613	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					819	820		10.1016/0140-6736(92)92687-B	http://dx.doi.org/10.1016/0140-6736(92)92687-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357246				2022-12-28	WOS:A1992JR16800006
J	PIETERSZ, RNI; REESINK, HW; PAUW, W; DEKKER, WJA; BUISMAN, L				PIETERSZ, RNI; REESINK, HW; PAUW, W; DEKKER, WJA; BUISMAN, L			PREVENTION OF YERSINIA-ENTEROCOLITICA GROWTH IN RED-BLOOD-CELL CONCENTRATES	LANCET			English	Note							PHAGOCYTOSIS; TEMPERATURE; STORAGE	In response to concern about Yersinia enterocolitica contamination of blood products, we have studied the effects on Y enterocolitica growth of holding whole blood at 22-degrees-C for 20 h and then removing leucocytes. Thirty pools of three bags of blood were inoculated with Y enterocolitica (2 x 10(1)-3 x 10(4) colony-forming units/ml). One bag in each pool was processed to red-blood-cell concentrate after 6 h at 4-degrees-C (RBC); the other two were held at 22-degrees-C for 20 h before processing to buffy-coat-depleted RBC (BCd-RBC). One of these bags was then depleted of leucocytes by filtration (Ld-RBC). All bags were stored at 4-degrees-C for 5 weeks. R B C bags showed Y enterocolitica growth after the shortest storage times, followed by BCd-RBC then Ld-RBC (p < 0.03-0.001). We recommend that whole blood should be held at 22-degrees-C to make use of inherent bactericidal activity; leucocytes should then be removed.	SLOTERVAART HOSP,DEPT MICROBIOL,AMSTERDAM,NETHERLANDS	Slotervaart Hospital	PIETERSZ, RNI (corresponding author), RED CROSS BLOOD BANK,POSTBOX 9137,1006 AC AMSTERDAM,NETHERLANDS.							GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; HOGMAN CF, 1991, TRANSFUSION, V31, P620, DOI 10.1046/j.1537-2995.1991.31791368338.x; HOPPE PA, 1992, TRANSFUSION, V32, P199, DOI 10.1046/j.1537-2995.1992.32392213799.x; MANARA FS, 1985, BIOCHEM BIOPH RES CO, V132, P696, DOI 10.1016/0006-291X(85)91188-X; PETERSON PK, 1977, INFECT IMMUN, V15, P175, DOI 10.1128/IAI.15.1.175-179.1977; PIETERSZ RNI, 1987, VOX SANG, V53, P203, DOI 10.1111/j.1423-0410.1987.tb05067.x; PIETERSZ RNI, 1989, VOX SANG, V56, P145, DOI 10.1111/j.1423-0410.1989.tb02017.x; PIETERSZ RNI, 1989, VOX SANG, V57, P29, DOI 10.1111/j.1423-0410.1989.tb04980.x; STOSSEL TP, 1975, SEMIN HEMATOL, V12, P83; 1991, MORBID MORTAL WEEKLY, V40, P176	10	63	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					755	756		10.1016/0140-6736(92)92296-R	http://dx.doi.org/10.1016/0140-6736(92)92296-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356179				2022-12-28	WOS:A1992JP86900005
J	DUNN, DT; NEWELL, ML; ADES, AE; PECKHAM, CS				DUNN, DT; NEWELL, ML; ADES, AE; PECKHAM, CS			RISK OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMISSION THROUGH BREAST-FEEDING	LANCET			English	Article							POSTNATAL TRANSMISSION; INFECTION; HIV; INFANT; MOTHER; WOMEN; MILK	Detection of human immunodeficiency virus type 1 (HIV-1) in breast milk by culture and polymerase chain reaction does not necessarily mean that breastfeeding is a route of transmission, although evidence from several case-reports points in that direction. We undertook a systematic review of published studies meeting criteria that allowed determination of quantitative risk of transmission via breastfeeding. Based on four studies in which mothers acquired HIV-1 postnatally, the estimated risk of transmission is 29% (95% CI 16-42%). Analysis of five studies showed that when the mother was infected prenatally, the additional risk of transmission through breastfeeding, over and above transmission in utero or during delivery, is 14% (95% CI 7-22%). Where there are safe alternatives to breastfeeding, universal named testing of pregnant women would provide an opportunity to advise more infected women not to breastfeed and might thereby reduce the number of vertically infected children. Since breastfeeding protects against infant deaths from infectious diseases, breastfeeding is still recommended where infectious diseases are a common cause of death in childhood, despite the additional risk of HIV transmission.			DUNN, DT (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Dunn, David/0000-0003-1836-4446				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BAUMSLAG N, 1987, LANCET, V2, P401; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COLEBUNDERS R, 1988, LANCET, V2, P1487; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; HEYMANN SJ, 1990, AM J PUBLIC HEALTH, V80, P1305, DOI 10.2105/AJPH.80.11.1305; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JELLIFFE DB, 1992, NEW ENGL J MED, V326, P642; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LEDERMAN SA, 1992, PEDIATRICS, V89, P290; NEWELL M-L, 1990, AIDS (London), V4, pS111; OXTOBY MJ, 1988, PEDIATR INFECT DIS J, V7, P825, DOI 10.1097/00006454-198807120-00001; PALASANTHIRAN P, IN PRESS J INFECT DI; ROGERS MF, 1987, LANCET, V2, P1278; RUFF A, 1992, 8 INT C AIDS AMST; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; THIRY L, 1985, LANCET, V2, P891; VANDEPERRE P, 1992, LANCET, V339, P1490; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VICTORA CG, 1987, LANCET, V2, P319; ZIEGLER JB, 1985, LANCET, V1, P896; 1988, LANCET, V2, P1043; 1985, MMWR, V34, P721; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1992, WEEKLY EPIDEMIOL REC, V67, P177	30	594	606	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					585	588		10.1016/0140-6736(92)92115-V	http://dx.doi.org/10.1016/0140-6736(92)92115-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355163				2022-12-28	WOS:A1992JM33400012
J	BIRKMEYER, JD; MARRIN, CAS; OCONNOR, GT				BIRKMEYER, JD; MARRIN, CAS; OCONNOR, GT			SHOULD PATIENTS WITH BJORK-SHILEY VALVES UNDERGO PROPHYLACTIC REPLACEMENT	LANCET			English	Article							MECHANICAL FAILURE; RELATIVE SURVIVAL; BIOPROSTHESIS; REOPERATION; PROSTHESIS; MORTALITY; POSITION; RISK	About 85 000 patients have undergone replacement of diseased heart valves with prosthetic Bjork-Shiley convexo-concave (CC) valves. These valves are prone to fracture of the outlet strut, which leads to acute valve failure that is usually fatal. Should patients with these valves undergo prophylactic replacement to avoid fracture? The incidence of strut fracture varies between 0% and 1.5% per year, depending on valve opening angle (60-degrees or 70-degrees), diameter (<29 mm or greater-than-or-equal-to 29 mm), and location (aortic or mitral). Other factors include the patient's life expectancy and the expected morbidity and mortality associated with reoperation. We have used decision analysis to identify the patients most likely to benefit from prophylactic reoperation. The incidence of outlet strut fracture was estimated from the data of three large studies on CC valves, and stratified by opening angle, diameter, and location. A Markov decision analysis model was used to estimate life expectancy for patients undergoing prophylactic valve replacement and for those not undergoing reoperation. Prophylactic valve replacement does not benefit patients with CC valves that have low strut fracture risks (60-degrees aortic valves and <29 mm, 60-degrees mitral valves). For most patients with CC valves that have high strut fracture risks (greater-than-or-equal-to 29 mm, 70-degrees CC), prophylactic valve replacement increases life expectancy. However, elderly patients with such valves benefit from prophylactic reoperation only if the risk of operative mortality is low. Patient age and operative risk are most important in recommendations for patients with CC valves that have intermediate strut fracture risks (<29 mm, 70-degrees valves and greater-than-or-equal-to 29 mm, 60-degrees mitral valves). For all patients and their doctors facing the difficult decision on whether to replace CC valves, individual estimates of operative mortality risk that take account of both patient-specific and institution-specific factors are essential.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,CTR EVALUAT CLIN SCI,HANOVER,NH 03756; DARTMOUTH HITCHCOCK MED CTR,DEPT SURG,LEBANON,NH 03766; DARTMOUTH HITCHCOCK MED CTR,DEPT COMMUNITY & FAMILY MED,LEBANON,NH 03766; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,PROGRAM MED INFORMAT SCI,HANOVER,NH 03756; DARTMOUTH HITCHCOCK MED CTR,DEPT MED,LEBANON,NH 03766	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College								ABDELNOOR M, 1990, EUR HEART J, V11, P23, DOI 10.1093/oxfordjournals.eurheartj.a059586; ANTUNES MJ, 1987, AM J CARDIOL, V59, P350, DOI 10.1016/0002-9149(87)90812-5; ANTUNES MJ, 1987, AM J CARDIOL, V59, P346, DOI 10.1016/0002-9149(87)90811-3; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BORTOLOTTI U, 1985, J THORAC CARDIOV SUR, V90, P564; COX DR, 1984, ANAL SURVIVAL DATA, P41; ENGLISH TAH, 1978, J THORAC CARDIOV SUR, V76, P56; ERICSSON A, 1992, EUR J CARDIO-THORAC, V6, P339, DOI 10.1016/1010-7940(92)90169-X; HIRATZKA LF, 1988, J AM COLL CARDIOL, V11, P1130, DOI 10.1016/S0735-1097(98)90075-4; HUSEBYE DG, 1983, J THORAC CARDIOV SUR, V86, P543; LINDBLOM D, 1990, J AM COLL CARDIOL, V15, P566, DOI 10.1016/0735-1097(90)90627-2; LINDBLOM D, 1986, J THORAC CARDIOV SUR, V92, P894; LINDBLOM D, 1989, J THORAC CARDIOV SUR, V97, P95; LYTLE BW, 1989, J THORAC CARDIOV SUR, V97, P675; LYTLE BW, 1986, ANN THORAC SURG, V43, P172; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P197; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PANSINI S, 1990, ANN THORAC SURG, V50, P569; PARR GVS, 1977, ANN THORAC SURG, V23, P319, DOI 10.1016/S0003-4975(10)64132-X; SCOTT WC, 1985, CIRCULATION, V72, P108; SETHI GK, 1987, J THORAC CARDIOV SUR, V93, P884; SYRACUSE DC, 1979, J THORAC CARDIOV SUR, V77, P346; VANDERGRAAF Y, 1992, LANCET, V339, P257, DOI 10.1016/0140-6736(92)91328-6; Weinstein MC, 1980, CLIN DECISION ANAL; 1987, VITAL STATISTICS US, P8	25	45	46	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					520	523		10.1016/0140-6736(92)91717-M	http://dx.doi.org/10.1016/0140-6736(92)91717-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354284	hybrid			2022-12-28	WOS:A1992JL23400011
J	COLAIANNI, LA				COLAIANNI, LA			RETRACTION, COMMENT, AND ERRATA POLICIES OF THE UNITED-STATES-NATIONAL-LIBRARY-OF-MEDICINE	LANCET			English	Article											COLAIANNI, LA (corresponding author), NATL LIB MED,BETHESDA,MD 20894, USA.								0	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					536	537		10.1016/0140-6736(92)91723-L	http://dx.doi.org/10.1016/0140-6736(92)91723-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354288				2022-12-28	WOS:A1992JL23400015
J	PLIML, W; VONARNIM, T; STABLEIN, A; HOFMANN, H; ZIMMER, HG; ERDMANN, E				PLIML, W; VONARNIM, T; STABLEIN, A; HOFMANN, H; ZIMMER, HG; ERDMANN, E			EFFECTS OF RIBOSE ON EXERCISE-INDUCED ISCHEMIA IN STABLE CORONARY-ARTERY DISEASE	LANCET			English	Article							MYOADENYLATE DEAMINASE DEFICIENCY; ADENINE-NUCLEOTIDES; GLOBAL-ISCHEMIA; METABOLISM; DOG; REDISTRIBUTION; STIMULATION; REPERFUSION; MYOCARDIUM; PHOSPHATE	There is no established treatment specifically aimed at protecting or restoring cardiac energy metabolism, which is greatly impaired by ischaemia. Even after reperfusion, myocardial content of ATP remains low for more than 72 h. Long-term post-ischaemic dysfunction and irreversibility of ischaemic damage have been associated with low ATP content. Evidence that the pentose sugar ribose stimulates ATP synthesis and improves cardiac function led us to test the possibility that ribose increases tolerance to myocardial ischaemia in patients with coronary artery disease (CAD). 20 men with documented severe CAD underwent two symptom-limited treadmill exercise tests on 2 consecutive days; we postulated that the ischaemia induced might bring about changes in ATP metabolism lasting for several days. Patients whose baseline tests showed reproducibility were randomly allocated 3 days of treatment with placebo or ribose 60 g daily in four doses by mouth. Exercise testing was repeated after treatment on day 5. At that time mean (95% confidence interval) treadmill walking time until 1 mm ST-segment depression was significantly greater in the ribose than in the placebo group (276 [220-331] vs 223 [188-259] s; p=0.002). The groups did not differ significantly in time to moderate angina. In the ribose-treated group the changes from baseline to day 5 in both time to ST depression and time to moderate angina were significant (p<0.005), but these changes were not significant in the placebo group. In patients with CAD, administration of ribose by mouth for 3 days improved the heart's tolerance to ischaemia. The presumed effects on cardiac energy metabolism offer new possibilities for adjunctive medical treatment of myocardial ischaemia.	UNIV MUNICH,INST PHYSIOL,W-8000 MUNICH 2,GERMANY; KLIN HOHENRIED,BERNRIED,GERMANY	University of Munich	PLIML, W (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,MED KLIN 1,DEPT MED,MARCHIONINI STR 15,W-8000 MUNICH 70,GERMANY.							ARNOLD JMO, 1985, J AM COLL CARDIOL, V6, P1026, DOI 10.1016/S0735-1097(85)80305-3; BAVARIA JE, 1990, J THORAC CARDIOV SUR, V100, P210; BRAUNWALD E, 1992, HEART DISEASE, P1179; DEBOER LWV, 1980, P NATL ACAD SCI-BIOL, V77, P5471, DOI 10.1073/pnas.77.9.5471; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; FOX AC, 1979, AM J CARDIOL, V43, P52, DOI 10.1016/0002-9149(79)90044-4; GERLACH E, 1963, NATURWISSENSCHAFTEN, V50, P228, DOI 10.1007/BF00639287; GINSBURG J, 1970, DIABETES, V19, P23, DOI 10.2337/diab.19.1.23; GORDON EE, 1991, HEART CARDIOVASCULAR, P151; GROSS M, 1989, KLIN WOCHENSCHR, V67, P1205, DOI 10.1007/BF01716208; HAAS GS, 1984, CIRCULATION, V70, P65; HEGEWALD MG, 1991, J AM COLL CARDIOL, V18, P1671, DOI 10.1016/0735-1097(91)90501-Y; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M, P69; JENNINGS RB, 1978, AM J PATHOL, V92, P187; MANFREDI JP, 1985, ANNU REV PHYSIOL, V47, P691, DOI 10.1146/annurev.ph.47.030185.003355; MARINI M, 1985, P SOC EXP BIOL MED, V180, P246; MAUSER M, 1985, CIRC RES, V56, P220, DOI 10.1161/01.RES.56.2.220; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PERLMUTTER NS, 1991, J NUCL MED, V32, P193; St Cyr J, 1986, Adv Exp Med Biol, V194, P401; SWAIN JL, 1982, AM J PHYSIOL, V242, pH818, DOI 10.1152/ajpheart.1982.242.5.H818; TAEGTMEYER H, 1985, J AM COLL CARDIOL, V6, P864, DOI 10.1016/S0735-1097(85)80496-4; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; ZIMMER HG, 1987, J MOL CELL CARDIOL, V19, P635, DOI 10.1016/S0022-2828(87)80371-1; ZIMMER HG, 1980, SCIENCE, V207, P319, DOI 10.1126/science.7350664; ZIMMER HG, 1983, SCIENCE, V220, P81, DOI 10.1126/science.6402820; ZIMMER HG, 1973, CIRC RES, V32, P635, DOI 10.1161/01.RES.32.5.635; ZIMMER HG, 1984, SCIENCE, V223, P712, DOI 10.1126/science.6420889; ZIMMER HG, 1978, PFLUG ARCH EUR J PHY, V376, P223, DOI 10.1007/BF00584954; ZOLLNER N, 1986, KLIN WOCHENSCHR, V64, P1281, DOI 10.1007/BF01785710	30	52	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					507	510		10.1016/0140-6736(92)91709-H	http://dx.doi.org/10.1016/0140-6736(92)91709-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354276				2022-12-28	WOS:A1992JL23400003
J	LAKIE, M; ARBLASTER, LA; ROBERTS, RC; VARMA, TRK				LAKIE, M; ARBLASTER, LA; ROBERTS, RC; VARMA, TRK			EFFECT OF STEREOTAXIC THALAMIC LESION ON ESSENTIAL TREMOR	LANCET			English	Note								The cause of essential (low-frequency) tremor is unknown and its relation to physiological (high-frequency) tremor is unclear. We assessed essential tremor in one patient before and after a stereotactic thalamic lesion. The procedure changed the size of the tremor in the right hand but not in the left. Persistence of a low-frequency component suggested that essential tremor was an additional feature superimposed on physiological tremor in this patient. The focus of essential tremor seems to be an autonomous central generator that is independent of physiological tremor mechanisms.	DUNDEE ROYAL INFIRM,DIRECTORATE NEUROSCI,DUNDEE,SCOTLAND; UNIV DUNDEE,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	LAKIE, M (corresponding author), UNIV BIRMINGHAM,APPL PHYSIOL RES UNIT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARBLASTER L, 1990, J PHYSIOL-LONDON, V423, pP71; ARBLASTER LA, 1990, J PHYSIOL-LONDON, V420, pP6; ELBE RJ, 1986, NEUROLOGY, V36, P225; LAKIE M, IN PRESS HDB TREMOR	4	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					206	207		10.1016/0140-6736(92)90470-N	http://dx.doi.org/10.1016/0140-6736(92)90470-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353137				2022-12-28	WOS:A1992JE75800005
J	MUTTI, A; ALINOVI, R; BERGAMASCHI, E; BIAGINI, C; CAVAZZINI, S; FRANCHINI, I; LAUWERYS, RR; BERNARD, AM; ROELS, H; GELPI, E; ROSELLO, J; RAMIS, I; PRICE, RG; TAYLOR, SA; DEBROE, M; NUYTS, GD; STOLTE, H; FELS, LM; HERBORT, C				MUTTI, A; ALINOVI, R; BERGAMASCHI, E; BIAGINI, C; CAVAZZINI, S; FRANCHINI, I; LAUWERYS, RR; BERNARD, AM; ROELS, H; GELPI, E; ROSELLO, J; RAMIS, I; PRICE, RG; TAYLOR, SA; DEBROE, M; NUYTS, GD; STOLTE, H; FELS, LM; HERBORT, C			NEPHROPATHIES AND EXPOSURE TO PERCHLOROETHYLENE IN DRY-CLEANERS	LANCET			English	Article							BRUSH-BORDER ANTIGEN; URINARY-EXCRETION; SOLVENT EXPOSURE; ORGANIC-SOLVENTS; KIDNEY-FUNCTION; GLOMERULONEPHRITIS; TETRACHLOROETHYLENE; GLYCOSAMINOGLYCANS; RADIOIMMUNOASSAY; IMMUNOASSAY	Even in specific risk groups, the relation between exposure to organic solvents and chronic renal diseases remains controversial. Thus, in a collaborative European study, we assessed the renal effects of occupational exposure to perchloroethylene (PCE) in dry-cleaners compared with matched controls who were simultaneously examined. Single high and low molecular weight proteins, kidney-derived antigens and enzymes, and prostanoids were measured in urine. Beta-2-microglobulin, creatinine, laminin fragments, and anti-glomerular basement membrane antibodies were also measured in serum. A canonical function based on 23 such variables correctly classified 93% of individuals as either PCE-exposed or controls; with 13 markers, group membership was identified in 87% of subjects. Increased high molecular weight protein in urine was frequently (17/50 vs 1/50, p < 0.0001) associated with tubular alterations. Changes were consistent with diffuse abnormalities along the nephron in workers exposed to low levels of PCE (median 15 parts per million). Generalised membrane disturbances might account for the increased release of laminin fragments, fibronectin, and glycosaminoglycans, for high molecular weight proteinuria, and for the increased shedding of epithelial membrane components from tubular cells with different location along the nephron (brush-border-antigens and Tamm-Horsfall glycoprotein). These findings of early renal changes indicate that solvent-exposed subjects, especially dry-cleaners, need to be monitored for the possible development of chronic renal diseases.	UNIV ANTWERP,DEPT NEPHROL HYPERTENS,EDEGEM,BELGIUM; HANOVER UNIV MED,DEPT NEPHROL,HANNOVER,GERMANY; CATHOLIC UNIV LOUVAIN,SCH MED,IND TOXICOL & OCCUPAT MED,B-1200 BRUSSELS,BELGIUM; CSIC,DEPT NEUROCHEM,EICOSANOIDS SECT,BARCELONA,SPAIN; UNIV LONDON KINGS COLL,BIOCHEM SECT,DIV BIOMOLEC SCI,LONDON WC2R 2LS,ENGLAND	University of Antwerp; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Consejo Superior de Investigaciones Cientificas (CSIC); University of London; King's College London	MUTTI, A (corresponding author), UNIV PARMA,SCH MED,IND TOXICOL LAB,I-43100 PARMA,ITALY.		Mutti, Antonio/ABE-3833-2021; Mutti, Antonio/AAB-9037-2020; Mutti, Antonio/C-1095-2011; BERNARD, Alfred M/A-6511-2010	Mutti, Antonio/0000-0003-2189-3808; Mutti, Antonio/0000-0003-2189-3808; BERNARD, Alfred M/0000-0003-3171-3743				ANDERSON K, 1912, BRIT MED J, V3, P881; ASKERGREN A, 1981, ACTA MED SCAND, V210, P103; ASKERGREN A, 1981, ACTA MED SCAND, V209, P479; BAGGIO B, 1987, CLIN BIOCHEM, V20, P449, DOI 10.1016/0009-9120(87)90013-0; BERNARD AM, 1983, CLIN CHEM, V29, P1007; DANIELL WE, 1988, JAMA-J AM MED ASSOC, V259, P2280; DIXIT SN, 1985, CONNECT TISSUE RES, V14, P31, DOI 10.3109/03008208509089841; ENGVALL E, 1986, METHOD ENZYMAT AN, P201; FISH AJ, 1985, J LAB CLIN MED, V105, P700; FRANCHINI I, 1983, INT ARCH OCC ENV HEA, V52, P1, DOI 10.1007/BF00380601; GELPI E, 1989, J CHROMATOGR-BIOMED, V492, P223, DOI 10.1016/S0378-4347(00)84470-9; HASHIMOTO DM, 1991, J OCCUP ENVIRON MED, V33, P516; HOTZ P, 1989, BRIT J IND MED, V46, P815; IMBRIANI M, 1988, ARCH ENVIRON HEALTH, V43, P292, DOI 10.1080/00039896.1988.10545952; INOUE G, 1973, GERONTOLOGY, V19, P73, DOI 10.1159/000211963; LAUWERYS R, 1983, INT ARCH OCC ENV HEA, V52, P69, DOI 10.1007/BF00380609; MACART M, 1988, CLIN CHEM, V34, P998; Mutti A, 1981, J Appl Toxicol, V1, P224, DOI 10.1002/jat.2550010408; MUTTI A, 1990, CLIN CHIM ACTA, V188, P93, DOI 10.1016/0009-8981(90)90153-J; MUTTI A, 1985, LANCET, V2, P914; NG TP, 1990, INT ARCH OCC ENV HEA, V62, P42; RAVNSKOV U, 1990, BRIT J IND MED, V47, P791; THORNLEY C, 1985, CLIN SCI, V68, P529, DOI 10.1042/cs0680529; VERPOOTEN GF, 1992, CLIN CHEM, V38, P642; VERPOOTEN GF, 1989, KIDNEY INT, V36, P617, DOI 10.1038/ki.1989.238; VIAU C, 1987, AM J IND MED, V11, P177, DOI 10.1002/ajim.4700110207; WHITEMAN P, 1973, BIOCHEM J, V131, P351, DOI 10.1042/bj1310351; YUEN CT, 1984, ANN CLIN BIOCHEM, V21, P295, DOI 10.1177/000456328402100411; ZIMMERMAN SW, 1975, LANCET, V2, P199	29	83	85	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					189	193		10.1016/0140-6736(92)90463-D	http://dx.doi.org/10.1016/0140-6736(92)90463-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353133				2022-12-28	WOS:A1992JE75800001
J	HAGIWARA, M; ALBERTS, A; BRINDLE, P; MEINKOTH, J; FERAMISCO, J; DENG, T; KARIN, M; SHENOLIKAR, S; MONTMINY, M				HAGIWARA, M; ALBERTS, A; BRINDLE, P; MEINKOTH, J; FERAMISCO, J; DENG, T; KARIN, M; SHENOLIKAR, S; MONTMINY, M			TRANSCRIPTIONAL ATTENUATION FOLLOWING CAMP INDUCTION REQUIRES PP-1-MEDIATED DEPHOSPHORYLATION OF CREB	CELL			English	Article							CYCLIC-AMP; PROTEIN PHOSPHATASE; GENE-TRANSCRIPTION; MOLECULAR-CLONING; SOMATOSTATIN GENE; CATALYTIC SUBUNIT; SEQUENCE; PHOSPHORYLATION; EXPRESSION; ONCOGENE	We have examined the mechanism by which the transcriptional activity of the cAMP-responsive factor CREB is attenuated following induction with forskolin. Metabolic labeling studies reveal that, after an initial burst of phosphorylation in response to cAMP, CREB is dephosphorylated and transcription of the cAMP-responsive somatostatin gene is correspondingly reduced. The phosphatase inhibitor 1 protein and okadaic acid both prevented the dephosphorylation of CREB at Ser-133 in PC12 cells and also augmented the transcriptional response to cAMP. Of the four Ser/Thr phosphatases described to date, only PP-1 appears to be similarly inhibited by these agents. As PP-1 specifically dephosphorylates CREB at Ser-133 and inhibits cAMP-dependent transcription, we propose that this phosphatase is the major regulator of CREB activity in cAMP-responsive cells.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; DUKE UNIV,DEPT PHARMACOL,DURHAM,NC 27710	University of California System; University of California San Diego; University of California System; University of California San Diego; Duke University	HAGIWARA, M (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.		Meinkoth, Judy L/G-2900-2010	Brindle, Paul/0000-0001-7172-8478	NCI NIH HHS [CA14195, CA50528] Funding Source: Medline; NIGMS NIH HHS [GM37828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037828, R01GM037828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, J NEUROSCI, V6, P803; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SASAKI K, 1984, J BIOL CHEM, V259, P5242	19	436	444	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					105	113		10.1016/0092-8674(92)90537-M	http://dx.doi.org/10.1016/0092-8674(92)90537-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1352481				2022-12-28	WOS:A1992JC95700012
J	LAPIDOT, T; PFLUMIO, F; DOEDENS, M; MURDOCH, B; WILLIAMS, DE; DICK, JE				LAPIDOT, T; PFLUMIO, F; DOEDENS, M; MURDOCH, B; WILLIAMS, DE; DICK, JE			CYTOKINE STIMULATION OF MULTILINEAGE HEMATOPOIESIS FROM IMMATURE HUMAN-CELLS ENGRAFTED IN SCID MICE	SCIENCE			English	Article							HUMAN-BONE-MARROW; STEM-CELLS; CORD BLOOD; IDENTIFICATION; LEUKEMIA; CULTURE; RAT	Severe combined immunodeficient (SCID) mice transplanted with human bone marrow were treated with human mast cell growth factor, a fusion of interleukin-3 and granulocyte-macrophage colony-stimulating factor (PIXY321), or both, starting immediately or 1 month later. Immature human cells repopulated the mouse bone marrow with differentiated human cells of multiple myeloid and lymphoid lineages; inclusion of erythropoietin resulted in human red cells in the peripheral blood. The bone marrow of growth factor-treated mice contained both multipotential and committed myeloid and erythroid progenitors, whereas mice not given growth factors had few human cells and only granulocyte-macrophage progenitors. Thus, this system allows the detection of immature human cells, identification of the growth factors that regulate them, and the establishment of animal models of human hematopoietic diseases.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Immunex Corporation; University of Toronto			Lapidot, Tsvee/A-1812-2010; Pflumio, Francoise/E-2074-2017	Pflumio, Francoise/0000-0001-8995-596X; Dick, John/0000-0002-9527-8317				CAROW CE, 1991, BLOOD, V78, P2216, DOI 10.1182/blood.V78.9.2216.bloodjournal7892216; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; DICK JE, 1986, TRENDS GENET, V2, P165, DOI 10.1016/0168-9525(86)90212-X; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; EAVES AC, 1984, CLIN HAEMATOL, V13, P371; FAUSER AA, 1978, BLOOD, V52, P1243; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; FULOP GM, 1986, J IMMUNOL, V136, P4438; GLUCK U, 1989, EXP HEMATOL, V17, P398; KAMELREID S, 1991, BLOOD, V78, P2973; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KAMELREID S, IN PRESS LEUKEMIA; LEARY AG, 1987, BLOOD, V69, P953; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MOORE MAS, 1991, BLOOD, V78, P1; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; PHILLIPS RA, 1985, COMP DIFFERENT ASSAY; ROWLEY SD, 1987, BLOOD, V69, P804; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; SZEBO K, 1990, CELL, V63, P225; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; TORBETT BE, 1991, IMMUNOL REV, V124, P139, DOI 10.1111/j.1600-065X.1991.tb00620.x; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS DE, 1991, CANCER S, V10, P2705; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	30	467	506	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1137	1141		10.1126/science.1372131	http://dx.doi.org/10.1126/science.1372131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1372131				2022-12-28	WOS:A1992HF63200045
J	HATTERSLEY, AT; LO, YMD; READ, SJ; EGLIN, RP; WAINSCOAT, JS; CLARK, A				HATTERSLEY, AT; LO, YMD; READ, SJ; EGLIN, RP; WAINSCOAT, JS; CLARK, A			FAILURE TO DETECT CYTOMEGALOVIRUS DNA IN PANCREAS IN TYPE-2 DIABETES	LANCET			English	Note							IMMEDIATE EARLY GENE; SEQUENCE	We have attempted to confirm the finding of cytomegalovirus (CMV) nucleic acid sequences in pancreas sections from patients with type 2 diabetes in a large population since this finding has major implications for the pathogenesis of the disorder. A highly sensitive nested polymerase chain reaction method was developed to detect the immediate-early CMV gene in DNA extracted from wax-embedded tissue sections. We could not confirm the previous findings; CMV DNA was not detected in pancreas sections from 43 type 2 diabetic patients or from 38 non-diabetic age-matched subjects, although the method detected CMV DNA, even in very low concentrations, in positive controls.	JOHN RADCLIFFE HOSP,DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT VIROL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; University of Oxford	HATTERSLEY, AT (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT MED,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND.		Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293; Hattersley, Andrew/0000-0001-5620-473X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; BEVAN IS, 1991, BRIT J HAEMATOL, V78, P94, DOI 10.1111/j.1365-2141.1991.tb04388.x; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LOHR JM, 1990, LANCET, P644; PAK CY, 1988, LANCET, V2, P1; STENBERG RM, 1984, J VIROL, V49, P190, DOI 10.1128/JVI.49.1.190-199.1984; 1985, WHO TECHN REP SER, V727	9	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					459	460		10.1016/0140-6736(92)91062-D	http://dx.doi.org/10.1016/0140-6736(92)91062-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1371324				2022-12-28	WOS:A1992HE93200007
J	GRAFFE, M; DONDON, J; CAILLET, J; ROMBY, P; EHRESMANN, C; EHRESMANN, B; SPRINGER, M				GRAFFE, M; DONDON, J; CAILLET, J; ROMBY, P; EHRESMANN, C; EHRESMANN, B; SPRINGER, M			THE SPECIFICITY OF TRANSLATIONAL CONTROL SWITCHED WITH TRANSFER-RNA IDENTITY RULES	SCIENCE			English	Article							SYNTHETASE EXPRESSION INVIVO; ESCHERICHIA-COLI; GENE-REGULATION; MESSENGER-RNA; THREONINE; LIGASE; LEVEL	The interaction of Escherichia coli threonyl-transfer RNA (tRNA) synthetase with the leader sequence of its own messenger RNA inhibits ribosome binding, resulting in negative translational feedback regulation. The leader sequence resembles the substrate (tRNA(Thr)) of the enzyme, and the nucleotides that mediate the correct recognition of the leader and the tRNA may be the same. A mutation suggested by tRNA identity rules that switches the resemblance of the leader sequence from tRNA(Thr) to tRNA(Met) causes the translation of the threonly-tRNA synthetase messenger RNA to become regulated by methionyl-tRNA synthetase. This identity swap in the leader messenger RNA indicates that tRNA identity rules may be extended to interactions of synthetases with other RNAs.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; INST BIOL MOLEC & CELLULAIRE,F-67084 STRASBOURG,FRANCE				ROMBY, Pascale/AGP-3328-2022					BUTLER JS, 1986, J BACTERIOL, V165, P198, DOI 10.1128/jb.165.1.198-203.1986; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LESTIENNE P, 1984, JB IOL CHEM, V2529, P5232; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MILLER JH, 1972, MOL GENETICS; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; NEIDHARDT FC, 1977, J BACTERIOL, V129, P378, DOI 10.1128/JB.129.1.378-387.1977; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINGER M, 1986, P NATL ACAD SCI USA, V83, P4384, DOI 10.1073/pnas.83.12.4384; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; SPRINGER MS, UNPUB	17	43	43	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					994	996		10.1126/science.1372129	http://dx.doi.org/10.1126/science.1372129			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1372129				2022-12-28	WOS:A1992HE60500044
J	HIGA, GM				HIGA, GM			G-CSF FOR FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							COLONY-STIMULATING FACTOR; GRANULOCYTE				HIGA, GM (corresponding author), W VIRGINIA UNIV,MORGANTOWN,WV 26506, USA.							BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; YOSHIDA T, 1990, CANCER, V66, P1904, DOI 10.1002/1097-0142(19901101)66:9<1904::AID-CNCR2820660908>3.0.CO;2-V	3	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					269	269						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1370181				2022-12-28	WOS:A1992HA43100014
J	HUMMEL, S; LEHTONEN, L				HUMMEL, S; LEHTONEN, L			COMPARISON OF ORAL-STEROID SPARING BY HIGH-DOSE AND LOW-DOSE INHALED STEROID IN MAINTENANCE TREATMENT OF SEVERE ASTHMA	LANCET			English	Article							CONTROLLED CLINICAL-TRIAL; DEPENDENT ASTHMA; DOUBLE-BLIND; BECLOMETHASONE DIPROPIONATE; PROGNOSTIC FACTORS; BRONCHIAL-ASTHMA; CORTICOSTEROIDS; METHOTREXATE; THERAPY	It is not clear whether high doses of inhaled steroids have a greater sparing effect than low doses on the requirement for systemic steroids. In a randomised, double-blind, multicentre study, we compared the effects of high-dose (1500 mug/day) and low-dose (300 mug/day) inhaled beclomethasone diproprionate (BDP) in patients with severe asthma requiring a daily oral prednisolone dose of 10-40 mg. During a 3-month run-in period, we tried to achieve optimum asthma control by means of oral steroid and inhaled BDP 300 mug/day. The patients were then allocated to high-dose (n = 71) or low-dose (n = 72) treatment by an independent observer who took into account various prognostic factors. BDP was administered by means of an aerosol inhaler with a spacer device. The dose of systemic steroid was reduced as much as possible during the 6-month study period while keeping the peak expiratory flow (PEF) constant and asthma clinically stable. There was no difference between the low-dose and high-dose treatment groups in the mean reduction in oral prednisolone dose achieved by the end of the study (5.2 [SD 7.9] vs 5.0 [9.4] mg/day). The maximum response to inhaled steroid was seen, however, only after several months' therapy in both groups. There were no differences between the groups in use of on-demand beta-agonist inhalations or in asthma symptoms, and PEF values were constant throughout the study. Both doses of BDP were well tolerated. High doses of inhaled steroid offer no further benefit over low doses in the maintenance treatment of severe steroid-dependent asthma when the inhaled steroid is administered with a spacer device.	ORION PHAMACEUT CO, RES CTR, SF-02101 ESPOO, FINLAND	Orion Corporation	HUMMEL, S (corresponding author), FACHKRANKENHAUS LUNGENHEILKUNDE & THORAXCHIRURG, BERLIN, GERMANY.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; CRANE J, 1992, LANCET, V339, P814, DOI 10.1016/0140-6736(92)91946-6; DAVIES BH, 1989, RES CLIN FORUMS, V11, P71; DYER PD, 1991, J ALLERGY CLIN IMMUN, V88, P208, DOI 10.1016/0091-6749(91)90330-Q; DYKEWICZ MS, 1986, ARCH INTERN MED, V146, P2369, DOI 10.1001/archinte.146.12.2369; FREEDMAN LS, 1976, BIOMETRICS, V32, P691, DOI 10.2307/2529759; GADDIE J, 1973, LANCET, V2, P280; KARALUS NC, 1987, NEW ZEAL MED J, V100, P305; LACRONIQUE J, 1991, EUR RESPIR J, V4, P807; LAURSEN LC, 1986, EUR J RESPIR DIS, V68, P19; MUNRO AJ, 1985, ORGANISING ANTIASTHM; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167, DOI 10.1164/ajrccm/140.1.167; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SMITH MJ, 1987, DRUGS, V33, P423, DOI 10.2165/00003495-198733050-00001; TARLO SM, 1988, CHEST, V93, P998, DOI 10.1378/chest.93.5.998; TOOGOOD JH, 1982, EUR J RESPIR DIS, V63, P100; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; 1976, BR J DIS CHEST, V70, P95; 1990, BMJ, V301, P771; 1979, BR J DIS CHEST, V73, P121	22	59	60	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	1992	340	8834-5					1483	1487		10.1016/0140-6736(92)92750-A	http://dx.doi.org/10.1016/0140-6736(92)92750-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361594				2022-12-28	WOS:A1992KD06900001
J	SHAPIRO, SH; ERNST, P; GRAYDONALD, K; MARTIN, JG; WOODDAUPHINEE, S; BEAUPRE, A; SPITZER, WO; MACKLEM, PT				SHAPIRO, SH; ERNST, P; GRAYDONALD, K; MARTIN, JG; WOODDAUPHINEE, S; BEAUPRE, A; SPITZER, WO; MACKLEM, PT			EFFECT OF NEGATIVE-PRESSURE VENTILATION IN SEVERE CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	LANCET			English	Article							DIAPHRAGM; TRIAL; INDEX	The hypothesis that patients with chronic obstructive pulmonary disease (COPD) have chronic inspiratory muscle fatigue was tested in an effectiveness trial in which negative pressure ventilation (NPV) was used to produce inspiratory muscle rest. In a double-blind study 184 patients with severe COPD were randomly allocated active or sham NPV treatment for a 12-week period of home use. The distance walked in a 6 min walk test was the primary outcome variable. Secondary outcome measures were cycle exercise endurance time, severity of dyspnoea, quality of life, arterial blood gas tensions, and respiratory muscle strength. The percentage reduction in amplitude of the diaphragmatic electromyographic signal multiplied by hours of NPV was used to reflect the dose of NPV so we could examine dose-response relations. Analysis was based on intention to treat. We found no evidence of a clinically or statistically significant difference in any outcome measure between active and sham groups. No dose-response relation was observed. Moreover, the intervention was poorly accepted despite substantial clinical support. We conclude that NPV as used in this study is difficult to apply and ineffective when used with the aim of resting the respiratory muscles in patients with stable COPD.	MONTREAL CHEST HOSP,MONTREAL,QUEBEC,CANADA; MAISONNEUVE ROSEMONT HOME CARE PROGRAM,MONTREAL,QUEBEC,CANADA; MCGILL UNIV,SCH PHYS & OCCUPAT THERAPY,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,SCH DIETET & HUMAN NUTR,MONTREAL H3A 2T5,QUEBEC,CANADA	McGill University; Universite de Montreal; McGill University; McGill University	SHAPIRO, SH (corresponding author), MCGILL UNIV,SCH PHYS & OCCUPAT THERAPY,DEPT EPIDEMIOL & BIOSTAT,1020 PINE AVE W,MONTREAL H3A 1A2,QUEBEC,CANADA.			Martin, James/0000-0001-7574-5363	NHLBI NIH HHS [HL34019] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034019] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; Braun N, 1984, CHEST, V85, p595S; BUTLAND RJA, 1982, BMJ, V284, P100; CELLI B, 1989, AM REV RESPIR DIS, V140, P1251, DOI 10.1164/ajrccm/140.5.1251; CROPP A, 1987, AM REV RESPIR DIS, V135, P1056; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GUTIERREZ M, 1988, AM REV RESPIR DIS, V138, P617, DOI 10.1164/ajrccm/138.3.617; LEVY RD, 1989, CHEST, V95, P95, DOI 10.1378/chest.95.1.95; LUGINBUHL R, 1987, SAS STAT GUIDE PERSO; MACKLEM PT, 1980, CHEST, V78, P753, DOI 10.1378/chest.78.5.753; MACKLEM PT, 1984, AM REV RESPIR DIS, V129, P102; MCGAVIN CR, 1976, BMJ-BRIT MED J, V1, P822, DOI 10.1136/bmj.1.6013.822; MCGAVIN CR, 1978, BMJ, V2, P1241; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SHAPIRO SH, 1991, J CLIN EPIDEMIOL, V44, P483, DOI 10.1016/0895-4356(91)90211-Q; SIMILOWSKI T, 1991, NEW ENGL J MED, V325, P917, DOI 10.1056/NEJM199109263251304; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STOLLER JK, 1986, AM REV RESPIR DIS, V134, P1129; ZIBRAK JD, 1988, AM REV RESPIR DIS, V138, P1515, DOI 10.1164/ajrccm/138.6.1515; 1990, AM REV RESPIR DIS, V142, P474	20	107	109	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1425	1429		10.1016/0140-6736(92)92620-U	http://dx.doi.org/10.1016/0140-6736(92)92620-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360558				2022-12-28	WOS:A1992KC28400002
J	MARKUSSIS, V; BESHYAH, SA; FISHER, C; SHARP, P; NICOLAIDES, AN; JOHNSTON, DG				MARKUSSIS, V; BESHYAH, SA; FISHER, C; SHARP, P; NICOLAIDES, AN; JOHNSTON, DG			DETECTION OF PREMATURE ATHEROSCLEROSIS BY HIGH-RESOLUTION ULTRASONOGRAPHY IN SYMPTOM-FREE HYPOPITUITARY ADULTS	LANCET			English	Article							HUMAN GROWTH-HORMONE; CARDIOVASCULAR-DISEASE; CAROTID ATHEROSCLEROSIS; FOLLOW-UP; PROGRESSION; ARTERIOSCLEROSIS; REGRESSION; POPULATION; ULTRASOUND; MORTALITY	Retrospective analysis suggests that there is increased mortality from vascular disease in hypopituitary adults, but vascular status before death is unknown. High resolution B-mode ultrasonic imaging of both carotid and femoral arteries was therefore done in 34 adult hypopituitary patients on routine replacement therapy and was compared with that in 39 matched controls. Changes were related to risk factors for vascular disease. Carotid intima-media thickness was greater in patients than in controls (mean [SD] 0.74 [0.16] vs 0.65 [0.13] mm, p < 0.02). This difference was seen in middle-aged and elderly patients. More patients than controls had one or more atheromatous plaques (65% vs 41%, p < 0.05). The percentage of individual arteries with a plaque was also higher in patients (32% vs 18%, p < 0.005). In multiple regression analysis, patients' age was the dominant factor determining carotid intima-media thickness. Symptom-free adults with hypopituitarism show an increased prevalence of atherosclerosis.	ST MARYS HOSP, SCH MED, METAB MED UNIT, LONDON W2 1PG, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, SCH MED, IRVINE LAB, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, SCH MED, ACAD SURG UNIT, HARROW HA1 3UJ, MIDDX, ENGLAND	Imperial College London; Imperial College London; Imperial College London; Imperial College London			Beshyah, Salem/H-3213-2016; Beshyah, Salem A/I-1533-2019	Beshyah, Salem/0000-0003-3650-9741; Beshyah, Salem A/0000-0003-3650-9741				BELCARO G, 1990, CURR THER RES CLIN E, V48, P116; BLACKETT PR, 1982, METABOLISM, V31, P117, DOI 10.1016/0026-0495(82)90121-4; ERNST E, 1991, BRIT MED J, V303, P596, DOI 10.1136/bmj.303.6803.596; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GARDNER MJ, 1989, STATISTICS CONFIDENC, P20; ISHIBASHI S, 1985, ACTA ENDOCRINOL-COP, V110, P456, DOI 10.1530/acta.0.1100456; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LIBBER SM, 1990, MEDICINE, V69, P46, DOI 10.1097/00005792-199001000-00004; MARGITIC SE, 1991, ARTERIOSCLER THROMB, V11, P443, DOI 10.1161/01.ATV.11.2.443; MERIMEE TJ, 1973, DIABETES, V22, P813, DOI 10.2337/diab.22.11.813; MERIMEE TJ, 1972, METABOLISM, V21, P1053, DOI 10.1016/0026-0495(72)90036-4; MERIMEE TJ, 1968, METABOLISM, V17, P1005, DOI 10.1016/0026-0495(68)90006-1; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; RICOTTA JJ, 1987, J VASC SURG, V6, P512, DOI 10.1067/mva.1987.avs0060512; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; TEALE JD, 1986, ANN CLIN BIOCHEM, V23, P413, DOI 10.1177/000456328602300406; WARRICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WUSTER C, 1991, KLIN WOCHENSCHR, V69, P769, DOI 10.1007/BF01797616	24	360	367	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1188	1192		10.1016/0140-6736(92)92892-J	http://dx.doi.org/10.1016/0140-6736(92)92892-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359261				2022-12-28	WOS:A1992JY38600004
J	MARTIN, J; HORWICH, AL; HARTL, FU				MARTIN, J; HORWICH, AL; HARTL, FU			PREVENTION OF PROTEIN DENATURATION UNDER HEAT-STRESS BY THE CHAPERONIN HSP60	SCIENCE			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; SHOCK PROTEINS; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; ATP HYDROLYSIS; COMPLEX; IMPORT; GROE; RECONSTITUTION	The increased synthesis of heat shock proteins is a ubiquitous physiological response of cells to environmental stress. How these proteins function in protecting cellular structures is not yet understood. The mitochondrial heat shock protein 60 (Hsp60) has now been shown to form complexes with a variety of polypeptides in organelles exposed to heat stress. The Hsp60 was required to prevent the thermal inactivation in vivo of native dihydrofolate reductase (DHFR) imported into mitochondria. In vitro, Hsp60 bound to DHFR in the course of thermal denaturation, preventing its aggregation, and mediated its adenosine triphosphate-dependent refolding at increased temperatures. These results suggest a general mechanism by which heat shock proteins of the Hsp60 family stabilize preexisting proteins under stress conditions.	SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LABS,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Memorial Sloan Kettering Cancer Center; Yale University; Howard Hughes Medical Institute; Yale University			Hartl, F. Ulrich/Y-8206-2019					APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DAUM G, 1982, J BIOL CHEM, V257, P3075; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GARVEY EP, 1989, BIOCHEMISTRY-US, V28, P2083, DOI 10.1021/bi00431a018; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KITTCHEL BB, 1978, BIOCHIM BIOPHYS ACTA, V534, P89; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Martin J., UNPUB; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN MY, 1992, EMBO J, V11, P71; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TEINTZE M, 1982, J BIOL CHEM, V257, P364; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	39	252	256	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					995	998		10.1126/science.1359644	http://dx.doi.org/10.1126/science.1359644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359644				2022-12-28	WOS:A1992JW79600035
J	COKER, RJ; NIEMAN, R; MCBRIDE, M; MITCHELL, DM; HARRIS, JRW; WEBER, JN				COKER, RJ; NIEMAN, R; MCBRIDE, M; MITCHELL, DM; HARRIS, JRW; WEBER, JN			COTRIMOXAZOLE VERSUS DAPSONE-PYRIMETHAMINE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA	LANCET			English	Letter									NATL LUNG & HEART INST,DEPT RESP MED,LONDON SW3,ENGLAND; ST MARYS HOSP,DEPT RESP MED,LONDON W2 1NY,ENGLAND	Imperial College London; Imperial College London	COKER, RJ (corresponding author), ST MARYS HOSP,DEPT GENITOURINARY MED,JEFFERISS WING,LONDON W2 1NY,ENGLAND.							ANTINORI, 1992, LANCET, V340, P788	1	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1099	1099		10.1016/0140-6736(92)93120-C	http://dx.doi.org/10.1016/0140-6736(92)93120-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357487				2022-12-28	WOS:A1992JV77500038
J	ROTHSTEIN, JD; GUIDOTTI, A; TINUPER, P; CORTELLI, P; AVONI, P; PLAZZI, G; LUGARESI, E; SCHOCH, P; MONTAGNA, P				ROTHSTEIN, JD; GUIDOTTI, A; TINUPER, P; CORTELLI, P; AVONI, P; PLAZZI, G; LUGARESI, E; SCHOCH, P; MONTAGNA, P			ENDOGENOUS BENZODIAZEPINE RECEPTOR LIGANDS IN IDIOPATHIC RECURRING STUPOR	LANCET			English	Note								"Endozepines" are endogenous ligands for the benzodiazepine recognition sites on gamma-aminobutyric acid A receptors in the nervous system. Idiopathic recurring stupor (IRS) is a syndrome of spontaneous stupor or coma that is not associated with known metabolic, toxic, or structural abnormalities but can be reversed by flumazenil, a pure benzodiazepine antagonist. We measured endozepine-2 and endozepine-4 by high-performance liquid chromatography and radioreceptor assay in serum and cerebrospinal fluid from three patients with IRS. During episodes of stupor there was a large (up to 300-fold compared with control patients) increase of endozepine-4 content in cerebrospinal fluid and serum, but a return to normal concentrations between attacks. Endozepine-4 may contribute to, or be the cause of, IRS. The reasons for abnormal concentrations of endozepine in blood and brain are unknown.	GEORGETOWN UNIV,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20057; UNIV BOLOGNA,INST NEUROL,I-40126 BOLOGNA,ITALY; HOFFMANN LA ROCHE AG,DIV PHARMA,PRECLIN RES,BASEL,SWITZERLAND	Georgetown University; University of Bologna; Roche Holding	ROTHSTEIN, JD (corresponding author), JOHNS HOPKINS UNIV,DEPT NEUROL,MEYER 5-119,600 N WOLFE ST,BALTIMORE,MD 21205, USA.		Cortelli, Pietro/K-6063-2016; Plazzi, Giuseppe/AAB-9627-2020; rothstein, jeffrey d/C-9470-2013; Tinuper, Paolo/AAB-7760-2020; Avoni, Patrizia/AAC-1879-2020	tinuper, paolo/0000-0002-0588-3063; Plazzi, Giuseppe/0000-0002-1051-0472; Cortelli, Pietro/0000-0002-3633-8818; AVONI, PATRIZIA/0000-0003-0719-6803	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001355] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01355] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COSTA E, 1987, PSYCHOPHARMACOLOGY 3, P425; GRIMM G, 1988, LANCET, V1, P1292; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P260, DOI 10.1016/0165-6147(91)90567-C; MENNINI T, 1983, ADV BIOCHEM PSYCHOPH, V38, P189; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; NUTT DJ, 1990, ARCH GEN PSYCHIAT, V47, P917; OLASMAA M, 1990, J NEUROCHEM, V55, P2015, DOI 10.1111/j.1471-4159.1990.tb05790.x; ROTHSTEIN JD, 1992, J NEUROCHEM, V58, P2102, DOI 10.1111/j.1471-4159.1992.tb10952.x; TINUPER P, 1992, ANN NEUROL, V31, P503, DOI 10.1002/ana.410310507; UNSELD E, 1989, BIOCHEM PHARMACOL, V38, P2473, DOI 10.1016/0006-2952(89)90091-9	10	47	47	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1002	1004		10.1016/0140-6736(92)93011-B	http://dx.doi.org/10.1016/0140-6736(92)93011-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357403	hybrid			2022-12-28	WOS:A1992JV01400005
J	DEGRAAF, MJM				DEGRAAF, MJM			40 YEARS OF BEING TREATED FOR NOCTURNAL ENURESIS	LANCET			English	Editorial Material											DEGRAAF, MJM (corresponding author), UNIV LIMBURG,ACAD HOSP,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.							GILRUSHTON H, 1989, J PEDIATR, V114, P691; NORGAARD JP, 1985, J UROLOGY, V134, P1029, DOI 10.1016/S0022-5347(17)47581-1; RITTIG S, 1989, AM J PHYSIOL, V256, P664	3	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					957	958		10.1016/0140-6736(92)92828-4	http://dx.doi.org/10.1016/0140-6736(92)92828-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357357				2022-12-28	WOS:A1992JT82300014
J	CROS, P; ALLIBERT, P; MANDRAND, B; TIERCY, JM; MACH, B				CROS, P; ALLIBERT, P; MANDRAND, B; TIERCY, JM; MACH, B			OLIGONUCLEOTIDE GENOTYPING OF HLA POLYMORPHISM ON MICROTITRE PLATES	LANCET			English	Article							LINKAGE DISEQUILIBRIUM; TYPING ANALYSIS; CLASS-II; HYBRIDIZATION; DNA; IDENTIFICATION; PROBES	Molecular analysis of mutations and polymorphisms that are of medical importance requires both accuracy and simplicity. In organ transplantation there is a need for an HLA typing procedure that combines the remarkable accuracy of oligonucleotide genotyping with the simplicity of conventional serological typing. We describe a simple semiautomated method of HLA class II typing consisting of an oligonucleotide hybridisation assay done on microtitre plates followed by automatic colorimetric reading. Individual HLA-DR generic typing for 30 DR specificities, including subtypes of DR1, DR2, DR13, DR14, and DR52, is done on a single plate. The entire typing assay can be completed in less than 4 hours. The procedure has been validated on more than a thousand haplotypes in prospective DR typing of kidney transplant patients, leukaemic patients, and their potential donors. The simplicity of this assay makes it suitable for routine laboratory use. It can be applied to genetic testing in general, including the testing of patients with multiple mutations.	BIOMERIEUX,NUCLEIC ACID PROBES LAB,LYON,FRANCE; HOP CANTONAL GENEVA,DIV IMMUNOL & ALLERGOL,TRANSPLANTAT IMMUNOL UNIT,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	bioMerieux; University of Geneva; University of Geneva								ANGELINI G, 1986, P NATL ACAD SCI USA, V83, P4489, DOI 10.1073/pnas.83.12.4489; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; DUNN AR, 1977, CELL, V12, P23, DOI 10.1016/0092-8674(77)90182-9; GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390; KELLER GH, 1989, DNA PROBES, P141; MACH B, 1991, HUM IMMUNOL, V30, P278, DOI 10.1016/0198-8859(91)90007-V; MACH B, 1990, MOL BIOL HLA CLASS 2, P201; MOREL C, 1990, HUM IMMUNOL, V29, P64, DOI 10.1016/0198-8859(90)90070-6; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; TIERCY JM, 1991, TISSUE ANTIGENS, V37, P161, DOI 10.1111/j.1399-0039.1991.tb01865.x; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121; TIERCY JM, 1988, P NATL ACAD SCI USA, V85, P198, DOI 10.1073/pnas.85.1.198; TIERCY JM, 1990, EUR J IMMUNOL, V20, P237, DOI 10.1002/eji.1830200202; TIERCY JM, 1991, TRANSPLANTATION, V51, P1110, DOI 10.1097/00007890-199105000-00034; WAKE CT, 1982, NATURE, V300, P372, DOI 10.1038/300372a0	16	67	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					870	873		10.1016/0140-6736(92)93284-T	http://dx.doi.org/10.1016/0140-6736(92)93284-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357296				2022-12-28	WOS:A1992JT32700003
J	ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M				ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M			LISTERIOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA WHO WERE TREATED WITH FLUDARABINE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article						LISTERIA INFECTIONS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; FLUDARABINE; PREDNISONE; ANTIGENS, CD4; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS	INFECTIONS; THERAPY; AGENT	Objective. To determine whether therapy with fludarabine plus prednisone in patients with chronic lymphocytic leukemia increases the risk for developing listeriosis. Design: Retrospective cohort study based on hospital surveillance data. Setting: Referral cancer center. Participants: A total of 795 patients with chronic lymphocytic leukemia who received care at The University of Texas M. D. Anderson Cancer Center between 1980 and 1990. Interventions: Patients were treated with fludarabine alone or fludarabine and prednisone. Measurements: The listeriosis attack rate was analyzed according to the type of treatment received. Results: Seven of 408 patients in the fludarabine group developed listeriosis (1.7%; 95% Cl, 0.2% to 6%) compared with 0 of 387 patients who received conventional chemotherapy alone (0% to 0.9%; P = 0.015). The 7 patients were among 248 patients who were treated with both fludarabine and prednisone; none of 160 patients treated with fludarabine alone developed listeriosis (P = 0.045 by the Fisher exact test). A dramatic reduction in CD4 counts occurred in patients after fludarabine and prednisone treatment and coincided with the development of listeriosis. Conclusion: The administration of fludarabine plus prednisone is associated with an increased incidence of listeriosis in patients with chronic lymphocytic leukemia. The depletion of CD4 cells may underlie the pathogenesis.			ANAISSIE, E (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AMPEL MN, 1990, 30TH P INT C ANT AG; ARMSTRONG D, 1990, PRINCIPLES PRACTICE, P1587; AROESTY JM, 1962, NEW YORK STATE J MED, V62, P1946; Bille J, 1988, B BUNDESAMTES GESUND, V3, P28; BOLDT DH, 1984, CANCER RES, V44, P4661; COX DR, 1953, BIOMETRIKA, V40, P354, DOI 10.1093/biomet/40.3-4.354; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; HANSEN MM, 1973, SCAND J HAEMATOL, P1; HANTEL A, 1989, CANCER, V64, P516, DOI 10.1002/1097-0142(19890715)64:2<516::AID-CNCR2820640226>3.0.CO;2-I; HEATH ME, 1985, AM J HEMATOL, V19, P63, DOI 10.1002/ajh.2830190109; KEATING MJ, 1988, LEUKEMIA, V2, P157; KEATING MJ, 1989, BLOOD, V74, P19; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOURIA DB, 1970, ANN NY ACAD SCI, V174, P545, DOI 10.1111/j.1749-6632.1970.tb45580.x; LOURIA DB, 1967, ANN INTERN MED, V67, P261, DOI 10.7326/0003-4819-67-2-261; MONSERRATCOSTA E, 1977, SANGRE, V22, P968; MYERS TJ, 1980, CANCER, V46, P619, DOI 10.1002/1097-0142(19800801)46:3<619::AID-CNCR2820460332>3.0.CO;2-I; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PISCIOTTA AV, 1957, ARCH INTERN MED, V99, P334, DOI 10.1001/archinte.1957.00260030012002; REVOL L, 1974, ENCY MED CHIRURGICAL; ROBERTSON LE, 1990, BLOOD, V76, pA314; SAMRA Y, 1984, POSTGRAD MED J, V60, P267, DOI 10.1136/pgmj.60.702.267; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHWARTZ B, 1988, LANCET, V2, P779; SHAW RK, 1960, ARCH INTERN MED, V106, P467, DOI 10.1001/archinte.1960.03820040005002; SPITZER PG, 1986, REV INFECT DIS, V8, P427; TRAVADE P, 1986, PRESSE MED, V15, P1715; TWOMEY JJ, 1973, ARCH INTERN MED, V132, P562, DOI 10.1001/archinte.132.4.562; UTMANN JE, 1959, ANN INTERN MED, V51, P501; WINSLOW DL, 1982, ANTIMICROB AGENTS CH, V22, P51, DOI 10.1128/AAC.22.1.51; 1989, MMWR, V38, P267	32	110	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					466	469		10.7326/0003-4819-117-6-466	http://dx.doi.org/10.7326/0003-4819-117-6-466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354425				2022-12-28	WOS:A1992JN25700004
J	KILIDIREAS, K; LATOV, N; STRAUSS, DH; GORIG, AD; HASHIM, GA; GORMAN, JM; SADIQ, SA				KILIDIREAS, K; LATOV, N; STRAUSS, DH; GORIG, AD; HASHIM, GA; GORMAN, JM; SADIQ, SA			ANTIBODIES TO THE HUMAN 60 KDA HEAT-SHOCK PROTEIN IN PATIENTS WITH SCHIZOPHRENIA	LANCET			English	Article							RHEUMATOID-ARTHRITIS; LYMPHOCYTE-T; MYCOBACTERIAL; CELLS; AUTOANTIBODIES; AUTOIMMUNITY; BACTERIAL; SURFACE; ANTIGEN; MYELIN	Immune mechanisms are thought to be important in a subpopulation of patients with schizophrenia. We examined the specificity of neural antibodies in patients with schizophrenia to identify a possible antigen. Serum antibodies from patients with schizophrenia and control subjects were tested for binding to protein extracts of human neuroblastoma cells by western blot. Protein antigens were characterised by aminoterminal and internal aminoacid sequence analysis. 14 of 32 (44%) otherwise healthy patients with schizophrenia had antibodies to a neuroblastoma protein of molecular weight 60 kDa. By partial sequence analysis, this protein was identified as the 60 kDa human heat-shock protein (hsp) that is the P1 mitochondrial protein, and which is 50% homologous to the mycobacterial 65 kDa hsp. Antigens that crossreact with hsp65 have been implicated in the pathogenesis of adjuvant-induced arthritis in rats and autoimmune diabetes in mice. Of 100 normal subjects or disease controls, antibodies to hsp60 were found in only 8 patients, all of whom had active infectious or inflammatory disease. Our results support the presence of abnormal immune reactivity involving hsp60 in a subset of patients with schizophrenia. The immune response may be related to the pathogenesis of the disease.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL,BLACK BLDG,ROOM 3-323,630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT SURG, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, DEPT CLIN PSYCHOBIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute			Sadiq, Saud/AAA-9871-2020		NIMH NIH HHS [MH00416] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGUAS AP, 1990, INFECT IMMUN, V58, P1461, DOI 10.1128/IAI.58.5.1461-1470.1990; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; COHEN IR, 1990, ISRAEL J MED SCI, V26, P673; COULIE PG, 1985, J EXP MED, V161, P88, DOI 10.1084/jem.161.1.88; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JARJOUR W, 1990, J EXP MED, V172, P1857, DOI 10.1084/jem.172.6.1857; JARJOUR WN, 1991, ARTHRITIS RHEUM-US, V34, P1133, DOI 10.1002/art.1780340909; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KIRCH DG, 1985, BIOL PSYCHIAT, V20, P1039, DOI 10.1016/0006-3223(85)90002-2; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCALLISTER CG, 1989, ARCH GEN PSYCHIAT, V46, P890; MUNK ME, 1989, J IMMUNOL, V143, P2844; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SADIQ SA, 1991, J NEUROSCI RES, V29, P319, DOI 10.1002/jnr.490290307; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SIROTA P, 1990, ISRAEL J MED SCI, V26, P694; SPATZ LA, 1990, J IMMUNOL, V144, P2821; SPIVAK B, 1991, AM J PSYCHIAT, V148, P244; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUNDIN U, 1989, Brain Behavior and Immunity, V3, P345, DOI 10.1016/0889-1591(89)90033-0; TSOULFA G, 1989, ANN RHEUM DIS, V48, P118, DOI 10.1136/ard.48.2.118; van Eden W, 1987, Concepts Immunopathol, V4, P144; VANDENBERG LH, 1990, J NEUROSCI RES, V25, P295, DOI 10.1002/jnr.490250305; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VILLEMAIN F, 1989, AM J PSYCHIAT, V2, P417; WANDWURTTENBERGER A, 1991, EUR J IMMUNOL, V21, P1089, DOI 10.1002/eji.1830210437; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	30	74	76	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1992	340	8819					569	572		10.1016/0140-6736(92)92105-O	http://dx.doi.org/10.1016/0140-6736(92)92105-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355154	hybrid			2022-12-28	WOS:A1992JM33400003
J	BLAU, JN				BLAU, JN			CLASSICAL MIGRAINE - SYMPTOMS BETWEEN VISUAL AURA AND HEADACHE ONSET	LANCET			English	Article								The gap between the end of the visual aura and headache onset in classical migraine has been called the free interval. In a retrospective study of twenty-five migraineurs who had noted a gap, only three reported feeling normal at that time: twenty-two described alterations in mood, detachment from the environment or other people, fears, disturbances of speech or thought, or somatic symptoms. The interval lasted less than an hour in seventeen of the twenty-two but in five persisted for 1 to 5 hours. These symptoms suggest involvement of the frontal and temporal cortices as well as the hypothalamus; they do not conform to Leao's spreading depression or a vascular mechanism, but are in keeping with a diffuse cerebral process with focal manifestations.			BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BLAU JN, 1992, LANCET, V339, P1202, DOI 10.1016/0140-6736(92)91140-4; BLAU JN, 1986, PRELUDE MIGRAINE ATT, P39; LAURITZEN M, 1984, BRAIN, V107, P457; PATON L, 1919, P ROY SOC MED, V12, P53; SELBY DK, 1983, GERIATRICS, V38, P42; WOLFF HG, 1963, HEADACHE OTHER HEAD, P230; 1988, CEPHALALGIA S7, V8, P21	7	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					355	356		10.1016/0140-6736(92)91415-5	http://dx.doi.org/10.1016/0140-6736(92)91415-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353815				2022-12-28	WOS:A1992JH12500014
J	EVANS, RJ; DERKACH, V; SURPRENANT, A				EVANS, RJ; DERKACH, V; SURPRENANT, A			ATP MEDIATES FAST SYNAPTIC TRANSMISSION IN MAMMALIAN NEURONS	NATURE			English	Article							MOUSE VAS-DEFERENS; AUTONOMIC NEUROTRANSMISSION; SURAMIN; CELLS; RAT; AUTORECEPTORS; VESICLES; SINGLE	IN addition to its diverse functions inside cells, ATP can act at several types of cell-surface receptor 1-3. One of these (P2X-purinoceptor) is believed to be a ligand-gated cation channel 1-6. The presence of P2X receptors on autonomic, sensory and central neurons suggests that ATP might be released to act as a fast excitatory synaptic transmitter. Here we record excitatory synaptic potentials and currents from cultured coeliac ganglion neurons which are mimicked by ATP, blocked by the P2-purinoceptor antagonist suramin, desensitized by alpha,beta-methylene-ATP and unaffected by antagonists acting at nicotine, 5-hydroxytryptamine, N-methyl-D-aspartate (NMDA), non-NMDA glutamate, gamma-aminobutyric acid (GABA), noradrenaline or adenosine receptors. We conclude that ATP is the neurotransmitter at this neuroneuronal synapse.			EVANS, RJ (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.							ALM P, 1979, NEUROSCIENCE, V4, P145, DOI 10.1016/0306-4522(79)90224-0; BEAN BP, 1990, J NEUROSCI, V10, P11; BEAN BP, 1990, J NEUROSCI, V10, P1; BENHAM CD, 1987, J PHYSIOL-LONDON, V387, P473, DOI 10.1113/jphysiol.1987.sp016585; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; BURNSTOCK G, 1986, ACTA PHYSIOL SCAND, V126, P67, DOI 10.1111/j.1748-1716.1986.tb07790.x; BURNSTOCK G, 1990, NEUROCHEM INT, V17, P357, DOI 10.1016/0197-0186(90)90158-P; COGGAN JS, 1991, J AUTONOM NERV SYST, V34, P147, DOI 10.1016/0165-1838(91)90081-D; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; EVANS RJ, IN PRESS BR J PHARM; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIED G, 1980, ACTA PHYSL SCAND, V493, P546; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; LAGERCRANTZ H, 1976, NEUROSCIENCE, V1, P81, DOI 10.1016/0306-4522(76)90002-6; NAKAZAWA K, 1990, BRIT J PHARMACOL, V101, P224, DOI 10.1111/j.1476-5381.1990.tb12117.x; SHEN KZ, 1990, J PHYSL, V431, P585; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V342, P198, DOI 10.1007/BF00166965; VONKUGELGEN I, 1989, N-S ARCH PHARMACOL, V340, P760, DOI 10.1007/BF00169686; WHITE TD, 1988, PHARMACOL THERAPEUT, V38, P129, DOI 10.1016/0163-7258(88)90095-2	24	508	515	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					503	505		10.1038/357503a0	http://dx.doi.org/10.1038/357503a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1351659				2022-12-28	WOS:A1992HY05200065
J	PETTOELLOMANTOVANI, M; CASADEVALL, A; KOLLMANN, TR; RUBINSTEIN, A; GOLDSTEIN, H				PETTOELLOMANTOVANI, M; CASADEVALL, A; KOLLMANN, TR; RUBINSTEIN, A; GOLDSTEIN, H			ENHANCEMENT OF HIV-1 INFECTION BY THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS	LANCET			English	Note							INVITRO	Patients with AIDS who become infected with Cryptococcus neoformans have a poor prognosis. We speculated that the presence of cryptococcal capsular polysaccharide may enhance HIV-1 infection. In an in-vitro study, the presence of cryptococcal polysaccharide significantly increased (p < 0.05) production of p24 antigen after infection of H9 cells with HIV-1 -infected H9 cells. We also found similar results when lymphocytes from an HIV-1 -infected patient were co-cultured with mononuclear cells from an uninfected individual. Our findings suggest a new pathogenic role for the capsular polysaccharide-namely, the capacity to enhance HIV-1 infectivity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT,FORSCHHEIMER BLDG,ROOM 403, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			MANTOVANI, Massimo PETTOELLO/AAC-1990-2019	MANTOVANI, Massimo PETTOELLO/0000-0002-0688-1131; Kollmann, Tobias/0000-0003-2403-9762	NATIONAL CANCER INSTITUTE [R35CA039838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI020671, P30AI027741, R01AI020671] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39838] Funding Source: Medline; NIAID NIH HHS [AI-20671, AI-27741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BHATTACHARJEE AK, 1984, REV INFECT DIS, V6, P619; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOLDSTEIN H, 1991, AIDS, V5, P1447, DOI 10.1097/00002030-199112000-00006; KOZEL TR, 1971, INFECT IMMUN, V3, P287, DOI 10.1128/IAI.3.2.287-294.1971; MILLER GPG, 1984, J IMMUNOL, V133, P166; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; Treseler C B, 1990, Infect Dis Clin North Am, V4, P789; WISEMAN G, 1991, AIDS RES HUM RETROV, V7, P839, DOI 10.1089/aid.1991.7.839	10	79	82	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1992	339	8784					21	23		10.1016/0140-6736(92)90142-P	http://dx.doi.org/10.1016/0140-6736(92)90142-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1370335				2022-12-28	WOS:A1992GY04300004
J	WOOLF, CJ; SHORTLAND, P; COGGESHALL, RE				WOOLF, CJ; SHORTLAND, P; COGGESHALL, RE			PERIPHERAL-NERVE INJURY TRIGGERS CENTRAL SPROUTING OF MYELINATED AFFERENTS	NATURE			English	Article							GROWTH-ASSOCIATED PROTEIN; LUMBAR SPINAL-CORD; DORSAL HORN; SOMATOTOPIC ORGANIZATION; SUBSTANTIA-GELATINOSA; RAT; NEURONS; SKIN; PROJECTIONS; TRANSECTION	THE central terminals of primary afferent neurons are topographically highly ordered in the spinal cord 1. Peripheral receptor sensitivity is reflected by dorsal horn laminar location: low-threshold mechanoreceptors terminate in laminae III and IV (refs 2, 3) and high-threshold nociceptors in laminae I, II and V (refs 4, 5). Unmyelinated C fibres, most of which are nociceptors 6, terminate predominantly in lamina II (refs 5, 7). There is therefore an anatomical framework for the transfer of specific inputs to localized subsets of dorsal horn neurons. This specificity must contribute to the relationship between a low-intensity stimulus and an innocuous sensation and a noxious stimulus and pain. We now show that after peripheral nerve injury the central terminals of axotomized myelinated afferents, including the large A-beta fibres, sprout into lamina II. This structural reorganization in the adult central nervous system may contribute to the development of the pain mediated by A-fibres that can follow nerve lesions in humans 8,9.	UNIV TEXAS,MED BRANCH,DEPT ANAT & NEUROSCI,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	WOOLF, CJ (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Shortland, Peter/AAF-5153-2019; Woolf, Clifford/A-9784-2010; Shortland, Peter J/A-2070-2016	Shortland, Peter/0000-0002-7598-9744; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT GJ, 1991, DAHLEM WORKSHOP NEW, P365; BROWN AG, 1977, J PHYSIOL-LONDON, V272, P779, DOI 10.1113/jphysiol.1977.sp012073; Brown AG, 1981, ORG SPINAL CORD; BRUSHART TM, 1980, NEUROSCI LETT, V17, P1, DOI 10.1016/0304-3940(80)90051-8; CAMBELL JN, 1988, PAIN, V32, P89; CASTROLOPES JM, 1990, J NEUROCYTOL, V19, P329, DOI 10.1007/BF01188402; COGGESHALL RE, 1991, NEUROSCI LETT, V131, P37, DOI 10.1016/0304-3940(91)90331-M; DEVOR M, 1991, BRIT MED BULL, V47, P619, DOI 10.1093/oxfordjournals.bmb.a072496; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; HOFFMAN PN, 1989, J NEUROSCI, V9, P893; KNYIHARCSILLIK E, 1987, CELL TISSUE RES, V247, P599, DOI 10.1007/BF00215754; LIGHT AR, 1979, J COMP NEUROL, V186, P133, DOI 10.1002/cne.901860203; LYNN B, 1982, BRAIN RES, V238, P29, DOI 10.1016/0006-8993(82)90768-5; MCMAHON SB, 1991, J COMP NEUROL, V304, P307, DOI 10.1002/cne.903040211; Mesulam M-M, 1982, TRACING NEURAL CONNE; PRICE DD, 1989, PAIN, V36, P273, DOI 10.1016/0304-3959(89)90086-9; RALSTON HJ, 1979, J COMP NEUROL, V184, P643, DOI 10.1002/cne.901840404; ROBERTSON B, 1985, NEUROSCIENCE, V14, P895, DOI 10.1016/0306-4522(85)90152-6; ROBERTSON B, 1991, J NEUROCYTOL, V20, P387, DOI 10.1007/BF01355535; SCADDING JW, 1989, TXB PAIN, P522; SHORTLAND P, 1989, J COMP NEUROL, V289, P416, DOI 10.1002/cne.902890307; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; SOMMERVAILLE T, 1991, NEUROSCIENCE, V45, P213, DOI 10.1016/0306-4522(91)90117-7; SUGIMOTO T, 1984, BRAIN RES, V321, P199, DOI 10.1016/0006-8993(84)90173-2; SUGIURA Y, 1986, SCIENCE, V234, P358, DOI 10.1126/science.3764416; SWETT JE, 1985, J COMP NEUROL, V231, P66, DOI 10.1002/cne.902310106; TETZLAFF W, 1989, J NEUROSCI, V9, P1303; WOOLF CJ, 1987, J COMP NEUROL, V261, P105, DOI 10.1002/cne.902610109; WOOLF CJ, 1990, NEUROSCIENCE, V34, P465, DOI 10.1016/0306-4522(90)90155-W	30	896	933	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					75	78		10.1038/355075a0	http://dx.doi.org/10.1038/355075a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1370574				2022-12-28	WOS:A1992GY22800054
J	BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG				BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG			EFFECTS OF DUAL-CHAMBER PACING WITH SHORT ATRIOVENTRICULAR DELAY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							PULSED DOPPLER ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; CONGESTIVE HEART-FAILURE; COMPARATIVE SURVIVAL; HEMODYNAMIC BENEFIT; GAS-EXCHANGE; BLOCK; EXERCISE; REGURGITATION; PACEMAKERS	Mitral or tricuspid regurgitation of long duration may so shorten the ventricular filling time in dilated cardiomyopathy that stroke volume is limited. We assessed the effects of changing the atrioventricular interval during temporary or permanent dual-chamber DDD pacing in twelve dilated cardiomyopathy patients with short ventricular filling times due to regurgitation. We measured ventricular filling time and cardiac output with doppler echocardiography and exercise capacity on a treadmill, at baseline and with the best atrioventricular delay during pacing. The durations of both mitral and tricuspid regurgitation were significantly shorter at the shorter atrioventricular interval (mean reductions 85 [95% Cl 60-110] ms and 110 [75-150] ms, respectively; p<0.001 for both). There were consequent increases in left-ventricular and right-ventricular filling times (65 [35-95] ms and 90 [60-120] ms, p<0.001). For each 50 ms reduction in atrioventricular delay, left-ventricular filling time increased by 35 ms in six subjects with presystolic mitral regurgitation and right-ventricular filling time by 30 ms in nine subjects with presystolic tricuspid regurgitation. At the short atrioventricular interval, cardiac output was greater than baseline (by 1.1 [0.8-1.4] I/min, p<0.01) and there were rises in exercise duration (104 [45-165] s, p<0.05) and maximum oxygen consumption (2.1 [1.5-2.7]ml kg-1min-1, p<0.05). There was a decrease in the Likert visual analogue score of breathlessness at peak exercise (8.6 [SD 2.1] vs 4.9 [3.1], p<0.01 ). Although from a small sample, these findings suggest that DDD pacing with a short atrioventricular delay may have therapeutic potential in patients with dilated cardiomyopathy, even in the absence of conventional indications for pacemaker implantation.			BRECKER, SJD (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT CARDIAC,SYDNEY ST,LONDON SW3 6NP,ENGLAND.							ALPERT MA, 1986, J AM COLL CARDIOL, V7, P925, DOI 10.1016/S0735-1097(86)80358-8; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; BULLER NP, 1988, BRIT HEART J, V59, P212; DAVIES NJH, 1979, RESP PHYSIOL, V36, P261, DOI 10.1016/0034-5687(79)90029-X; DICARLO LA, 1987, AM HEART J, V114, P746, DOI 10.1016/0002-8703(87)90784-8; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; LEE CH, 1991, BRIT HEART J, V65, P342; LIPKIN DP, 1985, BRIT HEART J, V54, P321; MBASSOUROUM M, IN PRESS BR HEART J; MEHTA D, 1989, BRIT HEART J, V61, P161; NG KSK, 1989, BRIT HEART J, V62, P246; OCCHETTA E, 1990, PACE, V13, P916, DOI 10.1111/j.1540-8159.1990.tb02129.x; OLDERSHAW PJ, 1983, BRIT HEART J, V49, P568; PANIDIS IP, 1986, J AM COLL CARDIOL, V7, P768, DOI 10.1016/S0735-1097(86)80335-7; REITER MJ, 1982, AM J CARDIOL, V49, P687, DOI 10.1016/0002-9149(82)91947-6; RITTER P, 1989, EUR HEART J, V10, P637, DOI 10.1093/oxfordjournals.eurheartj.a059541; ROKEY R, 1986, AM J CARDIOL, V57, P692, DOI 10.1016/0002-9149(86)90864-7; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; RUTISHAUSER W, 1966, CIRCULATION, V34, P807, DOI 10.1161/01.CIR.34.5.807; RYDEN L, 1988, PACE, V11, P1051, DOI 10.1111/j.1540-8159.1988.tb03951.x; SACHER HL, 1989, ANGIOLOGY, V40, P489, DOI 10.1177/000331978904000511; SCHNITTGER I, 1988, J AM COLL CARDIOL, V11, P83, DOI 10.1016/0735-1097(88)90170-2; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; WISH M, 1987, AM J CARDIOL, V60, P566, DOI 10.1016/0002-9149(87)90306-7; XIAO HB, 1991, BRIT HEART J, V66, P443; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1983, J AM COLL CARDIOL, V2, P755	30	243	263	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1308	1312		10.1016/0140-6736(92)92492-X	http://dx.doi.org/10.1016/0140-6736(92)92492-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360034				2022-12-28	WOS:A1992KA26200003
J	LEDFORD, DK				LEDFORD, DK			IMMUNOLOGICAL ASPECTS OF CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMIC NECROTIZING VASCULITIS; ACUTE RHEUMATIC-FEVER; WEGENERS GRANULOMATOSIS; CLINICAL-FEATURES; IMMUNE-RESPONSE; AUTOANTIBODIES; DIAGNOSIS; ARTERITIS; THERAPY; CLASSIFICATION		JAMES A HALEY VET ADM HOSP,ALLERGY IMMUNOL SECT,TAMPA,FL	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	LEDFORD, DK (corresponding author), UNIV S FLORIDA,COLL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL 33612, USA.							BARNERT AL, 1975, JAMA-J AM MED ASSOC, V232, P925, DOI 10.1001/jama.232.9.925; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1068; BOWLES NE, 1989, CIRCULATION, V80, P1128, DOI 10.1161/01.CIR.80.5.1128; BRASILE L, 1989, AM J MED, V87, P74; CHAUHAN A, 1990, ANN RHEUM DIS, V49, P320, DOI 10.1136/ard.49.5.320; Cupps T R, 1981, Major Probl Intern Med, V21, P1; DAHLBERG PJ, 1989, ARCH INTERN MED, V149, P161, DOI 10.1001/archinte.149.1.161; ELLING P, 1990, J RHEUMATOL, V17, P225; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FAUCI AS, 1979, NEW ENGL J MED, V301, P235, DOI 10.1056/NEJM197908023010503; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FERRARO G, 1990, CLIN EXP IMMUNOL, V79, P47; FRAMPTON G, 1990, CLIN EXP IMMUNOL, V82, P227; GIBSON LE, 1990, MAYO CLIN PROC, V65, P221, DOI 10.1016/S0025-6196(12)65016-2; GOLDSCHMEDING R, 1989, J CLIN INVEST, V84, P1577, DOI 10.1172/JCI114335; GUILLEVIN L, 1988, BRIT J RHEUMATOL, V27, P258; HUSBY G, 1976, J EXP MED, V144, P1094, DOI 10.1084/jem.144.4.1094; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; LEAVITT RY, 1986, AM J MED, V81, P79, DOI 10.1016/0002-9343(86)90186-5; LIBBY P, 1991, LAB INVEST, V64, P5; LOCKSHIN MD, 1988, ARTHRITIS RHEUM, V31, P697, DOI 10.1002/art.1780310601; MAZE SS, 1990, CLIN CARDIOL, V13, P69, DOI 10.1002/clc.4960130203; MELISH ME, 1990, J RHEUMATOL, V17, P2; MOORE PM, 1989, NEUROLOGY, V39, P167, DOI 10.1212/WNL.39.2.167; PARRILLO JE, 1987, PRINCIPLES IMMUNOLOG, P271; PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0; PERRY BC, 1937, ARCH DIS CHILD, V12, P233; RODGERS H, 1989, POSTGRAD MED J, V65, P515, DOI 10.1136/pgmj.65.766.515; ROTHFIELD N, 1985, TXB RHEUMATOLOGY, P1087; SERGENT JS, 1976, MEDICINE, V55, P1, DOI 10.1097/00005792-197601000-00001; SHELHAMER JH, 1985, ANN INTERN MED, V103, P121, DOI 10.7326/0003-4819-103-1-121; STOLLERMAN GH, 1985, TXB RHEUMATOLOGY, P1277; VALERIANOMARCET J, 1991, ARCH INTERN MED, V151, P1649, DOI 10.1001/archinte.151.8.1649; VASILJEVIC JD, 1990, AM HEART J, V120, P1370, DOI 10.1016/0002-8703(90)90250-2; 1992, JAMA-J AM MED ASSOC, V268, P2069	37	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2923	2929		10.1001/jama.268.20.2923	http://dx.doi.org/10.1001/jama.268.20.2923			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1359164				2022-12-28	WOS:A1992JY66800018
J	LAMMER, J; PILGER, E; DECRINIS, M; QUEHENBERGER, F; KLEIN, GE; STARK, G				LAMMER, J; PILGER, E; DECRINIS, M; QUEHENBERGER, F; KLEIN, GE; STARK, G			PULSED EXCIMER LASER VERSUS CONTINUOUS-WAVE ND-YAG LASER VERSUS CONVENTIONAL ANGIOPLASTY OF PERIPHERAL ARTERIAL OCCLUSIONS - PROSPECTIVE, CONTROLLED, RANDOMIZED TRIAL	LANCET			English	Article							TRANS-LUMINAL ANGIOPLASTY; CLINICAL-TRIALS; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; PROBE; RECANALIZATION; RESTENOSIS; BYPASS; VEIN	Early clinical studies of coronary and peripheral laser angioplasty showed that arterial occlusions could be recanalised by continuous-wave lasers delivered with contact probes and by pulsed lasers applied with multifibre catheters. However, whether laser-assisted angioplasty improves success rates in reopening occlusions and in long-term patency rates is unclear. We have compared the primary recanalisation and long-term patency rates after laser-assisted and conventional percutaneous transluminal angioplasty (PTA) of femoropopliteal artery occlusions in 116 consecutive symptomatic patients (excimer laser 37, Nd:YAG laser 40, PTA 39). Primary recanalisation was achieved in 81 patients (70%). The primary recanalisation rate achieved with the excimer laser was significantly lower than that with the Nd:YAG laser (49% vs 78%, p < 0.01) or with PTA (82%, p < 0.003). The overall angiographic recanalisation rate (primary and secondary recanalisation) after laser and PTA was 89%. After 3 months, clinical improvement was recorded in 76% of patients. Clinical long-term results were available in 94 (91%), and angiographic long-term results in 77 (75%), of 103 successfully recanalised patients. Life-table analysis of the long-term results revealed no significant difference of the restenosis rate between the three treatment groups. The 12-month patency rate was 60% as assessed clinically and 39% as judged by angiography. Primary and secondary recanalisation rates and long-term patency rates were significantly correlated with length of the occlusion. Our results suggest that PTA of femoropopliteal artery occlusions is only indicated if the occlusion is short (< 8 cm) and that laser-assisted angioplasty should only be used after failure of conventional PTA.	KARL FRANZENS UNIV,DEPT RADIOL,GRAZ,AUSTRIA; KARL FRANZENS UNIV,DEPT INTERNAL MED,GRAZ,AUSTRIA; KARL FRANZENS UNIV,DEPT MED COMP SCI,GRAZ,AUSTRIA; UNIV VIENNA,DEPT RADIOL,A-1010 VIENNA,AUSTRIA	University of Graz; University of Graz; University of Graz; University of Vienna			Quehenberger, Franz/AAV-1446-2020; Quehenberger, Franz/N-8825-2019; Quehenberger, Franz/E-7489-2010	Quehenberger, Franz/0000-0003-0764-9497; Quehenberger, Franz/0000-0003-0764-9497				ABELA GS, 1990, JACC, V15, pA2; ASHLEY S, 1990, LASER SURG MED, V10, P234, DOI 10.1002/lsm.1900100304; BELLI AM, 1991, RADIOLOGY, V181, P57, DOI 10.1148/radiology.181.1.1832232; BORST C, 1990, CARDIOVASC RES, V24, P665, DOI 10.1093/cvr/24.8.665; CEPEK P, 1991, CIRCULATION S1, V83, P70; CONSIGNY MP, 1991, JVIR, V2, P253; CUMBERLAND DC, 1986, LANCET, V1, P1457; DANIEL WW, 1987, BIOSTATISTICS F ANAL, P531; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; EICKHOFF JH, 1987, J VASC SURG, V6, P506; FRANCS PJ, 1991, MAINTENANCE ARTERIAL, P95; GESCHWIND HJ, 1991, CIRCULATION, V83, P787, DOI 10.1161/01.CIR.83.3.787; HANKE H, 1991, CIRCULATION, V83, P1380, DOI 10.1161/01.CIR.83.4.1380; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; JEANS WD, 1990, BRIT J RADIOL, V63, P19, DOI 10.1259/0007-1285-63-745-19; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KARSCH KR, 1989, LANCET, V2, P647; KREPEL VM, 1985, RADIOLOGY, V156, P325, DOI 10.1148/radiology.156.2.3160061; KRETSCHMER G, 1988, LANCET, V1, P797; LAMMER J, 1991, RADIOLOGY, V178, P335, DOI 10.1148/radiology.178.2.1987588; LAMMER J, 1991, SEMIN INTERVENT RAD, V8, P126, DOI 10.1055/s-2008-1074636; MURRAY A, 1989, LANCET, V2, P1471; ODINK HF, 1991, RADIOLOGY, V181, P61, DOI 10.1148/radiology.181.1.1832233; OOMEN A, 1990, LASER SURG MED, V10, P363; PILGER E, 1991, CIRCULATION, V83, P141, DOI 10.1161/01.CIR.83.1.141; SANBORN TA, 1989, RADIOLOGY, V172, P943, DOI 10.1148/172.3.943; SANBORN TA, 1988, CIRCULATION, V78, P769, DOI 10.1161/01.CIR.78.3.769; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; VERDAASDONK RM, 1991, LASER SURG MED, V11, P213, DOI 10.1002/lsm.1900110304; 1986, J VASC SURG, V4, P80	31	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1183	1188		10.1016/0140-6736(92)92891-I	http://dx.doi.org/10.1016/0140-6736(92)92891-I			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359260				2022-12-28	WOS:A1992JY38600003
J	LOK, ASF; KWAN, WK; MOECKLI, R; YARBOUGH, PO; CHAN, RT; REYES, GR; LAI, CL; CHUNG, HT; LAI, TST				LOK, ASF; KWAN, WK; MOECKLI, R; YARBOUGH, PO; CHAN, RT; REYES, GR; LAI, CL; CHUNG, HT; LAI, TST			SEROEPIDEMIOLOGICAL SURVEY OF HEPATITIS-E IN HONG-KONG BY RECOMBINANT-BASED ENZYME IMMUNOASSAYS	LANCET			English	Article							NON-B-HEPATITIS; TRANSMITTED NON-A; WATERBORNE NON-A; E VIRUS; IDENTIFICATION	The agent that causes the enterally transmitted form of non-A, non-B hepatitis has been cloned and called hepatitis E virus (HEV). We have carried out a seroepidemiological survey on the prevalence of hepatitis E in Hong Kong. In a retrospective study, serum from 394 patients with acute viral hepatitis and 355 healthy subjects was tested for antibodies to HEV (anti-HEV) with a recombinant-based enzyme immunoassay. 65 (16.5%) patients with hepatitis were positive for IgM anti-HEV and 23 (5.8%) were also positive for IgM anti-HEV. Of 18 patients diagnosed as having acute non-A, non-B, non-C hepatitis, 6 were IgM anti-HEV positive. 17 (6%) patients in whom acute hepatitis A was diagnosed were also infected with HEV. None of 70 patients with acute hepatitis B or C or exacerbation of chronic hepatitis B was IgM anti-HEV positive. 57 (16.1%) of the healthy subjects were positive for IgG anti-HEV. The prevalence of IgG anti-HEV was higher in subjects over 20 years old than in younger subjects (24% vs 4%, p < 0.0001). IgG anti-HEV was detected in 26% of subjects who were positive for IgG antibody to HAV and in 7% of those negative for that antibody (p < 0.0001). We demonstrated the validity of the recombinant-based enzyme immunoassays for the diagnosis of hepatitis E. Our results suggest that hepatitis E accounts for a third of non-A, non-B, non-C hepatitis in Hong Kong and that coinfection of hepatitis A and E can occur.	UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG; PRINCESS MARGARET HOSP,INFECT DIS UNIT,HONG KONG,HONG KONG; PRINCESS MARGARET HOSP,MED UNIT,HONG KONG,HONG KONG; GENELABS INC,REDWOOD CITY,CA	University of Hong Kong			Lok, Anna/B-8292-2009; Lai, Ching Lung/C-4298-2009	Yang, Shuman/0000-0002-9638-0890; Lai, Ching-Lung/0000-0002-5927-2436				ARANKALLE VA, 1988, LANCET, V1, P550; BRADLEY D, 1988, J GEN VIROL, V69, P731, DOI 10.1099/0022-1317-69-3-731; CHIN KP, 1991, J MED VIROL, V34, P191, DOI 10.1002/jmv.1890340312; GOLDSMITH R, 1992, LANCET, V339, P328, DOI 10.1016/0140-6736(92)91647-Q; GUST ID, 1987, J INFECT DIS, V156, P630, DOI 10.1093/infdis/156.4.630; KRAWCZYNSKI K, 1989, J INFECT DIS, V159, P1042, DOI 10.1093/infdis/159.6.1042; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SKIDMORE SJ, 1992, J MED VIROL, V37, P58, DOI 10.1002/jmv.1890370110; SKIDMORE SJ, 1991, LANCET, V337, P1541, DOI 10.1016/0140-6736(91)93227-Z; SONG DY, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P528; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; 1990, LANCET, V336, P1158	15	104	105	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1205	1208		10.1016/0140-6736(92)92901-Q	http://dx.doi.org/10.1016/0140-6736(92)92901-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359270				2022-12-28	WOS:A1992JY38600013
J	MONJOUR, L; SILVA, OA; VOULDOUKIS, I; NEOGY, AB; BRITO, MEF; FILHO, SPB; JARDIM, ML				MONJOUR, L; SILVA, OA; VOULDOUKIS, I; NEOGY, AB; BRITO, MEF; FILHO, SPB; JARDIM, ML			IMMUNOPROPHYLAXIS IN CUTANEOUS LEISHMANIASIS	LANCET			English	Letter									MAGALHAES FIOCRUZ,CTR PESQUISAS AGGEU,RECIFE,BRAZIL; UNIV FED PERNAMBUCO,DEPT DERMATOL,BR-50000 RECIFE,PE,BRAZIL	Fundacao Oswaldo Cruz; Universidade Federal de Pernambuco	MONJOUR, L (corresponding author), UNIV PARIS 06,INSERM,U313,F-75013 PARIS,FRANCE.							MONJOUR L, 1988, T ROY SOC TROP MED H, V82, P412, DOI 10.1016/0035-9203(88)90140-X; MONJOUR L, 1986, LANCET, V1, P1490; 1990, TROPICAL DISEASES, P14	3	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1098	1099		10.1016/0140-6736(92)93119-8	http://dx.doi.org/10.1016/0140-6736(92)93119-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357486				2022-12-28	WOS:A1992JV77500037
J	STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RAMOS, H; ZEEVI, A; RUDERT, WA; KOCOVA, M; RICORDI, C; ILDSTAD, S; MURASE, N				STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RAMOS, H; ZEEVI, A; RUDERT, WA; KOCOVA, M; RICORDI, C; ILDSTAD, S; MURASE, N			SYSTEMIC CHIMERISM IN HUMAN FEMALE RECIPIENTS OF MALE LIVERS	LANCET			English	Note							PCR	We have previously reported data from clinical and laboratory animal observations which suggest that organ tolerance after transplantation depends on a state of balanced lymphodendritic cell chimerism between the host and donor graft. We have sought further evidence to support this hypothesis by investigating HLA-mismatched liver allograft recipients. 9 of 9 female recipients of livers from male donors had chimerism in their allografts and extrahepatic tissues, according to in-situ hybridisation and molecular techniques 10 to 19 years post-transplantation. In 8 women with good graft function, evidence of the Y chromosome was found in the blood (6/8), skin (8/8), and lymph nodes (7/8). A ninth patient whose transplant failed after 12 years from recurrent chronic viral hepatitis had chimerism in her lymph nodes, skin, jejunum, and aorta at the time of retransplantation. Although cell migration is thought to take place after all types of transplantation, the large population of migratory cells in, and the extent of their seeding from, hepatic grafts may explain the privileged tolerogenicity of the liver compared with other organs.	UNIV PITTSBURGH,HLTH SCI CTR,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PEDIAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,HLTH SCI CTR,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	NIDDK NIH HHS [DK 29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; KASHIWAGI N, 1969, Surgical Forum (Chicago), V20, P374; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, IN PRESS TRANSPLANT; STARZL TE, IN PRESS N ENGL J ME; STARZL TE, 1969, EXPERIENCE HEPATIC T, P184; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6	8	324	333	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					876	877		10.1016/0140-6736(92)93286-V	http://dx.doi.org/10.1016/0140-6736(92)93286-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357298	Green Accepted			2022-12-28	WOS:A1992JT32700005
J	MONKHOUSE, WS				MONKHOUSE, WS			ANATOMY AND THE MEDICAL-SCHOOL CURRICULUM	LANCET			English	Editorial Material											MONKHOUSE, WS (corresponding author), ROYAL COLL SURG IRELAND,DEPT ANAT,ST STEPHENS GREEN,DUBLIN 2,IRELAND.							FITZGERALD MJT, 1992, J ANAT, V180, P203; FRASER RC, 1991, BRIT MED J, V303, P41, DOI 10.1136/bmj.303.6793.41; MCMANUS, 1991, LANCET, V337, P1519; MOY RH, 1979, NEW ENGL J MED, V301, P694, DOI 10.1056/NEJM197909273011305	4	37	40	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					834	835		10.1016/0140-6736(92)92695-C	http://dx.doi.org/10.1016/0140-6736(92)92695-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357254				2022-12-28	WOS:A1992JR16800014
J	BORGEAT, A; WILDERSMITH, OHG; WILDERSMITH, CH; FORNI, M; SUTER, PM				BORGEAT, A; WILDERSMITH, OHG; WILDERSMITH, CH; FORNI, M; SUTER, PM			ADJUVANT PROPOFOL FOR REFRACTORY CISPLATIN-ASSOCIATED NAUSEA AND VOMITING	LANCET			English	Letter							HIGH-DOSE METOCLOPRAMIDE; CHEMOTHERAPY; ONDANSETRON		UNIV GENEVA HOSP,DEPT GYNAECOL & OBSTET,CH-1211 GENEVEA,SWITZERLAND; UNIV BERN,INSELSPITAL,DEPT GASTROENTEROL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern	BORGEAT, A (corresponding author), UNIV GENEVA HOSP,DEPT ANAESTHESIOL,CH-1211 GENEVA,SWITZERLAND.		Wilder-Smith, Clive/V-4868-2019; Wilder-Smith, Oliver H.G./E-7541-2012; Wilder-Smith, Clive/W-4365-2019	Wilder-Smith, Oliver H.G./0000-0003-4390-2381; 				BORGEAT A, 1992, ANESTH ANALG, V74, P539; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MCCOLLUM JSC, 1988, ANAESTHESIA, V43, P239; SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4	5	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					679	680		10.1016/0140-6736(92)92222-2	http://dx.doi.org/10.1016/0140-6736(92)92222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355248				2022-12-28	WOS:A1992JM85100050
J	FEANY, MB; LEE, S; EDWARDS, RH; BUCKLEY, KM				FEANY, MB; LEE, S; EDWARDS, RH; BUCKLEY, KM			THE SYNAPTIC VESICLE PROTEIN SV2 IS A NOVEL TYPE OF TRANSMEMBRANE TRANSPORTER	CELL			English	Article							SEROTONIN TRANSPORTER; RAT-BRAIN; CLONING; EXPRESSION; GLYCOPROTEIN	The primary function of synaptic vesicles is to store and release neurotransmitter. Synaptic vesicles are locally recycled following exocytosis and rapidly refilled with neurotransmitter from the cytoplasm by a process that depends on the electrochemical gradient generated by a proton pump. Little is known about the molecules that import neurotransmitter into synaptic vesicles. We report here that the sequence of the synaptic vesicle protein SV2 identifies this protein as a novel type of transmembrane transporter. The deduced amino acid sequence of SV2 contains two sets of six predicted transmembrane domains: the six most N-terminal transmembrane domains are highly homologous to a subfamily of transporters that includes the human glucose transporter, while the six most C-terminal domains are homologous to the plasma membrane transporters for neurotransmitters. We propose that SV2 mediates transport of neurotransmitters into synaptic vesicles.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	FEANY, MB (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024, USA.			Feany, Mel/0000-0003-0315-7970; Buckley, Kathleen/0000-0003-0283-4917				AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5778, DOI 10.1021/bi00140a013; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CARLSON SS, 1983, J BIOL CHEM, V258, P1082; CARONI P, 1985, NATURE, V314, P441, DOI 10.1038/314441a0; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Esko J D, 1986, Methods Enzymol, V129, P237; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIGGINS C, 1989, NATURE, V341, P103, DOI 10.1038/341103a0; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KILTY J, 1991, SCIENCE, V254, P579; LIU Y, 1992, IN PRESS P NATL ACAD; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	25	221	228	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					861	867		10.1016/0092-8674(92)90319-8	http://dx.doi.org/10.1016/0092-8674(92)90319-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1355409				2022-12-28	WOS:A1992JL66300017
J	CORNBLEET, MA; KNOWLES, G; NORTH, N; LEONARD, RC				CORNBLEET, MA; KNOWLES, G; NORTH, N; LEONARD, RC			RECORDING OF OUTPATIENT CONSULTATIONS	LANCET			English	Letter											CORNBLEET, MA (corresponding author), WESTERN GEN HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							HOGBIN B, 1989, BRIT J HOSP MED, V41, P330; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	2	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					488	488		10.1016/0140-6736(92)91811-L	http://dx.doi.org/10.1016/0140-6736(92)91811-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354817				2022-12-28	WOS:A1992JJ87700041
J	THOMAIDES, TN; CHAUDHURI, KR; MAULE, S; WATSON, L; MARSDEN, CD; MATHIAS, CJ				THOMAIDES, TN; CHAUDHURI, KR; MAULE, S; WATSON, L; MARSDEN, CD; MATHIAS, CJ			GROWTH-HORMONE RESPONSE TO CLONIDINE IN CENTRAL AND PERIPHERAL PRIMARY AUTONOMIC FAILURE	LANCET			English	Article							SECRETION; HYPERGLYCEMIA; OUTFLOW	Patients with primary autonomic failure may have either pure autonomic failure (PAF) or multiple system atrophy (MSA) in which there is additional neurological involvement. Distinction between PAF and MSA at an early stage is important because a wide range of complications is associated with MSA, which has a poor response to drug therapy and a less favourable prognosis. We have investigated the growth hormone (GH) releasing effects of clonidine in patients with PAF and MSA to see whether this hormonal response could serve as a neuroendocrine marker to distinguish between the groups. Age-matched normal subjects were studied as controls. Both groups of patients had severe postural hypotension due to primary sympathetic failure of presumed central origin in MSA and peripheral origin in PAF. After clonidine, plasma GH concentrations increased in controls and PAF, with no change in MSA. Changes in plasma glucose and insulin concentrations were similar in all groups. Clonidine, therefore, stimulates growth hormone release in PAF but not MSA and may serve as a neuroendocrine marker in differentiating patients with MSA and a central autonomic defect from those with PAF with a peripheral defect.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT MED,CARDIOVASC MED UNIT,LONDON SW7 2AZ,ENGLAND; NATL HOSP NEUROL & NEUROSURG,LONDON,ENGLAND; UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,AUTON UNIT,LONDON,ENGLAND	Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London				Ray Chaudhuri, K/0000-0003-2815-0505	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBAROTH J, 1989, CLIN ENDOCRINOL, V30, P485, DOI 10.1111/j.1365-2265.1989.tb01419.x; Armstrong E, 1991, Clin Auton Res, V1, P135, DOI 10.1007/BF01826210; BANNISTER R, 1988, AUTONOMIC FAILURE TX, P281; BANNISTER R, 1992, AUTONOMIC FAILURE TX, P255; BARBIERI C, 1980, J PHARMACOL EXP THER, V214, P433; BRAMNERT M, 1984, J CLIN ENDOCR METAB, V58, P374, DOI 10.1210/jcem-58-2-374; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHEKLEY SA, 1981, BRIT J PSYCHIAT, V138, P51; DACOSTA DF, 1984, CLIN EXP HYPERTENS A, V6, P1843, DOI 10.3109/10641968409046089; DELITALA G, 1983, J CLIN ENDOCR METAB, V57, P1145, DOI 10.1210/jcem-57-6-1145; GEMMILL JD, 1988, LANCET, V1, P1018; GILAD I, 1979, LANCET, V2, P1242; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; HUNT GE, 1986, PSYCHONEUROENDOCRINO, V11, P317, DOI 10.1016/0306-4530(86)90017-X; KOONER JS, 1991, CIRCULATION, V84, P75, DOI 10.1161/01.CIR.84.1.75; LAL S, 1981, HORM METAB RES, V13, P648, DOI 10.1055/s-2007-1019362; MAY CN, 1988, CLIN SCI, V75, P71, DOI 10.1042/cs0750071; MAY CN, 1990, NEUROPHARMACOLOGY, V29, P545, DOI 10.1016/0028-3908(90)90066-Z; MAZZA E, 1990, Endocrinologia Experimentalis, V24, P211; MULLER EE, 1988, ADV BIOSCI, V69, P173; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P334; RAJPUT AH, 1990, CLIN NEUROPHARMACOL, V13, P553, DOI 10.1097/00002826-199012000-00007; REID JL, 1981, BRIT J CLIN PHARMACO, V12, P295, DOI 10.1111/j.1365-2125.1981.tb01217.x; REID JL, 1977, CLIN PHARMACOL THER, V21, P375; RUDMAN D, 1981, J CLIN INVEST, V67, P1364	25	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					263	266		10.1016/0140-6736(92)92355-J	http://dx.doi.org/10.1016/0140-6736(92)92355-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353191				2022-12-28	WOS:A1992JG66500003
J	GORDON, RD; KLEMM, SA; TUNNY, TJ; STOWASSER, M				GORDON, RD; KLEMM, SA; TUNNY, TJ; STOWASSER, M			PRIMARY ALDOSTERONISM - HYPERTENSION WITH A GENETIC-BASIS	LANCET			English	Article							SUPPRESSIBLE HYPER-ALDOSTERONISM	Exciting developments in knowledge of primary aldosteronism include description of new subtypes and elucidation of the genetic basis of one variety. Furthermore, relatively simple biochemical screening (aldosterone/renin ratio) has disclosed that primary aldosteronism is more common than previously thought, by diagnosing patients at an earlier, normokalaemic stage. The mutant gene discovered in the glucocorticoid-suppressible variety (FHI) codes for an aldosterone biosynythetic enzyme normally controlled by angiotensin II, and now controlled by corticotropin. The zona fasciculata is hyperplastic and makes aldosterone and "hybrid steroids" 18-oxocortisol and 18-hydroxycortisol in excess, in response to ACTH but not to angiotensin II. Adrenal tumours have not yet been described in this condition. Aldosterone-producing adenomas (Conn's syndrome) are also commonly composed of zona fasciculata-like cells, make "hybrid steroids" in excess and are very sensitive to ACTH but not to angiotensin II. We have described a new variety of aldosterone-producing adenoma which is responsive to angiotensin II (AII-responsive APA), consists of at least 20% zona glomerulosa-like cells, and does not make "hybrid steroids" in excess. We have also described a new familial variety of primary aldosteronism that includes tumours and is not glucocorticoid-suppressible (FHII). We propose that primary aldosteronism is a spectrum of genetic diseases expressed as either hyperplasia or neoplasia, and that morphological and genetic diversity explains biochemical and clinical behaviour.			GORDON, RD (corresponding author), UNIV QUEENSLAND,GREENSLOPES HOSP,DEPT MED,ENDOCRINE HYPERTENS RES UNIT,BRISBANE,QLD 4120,AUSTRALIA.		Stowasser, Michael/F-4121-2010; Gordon, Richard D/K-2555-2012					AXELROD L, 1992, NEW ENGL J MED, V326, P1617, DOI 10.1056/NEJM199206113262406; GOMEZSANCHEZ CE, 1988, J CLIN ENDOCR METAB, V67, P444, DOI 10.1210/jcem-67-3-444; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; GORDON RD, 1991, CLIN EXP PHARMACOL P, V18, P283, DOI 10.1111/j.1440-1681.1991.tb01446.x; GORDON RD, 1987, CLIN EXPT PHARM PHYS, V17, P175; HAMLET SM, 1985, CLIN EXP PHARMACOL P, V12, P249, DOI 10.1111/j.1440-1681.1985.tb02641.x; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; HOEFNAGELS WHL, 1982, NEW ENGL J MED, V306, P427; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MATSUO K, 1985, ACTA PATHOL JAPON, V35, P1511; MCKENNA TJ, 1991, J CLIN ENDOCR METAB, V73, P952, DOI 10.1210/jcem-73-5-952; MIURA K, 1968, J CLIN ENDOCR METAB, V28, P1807, DOI 10.1210/jcem-28-12-1807; STOWASSER M, 1992, CLIN EXP PHARMACOL P, V19, P319, DOI 10.1111/j.1440-1681.1992.tb00462.x; STOWASSER M, 1991, J HYPERTENS, V9, pS264; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; WOODLAND E, 1985, CLIN EXP PHARMACOL P, V12, P245, DOI 10.1111/j.1440-1681.1985.tb02640.x	17	85	87	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					159	161		10.1016/0140-6736(92)93225-C	http://dx.doi.org/10.1016/0140-6736(92)93225-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352575				2022-12-28	WOS:A1992JE38200013
J	HAMMOND, JMJ; POTGIETER, PD; SAUNDERS, GL; FORDER, AA				HAMMOND, JMJ; POTGIETER, PD; SAUNDERS, GL; FORDER, AA			DOUBLE-BLIND-STUDY OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT IN INTENSIVE-CARE	LANCET			English	Article							MULTIPLE TRAUMA PATIENTS; ORGAN-SYSTEM FAILURE; RESPIRATORY-TRACT; VENTILATED PATIENTS; COLONIZATION; PREVENTION; PNEUMONIA; INFECTIONS; UNIT; CEFOTAXIME	Selective decontamination of the digestive tract (SDD), by means of non-absorbable antibiotics, to prevent infection in intensive-care units (ICUs) remains controversial; there is evidence that the regimen reduces the incidence of secondary infection, but no convincing reduction in morbidity or mortality has been shown and the costs and effect on microbial resistance patterns need further study. In a double-blind, placebo-controlled trial, we have tried to find out whether SDD should be used routinely in all ICU patients at high risk of secondary infection. All patients admitted to the ICU who were thought likely to stay in the unit for at least 5 days and to need intubation for longer than 48 h were enrolled and randomly allocated to groups receiving placebo or SDD (amphotericin, colistin, and tobramycin applied to the oropharynx and enterally); all patients received intravenous cefotaxime for 72 h. Of 322 patients randomised, 83 were withdrawn (80 ICU stay or duration of intubation too short, 3 protocol violations). 239 medical, trauma, and surgical patients completed the trial period (114 SDD, 125 placebo). There were no differences between SDD and placebo groups in incidence of infection (30 [26%] vs 43 [34%] patients; p=0.22), duration of ICU stay (mean 16.2 [14.3] vs 16.8 [12.3] days), hospital stay (29.9 [SD 25.0] vs 31.9 [22.2] days), or mortality (21 [18%] vs 21 [17%]). SDD substantially increased the costs of intensive care. Mechanisms other than bacterial colonisation of the gut may bring about substantial numbers of secondary infections in ICUs. Routine use of SDD in multidisciplinary ICUs cannot be recommended.	UNIV CAPE TOWN,DEPT MED,RESP INTENS CARE UNIT,CAPE TOWN,SOUTH AFRICA; GROOTE SCHUUR HOSP,CAPE TOWN 7925,SOUTH AFRICA; UNIV CAPE TOWN,DEPT ANAESTHESIA,CAPE TOWN,SOUTH AFRICA; UNIV CAPE TOWN,DEPT MED MICROBIOL,CAPE TOWN,SOUTH AFRICA	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town								AERDTS SJA, 1990, J ANTIMICROB CHEMOTH, V26, P59, DOI 10.1093/jac/26.suppl_A.59; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTLETT JG, 1986, ARCH INTERN MED, V146, P868, DOI 10.1001/archinte.146.5.868; BORDER J, 1988, PERSPECTIVES CRITICA; BROWN RB, 1990, ANTIMICROB AGENTS CH, V34, P269, DOI 10.1128/AAC.34.2.269; CHANDRASEKAR PH, 1986, CRIT CARE MED, V14, P508, DOI 10.1097/00003246-198605000-00017; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DUMOULIN GC, 1982, LANCET, V1, P242; FEELEY TW, 1975, NEW ENGL J MED, V293, P471, DOI 10.1056/NEJM197509042931003; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KONRAD F, 1988, INTENS CARE MED S, V14, P311; LEDINGHAM IM, 1988, LANCET, V1, P785; MANDELLI M, 1989, CRIT CARE MED, V17, P501, DOI 10.1097/00003246-198906000-00003; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; Miranda D R, 1983, Acta Anaesthesiol Belg, V34, P223; NIEDERMAN MS, 1990, CHEST, V97, P170, DOI 10.1378/chest.97.1.170; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; STEPHENSON GW, 1990, ANESTHESIOLOGY, V72, P542; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; TURNER JS, 1990, CRIT CARE MED, V18, P966, DOI 10.1097/00003246-199009000-00012; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2	28	182	188	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					5	9		10.1016/0140-6736(92)92422-C	http://dx.doi.org/10.1016/0140-6736(92)92422-C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351620				2022-12-28	WOS:A1992JC35400002
J	SWERDLOW, DL; RIES, AA				SWERDLOW, DL; RIES, AA			CHOLERA IN THE AMERICA - GUIDELINES FOR THE CLINICIAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIBRIO-CHOLERAE; UNITED-STATES; EMERGENCE; RESISTANT; TRAVELERS; EPIDEMIC; DIARRHEA				SWERDLOW, DL (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ENTER DIS BRANCH, ATLANTA, GA 30333 USA.							[Anonymous], MANUAL CLIN MICROBIO; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P194; BHATTACHARYA SK, 1990, ANTIMICROB AGENTS CH, V34, P939, DOI 10.1128/AAC.34.5.939; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; DOUGLAS GR, 1990, PRINCIPLES PRACTICE, P1636; GANGAROSA EJ, 1974, CHOLERA, P381; GANGAROSA EJ, 1975, PRACTICE MED, V3, P1; GLASS RI, 1980, J INFECT DIS, V142, P939, DOI 10.1093/infdis/142.6.939; GREENOUGH WB, 1990, PRINCIPLES PRACTICE, P1636; JOHNSTON JM, 1983, NEW ENGL J MED, V309, P523, DOI 10.1056/NEJM198309013090903; KAPER JB, 1989, REV INFECT DIS, V11, pS568; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; Levine M M, 1990, Infect Dis Clin North Am, V4, P105; LOWRY PW, 1989, ARCH INTERN MED, V149, P2079, DOI 10.1001/archinte.149.9.2079; MCCORMACK WM, 1968, B WORLD HEALTH ORGAN, V38, P787; MHALU FS, 1979, LANCET, V1, P345; MILLER SI, 1989, ANN NY ACAD SCI, V569, P145, DOI 10.1111/j.1749-6632.1989.tb27365.x; MORRIS JG, 1981, ANN INTERN MED, V94, P656, DOI 10.7326/0003-4819-94-5-656; OUELLETTE M, 1988, ANN INST PASTEUR MIC, V139, P105; PAVIA AT, 1987, JAMA-J AM MED ASSOC, V258, P2374, DOI 10.1001/jama.1987.03400170060012; RIES AA, 1991, 31ST INT C ANT AG CH; Rosenberg Charles E, 1987, CHOLERA YEARS US 183; SANTOSHAM M, 1991, J PEDIATR-US, V118, pS44, DOI 10.1016/S0022-3476(05)81425-8; SNYDER JD, 1991, PEDIATRICS, V87, P28; SNYDER JD, 1982, JAMA-J AM MED ASSOC, V247, P2268, DOI 10.1001/jama.1982.03320410050031; STLOUIS ME, 1990, AM J EPIDEMIOL, V131, P719; SWERDLOW DL, 1991, 31ST INT C ANT AG CH; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; WEISSMAN JB, 1974, AM J EPIDEMIOL, V100, P487, DOI 10.1093/oxfordjournals.aje.a112061; YOUNG CR, 1986, MANUAL CLIN LABORATO, P363; 1991, MMWR, V40, P108; 1991, MMWR, V40, P287; 1991, WHOCDDSER804 PROGR C; 1991, MMWR, V40, P516; 1990, US PHS CDC908280 US; 1991, MMWR, V40, P258; 1991, MMWR, V40, P860; [No title captured]; 1990, WHOCDDSER80 PROGR CO; 1988, MMWR, V37, P617	41	37	39	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1495	1499		10.1001/jama.267.11.1495	http://dx.doi.org/10.1001/jama.267.11.1495			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1371570				2022-12-28	WOS:A1992HH48800030
J	ROSENFELD, MA; YOSHIMURA, K; TRAPNELL, BC; YONEYAMA, K; ROSENTHAL, ER; DALEMANS, W; FUKAYAMA, M; BARGON, J; STIER, LE; STRATFORDPERRICAUDET, L; PERRICAUDET, M; GUGGINO, WB; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				ROSENFELD, MA; YOSHIMURA, K; TRAPNELL, BC; YONEYAMA, K; ROSENTHAL, ER; DALEMANS, W; FUKAYAMA, M; BARGON, J; STIER, LE; STRATFORDPERRICAUDET, L; PERRICAUDET, M; GUGGINO, WB; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			INVIVO TRANSFER OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TO THE AIRWAY EPITHELIUM	CELL			English	Article							DEPENDENT PROTEIN-KINASE; INSITU HYBRIDIZATION; CHLORIDE CHANNELS; ADENOVIRUS TYPE-5; ESCHERICHIA-COLI; MESSENGER-RNAS; CELL-LINE; EXPRESSION; DNA; IDENTIFICATION	Direct transfer of the normal cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene to airway epithelium was evaluated using a replication-deficient recombinant adenovirus (Ad) vector containing normal human CFTR cDNA (Ad-CFTR). In vitro Ad-CFTR-infected CFPAC-1 CF epithelial cells expressed human CFTR mRNA and protein and demonstrated correction of defective cAMP-mediated Cl-permeability. Two days after in vivo intratracheal introduction of Ad-CFTR in cotton rats, in situ analysis demonstrated human CFTR gene expression in lung epithelium. PCR amplification of reverse transcribed lung RNA demonstrated human CFTR transcripts derived from Ad-CFTR, and Northern analysis of lung RNA revealed human CFTR transcripts for up to 6 weeks. Human CFTR protein was detected in epithelial cells using anti-human CFTR antibody 11-14 days after infection. While the safety and effectiveness remain to be demonstrated, these observations suggest the feasibility of in vivo CFTR gene transfer as therapy for the pulmonary manifestations of CF.	TRANSGENE SA,STRASBOURG,FRANCE; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Transgene SA; UNICANCER; Gustave Roussy; Johns Hopkins University	ROSENFELD, MA (corresponding author), NHLBI,PULM BRANCH,BETHESDA,MD 20892, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122, R01HL040178] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40178, HL 47122] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Evans MJ, 1989, LUNG CELL BIOL, P1; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAJAHMAD Y, 1986, J VIROL, V57, P267, DOI 10.1128/JVI.57.1.267-274.1986; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ MS, 1990, VIROLOGY, P01679; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JEFFERSON DM, 1990, AM J PHYSIOL, V259, pL496, DOI 10.1152/ajplung.1990.259.6.L496; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; ROSENFELD MA, 1991, CLIN RES, V39, pA311; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Strauss SE, 1984, ADENOVIRUSES, P451; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TRESIZE AEO, 1991, NATURE, V353, P434; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Weibel E.R., 1991, LUNG SCI F, V1, P711; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	53	907	1513	1	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					143	155		10.1016/0092-8674(92)90213-V	http://dx.doi.org/10.1016/0092-8674(92)90213-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370653				2022-12-28	WOS:A1992GZ58300016
